0001144204-15-063327.txt : 20151110 0001144204-15-063327.hdr.sgml : 20151110 20151106152040 ACCESSION NUMBER: 0001144204-15-063327 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20150930 FILED AS OF DATE: 20151106 DATE AS OF CHANGE: 20151106 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Lion Biotechnologies, Inc. CENTRAL INDEX KEY: 0001425205 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 753254381 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-36860 FILM NUMBER: 151206106 BUSINESS ADDRESS: STREET 1: 112 WEST 34TH STREET STREET 2: 17TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10120 BUSINESS PHONE: 212-946-4826 MAIL ADDRESS: STREET 1: 112 WEST 34TH STREET STREET 2: 17TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10120 FORMER COMPANY: FORMER CONFORMED NAME: Genesis Biopharma, Inc DATE OF NAME CHANGE: 20100319 FORMER COMPANY: FORMER CONFORMED NAME: FREIGHT MANAGEMENT CORP DATE OF NAME CHANGE: 20080128 10-Q 1 v423195_10q.htm FORM 10-Q

U. S. SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 10-Q

þ	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2015

¨	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________.

Commission File Number 001-36860

LION BIOTECHNOLOGIES, INC.

(Exact name of small business issuer as specified in its charter)

Nevada	75-3254381
(State or other jurisdiction of	(I.R.S. employer
incorporation or organization)	identification number)

112 W. 34^th Street, 17^th floor, New York, NY 10120

(Address of principal executive offices and zip code)

(212)946-4856

(Registrant’s telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes x No ¨

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes x No ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer ¨	Accelerated filer x
Non-accelerated filer ¨ (Do not check if a smaller reporting company)	Smaller reporting company ¨

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ¨ No þ

At October 31, 2015, the issuer had 47,833,934 shares of common stock, par value $0.000041666 per share, outstanding.

LION BIOTECHNOLOGIES, INC.

FORM 10-Q

For the Quarter Ended September 30, 2015

Table of Contents

		Page
PART I FINANCIAL INFORMATION
Item 1.	Condensed Financial Statements (Unaudited)		1
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations		17
Item 3.	Quantitative and Qualitative Disclosures About Market Risk		20
Item 4T.	Controls and Procedures		21

PART II OTHER INFORMATION
Item 1.	Legal Proceedings		21
Item 1A.	Risk Factors		21
Item 2.	Unregistered Sales of Securities and Use of Proceeds		22
Item 3.	Defaults Upon Senior Securities		22
Item 4.	Mine Safety Disclosure		22
Item 5.	Other Information		22
Item 6.	Exhibits		22

SIGNATURES			23

PART I. FINANCIAL INFORMATION

Item 1.

Condensed Financial Statements

LION BIOTECHNOLOGIES, INC.

Condensed Balance Sheets

(in thousands, except share information)

	September 30,			December 31,
	2015			2014
ASSETS		(unaudited)

Current Assets
Cash and cash equivalents	$	10,210		$	44,910
Money market funds		20,562			-
Short-term investments available for sale		79,374			-
Prepaid and other current assets		245			67
Total Current Assets		110,391			44,977

Property and equipment, net of accumulated depreciation of $794 and $103, respectively		1,833			1,532
Total Assets	$	112,224		$	46,509

LIABILITIES AND STOCKHOLDERS’ EQUITY

Current Liabilities
Accounts payable	$	1,161		$	1,249
Accrued expenses		1,608			328
Accrued payable to officers and former directors		86			86
Total Current Liabilities		2,855			1,663

Commitments and contingencies

Stockholders’ Equity
Preferred stock, $0.001 par value; 50,000,000 shares authorized, 3,694 shares and 5,694 shares issued and outstanding, respectively		-			-
Common stock, $0.000041666 par value; 150,000,000 shares authorized, 47,807,398 and 33,750,188 shares issued and outstanding, respectively		2			2
Common stock to be issued, 245,153 shares		245			245
Accumulated other comprehensive income		38			-
Additional paid-in capital		204,929			121,161
Accumulated deficit		(95,845	)		(76,562	)
Total Stockholders’ Equity		109,369			44,846

Total Liabilities and Stockholders’ Equity	$	112,224		$	46,509

The accompanying notes are an integral part of these condensed financial statements.

LION BIOTECHNOLOGIES, INC.

Condensed Statements of Operations

(in thousands, except per share information)

(Unaudited)

	For the Three Months Ended September 30,						For the Nine Months Ended September 30,
	2015			2014			2015			2014
Revenues	$	-		$	-		$	-		$	-
Costs and expenses
Operating expenses (includes $1,452, $658, $3,726, and $1,905, respectively in share-based compensation costs)		2,660			2,449			7,259			6,155
Research and development (includes $895, $282, $2,050, and $817, respectively in share-based compensation costs)		4,983			354			12,147			1,018
Total costs and expenses		7,643			2,803			19,406			7,173

Loss from operations		(7,643	)		(2,803	)		(19,406	)		(7,173	)
Interest income		8			5			123			5
Net Loss	$	(7,635	)	$	(2,798	)	$	(19,283	)	$	(7,168	)

Net Loss Per Share, Basic and Diluted	$	(0.16	)	$	(0.11	)	$	(0.44	)	$	(0.30	)

Weighted-Average Common Shares Outstanding, Basic and Diluted		47,271,593			26,632,908			43,398,650			24,107,787

The accompanying notes are an integral part of these condensed financial statements.

LION BIOTECHNOLOGIES, INC.

Condensed Statements of Comprehensive Loss

(in thousands)

(Unaudited)

	For the Three Months Ended September 30,						For the Nine Months Ended September 30,
	2015			2014			2015			2014
Net Loss	$	(7,635	)	$	(2,798	)	$	(19,283	)	$	(7,168	)
Other comprehensive income:
Unrealized gain on short-term investments		38			-			38			-

Comprehensive Loss	$	(7,597	)	$	(2,798	)	$	(19,245	)	$	(7,168	)

The accompanying notes are an integral part of these condensed financial statements.

LION BIOTECHNOLOGIES, INC.

Condensed Statements of Stockholders’ Equity

For the Nine Months Ended September 30, 2015

(in thousands, except share information)

(Unaudited)

										Common
										Stock		Additional							Total
	Preferred Stock					Common Stock				to be		Paid-In		Comprehensive		Accumulated			Stockholders’
	Shares			Amount		Shares		Amount		Issued		Capital		Income		Deficit			Equity

Balance - January 1, 2015		5,694		$	-		33,750,188	$	2	$	245	$	121,161	$	-	$	(76,562	)	$	44,846

Fair value of vested stock options													4,223							4,223
Common stock issued upon exercise of warrants							3,847,210		-				9,618							9,618
Common stock issued upon exercise of options							10,000		-				66							66
Common stock issued upon conversion of preferred shares		(2,000	)				1,000,000		-											-
Common stock sold in public offering, net of offering costs							9,200,000		-				68,308							68,308
Vesting of restricted shares issued for services													1,553							1,553
Unrealized gain on short-term investments															38					38
Net loss																	(19,283	)		(19,283	)

Balance - September 30, 2015		3,694		$	-		47,807,398	$	2	$	245	$	204,929	$	38	$	(95,845	)	$	109,369

The accompanying notes are an integral part of these condensed financial statements.

LION BIOTECHNOLOGIES, INC.

Condensed Statements of Cash Flows

(In thousands)

(Unaudited)

	For the Nine Months Ended
	September 30,
	2015			2014

Cash Flows From Operating Activities
Net loss		(19,283	)	$	(7,168	)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation		691			23
Fair value of vested stock options		4,223			1,896
Vesting of restricted shares issued for services		1,553			825
Changes in assets and liabilities:
Prepaid and other current assets		(179	)		118
Accounts payable and accrued expenses		1,193			(1,012	)

Net cash used in operating activities		(11,802	)		(5,318	)

Cash Flows From Investing Activities
Increase in money market funds		(20,562	)		-
Purchase of short-term investments		(95,236	)		-
Maturities of short-term investments		15,900			-
Purchases of property and equipment		(992	)		(167	)
Net cash used in investing activities		(100,890	)		(167	)

Cash Flows From Financing Activities
Proceeds from the issuance of common stock upon exercise of warrants		9,618			3,002
Proceeds from the issuance of common stock upon exercise of options		66
Proceeds from the issuance of common stock, net		68,308			-

Net cash provided by financing activities		77,992			3,002

Net Decrease In Cash And Cash Equivalents		(34,700	)		(2,483	)
Cash and Cash Equivalents, Beginning of Period		44,910			19,673
Cash and Cash Equivalents, End of Period		10,210		$	17,190

Supplement non-cash financing activities
Unrealized gain on short-term investments		38		$	-

The accompanying notes are an integral part of these condensed financial statements.

LION BIOTECHNOLOGIES, INC.

NOTES TO CONDENSED FINANCIAL STATEMENTS

For the Nine Months Ended September 30, 2015 and 2014 (Unaudited)

NOTE 1. GENERAL ORGANIZATION AND BUSINESS

Lion Biotechnologies, Inc. (the “Company,” “we,” “us” or “our”) is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel cancer immunotherapy products designed to harness the power of a patient’s own immune system to eradicate cancer cells. Our lead program is an adoptive cell therapy utilizing tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients’ tumors, for the treatment of metastatic melanoma. The TIL are then activated and expanded ex vivo and then infused back into the patient to fight their tumor cells. The Company was originally incorporated under the laws of the state of Nevada on September 17, 2007. Until March 2010, we were an inactive company known as Freight Management Corp. On March 15, 2010, we changed our name to Genesis Biopharma, Inc., and in 2011 we commenced our current business.

Basis of Presentation of Unaudited Condensed Financial Information

The unaudited condensed financial statements of the Company for the nine months ended September 30, 2015 and 2014 have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and pursuant to the requirements for reporting on Form 10-Q and Regulation S-K. Accordingly, they do not include all the information and footnotes required by accounting principles generally accepted in the United States of America for complete financial statements. However, such information reflects all adjustments (consisting solely of normal recurring adjustments), which are, in the opinion of management, necessary for the fair presentation of the financial position and the results of operations. Results shown for interim periods are not necessarily indicative of the results to be obtained for a full fiscal year. The balance sheet information as of December 31, 2014 was derived from the audited financial statements included in the Company’s financial statements as of and for the year ended December 31, 2014 included in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission (the “SEC”) on March 16, 2015. These financial statements should be read in conjunction with that report.

Liquidity

We are currently engaged in the development of therapeutics to fight cancer, we do not have any commercial products and have not yet generated any revenues from our biopharmaceutical business. We currently do not anticipate that we will generate any revenues during 2015 from the sale or licensing of any products. In addition, we have not generated any revenues from our prior business plans.

We have not had any revenues and are still in the development stage. As shown in the accompanying condensed financial statements, we have incurred a net loss of $19.3 million for the nine months ended September 30, 2015 and used $11.8 million of cash in our operating activities during the nine months ended September 30, 2015. As of September 30, 2015, we had $110.1 million of cash, money market funds, and short term investments on hand, stockholders’ equity of $109.4 million and had working capital of $107.5 million.

During 2015, we expect to further ramp up our operations, which will increase the amount of cash we will use in our operations. Our budget for 2015 includes increased spending on research and development activities, higher payroll expenses as we increase our professional staff, the costs associated with operating our new Tampa, Florida, research facility, as well as ongoing payments under the Cooperative Research and Development Agreement (CRADA) we have entered into with the National Cancer Institute (NCI). Based on the funds we had available on September 30, 2015, we believe that we have sufficient capital to fund our anticipated operating expenses for at least 24 months.

On March 3, 2015, the Company sold 9,200,000 shares of its common stock in an underwritten public offering at $8.00 per share for net proceeds of $68.3 million, after deducting expenses of the offering. On December 22, 2014, the Company sold 6,000,000 shares of its common stock in an underwritten public offering at $5.75 per share for net proceeds of $32.2 million after deducting expenses of the offering. On November 5, 2013, we completed a $23.3 million private placement of our securities to various institutional and individual accredited investors. Despite the amount of funds that we have raised, the estimated cost of completing the development of our TIL-based therapy, and of obtaining all required regulatory approvals to market those product candidates, may be substantially greater than the amount of funds we have available. Therefore, while we believe that our existing cash balances will be sufficient to fund our currently planned level of operations for at least 24 months, we will have to obtain additional funds in the future to complete our development plans. We intend to seek this additional funding through various financing sources, including possible sales of our securities, and in the longer term through strategic alliances with other pharmaceutical or biopharmaceutical companies.

LION BIOTECHNOLOGIES, INC.

NOTES TO CONDENSED FINANCIAL STATEMENTS

For the Nine Months Ended September 30, 2015 and 2014 (Unaudited)

NOTE 2. SUMMARY OF SIGNIFICANT ACCOUNTING PRACTICES

Cash and Cash Equivalents

The Company considers highly liquid investments with an original maturity of 90 days or less when purchased to be cash equivalents. The carrying amounts reported in the Balance Sheets for cash and cash equivalents are valued at cost, which approximates their fair value.

Short-term Investments

The Company’s short-term investments represent available for sale securities and are recorded at fair value and unrealized gains and losses are recorded within accumulated other comprehensive income (loss). The estimated fair value of the available for sale securities is determined based on quoted market prices or rates for similar instruments. In addition, the cost of debt securities in this category is adjusted for amortization of premium and accretion of discount to maturity. The Company evaluates securities with unrealized losses to determine whether such losses, if any, are other than temporary.

Property and Equipment

Property and equipment are recorded at cost and depreciated using the straight-line method over their estimated useful lives of two to five years. Maintenance and repairs of depreciable assets are charged against earnings as incurred. When properties are retired or otherwise disposed of, the cost and accumulated depreciation are removed from the accounts and gains or losses are credited or charged to earnings. Leasehold improvements are amortized over the lesser of their estimated useful life or lease term, whichever is shorter.

Net Income (Loss) Per Share

Basic net income (loss) per share is computed by dividing net income (loss) by the weighted average number of common shares outstanding for the period, excluding unvested shares of restricted common stock. Shares of restricted stock subject to vesting are included in basic weighted average common shares outstanding from the time they vest. Diluted earnings per share is computed by dividing the net income applicable to common stock holders by the weighted average number of common shares outstanding plus the number of additional common shares that would have been outstanding if all dilutive potential common shares had been issued, using the treasury stock method. Potential common shares are excluded from the computation when their effect is antidilutive. When calculating diluted net income per share, shares of restricted stock subject to vesting are included in diluted weighted average common shares outstanding as of their grant date.

At September 30, 2015 and 2014, basic and diluted net loss per share are the same, as the effect of potentially dilutive securities was antidilutive. At September 30, 2015, potentially dilutive securities include options to acquire 2,704,195 shares of common stock, warrants to acquire 7,237,216 shares of common stock, preferred stock that can be converted into 1,847,000 shares of common stock, and 494,001 shares of non-vested restricted stock. At September 30, 2014, potentially dilutive securities include options to acquire 1,098,750 shares of common stock, warrants to acquire 11,172,426 shares of common stock, and preferred stock that can be converted into 2,847,000 shares of common stock.

Fair Value Measurements

Under FASB ASC 820, Fair Value Measurements and Disclosures, fair value is defined as the price at which an asset could be exchanged or a liability transferred in a transaction between knowledgeable, willing parties in the principal or most advantageous market for the asset or liability. Where available, fair value is based on observable market prices or parameters or derived from such prices or parameters. Where observable prices or parameters are not available, valuation models are applied.

LION BIOTECHNOLOGIES, INC.

NOTES TO CONDENSED FINANCIAL STATEMENTS

For the Nine Months Ended September 30, 2015 and 2014 (Unaudited)

Assets and liabilities recorded at fair value in our financial statements are categorized based upon the level of judgment associated with the inputs used to measure their fair value. Hierarchical levels directly related to the amount of subjectivity associated with the inputs to fair valuation of these assets and liabilities, are as follows:

Level 1—Inputs are unadjusted, quoted prices in active markets for identical assets at the reporting date. Active markets are those in which transactions for the asset or liability occur in sufficient frequency and volume to provide pricing information on an ongoing basis.

The fair valued assets we hold that are generally included under this Level 1 are money market securities where fair value is based on publicly quoted prices.

Level 2—Are inputs, other than quoted prices included in Level 1, that are either directly or indirectly observable for the asset or liability through correlation with market data at the reporting date and for the duration of the instrument’s anticipated life.

The fair valued assets we hold that are generally assessed under Level 2 are corporate bonds and commercial paper. We utilize third party pricing services in developing fair value measurements where fair value is based on valuation methodologies such as models using observable market inputs, including benchmark yields, reported trades, broker/dealer quotes, bids, offers and other reference data. We use quotes from external pricing service providers and other on-line quotation systems to verify the fair value of investments provided by our third party pricing service providers. We review independent auditor’s reports from our third party pricing service providers particularly regarding the controls over pricing and valuation of financial instruments and ensure that our internal controls address certain control deficiencies, if any, and complementary user entity controls are in place.

Level 3—Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities and which reflect management’s best estimate of what market participants would use in pricing the asset or liability at the reporting date. Consideration is given to the risk inherent in the valuation technique and the risk inherent in the inputs to the model.

We do not have fair valued assets classified under Level 3.

Fair Value on a Recurring Basis

Financial assets measured at fair value on a recurring basis are categorized in the tables below based upon the lowest level of significant input to the valuations (in thousands):

	Assets at Fair Value as of September 30, 2015
	Level 1		Level 2		Level 3		Total
Money market funds	$	20,562	$	-	$	-	$	20,562

Corporate debt securities		-		79,374		-		79,374
Total	$	20,562	$	79,374	$		$	99,936

LION BIOTECHNOLOGIES, INC.

NOTES TO CONDENSED FINANCIAL STATEMENTS

For the Nine Months Ended September 30, 2015 and 2014 (Unaudited)

(Amounts in thousands, except share information)

Use of Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates include accounting for potential liabilities and the assumptions made in valuing stock instruments issued for services.

Stock-Based Compensation

The Company periodically grants stock options and warrants to employees and non-employees in non-capital raising transactions as compensation for services rendered. The Company accounts for stock option grants to employees based on the authoritative guidance provided by the Financial Accounting Standards Board where the value of the award is measured on the date of grant and recognized over the vesting period. The Company accounts for stock option grants to non-employees in accordance with the authoritative guidance of the Financial Accounting Standards Board where the value of the stock compensation is determined based upon the measurement date at either a) the date at which a performance commitment is reached, or b) at the date at which the necessary performance to earn the equity instruments is complete. Non-employee stock-based compensation charges generally are amortized over the vesting period on a straight-line basis. In certain circumstances where there are no future performance requirements by the non-employee, option grants are immediately vested and the total stock-based compensation charge is recorded in the period of the measurement date.

The Company issues restricted shares of its common stock for share-based compensation programs. The Company measures the compensation cost with respect to restricted shares to employees based upon the estimated fair value of the equity instruments at the date of the grant, and is recognized as expense over the period which an employee is required to provide services in exchange for the award.

The fair value of the Company’s common stock option grants is estimated using a Black-Scholes option pricing model, which uses certain assumptions related to risk-free interest rates, expected volatility, expected life of the common stock options, and future dividends. Compensation expense is recorded based upon the value derived from the Black-Scholes option pricing model, and based on actual experience. The assumptions used in the Black-Scholes option pricing model could materially affect compensation expense recorded in future periods.

Total stock-based compensation expense related to all of our stock-based awards was as follows (in thousands):

	For the Three Months Ended September 30,				For the Nine Months Ended September 30,
	2015		2014		2015		2014

Operating expenses	$	1,492	$	658	$	3,726	$	1,905
Research and development		895		282		2,050		817
Total stock-based compensation expense	$	2,387	$	940	$	5,776	$	2,722

LION BIOTECHNOLOGIES, INC.

NOTES TO CONDENSED FINANCIAL STATEMENTS

For the Nine Months Ended September 30, 2015 and 2014 (Unaudited)

(Amounts in thousands, except share information)

Research and Development

Research and development costs consist primarily of fees paid to consultants and outside service providers, patent fees and costs, and other expenses relating to the acquisition, design, development and testing of the Company’s treatments and product candidates. Research and development costs are expensed as incurred, unless the achievement of milestones, the completion of contracted work, or other information indicates that a different expensing schedule is more appropriate. The Company reviews the status of its research and development contracts on a quarterly basis.

Concentrations

Financial instruments, which potentially subject the Company to concentrations of credit risk, consist principally of cash and short-term investments.

The Company maintains cash balances at one bank. As of September 30, 2015, the Company’s cash balances were in excess of insured limits maintained at this bank. Management believes that the financial institution that hold the Company’s cash are financially sound and, accordingly, minimal credit risk exists.

At September 30, 2015, the Company’s short-term investments were invested in short-term fixed income debt securities of domestic and foreign high credit issuers and in money market funds. The Company’s investment policy limits investments to certain types of instruments such as certificates of deposit, money market instruments, obligations issued by the U.S. government and U.S. government agencies as well as corporate debt securities, and places restrictions on maturities and concentration by type and issuer. At September 30, 2015, approximately 56% of the Company’s short-term investments were invested in notes of five companies, 25% were invested in notes of various domestic issuers, and 19% were invested in notes of a foreign issuers. The average maturity of these notes was 66 days (See Note 3).

Recent Accounting Pronouncements

In May 2014, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2014-09, Revenue from Contracts with Customers. ASU 2014-09 is a comprehensive revenue recognition standard that will supersede nearly all existing revenue recognition guidance under current U.S. GAAP and replace it with a principle based approach for determining revenue recognition. ASU 2014-09 will require that companies recognize revenue based on the value of transferred goods or services as they occur in the contract. The ASU also will require additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to obtain or fulfill a contract. ASU 2014-09 is effective for interim and annual periods beginning after December 15, 2017. Early adoption is permitted in annual reporting periods beginning after December 15, 2016, and the interim periods within that year, and either full retrospective adoption or modified retrospective adoption is permitted. The Company is in the process of evaluating the impact of ASU 2014-09 on the Company’s financial statements and disclosures.

In June 2014, the FASB issued Accounting Standards Update No. 2014-12, Compensation – Stock Compensation (Topic 718). The pronouncement was issued to clarify the accounting for share-based payments when the terms of an award provide that a performance target could be achieved after the requisite service period. The pronouncement is effective for reporting periods beginning after December 15, 2015. The adoption of ASU 2014-12 is not expected to have a significant impact on the Company’s consolidated financial position or results of operations.

Other recent accounting pronouncements issued by the FASB, including its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the Securities and Exchange Commission did not or are not believed by management to have a material impact on the Company’s present or future consolidated financial statements.

LION BIOTECHNOLOGIES, INC.

NOTES TO CONDENSED FINANCIAL STATEMENTS

For the Nine Months Ended September 30, 2015 and 2014 (Unaudited)

(Amounts in thousands, except share information)

Reclassifications

In presenting the Company’s statement of operations for the three and nine month periods ended September 30, 2014, the Company has reclassified $0.8 million and $0.3 million, respectively, of stock-based compensation that was previously reflected as operating expenses to research and development expenses. The reclassification relates to stock-based compensation attributable to individuals working in the Company’s research and development activities, and had no impact on total costs and expenses, or on net loss.

NOTE 3. CASH, MONEY MARKET FUNDS, AND SHORT-TERM INVESTMENTS

Cash, money market funds, and short-term investments consist of the following (in thousands):

	September 30, 2015		December 31, 2014

Checking and savings accounts (reported as cash and cash equivalents)	$	10,210	$	45
Money market funds		20,562		-
Corporate debt securities (reported as short-term investments)		79,374		-
	$	110,146	$	45

Money market funds and short-term investments include the following securities with gross unrealized gains and losses (in thousands):

			Gross		Gross
			Unrealized		Unrealized
September 30, 2015	Cost		Gains		Gains		Fair Value
Money market funds	$	20,562	$	-	$	-	$	20,562
Corporate debt securities		79,336		38		-		79,374

Total	$	99,897	$	38	$	-	$	99,936

As of September 30, 2015, the contractual maturities of our money market funds and short-term investments were (in thousands):

	Within One
	Year
Money market funds	$	20,562
Corporate debt securities		79,374
	$	99,936

At September 30, 2015,the Company’s short-term investments were invested in short-term fixed income debt securities and notes of domestic and foreign high credit issuers and in money market funds. The Company’s investment policy limits investments to certain types of instruments such as certificates of deposit, money market instruments, obligations issued by the U.S. government and U.S. government agencies as well as corporate debt securities, and places restrictions on maturities and concentration by type and issuer. At September 30, 2015, the Company’s short-term investments totaled $80 million, of which 56% were invested in notes of five companies, 25% were invested in notes of other domestic issuers, and 19% were invested in notes of foreign issuers. The average maturity of these notes was 66 days. At September 30, 2015 the Company’s money-market funds totaled $20.6 million and were invested in a single fund, the Dreyfus Cash Management Money Market Fund, a no-load money market fund.

LION BIOTECHNOLOGIES, INC.

NOTES TO CONDENSED FINANCIAL STATEMENTS

For the Nine Months Ended September 30, 2015 and 2014 (Unaudited)

(Amounts in thousands, except share information)

NOTE 4. PROPERTY AND EQUIPMENT

Property and equipment are comprised of the following as of (in thousands):

	September 30, 2015			December 31, 2014
Laboratory equipment	$	1,563		$	688
Leasehold improvements		853			762
Computer, software, and office equipment		211			185
		2,627			1,635
Accumulated depreciation		(794	)		(103	)
	$	1,833		$	1,532

Depreciation expense for the three and nine months ended September 30, 2015 and 2014 was $266, $691, $5, and $23, respectively.

NOTE 5. STOCKHOLDERS’ EQUITY

Public offering

On March 3, 2015, the Company completed an underwritten public offering of 9,200,000 shares of its common stock at a price of $8.00 per share of common stock. The net proceeds to the Company from the offering were $68.3 million, after deducting underwriting discounts and commissions and offering expenses. The offering was made pursuant to the Company’s existing shelf registration statement on Form S-3, including a base prospectus, which was filed with the SEC on November 20, 2014 and declared effective on December 10, 2014, a preliminary prospectus supplement thereunder, and a registration statement on Form S-3 filed with the SEC on February 26, 2015.

Issuance of common stock upon conversion of preferred stock

During the nine months ended September 30, 2015, the Company issued 1,000,000 shares of common stock upon the conversion of 2,000 shares of Series A Convertible Preferred Stock. The number of conversion shares issued was determined on a formula basis of 500 common shares for each Series A Convertible Preferred Stock held consistent with the contract.

Common stock with vesting terms

During 2014, the Company granted 797,500 shares of its restricted common stock to nine of its employees in accordance with the terms of their employment agreements. The 797,500 shares vest over a period of three years. As these shares were granted to employees, the Company calculated the aggregate fair value of the 797,500 shares based on the trading prices of the Company’s stock at their grant dates and determined it to be $5.3 million, of which $1.3 million was expensed in 2014. The allocable portion of the fair value of the stock that vested during the nine months ended September 30, 2015 amounted to $1.5 million and was recognized as expense in the accompanying statements of operations. As of September 30, 2015, the amount of unvested compensation related to the unvested outstanding shares of restricted common stock was $2.5 million, which will be recorded as expense in future periods as the shares vest.

LION BIOTECHNOLOGIES, INC.

NOTES TO CONDENSED FINANCIAL STATEMENTS

For the Nine Months Ended September 30, 2015 and 2014 (Unaudited)

(Amounts in thousands, except share information)

When calculating basic net income (loss) per share, these shares are included in basic weighted average common shares outstanding from the time they vest. When calculating diluted net income (loss) per share, these shares are included in diluted weighted average common shares outstanding from the time they are granted, unless they are antidilutive. Shares of restricted stock granted above are subject to forfeiture to the Company or other restrictions that will lapse in accordance with a vesting schedule determined by our Board.

The following table summarizes restricted common stock activity:

	Number of Shares			Weighted Average Grant Date Fair Value
Non-vested shares, January 1, 2015		757,500		$	6.84
Granted
Vested		(233,499	)		4.37
Forfeited		(30,000	)		8.24
Non-vested shares, September 30, 2015		494,001		$	6.56

NOTE 6. STOCK OPTIONS AND WARRANTS

Stock Options

A summary of the status of stock options at September 30, 2015, and the changes during the nine months then ended, is presented in the following table:

						Weighted
				Weighted		Average		Aggregate
	Shares			Average		Remaining		Intrinsic
	Under			Exercise		Contractual		Value
	Option			Price		Life		(in thousands)
Outstanding at January 1, 2015		1,857,877		$	7.31		8.2	$	2,875
Granted		943,750			9.18		9.8
Exercised		(10,000	)
Expired/Forfeited		(87,432	)		5.92		7.29		-
Outstanding at September 30, 2015		2,704,195		$	8.05		8.16	$	64
Exercisable at September 30, 2015		883,449		$	8.63		6.67	$	98

During the nine months ended September 30, 2015, the Company granted options to purchase 943,750 shares of common stock to new employees and directors of the Company. The stock options generally vest between one and three years. The fair value of these options was determined to be $8.3 million using the Black-Scholes option pricing model based on the following assumptions: (i) volatility rate of 211%, (ii) discount rate of 1.57%, (iii) zero expected dividend yield, and (iv) expected life of 6 years.

LION BIOTECHNOLOGIES, INC.

NOTES TO CONDENSED FINANCIAL STATEMENTS

For the Nine Months Ended September 30, 2015 and 2014 (Unaudited)

(Amounts in thousands, except share information)

During the nine months ended September 30, 2015 and 2014, the Company recorded compensation costs of $4.1 million and $1.9 million, respectively, relating to the vesting of stock options. As of September 30, 2015, the aggregate value of unvested options was $10.3 million, which will continue to be amortized as compensation cost as the options vest over terms ranging from nine months to three years, as applicable.

On September 19, 2014, The Company’s Board of Directors adopted the Lion Biotechnologies, Inc. 2014 Equity Incentive Plan (the “2014 Plan”). The 2014 Plan was approved by our stockholders at the annual meeting of stockholders held in November 2014. The 2014 Plan as approved by the stockholders authorized the issuance up to an aggregate of 2,350,000 shares of common stock. On April 10, 2015 the Board amended the 2014 Plan, subject to stockholder approval, to increase the total number of shares that can be issued under the 2014 Plan by 1,650,000 from 2,350,000 shares to 4,000,000 shares. The increase in shares available for issuance under the 2014 Plan was approved by stockholders on June 12, 2015.

Warrants

A summary of the status of stock warrants at September 30, 2015, and the changes during the nine months then ended, is presented in the following table:

						Weighted
				Weighted		Average		Aggregate
	Shares			Average		Remaining		Intrinsic
	Under			Exercise		Contractual		Value
	Warrants			Price		Life		(in thousands)
Outstanding at December 31, 2014		11,084,426		$	2.51		3.85 years	$	59,518
Issued		-
Exercised		(3,847,210	)	$	2.50
Expired		-
Outstanding and exercisable at September 30, 2015		7,237,216		$	2.51		3.3 years	$	23,593

During the nine months ended September 30, 2015, the Company received $9.6 million in cash from the exercise of 3,847,210 warrants for the purchase of an equal number of shares of its common stock.

NOTE 7. LICENSE AND COMMITMENTS

National Institutes of Health and the National Cancer Institute

Cooperative Research and Development Agreement

Effective August 5, 2011, the Company signed a Cooperative Research and Development Agreement (CRADA) with the National Institutes of Health and the National Cancer Institute (NCI). Under the terms of the five-year cooperative research and development agreement, the Company will work with Dr. Steven A. Rosenberg, M.D., Ph.D., chief of NCI’s Surgery Branch, to develop adoptive cell immunotherapies that are designed to destroy metastatic melanoma cells using a patient’s tumor infiltrating lymphocytes.

LION BIOTECHNOLOGIES, INC.

NOTES TO CONDENSED FINANCIAL STATEMENTS

For the Nine Months Ended September 30, 2015 and 2014 (Unaudited)

(Amounts in thousands, except share information)

On January 22, 2015, the Company executed an amendment (the “Amendment”) to the CRADA to include four new indications. As amended, in addition to metastatic melanoma, the CRADA now also includes the development of TIL therapy for the treatment of patients with bladder, lung, triple-negative breast, and HPV-associated cancers. Under the Amendment, the NCI also has agreed to provide the Company with samples of all tumors covered by the Amendment for performing studies related to improving TIL selection and/or TIL scale-out production and process development. Although the CRADA has a five year term, either party to the CRADA has the right to terminate the CRADA upon 60 days’ notice to the other party.

National Institutes of Health

Development and Manufacture TIL

Effective October 5, 2011, the Company entered into a Patent License Agreement with the National Institutes of Health, an agency of the United States Public Health Service within the Department of Health and Human Services (“NIH”), which License Agreement was subsequently amended on February 9, 2015 and October 2, 2015. Pursuant to the License Agreement as amended, NIH granted to the Company an exclusive worldwide right and license to develop and manufacture certain proprietary autologous tumor infiltrating lymphocyte adoptive cell therapy products for the treatment of metastatic melanoma, ovarian cancer, breast cancer, and colorectal cancer. The License Agreement requires the Company to pay royalties based on a percentage of net sales (which percentage is in the mid-single digits and subject to certain annual minimum royalty payments), a percentage of revenues from sublicensing arrangements, and lump sum benchmark royalty payments on the achievement of certain clinical and regulatory milestones for each of the various indications and other direct costs incurred by NIH pursuant to the agreement.

NIH - Exclusive Patent License Agreement

On February 10, 2015, the Company entered into an exclusive Patent License Agreement with the NIH under which the Company received an exclusive, world-wide license to the NIH’s rights in and to two patent-pending technologies related to methods for improving tumor-infiltrating lymphocytes for adoptive cell therapy. The licensed technologies relate to the more potent and efficient production of TIL from melanoma tumors by selecting for T-cell populations that express various inhibitory receptors. Unless terminated sooner, the license shall remain in effect until the last licensed patent right expires.

In consideration for the exclusive rights granted under the exclusive Patent License Agreement, the Company agreed to pay the NIH a non-refundable upfront licensing fee which was recognized as research and development expense during the nine months ended September 30, 2015. The Company also agreed to pay customary royalties based on a percentage of net sales (which percentage is in the mid-single digits), a percentage of revenues from sublicensing arrangements, and lump sum benchmark payments upon the successful completion of the Company’s first Phase 2 clinical study, the successful completion of the Company’s first Phase 3 clinical study, the receipt of the first FDA approval or foreign equivalent for a licensed product or process resulting from the licensed technologies, the first commercial sale of a licensed product or process in the United States, and the first commercial sale of a licensed product or process in any foreign country.

H. Lee Moffitt Cancer Center

Research Collaboration Agreement

In September, 2014, we entered into a research collaboration agreement with the H. Lee Moffitt Cancer Center and Research Institute, Inc. to jointly engage in transitional research and development of adoptive tumor-infiltrating lymphocyte cell therapy with improved anti-tumor properties and process.

Exclusive License Agreement

On July 21, 2014, the Company entered into an Exclusive License Agreement (the “Moffitt License Agreement”), effective as of June 28, 2014, with the H. Lee Moffitt Cancer Center and Research Institute, Inc. (“Moffitt”) under which the Company received an exclusive, world-wide license to Moffitt’s rights in and to two patent-pending technologies related to methods for improving tumor-infiltrating lymphocytes for adoptive cell therapy. Unless earlier terminated, the term of the license extends until the earlier of the expiration of the last patent related to the licensed technology or 20 years after the effective date of the license agreement.

LION BIOTECHNOLOGIES, INC.

NOTES TO CONDENSED FINANCIAL STATEMENTS

For the Nine Months Ended September 30, 2015 and 2014 (Unaudited)

(Amounts in thousands, except share information)

Pursuant to the Moffitt License Agreement, the Company paid an upfront licensing fee which was recognized as research and development expense during 2014. A patent issuance fee will also be payable under the Moffitt License Agreement, upon the issuance of the first U.S. patent covering the subject technology. In addition, the Company agreed to pay milestone license fees upon completion of specified milestones, customary royalties based on a specified percentage of net sales (which percentage is in the low single digits) and sublicensing payments, as applicable, and annual minimum royalties beginning with the first sale of products based on the licensed technologies, which minimum royalties will be credited against the percentage royalty payments otherwise payable in that year. The Company will also be responsible for all costs associated with the preparation, filing, maintenance and prosecution of the patent applications and patents covered by the Moffitt License Agreement related to the treatment of any cancers in the United States, Europe and Japan and in other countries selected that the Company and Moffitt agreed to.

During the nine months ended September 30, 2015 and 2014, the Company recognized $2.5 million and $0.9 million respectively, of expenses related to its license agreements. The amounts were recorded as part of research and development expenses in the statement of operations. Additionally, during the nine months ended September 30, 2015, there were no net sales subject to certain annual minimum royalty payments or sales that would require us to pay a percentage of revenues from sublicensing arrangements. In addition, there were no benchmarks or milestones achieved that would require payment under the lump sum benchmark royalty payments on the achievement of certain clinical regulatory milestones for each of the various indications.

Future guaranteed commitments under all of the Company’s agreements amount to (in thousands):

Year	Amount
2015	$	3,104
2016		2,874
Total	$	5,978

NOTE 8. LEGAL PROCEEDINGS

On August 18, 2015, MBA Holdings, LLC filed a breach of contract lawsuit against the Company in the Superior Court of California, County of Los Angeles (MBA Holdings, LLC v. Lion Biotechnologies, Inc., Case BC 591513). The complaint alleges that the Company and MBA Holdings, LLC were parties to (i) a June 15, 2012 “Finder’s Fee Agreement”, (ii) a Confidentiality, Non-Disclosure and Non-Circumvention Agreement, dated June 13, 2012, and (iii) a Consulting Agreement, dated July 9, 2012, and that the Company breached these agreements by failing to compensate MBA Holdings for introducing Roth Capital Partners, LLC and Highline Research Advisors LLC to the Company in connection with the $23.3 million equity funding the Company completed in November 2013. MBA Holdings also alleges that the Company failed to register certain shares underlying a common stock purchase warrant that the Company issued to MBA Holdings. MBA Holdings has asked for damages in the amount of $7,746,000. The Company has not yet been served in the foregoing lawsuit.

The Company believes that there is no merit to the claims made by MBA Holdings in the complaint. On September 9, 2015 the Company provided MBA Holdings with evidence that the Company dealt with a certain investment banker on a financing transaction at least six months before MBA Holdings purportedly introduced the Company to the banker, and that a certain research analyst group were known to the Company prior to the purported introduction. Accordingly, the Company has demanded that MBA Holdings dismiss the lawsuit. To date, MBA Holdings has not served the complaint on the Company, dismissed the lawsuit, or responded to the Company’s last communications. Accordingly, on October 26, 2015 the Company renewed its demand on MBA and its counsel to dismiss the suit or face exposure to damages for malicious prosecution, voluntarily entered an appearance in the case, and initiated discovery proceedings for the purpose of pursuing an early resolution of the case in the Company’s favor. The Company intends to vigorously defend itself in this matter and will seek a prevailing-party award of its attorney’s fees and other litigation costs pursuant to contractual provisions in the agreements appended to MBA’s complaint.

There are no other pending legal proceedings to which the Company is a party or of which its property is the subject other than as previously reported.

Item 2.

Management’s Discussion and Analysis of Financial Condition and Results of Operations.

In this section, “we,” “our,” “ours” and “us” refer to Lion Biotechnologies, Inc.

This management’s discussion and analysis of financial condition as of September 30, 2015 and results of operations for the three- and nine month periods ended September 30, 2015 and 2014, respectively, should be read in conjunction with management’s discussion and analysis of financial condition and results of operations included in our Annual Report on Form 10-K for the year ended December 31, 2014 which was filed with the SEC on March 16, 2015.

Forward-Looking Statements

The discussion below includes forward-looking statements based upon current expectations that involve risks and uncertainties, such as our plans, objectives, expectations and intentions. Actual results and the timing of events could differ materially from those anticipated in these forward-looking statements as a result of a number of factors. We use words such as “anticipate,” “estimate,” “plan,” “project,” “continuing,” “ongoing,” “expect,” “believe,” “intend,” “may,” “will,” “should,” “could,” and similar expressions to identify forward-looking statements. All forward-looking statements included in this Quarterly Report are based on information available to us on the date hereof and, except as required by law, we assume no obligation to update any such forward-looking statements. For a discussion of some of the factors that may cause actual results to differ materially from those suggested by the forward-looking statements, please read carefully the information in the “Risk Factors” section in our Form 10-K for the year ended December 31, 2014. The identification in this Quarterly Report of factors that may affect future performance and the accuracy of forward-looking statements is meant to be illustrative and by no means exhaustive. All forward-looking statements should be evaluated with the understanding of their inherent uncertainty.

Background on the Company and Recent Events Affecting our Financial Condition and Operations

We are a clinical-stage biopharmaceutical company focused on the development and commercialization of novel cancer immunotherapy products designed to harness the power of a patient’s own immune system to eradicate cancer cells. Our lead program is an adoptive cell therapy utilizing tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients’ tumors, for the treatment of metastatic melanoma. TIL therapy is being developed in collaboration with the National Cancer Institute (NCI). A patient’s immune system, particularly their TIL, plays an important role in identifying and killing cancer cells. TIL consist of a heterogeneous population of T cells that can recognize a wide variety of cancer-specific mutations and can overcome tumor escape mechanisms. TIL therapy involves growing a patient’s TIL in special culture conditions outside the patient’s body, or ex vivo, and then infusing the T cells back into the patient in combination with interleukin-2 (IL-2). By taking TIL away from the immune-suppressive tumor microenvironment in the patient, the T cells can rapidly proliferate. Billions of TIL, when infused back into the patient, are more able to search out and eradicate the tumor.

During the third quarter of 2015, we initiated a Phase 2 clinical trial of our lead product candidate, LN-144, for the treatment of refractory metastatic melanoma. The single-arm study is expected to enroll approximately 20 evaluable patients with metastatic melanoma whose disease has progressed following treatment with at least one systemic therapy. The purpose of the study is to evaluate the safety, efficacy and feasibility of autologous TIL infusion (LN-144). The trial’s primary endpoints include safety, and feasibility of LN-144 production using our central manufacturing process. Secondary outcome measures include an additional feasibility measure of number of patients successfully infused with LN-144 and best overall response rate.

In 2011, we acquired from the National Institutes of Health (NIH) a non-exclusive, worldwide right and license to certain NIH patents and patent applications to develop and manufacture autologous TIL for the treatment of metastatic melanoma, ovarian, breast, and colorectal cancers. Under a Cooperative Research and Development Agreement (CRADA) with the U.S. Department of Health and Human Services, as represented by the NCI, we support the in vitro development of improved methods for the generation and selection of TIL, the development of large-scale production of TIL, and clinical trials using these improved methods of generating TIL. On January 22, 2015, we executed an amendment to the CRADA to include four new indications. On February 9, 2015, the NIH granted us an exclusive, worldwide license to treat metastatic melanoma with TIL therapy, and on October 2, 2015, the NIH license agreement was amended to include the exclusive rights to treat breast, lung, bladder and HPV-associated cancers with TIL therapy. The amendment also removed our non-exclusive rights to treat colorectal and ovarian cancers with TIL therapy. In addition to our CRADA, we also conduct research and development on TIL technology at our research facility in Tampa, Florida.

Recent Developments

On March 3, 2015 we closed an underwritten public offering of 9,200,000 shares of our common stock, including shares sold pursuant to the exercise in full of the underwriters’ option to purchase additional shares, at a price of $8.00 per share. The net proceeds to us from that public offering were approximately $68.3 million.

In July 2015, we leased temporary office space in New York, New York, until we locate a new office in New York to serve as our headquarters. The amount of rent we have to pay for our temporary offices is not material and may vary if we change or increase the number of offices we rent. Our Woodland Hills, California, offices were closed at end of August 2015.

Results of Operations

Revenues

As a development stage company that is currently engaged in the development of novel cancer immunotherapy products, we have not yet generated any revenues from our biopharmaceutical business or otherwise since our formation. We currently do not anticipate that we will generate any revenues during 2015 from the sale or licensing of any products. Our ability to generate revenues in the future will depend on our ability to complete the development of our product candidates and to obtain regulatory approval for them.

Operating Expenses

Operating expenses include compensation-related costs for our employees engaged in general and administrative activities (other than employees engaged in research and development), legal fees, audit and tax fees, consultants and professional services, and general corporate expenses. For the three months ended September 30, 2015, our operating expenses increased by $0.2 million, or 9%, and for the nine months ended September 30, 2015, our operating expenses increased by $1.1 million, or 18%, when compared to the same periods in 2014. The increase in our operating expenses during the three- and nine-month periods ended September 30, 2015 is due to the expansion of our company and an increase in our overall business activities, including increases in employment related expenses, insurance costs and investor relations expenses. Since September 30, 2014, we have increased the number of our officers and employees by 12 persons. In addition, in the three and nine month periods ended September 30, 2015, we incurred $1.5 million, and $3.7 million, respectively, of non-cash stock-based compensation costs, compared to $0.7 million and $1.9 million, respectively, for such costs in the same periods in 2014. Share based compensation includes stock and options granted to our executive officers, our employees, our directors, and our consultants and advisors. As a result of our increased operations and the additional employees, our operating expenses in the future are expected to continue to increase.

Research and Development.

Research and development expenses consist of expenses incurred in performing research and development activities, including compensation and benefits for research and development employees and consultants, rent at our research and development facility in Tampa, Florida, cost of laboratory supplies, manufacturing expenses, and fees paid to third parties, including the NCI and our third party contractor that will process and manufacture LN-144 for our clinical trials in patients. Research and development expenses also included amounts paid (i) to the National Institutes of Health under terms of our two license agreements, and (ii) to the NCI under the CRADA. During the three- and nine-month periods ended September 30, 2015, our research and development costs increased by $4.4 million and $10.9 million respectively, when compared to the same periods in 2014. The increases are mainly attributable to the expansion of our CRADA in 2015, the general expansion of our research and development efforts, and the establishment of our Tampa, Florida, research facility in the fourth quarter of 2014. None of these expenses were incurred in the first nine months of 2014. Research and development expenses in the first three quarters of 2015 and 2014 include payments made under license agreements. In addition, in the three and nine month periods ended September 30, 2015, we incurred $0.9 million and $2.1 million, respectively, of non-cash stock-based compensation costs, compared to $0.3 million and $0.8 million, respectively, in the same periods in 2014. We anticipate that our research and development costs will continue to increase in the future as we increase our research and development activities and accelerate the development of our technologies and product candidates.

Research and development activities are central to our business model. Product candidates in later stages of clinical development generally have higher development costs than those in earlier stages of clinical development, primarily due to the increased size and duration of later-stage clinical trials. We expect our research and development expenses to increase over the next several years as we continue to conduct our clinical trial for our lead product candidate, LN-144, and as we increase our research and development efforts on other cancer indications. We also expect to incur increased research and development expenses as we selectively identify and develop additional product candidates and in other licensed cancer indications. However, it is difficult to determine with certainty the duration and completion costs of our current or future preclinical programs and clinical trials of our product candidates.

The duration, costs and timing of our clinical trials and development of our product candidates will depend on a number of factors that include, but are not limited to, the number of patients that enroll in the trial, per patient trial costs, number of sites included in the trial, discontinuation rates of patients, duration of patient follow-up, efficacy and safety profile of the product candidate, and the length of time required to enroll eligible patients. Additionally, the probability of success for our product candidate will depend on a number of factors, including competition, manufacturing capability and commercial viability.

Net Loss

We had a net loss of $7.6 million and $19.3 million, for the three and nine month periods ended September 30, 2015, respectively, compared to $2.8 million and $7.2 million, for the three and nine month periods ended September 30, 2014, respectively. The increase in our net loss during 2015 is due to an increase in operating expenses, as described above, along with the expansion of our research and development activities. We anticipate that we will continue to incur net losses in the future as we continue to invest in our research and development, and we do not expect to generate any revenues in the near term.

Liquidity and Capital Resources

On March 3, 2015, we closed an underwritten public offering. The net proceeds to us from the public offering were $68.3 million, after deducting underwriting discounts and commissions and estimated offering expenses payable by us. In addition, during the nine months ended September 30, 2015, holders of our common stock purchase warrants exercised warrants to purchase a total of 3,847,210 shares for an aggregate purchase price of $9.6 million. As a result, as of September 30, 2015, we had $110.1 million in cash and cash equivalents. Cash in excess of immediate requirements is invested in accordance with our investment policy, primarily with a view to liquidity and capital preservation.

During the remainder of 2015, we expect to further ramp up our operations and our research and development efforts, which will increase the amount of cash we will use in our operations. Our budget for the remainder of 2015 includes increased spending on research and development activities (including costs associated with a Phase 2 multi-center clinical trial to treat about 20 patients with refractory metastatic melanoma that we initiated in the third quarter of 2015), higher payroll expenses as we increase our professional staff, increased expenses for operating a new research and development facility in Tampa, Florida, as well as ongoing payments under the CRADA. Based on the funds we had available on September 30, 2015, we believe that we have sufficient capital to fund our anticipated operating expenses for at least 24 months.

As of September 30, 2015, we had no long-term debt obligations or other similar long-term liabilities other than various obligations under our CRADA and our license agreements. We have no financial guarantees, debt or lease agreements or other arrangements that could trigger a requirement for an early payment or that could change the value of our assets. We do not have any bank credit lines.

Cash Flow

Net Cash Used in Operating Activities

Net cash used in operating activities was $11.8 million for the nine months ended September 30, 2015, compared with $5.3 million for the nine months ended September 30, 2014. The increase in cash used in operating activities of approximately $5.5 million resulted from the increase in our net loss, partially offset by increases in non-cash stock compensation expense and depreciation.

Net Cash Flow from Investing Activities

Net cash used in investing activities was $100.9 million for the nine months ended September 30, 2015, compared with $0.2 million for the nine months ended September 30, 2014. The increase was primarily due to the short-term investment purchases of the cash proceeds received in our March 2015 public offering and, to a lesser extent, to purchases of laboratory equipment and furniture for our Tampa, Florida, laboratory. The Tampa facility did not exist during the 2014 period.

Net Cash Flow from Financing Activities

Net cash provided by financing activities was $78.0 million for the nine months ended September 30, 2015, compared with $3.0 million for the nine months ended September 30, 2014. The increase was due to net proceeds of $68.3 million received from the March 3, 2015 public offering of our common stock, and $9.6 million received from common stock warrant exercises. We received $3.0 million of net proceeds from common stock warrant exercises in the nine months ended September 30, 2014.

Off-Balance Sheet Arrangements

We have not entered into any off-balance sheet financing arrangements.

Critical Accounting Policies and Estimates

In our Annual Report on Form 10-K for the year ended December 31, 2014, we disclosed our critical accounting policies and estimates upon which our financial statements are derived. There have been no changes to these policies since December 31, 2014 that are not included in Note 2 of the accompanying condensed consolidated financial statements for the nine months ended September 30, 2015. Readers are encouraged to read our Annual Report on Form 10-K in conjunction with this report.

Inflation

Inflation and changing prices have had no effect on our continuing operations over our two most recent fiscal years.

Item 3.

Quantitative and Qualitative Disclosures About Market Risk

The primary objective of our investment activities is to preserve capital. We do not utilize hedging contracts or similar instruments.

We are exposed to certain market risks relating primarily to interest rate risk on our cash and cash equivalents and risks relating to the financial viability of the institutions which hold our capital and through which we have invested our funds. To minimize this risk, we maintain our portfolio of cash equivalents and short-term investments in a variety of securities, including corporate bonds, commercial paper, money market funds and other government and non-government debt securities with maturities of less than one year. Due to the short-term maturities of our cash equivalents, a change in interest rates would not have a material effect on the fair market value of our cash equivalents.

Item 4.

Controls and Procedures

Evaluation of Disclosure Controls and Procedures

As of the end of the period covered by this quarterly report on Form 10-Q, our principal executive officer and our principal accounting officer (the “Certifying Officers”), evaluated the effectiveness of our disclosure controls and procedures. Disclosure controls and procedures are controls and procedures designed to reasonably assure that information required to be disclosed in our reports filed under the Securities Exchange Act of 1934 (the “Exchange Act”), such as this quarterly report on Form 10-Q, is recorded, processed, summarized and reported within the time periods specified in the SEC rules and forms. Disclosure controls and procedures are also designed to reasonably assure that such information is accumulated and communicated to our management, including the Certifying Officers, as appropriate to allow timely decisions regarding required disclosure. Based on these evaluations, the Certifying Officers have concluded, that, as of the end of the period covered by this quarterly report on Form 10-Q, our disclosure controls and procedures were not effective.

Changes in Controls over Financial Reporting

There has been no change in the Company’s internal control over financial reporting during the quarter ended September 30, 2015 that has materially affected, or is reasonably likely to materially affect, the Company’s internal control over financial reporting.

PART II. OTHER INFORMATION

Item 1.

Legal Proceedings

Item 1A.

Risk Factors

Information regarding risk factors appears under “Risk Factors” included in Item 1A, Part I, and under Item 7, Management’s Discussion and Analysis of Financial Condition and Results of Operations, of our Annual Report on Form 10-K for the year ended December 31, 2014. There have been no material changes from the risk factors previously disclosed in the above-mentioned periodic report.

Item 2.

Unregistered Sales of Securities and Use of Proceeds.

During the nine months ended September 30, 2015, 60 accredited investors who held warrants that we sold to them in the November 2013 in a private placement, exercised warrants to purchase 3,847,210 shares of common stock at an exercise price of $2.50 per share (for a total amount of $9.6 million). These shares were issued pursuant to an exemption available under Section 4(a)(2) of the Securities Act of 1933, as amended. No commissions were paid with respect to these warrants exercises.

Item 3.

Defaults Upon Senior Securities.

Nothing to report.

Item 4.

Mine Safety Disclosures

Nothing to report.

Item 5.

Other Information.

Nothing to report

Item 6.

Exhibits

Exhibit Number	Description of Exhibit

10.47	First Amendment to Patent License Agreement-Exclusive, effective October 2, 2015, between the Company and the National Institutes of Health*
31.1	Certification of Principal Executive Officer pursuant to Rule 13a-14 and Rule 15d-14(a), promulgated under the Securities and Exchange Act of 1934, as amended.
31.2	Certification of Principal Financial Officer pursuant to Rule 13a-14 and Rule 15d 14(a), promulgated under the Securities and Exchange Act of 1934, as amended.
32.1	Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (Chief Executive Officer).
32.2	Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (Chief Financial Officer).
101.INS	XBRL Instance Document
101.SCH	XBRL Taxonomy Extension Schema
101.CAL	XBRL Taxonomy Extension Calculation Linkbase
101.DEF	XBRL Taxonomy Extension Definition Linkbase
101.LAB	XBRL Taxonomy Extension Label Linkbase
101.PRE	XBRL Extension Presentation Linkbase

* Certain portions of the Exhibit have been omitted based upon a request for confidential treatment filed by us with the Commission. The omitted portions of the Exhibit have been separately filed by us with the Commission.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	Lion Biotechnologies, Inc.

November 6, 2015	By:	/s/ Elma Hawkins
		Elma Hawkins
		Chief Executive Officer (Principal Executive Officer)

November 6, 2015	By:	/s/ Molly Henderson
		Molly Henderson
		Chief Financial Officer (Principal Financial and Accounting Officer)

EX-10.47 2 v423195_ex10-47.htm EXHIBIT 10.47

Exhibit 10.47

NATIONAL INSTITUTES OF HEALTH

FIRST AMENDMENT TO L-107-2015/0

This is the first amendment (“First Amendment”) of the agreement by and between the National Institutes of Health (“NIH”) within the Department of Health and Human Services (“HHS”), and Lion Biotechnologies, Inc. having an effective date of February 9, 2015 and having NIH Reference Number L-107-2015/0 (“Agreement”). This First Amendment, having NIH Reference Number L-107-2015/1, is made between the NIH through the Office of Technology Transfer, NIH, having an address at 6011 Executive Boulevard, Suite 325, Rockville, Maryland 20852-3804, U.S.A., and Lion Biotechnologies, Inc., having an office at 112 West 34th Street, 17th Floor, New York, NY 10120 (the “Licensee”). This First Amendment includes, in addition to the amendments made below, 1) a Signature Page and 2) Attachment 1 (Royalty Payment Information).

WHEREAS, the NIH and the Licensee desire that the Agreement be amended a first time as set forth below in order to expand the License Field of Use and License Patent Rights under L-107-2015/0.

WHEREAS, the NIH and the Licensee desire that the Agreement terminates nonexclusive license L-129-2011, upon execution.

NOW, THEREFORE, in consideration of the mutual covenants and promises contained herein, the NIH and the

Licensee, intending to be bound, hereby mutually agree to the following:

The Cover Page’s "Serial Number(s) of Licensed Patent(s) or Patent Application(s)" section and Appendix A's Patent(s) or Patent Application(s)'s section shall be deleted and replaced with the following:

Group A

U.S. Provisional Patent Application No. 61/237,889, filed August 26, 2009 entitled “Adoptive cell therapy with young T cells” (HHS Ref No. E-273-2009/0-US-01);

II.

U.S. Patent No. 8,383,099 issued February 26, 2013 entitled “Adoptive cell therapy with young T cells” (HHS Ref No. E-273-2009/0-US-02);

III.

U.S. Patent No. 9,074,185issued July 7, 2015 entitled “Adoptive cell therapy with young T cells” (HHS Ref No. E-273-2009/0-US-03);

IV.

U.S. Provisional Patent Application No. 61/466,200 filed March 22, 2011entitled “Methods of growing tumor infiltrating lymphocytes in gas-permeable containers” (HHS Ref No. E-114- 2011/0-US-01);

PCT Application No. PCT/US2012/029744 filed March 20, 2012 entitled “Methods of growing tumor infiltrating lymphocytes in gas-permeable containers” (HHS Ref No. E-114-2011/0-PCT- 02);

VI.

U.S. Patent Application No. 13/424,646 filed May 20, 2012 entitled “Methods of growing tumor infiltrating lymphocytes in gas-permeable containers” (HHS Ref No. E-114-2011/0-US-03);

VII.

U.S. Provisional Patent Application No. 61/846,161 filed July 15, 2013 entitled "Methods of Preparing Anti-human Papillomavirus Antigen T Cells" (HHS Ref No. E-494-2013/0-US-01);

VIII.

PCT Application No. PCT/US2014/046478 filed July 14, 2014 entitled "Methods of Preparing Anti-human Papillomavirus Antigen T Cells" (HHS Ref No. E-494-2013/0-PCT-02);

A-128-2015

CONFIDENTIAL -NIH

First Amendment of L-107-2015/0 Model 09-2006 (updated 8-2012)

Final

Lion Biotechnologies, Inc. Page 1 of 12

September 30, 2015

Group B

U.S. Provisional Patent Application No. 60/408,681, filed September 6, 2002 entitled “Immunotherapy with in vitro-selected antigen-specific lymphocytes after nonmyeloablative lymphodepleting chemotherapy” (HHS Ref No. E-275-2002/0-US-01);

II.

PCT Application No. PCT/US2003/027873 filed September 5, 2003 entitled “Immunotherapy with in vitro-selected antigen-specific lymphocytes after nonmyeloablative lymphodepleting chemotherapy” (HHS Ref No. E-275-2002/1-PCT-01);

III.

U.S. Patent No. 8,034,334 issued October 11, 2011 entitled “Immunotherapy with in vitro-selected antigen-specific lymphocytes after nonmyeloablative lymphodepleting chemotherapy” (HHS Ref No. E-275-2002/1-US-02);

IV.

European Patent Application No. 03794636.5 filed April 4, 2005 entitled “Immunotherapy with in vitro-selected antigen-specific lymphocytes after nonmyeloablative lymphodepleting chemotherapy” (HHS Ref No. E-275-2002/1-EP-03);

Canadian Patent No. 2,497,552 issued May 27, 2014 entitled “Immunotherapy with in vitro- selected antigen-specific lymphocytes after nonmyeloablative lymphodepleting chemotherapy” (HHS Ref No. E-275-2002/1-CA-04);

VI.

Australian Patent No. 2003265948 issued September 3, 2009 entitled “Immunotherapy with in vitro-selected antigen-specific lymphocytes after nonmyeloablative lymphodepleting chemotherapy” (HHS Ref No. E-275-2002/1-AU-05);

VII.

U.S. Patent No. 8,287,857 issued October 16, 2012 entitled “Immunotherapy with in vitro-selected antigen-specific lymphocytes after nonmyeloablative lymphodepleting chemotherapy” (HHS Ref No. E-275-2002/1-US-06);

Appendix C, Paragraph IV shall be deleted in its entirety and replaced with the following:

IV.

The Licensee agrees to pay the NIH Benchmark royalties within sixty (60) days of achieving each Benchmark listed below by Licensee or its sublicensees for each Licensed Product or Licensed Process:

(a)

For successful completion of the first Licensee-sponsored Phase 2 clinical study in each indication of the Licensed Field of Use.

Melanoma: [* * *]

ii.

Breast cancer: [* * *]

iii.

Lung cancer: [* * *]

iv.

HPV-positive cancer: [* * *]

Bladder cancer: [* * *]

A-128-2015

CONFIDENTIAL -NIH

First Amendment of L-107-2015/0 Model 09-2006 (updated 8-2012)

Final

Lion Biotechnologies, Inc. Page 2 of 12

September 30, 2015

(b)

For successful completion of the first Licensee-sponsored Phase 3 clinical study for each indication in the Licensed Field of Use.

Melanoma: [* * *]

ii.

Breast Cancer: [* * *]

iii.

Lung cancer: [* * *]

iv.

HPV-positive cancer: [* * *]

Bladder Cancer: [* * *]

(c)

Upon the first FDA approval or foreign equivalent for a Licensed Product or Licensed Process

for each indication in the Licensed Field of Use.

Melanoma: [* * *]

ii.

Breast cancer: [* * *]

iii.

Lung cancer: [* * *]

iv.

HPV-positive cancer: [* * *]

]

Bladder cancer: [* * *]

(d)

For the First Commercial Sale of a Licensed Product or Licensed Process in the United States for each indication in the Licensed Field of Use.

Melanoma: [* * *]

ii.

Breast cancer: [* * *]

iii.

Lung cancer: [* * *]

iv.

HPV-positive cancer: [* * *]

Bladder cancer: [* * *]

(e)

For the First Commercial Sale of a Licensed Product or Licensed Process in any foreign country for each indication in the Licensed Field of Use.

Melanoma: [* * *]

ii.

Breast cancer: [* * *]

iii.

Lung cancer: [* * *]

iv.

HPV-positive cancer: [* * *]

Bladder cancer: [* * *]

A-128-2015

CONFIDENTIAL -NIH

First Amendment of L-107-2015/0 Model 09-2006 (updated 8-2012)

Final

Lion Biotechnologies, Inc. Page 3 of 12

September 30, 2015

(f)

The first time the aggregate Net Sales of all Licensed Products or Licensed Processes achieve the following thresholds, the Licensee pays the following one-time Benchmark royalties:

(1)

[* * *] when the aggregate Net Sales of all Licensed Products or Licensed Processes reaches five hundred fifty million dollars ($50,000,000.00).

(2)

[* * *] when the aggregate Net Sales of all Licensed Products or Licensed Processes reaches one billion dollars ($1,000,000,000.00).

For purposes of this Agreement, “successful completion of a Licensee-sponsored Phase 2 Clinical Study” shall mean, with respect to a specified construct, formulation and dose of a specified Licensed Product in a specified cancer indication, the statistical demonstration in a pivotal Phase 2 Clinical Study of safety and efficacy, sufficient to support a Phase 3 clinical trial submission by the Licensee for such specified construct, formulation and dose of such specified Licensed Product for the treatment of such specified cancer indication.

For purposes of this Agreement, “successful completion of a Licensee-sponsored Phase 3 Clinical Study” shall mean, with respect to a specified construct, formulation and dose of a specified Licensed Product in a specified cancer indication, the statistical demonstration in a pivotal Phase 3 Clinical Study of safety and efficacy, sufficient to support a BLA submission by the Licensee for such specified construct, formulation and dose of such specified Licensed Product for the treatment of such specified cancer indication.

For the purposes of this Agreement, there will be only one royalty payment required for each indication for each milestone. For example, there will be only one royalty payment due for each milestone above in HPV- positive cancer. Therefore, sub-indications of HPV-positive cancer will not each require separate royalty payments.

Appendix B will be deleted in its entirety and replaced with Appendix B in this agreement.

Appendix D will be deleted in its entirety and replaced with Appendix D in this agreement.

Appendix E shall be deleted in its entirety and replaced with Appendix E in this agreement.

Within sixty (60) days of the execution of this First Amendment, the Licensee shall pay the NIH an amendment issue royalty in the sum of [* * *] in two installments as follows: The first installment of [* * *] shall be payable within sixty (60) days from the effective date of this First Amendment; and the second installment of [* * *] shall be payable (i) on or before the one (1) year anniversary of the effective date of this First Amendment or (ii) on or before the termination date of this First Amendment, whichever occurs sooner. Payment options may be found in Attachment 1.

In the event any provision(s) of the Agreement is/are inconsistent with Attachment 1 and/or 2, such provision(s) is/are hereby amended to the extent required to avoid such inconsistency and to give effect to the shipping and payment information in such Attachment 1.

All terms and conditions of the Agreement not herein amended remain binding and in effect.

The terms and conditions of this First Amendment shall, at the NIH’s sole option, be considered by the NIH to be withdrawn from the Licensee’s consideration and the terms and conditions of this First Amendment, and the First Amendment itself, to be null and void, unless this First Amendment is executed by the Licensee and a fully executed original is received by the NIH within sixty (60) days from the date of the NIH’s signature found at the Signature Page.

10)

This First Amendment is effective upon execution by all parties.

SIGNATURES BEGIN ON NEXT PAGE

A-128-2015

CONFIDENTIAL -NIH

First Amendment of L-107-2015/0 Model 09-2006 (updated 8-2012)

Final

Lion Biotechnologies, Inc. Page 4 of 12

September 30, 2015

A-128-2015

CONFIDENTIAL -NIH

First Amendment of L-107-2015/0 Model 09-2006 (updated 8-2012)

Final

Lion Biotechnologies, Inc. Page 5 of 12

September 30, 2015

II. Official and Mailing Address for Financial notices (the Licensee’s contact person for royalty payments):

Peter Ho, Ph.D.

Director, Business Development 112 West 34th Street, 17th Floor

New York, NY 10120Phone: 212-946-4856

Email: peter.ho@lionbio.com

Any false or misleading statements made, presented, or submitted to the Government, including any relevant omissions, under this Agreement and during the course of negotiation of this Agreement are subject to all applicable civil and criminal statutes including Federal statutes 31 U.S.C. §§3801-3812 (civil liability) and 18 U.S.C. §1001 (criminal liability including fine(s) or imprisonment).

A-128-2015

CONFIDENTIAL -NIH

First Amendment of L-107-2015/0 Model 09-2006 (updated 8-2012)

Final

Lion Biotechnologies, Inc. Page6 of 12

September 30, 2015

APPENDIX B – LICENSED FIELDS OF USE AND TERRITORY

VIII.

Licensed Fields of Use:

The use of the Licensed Patent Rights to develop, manufacture, distribute, sell, and use unselected whole autologous tumor infiltrating lymphocyte (TIL) adoptive cell therapy products for the treatment of metastatic melanoma, lung, breast, bladder, and HPV-positive cancers. Specifically excluded from this Agreement are methods of generating or using selected subpopulations of TIL and the use of T cell receptors isolated from TIL.

Tumor infiltrating lymphocytes (TIL) are a subset of T lymphocytes (T cells) that migrate and are located within a tumor site. TIL isolated from these tumor sites exhibit natural anti-tumor activity without genetic modifications. For the avoidance of doubt, cell therapy products involving genetically modified TIL or TIL selected for reactivity against cancer-specific mutations are excluded from the Licensed Fields of Use, unless such cell therapy products are a combination of unselected, unmodified TIL therapy with the Licensee’s proprietary technologies or the Licensee’s in-licensed technologies.

IX.

Licensed Territory: Worldwide

A-128-2015

CONFIDENTIAL -NIH

First Amendment of L-107-2015/0 Model 09-2006 (updated 8-2012)

Final

Lion Biotechnologies, Inc. Page 7 of 12

September 30, 2015

APPENDIX D – BENCHMARKS AND PERFORMANCE

	Benchmark	Deadline

I.	*[ * ]*	*[ * ]*

II.	*[ * ]*	*[ * ]*
III.	*[ * ]*	*[ * ]*
IV	*[ * ]*	*[ * ]*


V.	*[ * ]*	*[ * ]*
VI.	*[ * ]*	*[ * ]*

VII.	*[ * ]*	*[ * ]*
VIII.	*[ * ]*	*[ * ]*
IX.	*[ * ]*	*[ * ]*
X.	*[ * ]*	*[ * ]*
XI.	*[ * ]*	*[ * ]*
XII.	*[ * ]*	*[ * ]*
XIII.	*[ * ]*	*[ * ]*

A-128-2015

CONFIDENTIAL -NIH

First Amendment of L-107-2015/0 Model 09-2006 (updated 8-2012)

Final

Lion Biotechnologies, Inc. Page 8 of 12

September 30, 2015

APPENDIX E – COMMERCIAL DEVELOPMENT PLAN

Licensee intends to use the licensed technology to develop and commercialize a product based on T cells derived from tumors or tumor-infiltrating lymphocytes (TIL) to treat patients with melanoma, HPV-associated cancers, bladder cancer, breast cancer, lung cancer, and other solid tumors.

In August 2011, Licensee entered into a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI) to develop and evaluate improved adoptive cell transfer (ACT) based immunotherapies using TIL to treat patients with metastatic melanoma utilizing the business development expertise and resources of Licensee (C-057-2011, NCI 02734). The CRADA includes the development of improved methods for the generation and selection of TIL, standard operating procedures (SOPs) for large-scale TIL growth, selection and testing to support the FDA approval of an ACT/TIL therapy approach. It further includes clinical trials designed and implemented to evaluate the clinical effectiveness of ACT/TIL therapy resulting from large-scale techniques in patients with metastatic melanoma based on the proprietary NCI Surgery Branch technology and approaches developed as part of the CRADA.

In January 2015, Licensee amended its CRADA with the NCI, increasing Licensee’s funding of ACT/TIL therapy research from $1 million to $2 million per year. This amendment to the original CRADA dated August 2011 expanded the scope of the research to include HPV-positive, lung, breast and bladder cancers. Specifically this CRADA will (1) support the in vitro development of improved methods for the large scale generation and selection of TIL with anti-tumor reactivity from patients with metastatic melanoma, bladder, lung, triple-negative breast, and HPV-positive cancers, based on ACT/TIL therapies developed by and proprietary to the NCI Surgery Branch, to be used for large scale production of TIL for the ACT treatment of patients with these cancers; (2) develop these approaches for large scale TIL generation that are in accord with Good Manufacturing Practice (GMP) procedures suitable for use in treating patients with metastatic melanoma, bladder, lung, triple-negative breast, and HPV- positive cancers; and (3) develop clinical trials using these improved methods of large scale TIL generation as well as improved patient preparative regimens with the goal of commercializing the ACT/TIL therapy approach for treating patients with metastatic melanoma, bladder, lung, triple-negative breast, and HPV-positive cancers.

Under the expanded CRADA, Licensee agrees to:

(a)

Develop, implement and evaluate GMP procedures for the large scale production of TIL suitable for infusion into patients with metastatic melanoma, bladder, lung, triple-negative breast, and HPV- positive cancers.

(b)

Conduct studies including scale-out for the methods of expansion of individualized lymphocyte treatments, assays for product and in-process performance, and harmonization assays for centralized process development and determination of TIL product consistency. Additional studies may be conducted for the development of qualifying assays and process development related to scale-out of the TIL expansion process.

(c)

Consult with the FDA to determine the appropriate clinical trial design necessary to secure approval for the commercial development of TIL therapy for patients with metastatic melanoma, bladder, lung, triple-negative breast, and HPV-positive cancers and sponsor the IND for these new clinical protocols and serve as the coordinating center for the multicenter licensing clinical trials.

(d)

Supply TIL in sufficient quantities to the NCI Surgery Branch and other multicenter sites to complete the planned clinical trials (including the licensing trial) needed for FDA approval of TIL. Support the establishment of a central facility for the processing and provision of TIL for the planned studies.

A-128-2015

CONFIDENTIAL -NIH

First Amendment of L-107-2015/0 Model 09-2006 (updated 8-2012)

Final

Lion Biotechnologies, Inc. Page 9 of 12

September 30, 2015

Furthermore, under the expanded CRADA, Licensee, NCI and the Surgery Branch agree to:

(e)

Develop SOPs for large scale TIL growth, selection and testing to support the FDA approval of the ACT/TIL therapy approach. Attend joint meetings with the FDA to define the exact format and criteria needed in the clinical trial(s) to obtain FDA approval.

(f)

Develop, conduct and evaluate multi-institutional clinical trials (to include the NCI Surgery Branch as a clinical trial site) for patients with metastatic melanoma, bladder, lung, triple-negative breast and HPV-positive cancers treated with TIL that can be used as licensing trials required for FDA approval and subsequent commercialization of TIL.

(g)

Conduct assays to be used in the selection of appropriate cells (based on both functional and phenotypic criteria) to optimize the effectiveness of the adoptive transfer.

(h)

Exchange information and expertise to further the successful development of TIL therapy for patients with metastatic melanoma, bladder, lung, triple-negative breast and HPV-positive cancers.

The overall strategy for commercial development and program prioritization for an ACT/TIL product for the treatment of metastatic melanoma, HPV-positive, breast, lung and bladder cancers will be informed by the results of the research under the amended CRADA is summarized below.

Clinical Development

[* * *]

A-128-2015

CONFIDENTIAL -NIH

First Amendment of L-107-2015/0 Model 09-2006 (updated 8-2012)

Final

Lion Biotechnologies, Inc. Page1 0 of 12

September 30, 2015

ATTACHMENT 1 – ROYALTY PAYMENT OPTIONS

The OTT License Number MUST appear on payments, reports and correspondence.

Automated Clearing House (ACH) for payments through U.S. banks only

The NIH encourages its licensees to submit electronic funds transfer payments through the Automated Clearing House (ACH). Submit your ACH payment through the U.S. Treasury web site located at: https://www.pay.gov/public/form/start/28680443. Locate the "NIH Royalty Payment Page" through the HHS link in the Pay.gov "Agency List".

Electronic Funds Wire Transfers

The following account information is provided for wire payments. In order to process payment via Electronic Funds Wire Transfer sender MUST supply the following information within the transmission:

Drawn on a U.S. bank account via FEDWIRE should be sent directly to the following account:

Beneficiary Account:	Federal Reserve Bank of New York or TREAS NYC
Bank:	Federal Reserve Bank of New York
ABA#	021030004
Account Number:	75080031
Bank Address:	33 Liberty Street, New York, NY 10045
Payment Details:	License Number (L-XXX-XXXX)
	Name of the Licensee

Drawn on a foreign bank account should be sent directly to the following account. Payment must be sent in U.S. Dollars (USD) using the following instructions:

Beneficiary Account:	Federal Reserve Bank of New York/ITS or FRBNY/ITS
Bank:	Citibank N.A. (New York)
SWIFT Code:	CITIUS33
Account Number:	36838868
Bank Address:	388 Greenwich Street, New York, NY 10013
Payment Details (Line 70):	NIH 75080031
	License Number (L-XXX-XXXX)
	Name of the Licensee

Detail of Charges (line 71a):	Charge Our

A-128-2015

CONFIDENTIAL -NIH

First Amendment of L-107-2015/0 Model 09-2006 (updated 8-2012)

Final

Lion Biotechnologies, Inc. Page 11 of 12

September 30, 2015

Checks

All checks should be made payable to “NIH Patent Licensing”

Checks drawn on a U.S. bank account and sent by US Postal Service should be sent directly to the following address:

National Institutes of Health (NIH)

P.O. Box 979071

St. Louis, MO 63197-9000

Checks drawn on a U.S. bank account and sent by overnight or courier should be sent to the following address:

US Bank

Government Lockbox SL-MO-C2GL 1005 Convention Plaza

St. Louis, MO 63101 Phone: 314-418-4087

Checks drawn on a foreign bank account should be sent directly to the following address:

National Institutes of Health (NIH) Office of Technology Transfer Royalties Administration Unit 6011 Executive Boulevard

Suite 325, MSC 7660

Rockville, Maryland 20852

A-128-2015

CONFIDENTIAL -NIH

First Amendment of L-107-2015/0 Model 09-2006 (updated 8-2012)

Final

Lion Biotechnologies, Inc. Page 12 of 12

September 30, 2015

EX-31.1 3 v423195_ex31-1.htm EXHIBIT 31.1

Exhibit 31.1

CERTIFICATION

I, Elma Hawkins, Chief Executive Officer of Lion Biotechnologies, Inc., certify that:

1.	I have reviewed this Quarterly Report on Form 10-Q of Lion Biotechnologies, Inc.;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.	I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under my supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under my supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report my conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.	I have disclosed, based on my most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Dated: November 6, 2015	By:	/s/ Elma Hawkins
		Elma Hawkins
		Chief Executive Officer

EX-31.2 4 v423195_ex31-2.htm EXHIBIT 31.2

Exhibit 31.2

CERTIFICATION

I, Molly Henderson, Chief Financial Officer of Lion Biotechnologies, Inc., certify that:

1.	I have reviewed this Quarterly Report on Form 10-Q of Lion Biotechnologies, Inc.;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.	I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

5.	I have disclosed, based on my most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Dated: November 6, 2015	By:	/s/ Molly Henderson
		Molly Henderson
		Chief Financial Officer

EX-32.1 5 v423195_ex32-1.htm EXHIBIT 32.1

Exhibit 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q of Lion Biotechnologies, Inc. (the “Company”) for the quarter ended September 30, 2015, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), Elma Hawkins, Chief Executive Officer of the Company, hereby certifies, pursuant to 18 U.S.C. §1350, as adopted pursuant to §906 of the Sarbanes-Oxley Act of 2002, that:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated: November 6, 2015	By:	/s/ Elma Hawkins
		Elma Hawkins
		Chief Executive Officer

This certification accompanies each Report pursuant to § 906 of the Sarbanes-Oxley Act of 2002 and shall not, except to the extent required by the Sarbanes-Oxley Act of 2002, be deemed filed by the Company for purposes of §18 of the Securities Exchange Act of 1934, as amended.

A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.

EX-32.2 6 v423195_ex32-2.htm EXHIBIT 32.2

Exhibit 32.2

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q of Lion Biotechnologies, Inc. (the “Company”) for the quarter ended September 30, 2015, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), Molly Henderson, Chief Financial Officer of the Company, hereby certifies, pursuant to 18 U.S.C. §1350, as adopted pursuant to §906 of the Sarbanes-Oxley Act of 2002, that:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated: November 6, 2015	By:	/s/ Molly Henderson
		Molly Henderson
		Chief Financial Officer

GRAPHIC 7 image_001.jpg GRAPHIC begin 644 image_001.jpg M_]C_X 02D9)1@ ! 0$ 8 !@ #_VP!# @&!@<&!0@'!P<)"0@*#!0-# L+ M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBI MJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W M^/GZ_]H " $! _ /?Z**************************************** M************************************************************ M*********************************************#R,444444444444 M444444444444444444444444444444444444444444444444444444444444 M444444444444444444444444444444444444444444444444444444444444 M444444444444444444444444444444444444444444444444444444444444 M444444444444444444444444444444444444444444444444444444444444 M444444444444444444444444444444444444444444444444444444444444 M444444444444444444444444444 YHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHZT44444444444 M444444444444444444444444444444444444444444444444444444444444 M444444444444444444444444444444444444444444444444444444444444 M444444444444444444444444444444444444444444444444444444444444 M444444444444444444444444444444444444444444444444444444444444 M444444444444444444444444444444444444444444444444444444444444 M444444444444444444444444444444444444444444444444444444444444 M444444444444444444444444444444444444444444444444444444444444 M444444444444444444444444444444444444444444444444444444444444 M444444444444444444444444444444444444444444444444444444444444 M444444444444444444444444444444444444444444444444444444444444 M444444444444444444444444444444444444444444444444444444444444 M444444444444444444444444444444444444444444444444444444444444 M444444444444444444444444444444444444444444444444444444444444 M444444444444444444444444444444444444444444444444444444444444 M4444444444444444444444444444444444444444444444445D:UXHT7PZ]N MFK7RVS7+;80R,WF'C@8!R>1Q5(>/O"YDMH_[6027,QMX4,3AFE&W*8VYW?,O M'N*:OQ"\)F]:S.M0),DWV=Q(K($DR1L8D Y!X)[5=N_%FA6.H/8W.HQQW", MJ."K%49L;59@-H8Y&%)R0"IR1Q MP:Z83Q&V%P)%\DIO#YXVXSG/IBLZ]\2Z-IVA1ZW=7\2:9(J,MT,LA#?=.0#P MYXJ[%XJT.?4K[38]1B:^L4,EQ;X.]%').,9(Y'3/4>M4 MKGX@>%;,VXN-7CC-S +F$-&_SQ')#CY?NX!.?:K-SXR\.VCZV-\2;%+,%.W#$ $X'/%3V?C'P]J&FIJ-GJD,]H]PML)(P3^]; M "D8R"1QP:MWWC?PWIUTUM=:M"DB(CRD*S+$K?=+L 0@/;< M16EJ6LZ?I&EOJ=]=)%8H S3X+* >AXSQR.:FL;VWU*Q@O;23S;>=!)$^"-RG MH>>QJ"76],AUB#2)+^!=1G4M':[QYC #)..H& >:I)XQ\/27%_ NK6_F6"/) M<@D@(J??.<8;:>#C.#P:70?%^@>)WG31=3AO6@ ,HC!^4'.,Y'L?RI;?Q;H% MUXAET"#5K:358@2]LK?,,=1Z$CN,Y%)9^,/#NH1W M*M(O+77OAS;OY]]-9WGFW][% [AB/+7S'8 X)VXY/;T%<5J>E:W=R>*[@:?> MW6COXB%Q>Z:EJRR7-N'.'CH'J#TKI]6CO9=>N=;\*-J45U?7<8GT6\L MG:VU!,JOF@LN$PO))P05/(XST&JVQ'QXT%TLY?L46E20NZP-Y2LQ?"D@;><_ MK71>-6GGTVW\.Z=#F74R86Y:.-(%&9 756V;E^0\1^&;[7+W5O$^@I)9>)],GB>!=C 31?9XP\.2 KC=O ([@@]>(2 MTFE^/_"-]<6%_):V7AM8)_*LY),2%#B,X4_,<@8_.L./P%J4OP^M="U"VFCU M-+>^U"RB5"WV:3?"T<18<*S!9.,_Q'O6OI5EJ=M\3],U35;>=[N?0I)=1N([ M9RBW#@D1Y (RJ!5Q[>]-^$DT^AZ5IMGJ,>HS7#%E2QFL9$6PP\K/+O*8Y0^I M8DX'%)I?A#4=*N_"^N:'YPLM3EM%URRV,"LB.&$NT\K\PY],GL371O9EOC]& MWV.1=/30?L@8P-Y);>3Y8.-OW3TI=4MMOQTT$QV;K80Z5+ SK;MY2LQ?"%@- MO3'%85G:W/AK2/'^B:GI]Y/?ZM5;-(+M)$VH%8 @;<\@GYGQFX MEU.">&W@V*BE2VW)[U&_;]S?K)"$MH@8X^$7.3@OR/XZYZ]NAKOQ*AM8= U*UEL M+>YM;*[CLC' ;B5&$LS.L:8+J=8Q$&,TB_*"2!A6 ZDUEK\(O JKM70453V%S,!_Z'1_PJ M+P+_ - %/_ F;_XN@?"+P(N=N@(N>N+B89_\?H_X5%X%SG^P5!]1!,Y_L"//K]HES_ .ATA^$/@0]?#\9_[>)?_BZ/^%0^ ^_A^,_6XE_^ M+IQ^$G@8C!T%2/0W,W_Q=-/PA\"$ 'P_&0!@ W$O'_C]*/A'X%"[1H*!?[OV MF;'Y;Z0?"'P&$*#P_&%/51<2X/X;Z5?A%X$0830$7/\ =N)1_P"STO\ PJ/P M+DG^P4R>I^TS<_\ C]-'P@\!AMP\/1!O43RY_P#0Z4_"+P(>N@1GW^T2_P#Q M=!^$7@1AAM C(][B4_\ L]!^$7@1AAM 0CT-Q,?_ &>C_A47@3&/[ 3'I]HF M_P#BZ7_A4?@;;M_L)=OI]IFQ_P"ATB_"/P*J[5T%0I["YF _]#H'PB\"*,+H M$8'H+B4?^STO_"I/ W_0"7_P)F_^+H_X5)X&/70EX_Z>9O\ XN@_"7P,<9T) M3CI_I,W'_C]!^$O@8YSH2G/7-S-_\71_PJ3P-_T EX_Z>9O_ (NMK0/".A>% MS<'1K 6IN-OFGS7?=MSC[Q/J:VZ********************************* M*******************************************#P/6@E:PT=]I%U-:V MRRVLPB*EW#$.DD>_C^'# CKR*H^$O']]XCU73],N8H++4H#/%J]BR'>DB ;6 M3YN$;)YP>F,]SH:/XY?5_&VN^'5MUB-M LVG22 @7*C*2-GNHD& 1U /I639 M>(_& MF3:2@(?[P#=0#[BM'5O'NN6OCJWT)[BRTR.[TV&ZB6>T::19Y'$8A.'4'YB< MGCH:Z7QGKNL>&_AS<:U&+0:I:0Q/*A0O$SDJK@<@XR3@Y[5F>"_'5_J_]L2: MHEO)IMA!'.FIVL3QQR;DW.F&)RRGC@]NV:@T_P"*J/\ #K5_$>HV#0W^E3O; MW%ARK+)OQ&ISR,AE!/J&]*UM+O\ Q0T>D7%]?Z,_V[9) M0V!R.><>E-JRG4M<$:S3I9JJ1!/[J9/7OENO-:U_X,MKCQ(_B.SN#9:P]A M)9-<)&&!W8VN5/5EQQ[<'H*QD^%ME9>(-#UG2KPV%UID?ERF.'<+H$8;=EN, MC=T[L36O9^$&M?B%?>+/[1+M=VHM3;&$ *HVD8;.I^([R^U)V_MI8L*D !M MGBQY;*V>H P?7)IZ?#O4TUZ+6F\4&6_33ET\O-8(X=%;<&(+%#+C:ZN23N!R?J34MM M\.3_ &WH6HZAK+7G]A1M'8@VJ(Q!7:/-;)WD8&,!>>>]0:1\-KO1C-';^(G^ MS7%\;VX LU65RS*719,Y5&V*" .U>@T44444444444444444444444444444 M444444444444444444444444444444444444444444444444444444444444 M444444444444444444444444444444444444444444444444444444444444 M44444444444444444444444444444444444444=Z,\XI,C.,\FEHHHHHHHHH MHHHHHHI,@D@$9'4>E+2$@8R0,G SWI:****:)$:1D5U+IC87FOZCH/BCQ?=6JF]\N\TVVAMKFY<1Q^H7+,"<#_"NJ\.ZG M<>*O#^H0ZC&MMO,=-\5:AI&I6379O;F:VM)= M#O%>=VC?4 S>2=N?O.(_O?\ 305L>)+_ %7PJ]Q9Z=*IU"UTJP3[?/M:@U>2._L; V,.IS:9(UN[F5G2W,X8 C&"!C&< M\^W->#X@>*)M#&IMX?A2WG6&>&>,^=Y<+@EV,2.7<)\HR,?>S@8(K5T;QO=Z MAXDL;"X6QBM+R!9+:9!(RW?[H.QBD^Z<-N!1L-@9[XK!^(L5YI^MW4-M/>C_ M (2&Q%M8B*Y=?+OTD79@@X0,K9/3.PYZUF:QJ4OB3X?ZAXF@\^ PQ6-G#&9I M$"RK*AF)&>S/LS@_<-;,OQ#\2FY;1K72;*XUQ+R[MPL;'RI!"L;C:&=3DB5< M\G&TG!Z43_$7Q##-J%[&PN8(;:^O7BNA) M&6+J(G;;P1QP?QV]L@^=^%_'NK^%O!-K%<6MI!B1C&/QKT73->UUO#6M76IV]BE_8B1X1'(&5T";T+JKMM)]-W3!'6N6B^(O MB**.UBOHM*$^I6-G>VCP1RD*)G"&,INR\G.5 *@\Y/&:?IGCOQ5KITV"R32+ M:::QNKFX:XAD;:8+CRB%"OC)&#@DXYY/%95KXMU'2M*T?7=1AM=3OAX;FO%N M2CI)DR1#8QW%=OS@L:ZMM/C$,KM-=1(+@10[ R/)%%(Q M5#;R$D@$$C R.1VKGQ\4- M9DT72-26"R'FV]M+=PB)FP9+@PDEBP$:X&5^\2[1(V57MEC#0,IW'!D++SS@*_' K<\+:_K%]9ZC-J\5BZP(D]N;*57: M2-E)Y568#D':<_,.PKF+'QWXKO\ P[/K,,&CB-K);VVB,H=W^>)9_'^MW-GI/]E#39+C5;>YO86F(1(UC90L#;G7+KN^RE+-*[+!YBNC _,&;H, % 3G-9]_XT\0:B(H+2^L[ M+@!Z<5TG_"3:HNI:]=Z7I5K M]J:;+HUGHMW-I-M9SW7B&QLS#%/(T3QCE)005RWS-DX MP>A!Q5R#QMXYN](UC5+:#29H+/4)=/AMTB<7$C+(H#*"VUFVEL*",D?A3_"O MBW6/$?Q$TM/[8@;3GT-KIH5MFC$CF8QD;2W#@H/4#Y@.N:?\7_$.JV4$"Z)] MI\S2)(M2NC#"[*P#?+&[+PHP&8[NP'K4?BKXD:Q#<)-X>FT_[ _A\ZRIN8&D M9L.!LR& &0>XXP:J7/Q1\0:?!JT%S#92W,5]86T$T,)5(AF^)+"T6)5(E8LNYI"^[[IS@#'(Y[5+_ ,+&\7SZR;6&;28X9-2U M&PC+6CED%N@<.?WG)(.,<"I+3XH^)-1ET&WL[.P\^?38]0NA*ZQK*#-Y;A6= MQMPH)XW')QC -6-+^(/B:\\56VG32::+6[OM3L8BMNX=#;(&1S\^"22,CCC/ M-7/!OBS5+?X)S^*;^Y&JWL<=QZ77<"3(VA^H,>1SRK#ZU:N/$VL77P;U;6OM,=OJEM%=1^? M#%@$Q2.FX*3\I(7U.">_2L&TU35-'\9ZO>VUY9RK)=:/:WN83_I!E7864AL+ M@/G^+)%=#X'\8:SXEU7S;K^S8]/N(I6BMTE'VB)DDVX*@DXQC=N PW3@UAZY MXAEU3Q#I=]/=6<%KIGB.:T6V9/WB>5!+F1WSG!P3@#H5[]:3>/?$.IVRVW]J MVMFYO-*=;F.W"[HKACN^4N3L&T'+;6(."!FM>#QUXFOY+^:PCTL: ME_:DC:G/:?,RQ7&/*.&&[)^?D_*JX'K4M[XV\6:SH.K7UC=V>EP6^@0ZD4^S M,\N98Y,A'WX'*9!([C@]X=.U?5]%\5ZI>6UY93I/>Z/;7A:$DSF6,*6!#83& M)78H#\Q.7 48P=IS[9?A7Q/JNG>!K&RT^XLX# MIV@R:L3:5:M?RP_;YHOM!A0;62-B=F5R3P, GU!JAX MXO98]#_LRT%PUYJC?94%L 95C(S*Z@D1%R#G:'(##DKL;J1R?K1#X[\16]O8SW8M9H[U[O386AMF&;^.5DAS M\QPL@!X[%3SBO4(1*L$8F=7E"@.RK@%L7-Y<7%DSRWDL4UPWGR#S'B_U9(#?P]OI5_3-(L= M'CN$L(/*6XG>YE^=FW2.L2O6=0 LGU 4?E5?4 MO"FAZQ5)(M/562Z%XO[ MQ\"8*$WXSUVC'TJ@?!/@S2X?)&GVMBMUVME-Y-S>QQ$6;FXCD MEQB)@I!;)Z?*6Y]ZHOH>A:KH'V$6MO/I5RWV@)$W[N0L_F;P5/.6.[-5KSP- MX8U"&:&[T>WF2:Y^U/O+$F4C!;.<@D ^H&*M'PMH1AOX#I=L8=055NHRORR MA1A3&%(V[OO#/4ANX.0>^:CUCP/H M6L6]_'+9I&]_&D5Q*@^9D0@J!V&,<'''45IZEH>F:Q#;Q:E91726T@EA$HSL M<# (]^:RM+\->$+JSBN-,L=/N+0V\EHCQ$21F(L=\?4@KNSD>M6U\-:?8>&K MS1=%M;?3X9XI$41Q_*&=<;B!U/X]JSM&\ :'I_A>#1KS3[.[Q%$EQ(8<>94"!4/+Y/0#CGMQ[4S3?"_A46 MEO/INE:>UJ\#+"T2 HT4G+ =BK9^AH'@;PLME#9KH5BMO [/'&L0 !;&[ZY M .>H %6]7@T17L;C5EM5:*816CS$#;(_RA4]STXJFW@3PH\4<;^'M-=(HC"B MM;J0J%MVT9[;B3^)]:V%TZR2:>9;2 27$:QS,(QF1%R%5O4#)X]ZATG0]*T& MV>WTG3[:RA=S(R6\80,Q[G%9MOHOA*VU>2RM]/TN/479=0DACC02$JWRRD#G MACP?4U)>>%O"YL'6]T;339QRM=N)8%V*^/F_>H[2/PEJ6N)?6L6E MW&JS60E65$0RO;M\H;/7:>F?3BHK'PYX+O+6\M+#2=(E@CD%K=)% A 9"&V- M@=02#@UIIX@.*MWNB:5J.G)IU[IUK/8IMV6\D0, M:XZ87IQVJIJMMXQ_LBR M^RW$OGRPB!=KR?WR,?>X'/6H=*LO#=VT%_I=KI\C6(>TAGAC7,(!PR*<< ME1CPAX;642C0M.\P.\F[[,F=SC#'IU(ZGO4O_",Z"#9D:+I_^@DFU_T9/W!) MR=G'R\\\=Z2+PSH%K=I>PZ-I\-Q&[2+,MNBLK-U8''!/<]Z72(]#2*^T_2(+ M..*"=H[J"WB"JLC ,0P P2011%X:T*&"*"+1[%(H9A/&BP* D@Z...&'0'M5 MB+2--@L);"&PMH[.7=YD"Q*$?=][*XP<]_6LRXTKPII\UK93Z=I<,EY(B01& MW0>:T2DK@8ZJ,X]*GLXO#UGXCO+>R@L8-9GB%Q="&)5ED0G 9B!D\YZ]ZGE\ M/:+-J)U&72+"2^)!-P]NAD) P/FQGIQ5=/!_AF."2%/#^EK%*H1T%HF&4-N M(QR W/UJ=_#FAR7%W*XNB&GD2,*\I P"Q'+8'K5&7PWX>33C;R:/IZV<3F?RS;H$ M5LHS:;:27L:&-+AH5,BJ>H#8R!R?S-0-X9T)H+:!M&L##:L6@C^SI MMB)Y.T8XS[5=FL;2X:1I[6"5I8C#(7C#%XSU0YZKR>.E(MA9K?F_6UA%X8A M9P@W^6#D+GKC)SBEEL+.>]@O);6%[JW#"&9D!>,-UVGJ,]ZJ-X=T1YWG?2+$ MS/,)VD-NNYI!G#DXY89.#UJE_P (G;+K5K=0RB#3[8F9--A@1(C<'=^^) R6 MPW3ID ]:Z"BBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBO+M0\=:E;ZIK9CU M*W6\T^XN(8= >WW2W*+ 7CD4CY^2-Q/W=O'7DT;GQEKZ7%G96?B&"ZANI=-< M:BMK&?+%RSHT9 X_A#CN!P<]:K'QOXFM-.EEGUR"65['5A&/LL:[)K-AM;OD MN,Y'3D8%2V_B_P 3PZT4G\007%K!?:8KJ+6)1)%=@;@2.@7G:1SZDU7?XB:V M-%;&N6PU&+2=1EFC\J//3-5B,>Z%XI7BD 7<-H#L4PQP!D M+D G-^S\9ZU_9,4L%[%#=6=GI9M-,2&-4U 3*GF$#&?O%E&S 79R.:T/#GB MC6Y?&6G6]WKJWEI>WVIVGV=HHE"K;M^[8%0"6(_#!Z=ZLZYXHU>#Q+J<5OJ' MDW%C?64%GI1C3_3HI=H=LD;C]Y\%3A?+Y[UI> ;_ %35?"][K%_X@>\$TDZ0 MYAB1;<1R2*&!4#.0%/S5PUEX[\2PZ5#/-K9NVO-&M[V5S;QYM-UR(I'4*O(5 M"2@(K0GU>^F\8:-#-XCN)-(MM;>WM[]'C"W :UW[&(7:Q5SY8/?<1U& M14TOQE>/H^EV^H>(O['BFMKR6*^@M8R)KE+IE6,H%P<)@[% +;NM;/A[Q1KN MH_$.:TN]8A@6*\F@;2)(#YIA"Y20 +\HZ-O+$?-M]*IZWK5]HOCGQ9Y>JW46 M\Z:ISM86]JS8FF12O1,GGH"Y)S73Z#?7NH^'_%%O/='4[&VEF@L;U@";B/R@ M2,J,/M8LNX=<>H->=:=XB\0Z%X6L4T[69+O2AI5B;VX>-6&DLSA&4%%SP@(( M(9EQN/6N]@US5;?X2ZKJL>M07UW;PSM;:AY#!&"_=/(^?'3=C!QGU-6:"69(6(\P2L@.,MOPK-TO7=8U&YT>%/&DDUE?WQC>: MUB"F)?L[LR;Y$Y.X*<8^3=CTQTECK^J7OP9M-4DU:"VU&5$C-Y.=BD^;L^9@ M#L+#C=CY2V>U<1>ZQ>3R'6+;4K^RU"U\-74JN\D2>.UMVU:4V$\US;3V\J@*%%MO0J@7A=_1RV7R>,"KGP[91XC\/)N& MX>#H 1GH?-Z?7VJB+G5]+\7ZTVB7US)J#^(&/]CD+Y<\#0*7E((W#!7A\X^7 M Y-=!\+M9U'6?M$]YKCZCN@C:>W:U=/LL_\ &I9L8)_N#@;>7TBX-GK% M\C:O=0:7<^([R.\OA*NZ#$0,1#X^0.W!;H=@'K5_0;CQ+XHU>UL+WQ'J.GR? MV+]I46Z)'YK^?)&DC J<;D$;E1CKVZ4FC:YXOO-2TJWNDU&*&_A6WFD+ F*> MT8&XD X60 J/4YZ5A6_C/5[FVN(%\1WL;7*V,D4A*F5&>Y,1.V% 9F,197-W( MWVC4W@G5F\V7YF9&SC)+#'(ZYK-BUW58;9([#4[T7-O!IW]BVQY2_1]HFW C M+X.\$\; JGCDG6^).V+Q*)+BYNDAD\.ZBD<09O*>3"_+@#&2,Y]=J^EMW4 MNH[X%34$M_)DE4SJN[8<\%"3SU SQ6+=:EKFG^+;S39?%%_;-IX7[,LMB]PU MU;^3EI6VX1L,6);&1L '7!HP:]>S1Z-:WWB74+&UDO[BWN[^"]$D\7W&JZ1;ZMJUU87GD6TEK;_8GNW=A(] MK%/;LMJ]P+FX:5FEB&T@' *H _ 7GCK5[XKZ]J>ESQQZ9>WUM.EA+7D1L MZNG'RJ3(^,_(V%"Y)[5BWFMWFH>*+.Y>6^DU>VUB(]1A6S>,VB26;W#7MMY>79F7$9PQ;+$9&T8]#D'Q)K"^'7SK5Q+) M#.&:9+N14U >03M@EV9BD!(8Q,,;L+TXJ]+KVO3>)M1$VO:AI4UNK-#9OITD MW^C& $2M@[/E8EF.-VX;1G(%=GX"U*>Y\-WS7LLLC6T[(;EKAIXI (U.Z*1@ M&*=3@\@[AVKSW1-3U.S\/:?8P:O-IL8\+HP9XF,<,WVE5R<#()4D$]5&6[4U M]2UD:A%JEF^JC4/[#OTLHWF>X229)Q]QL8D79\RDCG8F<\9T;37;O[/IYN/$ M6J3>';N[D$]\EM-"\+^5^[B#L6D(+Y)/0-A0<9%6)89G_9KM8EBG\U;6W#*L M1WIMG7<=N,\ $].V:S-1U;7[5S GB#4E\+2WLRVVM/#)-(3Y*%03'AB@D,@4 M]"5P<@5/]OU2SUG6KGSKP>8FBIJ=XL!BE$.U_.D"C.P\KN R5!/0BKK7?B:. MTBU"RN]3U#3QJD^G6ZB0AKBWE0"&8MWV2DC?W7GG&:V_!>L:I;V[R>*9KA)H MKE-$B&'=;F9&8&? 7@/D#<>/EKT*BBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB MBBBBBBBBH?LEM]K^U_9X?M(39YVP;]OINZX]JA32M.CC:--/M5C:3S2JPJ 7 M_O8QU]Z4Z5IQVI'S?\L5[]>W?O0-*TX# L+4?='^I7^'[O;MV]*4Z;8$R M$V-L3(27)B7YB<9)XYS@?E1_9EAOW_8;;=N#9\IIIS00M,LS1(94!"N5&Y0>H!I4ABCC,:1(J'JJJ /R MIJ6T$>-D,:X&!M0#CTI4@ACC2-(8U1#E%"@!?H.U'D0X4>5'A6W ;1P?7ZT[ M8GF&38N\C!;'./3-!1"Q8JI)&TG'4>E*JJBA44*H& , 4@C0!@$4!B2P ZD M]:I:OI%KK6DS:;=&5()0 3#(8V7!!!!'3! JMHWARTT:2:837-Y=SA5DN;N3 M?(RKG:O !). !U-;%)M4# 48^E& 01@8/448 Z <48'I2X&F63WE[8I1F0[]N00 MI!Y';ZUR&F_$S0=6TZ\NK)+R26RN$M[BT,:B:-G<(I*EL8W'&0?6DNOB9H]F M^O)-9ZB#H6S[;B)#M#G"D?-R#U^E6;3Q[IMYKNEZ.EG?I=:G9B^@WQH%$)!. MYCNXZ=.M=0CK(@=&#*>05.0:=11111111111111111111111111111111111 M1111111111111111111111111111111111111111111111111111111117!: M1X9FG^)'B+6KR&_MX3=6\MFPFVQ3;(/+;<@.&YSC(STQ7%WW@OQ'2U,<>2K?=# MD<#IC/I75?#/0+G0[2\DN='O-/FECA25)[J.7S9$4@LBI\H7&!N/S-WZ9/.I M\-M08>&M>LH)+#58+B*+5K5G4?:+<3!B202"1@'KR .X%5M4\*>(YT^)*1Z) M<.=1_LY7@_A6G111111111111111 M111111111111111111111111111111111111111111111111111111111111 M111111111111111111111111111111111111111111116);CQ/\ \)7=&X;2 MSX>,8^SA-_VD/@9W?PXSN_3WK;HHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHK$\1:[+I4<=M86HO-5N4 MD:VMBQ4$(N69B <*.!TY+*.]6M!UBW\0:!8:O:_ZF[@651G[N1R#[@Y'X5HT M44444445@^*?%VF>$+2TN-2:3%UN,] .36]114<4\,_F>3+') MY;E'V,#M8=0?0^U24A( ))P!U-BL(7N"OU* @?G M5[P[XY\/^*KB:VTN]+74*[I+>:)XI%7IG:P!(Y'(]:Z*BL_3M6PF\BY5<_NWQG'O^'H?2M"BBBBBBBBBBBBBBBBBBBBBN+\??$G2_ <,*SP MR7M_,-Z6D) 8(.KL?X5_F?QQV$$HGMXYE!"R(& /49&:DK&U[Q9H'AA8VUK5 M;:R,@)19&^9@.I"CD_E4^C>(-(\16ANM'U&WO85.&:%\[3Z$=0?K6E1139)$ MBB:21U2- 69F. H'4D^E$]W*CKR>3GGY1Z5I_"F1YO"MW,D$T.G2ZGV>@WVH^)=,73/L*,\ MK1W"S1RJHR60C!_!@#53PIKFK>)_!#ZM?V2:=-=+(]JB-DB(C]VYSW[_ *\9 MK.^#-P+GX4:*=Y=D$J,2:]OYYP%^/7A0>* M+G2YO.BL8-P&HD;D=E[!5!.#S@]_3FGZO\<- MD\G2;'5-2OI$+Q1):/&"H! M._Y@#M&#T'8U!\!K5SX2O-6?=F]G #$8\S8OS/[Y=G'X5T4WQ+TR&\F_XE^H MOI4%T+.75EC7[,LI8+C.[<5#'!8 C-=K37=8T+NP55&2S' %5=4U2TT?2;G4 M[R39:VT9E=AR<#L/4GH!W)K,\(>*[;Q=I,EY#;S6DT$[VUS:SC$D$BGE6_#! M_&F>'?%UMXCUC7]/MXMO]D70MFDW@^8<Q%5[OXE^$;2XD@_M=;B2+/FBSADN!&!U+&-2%' MUKH]/U"SU6QBO;"YBN;69=TFZMK$%G/%> ^8T.XLL:^D8VKG^\5 Y&:^F:Y.Y\8W_]O3:5IWA+6KSR M'"273(D,';E7=AN&#VI?'&C_ &C29M4T[P]8:QKUM%LLUNT4A*_ M%%EX T>25%#QW>M7,3E/)MP01&&'\3<'_OGMG$MBFK>!_'&B^'X]7GU;1=66 M81PWK;[BT,:[BP?^).@YZ9KK_$.M7>B6L4UIHE[JI=BK1VFW(=4\1:E\+/%5WK>CQ:.&LI%M[=;CS9=NT@ER!@9XX'OFLG4+BZ\3_ ST M#PWH.OVECK,EE9O<6]Q,87F@,0R%(&2"<9*^A'M6]\/;B:PU75O"M[I.D6-U MI<<,B/I:L(Y(Y <9W_,6&.2>N:] HHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH MHHHHHHHHHHHHK!?Q;91R,AL-:)4D$KI-P1^!V,XQ6/=:WXG\2V4&AS>&]5\-Z& M(1%=M#:23SS(!CRH]JX12."3SC]>6E\(ZK_:]YIFFMXCTOPU#*]_IODZ?-O2 MY8* K#&=J[20?0^I-=!XYUWQ;J?@+2]'_L?63=711-9N+33Y,^6/O! 0.6[] M!P1T-&]/LK,I;[;1WFOI5YC\[;P.<_,-N3SW)SV&?4]$\: M:U>27+:OX0U2P0%1!%'$96/'S%FX7KT ]#5B[\5F[M9K:;P9XDG@E5HI$-K& M RD8(YD'!%>:V4'Q!\-V;:3X:BUA=&+-Y"WVG1O/:*3G"D28;';/Y"NP\$3) MX0T)=+B\,>*)':1I[BZGMHMT\K?>8[9#[?@.M=+_ ,):_P#T+7B#_P !%_\ MBZXGXJOJ?B7PM:G2O#FLC4+*]BNX2]NO&W(/1B>^>G:J7B#0M;\0^++?Q3;R M>(])<6:V_D0Z>CRQ#DL%8R#;DD\XSU[5*_@71WMY)=1T+Q;KM^4(274YA( Q M'!V^8!C/8YK!^'OACQ!HFI:5<:YX0NDM])@F6!;6*%WGFE8[I)"7!X7"@<]! MCO3XM.\>7OB76=1N= O[)]4E:*34(S'+-!9C[L,*%P%)[MGWQGK-IEO\0=)\ M(-X-L- U"VL1=2*NJ[XS.EJ[$X6/$-#T#PMX2U) M;?3;N&9H+KRE25$!.&(DR26()]3DUF:WHWQ$US29;O4)==_MQ&26RM+%8H;. M%@P)#$29C:*@'FPVTT<^YN[$;UW]L G I M9=4USP[XC\/>$=:DU"_T6::&>WBG@A6Y)BSLB 5RI0N(_O'M@=*V)-&\<66O MZVV@1W=CI>M7/VF>1K:)KF!B,-Y?[W&3ZGVZ4]?A];6#"30K;QIH\CPK%=-9 MW$&;G'\;9D^\ OB'!)8Z! MJ=OH7B%S')8,(ALN^QB DP-W0@D#KZ #T8^(KS9G_A%M:)_NXM__ ([BF_\ M"27N/^14UO/I_HW_ ,>I1XBOB/\ D5=:'XV__P >I3XAO@@;_A%=9.>P:VR/ M_(U)_P )%?; W_"*ZUSVS;9_]'4\Z]?A-W_"+ZN>,X#VV?\ T;2+K]^PS_PB M^L#_ 'FMA_[5IW]N7_\ T+&J_P#?=M_\=J2TUF\N9XT?P]J=NC'!DF:#"^YV MR$_D#6O116;?:G=VESY4.BWUXFT'S8'A"YYX^=U.?P[UQ_C^UU3Q?X0OM'@\ M-:G'<.%DMIGEM@%E5@R_\M^0GV@QRVY7S,# M=C,H.,\U;;7M2# #PKJI7/)\VVX_\BUR?BF+QC=ZU8ZSX9T_4;6\MXVADM[V M:%K25#SDJLN0P/+3K\?B/Q;I%_J&J0J\=I;VKVR6UFK !BN9^'HI;:WUBX^T32W$%M)/$><(,S;2HR<5T?A[2;O0 MKN35+K0_$&L:W,GERWUY/:[E3KLC42X1,\X%=.-=U/82?"FJAAT7S;;G\?-J MEJMU=ZUHMWIM[X1U9K>[B:&1%N+8,5(P>?-XK(GT2RN_#EGH5]X U"[L[.$0 MP&>>U:1 !CA_-R#[C%,\*:$G@XWDVF^$]*_$$'C6]TS3]4O)[S^V8[6TLI;:,6SP^6LD@>38,$ L1A MMV .#FNH3Q8;;Q/K-E#!?7E\]]':6]G)+&L8(@\UBC8^5=@+'<2I/:N+^(WB"\T/Q(FW5=7M;+^R)[ MDI80I)B5'149MRG"_/R20.G(K63QEJVG:=865WIL>HZZFD_VE?);SJB+&#@E M#@AF)S@#C@\CBLC5O'ESKLVB7'AY)TTL:U9VTUWYX0S&10YB,>"2N'4$Y'/8 MCFI[7QS>Z\WA^]FT>]TZSNM1:*W>'44/GE$EW!T"Y*C8>.,G'/JS_A;2K8W. MH1Z!O@CLX;UGCNU)"2R^4J/A?EDSDE><8ZU=U'XFR6MW=Z?::#/>ZE#>SVT= MO"[-YB1(CE_E0D9\Q5 QC)Y(%7(O'&HS^)=+T=?#K(U_"+DB2Z"RV\.U=SR1 M[3MPQ* ;LDCM7:T444444444445X5JNB:]XK^.$@?3KB.RL;RVD%[)$52."$ M;]J,>I=V/3_''NM%%5-3&HFPD_LIK87HYC%T&,;>QV\C/J,X]#TKS35AXG\; M^)_#=G=>%KK2+?2=06^N[F6=7C)3HL;+][//Y]*]6HHHHHHHHHHHKB_%4&=3U+5-,DEU;33I]W',T1CW@[U&"KX!)7((.T\C]:V:***** M***********************************************Y6Y\ Z7>)JHGN M;UFU&[2],@D56MYT "O$0N5( YST]S45U\.],O)+N>74=4^V7%Q#=BZCG5) M8I8X_+#(54 97@@@@^E#?#G2"+@+=:@HG%MO_? DF!MZ')4DG<2Q)/))K,E^ M#OAZ5&C^W:PD+(T0B6[PJQM+YNP#;T#\^OJ3Q6KK'P\TC6M0GO)[C4(7N1#] MJ2WN-BW#1$&-G&.6&!R,5K:UX>M-;-G+++<6]W9.9+:ZMI-LL1(VM@D$$$<$ M$$&HH?"]K!!$B7NHB5;Q;R:<7)$EPX&,2$?>7 VX P!QQ3[OPY87_B"/5KA MI7GCM7M#"6!B:)_O*RXY!P/RK'7X<:)#;6]O#=:C#Y,6FR:&=+>WNFCA,L2X1]G3<% 'T%2?$'8VND6 M%G87%RLFF32W-DTTI8+,X;E\F36QAGM8] M0>X6>3*E95W(OE%2N1]X\\GCG?;X8>'O+),FI"X^TM=_:Q?2"<2,H5R'SD!@ M!GUP/05/:>!=!BU'^UK&YO8Q)Y.5AO&\IUAQY:XSRHQTSSSFNM!R,BBFQR)* MF^-U=3QN4Y%.IC2QK*L32()'R50L,MCK@4^BFO(D:[I'5!G&6.*%=77-UZJ\J@C\":L*P90RD%2,@@\&EHJM::A9:@LC65Y;W*QM ML8SQB-V1O,((9BP(9B02#DG(ZYJLGPZ$I;-;C1HC"U MM]D*-([ Q;BP'+=022#U'8BMK2-'L-"T]+'3;<06ZDMMW%B2>I+,22?32:-ILUS M\0-0NKFXL9+"ZW6U['=.AMS]G1\K@X^\V<=\XJE;^+-;LK*35UL;!M;DTG2F MEEG23=(9I6CPX# #D[A@#K6G)\0O$MEJ.H"XL=.N+;2&,%\L4@C>5Q#YA:,, M^[EN NTY /.>D.H>*O$TW_"/%-=T58[^_LVS9QL6$4J.Q5P6^Z"F <@MZ#!R M2_$G74T"#64AL6BU+3[Z[M81$Y:U-OSMD.[YP1P2 N&Q7H7AVYU"?2H/[7N+ M*34'03,MJI0!&Y7Y6)/MGVKS1M'T5['X@ZE?.;.:QU*8VM[',T;P,(490A!_ MOG[OFV_B3Q'9VVH:L+"S.JVNB:=>7S-;MYLL9W^8K?, &"AF' QR"*T[ MCQ)>7^L>'=5-MITUK=W-_)IDEQ&T;QPI;,4?<3A0Y4DDC[K"J4?BS4+N71WU M>S@N-1L]49)[:2S*2VS?9&E 0ARISM;:PSE6' -,OOB)XEL=#6]CFTVYDO=) M@U2$K =MLSS1QF)@&^8?O,!L@Y1N/3J](\4ZHGA_Q9QN[06,EMK,]K"UOS;M;RLP M);=\^[)&, #CK6I:^._$D;I8WE]:.]X^F;;U+4*+1;I'+97<0<% 3W<9]*I MW_B6_77M-U2ZCAO-0T8ZU!%+&FT7JPPHRM@>_P I Z$-BM.Y\=:WIEG<;]3M M+^)[*QO!?10JOV<3S>6Z!2[JO 8,6/J0#VJPOC;7M-TN/6 M[O6-/U+2;._1+TZ>!,WV>51M+,$4;E,(S<^:[;D10I+E1A!M(.X9.-& M7?'.=L8W?*!ABQ[X7C'6H$\>>*KE)M06]MK=H8-,N%TEK52UP;@[716SN _B M'4\@4J>+O%4T]JJ^([=$O&U1 ?L<9\H6K?(PYY+ 8.>,=L\U)8^/_$&J:UID M?]IZ3IRO:V$S6USD-=B>,-(8UVDL0Q(&&&W;\V1TR9O&?B:^\'7;SZZK/=^' M[F^5K>!(VB:.X6/"D9^\I;)[8R,5Z!XH\02:3X:T5K/6T\R\F6);O]R!./+9 MLAV_=IG .<'@$ 9(KB8_B%X@N].358M>M%CM[#3;B>W2",J\DTQBE5FZK@#) M Y!(Z=[MEKIUOXF>&;J\U*$W27VJ6W]F[45[-45E0'^,E@H)R<'/&,5M^*M" MT2/Q_P"$I)-/L6>^OKEKDRQJQF)MF W;NHR%P.@.*RKO7-5T:\\0PVNOQ6>D MZ-:[*BBBBBBBB MBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBN0O]*\ M V6M ZE!HL>I3R"7;36;??\ "+>&/$-MJM]=V]C=2V@L(%.% B#KZ#.,[!D\#@#&>:ERWPWT M_6I7N1X?BU-)2\AD$?F"3J2>^X=<]1730Z?I5Q++J4%K:R27T*K)<*@)GCQ\ MH)_B7!XJEJ5OX:ANM)M-1M;$3'=;Z=')"#CY,,B<<#:,$=,<5/;>&-"LTMTM MM'L8EMY3-#L@4>6_3<..#@ 9]!BHW\-^';>QNT;1M.2UE;SKA/LR[7*\[F&. M<')J;1!H\]C_ &CHT5L+:_\ WYE@B"><3_$>!D^YIJ^&-!2TFM%T73Q;3OYD ML/V9-CMZD8P35]K2W:T^R-!$UL4V&$H"FWIC'3'M7(7'BGX>I8R:-/=:5]B3 M<&M# #$ K'=\NW;@'.3T!KIO[&TB62SN#IMD[VB@6LGD*3".VPX^4?2H_P#A M'-#V*G]C:=L4,JK]E3 #?> X[]_6B;1]#M[6Y>;3=/CMVA"W!:! IC0/8[KTWHRE7'L1V'I5#2OAY8Z7=V\ZWURT:2BXFM8XXX8)I@ M$D,:* -N!@#'(!.3757=E:W\/DWEM#<19SLFC#KGUP:;:Z?964#06EG;V\+' M+1Q1*BGZ@"B'3K&VM/LD%E;Q6V=WDI$JIG.<[0,=>:=+96D]S%,]>W?O3AI]DKQ.+.W#0 MJ4C81+E%/4#C@4U=,T]5VK8VP788\"%?NGJO3HVA:*,@HC M("JD=,#MCM4*Z3IJJ573[0*0 0(5P0.G:I5L;1;IKI;6 7#?>E$8WGC')Z]* M=);02RI+)#&\D?W&9 2OT/:F-8VCB8-:P,)\>:#&#YF.F[U_&F_V;8[V?[%; M;F!#-Y2Y.3DYX]:4:?9!I&%G;AI%".1$N64=CQR*<+.U!C(MH08LB,B,?)GK MCTS4D4,4$>R&-(T'\** /TI]%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%% M%%%%%%%%%%%%%%%%%%%%%%%%%%>2PW6GZ3IOCS3?$JJ-1OKVXDCCD3<]["Z@ M0"+^_C&T ?=([5S-QIDTKO_='@YP-I(ZY8GO6C M;:YJ.DZ6)&FVW#)A?O+'T!SC\*35_$.H[[&.Q\6:I M%HDJ3/8ZH]C)(\\P=2L>%P9 %R%+##G=UP#7:^,=1N8+SP_#?:A>:9I%S'-] MLO+?]VR3A%,2LPSM!.\XS@D <]#S?A0W]_\ $+0+S7Y[B/49O#I,T#$JK.)1 M@,F, LGSE?49[5TOB1;>V^)/@E41$5I+XR!4XR\74X]6XR>I-:KXHM_%N MLVMC?W4&H6C3KIVCQV+M#-;B']TP.1&%!&N*Y[3KS5[;PG8VR3ZM:74>BVQT..V20++=J[^:CJ!ACG8"'X"DGU-7 MAJ=WJ?Q"N=+U'Q!J-@AU*6$R13S0K+&458X8P%V K)GYL@GGKG%==\.3KEU] MJDUJ>X,FE@Z3\T[,ES)&[%Y\'J6!09//#4^>*(?&&RA%N1:C0IH"!"?*W-*C M;QCB$L_DQ6H.5)1!OV=LI@G@9 )K 6_ M\37'A^>X^W^)X[ZQTB$QQD7";[D73 DKCY\1[,]7'C.$G5KV MWN+"[\EE6YC,3Y41PM'C8P)'R,G52VX$$TL<.L0:_IMD+O7[:QBM;-M.^RV\ MLBR#'[X.S, GS$Y#@X4#&, 'M/A=97,7A**_O[G59;^\+-.NH2R,8RKN %5^ M5XQ]>*[:BBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB MBBBBBBBBBBBBBBBBBBBBBBBBBBBBBL*R\5Z5J$VJ00F;[9I1/VFU>(K*HVY! M"GJ".A'6M+3M0@U/3;6_AWK#VURUOKFT2RCFN;>ZB M>5+R%0T "D#!;/4YXXYP:T0R%00R[>@(-!DC&W+J-_W>?O?2LO2?$%OK,>IM M;07 ;3KN2SE1U 9G0 G;S@@[ACI1H7B&R\0:%;ZQ;"6&UN 6C^T (Q4'&<9. M!FKMWJ%G803S7=U%#'!&992[@;$'5C[<5G-XGL(3-+<[K>P1(6CO9"/*F,IP MJKSG.<=0.M:C7=LD1E:XB6, L6+C ZG/M4-IJVGWUK:7-M>0R0WB;[=@X'F MC&?E!Y/%6([B&5Y$CFC=XSAU5@2I]_2N3N?"7A!&U-[AF\KYY[JV.H2^5$SY M+2>7OPC').X '/(YJKHGBO2]+\#3:E::'>VNAV$"3P%6CD,T+9.X'>?F')8, M=V3SDFM^3Q+#%K.D:7)9W0GU2%YH6PFU @!<,=V01N7H#G-7SJVFBTDNSJ%K M]FC;8\WG+L5O0G. ?:L>_P#&VE:5JUW:7[>1;VVGKJ#7C,#&T;.4 &#DDD=. M_&*FT?Q78:OJ>H6",D4UI<>0@:9#]H'EK)O3!Y&U@:WJ**************** M************************************************************ M*******\VU/PKJ5_>ZYK6EPM9Z];WK&SEF4!+R PQJT3X/*$JV,\@@'BN:N_ M"NO2:_H\K>&KA[>V73EDV21L&C6$I*A+/E0"V"BC:PRS$\4:=X.\11:%IUE9 M:1/IE]%H-[8R3[D4>>S(5.5;^+:X#=1D&IKCP?>:AJEK/!X8N+31'U*R>33' MV )L219I"H; 4YC''+[2<>N3=^#?%4OA_3K1/#LYEM(9/)82Q%T(O#(J?,^( MQY>,%/F/"Y &*]0\%V=_IR>)9;[3YX&N=7GNX48H3(C(F,8..JD M6 MN_#>E6E[X>>2XM?#]]:;9&B.RY9LQ8.[KU(/09'0U+>>#_$%])JBKH3/)>:5 M+%+)?>2Q$WV=$0PR!BWS,@RC<*1N!%/N?!>JW-MJ+IX51$=-)>.U)@^?R'8S M*/FP&VMCG&>1GUE/@W7VU=K8>'H19?VK?7@G\V+RPD]L8T4)G.%8@,,8^7O5 M:P\"ZZ)M%%YX<=H4L;2W58]12$64T+$L[A#UXZ[P!H.I:-JFI MM/ISVME*B^4UR8FG#[W9DWQG]Y&-V0SX;YB.U8-EX+UM/LD=QI,;W5A%J"W= MYYD>-5\[/E@\Y.6(8[\!2O%;;^&]2'P1_P"$<@TL1:HVFK:M;J\:@R[0&8L# MMY.3G.3]:H:IX%U!]5TV32;>[@W:1=VL]Q/?M*+:66,*A 9R1M(.=GJ.N*R+ M/P+K=OIULT?AB."<7$*W*G4EFD8)$Z>;'OS&@^8#D,V"<#(%5V^'_BB[\.R6 M%QI42RIXV5Z'H/6M9?!>L2ZZNKMH%M;3G7[6]!CFCW16 MJ0[&0,,< C[HZYKUFBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB MBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB MBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB MBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB MBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB MBBBBN3TGQ@USXQUSP_J$,=O]A EMIP2%GB !<\]"A90?KFJ&C_$NRNK._OM3 M0VENE_+:V<4<4DLTJ1QB0NRJ"1\AW'C@=33==\=36L&HW6DW6GW4,":?)'&8 M9-VRXE"[RV0K JP*[>F#FKR^.=/L9KY=2O5EQJ4EE;1V=E.SADC5S&PP=S\D MY'!R,=ZL3_$#PW!;6]RU[(]O-!'<>;';R.L<G-6;+Q_H6I36D5E)<7$ER< M%8X&8P_O/+_>?W1OXST[].:OZ#XFT_Q(DLFG"X:! &2:2$HDRDL R,?O#*GW M'&>M9;_$;P_%'/*\ETL"0RSQ3?9V*7*1'$AB(^]M[^W(R.:9XA\7RP_#G4/$ MNCQR126\9>-+ZU="V&QRA*G![&I?#/B*35;F[+ZSI=_9P1H'EMH'@,34+-0M[^=+&_5Q'K]E82 M02V@4QQ2A=RAMWS9W;@V..F.]=-XKUBYT70)I["%+C4I2(;*!S@23-]T'D<# M!8\CA352V\:V$_A;2-96.69]4");VMNH>1Y2"609('R[6R20!M-N#6M;?$[3K:T:/5+:_P#/ MLK6![VZ2W'D"22-650V>K%AC]<58M/B?HFH-;1V4%[<7$\LL7D(J;E,94,0= M^UQ\ZGY"Q(R1T-;6A^*++Q!\T M^SMM,U6>ZO&D0Q1P*6MVCD"2"3YN-I()QGCD9S3_ (B^*;OPIX6FO=-MQ,54A^*FE7%Y:VL6E:R\EQ;0W@*6ZLL=O(0!(Y#G:H!R?05!;?&/PS MZCH,6FR+8V5I#,;HLO+2#<.,YP1P.,Y!SCBF)\1=-_MB2QFL;VWACNKBT>\E M">4)(8_,;HQ;&T$YQVK.U7XG_9-,,MOHMT+R6.WN+6&X=%$UO-(L8DR&X(+* M"IP067/&2+UKXN:*^U.W\C4;R].H&V@L7$*E66!96",#C8%./S KH.>!@$C(!(K7\,^*(O$VBOJD%I+%;]8_WB M2F1=H/&PG!YP5/(((KGXOBK93,T2:-?O<"YMK80H\18&<,4#?/A6&Q@RGE3U MJOK?Q%:[\&7D^C6EY%J8T^YN67,8-D(F:,LQ.5;YU. ,Y /2MW4?%4VAZ-H3 M2:;=:E?:D$A2*W**6D\HN<[B /NFLN;XK:='%J%PFEZA-:V<,LOGHHVOY;!7 M&2<*J3WSV[6[-&RR1",*P# DI@,.<9ZC@5&OPTU;^QY[*35[-GDL=/M1)]G; ^ MR2;P<;N<]#^?M6K%X(U"/7?[1&H6VT:U)JH3R6S\\'D[,[O3G-<)/X5UW0]0 ML].M[9[UK*Q@A0-ITSVU^Z2O*NYTD"IM9E_UG ()Z=?5=:T*3Q ^EI>F V,$ MGG7=JREO-<*0F&!& K$GIR0/2N=7X=W=HT@TS58+2.#5/[2TV/[,76W8H4DC M8%_F1@2>-I!)-4#\*;^/39+>W\11+-=6=S8WCO8Y62*65Y?E7?\ *RL[IK2\*>$)/#FH:C>2WD$C7H3?%: MVY@B++G,A3O.:Z7Q#XO%5_P#A%)]3D=?$U[:: MO9F,*MH+$11[@0=[99BS#&!R ,GUK.F^'2&]O)+744MK::[L;F*V2U&V$6H M1!\W(.U>PQBL_4OA2VI0W<3Z\ZQW4EY(Z&S5U4W#AR5!/RL",;NNTD<=:OR? M#V::YGN)-;9Y9]1L]0=C:J,O;JJ@<$#YMJD_CZUO:MX<@UO6+&ZOS%<65HCX ML9H Z-(V ).>X&0./XC6 OPX-O;F.PUJ6T>#4WU'3S';H5M&?<'C"G@QD,>. M,54_X55Y>G"WM_$-U%,]MW55C=2.I^53^%&H_#VXUC3[>TU3Q%#[2TVY%_?R7#!I'.!QRJX X &*GU?P=8Z]JLEYJNR\A^RFW@MIX59(" M3EG7ON/&?H/2O.];^%VK:?I^A:5I5W+J&G6!N&W7%M#.T9DVX38S)E?O]SUQ MC'3L/#7@VYCNO[;UV5#J5UIHT^[M($58!&#\N .AQU )')QQBJL?PFT]/#3: M$=8U)[6*99K$DQ[K1E8L-N%^8Y8\MGC@8JQJ?PTM]6=I;G6M0::337TZ20K' M\Z.^]FP%P#GH!@ #I5:7X2:9<1:@)]3OGEO!:,)0$#0R6R;(W7"]<9SG.MZBTKZO>B^CNHF0212>4(F ^7!#(H!!!SBGP^ ;2TU-[RSU?5[=9 ME4W,"7/RW$BKM65B1NW]"2" 2!D'I5K0_!]IHD&J+]KN;F;4R#4" G8,1[Y)/)S4LOPN MTR2S,":IJ<#/%<6\TL+QAIH9W:1XV^0C&YB1@ C)&:WKKPS;W?\ 8>^[N@=' ME66%@5S(0A3Y_EYRI/3'6N6\1?#LIX9UZVT.YOYWOHY!;:;+<@6T+R-EV0$# M'5CR2!DXQFM=? MK*5OI;^_&L?:$NAJ&Z/S498_+"X"[-NPD$8P:?:> M-*LKF66.>[99M/DL)4>0$.LCM([DXSO+.Q)SCGI4=K\/K"WDTDR:EJ5U'I6Q MK:.=T.UD4JI!"A@,'E00#@9![])IMD=.TZ"T:[N;LQ+M,]RX:1_=B ,G\*M4 M444444444444444444444444444444444444444444444444444444444444 M444444444444444444444444444444444444444444444444444444444444 M444444444444444G.1Q]:6BBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB MBBBBBBBBD!!&001[4M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%% M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%>=Z)#>^-D\27=QK.HV-Q!J,]A:1V MMPT:VBQX"DH,!V).X[L\$ 8K.\,^)-8L-?O]*N$^W6=UKES9)=2W;^8DBVXD M"A2#B/Y3T/&[IQRF@?$&];3M'M-(T.YO8DLX+B\,MT9'C25G'^L;&2H0DENO M3CK6KX AU'4M:U_6-6N':YM]3N+*-8KF0Q[%(^4H?EPN!M(&?F;--\1ZU?>& MOB+!J0E(&E>14GP>% 9%4GT:LFU\8:I;^)-EZ:=1AENH9W>9Q$?*A6 M967"DX9''!Y!_.LO5/&6IRVMYK&D016E[<:;I-QODG>10EQ*5*[#\H()Z@R>&-:U' M2].$MY:WMS8_9[N;$:K;A\2+@*Q)&.]=3X>\2WESX;U#6-?A@L[>TEFQ-$'VRPQY_? -R% M;!('/&*\\\-ZWKLOCB:X4RBZU _:K2VO97VR6$QWK,V&*+Y2IM"@ Y<@GFNN M^)0>27PL(('N3/J@A,*730"5&BD.TNO;*@_A5#^UM;\/-I6CZ9:V=O/QQ MXP)TVWDMM%CFU&\BA@EW^8/+DB=PY6.0X ,9 .[YAZ8-5K;XG>(+?25U/4;3 M3Y8YM+N[F**W1U*RV\JQDLQ8_*Q.< < =35Z+Q=XQENM-L-NBQ3WMXT*3-^] M'EF!I%8K'*0#E&_BY&.G-+X(\6:UXG\5V,]U=PQ6=QH,=TUFD1 \TRNC$$MG MK&3WX./<\[XML+R37?B!-8V*RR6D5M<1W1OV@>S/D[F>,#@G*DD97)K9D\=Z M]Y>IWEI?:6ND:=IMG=)-?6T@EF-Q&=I;:V =P^Z!SD#CK4=IX]\4W]Q;Z;$V MGV]V;Z^LY9)[8LP$,*RHQ1), G)!&XC(_"M#1_'.IZ^UHWVG2;!4M[&6YMKI M6SU_LF:RO;B-BA1X/*N=IWN M6PP._P!!C KH?B1;V]ROA5+A%>*37K>)P3]Y65\K[@D#(]JR['1]-F^).H^' MK13/X?BLHKNZLQ*S0V]YO(50,X7HYYYP!@'L"1T-=->:)I4/Q(T_0=*A7^SKRSEDUC3XG/DJ$*F%V4'"DMD=M MPR#FKGPWT+3(TU&_BM$CNK;6+^WCD3((C\T@(?50 , ],5Z#111111111111 M1111111111111111111111111111111111111111111111111111111117-W MOA?P])K$EQ*SV]S??Z^&*\>);O Q\\:L _'M]:BD\+^%K#48&D86UW->R7D" MM>NC/.R;&*+NY^7C X [53T_P;X#O9K$V$5G=R:5&(HA'>&4HF\L%!=+AO[*ZLWN+>&])U">]FO M+07!O84M[A979D>-22J[2<#!)/ [FL[5="\)F^N#JPMEGU=$MWCN+HJ)PAR@ M52V,J>05&03QUJO)H7@FWE2.9[1)K-K86QTY?)L(I(;5?-?]TD@*N =V>0<5B>)/ MAUI5UHOEZHDR;(6=[8(4"[4WNY*D#)RQR2>E.7X;>#EMHK?^P+1HXI/,3=N9@?3<3G M;_LYQ[5JZOX;TC74MTU*R2=;9MT(W,OEG&,C:1@XKGH[+XFR06EUYP^S #RYL<,<=\'CV/'%:EMX2\/ MV@B$&D6B+"DD<8\L$*DF=ZX/9LG([TVT\(>';".WCM-%LH%MY6FA$<0&QV&" MP]R.,^G%2V/AC0M-GM9K+2;."6UC:*!XX@#$C$EE4]@23^9]:BN?"'AR\OI; MVZT2QGN9F#222PABY'3.>N*L2>'-%F>]>72[1VOHUBNMT0/G(HPJMZ@#IZ56 M@\&>&+:<3V^@:;%*,X>.V52,KM/0=UXJ:/POH,4]E/'HUBLMBA2U=8%!A4YX M4XX')_,U6N_!7AZYTUK%=*M((C"]NIB@0&-'.6"Y! R>?KSUJ[=^'](U"PM[ M&^TZWNK6V"^3'.@<)@8!&>^.]3V6EV&G6AM;&RM[:W.N0*K-X;T- MM*.EMI%B=/+^8;7R%\O=G.=N,9SS5FPTK3M*C=-/L;:T5SEQ!$J;CZG YI;' M3;'3(Y$L+."U21S(ZPQA S'JQQU/O5JBBBBBBBBBBBBBBBBBBBBBBBBBBBBB MBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBO'F&E3:1\0)/$IM_[:BN M[@1&X(\Z.((/LWE=P.FW;U;/>L#6;.^U"#5FUW4R;^'P;!=OS M+E6W -D8;+=>!6K:ZS)X8EN1:3V4<4MEI33:C'9PJ\44KLCRL5'S!5 W<#( M.#W?J?CO78M0MK&P\5:48$MWFAU.YAV1W[+,5**%1A(0H"XCVY8Y'3%==XR\ M07MAK5CIXU5=$M)["XN5OG1"'G3;MB.\$ 8+,1U., CFN?\ #DC^(OB79WFL M2(9I_#5K=26$D<96.0R$[0""RX8*XYW D9. !6GKFC:"OQ0\.64FGV!6\M=1 M>:-XU)E=S&Q+9Y)/SXS[XKF;CQOXFLK_ %Q+*_L@^FM=V\6B&)GF$<:_NI H M3. H#%BY#9QP<47FH#6?$7AHZ?XPDOU%W M/?$$VDC5AXE5#;:7IUY);)%"4DDDF,*-5N- M>5&U0M/)K%Q87>DNL82WLPCE9^F[ 4(V\G:V_'I7.:1XGU&P\&6<%KJS6,EG MH5OU:*WU&[F\4 MWQA_X2&32HXE$4<<<2DE2T@0E,C W88GH!SD8*+A;G3]+MII M(%2-5>?[2T;!P4SR@4D#'WL^U;&O:U=7P\;6,^M3W,#:?>M UI.OE(%8*D4D M97=&W\ ()$@8D=C2PZQJMKXCT_3XO$$MG:F&SDL=ULT[:BK*/-^91M8@_+\V M-H4'U-=I\+I+Z^\)1ZMJ&LWFHSWC-N6X*[82CNN% 48R,9S7;T4444444444 M444444444444444444444444444444444444444444444444444444444444 M44444444445@)JWAG51=:G_HUQ)I#,)I'MR9K8J,G@KO''/ Y[5?AM]*U6!- M02TMYTNHU82R0#G:M#[#9[8%^R0;;:O:KN6TEEAGE-N1(&CX<8QN.,5:TV[TW7;*UU>S59H9DWP3O$58KV M(W $#_&K$QM+19K^?R80D9,L[X7"#DY;T'6J$=_I7VJ>T:V\A;.2*-9)K?RX MF:7&T1L1AB20#M[G%:#6]K'&Q:&%4 RQ*@#'O26YM+J*.\M_)ECGB4I*@!#H M1D8/<8-2>1$-F(D^0Y3Y1\OT]*Y*Y^'VD-)>3SZAJ@MY97NC#]JPD,I)8R(< M;@0WS#+$ @<<5'H/B/0M(\(W%U;V^K1Z991K(M/35=+L'CN%NM2B:6V!@/*J 6R?X2 1D'U%;&%P3@8ZFL:Z\2Z59ZW M<:7=N8);>Q^WR2RKB,0[MI.[USVJ?3-:M-4O]4M((Y4FTZ<03^8F,L5# CU& M&%:=%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%% M%%%%%%%%%%%%%%%%%%%%%%%%%%%>4:EHFJ2W'B3Q%X?M9!JT=W+#+;21O&NH MVOE(NWD*19D N!-'OV[N%'WET[Q% M]NL[:V)D$$SL=MRPD &0J-Y>,EMQ<;1@#)KT?PA%MI!T356M8[S5 MB&.1"898F\A-V[E=VWZ$8J'3O#VNB\T$2:1XAMX(+*T2Q6V\N,6\J$^=YI?) MC#-EB1]Y2!@\ =M\-['4;'4=7%Q8WBV\JHZW=[$T4[N7R<^E4M5\-ZTFM:+-I<^M3S'2KV,3WC!EM)9 M(E$?( VG<.>O05@V/A?58-&@1?#NNE9+BW6^ANY(9%$B(ZM(D"E5D7)7+.>2 M0Q!VU7?PKXFU/PU)9WFA7IN(_#'V1?M!5MTZ7.\ '<>=HR*U5\-7W_"3_P!L M6GAF^L6&N6$D"C:#%:K"$EX5R .,$#.>.M>T444444444444444444444444 M444444444444444444444444444444444444444444444444444444444445 MSTGBZT_M:_M(87EMM,0MJ-[N58K;"[]O)RS FPW:6#7IEN8K81K*L>&D8*IR>VX@?C3;#Q-'),UMJU MN-)NC,(88[BXC87#%0<1D'YCS@CJ/QJT/$FAE+5QK%@4NR1;,+A,3'./E.>> M>.._%#^)-#CN9[=]8L%FMR!-&UP@,9)V@$9XYX^M5+KQKXU^U7 M-P]LJ"0';(@RP;^[C@<]V HT7Q78ZC81O=W>G6]X8&N9+>&^28)$&(W[A@%> M.3T!XJ[!XAT:YOX["#5+22[EC$L<*R@LRD!@0._RD'Z'/2N>UOQQ>:3KFI:? M#H8NTT^R6^EE%XL9,1W9PI7[PVMQGTYYK5@\9:#+9:986\.HVLERT[VJ1>:,M,@RT?LP&"1UK(T+Q[I6H^'] M(U#4;BVTZXU)-T=L\V<98J.<#J<#)QR<5J)XIT&2U2Y75K3R'D>)9#( N]%+ M.,GN "3Z8-5&\>>%$L!?2:]91VQD,6]Y-OSXW8P>.[ >+]'T#3 MY;:\DO9)$N"LIW0!8C(#@#!S@=^,CUK3\6>(8_"OARYUB6!IEA*+L#;1EF"@ ML<'"C.2<'CL:J:3XJ\_8FK+9VK3S+%93VUR9H;W*;LQMM'N,>JFJUYX^TJW: M.\BO[&;2A8SWZMU*^;YMWY3N2P41Q+@[G.(M4 MLH+:UCLK%F3WFIWUJ8(+>&YO[NZDUB*0>=+;SQLI@9>IPS#J< M80$/K6M\0-&OM?\-Q65E90W;_;()I(9I0BL MB.'92<'KC'XUSU]X.U+6=#GT./0K'1-/FNEG5XKGS9K=P"QE3@ ,6"* ,8&\ M]P*H7'@'7M0O].N[[2=(F#Z?#8W5LUU(D5LT3EA(BI@.ISG8>A Y[T^Y\ >( M[CPWJ&@-%I#1P+-]AU!B3<7&^<3!6./D&1\QR M8-:GOG@6YG.>U16_PUU7_A&_#MHUS!:WMD\]K?-$^X36 M,SLTD8.T7&HO;Z9<6$E\U]%=2/)]HAW+@QK&/DXP &[ M+^&&^)_!5]K/C&^U-]!T;4[.?3X[2);VZ9&C=68E^(SC[V.#GCK5+_A7/B&V MTJXTT7]GJ*ZEI$6F7=Q=LP:W*%]KH #O #D $@Y4'-6V\$^(H?$:2VTFGOIL M6N+JRR2S.)G_ -'$10@+CMG.><]JQK+X4ZU;0:9'.FB7@6R6SNENS*ZQ;)7= M9(P W#_ '6P,@N-IOP[\2V^KVMS=2:4UNNIV^H3+]IFEDRD!B8;G7YLYSSC\!Q5I?!7B M73-6M9[>?2YM/TR_N]0MF<2>>_G(_P C*JD'#.>0=2\'WAO1AR<,N1[9]JY&+X;ZK: W6FMIMBT>K0:C;Z6LDC6L6R-T M?#;006WYX4 ;0/>BU^'&MKI<=E=7U@3_ &;J5E))&'^]=2&0,%(Z X&,_P J M6U^'&L)K4-_)=:.VFVNV.V$\ #@\BNP;Q=HJ:U_9373"?SOL_F&)O*\[;O\KS,;=^WG;G-8.K_$2U M$5F^CS(VZ_LXYS=V\B*UM/)M$L9.T%3@X;D >3[\5W,-Q'>6<=S: MRH\4T8DBD'*L",@^XKA?#_Q%EO\ P7J&I:A9JNKV+^4UG$"/.=\"2<.&7 MOZ]A4^B_$.V?0]%GUD2+>:A#!-(;:U?R8?.8K&",X JS:?$K0KS5 M(;"*+4E::Z-FDTEDZ1&8%@4WD8S\IX]JJR>/$3Q'#(9<:$VD3WS V[>;NCF6 M,,,I3\4-"4(OV;5#<--- ;9+-GD62) [J0,C(5@>O\JS_ !A\ M2$MO#'VKPV99[IX;:Y$OV??'#',X">9DC:6&[ Y/'(KOKQKE+*=K.-);D1L8 MDD;:K/C@$]AFO.[GQAXET>?4]+O9--N[U9[*VM;NW@=(TFN&QL="QR57Y^#R M",XS5/7?B!K6C:9,EU/;P?8=4EL+S44MO,R!#YL3"+<.6R%;D@8)XR,:.H^+ M_$5O?^&8;J*'2[6^AA-Y>FV-S!Y\A \E75QL]F.1\PYXR;ZZQXET_P ;V-EJ M4^G36%]'<32001E6L(H_NNTA/S DA22!R>.E'CSQ)?:1H/\ ;6D:SIT-K!P= M\!N!<29&(RRL!&OJW./;OF:KXSURV^)5GH<3VJ07#VQMXMJLEQ$X8S.9,@JR M[3M7^+'0YX-*\?WGVG2=5U.>!-%UDWOEQF/:;-8-Q1BV?FW*C9]R,>^UX*\2 MZEXAOO$$>H0);"TND2WA4@LD;1*X#$?Q?-SZ$D=JJZ;KNL3^ O$&IS7R->V4 MUY'!)Y"@ 0LRKE>^=O/UJYXYUC5]"T&RNK%9VB^T(M_=6]N)I8(=IW2+'T/. M,\' )X-:7A'4GU?P]#>MJ=MJ:R._EW=LNU9$W';E?X6 P"/4&L;P]XV?5_'& MJ:1)Y'V,QF339(W!:18V,*_MK;5I;];[3[N. [H"$$9C?GYT91@CCJ:5OAU<7,\EO>:C"VDW&HC5 MI[>.%A)]H*X=5:?;2P)%']EV9MX MCG#$-DNP"KNZ \9.:MW'P[GU30]&T_6-8-S-I5SE+I8BKS6I&UH7^;GWUE>*AMBQ3[-C"YW#.[:.>,'4+NY!ET]9H_+N"I9"KM]Y2@(8$>F,5U>B0:W;W&I07TT ,5B67P\2UN;"^?4/,O[33S9[A"5BE< B.5DWKH"_R%N W3TXS6QK7@(:G.&L]4DTZ)-( M?2HE@B^>-696W!MPZ; ,8Z$\\UD:9\*YM/U=;_\ MV)E26>9;>+3DBC#RPB% ML!6X& "![?4EDWPEE;2/[.M_$DL$,UG;6MX%M%;S_LYS$XRWR$# ."<^U>BW M$4\EC)%#<>5<-&52?8&V-CAMO0X/.*XNT^'EZNF3V6H>)KB\!E6YMW%I%&T5 MPL@D$Q(R7;*CJ>F1]'3?#E7$5RFK2#5!";Q-:O;R^ M\0S7UK?.3=6:JW7P[LI];%['>S0VC7%K'?!>C>%]0 MU.[TNUB@-_(K,D<:JL850-JX'3(+?4FJI\$A6O+6'5[J+1[ZX>XN+ (A#,YW M.JOC7K746O7UO(DXFMU18RD7[LH4P5^93G<0>?-,,;R-N%VXRH7 ]\8.[>=.1OPS$@< # !P/85 M;HHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH MHHHHHHHHHHHHHHHHHHHHHHHHHHHHR/7IUHHHHHIC2QI(D;2(LCYV*6&6QUP. M]/HI&95&68 >I-(CK(NY&#+Z@Y%.HHHJE%J^F3WGV.+4;22Z&?W*3*7XZ_+G M/%7:*JC4K$N4%[;%Q-Y!7S5R)<9V=?O8(..M6JJ-JFGI<-;O?6RS+(L31F50 MP=AE5QG.2.0.XJW111111111111111111111111111111111111111111111 M111111111111111111111111111117DD-A-?^,O$Q:P=[2VU6/=??VF\)LT\ MJ-V*KT(R2QYQR>*W=;\>WPELK;1=-F@FFU2/3WDU6RECC;>'(>,@C>!L[=B* MQ+7XD^(1IJ7M]'HT:7%AXBU'4K$R-&T7 2&"[R%+*<,"6]JW?ADU^?!WAL>?:FP.E M&0WGF M7=][.<;,9[9SWJUH4T5KXL\;7%Q)Y<,-Q;LSNQVH@MD8_0:Y]B@;10EHUK'> M2&4A)3*F6>+)W$;B @P=V#SZ4M$\;>*;ZTA>2*QNY[S2DU"&*WB,97]^(W4% MW(9MIRH.,L .]*GQ U2^N8XM/N-.5(H(YY9-0!MC(#.\;@HZ(ZX_P"6384$?PMR."<;DWB?4;6Z MN1;26R6^FZK::6UB8OGECE$0W@YX.9"0.F$/X8&G>)-0BL_#NI79M]8N_+U> M4/)"OG*T08A$8?=W8 P!TP.@K0N?&VHP6]@8M=TFZCU*6 "XC 068>.1B&8[ ME&YD"KN&1SG)JUI_BS6!KNDV^J7UDUO/Y<#2Z:@FADF8/\K9(=-V%*L 5.#U MSD:OQ2*#X;ZQO"$;(P-_3/F+BN8AUB7PN?&M]Y5K:ZK"8772XLBW6+@"Z7CY MP0Q+$ 8V8(R,FROB;7)KZUL%\3Z0(KJ2ZVWT"+.(E2.-U!;Y4+E))_P"S2D,4: (DSXW-SG(51C@?7-68/$>H:A?SZ1?WC'[1+]ZR9'B:W#R9 M,;I\RL0@C96^8$Y!],JUUV75+;3;>UGMU6YTV;48K*V1 EOT2WBC<#/F*QR[ M9XVG( XK4N_$NLOK#PPZXD,)\0KIB 01D")[<29R1RP/0^_(/2L:[^(.KP:- M;R)K,4EY!$\DH\J-1(%O##N;KNRB\J@&,EB1\M:TVI&^U"$22VY$'C-8(F1% M4E?L^X X^\W.,GGI4WBOQ;=?;+F;1/$$<5E!HES?(8TC=9)HI F"6!XSD$#T MK/UO59=2UU[5KR%-FM:5]GD1(]T>^(L2#CYN+;D?#R\G?5('UJ* M*_-O),JYD$$CIO*J,' "YP,([5-/O5E>^M+RYNM,A(C4!Y/,/V:*WCCDE:9T0*TC N0.2<<9/M4E%%%%%%%%%%%%%%%%%%%%%%%%%%%% M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%<[<>!/#-U>7%W/I:R3 M7,GFSYE?;*WJR[L'IW%:NH:18:J;4WULDYM9A/ 6S^[D'1A[C)K,/@?PR;=; MG^'-'TJ2WDL-.@@>W@-O$R+RD1;<4!]-W.*@N/!_AV[NYKNXT>TEGG3#-Y"[XTQC:IQP,$C'O48\*^'Q$L0T:Q$:Q>2J^0N F[?M''3=\V/ M7FI/^$=T4M9,=)L2UBO'?FK$6EV$-M<6\5E;I!<,SS1B,; M9&;[Q8=R>^>M(VDZ:^H)J#V%JUY& J7!B4R*!G&&QGN?S--31=*CN%G33+-9 MDD>59%@4,KO]Y@<=3W/>FQZ%H\-E-91:58QVL[;I8%MT"2'U9<8)X'6DET6Q MW_:;2TL[>_2+RH;H6REXE P /8#MFJ\>CWL[[-6O[?4;3'-O)9* 3V/4_P J MT&TZQ>1)'L[=G2,Q(QB4E4/!4'' ]JR;SPCIEYJ6EW#00+:Z<)?+LA GE,T@ M&6(QU&.,>M;,EI;33132V\4DL.3$[("R9Z[3V_"FBPLUB\H6D CW^9M$8QOS MG=CUSWJM=:)I]S9W%N(%M_M#!WDMAY;[P=RN&'.X'D&JD.@3;HTNM2:>WC! MB6WCC+ ]F91T]0NW/>M8V=L3DVT).[?]P?>]?K2+9VJ !;:%0 0 (QT/6G"V M@&<01C+[S\@^]Z_7WH^S6^,>1'QP/D'KG^='V: -N\B/=QSL';I4%_IEOJ%A M+:/OA612N^!MCKGNK#IT%5M-T&WTXS.\TU[/,H1YKD(6*CHORJHQU/3J36H M% ' I:************************************************** M************************************************************ M************************************************************ M************************************************************ M************************************************************ M************************************************************ M***************************Y[_A-=$&ISZ>TMTLUO<);2L;.7RTE<@*I M?;M&=RX)..170U%<7,%I"9KF9(H@0"[M@9) _$D#\:I:/KMGKBWQL_-_P!" MNWLYA)&5(D3&<9ZCD&&<9[U?I-PYY''7VHW#CD<] M/>@,I9E# E>H!Z5SVK>,]-T=+N26*ZGCM)XK:>2",,$EDQM3DC)^9,XZ;A6C M+K$<6MV^E-;7/F3V[W EVCRU5" P8YZY9>W?ZU>:>)(WD>5%1/O,6 "_4]J1 MKB!%#/-&H(R"6 R/\D56U&_>P6U*6<]UY]PD#>25_=AC]]MQ'RCOC)]JEDO[ M2**21[F%4B0NY+CY5'4GVXK#\.>,+?Q!;BY-I)96TP1K.6>:,BY5P2-NUB0X MQRIY&1ZUN-?V:2M$UW LB\%3(,CIV_$?G21:A93R1I%=V\CR LBI("6 ."1S MS@U3O/$VB6%J;FXU6T6$3K;%A*IQ*QP%X[\_@,D\"DM=>@>"]N+X16%O;736 MZRSW,960#&'R#AUB+!0\\@17/<7:RF1HYE)MRBAL.O49!XHLO%MC<^)M4T*(;=9M2- M\]I9VME(D8N)+R,AMR@_,,_NSDXPW)ZUFZEXVA@\1VNAZ7;1:E>36XNF5+M( M_P!T6 !3/#M@E\9'RKG/(K8UGQ!I>@+:MJ=Y';_:IUMX=[8W.W]!W/:L_P - M>,M/\06DC-+;6EY$\PELVN5:1%CD9"Y'!"_+G..]:]MJVFWEE)>VM_;3VL6? M,FBE5D7 RW".8"+I0L[J"=BMSSP1WI^G>*]+O+'39+B\M;2[OK1+I;62==ZJR; MSUQG SSCL:6+QAX:F6-HM?TV19)1"A2Z0AG.,*,'K\R_F*CMO%5BMK<7&J7> MFV4:7DMM$PODD5PGIAXN\-M>0V:Z]IK7,S*L<2W*%G+?= /. M<<5,/$>B-/>0C5K/S+)2]RIF7]THX);G@ \$]CQ5#PKXKA\4IJTL"1""QOFM M4ECEWK*H16WYP,?>QCMCK5B/Q?X=F,8CUFRY[>O:HYO& M_A:W\GSO$&FIYP!CW7"C<"Q4$<],@C/M3SXQ\-BZNK;^V[$W%H"9XEF!:/#! M3D#G.X@8]3BG)XLT"4V0CU:U&SE MTN6WU!)=2M[*X*RD>4LI(#C@[AQD=CV-;=CX@TC4TM'L=0M[A;P2&W:-\B4( MS7,[I.[ 9RB[<-G#8&>-O/7CI?^$Q M\/9N -5@+0%0ZKDD[FV#:,?/EAM^7//%7#KFF#15U@WL0T]T5UGSPP8X&.Y) M) ZY.*S;CQYX6M+:WN+C6K6*.X=XXMQ()=" RXQD$$C(/(JYJGB;1=%NX;7 M4M1AMYI@&5')X4L%#-C[J[B!N.!DXS7#:_\ %2;3-1U86EK:S6FFW*6<@E\Y M93(X7#C"%=@9L%>IP2#R =;3OB!:V=G>3>*-3TBV$-RL"-:&4Y)3< RLN58C MG'-7A\2_!S-M778">0,(_) SCI][!X'4]JOQ>,?#]Q)9)!J4"6 /6M#5 M?$&E:)9QW5_=K'%+GRRBM(7 4L2JJ"2 H)) X'-5!XT\.M>6MJNJ1-)<^5Y3 M*K%"9!F,%P-H+#D D$\8ZUF7'Q0\*Q65]<07[W+6D$D[11P2!G"'#!25 )!( M!YXSDX'-6QX^\.*UM'/?^1+.B,$DB<;"REE1CMPK$ D*<$XX'(JC=_%+PO%H MUUJ5I=RWJVZ1R&.*"0,RR-M5AN497=P3T!XZ\5NZ?XGTG5-2DL+.X>2X16)! M@=5^7:' 8@ LI=05SD9Y%1MXMT1-6;3#>YNED,6!$Y4R!=YC#@;2^WG:#GVK M*\#^*-2\6Q7&I/#;PZ87DCAC\J5)D9)&7YBWRN"H!RN,$E2.*["BBBBBBBBB MBBBBBBBBBBBBBBBBBBBBN T'1+F7QWXCU!Y=3M8!J"310NA6WNA]G$9)R/FP MV3P?X0:X>ZT3Q))H$ZQV&LIK'V"[CUAP9,76?'G*TGWCN+;6?C/>N/3P_KZZK=7NE:;J=EJ M%QJVHK%,X=52&2V(B)YV@>85Y]5SVKLOAEIEQI]K>S366MVAE2$31:BR!?.1 M2',2*.AXRY^]QZ&N?\"7.N>&-'UJS_X1C57OKW6)9[<26^(A&Y4!G;/ !)' MM6!:>%M>-GI5OJN@ZM::2"Z%G+$\9AE@> JD3L3N9E(4!1QNRV1UK/TSP=KD&F:C9'1=7M M(KJQL [Q(K_Z3$09'*,V)!GJO<9QZ59L_!?BN37O#TVHZ=>V\,5K%Y']GO'B MSE24L=V\_(K [CMSUVC(&!T7PP\*:YHWB74+W6K:_2$FBFN&EB^SW(,N]& M'SNW+PF&CW]YX6\3:/;Q+)J]KKYO\ R'<*9T,ZSH03_>0;03QE2.QQ M+XW^TZWX=U[5)])NK*TM=#NH MZ%#R2,4<$*K'A?+ZGJ3QTK"L_".HK>Q:OI M_AV6+0?M%K+/H'(IVF\/KIR+YD0-E>*6S-UQAB58NN6R@R.E.O?AU>3:?KCR^'X+S4YM5MI M8;F3R0\\*^5YISN^4,8W.#@G?[FI;;P)J=EJZW5GX?MX=NNW=PCJ\28M9("B MKE3D+N/*CIR<9K)L_ ?B=;:5IO#41(.F3"!KJ#!:VD(=% & I1CC<2<#DDDB MMZU\(ZW9:J=1;1(Y[6+6[R[.FB6+$T4\2HKKD[=RE6X;'#'O6-YN6T:.VM96FC/DRBY>0(I;D!$95W=]GTKL?B/X>UGQ%#IJZ9803!8[F M.-FVVH EPW M;.T?7/M6OX>$>(-.\4:(]UIML8-,FOS-J2W"E[M9R65BN-V1T.?PXJ76O M M_J?C#5+D6%J8[Z\L;J#4RZ^9:+ %WJ 1NW-M(&./FY(Q6/'\.M>C\/ZQIS:9 M9O?-93V<&I&_D9KI9)0P_=M\L8ZLW7)''4FK^L^#-?N]6O\ 4X+"&53J45XE MFU\T/GI]E\EQO3E&!R0>^3]#:L] U;POJ@U>WT:Q6WLO#YMHX8KEBJS"0R! M2"Q7!V[NI/85N>)--U/Q%HWAV\M[&)+RUOK;4)K.YDVX 5MR;L'D%O3^&N/E M^&VMWNGQVQAM+25X]52>=96.E:D+W3K/3K MF^X9(+J6Y+$)MWN[G)/H!T ')KBE^'_BJ73X+:XL=,Q!IMAIX'VLMO\ L]SY MK,04QAE!&/<>]7)/ WB2WN;ZZM+339OM,VI1K!+<%52.Z*%900APPV[2,#C!>/ 6NVVD M>&K>PM;*UU&QM5@GO(I\(<.I=9(RF)D8*#V(8#GO6!XITR^T348X;N2RM'O; MW5)UEDN3&C6]R8P8PYB91(1GC&?E!!Z@[=AX1U;4K634+72K>PANO[*:WMI[ M@^9#':MEE)V=P!COZ@=*9%\+]9ALKJV2/2#-;R;[2\=Y7DNP)UF"2J>$4[<- MMSDG/8YZC1?"^K'1?%=KJK6UK-KMQ-*AM)6D\D21*G4JN2-N:P+/X;:G+X=F MT>^M=(M%NO)BN;FSEE>4I""4D4N.&W;0%Z*-W)R ,^[T;6]2\2?\(_=6VDC4 M)_"HL;B1&;RH5,S+YD8V)E(F4@C# M$JP8L?05':^!-?MK&"(R6<5M:ZG97D5G]IDF2!(23(L;LF[:Q(VH>>:UO M &F1'4-7UNU:Y&EW%P_]F0W$1B,2.0\Q"L 0&ESC(Z(,<4ESX-UF?5-9M5N] M/_L/59VNGDDC9KNWD:$1$1Y^7L,-U ) ]:R;#X3737'A35[GP1I.FRZG%-K&FS072W$BGRYI8GW M /CD@],]<\]:I6/@C4X?%=AKL\UCN^W75[=PINPIEA6)5C..!]8AU=+R2YL9$7Q!/J^W+@['B\M4Z=1US[50T3X<:UI59)8Q([O$R'Y75MW&<%221FM7QIX,U?7]5GN]-O;.*.YT>?2YDN5 M8E1(P;>NWOP.OI^6=<_#[79K^]N8K[3XH[F6R9H/WA5D@A:-D+## $MN&".F M#P35GP5X#UCPMJ>GSSWUA-;V^FFPE6*-PQ F>167)QD[^<^F .]+?^!=9GU^ MXNK>]L!9RZW:ZL%D5_,_=(%9"1QCY1C]:S#\+]566VN5N=%N+@-=).M_:&XB MV33&4.BG&)%)(]",5U/B#PSJES=:'J&AWUI!?:6DD(6[@+0RQR*JME4(P1L! M&,#M65)\/]1>>[M'U2";2]0N;:\O&>(I.)8=F1'M^4*_EK_NC.,\52?X:ZM< M:9%9S7]D-MKJ<#.JN?FNVW9 /]T\>XJ6/X=ZJNMR:D]SHLKW*0R7#2V&^2*: M.,(!"Y)*H=JY)R1SC!-5I/A?JDNE+9MJ=FK1Z);Z:C"-R"\,XE#$9^Z<8/>M M_0?".IZ;XONM;N+NSC2X1Q/#9(Z)=.Q!#NC,55E (RO+9Y]ZR^ KQ=4VM?P/ MI*:RVN1(4(F$Y!/ED]-@<[L]<<>];G@S0[SPYX=33+VXAN)4GFE\V%2H;S)& MDZ'IRQ'X5T%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%4'UO28KN>UDU.R2X@C\R M:)IU#1I_>89R!R.3ZU'#XBT.Y9%@UG3Y2\ODH$ND;=)C.T8/+8(XZU9.I6(L MI;TWEO\ 98MWF3>:-B;3ALMT&",&L@>./#+:E!8IK5FTD]J]VCB9=GEJ<$EL MX]>/16]*4^-_#?VS2[6/5[6:34Y'BMC%(&5F49.2.!S@?4@5,WB_PVD,DSZ] MIJQ1R")W-T@"NIP?R-+9^+?#NHRB*SUS3YY#";C;'<*2(QU8\\ =ZBD M\;^%HK1;J3Q!IR0,[1AVN% + 9(Z]<$'\1ZU"/'OAHZG)8C5(-T=FMZ9=P\O MRFZ$-W)'.!ZBM>VUC3KS2O[4@O87L K,;C?A%"DALD],$'.>F#7-ZY\1M$T[ M01J-C>6UVTETEI&-Y"I(Q'+X!*@ [CQD@<=:?+XMMM,?2(]8MK:WU[5%>*%( M6,B$*&9?WFW(1B%[9!;IP35?0?'?AOQ9X6,VHW&GJQM%GO[.5@ZQ*3C#;A@C M/'UQ6W%KEA)X7N=0T)K>Y@LXG"1(2BJT8YC(QE",8QCCTJAX5\8-XC\!KXHE MLX[1&CED$)F+ *A88H^;;G< M!PN[C)P,\5;E\=^%X9]0A?6;<2:>I:Z')\L!@I/3G#$ XS@]<5'#\0O"ES92 M7<&LPR0QS) =J.6,CC**%QN;(!(P#G!]*G'C?PT;JPMAJ\'G7Z(]L,-AP^=F M3C"EL' ."<<5-H_BO0]?N[BUTO48KF:W&7501E;%))$RBWE/SI]Y!\O+#^Z.:LCQQX<::RC340_P!M6)H72)V3$I(C MW,!A"Q! #$9(-9=U\0+2+Q;::?#/ VEFWNY;NZ>-U$9@QNVN<*P!)!QG!':N M@T;Q'I6O0W$FGW7F"V;;,KHT;1DC(W*P! (Y!K,;XA^%TM+FZ?4BD-O"MPS- M;R#?$S;1(@V_.FXXW+D5:N?&6AV?AV'7KBYEBT^:01H[6TH8L6*@;-NX<@]1 M_.J\7C_PY-<8SQ7-:#\489;"/5M M?N+>TLKQ6>W@2UE$L(5RK,YY#1X*?.,?,6&.*V[CXG^%;:XN89+RZS;S>1(R M6,S+YF0-@8)@GD<#K5B'XA>&9KV.U_M#RY'0MF6)D52$\PHQ(^5@AR0>1TZ\ M57\,^,7\1^*=8LXHV73[:UMI[4R6SQ2.)-^20W4':,$ =:2P^(^E7FG&[:TU M")CA(S3-/\ '6A:GK8TBVFN/M1EFA7S+:1$:2(_O$#, "PZX]*P M?%'Q&?3;O5+*RM9HY-+N+);F>6W9U=)I K! .^T@@\YYP.*OOX[TZ>?2YX;\ MVEH\UW'=0W-E)YF8(V9U)_Y9E<;N0J[2#D>_H:Y;3_B)'M9@^*WAWREE:+5%C:*&?>UDX40R':LI/]S=QGUZ9J M6[^*/ABSO;ZU>XF>2S25G,4>X/Y7^L"X. M74HK"2&2'RGCWIYBMAN<%>1^N*U_$?C/2_"\L::@MT59!(\D4.Y8DW!-S'CN MPX&3U.,"LV7XFZ%!->QRPZ@GV2Y-F9'M]DF&Z]?:HO^%F:2MW/;RZ;K$0MKA+:>5[3]W% M(Y4*K,#C)+K4%_\ $1'U6/2=,L;II9)+VVDN'0;8)(%&3C/S#+*?I69:_%"4 M_#ZXOFLKI];M-'BOV$L 2.;>"/,49YC#@YZ' XS6EHOC46D-U;ZS-?SW45W: MQ-YMG'$\0N0!$&V.58;L\CD9 (X)K2\+Z_=W'A[5K[59#,UA?WD),$/)CAD8 M#"KR3A>@Y-5!\3=*;;&FG:K)*OB: MK^!Y]0\,)=M>&R2\\WR%9;5#)L_>ACU)5Q@;OND]*ZWQ+XKM/"UA%=7EM=3J MZNQ\A%PJHNYBS,0HXZ#.6/ !-54\>Z9-/'Y%K?RV9V"6^2#,-NSQ"4"3GWBM9I(%V2B?/EL"&X'R\@_,,C(J)/B5I M\TUA%;Z1K-P]XTP40VZOL\J7RY"V&Z \\9X([\5GWGQ6@^RO_9VCWLMXES:1 M-!*8U(2=]JL0'X;@C:V""1D 9-:^G?$+2=3\4?V%!#=><9)8EFV Q^9%]]3@ MDKCD D $@X)[ON_$=UI'BF\TR>":^CDT]M0LHX$'FDHP62$#(#'E64GU(["N MGB?S84DV,FY0VUQ@KGL?>GT4444444444444444444444444444444444444 M445XSK_@/Q7>^(-1NX--T^6&66_6(+=")62X@\M7*;?OC^(DDG Q@"JVI^&Y MM L[HW,%M87]PFFC0Q;_ +QFOK=#\NU5QR6(R>Q.:]%U/PSCX?/H,%HE\_EH M&1IS"97WAG<.,[7)W,#_ 'L9XKBKGP)XPEL8F5=+N+N73+JRF-Z58J'G$J%@ M$VR2$#!; &XEN>[;'X=^*8]06XD^Q1JVHW<[,UX\LJ)V!2W'PQUJ]M8 M[5Q8VP8ZJ9)HY22/M1!CXV#( &TC/0\5=TSP'K-MJ&CW\VF:)!);W;SW,=M/ M*V_]PT:DM("6.YLXX"A0.356R^'.O6FFP6ZE3+13O)E&5 M,@D-D-_"P'!%=(W@[5+_ .&-WX:U#4\WUP'*W#-YFW]YO17; ,G 9L MDUE MZAX*\1:E/=ZJXTR'4+R^L)Y;=)W\M4M23]_9DLQ/H, #KBNC\3Z#J>I:SX?U M33)+19=,FE:2.Y9@KK)&4."HZC->8QBL8V2!690H))&YSQDDC/;M7 M.^'O!GC+1/"&G^&$N](CM+=W:>XCEE,DR%F;9@H H)8 G/0>]5]!^&.MZ%=: M5.EWI-TL>GC3[V"ZB>2,JLQD22,=V''!P,C.?2HGP=O[>SUZSBN=,D6\69;. M[F64W"+(P)5CG: !NZ#+$\XJ0_"G5YHM42[ETBX2^:S(0F53'Y$+1@HXY5LD M$'GH000:FB^$=VFOV=]<:A9ZA$;2WAO&O87:021# DB 8#)' +9QDGFMCX>? M#R7P5)+Y\NGW&Q&A@N8K=EN'C+[L2,6(XP.% 'KFFV7@35;75X+YKZS/DZS> M:F$"/R)T*!L:+X5:XEII5N=9T]ET]+7RM]O(VQX92^5PP'S \D@G MC P#5@_"K4KBUATJ[UJV;2[6WO;:V*6S";9<$,"QW;2591T R![\=3X;\+3Z M=HE[9:I)I[R7B>7(--LUM4V[2N<#DL*-"N=?TRTMH;F*WD@O(+HNT98'RG M#X !'4@5CP>!;FR\6WNK6M_:"UNK@WABEL5>99BH!42DY$9(!( SV!&2:QK? MX57MK;:/Y6L637-E;O:2O/IRS))$TAD!5'8[74L<'GW]#I-\/[S['/ NJ0_O M/$":R&:!OE"E3Y?WNOR#YO<\4VY^&GVG4=:!U5$TO5FEEE@%FAG221"K;9CR M%S\V,>V<9SI^%O"NIZ-JUQJ.J:Q#?S2V<%F!%:>3A8BVUC\S9)W'/2L^R\ 7 M^F7,%W8ZW$MS;7-V\'FVFY/)N&WLC@."S!@"&!'3&*T+GP1%_P ()8^%K*]: M&&T:W*SR1^8S>5(LG(R.25_6JVG^!+BRURPU)]4CD^RZA?7QC%L1O-SG*YWG M&W)Y[TW7/ $^KZWJ5['K MX+]K-Y(#;!R&MWW+AMPX/3\34:_#RYCODNX]:1 M9$U"]OU_T,'#7,93&"V"%W$\CGH:NZ+X%@T[PWK&B7%R'MM4\P/%:QF&*!73 M8PB0LVW/+=<9/ XK)A^&=[YJW5WXD,]] MJ+6862H(VMRVPL WSY#L&'&<] MN*LGX=W,%^FJ:;XAFL=6EDG:]N8[96$ZRE2RJC$[-NQ=IR<8YS22_#F;^UWN M[;7I([?['^]U/(Q4\OPVE:VUJQB\03QZ;J(F*6OV9"(7FSO.[[S+\S84D $YYQ4ES\ M.Y+G4KC4/[-/A]_PF-TLSZS/:(+5K M8Q"%95&7#;UW?=;@ D#ZUJZIX3_MCP3<^';W4[F9[A?WEZRKO+[P^=HPH&0,*.,<5G-\/C+I&LV< MVM3O/J=Y%?&Y\A 8Y8RA!VC@C,:Y'UJ"+X:^3=)=KKUT;H7=UZ@;O^W+ MN'S/L;W$<<,>V62V.8VY!P/8V9*".[9$$89B!E1M" M@A2,[1G/.6K\-572H;)O$6J2FRFAETV278WV,1'* +MPWH2V20!Z5/I7P]AT MNZM)EUF_F^SI=IAP@9_M#;W.Y5!!W $$5F0?"2VM[WTS^S;2Z0H9F9B&DG/&T$E5 &.S'N*ZJ)6CB1&= MI&50"[8RQ]3BGT444444444444444444444444444444444444444448'ITZ M444444444444444444444444444444444444444444444444444444444444 M444444444444444444444444444444444444444444444444444444444444 M444444444444444444444444444444444444444444444444444444444444 M444444444444444444444444444444444444444444444444444444444444 M444444444444444444444444444444444444444444444444444444444444 M44444444444444444A('4@4BYRV7#9/''04ZBBBBBBBBBBBBBBBBBBBBBBBB MBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB MBBBBL[6+LVUJL:2>5),VP2?\\U RS_@H/XXJE:W$NE^&EG*2/)(Q:**9R6&] MOE4D\\ \_C6U!)YUO%+C&] V/3(J2D9E1"S$*JC))Z 5DMX@C9A%;V=W-.Z[ MH8_+V^8O][)X"^YQUJW9:C%=P*[ P2^88GBD(W+(.J^A]>.HYJY15:]O8[& M22+(Y9@J1QKN9R>P'YG\*ADM[+6K6&61&DCZK\S(1ZY (Y^M4)?"&D,S216Y MCF/\18R#\5;(IUMHVFN[V]SIEJLT8!W(F ZGN/3Z=JL_V#8IS )[=AT,-PZ_ MIG%-MGN[/5%L9[DW44T;212.H$B;2H(;'!'S#!P/?-:M%%%%%%%%%%%%%%%% M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%% M%%%%%%%%%%8OB+3WN[>&Y1D_T-C*TE9UR]^NA6L^HS*]Q M/<>;L5<+$"C%4'KCCDUT<$L:-':%AYRQ!BN.W3/YU8JGJL33:5=(I 8QDC)X M..<57T-UN[(:BV?/N?F<'K'CC9_P'I]6]QJUPD#!M]O8QR\ CNQ_C/L.![]:OW=K/(?-MKN2*51\JG M!C/L1C^59Z7T=SJ$-S.OE+:VCRN"?N,3M;/TVL/QJ[HR.NDP,ZE6DS*5/;<2 MV/UJ_5:H16K+$%::X?[D,8RQ]SZ#W/%,LK.5)Y+R[8 M-=2J%POW8D'\*_U/?\JO4$@#). *SI=)YX=FG1G+*EREQ)L/W(5/S,?;D?G5.;5EAU3 M4-260-!+:F&S(/$KH>B^I+-QZXJ.SU:9[JVO1,7A_L_[."S<&YP'()]>,?7- M4M"UQ;O2-=>2Z M(F40F4E7;Y!O;GDAFSCZ<5T$%U_Q,A)8;!]O@:40N>CKC M:Y Z @X/T'>J_P#92VFL SR-<7-]931RS/U<@J< ?PC!. *Q;G48/[)D%P_E MZA,+<6\FS<4C"IEP>R@[R3V-;T?C72I;MXDX'^KC&.&9N@4GY0>]8 M\9DNM1DNUM[B;2I9V:=HXRV]-V8]HZE2P);';'J:VUUV_%S*SZ->FUD"BTVQ M_.QY#>8,_(,XQGMGZ4K>)8]+7R_$'EV4YR8RF6CE'^R<9R,@$?TJN=3FU_4+ M6WL91%;H_FS2QGF2>O2M^WM;>RB(B4+W=V.6;W9CR?QJJVMV MC2>7:B6\<'!%LFX+]6^Z/SIK?VS=Y"B"PC_O']])^7"C]:5-%M78O=2S7KGK MY\FY?^^!A1^578UMK:/9$(8HU_A4!0*SO^$J\._]!_2__ R/_&D/BWPV" ?$ M.DY/0?;8_P#&H_\ A,_"W_0RZ-_X'1?_ !5+_P )GX6_Z&71_P#P.B_^*IK> M-?"B+N;Q-HP'J;^+_P"*I&\<>$U +>)]&&1D?Z?%_P#%4W_A.O"/_0T:-_X' M1?\ Q5 \=>$3T\4:-_X'1_XTW_A/?"'S?\51H_R]?]-C_P :9_PL/P9_T-.C M_P#@8G^-+_PL'P<.OB?2?_ M/\:0_$+P#6Y7Q)IY^DH-(?B1X- S_PD5B1G'#Y MJQ9>._"NHR^7:Z_8.^"VUI@IP/KCUK0_X2#1<9_M>PQZ_:4_QH_X2#1?^@O8 M?^!*?XTG_"1:)G']L:?GKC[4G^-,'B?P^6VC7=,)]/MSC^W= M,X_Z>X_\:4>*/#YZ:[IA_P"WN/\ QJ>TUG2K^;R;/4K.YE W;(9U=L>N :O4 M5CZOXHTG0[F.WU":9)9$WJ([667(SCJBD"J'_"PO#?\ S]7G_@NN?_C=-_X6 M)X:W$?:+[C_J&7./_1="_$3PVV<3W^!U)TNZQ_Z+I1\0O#Q3>'U+;Z_V3=8_ M]%T)\0/#\B[D;4V'J-)NO_C=./C[0L?\Q3_P477_ ,;I&\?Z$J[MNJGV&D76 M?_1=-/Q T08_3T']C77_QNG_\)UI7_/GK MG_@FNO\ XW1_PG6E#_ESUO\ \$UU_P#&Z;_PGNE[RO\ 9^O<#.[^Q;K'_H%; MNFZA%JEC'>0Q7$4;DX6Y@>%Q@XY5@".GI5NBBBBBBBBBBBBBBBBBBBBBBBBB MBBBBBBBBBBBBBBBBBO,+I=%;7KBS74_&<@2^2SFN+?4I?(AGD(VH?GR!\PYQ MM&<9K4T_PIIDUN\MSJ'B:TQL67A?1]\)U$:?=2)JLP%NYC+[C^\Y7"D9Z9!':KUUX7\%M]G6.."S M@G?;%=7>HRJ9#T_=*TF2><9Z<]ZL:[I/@[3](G$5K:ZA=6I"_9?[1,1)W '< M5/! R>1VJ@VB^!KK4C8VUKI=M=!BC+?7[&4$#)Q%OSD#GG'TK2L-&\!:;HKW MT5[I\T"MY9G^UA$,F.%+*>OL<\4 M"@Y&23@#IUI(]%\(Z=J=E:^(?!%GI(OHW:VF,_G)N5=S(YXV-MR>X.#@US%M MK'@^[%B+/P;X>0:H[K8M->;0-F[(G&S*,=JXQN&7'/!KK=-TKX<2:!8ZCK.C M>&;&6[9PJQS)-&2KE3B3 !&< GH"<9K5AG\&6D&H-J6G^&K6UM;YK2$Q+')N MVJ#AAM^5P,Y49P!FK.G3:)J/BVZT>'0]*>UCL(+V&ZCC1A*LA8#C;C'R\$$Y MKH?[ T;_ *!%A_X#)_A3UT72D!":99*#U MU']*<-)TT=-/M!_VQ7_"E_LK3 MATL+7_ORO^%.&GV0)(M+<$]2(QS^E.^Q6F2?LL&3U_=BC[%:_P#/M#_W[%+] MDMO^?>+_ +X%.,$)&#$A'^Z*=Y%MT4$2-C&50 U+17,>)]7U6QUGP_I^FRVD?]IW$D$CW$ M#2;-L329 #K_ '_M)(?(;3HF*W*2ABI"DG81L;= MN...M(GQ1TA[UR8+A=+73(]1^WLF%(=BJKMZY)!7_>X]ZZ#PWXGTWQ58S76F MNY6"9K>9' W(XP2."0>"#D$CFMFBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB MBBBBBBBBBBBBBBBBBBBO,=2T'5F\;KJNE:3>:=J3W\:S7<$R?9+RS4C)F0MG M>%R!AJ,/@'Q-Y%V)?"L1 M\RWMLQ?:( A>*[\QE09)(9"0&6D5Q;V6@_8I+P.IVS^8'P ?F*A1M!_E4_BKP;J?BV;7I;B6 MZM-ELMOID<$L6V7;^\#-D$J3*%Z%>%7FL?Q5X5\7Z\CW0TJS:\U#01IMT&N@ MH@E67>6!P=P;L.WTT^WE:XM9;-A<3H1 &E:1205(*;G)(7!^51VS5O4/ ^M7?A3 MQ3IC6UK/7G)QE(=7UF2:RTZWCNH7M+& M<7&1:1/S(^P)\TDAX+9X!QSW73O _B"QOM-UN#2](M[VUN2TUB+V9TG!B,7F M&5PQ##)VK@X7(SDUK6?@*\G^$-OX1OYX;>^B0%9H"9$619/,4\@9&0,CZU=G MT;7]=UK2;[5[:QM8M'9[B.&WN&D^TW!0JIR4&Q!DGN>?;G'T/P7K^F6W@>*2 M.P/]@M<&YVW#?/YBLHV?)_MDG..F*J:7\/O$NCPVPMVT2?SK26RO8KL/+&B- M7=ZM/=L'F=&,4EN(A\ZKN4@KD MJI 8'!..NMX*\(ZOH&H6]QJ$EBR1:-;:;BW=R=T3,=WS*.#N_,5W5%%%%%%% M%%%%%%%%%%%%%%%%<_XB\/7>LZEH]]::DEG+IDSS)OMO-#ED*$'YACAC6-=_ M#D7@EN)M9GDU*YNXKF[N)85:.98U*K#Y7W?+&[(!S\P!.:H0?".&/3A8R:]= MR0_V>MB<0HK?),TT3@]BK-T[X&:[/0-*NM)L6BO=3DU&Y=MSS-$L2] %1>% M''XG)K5HHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH MJI>Z7I^I>7]OL+6Z\H[H_/A5]A]1D<&K=%%%%%%%%%%%%%%%%%%%%%%%%%%% M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%% M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%% M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%>=7GCG M54\5:MHT-WH$,UG=0P6UO=%Q+=>8JL N&X/S;02RV]S:KX3L[ M;4=+G.HP23:D(5+&'9%YGR@-QDY7G-:EO\2M!N'C54OU:2XMX 'M67'GY\ES MGHC8."?Q R*S/%/Q'BA$W]YH9E34(!, )[?(B:&1$D#C/',@ ^M:EYXPAGE MTEK.>XM[>YU+[,LIL_,2] 5B1&VX84[>'YSCC-5;7XK>';FRFO#%J,%O'9M> M*\]L5$L:N(VV<\D,P'..OIFNLTG4EU;3DO%MKBW#LR^7<* XVL1V)!!QD$$@ MC!%>:ZUXZU[3/&&LV%K=6]U):7=K%::2;0^9=)*JL^'4\;R64%W+KAB2#M^3/&#R>>*T_!/B&X\2^'1=WL$<%]#/+:W*1$E/,C8 MJ2N><'&?QKHZ************************************************ M***************************************\DNSXGMO$'B*YT_1;[&IW M".LCZ;'(83&BHKH3. 3A0P)'7MVJO#;:_%K0U%?#6M$+K$FJ*C00;OG@\G83 M]H]!G..M9,7AC7XM,MK2/2->C:WTP:?N6WMP) )Q+\W^DYVD#:5!&03S6YI5 MIK^G^"]8\.IX7U9H]0:Y\N58;2)8%FSD",3]MQQSZ#M4_P!E\1S_ /",C_A& M]8B?1('B\Q6M09=T7E%@?/\ E('(Z\UAZ?X-UZ#3M4M)]!U6=-0LHK9]HLX& M$D;%HYRWG$LX)R2>IYST FE\%WWV'7;6R\'ZO;KJ\$,#,UY:/Y6S&Y@#)RSE M06)ZD9JS#H'BFU2PM8/#VI"PT[4QJ-G;FXM3Y/# Q!O.SL^=L<9'3I45EX8\ M5V%G9Q0:#>>9:V,UD&DGM'#K+,)6W*7((XVXQR,^M:/AVT\;^&);:&R\.7#Z M8#.\]DU[;*@=VW+Y7)**O("Y(Q[UHZ4/%NG>(]9U@^%II/[5,3- VH0 1&-= MHP1UX]ZP[;PSXKM+^VO8M"N%FMKJ]NXR-0M^'N5PW$^[G(_6K)TKQZ=3EU* M*SNX+J:SBM)Y%OK7=(L>?F!,9 MU=9\9L3GP?9+QU.LC_XU3O[6\9E#CPGIX;L&UC_ M AIIU7QQV\*Z5[_ /$Y;_XS2KJ?C=FPWAC25'J=8;_XQ3OM_CC#?\4]HN?X M?^)M)^O[BF?;_'G_ $ -"_\ !K)_\8J7[5XW_P"@1H'_ (,IO_C%1_:?'V3_ M ,2OPX!V_P")A/\ _&:59_'I'.G^&Q_V_3G_ -I4+-X](^;3_#:GT^VSG_VE M0TOC[;\MGX:#=R;J5/S_ ./4GE_$ M_Q\^&0/^O><_\ L].6+QZ?O7?AL?2UG/\ [4%. M$7CO'-[X<_\ .?_ ..TUH/'A&%U#PX#Z_8IS_[5I#;^/L#&I^'!QR?[/GY/ M_?ZG"U\=[AG5O#VW'.-.FSG_ +_5TXSM&<$XYQ2T44444444444444444444 M4444444444444444444444444444444444444444445Y3J&N^)T\::U8Z3>: MC=RVNI6D<%G]D1K?R9(T>7S) GR ;C@[L].#5\>.;S6'TN?^R=0T^SDUC['! M-%>1$7+KYH9'7!(3,9].<8/'.?=?%Z\E\-W=[9Z";>Y.F?VA:>?<*ZNGG"$E M@HX(8@@=QZ5M2?$L6]_=QW&AW?V"P9XK^]AW2);RI$)'&=@4J"=N=P)/\..: M3PKK&K:OXXUE+]9;6VDTVTN(+07/F"+?OY' VL<#(YY'4\5S]QXIU;1='U;3 M]:U"<6]T]VFC:L&Q(LD4CJ()& QO.S*G'S#(ZUMZC\2CI&O76D'2A(MM%<[) M&N\NY@A$I+X4A0PR!R6XR5 -5H_BCJ97S)O#D,<,8L99F&H;BL5TP5,#8,N" M3D=,#K6UX:\;7?B/6&CCT.>/29#*+?4,G:3&Y7YL@#YMI(VDXQ@UV5%%%%%% M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%% M%%%%%%%%%%%%%%%%%%%%%%%%%%9.F^'[?3-8U74XKBY>;4W22=9&!0%5VKM M Q\H _"LJ/P!ID.FV-E'>:@J65^VHPOYJ[A,V[)/RX(^=N,=ZK+\+_#XL5LR MU\T*Z>VG*&GZ1-)YGI]X, 0?85,OPW\/_P!H27=Q<2%F#LV\D-U'S$D8Z9K+OOACX:U"^GO)HKP23RRS, ML=Y(B!Y5VR$*#@;AU]:G;X>Z"\$D)6[\N2*VA8?:G^[ :N:9X-T/1 M]9N-5LK5H[F=G<@S.T:,YRY1"=JEB!D@5O44444444444444444444444444 M444444444444444444444444444444444444444444444444444444444444 M444444444444444444444444444444444444444444444444444444444444 M444444444444444444444444444444444444444444444444576^LVN3;+=0 M&X'6(2#,=:MT4455M]2LKN\NK2WNH9;FT*BXB1P6B+#*AAVR*J7 M/B;0K.^-C+?#L]ZME%KFG/=,_EB);E"Q?. M-N,_>SVZU+)XCT6+5%TR35;-;YF"B S+NW'HN/4^G6M2BBBBBBBBBBBBBBBB MBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB MBBBBBBBBBBBBBO'+_P ,'Q5\1_%EE9OI]NT5SIT\MZ5S=0;8P?W6!P3C!)/? MH:IOXO\ %::3:WLOB>WCMK_4;FS:ZFABBBLO*,@0%U1OOX!RRG[N.,YJU-XQ MUII[B&[UBWN%FTN5HC:QQF(.MJ9"989%$B@D;PQRI#!2!63J_B*34['3[74- M42TCMFT6:TLD2...Z1]C22CY>0K$C"D!=G3FG7OCGQ1]AUF[/B2*SNX'9)=. M6W#26A%PJ G8K(0-I,OR]>5" M8[DXK#B\6>)[6W2ZLM:N=4N;NWU816\D:, 8''DLBJH).TEN>HXQ71_#6XM[ MGQ5XN>PU.YU&&5+)H;RZ!+2?NFSDX&<-D8[=*9X,FT:V\$2>'?$EN6UEKB7^ MT+*6)FFNIFD)$BC&7R-I#C@ #D8K-\.:C!!J>HK/J\1@D\27,BZ5]@\R2=FD M/E.C=>'V/GH O7BHHT\CX1:AX2O+2>7Q7++,KVXA8RW%RTQ99PV.5^ZWF9P M.O%>Q641R1N%)]LMO^?B'_OL4AO+4=;F'_OX*:VH62#+WENH]3*!_6D;4 M]/0X:^ME/H95_P :8=7TQ5W-J-H .I,Z_P"-)_;6E;-_]IV6T?Q?:%Q_.F?V M_HW_ $%[#_P)3_&C_A(-%_Z"]A_X$I_C2?\ "1:)D#^V=/R>@^U)_C4?_"4^ M'LX_M[2\^GVR/_&D_P"$J\._]!_2_P#P,C_QI&\6^&T&6\0Z2H]3>QC^M(WB MWPT@RWB'25'J;V,?UII\9>%UZ^)-'&1GF^B_^*H_X3/PM_T,NC_^!T7_ ,52 M?\)GX5P?^*ET;CK_ *?%_P#%5M@A@"""#R".]+1111111111111111111111 M111111111111111111111111111111111111111117E^K/X1BUVY$GB7Q+;W MLLTH9+.2YVLR?,ZKL0@A,\@$X[U;M/"_AN]BDB37/$2VQDC1?-U"9(KAG4.N MS. ^01T]*ET;PEH/B&Q&JV6L^))(Y#)#YDNI3H_RN592"/^G5,_RI?^%>>#/^A6T?\ \ T_PIR> M /!R9V^%M'&>O^A1_P"%/'@3P@%Q_P (OHV/>QC_ ,*4>!?"(8-_PB^BY'0_ M8(O_ (FG#P3X4#%AX8T;)Y)^P1?_ !-+_P (9X6_Z%K1O_ "+_XFC_A#/"W_ M $+6C?\ @!%_\33QX0\,KC;X=T@;>F+*/C_QVG?\(KX=_P"@!I?_ (!Q_P"% M#>%_#ZH2OA_3"<=!:1\_I3QX;T)5PNB:: 1C M4_PI5\.:&@PFBZ/TJ[THHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH MHHHHHHHHHHHHHHHHHHHHHHHKC?$%M M>/Y5)1111111111111111111111111111111111111111111111111111111 M111111111111111111111111111111111111111111111111111111111111 M111111111111111111111111111111111111111111111111111111111111 M111111111111111111111111111111111111111111111111111111111111 M111111111111111111111111111111111111111111111111111111111111 M1111111117+^,M5U'2YO#R:?<)%]NU:*SF#1A\QLK,<9Z$;/UKJ*P?&GB,>$ M_"&HZWY(F>VC'EQDX#.S!5!]LL,^U85WJWB#PMJV@KJ=^FJPZM*;66)+=8C% M,4+*8R/X2000Q.,@YKBM/\6>,]:ET!_M5_!#K\]S&5@CM?W/E&0CR68YP !N M#CG:<'FNLT'Q\?\ A'=/$5KK&O7C0-2.>XJS'\0FN)Y-,71+J/6C=_9([%IX\G]SYQL7OP.&KR:E+'JY@F9;HA20XE95SQMQP >*SO$'Q$U0_#5I+)UM?$<*O'?X" MG[*T+JDK8.1\S,H4?[?M6[<^/1!X@D\--87 ?9/%'<_:4$I:*'S-[#&%##.U MB\00Z=%I6V&<7#"07 M,D*PR&,^;'CY"S8P,G@^QJE\2?&EQX;N=/CL)T1[9EO[V,@YEMPVPQ+P?F8% MV'3_ %1H\?>+YQHVI6&@X:==%?4WO%N3#Y,1X1D(!+,2"<<# Z\BLS5?%.IW M\V@I8LT5I::[9V%S<"Z97N)3&&="@&"GS $D]0>*GA^*.L7.EZ=<1>%U-QJC M2FQACNC*72+/F,P"9'.T#K][)QBK8^)&HG49K1O#[07*637$=C/,5N+AA%O( MB^7:X#90@'<""<=JWO#_ (DN/$'A2XU2W.GFX3S%0QRN8MRC^,%0Z'/52,CW MXK@?"GB;5]/T,7J1?;KXZ,FKZ@+G4)"KQ@O@QJ0=LC -G&%&U!WKM?#7BS4O M$>O7\,>FV\6DVNS%R9V\UC)$DJ?)MP/E?GG@^M#C'(1<-UZL!5[7/B1JMEXTDT'3])MIBD]M @EE?S9Q,"3*@4 M$&-,#^)=_% M3Q#;M8:;&C QKCF:5Y M3:PVDQF:60-OV;PQP" %'W@,\],=:KCXOZS>:3X?;3-!BN=3U&VFN9;=68@K M'*8R$/;.UFR> !T-78/B7KDOBX::=/T\63ZP^EJVY_-SLWJQ[<<9]><8ZU>\ M >)==U3X;W^OZE/:3W(>YE@^5E4!"WRM_L@C QV]ZJV?Q$UQDMK>\M--2[U! M-.:T>+>8XOM6_P#U@)R2OEG !&20/>J[>+O$&I^(O[-D:Q2&U@U*"\A"/Y=R M\.P!@=V5!$@XSD$.,GC%GPWXOOI=,T^WL(M+L[/3]/T^6YAN9)-SI,F<1,23 M\HP!NW%CQQU,%E\0O%5_I2ZC!I%D]O=QI/;"%A+,B;\2?N5DW2E5P>-ASD8K MMO#FJW6LPVM]]LTZXL;BQBE7[.KAS*2=[88\(<# (R"#FM^BBBBBBBBBBBBB MBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBL3Q#X=_M^ M;29#>R6W]G7J7J!$5M[J" #GMAFZ>M:&GVD]G%*EQ?37C/,\BO*J@HK'(0;0 M. ./6FZMI5GKFDW6EZA%YMI=1F.5,XR#Z'L>X-8=IX-,=_9WFH:S>ZC+IT;) M8>>J 0%EVESM4;WQQEO?C)JGIGPZATM-!6+6;YAHLL\EON2+YO-!W!OEY^\V M.G6J]O\ "K3;2WLHK?5]6@:WA>VEDAE5&N8'D,AC FYFP1@\GFGWOPMTJ] MGFF;4M3B>6\GNR8I$&#-&(W4?)TVJ #U'.#R:U/"_@FS\*7$TUK?W]R9;:"U M(NG1@$B!"8PH/ 8BL2?X0Z+.DL1U76DAD2>/RDN5VK'*X=TY3D%AGG)Z<\"M M&Z^'6F7=]/?MJ&IQWTMQ'"--M/!?_"*P MW-Z+###S#*#+R^\_-CU)[5'J/P_T+4H=825)XWUCROMTL3[7E\O&WM@=,G & M35/_ (5AHG]IMJ N]5$QGDN<+=D*)9$V2-@#JPZ_X<5*?AMH9MQ!YM]Y8TO^ MR0//_P"7?=NV].OOZ4]OAYHS32S&:_,DLUM<,37%VD$7F2270M[Z26.\+;O\ EBZ 1\MG.YB,8'4FNT3P[9)4D8"E0%'\(P3TK%N/AEX;NK&UM'CO!';6S6:,EY(K-;DY\IF!RR#L#G M%22?#CPW)?1WGV>Z22.2*90E[*J^;&-J2$!L%P.-QYJ23X?>'9=!LM'>VG-M M8R-+:N+F02PL22=L@.X9R>,TC?#SPV[_4UJ:?X>T_3=.NK&W27R[MWDN)'F9I)78 %F?X6R*UM/T33]+N[ZZLX6CFOG62X/F,P9@-HP"< M# P.,< >E4;GP9H-YI%YI5S9-+97MP;FXB>>0[Y"0Q;.[(Y . <<5QE_\*;T M^(9KW1]NTC\&^'H](OM)&F1M87\K M37,+LS"1SC+H/!]*E7P-X:74AJ*Z3$+L7/VL2;FXFZ[\9QFK5EX8T33M.O-/L M]-@@M+UG:XA0$+(6&&S[$=A4)\&^'3!)"=)MS')!';LO./+C^XHYXVXXQR.U M/;PAX?=+-&TFV(LUD6#*\IY@^?GN6[D\D\]:1?!_AU+O3[H:-9^?IR".TD,8 M)A4= /IV].U1_P#"#^%\7&W0[)#<3">4QQ["SC.&R.01D]/4UHV>C:9I\ZS6 M=A;P2+ ML&CC"D1*253CL,GBKU%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%% M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%% M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%% M%%%%%%%%%%%%%%%%%%)N7=MW#/IF@,K?=8''H:6HUGA>3RUEC+C^$,,_E1!< M0W,7F6\T2-T;!AD'!&1[U$VH622^4]Y;K)G&PR@'/IC-6:*********** M************************************************************ M********************YSX@('^'?B+/5=.G=2.H94)!^H(!_"O.[>;7?!>G M_P!KVUE#8VNJ?8K&VM&NO.C65@2]PV2%3(X R 206IMWXZ\5:7J-Q?7]Q8.] MEH%YA<"/<65C@CY2PYP P[YK3M_%7C2[OM)TJ.^T6.XO+N:/SPHN M,1K#YJEA&^T,<$8SR"#]=3Q9'<)\4O"D]C8VES>-9WH N9#&H"^60=P5CD9; M''\1KG?#&I7^GW%WI=N+;3+G5?%-[;S721B5(-D0<(N0-Q)X&1TSQ7?>"O$C MZ_H<#WTEJ-2!E61(7&)5CE:/S57.=C%>O3M7!-X4N->\?>)8K"#3K5K;6+2Y M?4,D7$*B%&98PJ_QDR672] M0T^.,(]K'*DRJ@Z9 )P!@8IFF:-X3U*PL+[3=.TRXM(H'AM)8HE9%C;(=5XZ M'Y@?J?4U9M/"GA^P%I]DT:R@^QR-);^7"%\MV&&88[D GVJW/I6FW.IP7\] MG;R7UNI$,[(#)&#UP>H%5F\+: UK<6S:-8&"YE\Z:,VZXDD_OD8Y;WZU7NM- MT+1+U?$5R(+-;*S^R))M5(X82P..!TSCKP.V,G*:#J7A74KZ\FT*?3);R4![ MEK;:)''9FQR1[FKH\/:(J!!H^GA5#@*+9, .,..G\0Z^O>J26'A:YUZ6S72] M.?4[2*.1\V2[D0\)AMN/X< \8K:^S0&Z%T8(_M"H8Q+L&\*3DKGKC(Z5+4% MY>0:?937ERY2"!#)(P4MM4Y3?;I+&\1F7&#P#TK1HHHJ&VNK>]@ M\ZUF2:(LRAXVR,J2I&?8@C\*FHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHKF_B"Z)\.?$A=E4' M3;@ L<#)C( ^N<5P\DFE:GJ?@5?#J6NG&RUZY-S!X 0,=.*-+\6ZBFFVUQJ' MBRYN=#N;F)=0N[>W=9+!C$Y*&0CC=(%R /E[8W"BXU'4-/U74KZ#5]8N+M]% MLWAFDB*O);^A;)!)Q5TWVHZAKMCH]IXJU5=#N=5DAM-0AG M!EFC^S!V4.5.X++A0W/WB.<<=EXHUS3M<^$NO7^F77VFVEL)X4:QU)8;[7K M:0V&CO%&9)#-&S2?ON0,;]A!;CGJ1VJK>W&N S:?)JNO1Z+#JU[ +N.&>XF0 M[8_(R5(=ER9"IR1NP"#@59N;O68M7OH)-2UR21[!HWNEAE$M@1"@R\*_NY%+ M98-'\P8MUQ75^'KBZE^%VK&ZM;F.15NHTRTTHF&#AHA)^\V$G@-D_ABL&..? MQ#X2\$>']/T^]^WZ<]E/=74]I)"EF(5&_P"=P,L<;0%SGGM67I.A>)-:LM8C MFN_$=MKGV61I?,5H;<7*R;DVON^?=RHVC&P\]JN:_::]?V&E:IJ%OK=K;:K) M-/?VVGQO-+:N41+==@(( "L.C;OPWK\UG 3ZY[DFG7OA_6$ M,UF^G^(#X=CU:]1;>S7S)0CI&(G42=4SYN#GY2V>*M?\(WJB:Z;U]/UEYX-6 MTQ4DDD>3]P(E6X8D85L_.&(&#VZUVOPNTI]%\&KI\VF2V%Q#=3B59%P)#YA( M9>>5V[0#[5VE%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%% M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%,F,8A=I@#&HW-D9X'/2L/_A*_#T'A M5O$272KH_P Q,R0M@X8J?E SU!'2H]7\:>'= O(;>_N_*>54>OH:H6_C;1[K31? MQ?:C$;[^S]IMG#B?.W:5QD<\$UT6!C':J&F#3+43:9IQB4VC#SHD;)1G^?+= M\G.[)Y.,]!O MVO!#?(%M;]=.9VX5YSC"J?XN3C\#VYJUH.OVOB&Q>ZMHYH@D\L#1SJ%<-&Y1 MN 3QD5GZGXWT_3-1O+/[)?71L%B-[);1!EMO,^YNRP/(YX!P.3BMB#6--N7N MTAOH'-I+Y,^''[M]H;:??!'^15E;B%Y3$LL9D"[B@89 ]<>E49_$&D6S68DU M&V'VV8P6^) 1(X!) (^A_0=Q5^5_+B>38S[5)VH,DX[#WKEH_'=O=>&;+6]/ MT;5[Y;N:2)+6W@5I5*,RL7^;:HRGKW%4U^*&CMH#:B89HKG[-<74>GS.BS/' M"Q5R/F([''/.TXSBMZS71?$%S9:Y$(+B\M(RL;I+N:#>H+*0#@$C&B$74UF\QFB(22/(.0&)V[AC=CN*N:%XRTO6/#NEZM<30Z?_ &D# MY$%S.H9B&*X'J?IZUJOJ^FQW[6#ZA:+>*AD-NTRB0*!DG;G.,(AVNUO,L@4XS@E2<'!JW111111111111111111111111111111111 M11111111111111111111111111111111111111111111112$A5).< 9X&:\J MMM.O_P#A1&KZ8-.OA?2?;$CMFMG$K;YG9/EQGD,#GI6AXNO6GL;/03X>UJZM M+F"*2_FM+ MYB+@B#)QAF(P2?NKD=2,=#XVTBXUSP9=0VD934856[LP,;DGC M(= /#O%<5QJ&UBAN[*36%8D#R]6EB>,HI[*N[(]#M]*P%\*:B/ M#F^+2/$B3NRM):7D<\T) MK)[L6TJ3JP=#^Y0/&'SN8APV>.>O>HKC2]9\0>);S4-*;5=%\_3IK*>74$4A M'W+Y9A0-D=')(('*]37,-X#U^WCN3=Z59ZA;P>(+2YBMK6W6/?"D:J[('<@* M0 NTG^$DFKOAOPGJ=AXUTO6#HD]NSZIJ>(;G4=&TF^M-;C$:6.J6<\8BN%P-R7*LW*J<_PG(QC.,5BWW@.[N=;F@F\ M*136DGB>._DN5\G;+:M%M=<9W8#Y)'N>M12_#C7'O==@@T^6*Y?[9]BU/[+P[9(WC=E4(YSUZ'IZG\=CP+X:OO#^M:E++IL-G:7-C8QJ(G3'F MQ1L),A?=NO?%+X,\(_V7>ZIJ^H:6(=4FO[N6&19]Q:&5]P4@':#P!^%ZE!:?:VM8FF,/F" M,LJC+8)!YP#639^-;75;'0[S3(//AU.Y-LX>38]LX1G8.N#\PV,"/IV.:NIX MO\.2,JIK5BS-.MLH68',C9VJ/K@X]<<58M?$.CWTL,5KJ-O+),\D<:H^2S1_ M?'U7(SZ5S]WX[EL+[7-.N]+6/4+%(WL8!7/&KE?,C?;ED)4C..",&I;KQQJ&D:OJFE:M96L=XELLVE" M%V8:@S';L7(X8,5!'/WL]!70W^HZEIGA&ZU.XM;9]0MK1YY($E81[E4L5#8S MCCKCGVKG;KQQJ,EII4>F6%M)J-SH_P#;-Q%-(P1(@J_(I ^\S-@$\#!)S5VV M\9/?:YX9@MK:/[!KEA)>)(SGS4VJC;2N,?QCN>AK*U+QSKOAR]N_[=TNQ%M_ M9T]_!':SLTL7EE0$ER,?,74!EXSGKC-;WAS7M1N]8U+1-9AM4U"RBAGWVI;R MW24'C#<@JRL#Z\'C.!TM%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%% M%%%%%%%%%%%%%%)EM^-ORXZY[TM%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%9GB M*SN-0\-:G8VB1M<7-K)#&)7*KEE*\D D#GTKEK[P#+=ZY8ZM;W/V'SHW75;6 M-R4E
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end EX-101.INS 8 lbio-20150930.xml XBRL INSTANCE DOCUMENT 0001425205 2015-01-01 2015-09-30 0001425205 2015-09-30 0001425205 2014-12-31 0001425205 2015-07-01 2015-09-30 0001425205 2014-07-01 2014-09-30 0001425205 2014-01-01 2014-09-30 0001425205 us-gaap:OperatingExpenseMember 2015-07-01 2015-09-30 0001425205 us-gaap:OperatingExpenseMember 2014-07-01 2014-09-30 0001425205 us-gaap:OperatingExpenseMember 2015-01-01 2015-09-30 0001425205 us-gaap:OperatingExpenseMember 2014-01-01 2014-09-30 0001425205 us-gaap:ResearchAndDevelopmentExpenseMember 2015-07-01 2015-09-30 0001425205 us-gaap:ResearchAndDevelopmentExpenseMember 2014-07-01 2014-09-30 0001425205 us-gaap:ResearchAndDevelopmentExpenseMember 2015-01-01 2015-09-30 0001425205 us-gaap:ResearchAndDevelopmentExpenseMember 2014-01-01 2014-09-30 0001425205 us-gaap:PreferredStockMember 2014-12-31 0001425205 us-gaap:CommonStockMember 2014-12-31 0001425205 us-gaap:CommonStockMember 2015-01-01 2015-09-30 0001425205 us-gaap:PreferredStockMember 2015-01-01 2015-09-30 0001425205 us-gaap:PreferredStockMember 2015-09-30 0001425205 us-gaap:CommonStockMember 2015-09-30 0001425205 lbio:CommonStockToBeIssuedMember 2014-12-31 0001425205 us-gaap:AdditionalPaidInCapitalMember 2014-12-31 0001425205 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2014-12-31 0001425205 us-gaap:RetainedEarningsMember 2014-12-31 0001425205 us-gaap:AdditionalPaidInCapitalMember 2015-01-01 2015-09-30 0001425205 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2015-01-01 2015-09-30 0001425205 us-gaap:RetainedEarningsMember 2015-01-01 2015-09-30 0001425205 lbio:CommonStockToBeIssuedMember 2015-09-30 0001425205 us-gaap:AdditionalPaidInCapitalMember 2015-09-30 0001425205 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2015-09-30 0001425205 us-gaap:RetainedEarningsMember 2015-09-30 0001425205 2013-12-31 0001425205 2014-09-30 0001425205 2015-02-03 2015-03-03 0001425205 2015-03-03 0001425205 2014-11-22 2014-12-22 0001425205 2014-12-22 0001425205 2013-10-05 2013-11-05 0001425205 us-gaap:StockOptionMember 2015-01-01 2015-09-30 0001425205 us-gaap:WarrantMember 2015-01-01 2015-09-30 0001425205 us-gaap:ConvertiblePreferredStockMember 2015-01-01 2015-09-30 0001425205 us-gaap:RestrictedStockMember 2015-01-01 2015-09-30 0001425205 us-gaap:StockOptionMember 2014-01-01 2014-09-30 0001425205 us-gaap:WarrantMember 2014-01-01 2014-09-30 0001425205 us-gaap:ConvertiblePreferredStockMember 2014-01-01 2014-09-30 0001425205 lbio:FiveCompaniesMember us-gaap:AssetsTotalMember 2015-01-01 2015-09-30 0001425205 lbio:VariousOtherDomesticIssuersMember us-gaap:AssetsTotalMember 2015-01-01 2015-09-30 0001425205 lbio:ForeignIssuerMember us-gaap:AssetsTotalMember 2015-01-01 2015-09-30 0001425205 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel1Member us-gaap:MoneyMarketFundsMember 2015-09-30 0001425205 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel2Member us-gaap:MoneyMarketFundsMember 2015-09-30 0001425205 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel3Member us-gaap:MoneyMarketFundsMember 2015-09-30 0001425205 us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2015-09-30 0001425205 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel1Member us-gaap:CorporateDebtSecuritiesMember 2015-09-30 0001425205 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel2Member us-gaap:CorporateDebtSecuritiesMember 2015-09-30 0001425205 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel3Member us-gaap:CorporateDebtSecuritiesMember 2015-09-30 0001425205 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2015-09-30 0001425205 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel1Member 2015-09-30 0001425205 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel2Member 2015-09-30 0001425205 us-gaap:FairValueMeasurementsRecurringMember 2015-09-30 0001425205 us-gaap:MinimumMember 2015-01-01 2015-09-30 0001425205 us-gaap:CostOfSalesMember 2015-07-01 2015-09-30 0001425205 us-gaap:CostOfSalesMember 2014-07-01 2014-09-30 0001425205 us-gaap:CostOfSalesMember 2015-01-01 2015-09-30 0001425205 us-gaap:CostOfSalesMember 2014-01-01 2014-09-30 0001425205 us-gaap:MoneyMarketFundsMember 2015-09-30 0001425205 us-gaap:MoneyMarketFundsMember 2015-01-01 2015-09-30 0001425205 us-gaap:CorporateDebtSecuritiesMember 2015-09-30 0001425205 us-gaap:CorporateDebtSecuritiesMember 2015-01-01 2015-09-30 0001425205 us-gaap:EquipmentMember 2015-09-30 0001425205 us-gaap:EquipmentMember 2014-12-31 0001425205 us-gaap:LeaseholdImprovementsMember 2015-09-30 0001425205 us-gaap:LeaseholdImprovementsMember 2014-12-31 0001425205 us-gaap:OfficeEquipmentMember 2015-09-30 0001425205 us-gaap:OfficeEquipmentMember 2014-12-31 0001425205 lbio:SeriesConvertiblePreferredStockMember 2015-01-01 2015-09-30 0001425205 us-gaap:RestrictedStockMember 2014-01-01 2014-12-31 0001425205 us-gaap:RestrictedStockMember 2014-12-31 0001425205 us-gaap:RestrictedStockMember 2015-01-01 2015-09-30 0001425205 us-gaap:RestrictedStockMember 2015-09-30 0001425205 us-gaap:EmployeeStockOptionMember 2014-12-31 0001425205 us-gaap:EmployeeStockOptionMember 2014-01-01 2014-12-31 0001425205 us-gaap:EmployeeStockOptionMember 2015-01-01 2015-09-30 0001425205 us-gaap:EmployeeStockOptionMember 2015-09-30 0001425205 us-gaap:WarrantMember 2014-12-31 0001425205 us-gaap:WarrantMember 2014-01-01 2014-12-31 0001425205 us-gaap:WarrantMember 2015-01-01 2015-09-30 0001425205 us-gaap:WarrantMember 2015-09-30 0001425205 us-gaap:MinimumMember us-gaap:EmployeeStockOptionMember 2015-01-01 2015-09-30 0001425205 us-gaap:MaximumMember us-gaap:EmployeeStockOptionMember 2015-01-01 2015-09-30 0001425205 us-gaap:EmployeeStockOptionMember 2014-01-01 2014-09-30 0001425205 lbio:PlanTwoMember 2014-11-30 0001425205 lbio:PlanTwoMember 2015-03-10 2015-04-10 0001425205 lbio:PlanTwoMember 2015-09-30 0001425205 2015-10-31 iso4217:USD iso4217:USD xbrli:shares xbrli:shares xbrli:pure 10210000 44910000 20562000 79374000 245000 67000 110391000 44977000 1833000 1532000 112224000 46509000 1161000 1249000 1608000 328000 86000 86000 2855000 1663000 2000 2000 245000 245000 38000 204929000 121161000 -95845000 -76562000 109369000 44846000 112224000 46509000 794000 103000 0.001 0.001 50000000 50000000 3694 3694 5694 5694 0.000041666 0.000041666 150000000 150000000 47807398 47807398 33750188 33750188 245153 245153 2660000 2449000 7259000 6155000 4983000 354000 12147000 1018000 7643000 2803000 19406000 7173000 -7643000 -2803000 -19406000 -7173000 8000 5000 123000 5000 -7635000 -2798000 -19283000 -7168000 -0.16 -0.11 -0.44 -0.30 47271593 26632908 43398650 24107787 1452000 658000 3726000 1905000 895000 282000 2050000 817000 38000 38000 -7597000 -2798000 -19245000 -7168000 5694 33750188 2000 245000 121161000 -76562000 4223000 4223000 3847210 9618000 9618000 -2000 1000000 9200000 68308000 68308000 1553000 1553000 38000 -19283000 3694 47807398 2000 245000 204929000 38000 -95845000 10000 66000 66000 691000 23000 4223000 1896000 1553000 825000 179000 -118000 1193000 -1012000 -11802000 -5318000 20562000 95236000 15900000 992000 167000 -100890000 -167000 9618000 3002000 68308000 77992000 3002000 -34700000 -2483000 19673000 17190000 66000 38000 107500000 9200000 8.00 68300000 <div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';">NOTE 1. GENERAL ORGANIZATION AND BUSINESS   Lion Biotechnologies, Inc. (the Company, we, us or our) is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel cancer immunotherapy products designed to harness the power of a patient's own immune system to eradicate cancer cells. Our lead program is an adoptive cell therapy utilizing tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients' tumors, for the treatment of metastatic melanoma. The TIL are then activated and expanded ex vivo and then infused back into the patient to fight their tumor cells. The Company was originally incorporated under the laws of the state of Nevada on September 17, 2007. Until March 2010, we were an inactive company known as Freight Management Corp. On March 15, 2010, we changed our name to Genesis Biopharma, Inc., and in 2011 we commenced our current business.   Basis of Presentation of Unaudited Condensed Financial Information   The unaudited condensed financial statements of the Company for the nine months ended September 30, 2015 and 2014 have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and pursuant to the requirements for reporting on Form 10-Q and Regulation S-K. Accordingly, they do not include all the information and footnotes required by accounting principles generally accepted in the United States of America for complete financial statements. However, such information reflects all adjustments (consisting solely of normal recurring adjustments), which are, in the opinion of management, necessary for the fair presentation of the financial position and the results of operations. Results shown for interim periods are not necessarily indicative of the results to be obtained for a full fiscal year. The balance sheet information as of December 31, 2014 was derived from the audited financial statements included in the Company's financial statements as of and for the year ended December 31, 2014 included in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission (the SEC) on March 16, 2015. These financial statements should be read in conjunction with that report.   Liquidity   We are currently engaged in the development of therapeutics to fight cancer, we do not have any commercial products and have not yet generated any revenues from our biopharmaceutical business. We currently do not anticipate that we will generate any revenues during 2015 from the sale or licensing of any products. In addition, we have not generated any revenues from our prior business plans.   We have not had any revenues and are still in the development stage. As shown in the accompanying condensed financial statements, we have incurred a net loss of $19.3 million for the nine months ended September 30, 2015 and used $11.8 million of cash in our operating activities during the nine months ended September 30, 2015. As of September 30, 2015, we had $110.1 million of cash, money market funds, and short term investments on hand, stockholders' equity of $109.4 million and had working capital of $107.5 million.   During 2015, we expect to further ramp up our operations, which will increase the amount of cash we will use in our operations. Our budget for 2015 includes increased spending on research and development activities, higher payroll expenses as we increase our professional staff, the costs associated with operating our new Tampa, Florida, research facility, as well as ongoing payments under the Cooperative Research and Development Agreement (CRADA) we have entered into with the National Cancer Institute (NCI). Based on the funds we had available on September 30, 2015, we believe that we have sufficient capital to fund our anticipated operating expenses for at least 24 months.   On March 3, 2015, the Company sold 9,200,000 shares of its common stock in an underwritten public offering at $8.00 per share for net proceeds of $68.3 million, after deducting expenses of the offering. On December 22, 2014, the Company sold 6,000,000 shares of its common stock in an underwritten public offering at $5.75 per share for net proceeds of $32.2 million after deducting expenses of the offering. On November 5, 2013, we completed a $23.3 million private placement of our securities to various institutional and individual accredited investors. Despite the amount of funds that we have raised, the estimated cost of completing the development of our TIL-based therapy, and of obtaining all required regulatory approvals to market those product candidates, may be substantially greater than the amount of funds we have available. Therefore, while we believe that our existing cash balances will be sufficient to fund our currently planned level of operations for at least 24 months, we will have to obtain additional funds in the future to complete our development plans. We intend to seek this additional funding through various financing sources, including possible sales of our securities, and in the longer term through strategic alliances with other pharmaceutical or biopharmaceutical companies.</div> 6000000 5.75 32200000 23300000 <div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';"><div style="display: block;"> <div style="display: block;"> NOTE 2. SUMMARY OF SIGNIFICANT ACCOUNTING PRACTICES   <div> Cash and Cash Equivalents   The Company considers highly liquid investments with an original maturity of 90 days or less when purchased to be cash equivalents. The carrying amounts reported in the Balance Sheets for cash and cash equivalents are valued at cost, which approximates their fair value. </div>   <div> Short-term Investments   The Company's short-term investments represent available for sale securities and are recorded at fair value and unrealized gains and losses are recorded within accumulated other comprehensive income (loss). The estimated fair value of the available for sale securities is determined based on quoted market prices or rates for similar instruments. In addition, the cost of debt securities in this category is adjusted for amortization of premium and accretion of discount to maturity. The Company evaluates securities with unrealized losses to determine whether such losses, if any, are other than temporary. </div>   <div> Property and Equipment   Property and equipment are recorded at cost and depreciated using the straight-line method over their estimated useful lives of two to five years. Maintenance and repairs of depreciable assets are charged against earnings as incurred. When properties are retired or otherwise disposed of, the cost and accumulated depreciation are removed from the accounts and gains or losses are credited or charged to earnings. Leasehold improvements are amortized over the lesser of their estimated useful life or lease term, whichever is shorter. </div>   <div> Net Income (Loss) Per Share   Basic net income (loss) per share is computed by dividing net income (loss) by the weighted average number of common shares outstanding for the period, excluding unvested shares of restricted common stock. Shares of restricted stock subject to vesting are included in basic weighted average common shares outstanding from the time they vest. Diluted earnings per share is computed by dividing the net income applicable to common stock holders by the weighted average number of common shares outstanding plus the number of additional common shares that would have been outstanding if all dilutive potential common shares had been issued, using the treasury stock method. Potential common shares are excluded from the computation when their effect is antidilutive. When calculating diluted net income per share, shares of restricted stock subject to vesting are included in diluted weighted average common shares outstanding as of their grant date.   At September 30, 2015 and 2014, basic and diluted net loss per share are the same, as the effect of potentially dilutive securities was antidilutive. At September 30, 2015, potentially dilutive securities include options to acquire 2,704,195 shares of common stock, warrants to acquire 7,237,216 shares of common stock, preferred stock that can be converted into 1,847,000 shares of common stock, and 494,001 shares of non-vested restricted stock. At September 30, 2014, potentially dilutive securities include options to acquire 1,098,750 shares of common stock, warrants to acquire 11,172,426 shares of common stock, and preferred stock that can be converted into 2,847,000 shares of common stock. </div>   <div> Fair Value Measurements   Under FASB ASC 820, Fair Value Measurements and Disclosures, fair value is defined as the price at which an asset could be exchanged or a liability transferred in a transaction between knowledgeable, willing parties in the principal or most advantageous market for the asset or liability. Where available, fair value is based on observable market prices or parameters or derived from such prices or parameters. Where observable prices or parameters are not available, valuation models are applied.   Assets and liabilities recorded at fair value in our financial statements are categorized based upon the level of judgment associated with the inputs used to measure their fair value. Hierarchical levels directly related to the amount of subjectivity associated with the inputs to fair valuation of these assets and liabilities, are as follows:   Level 1Inputs are unadjusted, quoted prices in active markets for identical assets at the reporting date. Active markets are those in which transactions for the asset or liability occur in sufficient frequency and volume to provide pricing information on an ongoing basis.   The fair valued assets we hold that are generally included under this Level 1 are money market securities where fair value is based on publicly quoted prices.   Level 2Are inputs, other than quoted prices included in Level 1, that are either directly or indirectly observable for the asset or liability through correlation with market data at the reporting date and for the duration of the instrument's anticipated life.   The fair valued assets we hold that are generally assessed under Level 2 are corporate bonds and commercial paper. We utilize third party pricing services in developing fair value measurements where fair value is based on valuation methodologies such as models using observable market inputs, including benchmark yields, reported trades, broker/dealer quotes, bids, offers and other reference data. We use quotes from external pricing service providers and other on-line quotation systems to verify the fair value of investments provided by our third party pricing service providers. We review independent auditor's reports from our third party pricing service providers particularly regarding the controls over pricing and valuation of financial instruments and ensure that our internal controls address certain control deficiencies, if any, and complementary user entity controls are in place.   Level 3Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities and which reflect management's best estimate of what market participants would use in pricing the asset or liability at the reporting date. Consideration is given to the risk inherent in the valuation technique and the risk inherent in the inputs to the model.   We do not have fair valued assets classified under Level 3. </div>   <div> Fair Value on a Recurring Basis   Financial assets measured at fair value on a recurring basis are categorized in the tables below based upon the lowest level of significant input to the valuations (in thousands): <div>   <table style="border-collapse: collapse; font: 10pt times new roman, times, serif;" cellpadding="0" cellspacing="0" width="100%"> <tr style="vertical-align: bottom;"> <td style="font-size: 10pt; font-weight: bold; text-align: center; padding: 0px; font-family: 'Times New Roman';"></td> <td style="font-family: 'times new roman'; padding: 0px;"></td> <td style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;" colspan="14">Assets at Fair Value as of September 30, 2015</td> <td style="font-family: 'times new roman'; padding: 0px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="text-align: center; font-family: 'times new roman'; padding: 0px;"></td> <td style="font-size: 10pt; font-weight: bold; font-family: 'times new roman'; padding: 0px;"></td> <td style="font-size: 10pt; font-weight: bold; text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;" colspan="2">Level 1</td> <td style="font-size: 10pt; font-weight: bold; font-family: 'times new roman'; padding: 0px;"> </td> <td style="font-size: 10pt; font-weight: bold; font-family: 'times new roman'; padding: 0px;"> </td> <td style="font-size: 10pt; font-weight: bold; text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;" colspan="2">Level 2</td> <td style="font-size: 10pt; font-weight: bold; font-family: 'times new roman'; padding: 0px;"> </td> <td style="font-size: 10pt; font-weight: bold; font-family: 'times new roman'; padding: 0px;"> </td> <td style="font-size: 10pt; font-weight: bold; text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;" colspan="2">Level 3</td> <td style="font-size: 10pt; font-weight: bold; font-family: 'times new roman'; padding: 0px;"> </td> <td style="font-size: 10pt; font-weight: bold; font-family: 'times new roman'; padding: 0px;"> </td> <td style="font-size: 10pt; font-weight: bold; text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;" colspan="2">Total</td> <td style="font-size: 10pt; font-weight: bold; font-family: 'times new roman'; padding: 0px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="font-size: 10pt; text-align: left; text-indent: 10pt; font-family: 'times new roman'; padding: 0px; width: 36%;">Money market funds</td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px; width: 2%;"></td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px 10px 0px 0px; vertical-align: bottom; white-space: nowrap; width: 1%;">$</td> <td style="font-size: 10pt; text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; width: 12%;">20,562</td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 1%;"> </td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 2%;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px 10px 0px 0px; vertical-align: bottom; white-space: nowrap; width: 1%;">$</td> <td style="font-size: 10pt; text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; width: 12%;">-</td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 1%;"> </td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 2%;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px 10px 0px 0px; vertical-align: bottom; white-space: nowrap; width: 1%;">$</td> <td style="font-size: 10pt; text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; width: 12%;">-</td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 1%;"> </td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 2%;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px 10px 0px 0px; vertical-align: bottom; white-space: nowrap; width: 1%;">$</td> <td style="font-size: 10pt; text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; width: 12%;">20,562</td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="font-size: 10pt; text-align: left; text-indent: 10pt; font-family: 'times new roman'; padding: 0px; vertical-align: top;"> </td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px; vertical-align: top; text-align: left;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px; vertical-align: top; text-align: left; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px; vertical-align: top; text-align: left; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px; vertical-align: top; text-align: left; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="font-size: 10pt; text-align: left; text-indent: 10pt; font-family: 'times new roman'; padding: 0px;">Corporate debt securities</td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;">-</td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"> </td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;">79,374</td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"> </td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;">-</td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"> </td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;">79,374</td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"> </td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="font-size: 10pt; text-indent: 20pt; font-family: 'times new roman'; padding: 0px;">Total</td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;">$</td> <td style="font-size: 10pt; text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;">20,562</td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"> </td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;">$</td> <td style="font-size: 10pt; text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;">79,374</td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"> </td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;">$</td> <td style="font-size: 10pt; text-align: right; border-bottom: #000000 2.80pt double !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;">$</td> <td style="font-size: 10pt; text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;">99,936</td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;">  </td> </tr> </table>   </div> </div> <div> Use of Estimates   The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates include accounting for potential liabilities and the assumptions made in valuing stock instruments issued for services. </div>   <div> Stock-Based Compensation   The Company periodically grants stock options and warrants to employees and non-employees in non-capital raising transactions as compensation for services rendered. The Company accounts for stock option grants to employees based on the authoritative guidance provided by the Financial Accounting Standards Board where the value of the award is measured on the date of grant and recognized over the vesting period. The Company accounts for stock option grants to non-employees in accordance with the authoritative guidance of the Financial Accounting Standards Board where the value of the stock compensation is determined based upon the measurement date at either a) the date at which a performance commitment is reached, or b) at the date at which the necessary performance to earn the equity instruments is complete. Non-employee stock-based compensation charges generally are amortized over the vesting period on a straight-line basis. In certain circumstances where there are no future performance requirements by the non-employee, option grants are immediately vested and the total stock-based compensation charge is recorded in the period of the measurement date.   The Company issues restricted shares of its common stock for share-based compensation programs. The Company measures the compensation cost with respect to restricted shares to employees based upon the estimated fair value of the equity instruments at the date of the grant, and is recognized as expense over the period which an employee is required to provide services in exchange for the award.   The fair value of the Company's common stock option grants is estimated using a Black-Scholes option pricing model, which uses certain assumptions related to risk-free interest rates, expected volatility, expected life of the common stock options, and future dividends. Compensation expense is recorded based upon the value derived from the Black-Scholes option pricing model, and based on actual experience. The assumptions used in the Black-Scholes option pricing model could materially affect compensation expense recorded in future periods.     Total stock-based compensation expense related to all of our stock-based awards was as follows (in thousands): <div><div style="display: block;">                     <table style="border-collapse: collapse; font: 10pt times new roman, times, serif;" cellpadding="0" cellspacing="0" width="100%"> <tr style="vertical-align: bottom;"> <td style="font-size: 10pt; text-align: center; font-family: 'times new roman'; padding: 0px;"></td> <td style="font-size: 10pt; font-weight: bold; font-family: 'times new roman'; padding: 0px;"></td> <td style="font-size: 10pt; font-weight: bold; text-align: center; padding: 0px;" colspan="6">For the Three Months Ended September 30,</td> <td style="font-size: 10pt; font-weight: bold; font-family: 'times new roman'; padding: 0px;"></td> <td style="font-size: 10pt; font-weight: bold; font-family: 'times new roman'; padding: 0px;"> </td> <td style="font-size: 10pt; font-weight: bold; text-align: center; padding: 0px;" colspan="14">For the Nine Months Ended September 30,</td> <td style="font-size: 10pt; font-weight: bold; font-family: 'times new roman'; padding: 0px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-size: 10pt; text-align: center; font-family: 'times new roman'; padding: 0px;"></td> <td style="font-size: 10pt; font-weight: bold; font-family: 'times new roman'; padding: 0px;"></td> <td style="font-size: 10pt; font-weight: bold; text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;" colspan="2">2015</td> <td style="font-size: 10pt; font-weight: bold; font-family: 'times new roman'; padding: 0px;"></td> <td style="font-size: 10pt; font-weight: bold; font-family: 'times new roman'; padding: 0px;"> </td> <td style="font-size: 10pt; font-weight: bold; text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;" colspan="2">2014</td> <td style="font-size: 10pt; font-weight: bold; font-family: 'times new roman'; padding: 0px;"> </td> <td style="font-size: 10pt; font-weight: bold; font-family: 'times new roman'; padding: 0px;"> </td> <td style="font-size: 10pt; font-weight: bold; text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;" colspan="2">2015</td> <td style="font-size: 10pt; font-weight: bold; font-family: 'times new roman'; padding: 0px;"> </td> <td style="font-size: 10pt; font-weight: bold; font-family: 'times new roman'; padding: 0px;"> </td> <td style="font-size: 10pt; font-weight: bold; text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;" colspan="2">2014</td> <td style="font-size: 10pt; font-weight: bold; font-family: 'times new roman'; padding: 0px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top;"></td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px; vertical-align: top; text-align: left;"></td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top;" colspan="2"></td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px; vertical-align: top; text-align: left;"></td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px; vertical-align: top; text-align: left;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top;" colspan="2"> </td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px; vertical-align: top; text-align: left;"> </td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px; vertical-align: top; text-align: left;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top;" colspan="2"> </td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px; vertical-align: top; text-align: left;"> </td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px; vertical-align: top; text-align: left;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top;" colspan="2"> </td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px; vertical-align: top; text-align: left;"> </td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px; width: 36%;">Operating expenses</td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px; width: 2%;"></td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px 10px 0px 0px; vertical-align: bottom; white-space: nowrap; width: 1%;">$</td> <td style="font-size: 10pt; text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; width: 12%;">1,492</td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 1%;"> </td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 2%;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px 10px 0px 0px; vertical-align: bottom; white-space: nowrap; width: 1%;">$</td> <td style="font-size: 10pt; text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; width: 12%;">658</td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 1%;"> </td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 2%;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px 10px 0px 0px; vertical-align: bottom; white-space: nowrap; width: 1%;">$</td> <td style="font-size: 10pt; text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; width: 12%;">3,726</td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 1%;"> </td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 2%;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px 10px 0px 0px; vertical-align: bottom; white-space: nowrap; width: 1%;">$</td> <td style="font-size: 10pt; text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; width: 12%;">1,905</td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="font-size: 10pt; text-align: left; text-indent: 0px; font-family: 'times new roman'; padding: 0px;">Research and development</td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px;"> </td> <td style="font-size: 10pt; text-align: left; border-bottom: #000000 1pt solid !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"> </td> <td style="font-size: 10pt; text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;">895</td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"> </td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; text-align: left; border-bottom: #000000 1pt solid !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"> </td> <td style="font-size: 10pt; text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;">282</td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"> </td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; text-align: left; border-bottom: #000000 1pt solid !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"> </td> <td style="font-size: 10pt; text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;">2,050</td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"> </td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; text-align: left; border-bottom: #000000 1pt solid !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"> </td> <td style="font-size: 10pt; text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;">817</td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"> </td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px;">   Total stock-based compensation expense</td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;">$</td> <td style="font-size: 10pt; text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;">2,387</td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"> </td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;">$</td> <td style="font-size: 10pt; text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;">940</td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"> </td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;">$</td> <td style="font-size: 10pt; text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;">5,776</td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"> </td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;">$</td> <td style="font-size: 10pt; text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;">2,722</td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;">   </td> </tr> </table>   </div></div> </div> <div> Research and Development   Research and development costs consist primarily of fees paid to consultants and outside service providers, patent fees and costs, and other expenses relating to the acquisition, design, development and testing of the Company's treatments and product candidates. Research and development costs are expensed as incurred, unless the achievement of milestones, the completion of contracted work, or other information indicates that a different expensing schedule is more appropriate. The Company reviews the status of its research and development contracts on a quarterly basis. </div>   <div> Concentrations   Financial instruments, which potentially subject the Company to concentrations of credit risk, consist principally of cash and short-term investments.   The Company maintains cash balances at one bank. As of September 30, 2015, the Company's cash balances were in excess of insured limits maintained at this bank. Management believes that the financial institution that hold the Company's cash are financially sound and, accordingly, minimal credit risk exists.   At September 30, 2015, the Company's short-term investments were invested in short-term fixed income debt securities of domestic and foreign high credit issuers and in money market funds. The Company's investment policy limits investments to certain types of instruments such as certificates of deposit, money market instruments, obligations issued by the U.S. government and U.S. government agencies as well as corporate debt securities, and places restrictions on maturities and concentration by type and issuer. At September 30, 2015, approximately 56% of the Company's short-term investments were invested in notes of five companies, 25% were invested in notes of various domestic issuers, and 19% were invested in notes of a foreign issuers. The average maturity of these notes was 66 days (See Note 3). </div>   <div> Recent Accounting Pronouncements   In May 2014, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2014-09, Revenue from Contracts with Customers. ASU 2014-09 is a comprehensive revenue recognition standard that will supersede nearly all existing revenue recognition guidance under current U.S. GAAP and replace it with a principle based approach for determining revenue recognition. ASU 2014-09 will require that companies recognize revenue based on the value of transferred goods or services as they occur in the contract. The ASU also will require additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to obtain or fulfill a contract. ASU 2014-09 is effective for interim and annual periods beginning after December 15, 2017. Early adoption is permitted in annual reporting periods beginning after December 15, 2016, and the interim periods within that year, and either full retrospective adoption or modified retrospective adoption is permitted. The Company is in the process of evaluating the impact of ASU 2014-09 on the Company's financial statements and disclosures.   In June 2014, the FASB issued Accounting Standards Update No. 2014-12, Compensation Stock Compensation (Topic 718). The pronouncement was issued to clarify the accounting for share-based payments when the terms of an award provide that a performance target could be achieved after the requisite service period. The pronouncement is effective for reporting periods beginning after December 15, 2015. The adoption of ASU 2014-12 is not expected to have a significant impact on the Company's consolidated financial position or results of operations.   Other recent accounting pronouncements issued by the FASB, including its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the Securities and Exchange Commission did not or are not believed by management to have a material impact on the Company's present or future consolidated financial statements. </div>   <div> Reclassifications   In presenting the Company's statement of operations for the three and nine month periods ended September 30, 2014, the Company has reclassified $0.8 million and $0.3 million, respectively, of stock-based compensation that was previously reflected as operating expenses to research and development expenses. The reclassification relates to stock-based compensation attributable to individuals working in the Company's research and development activities, and had no impact on total costs and expenses, or on net loss. </div> </div> </div></div> <div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';"> Cash and Cash Equivalents   The Company considers highly liquid investments with an original maturity of 90 days or less when purchased to be cash equivalents. The carrying amounts reported in the Balance Sheets for cash and cash equivalents are valued at cost, which approximates their fair value. </div> 800000 300000 762000 <div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';"> Short-term Investments   The Company's short-term investments represent available for sale securities and are recorded at fair value and unrealized gains and losses are recorded within accumulated other comprehensive income (loss). The estimated fair value of the available for sale securities is determined based on quoted market prices or rates for similar instruments. In addition, the cost of debt securities in this category is adjusted for amortization of premium and accretion of discount to maturity. The Company evaluates securities with unrealized losses to determine whether such losses, if any, are other than temporary. </div> <div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';"> Property and Equipment   Property and equipment are recorded at cost and depreciated using the straight-line method over their estimated useful lives of two to five years. Maintenance and repairs of depreciable assets are charged against earnings as incurred. When properties are retired or otherwise disposed of, the cost and accumulated depreciation are removed from the accounts and gains or losses are credited or charged to earnings. Leasehold improvements are amortized over the lesser of their estimated useful life or lease term, whichever is shorter. </div> <div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';"> Net Income (Loss) Per Share   Basic net income (loss) per share is computed by dividing net income (loss) by the weighted average number of common shares outstanding for the period, excluding unvested shares of restricted common stock. Shares of restricted stock subject to vesting are included in basic weighted average common shares outstanding from the time they vest. Diluted earnings per share is computed by dividing the net income applicable to common stock holders by the weighted average number of common shares outstanding plus the number of additional common shares that would have been outstanding if all dilutive potential common shares had been issued, using the treasury stock method. Potential common shares are excluded from the computation when their effect is antidilutive. When calculating diluted net income per share, shares of restricted stock subject to vesting are included in diluted weighted average common shares outstanding as of their grant date.   At September 30, 2015 and 2014, basic and diluted net loss per share are the same, as the effect of potentially dilutive securities was antidilutive. At September 30, 2015, potentially dilutive securities include options to acquire 2,704,195 shares of common stock, warrants to acquire 7,237,216 shares of common stock, preferred stock that can be converted into 1,847,000 shares of common stock, and 494,001 shares of non-vested restricted stock. At September 30, 2014, potentially dilutive securities include options to acquire 1,098,750 shares of common stock, warrants to acquire 11,172,426 shares of common stock, and preferred stock that can be converted into 2,847,000 shares of common stock. </div> 211000 185000 2627000 <div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';"> Fair Value Measurements   Under FASB ASC 820, Fair Value Measurements and Disclosures, fair value is defined as the price at which an asset could be exchanged or a liability transferred in a transaction between knowledgeable, willing parties in the principal or most advantageous market for the asset or liability. Where available, fair value is based on observable market prices or parameters or derived from such prices or parameters. Where observable prices or parameters are not available, valuation models are applied.   Assets and liabilities recorded at fair value in our financial statements are categorized based upon the level of judgment associated with the inputs used to measure their fair value. Hierarchical levels directly related to the amount of subjectivity associated with the inputs to fair valuation of these assets and liabilities, are as follows:   Level 1Inputs are unadjusted, quoted prices in active markets for identical assets at the reporting date. Active markets are those in which transactions for the asset or liability occur in sufficient frequency and volume to provide pricing information on an ongoing basis.   The fair valued assets we hold that are generally included under this Level 1 are money market securities where fair value is based on publicly quoted prices.   Level 2Are inputs, other than quoted prices included in Level 1, that are either directly or indirectly observable for the asset or liability through correlation with market data at the reporting date and for the duration of the instrument's anticipated life.   The fair valued assets we hold that are generally assessed under Level 2 are corporate bonds and commercial paper. We utilize third party pricing services in developing fair value measurements where fair value is based on valuation methodologies such as models using observable market inputs, including benchmark yields, reported trades, broker/dealer quotes, bids, offers and other reference data. We use quotes from external pricing service providers and other on-line quotation systems to verify the fair value of investments provided by our third party pricing service providers. We review independent auditor's reports from our third party pricing service providers particularly regarding the controls over pricing and valuation of financial instruments and ensure that our internal controls address certain control deficiencies, if any, and complementary user entity controls are in place.   Level 3Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities and which reflect management's best estimate of what market participants would use in pricing the asset or liability at the reporting date. Consideration is given to the risk inherent in the valuation technique and the risk inherent in the inputs to the model.   We do not have fair valued assets classified under Level 3. </div> <div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';"> Fair Value on a Recurring Basis   Financial assets measured at fair value on a recurring basis are categorized in the tables below based upon the lowest level of significant input to the valuations (in thousands): <div>   <table style="border-collapse: collapse; font: 10pt times new roman, times, serif;" cellpadding="0" cellspacing="0" width="100%"> <tr style="vertical-align: bottom;"> <td style="font-size: 10pt; font-weight: bold; text-align: center; padding: 0px; font-family: 'Times New Roman';"></td> <td style="font-family: 'times new roman'; padding: 0px;"></td> <td style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;" colspan="14">Assets at Fair Value as of September 30, 2015</td> <td style="font-family: 'times new roman'; padding: 0px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="text-align: center; font-family: 'times new roman'; padding: 0px;"></td> <td style="font-size: 10pt; font-weight: bold; font-family: 'times new roman'; padding: 0px;"></td> <td style="font-size: 10pt; font-weight: bold; text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;" colspan="2">Level 1</td> <td style="font-size: 10pt; font-weight: bold; font-family: 'times new roman'; padding: 0px;"> </td> <td style="font-size: 10pt; font-weight: bold; font-family: 'times new roman'; padding: 0px;"> </td> <td style="font-size: 10pt; font-weight: bold; text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;" colspan="2">Level 2</td> <td style="font-size: 10pt; font-weight: bold; font-family: 'times new roman'; padding: 0px;"> </td> <td style="font-size: 10pt; font-weight: bold; font-family: 'times new roman'; padding: 0px;"> </td> <td style="font-size: 10pt; font-weight: bold; text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;" colspan="2">Level 3</td> <td style="font-size: 10pt; font-weight: bold; font-family: 'times new roman'; padding: 0px;"> </td> <td style="font-size: 10pt; font-weight: bold; font-family: 'times new roman'; padding: 0px;"> </td> <td style="font-size: 10pt; font-weight: bold; text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;" colspan="2">Total</td> <td style="font-size: 10pt; font-weight: bold; font-family: 'times new roman'; padding: 0px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="font-size: 10pt; text-align: left; text-indent: 10pt; font-family: 'times new roman'; padding: 0px; width: 36%;">Money market funds</td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px; width: 2%;"></td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px 10px 0px 0px; vertical-align: bottom; white-space: nowrap; width: 1%;">$</td> <td style="font-size: 10pt; text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; width: 12%;">20,562</td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 1%;"> </td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 2%;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px 10px 0px 0px; vertical-align: bottom; white-space: nowrap; width: 1%;">$</td> <td style="font-size: 10pt; text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; width: 12%;">-</td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 1%;"> </td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 2%;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px 10px 0px 0px; vertical-align: bottom; white-space: nowrap; width: 1%;">$</td> <td style="font-size: 10pt; text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; width: 12%;">-</td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 1%;"> </td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 2%;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px 10px 0px 0px; vertical-align: bottom; white-space: nowrap; width: 1%;">$</td> <td style="font-size: 10pt; text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; width: 12%;">20,562</td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="font-size: 10pt; text-align: left; text-indent: 10pt; font-family: 'times new roman'; padding: 0px; vertical-align: top;"> </td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px; vertical-align: top; text-align: left;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px; vertical-align: top; text-align: left; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px; vertical-align: top; text-align: left; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px; vertical-align: top; text-align: left; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="font-size: 10pt; text-align: left; text-indent: 10pt; font-family: 'times new roman'; padding: 0px;">Corporate debt securities</td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;">-</td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"> </td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;">79,374</td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"> </td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;">-</td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"> </td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;">79,374</td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"> </td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="font-size: 10pt; text-indent: 20pt; font-family: 'times new roman'; padding: 0px;">Total</td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;">$</td> <td style="font-size: 10pt; text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;">20,562</td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"> </td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;">$</td> <td style="font-size: 10pt; text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;">79,374</td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"> </td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;">$</td> <td style="font-size: 10pt; text-align: right; border-bottom: #000000 2.80pt double !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;">$</td> <td style="font-size: 10pt; text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;">99,936</td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;">  </td> </tr> </table>   </div> </div> <div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';"> Use of Estimates   The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates include accounting for potential liabilities and the assumptions made in valuing stock instruments issued for services. </div> <div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';"> Stock-Based Compensation   The Company periodically grants stock options and warrants to employees and non-employees in non-capital raising transactions as compensation for services rendered. The Company accounts for stock option grants to employees based on the authoritative guidance provided by the Financial Accounting Standards Board where the value of the award is measured on the date of grant and recognized over the vesting period. The Company accounts for stock option grants to non-employees in accordance with the authoritative guidance of the Financial Accounting Standards Board where the value of the stock compensation is determined based upon the measurement date at either a) the date at which a performance commitment is reached, or b) at the date at which the necessary performance to earn the equity instruments is complete. Non-employee stock-based compensation charges generally are amortized over the vesting period on a straight-line basis. In certain circumstances where there are no future performance requirements by the non-employee, option grants are immediately vested and the total stock-based compensation charge is recorded in the period of the measurement date.   The Company issues restricted shares of its common stock for share-based compensation programs. The Company measures the compensation cost with respect to restricted shares to employees based upon the estimated fair value of the equity instruments at the date of the grant, and is recognized as expense over the period which an employee is required to provide services in exchange for the award.   The fair value of the Company's common stock option grants is estimated using a Black-Scholes option pricing model, which uses certain assumptions related to risk-free interest rates, expected volatility, expected life of the common stock options, and future dividends. Compensation expense is recorded based upon the value derived from the Black-Scholes option pricing model, and based on actual experience. The assumptions used in the Black-Scholes option pricing model could materially affect compensation expense recorded in future periods.     Total stock-based compensation expense related to all of our stock-based awards was as follows (in thousands): <div><div style="display: block;">                     <table style="border-collapse: collapse; font: 10pt times new roman, times, serif;" cellpadding="0" cellspacing="0" width="100%"> <tr style="vertical-align: bottom;"> <td style="font-size: 10pt; text-align: center; font-family: 'times new roman'; padding: 0px;"></td> <td style="font-size: 10pt; font-weight: bold; font-family: 'times new roman'; padding: 0px;"></td> <td style="font-size: 10pt; font-weight: bold; text-align: center; padding: 0px;" colspan="6">For the Three Months Ended September 30,</td> <td style="font-size: 10pt; font-weight: bold; font-family: 'times new roman'; padding: 0px;"></td> <td style="font-size: 10pt; font-weight: bold; font-family: 'times new roman'; padding: 0px;"> </td> <td style="font-size: 10pt; font-weight: bold; text-align: center; padding: 0px;" colspan="14">For the Nine Months Ended September 30,</td> <td style="font-size: 10pt; font-weight: bold; font-family: 'times new roman'; padding: 0px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-size: 10pt; text-align: center; font-family: 'times new roman'; padding: 0px;"></td> <td style="font-size: 10pt; font-weight: bold; font-family: 'times new roman'; padding: 0px;"></td> <td style="font-size: 10pt; font-weight: bold; text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;" colspan="2">2015</td> <td style="font-size: 10pt; font-weight: bold; font-family: 'times new roman'; padding: 0px;"></td> <td style="font-size: 10pt; font-weight: bold; font-family: 'times new roman'; padding: 0px;"> </td> <td style="font-size: 10pt; font-weight: bold; text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;" colspan="2">2014</td> <td style="font-size: 10pt; font-weight: bold; font-family: 'times new roman'; padding: 0px;"> </td> <td style="font-size: 10pt; font-weight: bold; font-family: 'times new roman'; padding: 0px;"> </td> <td style="font-size: 10pt; font-weight: bold; text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;" colspan="2">2015</td> <td style="font-size: 10pt; font-weight: bold; font-family: 'times new roman'; padding: 0px;"> </td> <td style="font-size: 10pt; font-weight: bold; font-family: 'times new roman'; padding: 0px;"> </td> <td style="font-size: 10pt; font-weight: bold; text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;" colspan="2">2014</td> <td style="font-size: 10pt; font-weight: bold; font-family: 'times new roman'; padding: 0px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top;"></td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px; vertical-align: top; text-align: left;"></td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top;" colspan="2"></td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px; vertical-align: top; text-align: left;"></td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px; vertical-align: top; text-align: left;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top;" colspan="2"> </td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px; vertical-align: top; text-align: left;"> </td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px; vertical-align: top; text-align: left;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top;" colspan="2"> </td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px; vertical-align: top; text-align: left;"> </td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px; vertical-align: top; text-align: left;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top;" colspan="2"> </td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px; vertical-align: top; text-align: left;"> </td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px; width: 36%;">Operating expenses</td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px; width: 2%;"></td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px 10px 0px 0px; vertical-align: bottom; white-space: nowrap; width: 1%;">$</td> <td style="font-size: 10pt; text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; width: 12%;">1,492</td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 1%;"> </td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 2%;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px 10px 0px 0px; vertical-align: bottom; white-space: nowrap; width: 1%;">$</td> <td style="font-size: 10pt; text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; width: 12%;">658</td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 1%;"> </td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 2%;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px 10px 0px 0px; vertical-align: bottom; white-space: nowrap; width: 1%;">$</td> <td style="font-size: 10pt; text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; width: 12%;">3,726</td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 1%;"> </td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 2%;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px 10px 0px 0px; vertical-align: bottom; white-space: nowrap; width: 1%;">$</td> <td style="font-size: 10pt; text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; width: 12%;">1,905</td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="font-size: 10pt; text-align: left; text-indent: 0px; font-family: 'times new roman'; padding: 0px;">Research and development</td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px;"> </td> <td style="font-size: 10pt; text-align: left; border-bottom: #000000 1pt solid !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"> </td> <td style="font-size: 10pt; text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;">895</td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"> </td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; text-align: left; border-bottom: #000000 1pt solid !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"> </td> <td style="font-size: 10pt; text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;">282</td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"> </td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; text-align: left; border-bottom: #000000 1pt solid !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"> </td> <td style="font-size: 10pt; text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;">2,050</td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"> </td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; text-align: left; border-bottom: #000000 1pt solid !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"> </td> <td style="font-size: 10pt; text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;">817</td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"> </td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px;">   Total stock-based compensation expense</td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;">$</td> <td style="font-size: 10pt; text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;">2,387</td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"> </td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;">$</td> <td style="font-size: 10pt; text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;">940</td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"> </td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;">$</td> <td style="font-size: 10pt; text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;">5,776</td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"> </td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;">$</td> <td style="font-size: 10pt; text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;">2,722</td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;">   </td> </tr> </table>   </div></div> </div> <div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';"> Research and Development   Research and development costs consist primarily of fees paid to consultants and outside service providers, patent fees and costs, and other expenses relating to the acquisition, design, development and testing of the Company's treatments and product candidates. Research and development costs are expensed as incurred, unless the achievement of milestones, the completion of contracted work, or other information indicates that a different expensing schedule is more appropriate. The Company reviews the status of its research and development contracts on a quarterly basis. </div> <div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';"> Reclassifications   In presenting the Company's statement of operations for the three and nine month periods ended September 30, 2014, the Company has reclassified $0.8 million and $0.3 million, respectively, of stock-based compensation that was previously reflected as operating expenses to research and development expenses. The reclassification relates to stock-based compensation attributable to individuals working in the Company's research and development activities, and had no impact on total costs and expenses, or on net loss. </div> 1635000 <div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';"> Concentrations   Financial instruments, which potentially subject the Company to concentrations of credit risk, consist principally of cash and short-term investments.   The Company maintains cash balances at one bank. As of September 30, 2015, the Company's cash balances were in excess of insured limits maintained at this bank. Management believes that the financial institution that hold the Company's cash are financially sound and, accordingly, minimal credit risk exists.   At September 30, 2015, the Company's short-term investments were invested in short-term fixed income debt securities of domestic and foreign high credit issuers and in money market funds. The Company's investment policy limits investments to certain types of instruments such as certificates of deposit, money market instruments, obligations issued by the U.S. government and U.S. government agencies as well as corporate debt securities, and places restrictions on maturities and concentration by type and issuer. At September 30, 2015, approximately 56% of the Company's short-term investments were invested in notes of five companies, 25% were invested in notes of various domestic issuers, and 19% were invested in notes of a foreign issuers. The average maturity of these notes was 66 days (See Note 3). </div> <div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';"> Recent Accounting Pronouncements   In May 2014, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2014-09, Revenue from Contracts with Customers. ASU 2014-09 is a comprehensive revenue recognition standard that will supersede nearly all existing revenue recognition guidance under current U.S. GAAP and replace it with a principle based approach for determining revenue recognition. ASU 2014-09 will require that companies recognize revenue based on the value of transferred goods or services as they occur in the contract. The ASU also will require additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to obtain or fulfill a contract. ASU 2014-09 is effective for interim and annual periods beginning after December 15, 2017. Early adoption is permitted in annual reporting periods beginning after December 15, 2016, and the interim periods within that year, and either full retrospective adoption or modified retrospective adoption is permitted. The Company is in the process of evaluating the impact of ASU 2014-09 on the Company's financial statements and disclosures.   In June 2014, the FASB issued Accounting Standards Update No. 2014-12, Compensation Stock Compensation (Topic 718). The pronouncement was issued to clarify the accounting for share-based payments when the terms of an award provide that a performance target could be achieved after the requisite service period. The pronouncement is effective for reporting periods beginning after December 15, 2015. The adoption of ASU 2014-12 is not expected to have a significant impact on the Company's consolidated financial position or results of operations.   Other recent accounting pronouncements issued by the FASB, including its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the Securities and Exchange Commission did not or are not believed by management to have a material impact on the Company's present or future consolidated financial statements. </div> <div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';">   <table style="border-collapse: collapse; font: 10pt times new roman, times, serif;" cellpadding="0" cellspacing="0" width="100%"> <tr style="vertical-align: bottom;"> <td style="font-size: 10pt; font-weight: bold; text-align: center; padding: 0px; font-family: 'Times New Roman';"></td> <td style="font-family: 'times new roman'; padding: 0px;"></td> <td style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;" colspan="14">Assets at Fair Value as of September 30, 2015</td> <td style="font-family: 'times new roman'; padding: 0px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="text-align: center; font-family: 'times new roman'; padding: 0px;"></td> <td style="font-size: 10pt; font-weight: bold; font-family: 'times new roman'; padding: 0px;"></td> <td style="font-size: 10pt; font-weight: bold; text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;" colspan="2">Level 1</td> <td style="font-size: 10pt; font-weight: bold; font-family: 'times new roman'; padding: 0px;"> </td> <td style="font-size: 10pt; font-weight: bold; font-family: 'times new roman'; padding: 0px;"> </td> <td style="font-size: 10pt; font-weight: bold; text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;" colspan="2">Level 2</td> <td style="font-size: 10pt; font-weight: bold; font-family: 'times new roman'; padding: 0px;"> </td> <td style="font-size: 10pt; font-weight: bold; font-family: 'times new roman'; padding: 0px;"> </td> <td style="font-size: 10pt; font-weight: bold; text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;" colspan="2">Level 3</td> <td style="font-size: 10pt; font-weight: bold; font-family: 'times new roman'; padding: 0px;"> </td> <td style="font-size: 10pt; font-weight: bold; font-family: 'times new roman'; padding: 0px;"> </td> <td style="font-size: 10pt; font-weight: bold; text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;" colspan="2">Total</td> <td style="font-size: 10pt; font-weight: bold; font-family: 'times new roman'; padding: 0px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="font-size: 10pt; text-align: left; text-indent: 10pt; font-family: 'times new roman'; padding: 0px; width: 36%;">Money market funds</td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px; width: 2%;"></td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px 10px 0px 0px; vertical-align: bottom; white-space: nowrap; width: 1%;">$</td> <td style="font-size: 10pt; text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; width: 12%;">20,562</td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 1%;"> </td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 2%;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px 10px 0px 0px; vertical-align: bottom; white-space: nowrap; width: 1%;">$</td> <td style="font-size: 10pt; text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; width: 12%;">-</td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 1%;"> </td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 2%;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px 10px 0px 0px; vertical-align: bottom; white-space: nowrap; width: 1%;">$</td> <td style="font-size: 10pt; text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; width: 12%;">-</td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 1%;"> </td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 2%;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px 10px 0px 0px; vertical-align: bottom; white-space: nowrap; width: 1%;">$</td> <td style="font-size: 10pt; text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; width: 12%;">20,562</td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="font-size: 10pt; text-align: left; text-indent: 10pt; font-family: 'times new roman'; padding: 0px; vertical-align: top;"> </td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px; vertical-align: top; text-align: left;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px; vertical-align: top; text-align: left; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px; vertical-align: top; text-align: left; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px; vertical-align: top; text-align: left; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="font-size: 10pt; text-align: left; text-indent: 10pt; font-family: 'times new roman'; padding: 0px;">Corporate debt securities</td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;">-</td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"> </td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;">79,374</td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"> </td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;">-</td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"> </td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;">79,374</td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"> </td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="font-size: 10pt; text-indent: 20pt; font-family: 'times new roman'; padding: 0px;">Total</td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;">$</td> <td style="font-size: 10pt; text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;">20,562</td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"> </td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;">$</td> <td style="font-size: 10pt; text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;">79,374</td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"> </td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;">$</td> <td style="font-size: 10pt; text-align: right; border-bottom: #000000 2.80pt double !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;">$</td> <td style="font-size: 10pt; text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;">99,936</td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;">  </td> </tr> </table>   </div> <div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';"><div style="display: block;">                     <table style="border-collapse: collapse; font: 10pt times new roman, times, serif;" cellpadding="0" cellspacing="0" width="100%"> <tr style="vertical-align: bottom;"> <td style="font-size: 10pt; text-align: center; font-family: 'times new roman'; padding: 0px;"></td> <td style="font-size: 10pt; font-weight: bold; font-family: 'times new roman'; padding: 0px;"></td> <td style="font-size: 10pt; font-weight: bold; text-align: center; padding: 0px;" colspan="6">For the Three Months Ended September 30,</td> <td style="font-size: 10pt; font-weight: bold; font-family: 'times new roman'; padding: 0px;"></td> <td style="font-size: 10pt; font-weight: bold; font-family: 'times new roman'; padding: 0px;"> </td> <td style="font-size: 10pt; font-weight: bold; text-align: center; padding: 0px;" colspan="14">For the Nine Months Ended September 30,</td> <td style="font-size: 10pt; font-weight: bold; font-family: 'times new roman'; padding: 0px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-size: 10pt; text-align: center; font-family: 'times new roman'; padding: 0px;"></td> <td style="font-size: 10pt; font-weight: bold; font-family: 'times new roman'; padding: 0px;"></td> <td style="font-size: 10pt; font-weight: bold; text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;" colspan="2">2015</td> <td style="font-size: 10pt; font-weight: bold; font-family: 'times new roman'; padding: 0px;"></td> <td style="font-size: 10pt; font-weight: bold; font-family: 'times new roman'; padding: 0px;"> </td> <td style="font-size: 10pt; font-weight: bold; text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;" colspan="2">2014</td> <td style="font-size: 10pt; font-weight: bold; font-family: 'times new roman'; padding: 0px;"> </td> <td style="font-size: 10pt; font-weight: bold; font-family: 'times new roman'; padding: 0px;"> </td> <td style="font-size: 10pt; font-weight: bold; text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;" colspan="2">2015</td> <td style="font-size: 10pt; font-weight: bold; font-family: 'times new roman'; padding: 0px;"> </td> <td style="font-size: 10pt; font-weight: bold; font-family: 'times new roman'; padding: 0px;"> </td> <td style="font-size: 10pt; font-weight: bold; text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;" colspan="2">2014</td> <td style="font-size: 10pt; font-weight: bold; font-family: 'times new roman'; padding: 0px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top;"></td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px; vertical-align: top; text-align: left;"></td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top;" colspan="2"></td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px; vertical-align: top; text-align: left;"></td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px; vertical-align: top; text-align: left;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top;" colspan="2"> </td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px; vertical-align: top; text-align: left;"> </td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px; vertical-align: top; text-align: left;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top;" colspan="2"> </td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px; vertical-align: top; text-align: left;"> </td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px; vertical-align: top; text-align: left;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top;" colspan="2"> </td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px; vertical-align: top; text-align: left;"> </td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px; width: 36%;">Operating expenses</td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px; width: 2%;"></td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px 10px 0px 0px; vertical-align: bottom; white-space: nowrap; width: 1%;">$</td> <td style="font-size: 10pt; text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; width: 12%;">1,492</td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 1%;"> </td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 2%;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px 10px 0px 0px; vertical-align: bottom; white-space: nowrap; width: 1%;">$</td> <td style="font-size: 10pt; text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; width: 12%;">658</td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 1%;"> </td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 2%;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px 10px 0px 0px; vertical-align: bottom; white-space: nowrap; width: 1%;">$</td> <td style="font-size: 10pt; text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; width: 12%;">3,726</td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 1%;"> </td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 2%;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px 10px 0px 0px; vertical-align: bottom; white-space: nowrap; width: 1%;">$</td> <td style="font-size: 10pt; text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; width: 12%;">1,905</td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="font-size: 10pt; text-align: left; text-indent: 0px; font-family: 'times new roman'; padding: 0px;">Research and development</td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px;"> </td> <td style="font-size: 10pt; text-align: left; border-bottom: #000000 1pt solid !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"> </td> <td style="font-size: 10pt; text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;">895</td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"> </td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; text-align: left; border-bottom: #000000 1pt solid !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"> </td> <td style="font-size: 10pt; text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;">282</td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"> </td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; text-align: left; border-bottom: #000000 1pt solid !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"> </td> <td style="font-size: 10pt; text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;">2,050</td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"> </td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; text-align: left; border-bottom: #000000 1pt solid !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"> </td> <td style="font-size: 10pt; text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;">817</td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"> </td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px;">   Total stock-based compensation expense</td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;">$</td> <td style="font-size: 10pt; text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;">2,387</td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"> </td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;">$</td> <td style="font-size: 10pt; text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;">940</td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"> </td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;">$</td> <td style="font-size: 10pt; text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;">5,776</td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"> </td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;">$</td> <td style="font-size: 10pt; text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;">2,722</td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;">   </td> </tr> </table>   </div></div> 2704195 7237216 1847000 494001 1098750 11172426 2847000 0.56 0.25 0.19 20562000 20562000 79374000 79374000 20562000 79374000 99936000 P2Y P5Y 1492000 658000 3726000 1905000 895000 282000 2050000 817000 2387000 940000 5776000 2722000 <div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';">   <div> <table style="border-collapse: collapse; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; margin-left: 0.1px;" cellpadding="0" cellspacing="0" width="80%"> <tr style="vertical-align: bottom;"> <td style="font-size: 10pt; font-weight: bold; text-align: center; font-family: 'times new roman'; padding: 0px;"></td> <td style="font-family: 'Times New Roman';"></td> <td style="text-align: center; font-family: 'times new roman'; padding: 0px;" colspan="2">Within One</td> <td style="font-family: 'Times New Roman';"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-size: 10pt; font-weight: bold; text-align: center; font-family: 'times new roman'; padding: 0px;"></td> <td style="font-family: 'times new roman'; padding: 0px;"></td> <td style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;" colspan="2">Year</td> <td style="font-family: 'times new roman'; padding: 0px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="font-size: 10pt; text-align: left; /* text-indent: 10pt; */ font-family: 'times new roman'; padding: 0px; width: 84%;">Money market funds</td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px; width: 2%;"></td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px 10px 0px 0px; vertical-align: bottom; white-space: nowrap; width: 1%;">$</td> <td style="font-size: 10pt; text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; width: 12%;">20,562</td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="font-size: 10pt; text-align: left; /* text-indent: 10pt; */ font-family: 'times new roman'; padding: 0px;">Corporate debt securities</td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px;"></td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;">79,374</td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px; border-bottom: #000000 1pt solid !important; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="text-align: left; font-family: 'times new roman'; padding: 0px;"> </td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;">$</td> <td style="font-size: 10pt; text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;">99,936</td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px; border-bottom: #000000 2.80pt double !important; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> </tr> </table> </div>   </div> 79374000 110146000 45000 20562000 <div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';"> NOTE 3. CASH, MONEY MARKET FUNDS, AND SHORT-TERM INVESTMENTS   Cash, money market funds, and short-term investments consist of the following (in thousands): <div>   <table style="border-collapse: collapse; font: 10pt times new roman, times, serif;" cellpadding="0" cellspacing="0" width="100%"> <tr style="vertical-align: bottom;"> <td style="font: 10pt times new roman, times, serif; text-align: center; font-family: 'times new roman'; padding: 0px;"></td> <td style="font: 10pt times new roman, times, serif; font-family: 'times new roman'; padding: 0px;"></td> <td style="font: 10pt times new roman, times, serif; text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;" colspan="2"> September 30, 2015 </td> <td style="font: 10pt times new roman, times, serif; font-family: 'times new roman'; padding: 0px;"> </td> <td style="font-family: 'times new roman'; padding: 0px;"> </td> <td style="font: 10pt times new roman, times, serif; text-align: center; border-bottom: #000000 1pt solid !important; padding: 0px;" colspan="2"> December 31, 2014 </td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: center; padding: 0px; width: 20px;">   </td> </tr> <tr style="vertical-align: bottom;"> <td style="font: 10pt times new roman, times, serif; text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top;"></td> <td style="font: 10pt times new roman, times, serif; font-family: 'times new roman'; padding: 0px; vertical-align: top; text-align: left;"></td> <td style="font: 10pt times new roman, times, serif; text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top;" colspan="2"></td> <td style="font: 10pt times new roman, times, serif; font-family: 'times new roman'; padding: 0px; vertical-align: top; text-align: left;"> </td> <td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';"> </td> <td style="font: 10pt times new roman, times, serif; text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top;" colspan="2"> </td> <td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';"> </td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="font-size: 10pt; /* text-indent: 10pt; */ font-family: 'times new roman'; padding: 0px; text-align: left; width: 68%; padding-left: 0px;">Checking and savings accounts (reported as cash and cash equivalents)</td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px; width: 2%;"></td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px 10px 0px 0px; vertical-align: bottom; white-space: nowrap; width: 1%;">$</td> <td style="font-size: 10pt; text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; width: 12%;">10,210</td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 1%;"> </td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 2%;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px 10px 0px 0px; vertical-align: bottom; white-space: nowrap; width: 1%;">$</td> <td style="font-size: 10pt; text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; width: 12%;">45</td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="font-size: 10pt; text-align: left; /* text-indent: 10pt; */ font-family: 'times new roman'; padding: 0px;">Money market funds</td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px;"></td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;">20,562</td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;">-</td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="font-size: 10pt; text-align: left; /* text-indent: 10pt; */ font-family: 'times new roman'; padding: 0px;">Corporate debt securities (reported as short-term investments)</td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;">79,374</td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"> </td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;">-</td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"> </td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="text-align: left; font-family: 'times new roman'; padding: 0px;"> </td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;">$</td> <td style="font-size: 10pt; text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;">110,146</td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"> </td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;">$</td> <td style="font-size: 10pt; text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;">45</td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"> </td> </tr> </table> </div>   Money market funds and short-term investments include the following securities with gross unrealized gains and losses (in thousands):  <div>   <div> <table style="border-collapse: collapse; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; margin-left: 0.1px;" cellpadding="0" cellspacing="0" width="90%"> <tr style="vertical-align: bottom;"> <td style="font-size: 10pt; font-weight: bold; text-align: center; font-family: 'times new roman'; padding: 0px;"></td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px;"></td> <td style="font-size: 10pt; text-align: center; font-family: 'times new roman'; padding: 0px;" colspan="2"></td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px;"></td> <td style="font-size: 10pt; font-weight: bold; font-family: 'times new roman'; padding: 0px;"> </td> <td style="font-size: 10pt; font-weight: bold; text-align: center; font-family: 'times new roman'; padding: 0px;" colspan="2">Gross</td> <td style="font-size: 10pt; font-weight: bold; font-family: 'times new roman'; padding: 0px;"> </td> <td style="font-size: 10pt; font-weight: bold; font-family: 'times new roman'; padding: 0px;"> </td> <td style="font-size: 10pt; font-weight: bold; text-align: center; font-family: 'times new roman'; padding: 0px;" colspan="2">Gross</td> <td style="font-size: 10pt; font-weight: bold; font-family: 'times new roman'; padding: 0px;"> </td> <td style="font-size: 10pt; font-weight: bold; font-family: 'times new roman'; padding: 0px;"> </td> <td style="font-size: 10pt; font-weight: bold; text-align: center; font-family: 'times new roman'; padding: 0px;" colspan="2"> </td> <td style="font-size: 10pt; font-weight: bold; font-family: 'times new roman'; padding: 0px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-size: 10pt; font-weight: bold; text-align: center; font-family: 'times new roman'; padding: 0px;"></td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px;"></td> <td style="font-size: 10pt; text-align: center; font-family: 'times new roman'; padding: 0px;" colspan="2"></td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px;"></td> <td style="font-size: 10pt; font-weight: bold; font-family: 'times new roman'; padding: 0px;"> </td> <td style="font-size: 10pt; font-weight: bold; text-align: center; font-family: 'times new roman'; padding: 0px;" colspan="2">Unrealized</td> <td style="font-size: 10pt; font-weight: bold; font-family: 'times new roman'; padding: 0px;"> </td> <td style="font-size: 10pt; font-weight: bold; font-family: 'times new roman'; padding: 0px;"> </td> <td style="font-size: 10pt; font-weight: bold; text-align: center; font-family: 'times new roman'; padding: 0px;" colspan="2">Unrealized</td> <td style="font-size: 10pt; font-weight: bold; font-family: 'times new roman'; padding: 0px;"> </td> <td style="font-size: 10pt; font-weight: bold; font-family: 'times new roman'; padding: 0px;"> </td> <td style="font-size: 10pt; font-weight: bold; text-align: center; font-family: 'times new roman'; padding: 0px;" colspan="2"> </td> <td style="font-size: 10pt; font-weight: bold; font-family: 'times new roman'; padding: 0px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-size: 10pt; font-weight: bold; text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;">September 30, 2015</td> <td style="font-size: 10pt; font-weight: bold; font-family: 'times new roman'; padding: 0px;"></td> <td style="font-size: 10pt; font-weight: bold; text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;" colspan="2">Cost</td> <td style="font-size: 10pt; font-weight: bold; font-family: 'times new roman'; padding: 0px;"></td> <td style="font-size: 10pt; font-weight: bold; font-family: 'times new roman'; padding: 0px;"> </td> <td style="font-size: 10pt; font-weight: bold; text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;" colspan="2">Gains</td> <td style="font-size: 10pt; font-weight: bold; font-family: 'times new roman'; padding: 0px;"> </td> <td style="font-size: 10pt; font-weight: bold; font-family: 'times new roman'; padding: 0px;"> </td> <td style="font-size: 10pt; font-weight: bold; text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;" colspan="2">Gains</td> <td style="font-size: 10pt; font-weight: bold; font-family: 'times new roman'; padding: 0px;"> </td> <td style="font-size: 10pt; font-weight: bold; font-family: 'times new roman'; padding: 0px;"> </td> <td style="font-size: 10pt; font-weight: bold; text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;" colspan="2">Fair Value</td> <td style="font-size: 10pt; font-weight: bold; font-family: 'times new roman'; padding: 0px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="font-size: 10pt; text-align: left; text-indent: 10pt; font-family: 'times new roman'; padding: 0px; width: 36%;">Money market funds</td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px; width: 2%;"></td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px 10px 0px 0px; vertical-align: bottom; white-space: nowrap; width: 1%;">$</td> <td style="font-size: 10pt; text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; width: 12%;">20,562</td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 1%;"> </td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 2%;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px 10px 0px 0px; vertical-align: bottom; white-space: nowrap; width: 1%;">$</td> <td style="font-size: 10pt; text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; width: 12%;">-</td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 1%;"> </td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 2%;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px 10px 0px 0px; vertical-align: bottom; white-space: nowrap; width: 1%;">$</td> <td style="font-size: 10pt; text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; width: 12%;">-</td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 1%;"> </td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 2%;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px 10px 0px 0px; vertical-align: bottom; white-space: nowrap; width: 1%;">$</td> <td style="font-size: 10pt; text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; width: 12%;">20,562</td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="font-size: 10pt; text-align: left; text-indent: 10pt; font-family: 'times new roman'; padding: 0px;">Corporate debt securities</td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;">79,336</td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"> </td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;">38</td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"> </td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;">-</td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"> </td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;">79,374</td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"> </td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="font-size: 10pt; text-align: left; text-indent: 10pt; font-family: 'times new roman'; padding: 0px; vertical-align: top;"> </td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px; vertical-align: top; text-align: left;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px; vertical-align: top; text-align: left; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px; vertical-align: top; text-align: left; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px; vertical-align: top; text-align: left; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="font-size: 10pt; text-indent: 20pt; font-family: 'times new roman'; padding: 0px;">Total</td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;">$</td> <td style="font-size: 10pt; text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;">99,897</td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"> </td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;">$</td> <td style="font-size: 10pt; text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;">38</td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"> </td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;">$</td> <td style="font-size: 10pt; text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;">-</td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"> </td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;">$</td> <td style="font-size: 10pt; text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;">99,936</td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"> </td> </tr> </table> </div>    </div> As of September 30, 2015, the contractual maturities of our money market funds and short-term investments were (in thousands):  <div>   <div> <table style="border-collapse: collapse; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; margin-left: 0.1px;" cellpadding="0" cellspacing="0" width="80%"> <tr style="vertical-align: bottom;"> <td style="font-size: 10pt; font-weight: bold; text-align: center; font-family: 'times new roman'; padding: 0px;"></td> <td style="font-family: 'Times New Roman';"></td> <td style="text-align: center; font-family: 'times new roman'; padding: 0px;" colspan="2">Within One</td> <td style="font-family: 'Times New Roman';"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-size: 10pt; font-weight: bold; text-align: center; font-family: 'times new roman'; padding: 0px;"></td> <td style="font-family: 'times new roman'; padding: 0px;"></td> <td style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;" colspan="2">Year</td> <td style="font-family: 'times new roman'; padding: 0px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="font-size: 10pt; text-align: left; /* text-indent: 10pt; */ font-family: 'times new roman'; padding: 0px; width: 84%;">Money market funds</td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px; width: 2%;"></td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px 10px 0px 0px; vertical-align: bottom; white-space: nowrap; width: 1%;">$</td> <td style="font-size: 10pt; text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; width: 12%;">20,562</td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="font-size: 10pt; text-align: left; /* text-indent: 10pt; */ font-family: 'times new roman'; padding: 0px;">Corporate debt securities</td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px;"></td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;">79,374</td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px; border-bottom: #000000 1pt solid !important; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="text-align: left; font-family: 'times new roman'; padding: 0px;"> </td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;">$</td> <td style="font-size: 10pt; text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;">99,936</td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px; border-bottom: #000000 2.80pt double !important; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> </tr> </table> </div>   </div> At September 30, 2015,the Company's short-term investments were invested in short-term fixed income debt securities and notes of domestic and foreign high credit issuers and in money market funds. The Company's investment policy limits investments to certain types of instruments such as certificates of deposit, money market instruments, obligations issued by the U.S. government and U.S. government agencies as well as corporate debt securities, and places restrictions on maturities and concentration by type and issuer. At September 30, 2015, the Company's short-term investments totaled $80 million, of which 56% were invested in notes of five companies, 25% were invested in notes of other domestic issuers, and 19% were invested in notes of foreign issuers. The average maturity of these notes was 66 days. At September 30, 2015 the Company's money-market funds totaled $20.6 million and were invested in a single fund, the Dreyfus Cash Management Money Market Fund, a no-load money market fund. </div> <div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';">   <table style="border-collapse: collapse; font: 10pt times new roman, times, serif;" cellpadding="0" cellspacing="0" width="100%"> <tr style="vertical-align: bottom;"> <td style="font: 10pt times new roman, times, serif; text-align: center; font-family: 'times new roman'; padding: 0px;"></td> <td style="font: 10pt times new roman, times, serif; font-family: 'times new roman'; padding: 0px;"></td> <td style="font: 10pt times new roman, times, serif; text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;" colspan="2"> September 30, 2015 </td> <td style="font: 10pt times new roman, times, serif; font-family: 'times new roman'; padding: 0px;"> </td> <td style="font-family: 'times new roman'; padding: 0px;"> </td> <td style="font: 10pt times new roman, times, serif; text-align: center; border-bottom: #000000 1pt solid !important; padding: 0px;" colspan="2"> December 31, 2014 </td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: center; padding: 0px; width: 20px;">   </td> </tr> <tr style="vertical-align: bottom;"> <td style="font: 10pt times new roman, times, serif; text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top;"></td> <td style="font: 10pt times new roman, times, serif; font-family: 'times new roman'; padding: 0px; vertical-align: top; text-align: left;"></td> <td style="font: 10pt times new roman, times, serif; text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top;" colspan="2"></td> <td style="font: 10pt times new roman, times, serif; font-family: 'times new roman'; padding: 0px; vertical-align: top; text-align: left;"> </td> <td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';"> </td> <td style="font: 10pt times new roman, times, serif; text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top;" colspan="2"> </td> <td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';"> </td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="font-size: 10pt; /* text-indent: 10pt; */ font-family: 'times new roman'; padding: 0px; text-align: left; width: 68%; padding-left: 0px;">Checking and savings accounts (reported as cash and cash equivalents)</td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px; width: 2%;"></td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px 10px 0px 0px; vertical-align: bottom; white-space: nowrap; width: 1%;">$</td> <td style="font-size: 10pt; text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; width: 12%;">10,210</td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 1%;"> </td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 2%;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px 10px 0px 0px; vertical-align: bottom; white-space: nowrap; width: 1%;">$</td> <td style="font-size: 10pt; text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; width: 12%;">45</td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="font-size: 10pt; text-align: left; /* text-indent: 10pt; */ font-family: 'times new roman'; padding: 0px;">Money market funds</td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px;"></td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;">20,562</td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;">-</td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="font-size: 10pt; text-align: left; /* text-indent: 10pt; */ font-family: 'times new roman'; padding: 0px;">Corporate debt securities (reported as short-term investments)</td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;">79,374</td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"> </td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;">-</td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"> </td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="text-align: left; font-family: 'times new roman'; padding: 0px;"> </td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;">$</td> <td style="font-size: 10pt; text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;">110,146</td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"> </td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;">$</td> <td style="font-size: 10pt; text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;">45</td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"> </td> </tr> </table> </div> <div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';">   <div> <table style="border-collapse: collapse; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; margin-left: 0.1px;" cellpadding="0" cellspacing="0" width="90%"> <tr style="vertical-align: bottom;"> <td style="font-size: 10pt; font-weight: bold; text-align: center; font-family: 'times new roman'; padding: 0px;"></td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px;"></td> <td style="font-size: 10pt; text-align: center; font-family: 'times new roman'; padding: 0px;" colspan="2"></td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px;"></td> <td style="font-size: 10pt; font-weight: bold; font-family: 'times new roman'; padding: 0px;"> </td> <td style="font-size: 10pt; font-weight: bold; text-align: center; font-family: 'times new roman'; padding: 0px;" colspan="2">Gross</td> <td style="font-size: 10pt; font-weight: bold; font-family: 'times new roman'; padding: 0px;"> </td> <td style="font-size: 10pt; font-weight: bold; font-family: 'times new roman'; padding: 0px;"> </td> <td style="font-size: 10pt; font-weight: bold; text-align: center; font-family: 'times new roman'; padding: 0px;" colspan="2">Gross</td> <td style="font-size: 10pt; font-weight: bold; font-family: 'times new roman'; padding: 0px;"> </td> <td style="font-size: 10pt; font-weight: bold; font-family: 'times new roman'; padding: 0px;"> </td> <td style="font-size: 10pt; font-weight: bold; text-align: center; font-family: 'times new roman'; padding: 0px;" colspan="2"> </td> <td style="font-size: 10pt; font-weight: bold; font-family: 'times new roman'; padding: 0px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-size: 10pt; font-weight: bold; text-align: center; font-family: 'times new roman'; padding: 0px;"></td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px;"></td> <td style="font-size: 10pt; text-align: center; font-family: 'times new roman'; padding: 0px;" colspan="2"></td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px;"></td> <td style="font-size: 10pt; font-weight: bold; font-family: 'times new roman'; padding: 0px;"> </td> <td style="font-size: 10pt; font-weight: bold; text-align: center; font-family: 'times new roman'; padding: 0px;" colspan="2">Unrealized</td> <td style="font-size: 10pt; font-weight: bold; font-family: 'times new roman'; padding: 0px;"> </td> <td style="font-size: 10pt; font-weight: bold; font-family: 'times new roman'; padding: 0px;"> </td> <td style="font-size: 10pt; font-weight: bold; text-align: center; font-family: 'times new roman'; padding: 0px;" colspan="2">Unrealized</td> <td style="font-size: 10pt; font-weight: bold; font-family: 'times new roman'; padding: 0px;"> </td> <td style="font-size: 10pt; font-weight: bold; font-family: 'times new roman'; padding: 0px;"> </td> <td style="font-size: 10pt; font-weight: bold; text-align: center; font-family: 'times new roman'; padding: 0px;" colspan="2"> </td> <td style="font-size: 10pt; font-weight: bold; font-family: 'times new roman'; padding: 0px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-size: 10pt; font-weight: bold; text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;">September 30, 2015</td> <td style="font-size: 10pt; font-weight: bold; font-family: 'times new roman'; padding: 0px;"></td> <td style="font-size: 10pt; font-weight: bold; text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;" colspan="2">Cost</td> <td style="font-size: 10pt; font-weight: bold; font-family: 'times new roman'; padding: 0px;"></td> <td style="font-size: 10pt; font-weight: bold; font-family: 'times new roman'; padding: 0px;"> </td> <td style="font-size: 10pt; font-weight: bold; text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;" colspan="2">Gains</td> <td style="font-size: 10pt; font-weight: bold; font-family: 'times new roman'; padding: 0px;"> </td> <td style="font-size: 10pt; font-weight: bold; font-family: 'times new roman'; padding: 0px;"> </td> <td style="font-size: 10pt; font-weight: bold; text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;" colspan="2">Gains</td> <td style="font-size: 10pt; font-weight: bold; font-family: 'times new roman'; padding: 0px;"> </td> <td style="font-size: 10pt; font-weight: bold; font-family: 'times new roman'; padding: 0px;"> </td> <td style="font-size: 10pt; font-weight: bold; text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;" colspan="2">Fair Value</td> <td style="font-size: 10pt; font-weight: bold; font-family: 'times new roman'; padding: 0px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="font-size: 10pt; text-align: left; text-indent: 10pt; font-family: 'times new roman'; padding: 0px; width: 36%;">Money market funds</td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px; width: 2%;"></td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px 10px 0px 0px; vertical-align: bottom; white-space: nowrap; width: 1%;">$</td> <td style="font-size: 10pt; text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; width: 12%;">20,562</td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 1%;"> </td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 2%;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px 10px 0px 0px; vertical-align: bottom; white-space: nowrap; width: 1%;">$</td> <td style="font-size: 10pt; text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; width: 12%;">-</td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 1%;"> </td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 2%;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px 10px 0px 0px; vertical-align: bottom; white-space: nowrap; width: 1%;">$</td> <td style="font-size: 10pt; text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; width: 12%;">-</td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 1%;"> </td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 2%;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px 10px 0px 0px; vertical-align: bottom; white-space: nowrap; width: 1%;">$</td> <td style="font-size: 10pt; text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; width: 12%;">20,562</td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="font-size: 10pt; text-align: left; text-indent: 10pt; font-family: 'times new roman'; padding: 0px;">Corporate debt securities</td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;">79,336</td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"> </td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;">38</td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"> </td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;">-</td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"> </td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;">79,374</td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"> </td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="font-size: 10pt; text-align: left; text-indent: 10pt; font-family: 'times new roman'; padding: 0px; vertical-align: top;"> </td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px; vertical-align: top; text-align: left;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px; vertical-align: top; text-align: left; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px; vertical-align: top; text-align: left; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px; vertical-align: top; text-align: left; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="font-size: 10pt; text-indent: 20pt; font-family: 'times new roman'; padding: 0px;">Total</td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;">$</td> <td style="font-size: 10pt; text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;">99,897</td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"> </td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;">$</td> <td style="font-size: 10pt; text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;">38</td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"> </td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;">$</td> <td style="font-size: 10pt; text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;">-</td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"> </td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;">$</td> <td style="font-size: 10pt; text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;">99,936</td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"> </td> </tr> </table> </div>    </div> 266000 20562000 79336000 38000 79374000 99897000 38000 99936000 99936000 1563000 688000 853000 691000 5000 23000 <div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';"> NOTE 4. PROPERTY AND EQUIPMENT   Property and equipment are comprised of the following as of (in thousands): <div>   <div align="center"> <table style="border-collapse: collapse; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; margin-left: 0.1px; margin-right: 0.1px;" cellpadding="0" cellspacing="0" width="90%"> <tr style="vertical-align: bottom;"> <td style="font-size: 10pt; text-align: center; font-family: 'times new roman'; padding: 0px;"></td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px;"></td> <td style="font-size: 10pt; text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;" colspan="2">September 30, 2015</td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px;"> </td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px;"> </td> <td style="font-size: 10pt; text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;" colspan="2">December 31, 2014 </td> <td style="font-size: 10pt; text-align: center; font-family: 'times new roman'; padding: 0px; width: 20px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px; width: 66%;">Laboratory equipment</td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px; width: 2%;"></td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px 10px 0px 0px; vertical-align: bottom; white-space: nowrap; width: 1%;">$</td> <td style="font-size: 10pt; text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; width: 13%;">1,563</td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 1%;"> </td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 2%;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px 10px 0px 0px; vertical-align: bottom; white-space: nowrap; width: 1%;">$</td> <td style="font-size: 10pt; text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; width: 13%;">688</td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px;">Leasehold improvements</td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px;"></td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;">853</td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;">762</td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px;">Computer, software, and office equipment</td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px;"></td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;">211</td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"> </td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;">185</td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"> </td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px;"> </td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;">2,627</td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;">1,635</td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px;">Accumulated depreciation</td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;">(794</td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px 10px 0px 0px; vertical-align: bottom; white-space: nowrap;">)</td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;">(103</td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px 10px 0px 0px; vertical-align: bottom; white-space: nowrap;">)</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px;"> </td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;">$</td> <td style="font-size: 10pt; text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;">1,833</td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"> </td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;">$</td> <td style="font-size: 10pt; text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;">1,532</td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"> </td> </tr> </table> </div>   </div> Depreciation expense for the three and nine months ended September 30, 2015 and 2014 was $266, $691, $5, and $23, respectively. </div> <div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';">   <div align="center"> <table style="border-collapse: collapse; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; margin-left: 0.1px; margin-right: 0.1px;" cellpadding="0" cellspacing="0" width="90%"> <tr style="vertical-align: bottom;"> <td style="font-size: 10pt; text-align: center; font-family: 'times new roman'; padding: 0px;"></td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px;"></td> <td style="font-size: 10pt; text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;" colspan="2">September 30, 2015</td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px;"> </td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px;"> </td> <td style="font-size: 10pt; text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;" colspan="2">December 31, 2014 </td> <td style="font-size: 10pt; text-align: center; font-family: 'times new roman'; padding: 0px; width: 20px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px; width: 66%;">Laboratory equipment</td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px; width: 2%;"></td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px 10px 0px 0px; vertical-align: bottom; white-space: nowrap; width: 1%;">$</td> <td style="font-size: 10pt; text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; width: 13%;">1,563</td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 1%;"> </td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 2%;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px 10px 0px 0px; vertical-align: bottom; white-space: nowrap; width: 1%;">$</td> <td style="font-size: 10pt; text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; width: 13%;">688</td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px;">Leasehold improvements</td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px;"></td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;">853</td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;">762</td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px;">Computer, software, and office equipment</td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px;"></td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;">211</td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"> </td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;">185</td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"> </td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px;"> </td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;">2,627</td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;">1,635</td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px;">Accumulated depreciation</td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;">(794</td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px 10px 0px 0px; vertical-align: bottom; white-space: nowrap;">)</td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;">(103</td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px 10px 0px 0px; vertical-align: bottom; white-space: nowrap;">)</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px;"> </td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;">$</td> <td style="font-size: 10pt; text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;">1,833</td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"> </td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;">$</td> <td style="font-size: 10pt; text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;">1,532</td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"> </td> </tr> </table> </div>   </div> 5300000 1300000 1500000 2500000 757500 6.84 233499 4.37 30000 <div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';"> NOTE 5. STOCKHOLDERS' EQUITY   Public offering    On March 3, 2015, the Company completed an underwritten public offering of 9,200,000 shares of its common stock at a price of $8.00 per share of common stock. The net proceeds to the Company from the offering were $68.3 million, after deducting underwriting discounts and commissions and offering expenses. The offering was made pursuant to the Company's existing shelf registration statement on Form S-3, including a base prospectus, which was filed with the SEC on November 20, 2014 and declared effective on December 10, 2014, a preliminary prospectus supplement thereunder, and a registration statement on Form S-3 filed with the SEC on February 26, 2015.   Issuance of common stock upon conversion of preferred stock   During the nine months ended September 30, 2015, the Company issued 1,000,000 shares of common stock upon the conversion of 2,000 shares of Series A Convertible Preferred Stock. The number of conversion shares issued was determined on a formula basis of 500 common shares for each Series A Convertible Preferred Stock held consistent with the contract.   Common stock with vesting terms   During 2014, the Company granted 797,500 shares of its restricted common stock to nine of its employees in accordance with the terms of their employment agreements. The 797,500 shares vest over a period of three years. As these shares were granted to employees, the Company calculated the aggregate fair value of the 797,500 shares based on the trading prices of the Company's stock at their grant dates and determined it to be $5.3 million, of which $1.3 million was expensed in 2014. The allocable portion of the fair value of the stock that vested during the nine months ended September 30, 2015 amounted to $1.5 million and was recognized as expense in the accompanying statements of operations. As of September 30, 2015, the amount of unvested compensation related to the unvested outstanding shares of restricted common stock was $2.5 million, which will be recorded as expense in future periods as the shares vest.    When calculating basic net income (loss) per share, these shares are included in basic weighted average common shares outstanding from the time they vest. When calculating diluted net income (loss) per share, these shares are included in diluted weighted average common shares outstanding from the time they are granted, unless they are antidilutive. Shares of restricted stock granted above are subject to forfeiture to the Company or other restrictions that will lapse in accordance with a vesting schedule determined by our Board.   The following table summarizes restricted common stock activity: <div> <div style="display: block;">   <div> <table style="border-collapse: collapse; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; margin-left: 0.1px;" cellpadding="0" cellspacing="0" align="center" width="100%"> <tr style="vertical-align: bottom;"> <td style="font-size: 10pt; text-align: center; font-family: 'times new roman'; padding: 0px;"></td> <td style="font: 10pt times new roman, times, serif; font-family: 'times new roman'; padding: 0px;"></td> <td style="font: 10pt times new roman, times, serif; text-align: center; border-bottom: #000000 1pt solid !important; padding: 0px;" colspan="2"> Number of Shares </td> <td style="font: 10pt times new roman, times, serif; font-family: 'times new roman'; padding: 0px;"> </td> <td style="font: 10pt times new roman, times, serif; font-family: 'times new roman'; padding: 0px;"> </td> <td style="font: 10pt times new roman, times, serif; text-align: center; border-bottom: #000000 1pt solid !important; padding: 0px;" colspan="2"> Weighted Average Grant Date Fair Value  </td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: center; padding: 0px; width: 20px;" colspan="4">        </td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px; width: 70%;">Non-vested shares, January 1, 2015</td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px; width: 1%;"></td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px; width: 1%;"> </td> <td style="font-size: 10pt; text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; width: 12%;">757,500</td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 1%;"> </td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 1%;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px 10px 0px 0px; vertical-align: bottom; white-space: nowrap; width: 1%;">$</td> <td style="font-size: 10pt; text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; width: 12%;">6.84</td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="font-size: 10pt; text-indent: 0.25in; font-family: 'times new roman'; padding: 0px;">Granted</td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px;"></td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px;"> </td> <td style="font-size: 10pt; text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="font-size: 10pt; text-indent: 0.25in; font-family: 'times new roman'; padding: 0px;">Vested</td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px;"></td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px;"> </td> <td style="font-size: 10pt; text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;">(233,499</td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;">)</td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;">4.37</td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="font-size: 10pt; text-indent: 0.25in; font-family: 'times new roman'; padding: 0px;">Forfeited</td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;"> </td> <td style="font-size: 10pt; text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;">(30,000</td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px 10px 0px 0px; vertical-align: bottom; white-space: nowrap;">)</td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;">8.24</td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"> </td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px;">Non-vested shares, September 30, 2015</td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px;"> </td> <td style="font-size: 10pt; text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;">494,001</td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"> </td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;">$</td> <td style="font-size: 10pt; text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;">6.56</td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"> </td> </tr> </table> </div>   </div> </div> </div> <div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';"> <div style="display: block;">   <div> <table style="border-collapse: collapse; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; margin-left: 0.1px;" cellpadding="0" cellspacing="0" align="center" width="100%"> <tr style="vertical-align: bottom;"> <td style="font-size: 10pt; text-align: center; font-family: 'times new roman'; padding: 0px;"></td> <td style="font: 10pt times new roman, times, serif; font-family: 'times new roman'; padding: 0px;"></td> <td style="font: 10pt times new roman, times, serif; text-align: center; border-bottom: #000000 1pt solid !important; padding: 0px;" colspan="2"> Number of Shares </td> <td style="font: 10pt times new roman, times, serif; font-family: 'times new roman'; padding: 0px;"> </td> <td style="font: 10pt times new roman, times, serif; font-family: 'times new roman'; padding: 0px;"> </td> <td style="font: 10pt times new roman, times, serif; text-align: center; border-bottom: #000000 1pt solid !important; padding: 0px;" colspan="2"> Weighted Average Grant Date Fair Value  </td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: center; padding: 0px; width: 20px;" colspan="4">        </td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px; width: 70%;">Non-vested shares, January 1, 2015</td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px; width: 1%;"></td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px; width: 1%;"> </td> <td style="font-size: 10pt; text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; width: 12%;">757,500</td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 1%;"> </td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 1%;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px 10px 0px 0px; vertical-align: bottom; white-space: nowrap; width: 1%;">$</td> <td style="font-size: 10pt; text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; width: 12%;">6.84</td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="font-size: 10pt; text-indent: 0.25in; font-family: 'times new roman'; padding: 0px;">Granted</td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px;"></td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px;"> </td> <td style="font-size: 10pt; text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="font-size: 10pt; text-indent: 0.25in; font-family: 'times new roman'; padding: 0px;">Vested</td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px;"></td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px;"> </td> <td style="font-size: 10pt; text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;">(233,499</td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;">)</td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;">4.37</td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="font-size: 10pt; text-indent: 0.25in; font-family: 'times new roman'; padding: 0px;">Forfeited</td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;"> </td> <td style="font-size: 10pt; text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;">(30,000</td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px 10px 0px 0px; vertical-align: bottom; white-space: nowrap;">)</td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;">8.24</td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"> </td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px;">Non-vested shares, September 30, 2015</td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px;"> </td> <td style="font-size: 10pt; text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;">494,001</td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"> </td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;">$</td> <td style="font-size: 10pt; text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;">6.56</td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"> </td> </tr> </table> </div>   </div> </div> 1000000 2000 500 797500 P3Y 8.24 494001 6.56 false --12-31 2015-09-30 Accelerated Filer Lion Biotechnologies, Inc. 0001425205 47833934 2015 Q3 10-Q <div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';">     <div> <table style="border-collapse: collapse; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; margin-left: 0.1px;" cellpadding="0" cellspacing="0" width="100%"> <tr style="vertical-align: bottom;"> <td style="font-size: 10pt; font-weight: bold; text-align: center; font-family: 'times new roman'; padding: 0px;"></td> <td style="font-family: 'Times New Roman';"></td> <td style="text-align: center; font-family: 'times new roman'; padding: 0px;" colspan="2"></td> <td style="font-family: 'Times New Roman';"></td> <td style="font-family: 'Times New Roman';"></td> <td style="text-align: center; font-family: 'times new roman'; padding: 0px;" colspan="2"></td> <td style="font-family: 'Times New Roman';"> </td> <td style="font-family: 'Times New Roman';"> </td> <td style="font-family: 'times new roman'; padding: 0px; text-align: center;" colspan="2">  Weighted </td> <td style="font-family: 'times new roman'; padding: 0px; text-align: left;"> </td> <td style="font-family: 'times new roman'; padding: 0px; text-align: left;"> </td> <td style="font-family: 'times new roman'; padding: 0px; text-align: left;" colspan="2">  </td> <td style="font-family: 'times new roman'; padding: 0px; text-align: left;" colspan="12"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-size: 10pt; font-weight: bold; text-align: center; font-family: 'times new roman'; padding: 0px;"></td> <td style="font-size: 10pt; font-weight: bold; font-family: 'times new roman'; padding: 0px;"></td> <td style="font-size: 10pt; font-weight: bold; text-align: center; font-family: 'times new roman'; padding: 0px;" colspan="2"></td> <td style="font-size: 10pt; font-weight: bold; font-family: 'times new roman'; padding: 0px;"></td> <td style="font-family: 'Times New Roman';"></td> <td style="text-align: center; font-family: 'times new roman'; padding: 0px;" colspan="2">Weighted</td> <td style="font-family: 'Times New Roman';"> </td> <td style="font-family: 'Times New Roman';"> </td> <td style="font-size: 10pt; font-weight: bold; text-align: center; font-family: 'times new roman'; padding: 0px;" colspan="2">Average</td> <td style="font-family: 'Times New Roman';"> </td> <td style="font-family: 'Times New Roman';"> </td> <td style="font-size: 10pt; font-weight: bold; text-align: center; font-family: 'times new roman'; padding: 0px;" colspan="2">Aggregate</td> <td style="font-family: 'Times New Roman';"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-size: 10pt; font-weight: bold; text-align: center; font-family: 'times new roman'; padding: 0px;"></td> <td style="font-size: 10pt; font-weight: bold; font-family: 'times new roman'; padding: 0px;"></td> <td style="font-size: 10pt; font-weight: bold; text-align: center; font-family: 'times new roman'; padding: 0px;" colspan="2">Shares</td> <td style="font-size: 10pt; font-weight: bold; font-family: 'times new roman'; padding: 0px;"></td> <td style="font-size: 10pt; font-weight: bold; font-family: 'times new roman'; padding: 0px;"></td> <td style="font-size: 10pt; font-weight: bold; text-align: center; font-family: 'times new roman'; padding: 0px;" colspan="2">Average</td> <td style="font-size: 10pt; font-weight: bold; font-family: 'times new roman'; padding: 0px;"> </td> <td style="font-size: 10pt; font-weight: bold; font-family: 'times new roman'; padding: 0px;"> </td> <td style="font-size: 10pt; font-weight: bold; text-align: center; font-family: 'times new roman'; padding: 0px;" colspan="2">Remaining</td> <td style="font-size: 10pt; font-weight: bold; font-family: 'times new roman'; padding: 0px;"> </td> <td style="font-size: 10pt; font-weight: bold; font-family: 'times new roman'; padding: 0px;"> </td> <td style="font-size: 10pt; font-weight: bold; text-align: center; font-family: 'times new roman'; padding: 0px;" colspan="2">Intrinsic</td> <td style="font-family: 'Times New Roman';"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-size: 10pt; font-weight: bold; text-align: center; font-family: 'times new roman'; padding: 0px;"></td> <td style="font-size: 10pt; font-weight: bold; font-family: 'times new roman'; padding: 0px;"></td> <td style="font-size: 10pt; font-weight: bold; text-align: center; font-family: 'times new roman'; padding: 0px;" colspan="2">Under</td> <td style="font-size: 10pt; font-weight: bold; font-family: 'times new roman'; padding: 0px;"></td> <td style="font-size: 10pt; font-weight: bold; font-family: 'times new roman'; padding: 0px;"></td> <td style="font-size: 10pt; font-weight: bold; text-align: center; font-family: 'times new roman'; padding: 0px;" colspan="2">Exercise</td> <td style="font-size: 10pt; font-weight: bold; font-family: 'times new roman'; padding: 0px;"> </td> <td style="font-size: 10pt; font-weight: bold; font-family: 'times new roman'; padding: 0px;"> </td> <td style="font-size: 10pt; font-weight: bold; text-align: center; font-family: 'times new roman'; padding: 0px;" colspan="2">Contractual</td> <td style="font-size: 10pt; font-weight: bold; font-family: 'times new roman'; padding: 0px;"> </td> <td style="font-size: 10pt; font-weight: bold; font-family: 'times new roman'; padding: 0px;"> </td> <td style="font-size: 10pt; font-weight: bold; text-align: center; font-family: 'times new roman'; padding: 0px;" colspan="2">Value </td> <td style="font-family: 'Times New Roman';"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-size: 10pt; font-weight: bold; text-align: center; font-family: 'times new roman'; padding: 0px;"> </td> <td style="font-size: 10pt; font-weight: bold; font-family: 'times new roman'; padding: 0px;"> </td> <td style="font-size: 10pt; font-weight: bold; text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;" colspan="2">Warrants</td> <td style="font-size: 10pt; font-weight: bold; font-family: 'times new roman'; padding: 0px;"> </td> <td style="font-size: 10pt; font-weight: bold; font-family: 'times new roman'; padding: 0px;"> </td> <td style="font-size: 10pt; font-weight: bold; text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;" colspan="2">Price</td> <td style="font-size: 10pt; font-weight: bold; font-family: 'times new roman'; padding: 0px;"> </td> <td style="font-size: 10pt; font-weight: bold; font-family: 'times new roman'; padding: 0px;"> </td> <td style="font-size: 10pt; font-weight: bold; text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;" colspan="2">Life</td> <td style="font-size: 10pt; font-weight: bold; font-family: 'times new roman'; padding: 0px;"> </td> <td style="font: 10pt times new roman, times, serif; font-family: 'times new roman'; padding: 0px;"> </td> <td style="font: 10pt times new roman, times, serif; text-align: center; border-bottom: #000000 1pt solid !important; padding: 0px;" colspan="2"> (in thousands) </td> <td style="font-family: 'times new roman'; padding: 0px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px; width: 40%;">Outstanding at December 31, 2014</td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px; width: 1%;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px; width: 1%;"> </td> <td style="font-size: 10pt; text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; width: 12%;">11,084,426</td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 1%;"> </td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 1%;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px 10px 0px 0px; vertical-align: bottom; white-space: nowrap; width: 1%;">$</td> <td style="font-size: 10pt; text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; width: 12%;">2.51</td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 1%;"> </td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 1%;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 1%;"> </td> <td style="font-size: 10pt; text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; width: 12%;">3.85 years</td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 1%;"> </td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 1%;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px 10px 0px 0px; vertical-align: bottom; white-space: nowrap; width: 1%;">$</td> <td style="font-size: 10pt; text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; width: 12%;">59,518</td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px;">Issued</td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px;"> </td> <td style="font-size: 10pt; text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;">-</td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"> </td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"> </td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"> </td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px;">Exercised</td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px;"> </td> <td style="font-size: 10pt; text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;">(3,847,210</td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;">)</td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;">$</td> <td style="font-size: 10pt; text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;">2.50</td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"> </td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"> </td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px;">Expired</td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;"> </td> <td style="font-size: 10pt; text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;">-</td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"> </td> <td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px;">Outstanding and exercisable at September 30, 2015</td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px;"> </td> <td style="font-size: 10pt; text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;">7,237,216</td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"> </td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;">$</td> <td style="font-size: 10pt; text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;">2.51</td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"> </td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;">3.3 years</td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"> </td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;">$</td> <td style="font-size: 10pt; text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;">23,593</td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px; /* border-bottom: #000000 2.80pt double !important; */ white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> </tr> </table> </div>   </div> 1857877 7.31 943750 9.18 <div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';"> NOTE 6. STOCK OPTIONS AND WARRANTS   Stock Options   A summary of the status of stock options at September 30, 2015, and the changes during the nine months then ended, is presented in the following table: <div>   <div> <table style="border-collapse: collapse; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; margin-left: 0.1px;" cellpadding="0" cellspacing="0" width="100%"> <tr style="vertical-align: bottom;"> <td style="font-size: 10pt; font-weight: bold; text-align: center; font-family: 'times new roman'; padding: 0px;"></td> <td style="font-family: 'Times New Roman';"></td> <td style="text-align: center; font-family: 'times new roman'; padding: 0px;" colspan="2"></td> <td style="font-family: 'Times New Roman';"></td> <td style="font-family: 'Times New Roman';"></td> <td style="text-align: center; font-family: 'times new roman'; padding: 0px;" colspan="2"></td> <td style="font-family: 'Times New Roman';"> </td> <td style="font-family: 'Times New Roman';"> </td> <td style="font-family: 'times new roman'; padding: 0px; text-align: center;" colspan="2">  Weighted </td> <td style="font-family: 'times new roman'; padding: 0px; text-align: left;"> </td> <td style="font-family: 'times new roman'; padding: 0px; text-align: left;"> </td> <td style="font-family: 'times new roman'; padding: 0px; text-align: left;" colspan="14">              </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-size: 10pt; font-weight: bold; text-align: center; font-family: 'times new roman'; padding: 0px;"></td> <td style="font-size: 10pt; font-weight: bold; font-family: 'times new roman'; padding: 0px;"></td> <td style="font-size: 10pt; font-weight: bold; text-align: center; font-family: 'times new roman'; padding: 0px;" colspan="2"></td> <td style="font-size: 10pt; font-weight: bold; font-family: 'times new roman'; padding: 0px;"></td> <td style="font-family: 'Times New Roman';"></td> <td style="text-align: center; font-family: 'times new roman'; padding: 0px;" colspan="2">Weighted</td> <td style="font-family: 'Times New Roman';"> </td> <td style="font-family: 'Times New Roman';"> </td> <td style="font-size: 10pt; font-weight: bold; text-align: center; font-family: 'times new roman'; padding: 0px;" colspan="2">Average</td> <td style="font-family: 'Times New Roman';"> </td> <td style="font-family: 'Times New Roman';"> </td> <td style="font-size: 10pt; font-weight: bold; text-align: center; font-family: 'times new roman'; padding: 0px;" colspan="2">Aggregate</td> <td style="font-family: 'Times New Roman';"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-size: 10pt; font-weight: bold; text-align: center; font-family: 'times new roman'; padding: 0px;"></td> <td style="font-size: 10pt; font-weight: bold; font-family: 'times new roman'; padding: 0px;"></td> <td style="font-size: 10pt; font-weight: bold; text-align: center; font-family: 'times new roman'; padding: 0px;" colspan="2">Shares</td> <td style="font-size: 10pt; font-weight: bold; font-family: 'times new roman'; padding: 0px;"></td> <td style="font-size: 10pt; font-weight: bold; font-family: 'times new roman'; padding: 0px;"></td> <td style="font-size: 10pt; font-weight: bold; text-align: center; font-family: 'times new roman'; padding: 0px;" colspan="2">Average</td> <td style="font-size: 10pt; font-weight: bold; font-family: 'times new roman'; padding: 0px;"> </td> <td style="font-size: 10pt; font-weight: bold; font-family: 'times new roman'; padding: 0px;"> </td> <td style="font-size: 10pt; font-weight: bold; text-align: center; font-family: 'times new roman'; padding: 0px;" colspan="2">Remaining</td> <td style="font-size: 10pt; font-weight: bold; font-family: 'times new roman'; padding: 0px;"> </td> <td style="font-size: 10pt; font-weight: bold; font-family: 'times new roman'; padding: 0px;"> </td> <td style="font-size: 10pt; font-weight: bold; text-align: center; font-family: 'times new roman'; padding: 0px;" colspan="2">Intrinsic</td> <td style="font-family: 'Times New Roman';"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-size: 10pt; font-weight: bold; text-align: center; font-family: 'times new roman'; padding: 0px;"></td> <td style="font-size: 10pt; font-weight: bold; font-family: 'times new roman'; padding: 0px;"></td> <td style="font-size: 10pt; font-weight: bold; text-align: center; font-family: 'times new roman'; padding: 0px;" colspan="2">Under</td> <td style="font-size: 10pt; font-weight: bold; font-family: 'times new roman'; padding: 0px;"></td> <td style="font-size: 10pt; font-weight: bold; font-family: 'times new roman'; padding: 0px;"></td> <td style="font-size: 10pt; font-weight: bold; text-align: center; font-family: 'times new roman'; padding: 0px;" colspan="2">Exercise</td> <td style="font-size: 10pt; font-weight: bold; font-family: 'times new roman'; padding: 0px;"> </td> <td style="font-size: 10pt; font-weight: bold; font-family: 'times new roman'; padding: 0px;"> </td> <td style="font-size: 10pt; font-weight: bold; text-align: center; font-family: 'times new roman'; padding: 0px;" colspan="2">Contractual</td> <td style="font-size: 10pt; font-weight: bold; font-family: 'times new roman'; padding: 0px;"> </td> <td style="font-size: 10pt; font-weight: bold; font-family: 'times new roman'; padding: 0px;"> </td> <td style="font-size: 10pt; font-weight: bold; text-align: center; font-family: 'times new roman'; padding: 0px;" colspan="2">Value </td> <td style="font-family: 'Times New Roman';"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-size: 10pt; font-weight: bold; text-align: center; font-family: 'times new roman'; padding: 0px;"> </td> <td style="font-size: 10pt; font-weight: bold; font-family: 'times new roman'; padding: 0px;"> </td> <td style="font-size: 10pt; font-weight: bold; text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;" colspan="2">Option</td> <td style="font-size: 10pt; font-weight: bold; font-family: 'times new roman'; padding: 0px;"> </td> <td style="font-size: 10pt; font-weight: bold; font-family: 'times new roman'; padding: 0px;"> </td> <td style="font-size: 10pt; font-weight: bold; text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;" colspan="2">Price</td> <td style="font-size: 10pt; font-weight: bold; font-family: 'times new roman'; padding: 0px;"> </td> <td style="font-size: 10pt; font-weight: bold; font-family: 'times new roman'; padding: 0px;"> </td> <td style="font-size: 10pt; font-weight: bold; text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;" colspan="2">Life</td> <td style="font-size: 10pt; font-weight: bold; font-family: 'times new roman'; padding: 0px;"> </td> <td style="font: 10pt times new roman, times, serif; font-family: 'times new roman'; padding: 0px;"> </td> <td style="font: 10pt times new roman, times, serif; text-align: center; border-bottom: #000000 1pt solid !important; padding: 0px;" colspan="2"> (in thousands) </td> <td style="font-family: 'times new roman'; padding: 0px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px; width: 40%;">Outstanding at January 1, 2015</td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px; width: 1%;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px; width: 1%;"> </td> <td style="font-size: 10pt; text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; width: 12%;">1,857,877</td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 1%;"> </td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 1%;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px 10px 0px 0px; vertical-align: bottom; white-space: nowrap; width: 1%;">$</td> <td style="font-size: 10pt; text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; width: 12%;">7.31</td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 1%;"> </td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 1%;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 1%;"> </td> <td style="font-size: 10pt; text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; width: 12%;">8.2</td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 1%;"> </td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 1%;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px 10px 0px 0px; vertical-align: bottom; white-space: nowrap; width: 1%;">$</td> <td style="font-size: 10pt; text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; width: 12%;">2,875</td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px;">Granted</td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px;"> </td> <td style="font-size: 10pt; text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;">943,750</td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;">9.18</td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;">9.8</td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"> </td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px;">Exercised</td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px;"> </td> <td style="font-size: 10pt; text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;">(10,000</td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;">)</td> <td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"> </td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"> </td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"> </td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px;">Expired/Forfeited</td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;"> </td> <td style="font-size: 10pt; text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;">(87,432</td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px 10px 0px 0px; vertical-align: bottom; white-space: nowrap;">)</td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;">5.92</td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"> </td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;">7.29</td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"> </td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;">-</td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"> </td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px;">Outstanding at September 30, 2015</td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px;"> </td> <td style="font-size: 10pt; text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;">2,704,195</td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"> </td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;">$</td> <td style="font-size: 10pt; text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;">8.05</td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"> </td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;">8.16</td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"> </td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;">$</td> <td style="font-size: 10pt; text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;">64</td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"> </td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px;">Exercisable at September 30, 2015</td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px;"> </td> <td style="font-size: 10pt; text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;">883,449</td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"> </td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;">$</td> <td style="font-size: 10pt; text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;">8.63</td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"> </td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;">6.67</td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"> </td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;">$</td> <td style="font-size: 10pt; text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;">98</td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"> </td> </tr> </table> </div>   </div> During the nine months ended September 30, 2015, the Company granted options to purchase 943,750 shares of common stock to new employees and directors of the Company. The stock options generally vest between one and three years. The fair value of these options was determined to be $8.3 million using the Black-Scholes option pricing model based on the following assumptions: (i) volatility rate of 211%, (ii) discount rate of 1.57%, (iii) zero expected dividend yield, and (iv) expected life of 6 years.   During the nine months ended September 30, 2015 and 2014, the Company recorded compensation costs of $4.1 million and $1.9 million, respectively, relating to the vesting of stock options. As of September 30, 2015, the aggregate value of unvested options was $10.3 million, which will continue to be amortized as compensation cost as the options vest over terms ranging from nine months to three years, as applicable.   On September 19, 2014, The Company's Board of Directors adopted the Lion Biotechnologies, Inc. 2014 Equity Incentive Plan (the 2014 Plan). The 2014 Plan was approved by our stockholders at the annual meeting of stockholders held in November 2014. The 2014 Plan as approved by the stockholders authorized the issuance up to an aggregate of 2,350,000 shares of common stock. On April 10, 2015 the Board amended the 2014 Plan, subject to stockholder approval, to increase the total number of shares that can be issued under the 2014 Plan by 1,650,000 from 2,350,000 shares to 4,000,000 shares. The increase in shares available for issuance under the 2014 Plan was approved by stockholders on June 12, 2015.   Warrants   A summary of the status of stock warrants at September 30, 2015, and the changes during the nine months then ended, is presented in the following table: <div>     <div> <table style="border-collapse: collapse; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; margin-left: 0.1px;" cellpadding="0" cellspacing="0" width="100%"> <tr style="vertical-align: bottom;"> <td style="font-size: 10pt; font-weight: bold; text-align: center; font-family: 'times new roman'; padding: 0px;"></td> <td style="font-family: 'Times New Roman';"></td> <td style="text-align: center; font-family: 'times new roman'; padding: 0px;" colspan="2"></td> <td style="font-family: 'Times New Roman';"></td> <td style="font-family: 'Times New Roman';"></td> <td style="text-align: center; font-family: 'times new roman'; padding: 0px;" colspan="2"></td> <td style="font-family: 'Times New Roman';"> </td> <td style="font-family: 'Times New Roman';"> </td> <td style="font-family: 'times new roman'; padding: 0px; text-align: center;" colspan="2">  Weighted </td> <td style="font-family: 'times new roman'; padding: 0px; text-align: left;"> </td> <td style="font-family: 'times new roman'; padding: 0px; text-align: left;"> </td> <td style="font-family: 'times new roman'; padding: 0px; text-align: left;" colspan="2">  </td> <td style="font-family: 'times new roman'; padding: 0px; text-align: left;" colspan="12"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-size: 10pt; font-weight: bold; text-align: center; font-family: 'times new roman'; padding: 0px;"></td> <td style="font-size: 10pt; font-weight: bold; font-family: 'times new roman'; padding: 0px;"></td> <td style="font-size: 10pt; font-weight: bold; text-align: center; font-family: 'times new roman'; padding: 0px;" colspan="2"></td> <td style="font-size: 10pt; font-weight: bold; font-family: 'times new roman'; padding: 0px;"></td> <td style="font-family: 'Times New Roman';"></td> <td style="text-align: center; font-family: 'times new roman'; padding: 0px;" colspan="2">Weighted</td> <td style="font-family: 'Times New Roman';"> </td> <td style="font-family: 'Times New Roman';"> </td> <td style="font-size: 10pt; font-weight: bold; text-align: center; font-family: 'times new roman'; padding: 0px;" colspan="2">Average</td> <td style="font-family: 'Times New Roman';"> </td> <td style="font-family: 'Times New Roman';"> </td> <td style="font-size: 10pt; font-weight: bold; text-align: center; font-family: 'times new roman'; padding: 0px;" colspan="2">Aggregate</td> <td style="font-family: 'Times New Roman';"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-size: 10pt; font-weight: bold; text-align: center; font-family: 'times new roman'; padding: 0px;"></td> <td style="font-size: 10pt; font-weight: bold; font-family: 'times new roman'; padding: 0px;"></td> <td style="font-size: 10pt; font-weight: bold; text-align: center; font-family: 'times new roman'; padding: 0px;" colspan="2">Shares</td> <td style="font-size: 10pt; font-weight: bold; font-family: 'times new roman'; padding: 0px;"></td> <td style="font-size: 10pt; font-weight: bold; font-family: 'times new roman'; padding: 0px;"></td> <td style="font-size: 10pt; font-weight: bold; text-align: center; font-family: 'times new roman'; padding: 0px;" colspan="2">Average</td> <td style="font-size: 10pt; font-weight: bold; font-family: 'times new roman'; padding: 0px;"> </td> <td style="font-size: 10pt; font-weight: bold; font-family: 'times new roman'; padding: 0px;"> </td> <td style="font-size: 10pt; font-weight: bold; text-align: center; font-family: 'times new roman'; padding: 0px;" colspan="2">Remaining</td> <td style="font-size: 10pt; font-weight: bold; font-family: 'times new roman'; padding: 0px;"> </td> <td style="font-size: 10pt; font-weight: bold; font-family: 'times new roman'; padding: 0px;"> </td> <td style="font-size: 10pt; font-weight: bold; text-align: center; font-family: 'times new roman'; padding: 0px;" colspan="2">Intrinsic</td> <td style="font-family: 'Times New Roman';"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-size: 10pt; font-weight: bold; text-align: center; font-family: 'times new roman'; padding: 0px;"></td> <td style="font-size: 10pt; font-weight: bold; font-family: 'times new roman'; padding: 0px;"></td> <td style="font-size: 10pt; font-weight: bold; text-align: center; font-family: 'times new roman'; padding: 0px;" colspan="2">Under</td> <td style="font-size: 10pt; font-weight: bold; font-family: 'times new roman'; padding: 0px;"></td> <td style="font-size: 10pt; font-weight: bold; font-family: 'times new roman'; padding: 0px;"></td> <td style="font-size: 10pt; font-weight: bold; text-align: center; font-family: 'times new roman'; padding: 0px;" colspan="2">Exercise</td> <td style="font-size: 10pt; font-weight: bold; font-family: 'times new roman'; padding: 0px;"> </td> <td style="font-size: 10pt; font-weight: bold; font-family: 'times new roman'; padding: 0px;"> </td> <td style="font-size: 10pt; font-weight: bold; text-align: center; font-family: 'times new roman'; padding: 0px;" colspan="2">Contractual</td> <td style="font-size: 10pt; font-weight: bold; font-family: 'times new roman'; padding: 0px;"> </td> <td style="font-size: 10pt; font-weight: bold; font-family: 'times new roman'; padding: 0px;"> </td> <td style="font-size: 10pt; font-weight: bold; text-align: center; font-family: 'times new roman'; padding: 0px;" colspan="2">Value </td> <td style="font-family: 'Times New Roman';"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-size: 10pt; font-weight: bold; text-align: center; font-family: 'times new roman'; padding: 0px;"> </td> <td style="font-size: 10pt; font-weight: bold; font-family: 'times new roman'; padding: 0px;"> </td> <td style="font-size: 10pt; font-weight: bold; text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;" colspan="2">Warrants</td> <td style="font-size: 10pt; font-weight: bold; font-family: 'times new roman'; padding: 0px;"> </td> <td style="font-size: 10pt; font-weight: bold; font-family: 'times new roman'; padding: 0px;"> </td> <td style="font-size: 10pt; font-weight: bold; text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;" colspan="2">Price</td> <td style="font-size: 10pt; font-weight: bold; font-family: 'times new roman'; padding: 0px;"> </td> <td style="font-size: 10pt; font-weight: bold; font-family: 'times new roman'; padding: 0px;"> </td> <td style="font-size: 10pt; font-weight: bold; text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;" colspan="2">Life</td> <td style="font-size: 10pt; font-weight: bold; font-family: 'times new roman'; padding: 0px;"> </td> <td style="font: 10pt times new roman, times, serif; font-family: 'times new roman'; padding: 0px;"> </td> <td style="font: 10pt times new roman, times, serif; text-align: center; border-bottom: #000000 1pt solid !important; padding: 0px;" colspan="2"> (in thousands) </td> <td style="font-family: 'times new roman'; padding: 0px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px; width: 40%;">Outstanding at December 31, 2014</td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px; width: 1%;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px; width: 1%;"> </td> <td style="font-size: 10pt; text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; width: 12%;">11,084,426</td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 1%;"> </td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 1%;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px 10px 0px 0px; vertical-align: bottom; white-space: nowrap; width: 1%;">$</td> <td style="font-size: 10pt; text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; width: 12%;">2.51</td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 1%;"> </td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 1%;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 1%;"> </td> <td style="font-size: 10pt; text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; width: 12%;">3.85 years</td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 1%;"> </td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 1%;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px 10px 0px 0px; vertical-align: bottom; white-space: nowrap; width: 1%;">$</td> <td style="font-size: 10pt; text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; width: 12%;">59,518</td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px;">Issued</td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px;"> </td> <td style="font-size: 10pt; text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;">-</td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"> </td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"> </td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"> </td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px;">Exercised</td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px;"> </td> <td style="font-size: 10pt; text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;">(3,847,210</td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;">)</td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;">$</td> <td style="font-size: 10pt; text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;">2.50</td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"> </td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"> </td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px;">Expired</td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;"> </td> <td style="font-size: 10pt; text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;">-</td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"> </td> <td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px;">Outstanding and exercisable at September 30, 2015</td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px;"> </td> <td style="font-size: 10pt; text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;">7,237,216</td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"> </td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;">$</td> <td style="font-size: 10pt; text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;">2.51</td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"> </td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;">3.3 years</td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"> </td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;">$</td> <td style="font-size: 10pt; text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;">23,593</td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px; /* border-bottom: #000000 2.80pt double !important; */ white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> </tr> </table> </div>   </div> During the nine months ended September 30, 2015, the Company received $9.6 million in cash from the exercise of 3,847,210 warrants for the purchase of an equal number of shares of its common stock. </div> <div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';">   <div> <table style="border-collapse: collapse; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; margin-left: 0.1px;" cellpadding="0" cellspacing="0" width="100%"> <tr style="vertical-align: bottom;"> <td style="font-size: 10pt; font-weight: bold; text-align: center; font-family: 'times new roman'; padding: 0px;"></td> <td style="font-family: 'Times New Roman';"></td> <td style="text-align: center; font-family: 'times new roman'; padding: 0px;" colspan="2"></td> <td style="font-family: 'Times New Roman';"></td> <td style="font-family: 'Times New Roman';"></td> <td style="text-align: center; font-family: 'times new roman'; padding: 0px;" colspan="2"></td> <td style="font-family: 'Times New Roman';"> </td> <td style="font-family: 'Times New Roman';"> </td> <td style="font-family: 'times new roman'; padding: 0px; text-align: center;" colspan="2">  Weighted </td> <td style="font-family: 'times new roman'; padding: 0px; text-align: left;"> </td> <td style="font-family: 'times new roman'; padding: 0px; text-align: left;"> </td> <td style="font-family: 'times new roman'; padding: 0px; text-align: left;" colspan="14">              </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-size: 10pt; font-weight: bold; text-align: center; font-family: 'times new roman'; padding: 0px;"></td> <td style="font-size: 10pt; font-weight: bold; font-family: 'times new roman'; padding: 0px;"></td> <td style="font-size: 10pt; font-weight: bold; text-align: center; font-family: 'times new roman'; padding: 0px;" colspan="2"></td> <td style="font-size: 10pt; font-weight: bold; font-family: 'times new roman'; padding: 0px;"></td> <td style="font-family: 'Times New Roman';"></td> <td style="text-align: center; font-family: 'times new roman'; padding: 0px;" colspan="2">Weighted</td> <td style="font-family: 'Times New Roman';"> </td> <td style="font-family: 'Times New Roman';"> </td> <td style="font-size: 10pt; font-weight: bold; text-align: center; font-family: 'times new roman'; padding: 0px;" colspan="2">Average</td> <td style="font-family: 'Times New Roman';"> </td> <td style="font-family: 'Times New Roman';"> </td> <td style="font-size: 10pt; font-weight: bold; text-align: center; font-family: 'times new roman'; padding: 0px;" colspan="2">Aggregate</td> <td style="font-family: 'Times New Roman';"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-size: 10pt; font-weight: bold; text-align: center; font-family: 'times new roman'; padding: 0px;"></td> <td style="font-size: 10pt; font-weight: bold; font-family: 'times new roman'; padding: 0px;"></td> <td style="font-size: 10pt; font-weight: bold; text-align: center; font-family: 'times new roman'; padding: 0px;" colspan="2">Shares</td> <td style="font-size: 10pt; font-weight: bold; font-family: 'times new roman'; padding: 0px;"></td> <td style="font-size: 10pt; font-weight: bold; font-family: 'times new roman'; padding: 0px;"></td> <td style="font-size: 10pt; font-weight: bold; text-align: center; font-family: 'times new roman'; padding: 0px;" colspan="2">Average</td> <td style="font-size: 10pt; font-weight: bold; font-family: 'times new roman'; padding: 0px;"> </td> <td style="font-size: 10pt; font-weight: bold; font-family: 'times new roman'; padding: 0px;"> </td> <td style="font-size: 10pt; font-weight: bold; text-align: center; font-family: 'times new roman'; padding: 0px;" colspan="2">Remaining</td> <td style="font-size: 10pt; font-weight: bold; font-family: 'times new roman'; padding: 0px;"> </td> <td style="font-size: 10pt; font-weight: bold; font-family: 'times new roman'; padding: 0px;"> </td> <td style="font-size: 10pt; font-weight: bold; text-align: center; font-family: 'times new roman'; padding: 0px;" colspan="2">Intrinsic</td> <td style="font-family: 'Times New Roman';"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-size: 10pt; font-weight: bold; text-align: center; font-family: 'times new roman'; padding: 0px;"></td> <td style="font-size: 10pt; font-weight: bold; font-family: 'times new roman'; padding: 0px;"></td> <td style="font-size: 10pt; font-weight: bold; text-align: center; font-family: 'times new roman'; padding: 0px;" colspan="2">Under</td> <td style="font-size: 10pt; font-weight: bold; font-family: 'times new roman'; padding: 0px;"></td> <td style="font-size: 10pt; font-weight: bold; font-family: 'times new roman'; padding: 0px;"></td> <td style="font-size: 10pt; font-weight: bold; text-align: center; font-family: 'times new roman'; padding: 0px;" colspan="2">Exercise</td> <td style="font-size: 10pt; font-weight: bold; font-family: 'times new roman'; padding: 0px;"> </td> <td style="font-size: 10pt; font-weight: bold; font-family: 'times new roman'; padding: 0px;"> </td> <td style="font-size: 10pt; font-weight: bold; text-align: center; font-family: 'times new roman'; padding: 0px;" colspan="2">Contractual</td> <td style="font-size: 10pt; font-weight: bold; font-family: 'times new roman'; padding: 0px;"> </td> <td style="font-size: 10pt; font-weight: bold; font-family: 'times new roman'; padding: 0px;"> </td> <td style="font-size: 10pt; font-weight: bold; text-align: center; font-family: 'times new roman'; padding: 0px;" colspan="2">Value </td> <td style="font-family: 'Times New Roman';"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-size: 10pt; font-weight: bold; text-align: center; font-family: 'times new roman'; padding: 0px;"> </td> <td style="font-size: 10pt; font-weight: bold; font-family: 'times new roman'; padding: 0px;"> </td> <td style="font-size: 10pt; font-weight: bold; text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;" colspan="2">Option</td> <td style="font-size: 10pt; font-weight: bold; font-family: 'times new roman'; padding: 0px;"> </td> <td style="font-size: 10pt; font-weight: bold; font-family: 'times new roman'; padding: 0px;"> </td> <td style="font-size: 10pt; font-weight: bold; text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;" colspan="2">Price</td> <td style="font-size: 10pt; font-weight: bold; font-family: 'times new roman'; padding: 0px;"> </td> <td style="font-size: 10pt; font-weight: bold; font-family: 'times new roman'; padding: 0px;"> </td> <td style="font-size: 10pt; font-weight: bold; text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;" colspan="2">Life</td> <td style="font-size: 10pt; font-weight: bold; font-family: 'times new roman'; padding: 0px;"> </td> <td style="font: 10pt times new roman, times, serif; font-family: 'times new roman'; padding: 0px;"> </td> <td style="font: 10pt times new roman, times, serif; text-align: center; border-bottom: #000000 1pt solid !important; padding: 0px;" colspan="2"> (in thousands) </td> <td style="font-family: 'times new roman'; padding: 0px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px; width: 40%;">Outstanding at January 1, 2015</td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px; width: 1%;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px; width: 1%;"> </td> <td style="font-size: 10pt; text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; width: 12%;">1,857,877</td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 1%;"> </td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 1%;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px 10px 0px 0px; vertical-align: bottom; white-space: nowrap; width: 1%;">$</td> <td style="font-size: 10pt; text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; width: 12%;">7.31</td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 1%;"> </td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 1%;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 1%;"> </td> <td style="font-size: 10pt; text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; width: 12%;">8.2</td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 1%;"> </td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 1%;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px 10px 0px 0px; vertical-align: bottom; white-space: nowrap; width: 1%;">$</td> <td style="font-size: 10pt; text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; width: 12%;">2,875</td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px;">Granted</td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px;"> </td> <td style="font-size: 10pt; text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;">943,750</td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;">9.18</td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;">9.8</td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"> </td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px;">Exercised</td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px;"> </td> <td style="font-size: 10pt; text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;">(10,000</td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;">)</td> <td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"> </td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"> </td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"> </td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px;">Expired/Forfeited</td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;"> </td> <td style="font-size: 10pt; text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;">(87,432</td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px 10px 0px 0px; vertical-align: bottom; white-space: nowrap;">)</td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;">5.92</td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"> </td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;">7.29</td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"> </td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;">-</td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"> </td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px;">Outstanding at September 30, 2015</td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px;"> </td> <td style="font-size: 10pt; text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;">2,704,195</td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"> </td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;">$</td> <td style="font-size: 10pt; text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;">8.05</td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"> </td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;">8.16</td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"> </td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;">$</td> <td style="font-size: 10pt; text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;">64</td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"> </td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px;">Exercisable at September 30, 2015</td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px;"> </td> <td style="font-size: 10pt; text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;">883,449</td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"> </td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;">$</td> <td style="font-size: 10pt; text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;">8.63</td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"> </td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;">6.67</td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"> </td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;">$</td> <td style="font-size: 10pt; text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;">98</td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"> </td> </tr> </table> </div>   </div> 3847210 10000 87432 5.92 2704195 8.05 883449 8.63 P8Y2M12D 2875000 P9Y9M18D P7Y3M14D P8Y1M28D 64000 P6Y8M1D 98000 11084426 2.51 P3Y10M6D 59518000 2.50 7237216 2.51 P3Y3M18D 23593000 23593000 P3Y3M18D 2.51 7237216 P1Y P3Y 8300000 2.11 0.0157 0.00 P6Y 4100000 1900000 10300000 P9M P3Y 2350000 1650000 4000000 <div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';"> <div style="display: block;"> NOTE 7. LICENSE AND COMMITMENTS   National Institutes of Health and the National Cancer Institute   Cooperative Research and Development Agreement Effective August 5, 2011, the Company signed a Cooperative Research and Development Agreement (CRADA) with the National Institutes of Health and the National Cancer Institute (NCI). Under the terms of the five-year cooperative research and development agreement, the Company will work with Dr. Steven A. Rosenberg, M.D., Ph.D., chief of NCI's Surgery Branch, to develop adoptive cell immunotherapies that are designed to destroy metastatic melanoma cells using a patient's tumor infiltrating lymphocytes.    On January 22, 2015, the Company executed an amendment (the Amendment) to the CRADA to include four new indications. As amended, in addition to metastatic melanoma, the CRADA now also includes the development of TIL therapy for the treatment of patients with bladder, lung, triple-negative breast, and HPV-associated cancers. Under the Amendment, the NCI also has agreed to provide the Company with samples of all tumors covered by the Amendment for performing studies related to improving TIL selection and/or TIL scale-out production and process development. Although the CRADA has a five year term, either party to the CRADA has the right to terminate the CRADA upon 60 days' notice to the other party.   National Institutes of Health   Development and Manufacture TIL Effective October 5, 2011, the Company entered into a Patent License Agreement with the National Institutes of Health, an agency of the United States Public Health Service within the Department of Health and Human Services (NIH), which License Agreement was subsequently amended on February 9, 2015 and October 2, 2015. Pursuant to the License Agreement as amended, NIH granted to the Company an exclusive worldwide right and license to develop and manufacture certain proprietary autologous tumor infiltrating lymphocyte adoptive cell therapy products for the treatment of metastatic melanoma, ovarian cancer, breast cancer, and colorectal cancer. The License Agreement requires the Company to pay royalties based on a percentage of net sales (which percentage is in the mid-single digits and subject to certain annual minimum royalty payments), a percentage of revenues from sublicensing arrangements, and lump sum benchmark royalty payments on the achievement of certain clinical and regulatory milestones for each of the various indications and other direct costs incurred by NIH pursuant to the agreement.   NIH - Exclusive Patent License Agreement On February 10, 2015, the Company entered into an exclusive Patent License Agreement with the NIH under which the Company received an exclusive, world-wide license to the NIH's rights in and to two patent-pending technologies related to methods for improving tumor-infiltrating lymphocytes for adoptive cell therapy. The licensed technologies relate to the more potent and efficient production of TIL from melanoma tumors by selecting for T-cell populations that express various inhibitory receptors. Unless terminated sooner, the license shall remain in effect until the last licensed patent right expires.   In consideration for the exclusive rights granted under the exclusive Patent License Agreement, the Company agreed to pay the NIH a non-refundable upfront licensing fee which was recognized as research and development expense during the nine months ended September 30, 2015. The Company also agreed to pay customary royalties based on a percentage of net sales (which percentage is in the mid-single digits), a percentage of revenues from sublicensing arrangements, and lump sum benchmark payments upon the successful completion of the Company's first Phase 2 clinical study, the successful completion of the Company's first Phase 3 clinical study, the receipt of the first FDA approval or foreign equivalent for a licensed product or process resulting from the licensed technologies, the first commercial sale of a licensed product or process in the United States, and the first commercial sale of a licensed product or process in any foreign country.   H. Lee Moffitt Cancer Center   Research Collaboration Agreement In September, 2014, we entered into a research collaboration agreement with the H. Lee Moffitt Cancer Center and Research Institute, Inc. to jointly engage in transitional research and development of adoptive tumor-infiltrating lymphocyte cell therapy with improved anti-tumor properties and process.   Exclusive License Agreement On July 21, 2014, the Company entered into an Exclusive License Agreement (the Moffitt License Agreement), effective as of June 28, 2014, with the H. Lee Moffitt Cancer Center and Research Institute, Inc. (Moffitt) under which the Company received an exclusive, world-wide license to Moffitt's rights in and to two patent-pending technologies related to methods for improving tumor-infiltrating lymphocytes for adoptive cell therapy. Unless earlier terminated, the term of the license extends until the earlier of the expiration of the last patent related to the licensed technology or 20 years after the effective date of the license agreement.    Pursuant to the Moffitt License Agreement, the Company paid an upfront licensing fee which was recognized as research and development expense during 2014. A patent issuance fee will also be payable under the Moffitt License Agreement, upon the issuance of the first U.S. patent covering the subject technology. In addition, the Company agreed to pay milestone license fees upon completion of specified milestones, customary royalties based on a specified percentage of net sales (which percentage is in the low single digits) and sublicensing payments, as applicable, and annual minimum royalties beginning with the first sale of products based on the licensed technologies, which minimum royalties will be credited against the percentage royalty payments otherwise payable in that year. The Company will also be responsible for all costs associated with the preparation, filing, maintenance and prosecution of the patent applications and patents covered by the Moffitt License Agreement related to the treatment of any cancers in the United States, Europe and Japan and in other countries selected that the Company and Moffitt agreed to.   During the nine months ended September 30, 2015 and 2014, the Company recognized $2.5 million and $0.9 million respectively, of expenses related to its license agreements. The amounts were recorded as part of research and development expenses in the statement of operations. Additionally, during the nine months ended September 30, 2015, there were no net sales subject to certain annual minimum royalty payments or sales that would require us to pay a percentage of revenues from sublicensing arrangements. In addition, there were no benchmarks or milestones achieved that would require payment under the lump sum benchmark royalty payments on the achievement of certain clinical regulatory milestones for each of the various indications.   Future guaranteed commitments under all of the Company's agreements amount to (in thousands): <div>   <div align="center"> <table style="border-collapse: collapse; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; margin-left: 0.1px; margin-right: 0.1px;" cellpadding="0" cellspacing="0" width="30%"> <tr style="vertical-align: bottom;"> <td style="font-size: 10pt; text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;">Year</td> <td style="font-size: 10pt; text-align: center; font-family: 'times new roman'; padding: 0px; width: 20px;"> </td> <td style="font-size: 10pt; text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;" colspan="2">Amount </td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="font-size: 10pt; text-align: center; font-family: 'times new roman'; padding: 0px; width: 49%;">2015</td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px 10px 0px 0px; vertical-align: bottom; white-space: nowrap; width: 1%;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px 10px 0px 0px; vertical-align: bottom; white-space: nowrap; width: 1%;">$</td> <td style="font-size: 10pt; text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; width: 48%;">3,104</td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="font-size: 10pt; text-align: center; font-family: 'times new roman'; padding: 0px;">2016</td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;">2,874</td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"> </td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="font-size: 10pt; text-align: center; font-family: 'times new roman'; padding: 0px;">Total</td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px 10px 0px 0px; vertical-align: bottom; white-space: nowrap;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;">$</td> <td style="font-size: 10pt; text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;">5,978</td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"> </td> </tr> </table> </div>   </div> </div> </div> <div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';">   <div align="center"> <table style="border-collapse: collapse; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; margin-left: 0.1px; margin-right: 0.1px;" cellpadding="0" cellspacing="0" width="30%"> <tr style="vertical-align: bottom;"> <td style="font-size: 10pt; text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;">Year</td> <td style="font-size: 10pt; text-align: center; font-family: 'times new roman'; padding: 0px; width: 20px;"> </td> <td style="font-size: 10pt; text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;" colspan="2">Amount </td> <td style="font-size: 10pt; font-family: 'times new roman'; padding: 0px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="font-size: 10pt; text-align: center; font-family: 'times new roman'; padding: 0px; width: 49%;">2015</td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px 10px 0px 0px; vertical-align: bottom; white-space: nowrap; width: 1%;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px 10px 0px 0px; vertical-align: bottom; white-space: nowrap; width: 1%;">$</td> <td style="font-size: 10pt; text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; width: 48%;">3,104</td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="font-size: 10pt; text-align: center; font-family: 'times new roman'; padding: 0px;">2016</td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-size: 10pt; text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;">2,874</td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"> </td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="font-size: 10pt; text-align: center; font-family: 'times new roman'; padding: 0px;">Total</td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px 10px 0px 0px; vertical-align: bottom; white-space: nowrap;"> </td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;">$</td> <td style="font-size: 10pt; text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;">5,978</td> <td style="font-size: 10pt; text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"> </td> </tr> </table> </div>   </div> 3104000 2874000 5978000 2500000 900000 <div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';">NOTE 8. LEGAL PROCEEDINGS   On August 18, 2015, MBA Holdings, LLC filed a breach of contract lawsuit against the Company in the Superior Court of California, County of Los Angeles (MBA Holdings, LLC v. Lion Biotechnologies, Inc., Case BC 591513). The complaint alleges that the Company and MBA Holdings, LLC were parties to (i) a June 15, 2012 Finder's Fee Agreement, (ii) a Confidentiality, Non-Disclosure and Non-Circumvention Agreement, dated June 13, 2012, and (iii) a Consulting Agreement, dated July 9, 2012, and that the Company breached these agreements by failing to compensate MBA Holdings for introducing Roth Capital Partners, LLC and Highline Research Advisors LLC to the Company in connection with the $23.3 million equity funding the Company completed in November 2013. MBA Holdings also alleges that the Company failed to register certain shares underlying a common stock purchase warrant that the Company issued to MBA Holdings. MBA Holdings has asked for damages in the amount of $7,746,000. The Company has not yet been served in the foregoing lawsuit.   The Company believes that there is no merit to the claims made by MBA Holdings in the complaint. On September 9, 2015 the Company provided MBA Holdings with evidence that the Company dealt with a certain investment banker on a financing transaction at least six months before MBA Holdings purportedly introduced the Company to the banker, and that a certain research analyst group were known to the Company prior to the purported introduction. Accordingly, the Company has demanded that MBA Holdings dismiss the lawsuit. To date, MBA Holdings has not served the complaint on the Company, dismissed the lawsuit, or responded to the Company's last communications. Accordingly, on October 26, 2015 the Company renewed its demand on MBA and its counsel to dismiss the suit or face exposure to damages for malicious prosecution, voluntarily entered an appearance in the case, and initiated discovery proceedings for the purpose of pursuing an early resolution of the case in the Company's favor. The Company intends to vigorously defend itself in this matter and will seek a prevailing-party award of its attorney's fees and other litigation costs pursuant to contractual provisions in the agreements appended to MBA's complaint.    There are no other pending legal proceedings to which the Company is a party or of which its property is the subject other than as previously reported.</div> 7746000 EX-101.SCH 9 lbio-20150930.xsd XBRL TAXONOMY EXTENSION SCHEMA 001 - Document - Document And Entity Information link:presentationLink link:calculationLink link:definitionLink 002 - Statement - Condensed Balance Sheets link:presentationLink link:calculationLink link:definitionLink 003 - Statement - Condensed Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 004 - Statement - Condensed Statements of Operations link:presentationLink link:calculationLink link:definitionLink 005 - Statement - Condensed Statements of Operations (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 006 - Statement - Condensed Statements of Comprehensive Loss link:presentationLink link:calculationLink link:definitionLink 007 - Statement - Condensed Statements of Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 008 - Statement - Condensed Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 101 - Disclosure - GENERAL ORGANIZATION AND BUSINESS link:presentationLink link:calculationLink link:definitionLink 102 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING PRACTICES link:presentationLink link:calculationLink link:definitionLink 105 - Disclosure - STOCKHOLDERS' EQUITY link:presentationLink link:calculationLink link:definitionLink 106 - Disclosure - STOCK OPTIONS AND WARRANTS link:presentationLink link:calculationLink link:definitionLink 107 - Disclosure - LICENSE AND COMMITMENTS link:presentationLink link:calculationLink link:definitionLink 103 - Disclosure - CASH, MONEY MARKET FUNDS, AND SHORT-TERM INVESTMENTS link:presentationLink link:calculationLink link:definitionLink 108 - Disclosure - LEGAL PROCEEDINGS link:presentationLink link:calculationLink link:definitionLink 109 - Disclosure - SUBSEQUENT EVENTS link:presentationLink link:calculationLink link:definitionLink 202 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING PRACTICES (Policies) link:presentationLink link:calculationLink link:definitionLink 302 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING PRACTICES (Tables) link:presentationLink link:calculationLink link:definitionLink 305 - Disclosure - STOCKHOLDERS' EQUITY (Tables) link:presentationLink link:calculationLink link:definitionLink 306 - Disclosure - STOCK OPTIONS AND WARRANTS (Tables) link:presentationLink link:calculationLink link:definitionLink 303 - Disclosure - CASH, MONEY MARKET FUNDS, AND SHORT-TERM INVESTMENTS (Tables) link:presentationLink link:calculationLink link:definitionLink 40101 - Disclosure - GENERAL ORGANIZATION AND BUSINESS (Details) link:presentationLink link:calculationLink link:definitionLink 40201 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING PRACTICES (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 40202 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING PRACTICES (Schedule of Assets Measured at Fair Value) (Details) link:presentationLink link:calculationLink link:definitionLink 40501 - Disclosure - STOCKHOLDERS' EQUITY (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 40502 - Disclosure - STOCKHOLDER'S EQUITY (Schedule of Restricted Stock Activity) (Details) link:presentationLink link:calculationLink link:definitionLink 40601 - Disclosure - STOCK OPTIONS AND WARRANTS (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 40602 - Disclosure - STOCK OPTIONS AND WARRANTS (Schedule of Status of Stock Options) (Details) link:presentationLink link:calculationLink link:definitionLink 40603 - Disclosure - STOCK OPTIONS AND WARRANTS (Schedule of Status of Stock Warrants) (Details) link:presentationLink link:calculationLink link:definitionLink 40701 - Disclosure - LICENSE AND COMMITMENTS (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 40301 - Disclosure - CASH, MONEY MARKET FUNDS, AND SHORT-TERM INVESTMENTS (Schedule of Cash, Money Market Funds, and Short-Term Investments) (Details) link:presentationLink link:calculationLink link:definitionLink 40302 - Disclosure - CASH, MONEY MARKET FUNDS, AND SHORT-TERM INVESTMENTS (Schedule of Gross Unrealized Gains and Losses) (Details) link:presentationLink link:calculationLink link:definitionLink 40303 - Disclosure - CASH, MONEY MARKET FUNDS, AND SHORT-TERM INVESTMENTS (Schedule of Contractual Maturities) (Details) link:presentationLink link:calculationLink link:definitionLink 40304 - Disclosure - CASH, MONEY MARKET FUNDS, AND SHORT-TERM INVESTMENTS (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 40901 - Disclosure - SUBSEQUENT EVENTS (Details) link:presentationLink link:calculationLink link:definitionLink 40203 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING PRACTICES (Schedule of Stock-Based Compensation) (Details) link:presentationLink link:calculationLink link:definitionLink 104 - Disclosure - PROPERTY AND EQUIPMENT link:presentationLink link:calculationLink link:definitionLink 304 - Disclosure - PROPERTY AND EQUIPMENT (Tables) link:presentationLink link:calculationLink link:definitionLink 40401 - Disclosure - PROPERTY AND EQUIPMENT (Details) link:presentationLink link:calculationLink link:definitionLink 307 - Disclosure - LICENSE AND COMMITMENTS (Tables) link:presentationLink link:calculationLink link:definitionLink 40702 - Disclosure - LICENSE AND COMMITMENTS (Schedule of Purchase Obligation) (Details) link:presentationLink link:calculationLink link:definitionLink 40801 - Disclosure - LEGAL PROCEEDINGS (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 10 lbio-20150930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 11 lbio-20150930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 12 lbio-20150930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE The amount of exchange transaction inducement costs capitalized during the period. Cost To Induce Exchange Transaction Cost to induce exchange transaction Fair Value of Vested Warrants Granted for Services Vesting of restricted shares issued for services Number of shares issued upon exercise of warrant. Common Stock Issued Upon Exercise Of Warrants Shares Common stock issued upon exercise of warrants (in shares) The amount of exchange transaction inducement costs capitalized during the period. Common Stock Issued Upon Exercise Of Warrants Amount Common stock issued upon exercise of warrants Common Stock To Be Issued [Member] Common Stock To Be Issued [Member] Value of common stock to be issued as of balance sheet date. Common Stock To Be Issued Value Common stock to be issued, 245,153 shares Number of shares of common stock to be issued. Common Stock To Be Issued Shares Common stock to be issued shares Document And Entity Information [Abstract] Represents the value of working capital which is the difference between current assets and current liabilities. Working Capital Working capital Share Based Compensation Arrangement By Share Based Payment Award Options Additional Disclosures Abstract1 [Abstract] Weighted Average Remaining Contractual Life Weighted average remaining contractual term for option awards grants in period, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Remaining Contractual Term Granted Amendment Flag Aggregate Intrinsic Value [Abstract] Aggregate Intrinsic Value Weighted average remaining contractual term for option awards forfeitures and expirations in period, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Remaining Contractual Term Expired/Forfeited Aggregate Intrinsic Value Abstract1 [Abstract] Aggregate Intrinsic Value Series A Convertible Preferred Stock [Member] Current Fiscal Year End Date Plan Two [Member] Plan Two [Member] 2014 Plan [Member] Five Companies [Member] Five Companies [Member] Document Information [Line Items] Various Other Domestic Issuers [Member] Various Other Domestic Issuers [Member] Document Information [Table] Foreign Issuer [Member] Foreign Issuer [Member] The total intrinsic value of expirations and forfeitures during the period. Share Based Compensation Arrangement By Share Based Payment Award Expirations And Forfeitures In Period Intrinsic Value Expired/Forfeited Document Period End Date The weighted-average time to maturity for money market funds and short-term investments. Money Market Funds And Short Term Investments Weighted Average Time To Maturity Weighted-average time to maturity The amount of stock-based compensation cost that was reclassified during the period. Reclassification Of Stock Based Compensation Cost Stock-based compensation cost reclassified Award Type [Axis] Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Filer Category Entity Public Float Entity Registrant Name Entity Central Index Key Entity Common Stock, Shares Outstanding Document Fiscal Year Focus Document Fiscal Period Focus Document Type SUMMARY OF SIGNIFICANT ACCOUNTING PRACTICES [Abstract] Accounts Payable, Current Accounts payable Accounts Payable, Related Parties, Current Accrued payable to officers and former directors Accrued Liabilities Accrued compensation payable in shares of stock Accrued Liabilities, Current Accrued liabilities Accrued expenses Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Property and equipment, accumulated depreciation Less: Accumulated depreciation and amortization Accumulated depreciation AOCI Attributable to Parent [Member] Comprehensive Income [Member] Accumulated Other Comprehensive Income (Loss), Net of Tax Accumulated other comprehensive income Additional Paid in Capital Additional paid-in capital Additional Paid-in Capital [Member] Additional Paid-In Capital [Member] Adjustments to Additional Paid in Capital, Fair Value Fair value of vested stock options Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Adjustments to reconcile net loss to net cash used in operating activities: Adjustments to Additional Paid in Capital, Share-based Compensation, Restricted Stock Unit or Restricted Stock Award, Requisite Service Period Recognition Vesting of restricted shares issued for services Allocated Share-based Compensation Expense Allocable portion of the fair value that vested recognized as expense Share-based compensation Amortization of Debt Discount (Premium) Amortization of discount on convertible notes Amortization of Financing Costs Financing costs Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities, Name [Domain] Antidilutive Securities [Axis] Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Assets [Abstract] ASSETS Assets, Fair Value Disclosure Assets, fair value Assets Total Assets Assets, Total [Member] Short-term investments [Member] Assets, Current Total Current Assets Assets, Current [Abstract] Current Assets Available-for-sale Securities Corporate debt securities Short-term investments available for sale Corporate debt securities (reported as short-term investments) Available-for-sale Securities, Current Short-term investments available for sale Business Description and Basis of Presentation [Text Block] GENERAL ORGANIZATION AND BUSINESS Cash and Cash Equivalents, Policy [Policy Text Block] Cash and Cash Equivalents Cash, Cash Equivalents, and Short-term Investments [Text Block] CASH, MONEY MARKET FUNDS, AND SHORT-TERM INVESTMENTS Cash and Cash Equivalents, at Carrying Value Cash and Cash Equivalents, End of Period Cash and Cash Equivalents, Beginning of Period Checking and savings accounts (reported as cash and cash equivalents) Cash and cash equivalents Cash and Cash Equivalents, Period Increase (Decrease) Net Decrease In Cash And Cash Equivalents Cash Equivalents, at Carrying Value Total CASH, MONEY MARKET FUNDS, AND SHORT-TERM INVESTMENTS [Abstract] Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract] Supplement non-cash financing activities Cash, Cash Equivalents, and Short-term Investments Cash, money market funds and short-term investments Total Class of Stock [Line Items] Class of Stock [Domain] Commitments and Contingencies Commitments and contingencies LICENSE AND COMMITMENTS LICENSE AND COMMITMENTS [Abstract] Common Stock, Value, Issued Common stock, $0.000041666 par value; 150,000,000 shares authorized, 47,807,398 and 33,750,188 shares issued and outstanding, respectively Common Stock, Shares, Issued Common stock, shares issued Common Stock, Shares Authorized Common stock, shares authorized Common Stock, Par or Stated Value Per Share Common stock, par value (in dollars per share) Common Stock [Member] Common Stock [Member] Common Stock, Shares, Outstanding Common stock, shares outstanding Comprehensive Income (Loss), Net of Tax, Attributable to Parent Comprehensive income Comprehensive Loss Concentration Risk, Credit Risk, Policy [Policy Text Block] Concentrations Concentration Risk [Line Items] Concentration Risk Benchmark [Domain] Concentration Risk [Table] Concentration Risk, Percentage Concentration risk percentage Concentration Risk Benchmark [Axis] Conversion of Stock, Shares Issued Conversion of Stock, Shares Converted Convertible Preferred Stock [Member] Corporate Debt Securities [Member] Cost of Sales [Member] Operating expenses [Member] Depreciation, Depletion and Amortization, Nonproduction Depreciation Depreciation Depreciation expense Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net Change in fair value of derivative liabilities Disclosure of Compensation Related Costs, Share-based Payments [Text Block] STOCK OPTIONS AND WARRANTS STOCK OPTIONS AND WARRANTS [Abstract] Earnings Per Share, Policy [Policy Text Block] Net Income (Loss) Per Share Earnings Per Share, Basic and Diluted Net Loss Per Share, Basic and Diluted Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items] Employee Stock Option [Member] Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition Unrecognized compensation cost, period for recognition Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized Unrecognized compensation cost Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Share-based Awards Other than Options Unrecognized compensation cost Equipment [Member] Laboratory equipment [Member] Equity Component [Domain] Asset Class [Axis] Asset Class [Domain] Fair Value Measurement, Policy [Policy Text Block] Fair Value Measurements Fair Value Measurements, Recurring and Nonrecurring [Table] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Measurements, Recurring [Member] Measurement Frequency [Axis] Fair Value, Hierarchy [Axis] Fair Value of Financial Instruments, Policy [Policy Text Block] Fair Value on a Recurring Basis Fair Value Hierarchy [Domain] Fair Value, Measurement Frequency [Domain] Fair Value, Assets Measured on Recurring Basis [Table Text Block] Schedule of Assets Measured at Fair Value Fair Value, Inputs, Level 3 [Member] Fair Value, Inputs, Level 1 [Member] Fair Value, Inputs, Level 2 [Member] Impairment of Intangible Assets (Excluding Goodwill) Impairment of intangible asset Income Statement Location [Axis] Condensed Statements of Operations [Abstract] Income Statement Location [Domain] Increase (Decrease) in Other Current Assets Increase in money market funds Increase (Decrease) in Operating Capital [Abstract] Changes in assets and liabilities: Increase (Decrease) in Other Accounts Payable and Accrued Liabilities Accounts payable and accrued expenses Increase (Decrease) in Prepaid Expense and Other Assets Prepaid and other current assets Interest Expense Interest expense Investment Owned, at Fair Value Fair Value Investment Income, Interest Interest income Investments Classified by Contractual Maturity Date [Table Text Block] Schedule of Contractual Maturities Leasehold Improvements [Member] Leasehold improvements [Member] Liabilities, Current Total Current Liabilities Liabilities, Current [Abstract] Current Liabilities Liabilities and Equity [Abstract] LIABILITIES AND STOCKHOLDERS' EQUITY Liabilities and Equity Total Liabilities and Stockholders' Equity License Costs License agreement expense Contingencies Disclosure [Text Block] LEGAL PROCEEDINGS LEGAL PROCEEDINGS [Abstract] Loss Contingency, Damages Sought, Value Damages sought Major Types of Debt and Equity Securities [Domain] Customer [Axis] Major Types of Debt and Equity Securities [Axis] Marketable Securities, Policy [Policy Text Block] Short-term Investments Maximum [Member] Minimum [Member] Money Market Funds [Member] Money Market Funds, at Carrying Value Money market funds Customer [Domain] Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract] Cash Flows From Financing Activities Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract] Cash Flows From Operating Activities Net Income (Loss) Available to Common Stockholders, Basic Net Loss Attributable to Common Stockholders Net Cash Provided by (Used in) Investing Activities, Continuing Operations Net cash used in investing activities Net Cash Provided by (Used in) Operating Activities, Continuing Operations Net cash used in operating activities Net cash used in operating activities Net Income (Loss) Attributable to Parent Net Loss Net Loss Net loss Net Income (Loss) Attributable to Parent Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract] Cash Flows From Investing Activities Net Cash Provided by (Used in) Financing Activities, Continuing Operations Net cash provided by financing activities New Accounting Pronouncements, Policy [Policy Text Block] Recent Accounting Pronouncements Noncash Merger Related Costs Cost of Lion transaction - related party Common stock issued for Lion transaction Nonoperating Income (Expense) [Abstract] Other income (expense) Other income Office Equipment [Member] Computer, software, and office equipment [Member] Operating Expenses [Abstract] Costs and expenses Operating Expenses Total costs and expenses Operating Income (Loss) Loss from operations Operating Expense [Member] Operating Costs and Expenses Operating expenses GENERAL ORGANIZATION AND BUSINESS [Abstract] Other Significant Noncash Transaction, Value of Consideration Received Unrealized gain on short-term investments Other Comprehensive Income (Loss), Unrealized Holding Gain (Loss) on Securities Arising During Period, Net of Tax Unrealized gain on short-term investments Other Nonoperating Income (Expense) Total other income (expense) Other Preferred Stock Dividends and Adjustments Deemed dividend related to beneficial conversion feature of convertible preferred stock Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract] Other comprehensive income: Payments to Acquire Available-for-sale Securities Purchase of short-term investments Payments to Acquire Property, Plant, and Equipment Purchases of property and equipment Plan Name [Axis] Plan Name [Domain] Preferred Stock, Par or Stated Value Per Share Preferred stock, par value (in dollars per share) Preferred Stock, Value, Issued Preferred stock, $0.001 par value; 50,000,000 shares authorized, 3,694 shares and 5,694 shares issued and outstanding, respectively Preferred Stock, Shares Issued Preferred stock, shares issued Preferred Stock, Shares Authorized Preferred stock, shares authorized Preferred Stock, Shares Outstanding Preferred stock, shares outstanding Preferred Stock [Member] Preferred Stock [Member] Prepaid Expense and Other Assets, Current Prepaid and other current assets Reclassification, Policy [Policy Text Block] Reclassifications Proceeds from Warrant Exercises Proceeds from warrant exercises Proceeds from the issuance of common stock upon exercise of warrants Proceeds from Issuance of Private Placement Proceeds from issuance of private placement Proceeds from Issuance of Common Stock Proceeds from the issuance of common stock, net Proceeds from Stock Options Exercised Proceeds from the issuance of common stock upon exercise of options Proceeds from Sale and Maturity of Available-for-sale Securities Maturities of short-term investments Property, Plant and Equipment [Table Text Block] Schedule of Property and Equipment Property, Plant and Equipment, Type [Axis] Property, Plant and Equipment, Policy [Policy Text Block] Property and Equipment PROPERTY AND EQUIPMENT [Abstract] Property, Plant and Equipment, Useful Life Property and equipment, useful life Property, Plant and Equipment, Type [Domain] Property and equipment, net Property, Plant and Equipment, Net Property and equipment, net Property and equipment, net of accumulated depreciation of $794 and $103 Property, Plant and Equipment, Gross Property and equipment, gross Property, Plant and Equipment [Line Items] Property, Plant and Equipment Disclosure [Text Block] PROPERTY AND EQUIPMENT Range [Domain] Range [Axis] Recorded Unconditional Purchase Obligations [Table Text Block] Schedule of Purchase Obligation Recorded Unconditional Purchase Obligation Total Recorded Unconditional Purchase Obligation Due in Second Year 2016 Recorded Unconditional Purchase Obligation Due in Next Twelve Months 2015 Research and Development Expense Research and development expense Research and development Research and Development Expense, Policy [Policy Text Block] Research and Development Research and Development Expense [Member] Research and development [Member] Restricted Stock [Member] Restricted common stock [Member] Retained Earnings [Member] Accumulated Deficit [Member] Retained Earnings (Accumulated Deficit) Accumulated deficit Revenues Revenues Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost Stock-based compensation expense Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term Expected life Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Outstanding, ending balance Outstanding, beginning balance Outstanding Outstanding Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value Fair value of options Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Exercisable Exercisable ending balance Exercisable Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Nonvested Nonvested, fair value Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Schedule of Status of Stock Options Schedule of Nonvested Restricted Stock Units Activity [Table Text Block] Schedule of Restricted Stock Activity Schedule of Cost-method Investments [Table] Schedule of Cost-method Investments [Line Items] Cash, Cash Equivalents and Investments [Table Text Block] Schedule of Cash, Money Market Funds and Short-Term Investments Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table] Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block] Schedule of Stock-Based Compensation Property, Plant and Equipment [Table] Schedule of Stock by Class [Table] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Status of Stock Warrants Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period Vesting period Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period Granted Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Granted Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number Non-vested shares, September 30, 2015 Non-vested shares, January 1, 2015 Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Exercised Exercised Share-based Compensation Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Non-vested shares, September 30, 2015 Non-vested shares, January 1, 2015 Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Number of Shares Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross Issued Granted Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Accrued compensation payable in shares of stock [Line Items] Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized Number of additional shares authorized Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Weighted Average Grant Date Fair Value Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Forfeited Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period Forfeited Forfeited Share Price Share price Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Granted, exercise price Issued Granted Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price Exercisable Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate Expected dividend yield Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period Expired Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Vested Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number Exercisable Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price Expired/Forfeited Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract] Weighted Average Exercise Price Weighted Average Exercise Price Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period Vested (in shares) Vested Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate Expected volatility Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value Aggregate fair value Vested, fair value Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized Number of shares authorized Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Discount rate Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period Expired/Forfeited Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value Granted Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block] Stock-Based Compensation Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value Exercisable ending balance Exercisable Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value Outstanding, ending balance Outstanding, beginning balance Equity Award [Domain] Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number Outstanding, ending balance Outstanding, beginning balance Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price Outstanding, ending balance Outstanding, beginning balance Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward] Shares Under Option Shares Under Warrants Shares, Outstanding Balance (in shares) Balance (in shares) Significant Accounting Policies [Text Block] SUMMARY OF SIGNIFICANT ACCOUNTING PRACTICES Statement [Line Items] Condensed Statements of Stockholders' Equity [Abstract] Condensed Statements of Cash Flows [Abstract] Statement of Comprehensive Income [Abstract] Equity Components [Axis] Statement [Table] Condensed Balance Sheets [Abstract] Class of Stock [Axis] Stock Issued During Period, Value, Stock Options Exercised Common stock issued upon exercise of options Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period Common stock issued upon exercise of options (in shares) Purchase of common stock Exercised Exercised Stock Issued During Period, Shares, Other Common stock sold in public offering, net of offering costs (in shares) Stock Issued During Period, Value, Conversion of Convertible Securities Common stock issued upon conversion of preferred shares Stock Issued During Period, Shares, New Issues Shares issued during period Stock Issued During Period, Shares, Conversion of Convertible Securities Common stock issued upon conversion of preferred shares (in shares) Stock or Unit Option Plan Expense Fair value of vested stock options Fair value of vested stock options Equity Option [Member] Stock Issued During Period, Value, Other Common stock sold in public offering, net of offering costs STOCKHOLDERS' EQUITY Stockholders' Equity Attributable to Parent [Abstract] Stockholders' Equity STOCKHOLDERS' EQUITY [Abstract] Stockholders' Equity Attributable to Parent Balance Balance Stockholder's equity Total Stockholders' Equity Subsequent Event Type [Axis] Subsequent Event [Line Items] Subsequent Event [Member] SUBSEQUENT EVENTS SUBSEQUENT EVENTS [Abstract] Subsequent Event Type [Domain] Subsequent Event [Table] Trading Securities, Unrealized Holding Gain Gross Unrealized Gains Trading Securities, Unrealized Holding Loss Gross Unrealized Losses Trading Securities, Cost Amortized Cost Unrealized Gain (Loss) on Investments [Table Text Block] Schedule of Unrealized Gains and Losses Use of Estimates, Policy [Policy Text Block] Use of Estimates Warrant [Member] Warrant [Member] Weighted Average Number of Shares Outstanding, Basic and Diluted Weighted-Average Common Shares Outstanding, Basic and Diluted EX-101.PRE 13 lbio-20150930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 14 R39.htm IDEA: XBRL DOCUMENT v3.3.0.814

LICENSE AND COMMITMENTS (Schedule of Purchase Obligation) (Details)
$ in Thousands

Sep. 30, 2015

USD ($)

LICENSE AND COMMITMENTS [Abstract]

2015 $ 3,104

2016 2,874

Total $ 5,978

X

- References
No definition available.
+ Details

Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of the recorded obligation to transfer funds in the future for fixed or minimum amounts or quantities of goods or services at fixed or minimum prices (for example, as in take-or-pay contracts or throughput contracts).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 440

-SubTopic 10

-Section 50

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6394976&loc=d3e25383-109308

+ Details

Name: us-gaap_RecordedUnconditionalPurchaseObligation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of the recorded unconditional purchase obligation maturing in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 440

-SubTopic 10

-Section 50

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6394976&loc=d3e25383-109308

+ Details

Name: us-gaap_RecordedUnconditionalPurchaseObligationDueInSecondYear

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of the recorded unconditional purchase obligation maturing in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 440

-SubTopic 10

-Section 50

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6394976&loc=d3e25383-109308

+ Details

Name: us-gaap_RecordedUnconditionalPurchaseObligationDueWithinOneYear

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

EXCEL 15 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0````(`,!Z9D?SW$M9R0$``$H:```3````6T-O;G1E;G1?5'EP97-= M+GAM;,V9RT[#,!!%?Z7*%C6N[?(494/9`A+\@$FFC=4XMFRWE+_'3@%!51"O M2G>31^]X[DW&.9N>WS\Y"H.U:;LP*9H8W1ECH6K(J%!:1UU29M8;%=.MGS.G MJH6:$Q.CT1&K;!>IB\.8>Q07YS;"/7X4C?)4WT6?YKO[VWA? ML+\<>:[]]6=#[\7`^M,>(?&C'`(DAP3),0;)<0B2XP@DQS%(CA.0'*<@.?@( M)0@*43D*4CD*4SD*5#D*53D*5CD*5SD*6#D*604*604*604*604*604*604* M604*604*604*604*624*624*624*624*624*624*624*624*624*624*6<[%````*P(```L```!?.0Q(OW[CMB` MPD.MQ-*O>X^NO`ZIK`XTHO8<4M?'5$Q^#*G*_=ITJK$"2+8CCVG!D4*>-BP> M-9?20D0[8$NP+,L5R*V.V:SGVL7.U49V[M,41Y26M#;3"&>6X9MY6&3I//B) M]!=C;IK>TI;MR5/0!_ZS#0//>997'L=V+YRO+0O]C^AY%.!)T:'B1?4C9@,2 M[2F]@OIZ`(4QOCLEFI2"(S>C@KN_V/P"4$L#!!0````(`,!Z9D<;CBH[JP$` M`(@9```:````>&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'/%V<>$5==>.V[0L$'8UH+F2FM+Y]4Q?%7N:C"^';)"0#9_X0^!&291/R MQ9,_E_'8-J$Z=F'T7I^;L!CNK[(JQF[A7-A6OB[#0]OY9EC=MWU=QN&R/[BN MW)[*@W>:YQ/7W\[)ULN?LT>;W2KK-SO)1B]E?_!QE;VU_2E4WL?@KB=YX MEB^=_\_V[7Y_W/K'=OM:^R;^4>&^-LA<.DC304H)LG2048**=%!!"1JG@\:4 MH$DZ:$()FJ:#II2@63IH1@F:IX/FE"#)@8PY)PEAS=%:`-?"\5H`V,(16P#9 MPC%;`-K"45L`V\)Q6P#RM%;@=Y*>M=&+]LBM'+T5Z*TBM'+T5Z*TAM'+T-Z&TAC"4=O`WH;1V\#>AM';P-Z&T=O`WH;1V\#>AM';P-Z&T?O`NA=#G[^Z=(^_739?T!4$L#!!0````(`,!Z9D=)TEBSZP(``'(+```0````9&]C M4')O<',O87!P+GAM;+U676_:,!3]*Q8O[:2N`G.MS[L>YU\8#*MK]*65%U9@773C!])/$V]OWF1HL[PD51::=[WE:_6H*-O?)-<)S2QRE. MN3`':]E?DT@R_MJFM3RV2S&+BJ:+NU#E)UK@`0M2+*]::\Q33&4+B/2/^NRV MJK"5M5QGN9#V>N4"+7:11IU9>:K;#MU%Y8P ME1D1_F**N?Q/4I0U;83H=5I;U6]<`(O&`%*IQA$XM`JEFK,DZ01!TD6 M/26L61PL$C#*M)PQ]&!@38`?C"W/^6V%CN\!RQN"ZQER/*CEH)GK6L$<^".` MG+'GC!S;\D)@V;8_\T)'GYN%;LZ`ZWMP#A3Y%H9@-/.&Z*P,AK2<:>!/81#. M2PC\-7.F+O1"?4JA;]_>^),A#-!)B0WG^X'`GQ9UHM+QO14$*GU]"A/'AAZ" M)=#V7=<)BQ3V8.%8":F2MB$<.MY8CSHH7N?[$9P?S07O_&P@.#@-\8.Z2[Y\ M6OE/,+0M*'E-^K`)U'RTN[WF2G?UQ_LPY_((CGX*#G:T>\04=/53<)!ST3Z" MTVDT;4,B<9KI>ZJ?-@_SXL)>DX\X)ZCF(/6O%Z\R`AK/J(K6F*.B->=F9'T6/2D3X!``!I`P``$0```&1O8U!R;W!S+V-O&ULS9-- M3\,P#(;_"NJ]2[-I0XJZ'@!Q8A(20R!N(?&VL.9#B:>N_YXLZUK&N.S&K:[] M/GX=)Z5P3%@/S]XZ\*@@W.QU;0(3;IYM$!TC)(@-:!Y&L<+$Y,IZS3&&?DT< M%UN^!C(NBAG1@%QRY.0`S%U/S*I2"B8\<+2^PTO1X]W.UPDF!8$:-!@,A(XH MR:I7LS6V,249]%49'=<\X,)*M5(@[]JA[#(5.R-X'8YRD'W[]/=/#RE#LJYR M'U1?U33-J)FDNC@P)>^+IY=T-KDR`;D1$%5!,6P=S+-3Y[?)_.50 M67,5+F%^B!,L[#Z_0.#UH$Z8+ML6VL9Z&:ITOX;H\'+BRM;6M\?4K^CL557? M4$L#!!0````(`,!Z9D>97)PC$`8``)PG```3````>&PO=&AE;64O=&AE;64Q M+GAM;.U:6W/:.!1^[Z_0>&?V;0O&-H&VM!-S:7;;M)F$[4X?A1%8C6QY9)&$ M?[]'-A#+E@WMDDVZFSP$+.G[SD5'Y^@X>?/N+F+HAHB4\GA@V2_;UKNW+][@ M5S(D$4$P&:>O\,`*I4Q>M5II`,,X?+&A`T%116F]?(+3E'S/X%/F7/Z3H=,H%N,!M8('_.;Z?D3EJ(X53"Q,!J9S]6:\?1TDB`@LE]E`6Z M2?:CTQ4(,@T[.IU8SG9\]L3MGXS*VG0T;1K@X_%X.+;+THMP'`3@4;N>PIWT M;+^D00FTHVG09-CVVJZ1IJJ-4T_3]WW?ZYMHG`J-6T_3:W?=TXZ)QJW0>`V^ M\4^'PZZ)QJO0=.MI)B?]KFNDZ19H0D;CZWH2%;7E0-,@`%AP=M;,T@.67BGZ M=90:V1V[W4%<\%CN.8D1_L;%!-9ITAF6-$9RG9`%#@`WQ-%,4'RO0;:*X,*2 MTER0UL\IM5`:")K(@?5'@B'%W*_]]9>[R:0S>IU].LYKE']IJP&G[;N;SY/\ M<^CDGZ>3UTU"SG"\+`GQ^R-;88C'(CN]WV6'WV3T=N(]>IP+,BUY1&)$6?R"VZY!$XM4D-,A,_ M")V&F&I0'`*D"3&6H8;XM,:L$>`3?;>^",C?C8CWJV^:/5>A6$G:A/@01AKB MG'/F<]%L^P>E1M'V5;SOX%^9PU"AR1&QT"9QNS1B&$:;OP'J\DCIJMPA$K0CYB&38:CFED)O816:I^J MAS0^J!XR"@7QN1X^Y7IX"C>6QKQ0KH)[`?_1VC?"J_B"P#E_+GW/I>^Y]#VA MTK\>WZ MV22$KYI9+2,6D$N!LT$DN/R+RO`JQ`GH9%LE"0AMNZ5/U2I77 MY:^Y*+@\6^3IKZ%T/BS/^3Q?Y[3-"S-#MW)+ZK:4OK4F.$KTL@'37[]EUVY".E,%.70[@:0KX#;;J=W#HXGIB1N0K34I!OP_GIQ7@: MXCG9!+E]F%=MY]C1T?OGP5&PH^\\EAW'B/*B(>ZAAIC/PT.'>7M?F&>5QE`T M%&ULK"0L1K=@N-?Q+!3@9&`MH`>#KU$"\E)58#%;Q@,KD*)\3(Q%Z'#GEUQ? MX]&2X]NF9;5NKREW&6TB4CG":9@39ZO*WF6QP54=SU5;\K"^:CVT%4[/_EFM MR)\,$4X6"Q)(8Y07IDJB\QE3ON>;G*YZ(G;ZEW?!8/+]<,E'#^4[ MYU_T74.N?O;=X_INDSM(3)QYQ1$!=$4"(Y4 MU#VT%SU&\Z.9X!ZSAW.;>KC"1:S_6-8>^3+?.7#;.MX#7N83+$.D?L%]BHJ` M$:MBOKJO3_DEG#NT>_&!()O\UMND]MW@#'S4JUJE9"L1/TL'?!^2!F.,6_0T M7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5`Y3_;U`UH]@TT M')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%`````@`P'IF1V8:/]!G M`@``<@P```T```!X;"]S='EL97,N>&ULS5==:]LP%/TK0AVCA1';"4G;U3:, M0F"PE4'SL+*;1/H4=]=QSU'N8> M\;TA]IHCCL-,\.ZDA]`!<5B^@B6B.CXPX7-!A01*IY)V8!&.&'81CXB21!(# M9H@1NG+PT``V^YHX1KB05MLI]'4&?J'Z(,= M]'&(UJQ@(21YU?$F$>8:P!*")9:*S#>1OQ(5,URK)H.].MOE\-0EOZ>G\^]: MYT:GX$=OS\GB%GJJ6(+EU+X6C[5/NS6^P,``"D.```/````>&PO=V]R M:V)O;VLN>&ULE9=1;]HZ%(#_BI67]4K3A3A`6S0FI2'0:)!P2>C4^^8F9E@U M,8I-N^W77SLIW>'61/!$[,1?SK$_3NPOLUR.A;Y?DM+U<'=[J!344X4$Z7&'V5$&@Z$,D5>Z$9>1HY70>1O1(3QA6MQD31:27V M.U;^T"P'K5DE56K2K9_)I7@O-ZE+E1#])O MD.\].D;%\J,'%7E:FI48.8.N!KXPR9X89^K7R*FO.369=/Z72CW]?ZY064_. M88F17Q8H+)6FH*AL%D]/C8E!/QP5]8NK(=,7552XS51!4"#*@I:2%NB.<%+F M%-6Y2$#`@(#/)Z"K!:DH#,4#(*\-E"J]-"8]B<0:)3M:Z:P`J`=`O4M!?0#J M`U#_?%`@MOJOL0&@`0`-S@>E2N3/&P%`UP!T?4%$1&[0A`/0#0#=?`1-PSA< M^C.4+*=^'/WK9U$2(S\>H[M5&L4A`-T"T.U'4+J:S_WE(THF*(VF<32)`C_. MD!\$R2K.(FAB%ZK8M23GI_>?T3R)PT>DF=_"#$U6\3C]7`>60M21U1:M%\MD M$2ZSQWID^,\J6LS#.(,$:+5KT3K-DN#;?3(;A\OT4XW('N%X*+-KL;D>CY*% MF=BT#N.[OUSJJ3G*`YKL6E2>14$8IV$]/DCF\R@S>1PAH,.N1>)9.-7KK"UJ-N.NH$HZ*YKD;=5%/<6HJ"]KD5?NRCH M2A=S3N5?L`Q"?;%%7YLQ5A"4%UOD/:U.C8.HH]ILL?B$/X>P(`H*C2U"MU8, MW(,H:#6V6-VJ`H8%&D.[L<7N=M0`HJ#K^%+7,70=0]>QK4RW"8JAZQBZCB]U M'4/7,70=6UQO17E=^*6&KGN7EFK/A2AHNW=VJ4978ZH(XU!1#]KNG5FST55, M*K-_>*$0=;07.56^&]2G]!V5ZLURL><4012TW;/9WO)WUK%!%+3=L]G>@M*Q M012TW;/9WH;RH.T>M-VSV'ZRR#0S#U'0=L]B^TE4,_,0!6WW++9_^.Z]*P6+ M<0^:WK-5]=5=JI??*!D^-+'8,-#RGONVD?^S=]?'%U;2PIQL9/T*?33(S7%' M_S3;D5[??*M,>ZZ/0"/'G%/TD63/>:#[DG(F2+V;;\B'`\[7_P!02P,$%``` M``@`P'IF1U)[`0L_`@``C@<``!@```!X;"]W;W)K6A=E[Y67![K)M.O+*`W&G%/,_1]*R81^"\+GQUMQJ MJ3>BLHAFWJ6AI!,-ZP).KOOP`'8G@#3$('XV9!"+>:"=/S/VKA??+_LPUCZ0 MEE12F\!J>)`3:5MM22G_GHQ^:FKBG,.(PG"9AH?@*<"'`FP.R_ M!#01T$P`B8ET],S$]05+7!:<#0$??T:/]3\'.Z1NKM*;YJ+,F8I,J-U'&1?1 M0YN9$,<1`1<(,",B97L6@#Z!(W3H\%^!DXM`?@'DC0`9.EK0$S\]\=(30T\6 M]-2Z`!>Q\0ND7H'4H6>6P(A(#:(;;SB!*8Q3O\S&*[-Q9')+QD5L_0*95R!S MZ,!.%0]D)5=RKT3N\NUDR9V[2K(E;K]#6%4)6+![(BH1^)GR5%;L6 M[-3R85:2"ZS4+W`MV/GEP^0K*MXB/@#H6MC:*B-FLZST>$7%7\D`.2H0V"K( M20`8`[M2HL7S1PF_F;8@@HK=.].%%KMSZSE`\WQ^PLNBQS?R`_-;TXG@S*1Z MA,U3>65,$N5,_*+F9'-[EEG4`#``!Y#@``&````'AL+W=O2 M=A,>^:Y];,,!%A=;O=9'8QKOOND?F^;T&`3U]FB*M'ZP)U.Z?_:V*M+& M'5:'H#Y5)MUU144>",9T4*19Z:\6W;FG:K6PYR;/2O-4>?6Y*-+JS]KD]K+T MN7\]\9P=CDU[(E@M@EO=+BM,66>V]"JS7_J?^>-&J#;2)7YFYE*/]KT6_L7: MU_;@^V[ILY;!Y&;;M$VD;O-F-B;/VY9ZX;6UQ+?*](W_MM5G;; M2_]/S(8RND`,!>)6P-7=`CD42%`0]&3=N+ZD3;I:5/;B5?UBG-)VS?FC=#.W M;4]V$]7]YT96N[-O*R$6P5O;SA!9]Q$QCDP3&R(A;Y'`]7^#$"2$Z.KEN%[1 M]9*LEUV]&M>'8!!]).HB91?A3'`&!H)32B6CU(1%D2P*LVC`TD?"42^"A1I. M*M%01(.$)$B(ZV,`$B*0*)&1`B!$0S,@F@31N#X!(!K/B`(KN-%H;?0,1D1B M1`A#@N5?1PB#QXQ1TW)"9K#$$N1>94BM6,$@6M1(&5J*`2 M!2$[ZDE,Y*A'<3#Z2#BE!_,CK0Y967LOMG'?&]U7P=[:QK@FV8,;W=%]!]X. M51K-HUT[B!#2`*7:&Z=O7%T+!=IID$6SS_^=\!R?'Y",9WFB% M,7,^VJ:C.[=BK-]Z'CU6N$5T0WK<\3MG,K2(\>EP\6@_8'22IK;Q?`!BKT5U MYQ:Y7'L9BIQ<65-W^&5PZ+5MT?!GCQLR[ESHWA9>ZTO%Q()7Y-[L.]4M[FA- M.F?`YYW[&6Y+Z`N)5/RL\4@78T?`'PAY$Y/OIYT+!`-N\)&)$(A?WG&)FT9$ MXIE_3T'_Y13&Y?@6_:LLE^,?$,4E:7[5)U9Q6N`Z)WQ&UX:]DO$;GFJ(1,`C M::C\=HY7RDA[L[A.BS[4M>[D=51WXGBRV0W^9/!G`_R_(9@,@6;P%)FLZPMB MJ,@',CJ#VHP>B3V'VX`_N:-8E`]*WN.54;[Z7H1I[KV+.)-DKR3^0N*O%:5% M$?(7PKA"_]P1(BL_L#JS^0_G#ACX!6A)(D4M))29*%6AFF!H([=816 MCM#D@!J'DJ2+'&`#@*8J'ZE6+)&5)3)9M&W;*TFTR!(!]=%PGA"NB&(K46P2 M!1I1;"0*8F.;3%&T%*U($BM)8I)H2?;),R2FZ#Y):B5)39)((U&2;)$DW,`X MCO$GH$G+IZ0KJLQ*E9E4L4:5&:7#.S^>9Y0K)M%V;9T*F%2)WJJ`D2Q,4I`$ M6:JW+%,9!$D$8)K>H;K3/Z%)9310^#25J7Q`96^HT#>I,IW*-W+Y803U_V3Y M6*>(O,61TZ,+_H&&2]U1YT`8/[WD&7,FA&$>$VQXM(J_5&PO M=V]R:W-H965T&ULC9==DYHP%(;_"L-]%Q("`4>=63\Z[45G M=GK17K,:E5D@%N*Z_?=-`BJ>'-S>",3G/2?O24+"]"R;M_8@A/(^JK)N9_Y! MJ>,D"-K-051Y^R2/HM;_[&13Y4H_-ON@/38BWUI1508T#).@RHO:GT]MVTLS MG\J3*HM:O#1>>ZJJO/F[$*4\SWSB7QI^%ON#,@W!?!I<==NB$G5;R-IKQ&[F M/Y/)FC"#6.)7(<[MX-XSG7^5\LT\?-_._-#T091BHTR(7%_>Q5*4I8FD,__I M@]YR&N'P_A+]J[6KN_^:MV(IR]_%5AUT;T/?VXI=?BK53WG^)GH/L0FXD65K M?[W-J56RNDA\K\H_NFM1V^NY^R>AO0P7T%Y`KX)K'EP0]8+H)F`/!:P7L/_- M$/>"&&0(.N^VTPWW,3>SBDQB/38;TVB'POZG:]?JUO=Y$DZ# M=Q.G1Q8=0H<(N4=6+G(C`IW_V@F*=6)!'3F]3[!TB00@JT^#K!\&N>MFA-8J MLOIHJ(]P/4/US.K94,]`K5V$W6#^/<^T'WEF="73\4^J'.VM>C'<70 M$X)1GJ70%X*1C,)EOD:SDF1D>1)\3R*1:R^"]CK&S(U;IO"))-#?".?L]CC' M(N9_MR12T+\AD29#VE3FCVU/@ M+?Q\>LSWXD?>[(NZ]5ZETF=)>^+;2:F$-A`^Z:X?]%?$]:$4.V5NN;YONG-U M]Z#D\?*9&PO M=V]R:W-H965T&ULC57=[U\20Z!3$!1*[;[^`QAADVKT1^#CG^SG`9]YQ\2$K0E3PR6@CUV&E5+L" M0)8585@^\)8T>N?(!<-*+\4)R%80?+`D1D$210@P7#=AD5O;FRAR?E:T;LB; M".29,2S^;@CEW3J,PZOAO3Y5RAA`D8.1=Z@9:63-FT"0XSI\BE?/R"`LX%=- M.CF9!R;W/>8G)`,A&0EC'#]A,1`6-T+Z)2$=".G_1H`#`3H10%^[56Z'%2YR MP;M`]*?=8G.IXA749U,:HST*NZ>UD]IZ*3*8@XOQ,T`V/2290%!\#]G-(3<$ MT/'')!)?$IMD1D_N`VSG".1`=M\Z>?[2R5V:"Z]6"\M/IUHA/S_U\M,Y/W.T M[B&9A32]D"ETQ9B#$%PZ:LPQBRQ!CB">:(\1])<$O27!>4E+/Q]Y^>A[2=`L MR>6CB[X[]@O%VVNO'W\XQ3]02P,$%`````@`P'IF1W&Q47Y$`@`` M5@<``!@```!X;"]W;W)KU#2'$N)G98/OZG/LX%UTG/:%OK,28 M6Q]-W;*-77+>K0%@18D;Q)Y(AUMQ:)J0,Z^K%K]0BYV;!M&_&:Y)O[%=^VIXK4XEEP:0)F#B':H&MZPBK47Q M<6,_N^M=)!$*\+O"/9OM+9G[GI`W>?AYV-B.3`'7N.#2`Q++!>>XKJ4C$?A] M]'D+*8GS_=7[=U6MR'Z/&,Y)_::OI/^!QQ("Z;`@-5-? MJS@S3IHKQ;8:]#&L5:O6?K@)XY%F)L"1`"?"%,=,\$:"=R/X#PG^2/"_&B$8 M"8$6`0RU*^6VB*,TH:2WZ-#M#LF?RET'HC>%-*I6J#NA'1/62QJM$G"1?D9( M-D#@#!*Z]Y#M$G)#`!%_2@*:DLC@@@[O`^1+1*A!MI\ZV3UTF9]3*4WQO MQH\=,]\W\GW%]^=::REF`R12D%9!OD6A%VAJ&%`P6L6:(`:4NX*QIZEB"NF& ML;FPP%A8L!3F/_T/C?QP(4RL"S-`@EF6GE9OOO0"(TV2S[WL'GJYJR4RUA(M M:]$4SR*#XL%*RS4WH`Q--J!$DWWMC]F90BZ;#&93H\'TI.8ULPIR;KGL[\PZ M/0G/4$X=S9ZYZ]PUV+?B"1DF_LU]FG3HA'\A>JI:9NT)%[-.3:0C(1R+Y)TG MT;!2/'+3H<9'+K>1V--A[@\'3KKK*S8]I>D_4$L#!!0````(`,!Z9D<:T"+$ M;`,``,H.```8````>&PO=V]R:W-H965T&ULA9?+JRPN'_5!Y?6=K2ZRN*I/BYU='@H5;UI1 MEMI2"-_.XB0?3)CJW"K6=C'[`TPJ"!FF)WXDZE8-CJS'_KO5'<_)S,QF)QH-* MU;IJ0L3USZ>:JS1M(M69__9!KSD;X?#X''W9/FYM_STNU5RG?Y)-M:_=BI&U M4=OXF%9O^K12_3-X3<"U3LOVO[4^EI7.SI*1E<5?W6^2M[^G[DXH>ADOD+U` M7@0`-P5.+W`N`NG=%+B]P+T*Y$V!UPN\B\"YG<'O!?Y5X-\4!+T@N`IN5RGL M!>'U&:)V>+OA:`=S$5?Q=%SHDU5T,_`0-Q,=GL)ZNJR;B^WL:._5PUG65S^G MH3NV/YLX/3+K$#E$/!.9,XAO(@L&"4SDF4%"$UDR2&0B+Q2)A(FL&`0NB%W7 MZU(TR19-MGIWJ)>H:!T2M$C>(JX;NJ@HZ^GQ6-]!#XGB_Y^CEL_1Q:/P=5ID.\01K/C]#,7%#(<0)/P&#:&&Y!7P"6)7"F1Y>4=R'#BL4X\Z@0-Y,PC22(?T%NRH''P,"[OQ#',^JQ9GYK% M[[Q/QR=T`PF"SQ.P>0*:!SW,+"!STL=6:!12DH"X'40QC(:LT9`:Q0,3DA0@ MZC\^2\1FB6@6U`%G%"%=Y29BN&A6?F[=$"0""-1GYSTT?-X'*3"V8+"V+-\5 M!KY9RH"QA#K,N1(Z`@\4$XO,EY[QO@UEFN:7$J`M%X3$;B1]6^6M`O%M M%VC?!>'@`M&F"IZ'>]T]RK3#]UV@C3?$RRC0INJ@L7KIF8!G3"=\WP7:,$&0 M;1!MF0\0R1"59G6?,RWQW15H>P6!%X,>,I9U$3E^A-]#&HQT!"86WFAP"-EI M<)!P(TFV:93#([MBF(?("P3E*UK9K#H#XNND^M M[J32A_.7X^7S=?H?4$L#!!0````(`,!Z9D>M.\OAG`,``/P/```8````>&PO M=V]R:W-H965T&ULC9=-CZ,X$(;_"LJ]!U M5AK-8?=,)TZ"!G`62&?VWZ_YZ#1QE:6Y!#!OE=^R\>-X?;/MS^YL3!_]JJNF M>UF=^_[R',?=_FSJHOMB+Z9Q;XZVK8O>/;:GN+NTICB,0745HQ`RKHNR66W6 M8]OW=K.VU[XJ&_.]C;IK71?M?UM3V=O+"E8?#3_*T[D?&N+-.K[''\"]'SX@F0.2 MSX!TK'1R-M;U1]$7FW5K;U$[3<:E&.82=Y*R3G)E@KY=M3GO),M\*%>68 M\4XTZT33R87`3\#P M"3*_J)06A2*3I"B:#%7`#L\GR!@[TK>343LZPT3Z=FBRH!V>=L#ACNQAE&60 M:2%\-S17T`W//*#06ZZIV0TEVI/69*84L^7(D!T>?,"0#P@M*-7``"0T`4?`KD"8B4@(#>YK5%"CV8V2@I0H9XD&) M#"C1!R4RH!1(#4DR9:!`A]8QSTI4#`H"NROR?$/*MYPLO9Q^7F1!T#QD0<2+ M0U5MVM-XV.RBO;TV_7!\6;3>#[2O.!S*O/:M.^A.Q]+/-)OUI3B9OXKV5#9= M]&9[=^0;#V9':WOC+(HO;D[.[BA^?ZC,L1]NE;MOI\/I]-#;R\=9^W[@W_P/ M4$L#!!0````(`,!Z9D?%#2]YGP$``+$#```8````>&PO=V]R:W-H965T&UL?5/;;MP@$/T5Q`<$+W9Z67DM95-5[4.E*`_M,VN/;11@7,#K M].\+>.U8J=478(8Y9\X,0SFA?7$]@">O6AEWHKWWPY$Q5_>@A;O#`4RX:=%J MX8-I.^8&"Z))(*T8S[(/3`MI:%4FWY.M2AR]D@:>+'&CUL+^.8/"Z40/='$\ MRZ[WT<&JDJVX1FHP3J(A%MH3?3@Z"4!>\U^K`/Y?L&HEN,>[1,4NP1%(BC^6^).3/Z^2+;IJ0;;I=%Q MI,;1I$'=>-?I?.#I3=["JW(0'?P0MI/&D0OZ\+*I_RVBAR`EN[NGI`__9S44 MM#X>/X:SG4=J-CP.RP=9?VGU%U!+`P04````"`#`>F9'W70QN9\!``"Q`P`` M&0```'AL+W=O6B?67M\48!Q`*_3OR_@M>,D5E^`&>:<.3,,^8CFQ;8`CKPI MJ>V1ML[U!\9LV8(2]@9[T/ZF1J.$\Z9IF.T-B"J"E&0\2;XQ)3I-BSSZGDR1 MX^!DI^')$#LH)K$))1748I#N&<=?<"UA'PA+E#:NI!RL0S5#*%'B;=H[ M'?=QNMG/L&T`OP+X`OB11.%3HBCSIW"BR`V.Q$RM[45XP=V!^T:4P1GKCG=> MJ/7>2[%+>@:?4G!MU*<^!6_>#$,^H'FQ+8`C;TIJ>Z2M<]V!,5NVH+B]P0ZTOZG1*.Z\:1IF M.P.\BB`E69HD>Z:XT+3(H^_)%#GV3@H-3X;87BEN_IU`XG"D&WIU/(NF=<'! MBIS-N$HHT%:@)@;J([W?'$Y9B(@!?P0,=G$F0?L9\248OZHC38($D%"ZP,#] M=H$'D#(0^<2O$^='R@!Y MP8&8L;4=#R^X.:2^$65PQKKCG1=JO?=2;+:[G%T"T11S&F/29$VPK>?%.[7";)5@BP29/\M<2WF]DL2MNBI`M/$T;&DQ%[' M05UXY^F\3^.;?(07><<;^,U-([0E9W3^96/_:T0'7DIRLZ.D]?]G-B34+AQO M_=F,(S4:#KOK!YE_:?$.4$L#!!0````(`,!Z9D?&PO=V]R:W-H965T0/"%[LI.G*:RF; M*DH/E:(4EMUH+B]PAZTOVG0*.Z\:5IJ>P.\CB`E*4O3&ZJXT$E91-^3*0LX!RD#D4_\-G-^I@S`]?G"_A"K]>I/ MW,(]RM^B=IT7FR:DAH8/TCWC^`AS"=>!L$)IXTJJP3I4%TA"%'^?=J'C/DXW M63[#M@%L!K`%<)M&X5.B*/,'=[PL#([$3*WM>7C!W9[Y1E3!&>N.=UZH]=YS MN/9%X?=M@GR3((\$ M^7]+W(C)T[^2T%5/%9@VCHXE%0XZ#NK*NTSG'8MO\AE>%CUOX1"GIU75".O]_%D-"X\+QFS^;::0FPV%_^2#++RT_`%!+`P04```` M"`#`>F9':_W*)W^?0%[':=U M^P+,,.?,F6$H)S2OM@=PY$U);8^T=VXX,&;K'A2W-SB`]CZ3WZ>%4A(@8\%W`9#=G$K2?$5^#\;4YTB1(``FU"PS<;Q=X M`"D#D4_\<^%\3QF`V_.5_3%6Z]6?N84'E#]$XWHO-J&D@9:/TKW@]`1+";>! ML$9IXTKJT3I45P@EBK_-N]!QG^:;/%M@^X!L`60KX',2A<^)HLPOW/&J-#@1 M,[=VX.$%TT/F&U$'9ZP[WGFAUGLO55JD);L$HB7F-,=DVY@U@GGV-46VE^*4 M_07/]N'YKL(\PO,/"O]!4.P2%)&@^&^)>S'Y'TG8IJ<*3!='QY(:1QT'=>-= MI_,^/B)[#Z_*@7?PC9M.:$O.Z/S+QOZWB`Z\E.3FEI+>_Y_5D-"Z MJ=EP.%P_R/I+J]]02P,$%`````@`P'IF1[)1HBB@`0``L0,``!D```!X;"]W M;W)K&UL?5/!;MP@$/T5Q`<$+^M-HY774C95U1XJ M13FT9]8>VRC`N(#7Z=\7L-=Q6JL78(9Y;]X,0S&B?74=@"=O6AEWHIWW_9$Q M5W6@A;O#'DRX:=!JX8-I6^9Z"Z).(*T8S[)[IH4TM"R2[]F6!0Y>20//EKA! M:V%_GT'A>*([>G.\R+;ST<'*@BVX6FHP3J(A%IH3?=P=SWF,2`$_)(QN=291 M^P7Q-1K?ZA/-H@104/G((,)VA2=0*A*%Q+]FSO>4$;@^W]B_I&J#^HMP\(3J MIZQ]%\1FE-30B$'Y%QR_PES"(1)6J%Q:234XC_H&H42+MVF7)NWC=+-_F&'; M`#X#^`)XR)+P*5&2^5EX41861V*GUO8BON#NR$,CJNA,=:>[(-0%[[7%GTHH7OPK;2.')!'UXV];]! M]!"D9'<'2KKP?Q9#0>/C\5,XVVFD)L-C?_L@RR\M_P!02P,$%`````@`P'IF M1\+G2_"?`0``L0,``!D```!X;"]W;W)K&UL?5/! M;MP@$/T5Q`<$+^LTZ.VXK=4+,,.\ M-V^&H1C1OKH.P)-WK8P[TL[[_L"8JSK0PMU@#R;<-&BU\,&T+7.]!5$GD%:, M9]DGIH4TM"R2[]F6!0Y>20//EKA!:V%_G4#A>*0[.CM>9-OYZ&!EP19<+348 M)]$0"\V1/NP.ISQ&I(`?$D:W.I.H_8SX&HUO]9%F40(HJ'QD$&&[P",H%8E" MXKO<"WA-A)6J%Q: M234XCWJ&4*+%^[1+D_9QNMG/L&T`OP+X`KC/DO`I49+Y)+PH"XLCL5-K>Q%? M<'?@H1%5=*:ZTUT0ZH+W4N[RNX)=(M$UYC3%\'7,$L$"^Y*";Z4X\7_@?!N^ MWU2X3_#]'PKOMPGR38(\$>3_+7$KYO-?2=BJIQILFT;'D0H'DP9UY5VF\X&G M-_D(+XM>M/!=V%8:1\[HP\NF_C>('H*4[.:6DB[\G\50T/AXO`MG.XW49'CL MYP^R_-+R-U!+`P04````"`#`>F9'IEBZAI\!``"Q`P``&0```'AL+W=O9;=,"VEHD2??HRUR[+V2!AXM<;W6POXY M@<+A2#?TZGB23>NC@Q4YFW&5U&"<1$,LU$=ZMSF<=C$B!?R4,+C%F43M9\3G M:'ROCC2+$D!!Z2.#"-L%[D&I2!02_YXX7U-&X/)\97](U0;U9^'@'M4O6?DV MB,THJ:`6O?)/.'R#J81])"Q1N;22LG<>]15"B18OXRY-VH?QAG^98.L`/@'X M#/B<)>%CHB3SJ_"BR"T.Q(ZM[41\P2['99SF[1*(I MYC3&\&7,',$"^YR"KZ4X\0]PO@[?KBK<)OCVC<)_Y-^M$NP2P>Z_):[%O%?) M%CW58)LT.HZ4V)LTJ`OO/)UW/+W):WB1=Z*!'\(VTCAR1A]>-O6_1O00I&0W M>TK:\']F0T'MX_%3.-MQI$;#8W?](/,O+?X"4$L#!!0````(`,!Z9D<'>'4C M-@(``!L(```9````>&PO=V]R:W-H965TW,.6-FQI-B M$/)#-93JX).S3NW"1NM^&T6J:B@GZDGTM#,G9R$YT68IZTCUDI*3,^(LPG&< M19RT75@6;N]-EH6X:-9V]$T&ZL(YD?\.E(EA%Z+POO'>UHVV&U%91)/=J>6T M4ZWH`DG/NW"/M@>46HA#_&[IH&;SP#I_%.+#+GZ>=F%L?:",5MI2$#-BZ+-@?]J3;HRW<1BI+`!"N08.4(5M^NN/*N"&%26"0%15*`(/-$($P.BV2@ M2`80K#T1"+.!17)0)'\DR&)/!,(LY,0:%%D#!-@3@3`+@=^`(AN`P`\\A%D( MO*UNJ()B@,(//0A:B#U:J%0$4/C1!T$+X4=@N>X1?J3(_00`00L9@."Z1@E` MX><`"%I(`@27/P)J._?3``0MY0'\`B"@O/.'/(!`?AY$L\>;4UF['J6"2EPZ MUQ)GNU,?W&/W^'_!RZ(G-?U%9-UV*C@*;5J(>^C/0FAJ?(F?C"^-Z=33@M&S MMM/&PO=V]R:W-H965T+ZSQDD3J9X2$ MGP(FLYD3[_V"^.87W^M3DGH+(*&RGH&[X0K/(*4GZY9SG'+;-63.H8U\E6$SBS/Z#LS@\CSK,`SS?JN=YG&`7)=@% M@MT_)7Z^*S&2D,N:-WS"9?<(%IP5M('YZ5S3;HN)#363Q_=7,_O=EY8 M')8N7'\%Y5]02P,$%`````@`P'IF1]6)EFF]`0``>P0``!D```!X;"]W;W)K M&UL;53=;ILP%'X5BP>HB2$TBPA2TVG:+B95O=BN M'3B`5?\PVX3N[6<;0FGF&VP??S_G&!^7D])OI@>PZ%UP:4Y);^UPQ-C4/0AJ M'M0`TNVT2@MJW5)WV`P::!-(@F.2I@46E,FD*D/L15>E&BUG$EXT,J,05/\] M`U?3*=DEM\`KZWKK`[@J\C57B1DF0H._SR&08IWFGR!=:G$`6 M`ED)AS0D/AN%-+]22ZM2JPGI^6@'ZO_@[DC<0=0^&.H.>RY1XZ+7:G?(2GSU M0@OF/&/(%K,BL%-?+4C,XDS^HY,X/8MFF`5ZMG7/BKA`'A7(@T#^J<3\KL08 M9A\WV4=-]A&!XLXDAGF,FQ11DR(B<+@SB6&^W)G@S>T0H+O0!`;5:I2AY3;1 MM<^>2+A='_"J'&@'/ZGNF#3HHJR[H^$FM4I9<*FD#Z[@WKT$ZX)#:_WTTU/]`U!+`P04````"`#`>F9'%M]!-J$!``"Q`P``&0```'AL M+W=O+V"GO0_J9!H[CSIFF9[0WP.H*49%F2W##%A:9E$7W/IBQP<%)H>#;$ M#DIQ\^\($L<#3>GL>!%MYX*#E05;<+50H*U`30PT!WJ7[H^[$!$#_@@8[>I, M@O83XFLP?M4'F@0)(*%R@8'[[0SW(&4@\HG?+IP?*0-P?9[9'V.U7OV)6[A' M^5?4KO-B$TIJ:/@@W0N.3W`IX3H05BAM7$DU6(=JAE"B^/NT"QWW<;K)9]@V M(+L`L@7P,XG"IT11Y@-WO"P,CL1,K>UY>,%TG_E&5,$9ZXYW7JCUWG.9WB8% M.P>B2\QQBLG6,4L$\^Q+BFPKQ3'[!L^VX?FFPCS"\W7V_':;8+=)L(L$NT\E MIE]*W(KYJI*M>JK`M'%T+*EPT'%05]YE.N^R^"8?X671\Q9^<],*;&UL M=5/!;MP@$/T5Y`\(7NQ-TY774C95E1XJ13FD9]8>VRC`N(#7Z=\'L-=Q4_<" MS##OS9MA*$8TK[8#<.1-26V/2>=`*\C M2$G*TO26*BYT4A;1]V3*`@.3]2!N#Z?&7_'JOUZL_;)J2&A@_2/>/X"',)^T!8 MH;1Q)=5@':HK)"&*OTV[T'$?IYOL;H9M`]@,8`O@+HW"IT11YC?N>%D8'(F9 M6MOS\(*[`_.-J((SUAWOO%#KO9=R]S4KZ"40S3&G*8:M8Y8(ZMF7%&PKQ8G] M`V?;\&Q381;AV3I[_A^"?),@CP3Y7R7FGTK%GTO(6?W+1"6W)&YU\V]K]!=."EI#?[A'3^_RR&A,:%XQ=_ M-M-(38;#_OI!EE]:O@-02P,$%`````@`P'IF1W8I:OBQ`0``%@0``!D```!X M;"]W;W)K&UL;53-;N,@$'X5Y``''W;=?P([K)EP,#//]###.!M0?I@&PY%/)UAR2QMIN M3ZDI&E#!E`2E*6IO=4<=$F>19B;SK/L+=2M/"F MB>F5XOK?$20.AV257`+OHFZL#]`\HS.N%`I:([`E&JI#\K3:'[<^(R3\%C"8 MQ9QX[R?$#[]X*0])ZBV`A,)Z!NZ&,SR#E)[("?^=.+\D/7`YO[#_#-4Z]R=N MX!GE'U':QIE-$U)"Q7MIWW'X!5,)P6&!TH0O*7IC45T@"5'\;>K MQ_N,GCW1E',<<]@R9\Z@CGV68#&)([N!LSA\'76X#O#U4GVSC1-LH@2;0+#Y M5N+#58FQG%U<9!L5V48('J]$;G-<;UR)T,7%*=!U>)^&%-BWH1L6T;D%GEBX M^*_T/.MX#:]&M>D\T)"9?WTPF9'Q>V8FJ`!``"Q`P``&0```'AL+W=O5=2VV/2.=+.FZ:EMC?`ZPA2DK(T_485%SHIB^A[,66!@Y-"PXLA=E"*FW\G MD#@>DUTR.UY%V[G@H&5!%UPM%&@K4!,#S3&YWQU.>8B(`;\%C'9U)D'[&?$M M&$_U,4F#!)!0N<#`_7:!!Y`R$/G$?Z^%D8'(F96MOS\(*[`_.-J((SUAWOO%#KO9>2I;N"7@+1->8T MQ;!5S"V">O8E!=M*<6)?X&P;GFTJS"(\6V?/?VP3Y)L$>23(/Y3(/I6X%9-] M2D)7/55@VC@ZEE0XZ#BH*^\RG?-_6\0'7@I MZ=T^(9W_/XLAH7'A^-V?S312D^&PGS_(\DO+_U!+`P04````"`#`>F9'7M8M M.PH#``#L"P``&0```'AL+W=OH4:D!XD(<9]]^DX`(2;OCC4#X_^ZO M7UGU49\HY=97D9?UQ#YQ?AXY3KT[T2*M7]B9EN+-@55%RL5C=73JTO";QG[D`^;_<1&DH'F=,=E MB%1DAO>3\ MG5W7M*W!EP%W+*_5K[6[U)P5-XMM%>E7<\U*=;TV;R+4VF`#:0VD,W1Y8(/; M&MR[P?NOP6L-WK,&OS7XSR(%K2%X-D/8&L)G,T2M(7HV0]P:8LW@-.NG5G^1 M\G0ZKMC5JIHM>T[ER<"C6.ROG1Q4VTF]$^M?B]'/*4'>V/F4@5K-K-&0@<8? M:I:F)L!#26)*[@I'0':D!"*=$8`B&*:80YIPJ%E`FDBK!M`,%2M3$6B2Y-L@ MZ^^#;(`@+CQK+KB^KO*[_4EW$1S``P-X*H#7#Z!OD&6C"96F5)H?8>!J6V0% MJ$@8:U.?`"HA5 MD,XS-W4!&NH&0+('@#X("$#2CL6L%?6G2#O'\U8B+YW&?PD?[##\X.N$S3-* M#!ALP`21:TP/(',),5;U032MO#5`1L('M8'?LU=,@(G6_ED7K:A/0US76%*G M][DO:'54S6)M[=BEY#)%;[1K2%]5/ZJ-S_!H@8'Q)1ZMH/$$C]9-&WI/.QV? MTR/]F5;'K*RM+>.B>5$MQH$Q3D55Z$5LTI-HO;N'G!ZXO`W%?=4TH\T#9^=; M;]TU^--_4$L#!!0````(`,!Z9D&PO=V]R:W-H M965T%K+U&[);^$WU<,V(@ M%O&K$.=V\.P9\6]2OIN7']NE3XP&48J-,A1BU:T?.=`H"SX,48]Y[C`PP"SH/60U MA=P0@19P50&8BF>8]@"C'J:0$6+]7Y([$0PM!;/Q[*X4"YP@1`E"2Q#>$<2C M-#!,@G<2H9U$B,H4)UB@!(NI`B"C/]YA:#)K.+PM%#?E$849A>M`PXQA8/'1-5QD$2"F-(02'ORCN4,H059&#`O&NIIBM7=7%W4CC+Y0&]R--YI0F MF60T#[AY M`%O?7!2X>0!9O1@99XN!7+L!W&&`.(PY1B+@?H#%%[+%_0#(\C3-%@,Y%D'` M30.(:9ACQ@?<#)#.SY;A9F#(NC/)%@6-)^!@L/>L1+.WF_C6V\A3K`[Z MB'-]*<5.F<=8/S?=IK][4?)X.<-<#U+Y/U!+`P04````"`#`>F9'(Z-V?Z," M``""#```&0```'AL+W=O[?SW8"@W)<)2_$=LX]]YXX)[[, M3ZI]TSLI3?1>5XU>Q#MC]K,DT:N=K(5^4'O9V#L;U=;"V&F[3?2^E6+M@^HJ MH6DZ26I1-O%R[M>>V^5<'4Q5-O*YC?2AKD7[]U%6ZK2(27Q>>"FW.^,6DN4\ MN<2MRUHVNE1-U,K-(OY"9H^,.8A'_"KE25^-(U?\JU)O;O)CO8A35X.LY,HX M"F$O1_DDJ\HQVM+_.5W@]?C,_LW+M>6_"BV?5/6[7)N=K3:-H[7_9PO5=O6XI&PR3XZ.J,<\=AAZ M@\DOF,3R7Y)0F(1Z`G9#,,4$#!(P3\!O"(H/57:8W&,:CRF*XDK+31H.T_#[ M-#S%!!DDR(8+G4""R0"A'2:[$DK3;$)QFARFR8%0@@FFD&`Z7&@!"8H!0HL[ MH7G!._4PO-@P!CN&A5P2;@>0C]&([D.D0O0`4^(P2;!H"7,.SP)<8 M^X&FP\52[`=*!HCM0?DP\]+`N0%LPP-?=(K]0-D(O=@/%!P+]WH!*'1&8L]0 MX!D>HL!FH),18K$9*#@:[L7FHS87>X8"._!0L=@/M!C16&`_,'`^W+<6`!38 M&88]PX!G>!&@P&9@8[JH0!LUJ(\"H(]BDZOV&UL MC5;;)6LI^R-EX0(YZ.I6[YV2R&Z%0"\*$F#^1/M2"O?G"AKL)!;=@:\ M8P0?-:FI`?2\"#2X:MT\T[$7EF?T(NJJ)2_,X9>FP>SOAM2T7[N^>PV\5N=2 MJ`#(,S#QCE5#6E[1UF'DM':?_=7>]Q1$(WY5I.>SM:.*/U#ZIC8_CFO74S60 MFA1"26#Y>"=;4M=*26;^,XK>4?,"=;6O^NCJ*4U7JN188DE6PP_,059>T*6G@*[0&05B!YW-;8*Q`^X.F#0K$\_3,V/ M;`F*4&*XNL0$,31=M61+/63O*;'VE%AZ"NT"J54@?=Q5-4EMH\%[P-<1-/^` MDA09OEI`,#%_OC:09\ZBO2V?'QM]@=GT:P@[ZWN'.P6]M$)Y,HM.=]LS5-/3 MB&_\U=:WQ'?J+M33]B:?9QT^DY^8G:N6.PF9'6+.[!`L"``!% M!@``&0```'AL+W=O]Z,S.7K37Q&!T%L4"B=NW+Z"Q!MG.WH2_8JF&_`)$SPD^&U)+010$"6AQT_EY M9N9>>)ZQJZ1-1UZX)ZYMB_F?9T+9L/=#_S[QVEQJJ2=`GH&9=VY:THF&=1XG MU=[_$NZ.B488P,^&#&+1][3W$V-O>O#]O/<#;8%04DJM@%5S(P6A5`NIC7]/ MFO^VU,1E_Z[^U:15[D]8D(+17\U9ULILX'MG4N$KE:]L^$:F"$@+EHP*\^N5 M5R%9>Z?X7HO?Q[;I3#N,*YM@HKD)T42(9D((_TN()T+\60*<"/"S!#01D$4` M8W93N0.6.,\X&SP^GG:/]4<5[I`ZFU)/FJ,P:ZIV0LW>\@BA#-RTT(1Y'C'1 M$O.(*!R(^!%R6$,22^7H4$')C`$JQQPF_$I+K:Y@)6C$FBY((GE:Q6;_H\H*22NINJ M/A^?N7$@67]_M.=_COPO4$L#!!0````(`,!Z9D=.Y;!0;`(``#$)```9```` M>&PO=V]R:W-H965TU#6%9&"3V$K!Y\]Z,/2]VVG+Q)@M*E?->L5KN MW4*I9N=Y,B]H1>03;VBMOURXJ(C20W'U9",H.=N@BGG8]S=>11>YCXK6\%LI,>%GJ#7'GLJ*U+'GM"'K9NP>T M.Z+$0"SB=TE;.7IW3/(GSM_,X.=Y[_HF!\IHK@P%T8\[?::,&2:M_+/W!_MW6ZY._T0D?>;L3WE6A<[6=YTSO9`;4Z^\_4'[&B)#F',F[:^3WZ3B MU2/$=2KRWCW+VC[;[LO6[\/@`-P'X"$`=XEW0C;-;T21+!6\=42WM@TQ6XAV M6"]$;B9MW?:;3E3JV7N&HR3U[H:HQQP[#!YAT(#P-/L@@2&)(YZ%XR"&"0(P MQ\`2!&."C0\3A"!!:`G"3P1H4F2'B2VFMI@DV28+>4:@3`3(X(E,-),)MK#& M!M38`!K!1`/`+-01@QHQH!%.-&)@N9)@`\ML09GM7"9\'P;9$T1?Z!'8=@FPWZY,.%(WJC9-@R1,(]AZ"S#?KD[G[EOY% M$.P]!)AOWB<`:*E/8(>B9$V?)+-J]+K%X43)&QUI%157>W)+)^>WVEX41K/# M[>"`[9'X`<_2AESI+R*N92V=$U?Z8+7'WX5S174V_I/>OT+?7X8!HQ=E7F/] M+KH3O1LHWCPN*,,M*?L/4$L#!!0````(`,!Z9D<12%&PO=V]R:W-H965T&8-7&U'9"]^_K"Z&4>/<%>\;G')\9&Y= M4L,.(5EWP+"\XP/T>J7E@F&E0W%"0QCTDO`^$-#NPQ_Q[I`;A`6\ M$!CE8AX8[T?.WTSPN]F'D;$`%&IE%+`>+G``2HV0WOA]TOS:TA"7\ZOZHZU6 MNS]B"0=.7TFC.FTV"H,&6GRFZIF/OV`JP3JL.97V&]1GJ3B[4L*`X0\WDMZ. MHUNYCR::GY!,A&0FQ-E_">E$2%<$Y)S9NGYBA:M2\#$0[BP&;(X\WJ6Z<[5) MVD;9-5V9U-E+E6SR$EV,T(1Y<)ADB?F..'@0Z0Q!VL#L(O&Z2"P_7?#C=.,7 M2+T"J17(OI6QJL)!"@OI'23*-^M*/$*%WTCF-9)YC*R=.$R^<%)LTR);.?$H M_<-)[G62W_#OUP>;W[1DN]W>-!XM[M*`3_`'BQ/I97#D2E]+>WE:SA5HQ>A. M2W;ZM9@#"JTRTT+/A?N!7*#X<'T.YC>I^@102P,$%`````@`P'IF1P)TS:LO M`@``=`<``!D```!X;"]W;W)K&ULE57;CILP$/T5 MQ`2F4V?"RU!MXI[*B MM2QY[0AZWKH[M#F@T$`LXE=)6SF:.\;\D?,/L_AQVKJ^\4`9S961('JXT0-E MS"CIR)^]Z".F(8[G=_5O-EUM_T@D/7#VNSRI0KOU7>=$S^3*U#MOO],^A\@( MYIQ)^^OD5ZEX=:>X3D6^NK&L[=AV)RN_I\$$W!/P0!CBP(2@)P0/@BV=USFS M>;T21;)4\-81W<=HB/GF:!/HRN5FTQ;*GNG,I-Z]93A.4N]FA'K,OL/@$08- M"$^K#R$P%&*/9W3\;X`#@`C@"`&81&#YP9B/UK!`"`J$5B`<"ZPF1>@@B874 M%I*L@R2<9`(();"1"#02S?GQQ$@T,X+]*)Z6%!!:,!*#1N(Y'R^4-`$%DN>_ MR0H46,T=!/ZD%A!FX;^Y!H.L`0$,"YC;`&H@__E$T4(/HB=2!4$+78+`1MPA M#$B$"Q)PIZ'_:#4$]QH">F2>+02*)G&\T25747&QE[]TF!VV ME^0#GJ4-N="?1%S*6CI'KO15:R_$,^>*:B_^B^ZE0C^!PX+1LS+31,]%]RAT M"\6;^QLW/+397U!+`P04````"`#`>F9'3Q,:\,H"``!S"P``&0```'AL+W=O MS$QLAVD/G4%OH^]FI2-FV=Z[KG-,W82 M5=G0Y];AI[HF[=\EK=AYX2+W,O%2[@]"37AYYEUYV[*F#2]9X[1TMW`?T;Q` M6$$TXE=)SWSP[BCSKXR]J<&/[<+UE0=:T8U0$D0^WNF*5I52DI'_]**WF(HX M?+^H%WJYTOXKX73%JM_E5ARD6]]UMG1'3I5X8>?OM%]#K`0WK.+ZU]F(Z-?GHGF6CG^?N2YSV-)@0](3@2KC&@0EA3PAOA.B_A*@G1%,CQ#TAGAH! M]P1L$+PN63K5:R)(GK7L[+3=^3@2=0S1',O-W*A)O7?ZFTPVE[/O>8#3S'M7 M0CUFV6&"`0:C>\C:AMP0GC1P=1%`+I:!10_N`ZQL!#8@ZT]%GCX7*0"1$%Y) M".8SU/QPR$<8%HA`@4@+1'<;,C,VI,,D&M/TF"`QTC$%5-@@A,,8]AN#?F/; M;^(;?CM,/(CR+9E%AM\IH`(`(7]D@S#H%P-^C=.\Q%84E(:AX7<*J`!`<1C` M?A/0;P+X-0[M,K&B!!@;%RBQ=CHV%F2KX)F1F2=;9>QZI.!J4F`U(P(S4&`V M_7ZI?Q2HXOD3;E@/NM\X;!Z!2:@"0.$T'?$\4J41D+=H1`(LL8\H^$+FX-J& MPBF9"ZW5IK&5N`F@`@`E>.3N(+B8(J":)B/E#<'U#<5?R!M<MO=@*H`$`H-1?M#1J$FK9[W^\7'0#48QOP2S5<(F%^C M^5/7#=[D\^Q(]O0G:?=EPYU7)F1;HYN/'6."2N_^@\SV07;`UT%%=T*])O*] M[7K";B#8\=+B7OOL_!]02P,$%`````@`P'IF1QI2[`;M`@``OPL``!D```!X M;"]W;W)K&ULE5;;;J,P$/T5Q`<4QEP3$:0F:;3[ ML%+5A]UGFC@)*N`L=IKNWZ]M""'V4+5]*,:<,^>,+Y/)+JQ]XT=*A?-15PU? MN$R\W/T!I`"ED2D46D(P+837%4`*2VK4 M_378E06FMPBO&X!L]'HIH58WX)\Q4@\VN8/W6=Y2U\ MGIV*`_U5M(>RX*GH7JAA(L=MUU]V+X*= MKNWRT+/G_P%02P,$%`````@`P'IF1\[%@J`U`@``U@8``!D```!X;"]W;W)K M&UL=95=DYL@%(;_BN-](^)WQCB3;*?37G1F9R_: M:V)(=%;$!;)N_WT!C>OJ\48!SWF?%Y!#WG/Q*BM*E?/!FE8>W$JI;N]YLJPH M(W+'.]KJ+U[`0E%YO$&@\C%'N,U*U;Y';L610YOZNF;NFS<.2= M,2+^G6C#^X/KNX^!E_I6*3/@%;DWY5UJ1EM9\]81]'IPC_[^Y&,38B/^U+27 ML[9CS)\Y?S6=7Y>#BXP'VM!2&0FB7^_TB3:-4=+DMU'TDVD2Y^V'^@\[76W_ M3"1]XLW?^J(J[1:YSH5>R;U1+[S_2<\2\79(\5U&/D8WG5K MW_WP)?''-#@!CPEX2@B0-3Z`K,WO1)$B%[QWQ+"V'3%;Z.^Q7HC2#-IYVV_: MJ-2C[P5.L]Q[-T)CS&F(P;,8?XKPM/J$P!#BA%?I.$.P0`!Z#*Q`\$5@PT$( M"H16(/PB@!>3'&(B&]/:F"1*(K1A-`(Y$<`)%IQHQ?F&@R#,,A@4@Z`8`(4+ M4+P&!0AM32@!.0G`B1:<9,4)LQ"AC0U*04X*['`,"V2@0`88319&AQAS1B>G M\2X-88P)@XX+`D#I\KP,03Z>K\DN2#9(&P?3!TBKD^FO2>D.;\T)/)]''Z]( MP>PW&4D86KUHN4G>K.XP*FZVO$JGY/?65O/9Z%3"C[:">Y_A1=Z1&_U-Q*UN MI7/F2E<_6Z.NG"NJW:"=_MTJ?E6DFNBV&LCMT%.\>M\ATE17_`5!+ M`P04````"`#`>F9'+4M*'T@#``#O#@``&0```'AL+W=OR9VTFD?.I/)0_M,;-EF`L@%.4[_ MOD)@&TNKC.L'`^+LGM6BL]+F)]&^=WO.I?=95TTW]_=2'F9!T*WWO"ZZ!W'@ MC7JS%6U=2/78[H+NT/)BHXWJ*@!"XJ`NRL9?Y'KLI5WDXBBKLN$OK=<=Z[IH M_RYY)4YSG_KG@==RMY?]0+#(@XO=IJQYTY6B\5J^G?N/=/;,-$0C?I7\U$WN MO3[X-R'>^XR=U&HRP=?\:KJ/2GF/Z/3*V=O.+T_>_^FIZO" M?RLZOA+5[W(C]RI:XGL;OBV.E7P5I^]\G$/4.UR+JM/_WOK825&?37RO+CZ' M:]GHZVEXDV2C&6X`HP%<#"X\N`$;#=B]!N%H$%X-PB\-HM$@,@R"8>XZ.WSN0]&O*CJ+U+=9]X/Z4^AW*G>=&OU8,$+SX*-W-&*6`P8F&"#1 M+69E8ZY>`A7!)0S`PEB"9SBP*BQ=)=9^7AXIO97^;J/MVZ,>&!RD.Y_;RTN,N_@%02P,$%``` M``@`P'IF1U!LUU@/`P``!`T``!D```!X;"]W;W)K&ULE5=-CYLP$/TKB'O!'WR8%4':I*K:0Z75'MHSFS@)6L`I.)OMOZ\Q#@MX M6-$<`I@W\YZ'\<.D-]&\MF?.I?->E76[<<]27AY\O]V?>96WGKCP6MTYBJ;* MI;IL3GY[:7A^T$%5Z1.$(K_*B]K-4CWVU&2IN,JRJ/E3X[37JLJ;OUM>BMO& MQ>Y]X+DXG64WX&>I/\0=BHK7;2%JI^''C?N('W8D["`:\:O@MW9T[G3B7X1X M[2Y^'#8NZC3PDN]EER)7AS>^XV7995+,?TS2#\XN<'Q^S_Y-3U?)?\E;OA/E M[^(@STHM(K8V0@2QP/&5PH&&022L25V@AD%@*`P M`P4G2G4\G4PT@A,$8()`)P@F">)9I7I,J#%U7RD6QFRI%B%(%%I$A,T*O@TM MHB2@<8A@G@CDB>P)H6C&$UD\7S!2/Y@G!GEBH'!LQA/;/"P.*(%Y&,C#`)YD MQL,L'A*C`">SEM_9N$\?9`(*2FQ!%,T$)1818S0($IBG2+'@ M`WA%>QM01S?(C;U%)G"I/V*RHK\-")-QAWN8+3#!2Q[3%9UG0!.FT$L6.@_# MWH`A,]@V#8PX!MVVT+FLO3* MA5V#H!5M`8(6EB&!K85@H`\6#([`GD%LS[#=R8#BL;FS>.$9$]@RR!K+`$!D MJ?2P7Y`U?F%`X_E$\[8&,)_,&;8'LL8>#&A,E,S;P!]M.BO>G/1FO'7VXEKK MO?]H=-CP/Q*]:?V`9^DE/_&?>7,JZM9Y$5)M??4&]2B$Y$H*\I24L_HD&2Y* M?I3=::S.FWZ3WE](<;E_&PO=V]R:W-H965T[$^>+MO=[6[WO+,^Q=Q M8$P&;VW3B65XD/)X'T5B1./:,;HU0VT0XCA=1 M2^LNK$IS]]A7)3_)IN[88Q^(4]O2_N^*-?R\#%%XN7BJ]P>I+Z*JC$:Y;=VR M3M2\"WJV6X8/Z'Z-#<0@?M7L+";[0!O_S/F+/OS8+L-8V\`:MI%:!57+*UNS MIM&:%/,?J_2=4PM.]Q?MWXR[ROQG*MB:-[_KK3PH:^,PV+(=/37RB9^_,^M# MJA5N>"/,;[`Y"XTCUFZ-[HB*WT9*)'$9O6I%%K,:,'B" M0=>(M8_`639B(F7!:`:&S%AA7X%#`2`(S$!`1XF1)U>.(EA!`BI(C()DJ@!G M3J0&3&HPW1`I%.=)@A+WV<1^_80%:5/@6$;>N MBD\MNB+2[0BJX-C/;#*3V6BF":`;+Z0!E$W>."U2 ME,_\7\)5C^,;\MN"IAT&D[1P'G)M8;<:!/<0#/20Q*UL"\IF#1J8HLGTTK)^ M;Z8Z$6SXJ3-#Y.1VG!P?L)E^WN%5>:1[]I/V^[H3P3.7:H8RD\Z.<\F4-?&= M"LQ!S;;CH6$[J;>9VO?#M#<<)#]>AM=Q@J[^`5!+`P04````"`#`>F9'M^>7 M=,@!``!#!```&0```'AL+W=OL'U]SKF;+_DH MU;MN`0SZY$SH0]0:T^\QUF4+G.J-[$'8FUHJ3HT]J@;K7@&M/(DS3.+X`7/: MB:C(O>U5%;D<#.L$O"JD!\ZI^G<$)L=#E$17PUO7M,89<)'CF5=U'(3NI$`* MZD/TE.Q/F4-XP)\.1KW8(Q?[6?,*6P=8*E9-I_43EH M(_F5$B%./\/:";^.X6873[1U`ID(9";,?M8)Z41(;P1?.APB\WD]4T.+7,D1 MJ="+GKJ6)_O45JYT1E\H?V>GRP"SQW6!;%4@\P+9ERH\WE4A8))0*A'RV&SO M,ED!Q9L?=Z'@17,XJ,8_6HU*.0CCRK"PSG/Q1%QS[^Q'.R_A>=]DBKRG#?RF MJNF$1F=I[-/Q#:ZE-&!CC#?;"+5VHN<#@]JX[<[N57CDX6!D?QW9^;]1_`=0 M2P,$%`````@`P'IF1W'A.&UL=5/;CILP$/T5Q`>LP<"2C0A2L]6J?:BTVH?VV8$A6.L+:SMA M^_?UA5"4NB_8,SYSSIDQ;F:IWO4(8))/SH0^I*,QTQXAW8W`B7Z0$PA[,DC% MB;&A.B,]*2"]+^(,X2Q[1)Q0D;:-S[VJMI$7PZB`5Y7H"^=$_3X"D_,AS=-; MXHV>1^,2J&W06M=3#D)3*1(%PR']DN^/E4-XP$\*L][L$^?]).6["[[WAS1S M%H!!9QP#L! M7)AYD_,W6%KP#CO)M/\FW44;R6\E:<+)9UBI\.L<3G;94A8OP$L!7@MP,!Z$ MO,VOQ)"V47).5!CM1-P-YGML!]&YI._;GUFCVF:O;5$^->CJB!;,,6#P!H.+ M>L4@R[^*X*@(]@3%AB`O=W&"(DI0>(+*$XC@(,NK.YL!5&]`19Z5<9DR*E/& M9![O9"*@7?T?F2HJ4WF&&UL M=53+;IPP%/T5BP^(`4.F&C%(F:FB=E$IRJ)=>^#R4/P@MAG2OZ]M&$)F7!;8 MOC[GGG/]*B:IWG0'8-`'9T(?HLZ888^QKCK@5#_(`82=::3BU-BA:K$>%-#: MDSC#:1P_8DY[$96%C[VHLI"C8;V`%X7TR#E5?X_`Y'2(DN@:>.W;SK@`+@N\ M\NJ>@]"]%$A!DOTI=P@/^-W#I#=]Y+R?I7QS@Y_U(8J=!6!0&9>!VN8" M)V#,);+"[TO.3TE'W/:OV9]]M=;]F6HX2?:GKTUGS<81JJ&A(S.O M8269]G]4C=I(?J5$B-./N>V%;Z=Y)LL66IB0+H1T):PZ80)9".2&@&=GOJ[O MU-"R4')":MZ+@;HM3_;$KESE@GZA_)RM3-OHI21Y7."+2[1@CC,FW6#2./^* M.=UCDA6!K8/51AJR<4P#$M]N)`*8L`0)5DH\G6P=YO_QF`439#Y!MM5/LINE MFC$[CQ$SAI#8?6&E/*B4WRF1C=5Y-?([I=TN>[P7PIN3P$&U_H9H5,E1^/NX MB:Z7\"GU)^D37A8#;>$756TO-#I+8\^C/S6-E`:LG?C!^NGL,[$.&=7>V MK^:;,P^,'*[OP/H8E?\`4$L#!!0````(`,!Z9D<2&,".\`$``"X%```9```` M>&PO=V]R:W-H965T.R!RSKGW7(1\Y.)=M@#*^V"TET>_ M56HX("3+%AB13WR`7N_47#"B]%(T2`X"2&5)C"(Q5U'D_*IH MU\.K\.25,2)^GX#R\>B'_CWPUC6M,@%4Y&CA51V#7G:\]P341_\E/)PS@["` M'QV,KC!&2@U0CKQKUGSD=(0U_.[^A?K M5E=_(1+.G/[L*M7J8@/?JZ`F5ZK>^/@59@N)$2PYE?;KE5>I.+M3?(^1CVGL M>CN.TTX2S30W`<\$O!"6/&Y"-!.B!R&V3J?*K*_/1)$B%WSTQ'06`S%''AXB MW;G2!&VC[)YV)G7T5D0)SM'-",V8TX3!*TRX()!67U)@5XH3WM$W"HOYE(;/&R=[4!0$__"2.$M) M=J5@'+L%4J=`^O_-R)P"V;X92;QIQH1)UCZ?XPR'P2816OV'#$1C[Z?T2G[M ME3GQ571Y`EZP^8\W\9-^&J:;_)`I\H$T\)V(INNE=^%*WQ+[+]><*]!E!D^Z MPE8_7LN"0JW,---S,=WG::'X<'^=EB>R^`-02P,$%`````@`P'IF1Z%S57A? M,@``8/(``!0```!X;"]S:&%R9613=')I;F=S+GAM;.U]:6\CQ[7HYZM?43#F MP1+0XHBD%M+/,<#1,J-86T2-#=_@?6B11:IMLIOI11H%]U\DN/D__F7O;%5= MO9&49@PX#I&,+)&UGCIU]G/JVR1)U:?Y+$S^]-5#FBZ^>?LV&3WHN9^THH4. MX9M)%,_]%/Z,IV^31:S]WL[1V^G?M!^)7*PN!OF3Z.LC#]TU?= M@X.OOOLV";[[-OWN)!IEO?5#^\GJ4PI?M^B_M>MQ%_/4B M"+4Z3_4\^7_E#K+F6ST-DC3VH>>5/]?E5AWVVZ8 MZBR8Z5@=0[]I%%?F&8Q&&KZ';\?QRFT>@73PWIT-1UEB:I'XZ# M<-H(Z+OG167![;W=OU06`JW'U.-LYE>&F_BSI#*,G>-&QT$T;H2/09>M__JO MI3@AL);1SN#C"E[^I;NJ-YU4;=_C"`X[3`#0[_R9'XXT@!%N4@*7X./P1&V_ MV5%O5!"JNXN$'8UILE#X`ZHYD9W[MSNZB%*"^ M?/VU82>Q`L3,]/]5!WO>WA[]$Q:A M_"P%I`K^KL>>ZGJ'<"[F"UC2@?M!D"0(%T*AG$1Y"KY;`"B"1SVK$EPF<.YZ M]O;VVX>'A^ZJVLN7M7_D]?:.O&Z_1Y-WN]X1=&CW>E]J97C&]UJ&`4*P?^"U M#[H-3'3@X+5J)=N MJ-A[Y6YJF]=OI;;IFOLHW+^&:Y>CSS"%@V>R":SD>H%R%AS^^AR_N[887)4' M5J^B&9UO]:,.L[JM)<("FGB2#!].&UO<@LS@QR,61\8PT2RBRU)/$$8K9[R( MDD1-XFBN(KNURJJ(^C&]4]LR4@7ESD.05T!4:2",5R`MX&1-GZ/@R)*Q!X0C M"4:T[)-@EJ75L_M1!],'^'QW\`B+GFHK8%>66O4:[LK2/HT,`VT@9[/H:7U&X70Y0U$C M9XL#U-KJU?OQSYFQ>X#8"+)_!`HSZ.FAP`(_Q=_))I/A.I$WV)%].W*%H9PL M426.'WQ0S1," MS!69UW+KU'MTOY7P"NS>UX?761#" M+5@.+U!%1UJ/128&(86N)UT>6.S()0]KLX'/&;.!J*\_)%&K1G`"]!\#E&7N MG]7$@J<9I-@1."RC%$D),`AZ)^B7TV;+J#6AEAN"@*ZG01@*>63S\0MZH]FZ ML=\P6RQF+**&4;A+6UYGF^]/KTYO!Q?J^O;]X.K\OP=WY]=7:G!UHMY]')Y? MG0Z'+^ZP1!2^NKX[5>V66CU&LZ-$;2,._/H/E,K\\-G[]9_PQY/F_V8)_`>X MRZ__B++XUW_N`*XH7XUF08C:S"ZH2J!!W0?1`CC#W!_IC+0<$LYA+&!,([IU M,#=.XBB=8LZ)I!6L9DRZX'=PLH1'])L'L6[03@) M9JD0X]GS?/$0C9Y3E$#NSB]V//7T$*#Z%6MUQ_/!1F(8=# MC!WWE<*M28VZ-->I#X`'2,.OP)RCN=\"!@J#GE_0X-`C9`PEJ5ET>)\4#_U) M/0:/$7U([6#-=$3W/@I5(8"&`,E+04A-4%_&#T'^I7494.&4@C1`OP#.<0"W MT9_-GDD=BQ<1>[>`6VC>QLQ_(L*-O^,.B.)B36H^=`P!0PERQ[`B M.-]0!FL?>/F`(V+=:!J.5>C/R:+_7@-:P>F_,]C-U\4CT`$;@V]@OKB&CR%M@(1"6N@`KC_<0EID M@$:@8.YL*G!`@"M;9#$R*L)*'"Y&GA_+MG$(6"H($<0.0G4&?14Z/*GOK9ZB M$HE##7>_;ZD!;06:SIX]'.Q9C4$FC,@$-2C+`8W=]H/C,--)'7+SO2,';@#.`A;0^4$TT MK(@H+72_B4BO/K#I:`-UGY)W;BX52`N@=B1_GR#9!97E1PG?Z MPNYH$26!!2J?9I+-&']S>V(+#HX_!OD0KK:+*`OBVPF1/#PYLXR`"!!1=Z0- M,K,9GNW(T7WJ!Z&H3@#U#``V83_RL_9C)F[WHOI0W$41$6B9(,W(_1&;`9'! M`DG'F3:`MNJ;UV^ MAXEGT(,N./89(GKDCJ'33TPLR6X*DB."0R2(X>DQB@B1);&'3%8(FDD].N.Y M9J`KW^,)^;10P-6?LW!$@)95@,+)=[L%@@S'0=3CUI_EF M76F#D0"8-DDH2<[7F/L3$Q`"0*0/*62"!T*`&F#+9\`*ON+,9I]AD6R^ M%[,X\(.J;)1SAA_=QZWNJK=;O7@ MQUZK#9C>;^W#SZ/6@3K)H4@CH>8]8MDGB\G8#(+@`A0L`D%.G`R)?.*-B6I# M:Y\C-R!]"O4&>@`,A\4O_.W@Y/!CCU_39ZD,0NREH1=^6*A/F99_SP$9$PSN$W; M5\?G.R2CY5H*F3=XQ+$3-U,04(W$1/ARKV6%I)DF%$"`G1XL5GA`I9 M3LSO^=@!ISTB8DLI:B))JCK[(K@YXFO7S._*>F1U['L=B9/HM>#'80\0_]#& M3ARTC@Y4M]/JJ$ZW58FK&7Z\O!S<_J2NS]3P_/W5^=GY\>#J3@V.CZ\_7MV= M7[U7-[>#X[OSX].*&ON"KJL4VDY+O6"TK48-OZ"AD`2$3AFZ%D!P9\1("D%2 M+-2&5I,!*8=,5"0M]??4V'].B+(B[7M"[6DA]JBQR!7E*"\6)$9^'!,98[J0 M"#/+654IW(&$P*;`,2*FY(@8(XK@#;6RV@+N\:=@3D(E:VP3Z[9H;3FA8>?. MKN\*@D&]'0Y7S.)<32292HHB`BX0C:[QF)>8KX&^SHI..3&3`J762;$K'@=K M'6M$TZAM'&*'`8[VO3EUF!3<-D2;EZX_0`$.=T_2X;VA"W_+(AQ-#*#`!4>: M,"$F4--`P1R&1>D44#L34;W`9PT]Q86,]7U:F!;Q`.8>2;0HF1U(&C429Z[V@6]QQ4\2=0#8QU$'849\Q+&X M5L)AK(C/BHX'W`%E`OPF"XT#4GH5G$.N#;=E`AM*_B/V4F7W/XND8TWBL2YH M#?<$B\KRERS:B*%P!)HU:QR[94(H%+!TM-@F:X"3[!8Y2(&\@4QK(BX+QF]Q MN'\6N!>SC*V(>6,_=VX7^S&K)\TE-Y6X@^&U`&%GC)M&(K4`^@$LOS(0RAC4 MV406YEB.1K\D`UK`6V0T;ZF;AI$0D(PAKO+)<&6R01Q+;LAD@@=/QLTT,*L$ M21Z;@)8R(F,)+&0LI^8<@STWKQ[]UL8M,_8+L,LW]BW8PY2R`L9PST%Y2)>9 MLSQ!8Z(HSH9(/=0"A/R);D^IX1WO[7KM_H(Z\3A?^M0]5V^OM'Y%PM]_?]S":M^WM]7L8 M`0O*CM<^ZGC[G4/H*LVV*)3A!^*)EX1BHHI_)"G\;#!\IP;#8]7KP(J;VG)0 M5#("$&9X2(-:CV>3&"!*4+V)`W5Z9H/$B9@'DW>+;,BH!^!Q_`P:TUS"TPO: M"5OM`.L3=ODA(^2E5V4B]2$`E`,9CE1S&CN1N.T9ZK`L=8B],=?J!+E1TWI> M-C]*_&8RUPX&6E>]BYCYJ(\BQ0R]C]^H"]IO^]=_G?.0^'T6&MG`,Y*)B"2! M&/ZUB"HLFX#<&[+QPV>Z4?T-/@(FZ2RX07$B`^EF,)/-G_M<]1GU86;;A+-*'.,JF M#T!58T)H:U>3_<+9^_4843`TCK.X8,K-!=VODX(Z.PLF^C6'A"V2Q!Z2@)'I M@?$FJ?L(E?.B\U`M?"#B9(9BCQRB;1!C?@:*F@:O3(0,L1ZV)I#`DI_NW*5P M2\\^O]#,EL6CRJ(Q7-]Y-$9*PLS<.28!N<$*/GQ";;@8#_BM>@[T;)QXN8X( M=VZ,E.$^CG[1\=LQB.@`'L(B_#3`QA1/E#BY.Q0#A6XI.EZQD[L7B@?X$ M@CUE&Q0!9"YD8;PH9&$;!^"-LR\U808?!Y/GW/)O]2U7@W3C!9#X+SFB?`6T M\%@_!OH)$5^C"8QH/MK4H_AKHTH[)LJUQJ7O`Y1R8J+S4S^V$B^(4D`HT>A/"8+YH$1NT"8[TH8*=7_]U\?0P3_#E\SM2[*%8-D] M6D32E$W'860PU;=<+G0N+7K?`UBJXXRK4;3YQCNTR!@(F)>(M\IQ)<%QWF,8 MN-'?*#(&YS1Z-QT:D!FZGR1]BTG5G%(#"6S@=\=B$^(SA?L]!?876O=BD*!' M',E`F!I+38X"%$F!V;>Y!ZNN0RX)X%]$%PBI76]##9T`7`'&)''9;KO2& MW%'=6O<=>YIS%[(,)52M+(-1Y]SW1[RU(GS))E)$'CP,IS;<`@!C:+PZ*UJ(J5Z`_V\ M@\,._+(K__B#K6/+6,H6F5UUU/>Z1_OVERW.BW#&D@9OX'_]OM?O'FY]Y,BK M4\%?MJVQ![V&;A3<@'B/4>Y!=/VRSG7Q4R?.16/CT"^YH4P,=Z"#SHW207>= ME9_\[B`6B0T3U>-ZH9_5+*,;L-(M>8MI8Q^>92RWON@K=K4#ZRVN+D=<3H6D M%>,B*UY_MJB0P)N1!YQ]PR,B*>,`F:E1H5'\M5!JJ:&#W3GP;-!`?F8H-N5* M?QD\0JQU(3ZMK8H3G_W727UHV#OX\VB^`]8,^6` M\4+@.M-D$TN.P5'`:Z)G+6O%\+?\$U@DQ\.Q3R/V`S98N(J!S_8'^BWD7P'Q'Z#+7*6=D3?ADXM-1$M`F^LBT"H84:+Z`($D]CD;0&$(-V+]UX MY03*@3A+P"`[^)S=\ZH*)UIG)K<:%E2D\^`*@/18<>T2_?"27$KK$>B-$O1B#)[8BV@^?K1L4!71A*_ M.4&@O(X:8F.Q>YEOJ0;':A@;G83$$28NP0"Z*7PKQR.!J]R4T*Z+NTH$FF-% M<;5<;6)UK'4`Z5A9-R]%#'Y=@G\1?6!6U[M"FI%Z!RK'+[O#$6CV>(@+.1H6 MR4GD-1[*#%FR07>7`3JF-A2C=RUE"[G*0A1P?2-` MHT?%H16Y602K!:1DJS7"'TWA.88@"SRV):+H)]9Q=%$DXNOF`'VO$O&?YMEL M19)C(]QY6@E5P_"\<3!FT7L%&-C_M>`H,3^QH6`>*-`SDR``P@2&ZMA0^@"^ M24%A3#S+*V;6E4Z6%9]HRU,4_T(R"`/!-5%+J*EQ"OJB/^`,O!R2YU&(R69$ M5T!6T!RJ`2=6X8UL[$I$\/+3S'+%QI@OL\Z$I8R_93YH1FC78@D#E%P@+F%J M,M+/Z@Q7AD"[OBGKPG.6Q]CD#H>``C`'*1%NST5'5%II)!,(ARNO#S`I,7!@ M#RG%AE`W"<0E9AJ1Y!3^0@&#M?8!K\S-"D-0[@#S1LW!@4'((OTLF".8S=QL M,"%7`<_GY!)(Q)<<>5%9#22XC&Q$^+78NRM+0H2UW1#<$0:'`8@\D>\E.AUD M[`#CM!THP^H!Q$FCA[$X6T-(CT!"!,"@D!H_"3[19^3P+9M&,,H$/D]2<:G" M7=!PVRFPRJR21#RQ(-?F#[9*<4?YR@`'9\'HV9R'NV3$/A$>TN>%-L=GA2UC M?L=&I*6+*62L*=S<*ZZC@/[1_2R8"DJ+KBW2],?6L*6F*)"%EHY5/I.:3&Z4 MXZC)ML3DE.RTN1#,=RDT,3N!I;_.9:,5P;Y%=$0(-Z*`$PL&N'5PJ#H'JMT' M)C.B",I<";R)HQ!^'XD*<8X1AL_B-E];<]Q&K_&.`5QMPX\+DH&W!\./.Z!L MM6B*W;V^IZ3H"8M2QY:8D9A^G`%]GI,G`#J:/I*&5@@#,]8?D:?91R&S2[P& MQN`F&<@!P")0923COT^AL9(<43>(5:79$&LR?`@%W@\&-Z+VTWD"H1;K76ZT M$XF/#L3'D%A@(T9Y;IBSN%E:M\CZO!..C#8.=M(>[#`%VT@NX*-]1M+BIQ&F M3;@V&8YU<-RVU@_B8U%'O*FX('^61,75.`$RCL7/OX\R)HLA8C,&4Y"5SL.@ M(.-,092CJ\SAE:[QCI,M250$@2:Q844C08:1L$M"-,PN MX99BP*%,F5BG<63JIN6+@\V"'L).BX8F[OK+-@%K2<`$96;-$JIH#+@!-.58 M'!?BT7J9,P6C--M=_HPYH0ZEP\B7-4B8)5[MCE?4'G_]7RF=4OAT^RY:`*L\ M:O%$%LF"T`!H)WT1)1#Q;8Y$ MW#H/S4CFHCNRJULH*C^8/#.:3`;DIK`)KA;G&O)<]XM9$P\^<8#E/ZG)P^_WIG3K[>'4R]"C7?OCA^O9N]^[T]E*=7_UP M.KR[/+VZJ^1)O&:,50D3W99ZU;"8,.'5R.;>$D7-ZG?&2T^8WW"6V\PC\QK[Q_2E*IFRB4@-.["(OS*T?C3&,-3EV5+E"'^GGK0 MSRVG]%G^:\V9*"PMJ-[3T/PS=\%_*5\Z0JU[J+J]JC.]W_=Z?;2(=7LR&KO2 M5VCW1O;*\B0=T4S1`EG%Z&6G07IP&90_LA!T'>HM+"R]#!(K-@Z;S3=5JZO] MMMHZNW#3C=[^[Z&WKX4,Y*4C3M7;L[H]#-`ZK%3[N;V^.;V]^XG8P.E?/I[? M(.E?K]4JMK/?4@T=EZ3YD-(>D(I:9B`<\+.:C503W;I4LSSOKH^__W!]<7)Z._R:3NWNIW7:-.-# M?6UZ0A*0ZVO'NBE6QEN1V6K<]*A"LQWF*48ELE)ACS(U:S)@SY>6S6HL($A- M3O(0HG6.HKARH4EMFX';X3Q<^%>H&$@LWP0-L"Z7YZ67)%;RQ<*@1_TC#P=B M5#G`#'?Z!X<._RJY//>K\MIHED2[&46_32[8.FE&+US<*Y*):I9'$>D,7==O M)%$>A>2>)7EUYGR`*#UJB;.UV5!PORP;CU M`_?:[G2[WGZ_#_1TO]4]0J\Q`A*_Z?+5VH$+W]FOFZF&8)ID*9P,6&@M`537 M-UA*;4CL[V@1J-K;KF*@1X*;:SOS):D:PD%&,@I/;L%M-@Y6`KF:_`' MB*W`V$+']40MQ9M)E,TC8QWKY7D40@EUOK&G7T6#P72*@?6IWI*K8KZXU>AC M(UL(2$@@S06C+*@L+6M9LFF%9P"S@O M8%?O"'6-HU:WC:A"KO?>T8'!--7?IX(*LZ@!]M5"@/]\W$7!6TMG.O M![=AOT]=0<@Y;!U28$'O\]B5(5U.[J&I<6"A@RY89CG(64D>:AT2=)TUV&C4RKA6U+091^+N+3ZH/C#&F@B7M)UH8Y1Y,_-M%21J@1_\^D\Q]]I/.`YF0=*GIJS25#>2T4]DG'=BV;@2D;$'Q M/#"`N;\X?\?K\@LL*/'*;_M6IOG1!`^OI%(VS/@/2J8L)-8F5-6J76T0%GO[ ME+3[!B6YMNJV>D@C#OK>0;NW)179=UWJU*7L7C2![7"G/4.GRI2(@N-7$9<\ MN]BN`-663M<[Z'<_C\*@+9TBYX!8M0Z577CE>8GSX].KX2GQQ./KR\OS>GMJ M0[-7Z2I'+=4TG"TA9,WSA-0?M#]+'RS6-A<:>F%=HU/K31EDTRQ)%3M)VJ5Z M/UP$U7]UU:1*@:17[D[**'VT99RL,XIC8Q[U+M6I&SGK;"YA9=99W"R)P!B' MQW[FR@G80YM_+L&&7EZ+FN(*N4=S4!LGDQ6JZ@VE0H ME@H\&T"SQK_,%;GB2G:98HDDJ-K MD/!P1%'SLC6-6`"KQ> M=/P0LA4"J(LX!VM)_#FE7D5L:)S\FQ!?QXD'(7,5?[C12KCUR'T#0B6\DAU\'Z&HW*P<@JL5$^ M`L)/D(O&7,,X)W[7()LA)ZFE?H5:;[ZZX*&75BL)(]#,4G;H,E-%KS8/<&GQW:^2&;^Z'ID:CM7_]Q=?X! M;JB)N:Q9,KJ@LON$"B9@IK]<32K4J>]CH@]]1X`V@.H87_I-J59N=0[?N?"P M'BOYEXP2?LA592C&"LCO;/R$MX3QA+/X>&27EH88A9X?JK']<\BKIA1F$#]1 MLHZR%32QH?2VK":&VA"J3`#LUA37IA+/Y M`N5ZITA!>0J;BU>,K[:)35(P7D+EJ!0SVNKS^&LZ1\SU,I)M@)%B[[>Q0`)0>A&HG'M7+1VK1Q;)#_N+5F#$L$R.)HP MSV"KR,?NF!Y?O5VZ>\Z-D\&P#@)>2$X.#/D2/T42S;]K"H>Z^JS+D+B&A=2* ML?8N!0.Z1(H/F#H6(Y&I4S=XHK4I<>N7$]4:Q7?C MQVK0W)N4Q%)6+,IGQ75S\"?>Q]^.P/X&E#*O<6ORQY)LA"(DG2BV8BI'U16<+;6$P7,F=@K[<"GKR8I)Z@H@Y):DUP\JSR?0KBD@*0;: M]@%+JV#R&="J-#6J\#%Q@USW/L9G5LDEC4>2]W)AP(D\7DBT#'#K/UK.7($"*S%ZQ4 MA1%7.8LUO4W>-;+50G4RXL&&]1;+^%4)$+E>.WND*2=."'1^ZF[ZMEF5(U:6 MM:U&9"JB*>5G8D##;\)YV2DP,%"P!GX:FU(8D,G>:_OZ7"YA+%F_96/NJV$Y MG:4`*YF13"2V9J]16RS0:\HCUTLL5DNPH*?T5(G<! MO_(6JK,0)F#E*.?T`MB\,=-&BD]#^6B&U9>0-'7 ME"U$:;K^G0%:0EX]R<.G20*T!U*.I@[Y`4MF&1BFYQ(`P4&!=JX_\N<5^UTC MQI>I1\'.0*%);'!LD$).,V1N-/.?_84?FL!*4\@@_*+J(:$@0>J^U2#Y_D5)TU+$Q-1*!:"5 MX_DPG%8-Z&O.T\>\^_;>/OY!56J=Z.`#KW_4JX1F7)R^'UQ@Z.'QZ>G)^=7[ MJD^HW&!5($8/V':E#X@8XGQI]XP!X/+=0'V(9L@PX7`O+H[EM1R?K$ELO3"Q MR?3<61:DA1MEP\(86X89Y2J`B!!E,3^&[<\"N!5AX&-N42;9<1<1/MDSU42- MJHMX;"WQ67L8YZ_5NV-UT&\?M+OBE2;*B?<(SU)/W63F`NI5)J-(9"K%QY52 MM@,@>2P122Y/!^2I,RS7B`4:SW1!F/*@/74XCD!XH,*T/A?RP+"=$R>)$";' MCXZI*,XC-G1%:4]QD@G/RT&#'::H,(&9P6@?-=UFQH+:,;I":??W4GL(/W39 M/9D=)CZ1(BE$SA$*N@`LD_Q'1!J;WD:8SRIULVX`?B%57$"0DI48GZ7`FVQ% MQ,'X,4C0S(%-2F99+A@7ZL(S251A`CVU1][1/KWY4:#"E:QU+KV.Q1X!":WP M,@*LF$M),MAI84\V-51PIU6,MS`FZ8*08^IP%0:B%6NJP3+25=ACD5.;26NL MB$ZH.6;D4U52&(-M$"_ENGW` ML^F!'7?O1'S1%2>&FNM!K-<&/[5IZ8(^;"T62I9JC,I264K1) M-"L(,B-Y@KEDU/$?HY*012+1F`OR!M,(,##!`O-ZHAE,>C91YIV1N9\:C92S MXK7^A7+6]2,3MEWV$7(BJ10@@3[`F#1-;^K#L!R#E0VG;HB6:X)W/+0%-3[^5-&=J68`;RN*N;0L M-@FX-C'G*P0&85I=_^%:6*YE/_JM)ZK7XW;R_5/0S?\!33 M"YIN7FW:O-JT>;5I\VK3'_75IC(I;'B8:>-F\];=YZVKSUM'GK26_> M>MJ\];1YZVGSUM/O\*VG)<)<5//TTUKFJ\WS4;_;YZ,JYI[R'UJ/3/ZYNFJS=-5FZ>K'C9/5]F8&@+&YNFJS=-5FZ>K-D]7 M;9ZN^O=YNJJBN#35(%FWW>;)J\V35Y_SY%4E3*KP9-7R;S?O8VW>Q]*;]['^ MZ'6VZ]_'JC*HY<]EO;3]YGFMS?-:F^>U-L]K;9[7VCROM7E>:_.\UA=_7JM& M("F^MK6RP;_/[86CE9ZUZC/\S35FN] M)[4.>&]S#R?+_@.)4EROK/M_^F,U:\%X:(WNA3=GUKN?F_=??F?OO[SDI,US M%;^KH_Z/>$-CW7:VND7^M`/[\4T_O3J]/;P86ZOGT_N#K_[P$2 M(-K"NX_#\ZO3(:S_1*=^,`,!:U=]')ZH[3<(W+J]P=_OS!&7 M)VH7E(#RMY=8<&Q/7@XL?PG(T3*/*>Q7,HJC1^C)-I+J>\\-[R,O\=/5QDAR MGBNHSQQD4V[S8Q23G"R!B=5:!0PIQE@),&6=NK8I9QO5)(5C>0Q)GG"+]T'S M1V1_9&&O\]*_2,^^PLN+AJJ=AJ.'4[X,9K,Z6X01I3QZP2@MY:__]0)UP7-, M1*E4\:K/;??R'/1)!2`'7.YQJ3-8W:(S<=G$P\9P,Y3273M&N:<\(B5\[:^7 M1#TJXP^N=Q4LVYZ`3 M^:;SHHH5E#QL[>W]G_*G/TC-LBQ=B%AS6H[GYD9?.$'XET[P M=;X&*7$7EU)PEMY5&M]S8B`K&%^U]C0CI]&73U!?=JY^4P]WJ^>2V&C,F)_3 M![#K!>M><\0ON;W.9_7Y4MOK_%;;ZW[QI78_;ZFO)A--YNDEXDCSY7<\@@67 MXR"O_(_N';?=#7L.U0!]A"7_)5GN7B5-B%VYW+[&TKV$8];;N!N)PZN,TNM8 MG[TEYN?7'!,)^*+Y567X+V&%;B:L*G"^8;9-T5TH\ MN;7.EC(HFT^"O2OZ8NU"5[:J-:E_U^B<^Q*X6VNQ?@UV-N+*EUGT.OI6X]J: MS-XO'ZA!_YKB2590I,&DO.Z@H:[@U8EKF6X@EK6&]";JUV!2;Y:DUC2Q-_*[ M6OOXRL-]N1VEL]207';166U+1!VD]IXI6\;6M9?T$"6PVDE,LQ6E MJ)"C5OZV6Z_57442S;M,?AXV)&S5K6#Y2$C`;.1;Q3A0U32H$/Q`O48?=M#G MZZ%%G[7\*`YJ+55^OVM1+/$6?Q4H&B[AE7\JKM;*:<)\O+F6OL@PZ=D])%3?6 M^^I96W=`Y0N3O.BZR);K138Z.*KUI\% M9=,?W.^7'>)R^NV9_%8.R+3!Y>51^E)]ONK10,!5/1F?/F_1RR[X&C[?XM5? M/O7G22+"^-D;R"-7U-O2&UA/YDV= MWZ72/'>)NCK&1-([F(U&5_Q!=$XP9W^G?U M\K`@;(/PZ@"Y_C!,N_:>:7A8V\X-)5B.]8T^Z,]QZEV4GTMKU,^:9E_AZE[? MME%]XZ=F-Q5>*X]%)%A8L<8W^FX(XC9JS:<_\')?;F:T+WVKT\>5GDX#`*F9'\]Q+6@"``!X M;"]?&UL4$L! M`A0#%`````@`P'IF1]%CTI$^`0``:0,``!$``````````````(`!Y`<``&1O M8U!R;W!S+V-O&UL4$L!`A0#%`````@`P'IF1YEF9'9AH_T&<"``!R#```#0``````````````@`&2#P``>&PO5/NS6^P,``"D.```/``````````````"` M`202``!X;"]W;W)K8F]O:RYX;6Q02P$"%`,4````"`#`>F9'4GL!"S\"``". M!P``&```````````````@`%,%@``>&PO=V]R:W-H965T&UL M4$L!`A0#%`````@`P'IF1S>Y99U``P``>0X``!@``````````````(`!P1@` M`'AL+W=OF9'#(DX,R$#``"W#```&``````````````` M@`'/'@``>&PO=V]R:W-H965T&UL4$L!`A0#%`````@`P'IF M1^'58\`>`@``?`8``!@``````````````(`!)B(``'AL+W=OF9'&M`BQ&P#``#*#@``&```````````````@`'T)@``>&PO=V]R:W-H M965T&UL4$L!`A0#%`````@`P'IF1ZT[R^&<`P``_`\``!@` M`````````````(`!EBH``'AL+W=OF9'W70QN9\!``"Q M`P``&0``````````````@`$],```>&PO=V]R:W-H965T&UL4$L!`A0#%`````@`P'IF1]S' M,"NA`0``L0,``!D``````````````(`!ZC,``'AL+W=OF9':_W*&PO=V]R:W-H965TR4:(HH`$``+$#```9``````````````"``9&UL4$L!`A0#%`````@`P'IF1\+G2_"?`0``L0,``!D` M`````````````(`!;CD``'AL+W=OF9'IEBZAI\!``"Q`P``&0``````````````@`%$.P``>&PO M=V]R:W-H965T'4C-@(` M`!L(```9``````````````"``1H]``!X;"]W;W)K&UL4$L!`A0#%`````@`P'IF1W(.4)NN`0``%@0``!D``````````````(`! MAS\``'AL+W=OF9' MU8F6:;T!``![!```&0``````````````@`%L00``>&PO=V]R:W-H965T&UL4$L!`A0#%``` M``@`P'IF1SWBQ_&C`0``L0,``!D``````````````(`!.$4``'AL+W=O&PO=V]R:W-H965T&UL4$L!`A0#%`````@`P'IF1U[6+3L* M`P``[`L``!D``````````````(`!T4H``'AL+W=OF9'-MLE2@8#``!4#0``&0`````````````` M@`$23@``>&PO=V]R:W-H965T&UL4$L!`A0#%`````@`P'IF1Y(``CU?`@``'P@``!D````` M`````````(`!*50``'AL+W=OF9'6+.[!`L"``!%!@``&0``````````````@`&_5@``>&PO=V]R M:W-H965T&UL M4$L!`A0#%`````@`P'IF1Q%(5S?#`0``GP0``!D``````````````(`!I%L` M`'AL+W=OF9'`G3- MJR\"``!T!P``&0``````````````@`&>70``>&PO=V]R:W-H965T&UL4$L!`A0#%`````@` MP'IF1QI2[`;M`@``OPL``!D``````````````(`!!6,``'AL+W=O&PO=V]R:W-H965T&UL4$L!`A0#%`````@`P'IF1U!LUU@/`P`` M!`T``!D``````````````(`!%&P``'AL+W=OF9'*EPAR\T"``!-"P``&0``````````````@`%: M;P``>&PO=V]R:W-H965TW MYY=TR`$``$,$```9``````````````"``5YR``!X;"]W;W)K&UL4$L!`A0#%`````@`P'IF1W'A.F9'D#>#3-$!``"8!```&0``````````````@`%#=@``>&PO=V]R:W-H M965T&UL4$L! M`A0#%`````@`P'IF1Z%S57A?,@``8/(``!0``````````````(`!&UL4$L%!@`````R`#(`D`T```.M```````` ` end XML 16 R33.htm IDEA: XBRL DOCUMENT v3.3.0.814

STOCKHOLDERS' EQUITY (Narrative) (Details) - USD ($)
$ / shares in Units, $ in Thousands
1 Months Ended 9 Months Ended 12 Months Ended

Mar. 03, 2015

Dec. 22, 2014

Sep. 30, 2015

Sep. 30, 2014

Dec. 31, 2014

Class of Stock [Line Items]

Shares issued during period 9,200,000 6,000,000

Share price $ 8.00 $ 5.75

Proceeds from the issuance of common stock, net $ 68,300 $ 32,200 $ 68,308

Conversion of Stock, Shares Issued 1,000,000

Conversion of Stock, Shares Converted 2,000

Restricted Stock [Member]

Class of Stock [Line Items]

Granted 797,500

Vesting period 3 years

Nonvested, fair value $ 5,300

Share-based compensation $ 1,300

Vested, fair value $ 1,500

Unrecognized compensation cost $ 2,500

Series A Convertible Preferred Stock [Member]

Class of Stock [Line Items]

Conversion of Stock, Shares Converted 500

X

- Definition
Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 14.F)

-URI http://asc.fasb.org/extlink&oid=27013229&loc=d3e301413-122809

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (h)(1)(i)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 14

-Section F

+ Details

Name: us-gaap_AllocatedShareBasedCompensationExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_ClassOfStockLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4332-108586

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4304-108586

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4313-108586

+ Details

Name: us-gaap_ConversionOfStockSharesConverted1

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4313-108586

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4332-108586

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4304-108586

+ Details

Name: us-gaap_ConversionOfStockSharesIssued1

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Unrecognized cost of unvested share-based awards, other than options, awarded to employees as compensation.
+ References
No definition available.
+ Details

Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
The cash inflow from the additional capital contribution to the entity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 14

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3255-108585

+ Details

Name: us-gaap_ProceedsFromIssuanceOfCommonStock

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Period which an employee's right to exercise an award is no longer contingent on satisfaction of either a service condition, market condition or a performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (a)(1)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(2)(iii)(1)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (d)(2)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Price of a single share of a number of saleable stocks of a company.
+ References
No definition available.
+ Details

Name: us-gaap_SharePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Intrinsic value of equity-based compensation awards not vested. Excludes stock and unit options.
+ References
No definition available.
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Number of new stock issued during the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30

-Article 5

+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementClassOfStockAxis=lbio_SeriesConvertiblePreferredStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 17 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 18 R25.htm IDEA: XBRL DOCUMENT v3.3.0.814

SUMMARY OF SIGNIFICANT ACCOUNTING PRACTICES (Narrative) (Details) - USD ($)
$ in Millions
3 Months Ended 9 Months Ended

Sep. 30, 2014

Sep. 30, 2015

Sep. 30, 2014

Property, Plant and Equipment [Line Items]

Property and equipment, useful life 5 years

Concentration Risk [Line Items]

Stock-based compensation cost reclassified $ 0.8 $ 0.3

Equity Option [Member]

Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]

Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 2,704,195 1,098,750

Warrant [Member]

Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]

Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 7,237,216 11,172,426

Convertible Preferred Stock [Member]

Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]

Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 1,847,000 2,847,000

Restricted Stock [Member]

Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]

Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 494,001

Minimum [Member]

Property, Plant and Equipment [Line Items]

Property and equipment, useful life 2 years

Five Companies [Member] | Short-term investments [Member]

Concentration Risk [Line Items]

Concentration risk percentage 56.00%

Various Other Domestic Issuers [Member] | Short-term investments [Member]

Concentration Risk [Line Items]

Concentration risk percentage 25.00%

Foreign Issuer [Member] | Short-term investments [Member]

Concentration Risk [Line Items]

Concentration risk percentage 19.00%

X

- Definition
The amount of stock-based compensation cost that was reclassified during the period.
+ References
No definition available.
+ Details

Name: lbio_ReclassificationOfStockBasedCompensationCost

Namespace Prefix: lbio_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Antidilution

-URI http://asc.fasb.org/extlink&oid=6505113

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Diluted Earnings Per Share

-URI http://asc.fasb.org/extlink&oid=6510752

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Contingent Stock Agreement

-URI http://asc.fasb.org/extlink&oid=6508534

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

+ Details

Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_ConcentrationRiskLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-Section 50

-Paragraph 18

-URI http://asc.fasb.org/extlink&oid=51801978&loc=d3e6351-108592

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 20

-URI http://asc.fasb.org/extlink&oid=49121117&loc=d3e13531-108611

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-Section 50

-Paragraph 20

-URI http://asc.fasb.org/extlink&oid=51801978&loc=d3e6404-108592

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 21

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=49121117&loc=d3e13537-108611

+ Details

Name: us-gaap_ConcentrationRiskPercentage1

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_PropertyPlantAndEquipmentLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.
+ References
No definition available.
+ Details

Name: us-gaap_PropertyPlantAndEquipmentUsefulLife

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertiblePreferredStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RangeAxis=us-gaap_MinimumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_MajorCustomersAxis=lbio_FiveCompaniesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AssetsTotalMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_MajorCustomersAxis=lbio_VariousOtherDomesticIssuersMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_MajorCustomersAxis=lbio_ForeignIssuerMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 19 R37.htm IDEA: XBRL DOCUMENT v3.3.0.814

STOCK OPTIONS AND WARRANTS (Schedule of Status of Stock Warrants) (Details) - Warrant [Member] - USD ($)
$ / shares in Units, $ in Thousands
9 Months Ended 12 Months Ended

Sep. 30, 2015

Dec. 31, 2014

Shares Under Warrants

Outstanding, beginning balance 11,084,426

Issued

Exercised (3,847,210)

Expired

Outstanding, ending balance 7,237,216 11,084,426

Exercisable 7,237,216

Weighted Average Exercise Price

Outstanding, beginning balance $ 2.51

Exercised 2.50

Outstanding, ending balance 2.51 $ 2.51

Exercisable $ 2.51

Weighted Average Remaining Contractual Life

Outstanding 3 years 3 months 18 days 3 years 10 months 6 days

Exercisable 3 years 3 months 18 days

Aggregate Intrinsic Value

Outstanding, beginning balance $ 59,518

Outstanding, ending balance 23,593 $ 59,518

Exercisable ending balance $ 23,593

X

- References
No definition available.
+ Details

Name: lbio_AggregateIntrinsicValueAbstract1Abstract

Namespace Prefix: lbio_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: lbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract1Abstract

Namespace Prefix: lbio_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(iii)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(iii)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(iv)(4)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Gross number of share options (or share units) granted during the period.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of options outstanding, including both vested and non-vested options.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(i)-(ii)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(i)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of fully vested and expected to vest options that are exercisable.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (e)(2)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount by which the current fair value of the underlying stock exceeds the exercise price of fully vested and expected to vest options outstanding.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (e)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Weighted average price at which option holders acquired shares when converting their stock options into shares.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (e)(1)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of share options (or share units) exercised during the current period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(iv)(2)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28,29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30

-Article 5

+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_AwardTypeAxis=us-gaap_WarrantMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 20 R9.htm IDEA: XBRL DOCUMENT v3.3.0.814

GENERAL ORGANIZATION AND BUSINESS
9 Months Ended

Sep. 30, 2015

GENERAL ORGANIZATION AND BUSINESS [Abstract]

GENERAL ORGANIZATION AND BUSINESS
NOTE 1. GENERAL ORGANIZATION AND BUSINESS

Lion Biotechnologies, Inc. (the “Company,” “we,” “us” or “our”) is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel cancer immunotherapy products designed to harness the power of a patient's own immune system to eradicate cancer cells. Our lead program is an adoptive cell therapy utilizing tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients' tumors, for the treatment of metastatic melanoma. The TIL are then activated and expanded ex vivo and then infused back into the patient to fight their tumor cells. The Company was originally incorporated under the laws of the state of Nevada on September 17, 2007. Until March 2010, we were an inactive company known as Freight Management Corp. On March 15, 2010, we changed our name to Genesis Biopharma, Inc., and in 2011 we commenced our current business.

Basis of Presentation of Unaudited Condensed Financial Information

The unaudited condensed financial statements of the Company for the nine months ended September 30, 2015 and 2014 have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and pursuant to the requirements for reporting on Form 10-Q and Regulation S-K. Accordingly, they do not include all the information and footnotes required by accounting principles generally accepted in the United States of America for complete financial statements. However, such information reflects all adjustments (consisting solely of normal recurring adjustments), which are, in the opinion of management, necessary for the fair presentation of the financial position and the results of operations. Results shown for interim periods are not necessarily indicative of the results to be obtained for a full fiscal year. The balance sheet information as of December 31, 2014 was derived from the audited financial statements included in the Company's financial statements as of and for the year ended December 31, 2014 included in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission (the “SEC”) on March 16, 2015. These financial statements should be read in conjunction with that report.

Liquidity

We are currently engaged in the development of therapeutics to fight cancer, we do not have any commercial products and have not yet generated any revenues from our biopharmaceutical business. We currently do not anticipate that we will generate any revenues during 2015 from the sale or licensing of any products. In addition, we have not generated any revenues from our prior business plans.

We have not had any revenues and are still in the development stage. As shown in the accompanying condensed financial statements, we have incurred a net loss of $19.3 million for the nine months ended September 30, 2015 and used $11.8 million of cash in our operating activities during the nine months ended September 30, 2015. As of September 30, 2015, we had $110.1 million of cash, money market funds, and short term investments on hand, stockholders' equity of $109.4 million and had working capital of $107.5 million.

During 2015, we expect to further ramp up our operations, which will increase the amount of cash we will use in our operations. Our budget for 2015 includes increased spending on research and development activities, higher payroll expenses as we increase our professional staff, the costs associated with operating our new Tampa, Florida, research facility, as well as ongoing payments under the Cooperative Research and Development Agreement (CRADA) we have entered into with the National Cancer Institute (NCI). Based on the funds we had available on September 30, 2015, we believe that we have sufficient capital to fund our anticipated operating expenses for at least 24 months.

On March 3, 2015, the Company sold 9,200,000 shares of its common stock in an underwritten public offering at $8.00 per share for net proceeds of $68.3 million, after deducting expenses of the offering. On December 22, 2014, the Company sold 6,000,000 shares of its common stock in an underwritten public offering at $5.75 per share for net proceeds of $32.2 million after deducting expenses of the offering. On November 5, 2013, we completed a $23.3 million private placement of our securities to various institutional and individual accredited investors. Despite the amount of funds that we have raised, the estimated cost of completing the development of our TIL-based therapy, and of obtaining all required regulatory approvals to market those product candidates, may be substantially greater than the amount of funds we have available. Therefore, while we believe that our existing cash balances will be sufficient to fund our currently planned level of operations for at least 24 months, we will have to obtain additional funds in the future to complete our development plans. We intend to seek this additional funding through various financing sources, including possible sales of our securities, and in the longer term through strategic alliances with other pharmaceutical or biopharmaceutical companies.

X

- Definition
The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).
+ References
No definition available.
+ Details

Name: us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 21 R29.htm IDEA: XBRL DOCUMENT v3.3.0.814

CASH, MONEY MARKET FUNDS, AND SHORT-TERM INVESTMENTS (Schedule of Gross Unrealized Gains and Losses) (Details)
$ in Thousands
9 Months Ended

Sep. 30, 2015

USD ($)

Schedule of Cost-method Investments [Line Items]

Amortized Cost $ 99,897

Gross Unrealized Gains $ 38

Gross Unrealized Losses

Fair Value $ 99,936

Money Market Funds [Member]

Schedule of Cost-method Investments [Line Items]

Amortized Cost $ 20,562

Gross Unrealized Gains

Gross Unrealized Losses

Fair Value $ 20,562

Corporate Debt Securities [Member]

Schedule of Cost-method Investments [Line Items]

Amortized Cost 79,336

Gross Unrealized Gains $ 38

Gross Unrealized Losses

Fair Value $ 79,374

X

- Definition
Value of the investment at close of period. For schedules of investments that are categorized, the value would be aggregated by category. For investment in and advances to affiliates, if operations of any controlled companies are different in character from those of the company, group such affiliates within divisions and by type of activities.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 946

-SubTopic 320

-Section S99

-Paragraph 1

-Subparagraph (SX 210.12-12.Column C.3,4)

-URI http://asc.fasb.org/extlink&oid=50485924&loc=d3e611133-123010

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 946

-SubTopic 320

-Section S99

-Paragraph 4

-Subparagraph (SX 210.12-12C.Column C.7)

-URI http://asc.fasb.org/extlink&oid=50485924&loc=d3e611225-123010

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 946

-SubTopic 320

-Section S99

-Paragraph 6

-Subparagraph (SX 210.12-14.Column E.2,3)

-URI http://asc.fasb.org/extlink&oid=50485924&loc=d3e611322-123010

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 946

-SubTopic 320

-Section S99

-Paragraph 5

-Subparagraph (SX 210.12-13.Column C.6)

-URI http://asc.fasb.org/extlink&oid=50485924&loc=d3e611282-123010

+ Details

Name: us-gaap_InvestmentOwnedAtFairValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_ScheduleOfCostMethodInvestmentsLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Cost of investments in debt and equity securities and other forms of securities that provide ownership interests classified as trading.
+ References
No definition available.
+ Details

Name: us-gaap_TradingSecuritiesCost

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of unrealized holding gain before loss recognized in the income statement for investments in trading securities.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.7(c))

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 35

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=27723805&loc=d3e24584-111560

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 50

-Paragraph 9

-Subparagraph (e)

-URI http://asc.fasb.org/extlink&oid=27724398&loc=d3e27357-111563

+ Details

Name: us-gaap_TradingSecuritiesUnrealizedHoldingGain

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of unrealized holding loss before gain recognized in the income statement for investments in trading securities.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 35

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=27723805&loc=d3e24584-111560

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.7(c))

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Trading Securities

-URI http://asc.fasb.org/extlink&oid=6526789

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 50

-Paragraph 9

-Subparagraph (e)

-URI http://asc.fasb.org/extlink&oid=27724398&loc=d3e27357-111563

+ Details

Name: us-gaap_TradingSecuritiesUnrealizedHoldingLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=us-gaap_MoneyMarketFundsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=us-gaap_CorporateDebtSecuritiesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 22 R28.htm IDEA: XBRL DOCUMENT v3.3.0.814

CASH, MONEY MARKET FUNDS, AND SHORT-TERM INVESTMENTS (Schedule of Cash, Money Market Funds, and Short-Term Investments) (Details) - USD ($)
$ in Thousands

Sep. 30, 2015

Dec. 31, 2014

Sep. 30, 2014

Dec. 31, 2013

CASH, MONEY MARKET FUNDS, AND SHORT-TERM INVESTMENTS [Abstract]

Checking and savings accounts (reported as cash and cash equivalents) $ 10,210 $ 44,910 $ 17,190 $ 19,673

Money market funds 20,562

Corporate debt securities (reported as short-term investments) 79,374

Total $ 110,146 $ 45

X

- Definition
Amount of investment in debt and equity securities categorized neither as held-to-maturity nor trading.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 25

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=51813488&loc=d3e22054-111558

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 50

-Paragraph 5

-Subparagraph (aa)

-URI http://asc.fasb.org/extlink&oid=27724398&loc=d3e27232-111563

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=49167202&loc=d3e26610-111562

+ Details

Name: us-gaap_AvailableForSaleSecurities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash

-URI http://asc.fasb.org/extlink&oid=6506951

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3044-108585

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash Equivalents

-URI http://asc.fasb.org/extlink&oid=6507016

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.1)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash Equivalents

-URI http://asc.fasb.org/extlink&oid=6507016

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash

-URI http://asc.fasb.org/extlink&oid=6506951

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.1)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_CashCashEquivalentsAndShortTermInvestments

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Investment in short-term money-market instruments (such as commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and so forth) which are highly liquid (that is, readily convertible to known amounts of cash) and so near their maturity that they present an insignificant risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify as cash equivalents by definition. Original maturity means an original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three-years ago does not become a cash equivalent when its remaining maturity is three months.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash Equivalents

-URI http://asc.fasb.org/extlink&oid=6507016

+ Details

Name: us-gaap_MoneyMarketFundsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

XML 23 R30.htm IDEA: XBRL DOCUMENT v3.3.0.814

CASH, MONEY MARKET FUNDS, AND SHORT-TERM INVESTMENTS (Schedule of Contractual Maturities) (Details) - USD ($)
$ in Thousands

Sep. 30, 2015

Dec. 31, 2014

CASH, MONEY MARKET FUNDS, AND SHORT-TERM INVESTMENTS [Abstract]

Money market funds $ 20,562

Corporate debt securities 79,374

Total $ 99,936

X

- Definition
Amount of investment in debt and equity securities categorized neither as held-to-maturity nor trading.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 25

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=51813488&loc=d3e22054-111558

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 50

-Paragraph 5

-Subparagraph (aa)

-URI http://asc.fasb.org/extlink&oid=27724398&loc=d3e27232-111563

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=49167202&loc=d3e26610-111562

+ Details

Name: us-gaap_AvailableForSaleSecurities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.1)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash Equivalents

-URI http://asc.fasb.org/extlink&oid=6507016

+ Details

Name: us-gaap_CashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Investment in short-term money-market instruments (such as commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and so forth) which are highly liquid (that is, readily convertible to known amounts of cash) and so near their maturity that they present an insignificant risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify as cash equivalents by definition. Original maturity means an original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three-years ago does not become a cash equivalent when its remaining maturity is three months.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash Equivalents

-URI http://asc.fasb.org/extlink&oid=6507016

+ Details

Name: us-gaap_MoneyMarketFundsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

XML 24 R31.htm IDEA: XBRL DOCUMENT v3.3.0.814

CASH, MONEY MARKET FUNDS, AND SHORT-TERM INVESTMENTS (Narrative) (Details) - USD ($)
$ in Thousands
9 Months Ended

Sep. 30, 2015

Dec. 31, 2014

Concentration Risk [Line Items]

Short-term investments available for sale $ 79,374

Money market funds $ 20,562

Five Companies [Member] | Short-term investments [Member]

Concentration Risk [Line Items]

Concentration risk percentage 56.00%

Various Other Domestic Issuers [Member] | Short-term investments [Member]

Concentration Risk [Line Items]

Concentration risk percentage 25.00%

Foreign Issuer [Member] | Short-term investments [Member]

Concentration Risk [Line Items]

Concentration risk percentage 19.00%

X

- Definition
Amount of investment in debt and equity securities categorized neither as held-to-maturity nor trading.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 25

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=51813488&loc=d3e22054-111558

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 50

-Paragraph 5

-Subparagraph (aa)

-URI http://asc.fasb.org/extlink&oid=27724398&loc=d3e27232-111563

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=49167202&loc=d3e26610-111562

+ Details

Name: us-gaap_AvailableForSaleSecurities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_ConcentrationRiskLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-Section 50

-Paragraph 18

-URI http://asc.fasb.org/extlink&oid=51801978&loc=d3e6351-108592

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 20

-URI http://asc.fasb.org/extlink&oid=49121117&loc=d3e13531-108611

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-Section 50

-Paragraph 20

-URI http://asc.fasb.org/extlink&oid=51801978&loc=d3e6404-108592

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 21

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=49121117&loc=d3e13537-108611

+ Details

Name: us-gaap_ConcentrationRiskPercentage1

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Investment in short-term money-market instruments (such as commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and so forth) which are highly liquid (that is, readily convertible to known amounts of cash) and so near their maturity that they present an insignificant risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify as cash equivalents by definition. Original maturity means an original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three-years ago does not become a cash equivalent when its remaining maturity is three months.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash Equivalents

-URI http://asc.fasb.org/extlink&oid=6507016

+ Details

Name: us-gaap_MoneyMarketFundsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: us-gaap_MajorCustomersAxis=lbio_FiveCompaniesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AssetsTotalMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_MajorCustomersAxis=lbio_VariousOtherDomesticIssuersMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_MajorCustomersAxis=lbio_ForeignIssuerMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 25 R8.htm IDEA: XBRL DOCUMENT v3.3.0.814

Condensed Statements of Cash Flows - USD ($)
$ in Thousands
9 Months Ended

Sep. 30, 2015

Sep. 30, 2014

Cash Flows From Operating Activities

Net loss $ (19,283) $ (7,168)

Adjustments to reconcile net loss to net cash used in operating activities:

Depreciation 691 23

Fair value of vested stock options 4,223 1,896

Vesting of restricted shares issued for services 1,553 825

Changes in assets and liabilities:

Prepaid and other current assets (179) 118

Accounts payable and accrued expenses 1,193 (1,012)

Net cash used in operating activities (11,802) $ (5,318)

Cash Flows From Investing Activities

Increase in money market funds (20,562)

Purchase of short-term investments (95,236)

Maturities of short-term investments 15,900

Purchases of property and equipment (992) $ (167)

Net cash used in investing activities (100,890) (167)

Cash Flows From Financing Activities

Proceeds from the issuance of common stock upon exercise of warrants 9,618 $ 3,002

Proceeds from the issuance of common stock upon exercise of options 66

Proceeds from the issuance of common stock, net 68,308

Net cash provided by financing activities 77,992 $ 3,002

Net Decrease In Cash And Cash Equivalents (34,700) (2,483)

Cash and Cash Equivalents, Beginning of Period 44,910 19,673

Cash and Cash Equivalents, End of Period 10,210 $ 17,190

Supplement non-cash financing activities

Unrealized gain on short-term investments $ 38

X

- References
No definition available.
+ Details

Name: lbio_FairValueOfVestedWarrantsGrantedForServices

Namespace Prefix: lbio_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash

-URI http://asc.fasb.org/extlink&oid=6506951

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3044-108585

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash Equivalents

-URI http://asc.fasb.org/extlink&oid=6507016

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.1)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 830

-SubTopic 230

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=49171198&loc=d3e33268-110906

+ Details

Name: us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

+ Details

Name: us-gaap_DepreciationAndAmortization

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_IncreaseDecreaseInOperatingCapitalAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in other obligations or expenses incurred but not yet paid.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in other current operating assets not separately disclosed in the statement of cash flows.
+ References
No definition available.
+ Details

Name: us-gaap_IncreaseDecreaseInOtherCurrentAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in the value of prepaid expenses and other assets not separately disclosed in the statement of cash flows, for example, deferred expenses, intangible assets, or income taxes.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) of financing activities, excluding discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 26

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3574-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3521-108585

+ Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) of investing activities, excluding discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 26

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3574-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3521-108585

+ Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 25

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3536-108585

+ Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Net Income

-URI http://asc.fasb.org/extlink&oid=51831255

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.18)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.22)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Other Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=51831270

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 19

-Article 5

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 20

-Article 9

+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The value of the noncash (or part noncash) consideration received in a transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of a transaction not resulting in cash receipts or cash payments in the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4332-108586

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4313-108586

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4304-108586

+ Details

Name: us-gaap_OtherSignificantNoncashTransactionValueOfConsiderationReceived1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The cash outflow to acquire debt and equity securities not classified as either held-to-maturity securities or trading securities which would be classified as available-for-sale securities and reported at fair value, with unrealized gains and losses excluded from earnings and reported in a separate component of shareholders' equity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Investing Activities

-URI http://asc.fasb.org/extlink&oid=6516133

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 13

-Subparagraph (a),(b)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3213-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 45

-Paragraph 11

-URI http://asc.fasb.org/extlink&oid=49167202&loc=d3e26853-111562

+ Details

Name: us-gaap_PaymentsToAcquireAvailableForSaleSecurities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Investing Activities

-URI http://asc.fasb.org/extlink&oid=6516133

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 13

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3213-108585

+ Details

Name: us-gaap_PaymentsToAcquirePropertyPlantAndEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash inflow from the additional capital contribution to the entity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 14

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3255-108585

+ Details

Name: us-gaap_ProceedsFromIssuanceOfCommonStock

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The cash inflow associated with the sale or maturity (principal being due) of securities not classified as either held-to-maturity securities or trading securities which are classified as available-for-sale securities.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 12

-Subparagraph (a),(b)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3179-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 45

-Paragraph 11

-URI http://asc.fasb.org/extlink&oid=49167202&loc=d3e26853-111562

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Investing Activities

-URI http://asc.fasb.org/extlink&oid=6516133

+ Details

Name: us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The cash inflow associated with the amount received from holders exercising their stock options. This item inherently excludes any excess tax benefit, which the entity may have realized and reported separately.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (j)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 14

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3255-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

+ Details

Name: us-gaap_ProceedsFromStockOptionsExercised

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The cash inflow associated with the amount received from holders exercising their stock warrants.
+ References
No definition available.
+ Details

Name: us-gaap_ProceedsFromWarrantExercises

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The noncash expense that accounts for the value of stock or unit options distributed to employees as compensation.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

+ Details

Name: us-gaap_StockOptionPlanExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

XML 26 R32.htm IDEA: XBRL DOCUMENT v3.3.0.814

PROPERTY AND EQUIPMENT (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended

Sep. 30, 2015

Sep. 30, 2014

Sep. 30, 2015

Sep. 30, 2014

Dec. 31, 2014

Property, Plant and Equipment [Line Items]

Property and equipment, gross $ 2,627 $ 2,627 $ 1,635

Accumulated depreciation (794) (794) (103)

Property and equipment, net 1,833 1,833 1,532

Depreciation expense 266 $ 5 691 $ 23

Laboratory equipment [Member]

Property, Plant and Equipment [Line Items]

Property and equipment, gross 1,563 1,563 688

Leasehold improvements [Member]

Property, Plant and Equipment [Line Items]

Property and equipment, gross 853 853 762

Computer, software, and office equipment [Member]

Property, Plant and Equipment [Line Items]

Property and equipment, gross $ 211 $ 211 $ 185

X

- Definition
Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.14)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

+ Details

Name: us-gaap_Depreciation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.13)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_PropertyPlantAndEquipmentGross

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_PropertyPlantAndEquipmentLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.13)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 13

-Subparagraph a

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 8

-Article 7

+ Details

Name: us-gaap_PropertyPlantAndEquipmentNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 27 R40.htm IDEA: XBRL DOCUMENT v3.3.0.814

LEGAL PROCEEDINGS (Details) - USD ($)
1 Months Ended 9 Months Ended

Nov. 05, 2013

Sep. 30, 2015

LEGAL PROCEEDINGS [Abstract]

Proceeds from issuance of private placement $ 23,300,000

Damages sought $ 7,746,000

X

- References
No definition available.
+ Details

Name: us-gaap_LossContingencyAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The value (monetary amount) of the award the plaintiff seeks in the legal matter.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 450

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14326-108349

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 450

-SubTopic 20

-Section 50

-Paragraph 9

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14557-108349

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 450

-SubTopic 20

-Section 50

-Paragraph 4

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14435-108349

+ Details

Name: us-gaap_LossContingencyDamagesSoughtValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 14

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3255-108585

+ Details

Name: us-gaap_ProceedsFromIssuanceOfPrivatePlacement

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

XML 28 R2.htm IDEA: XBRL DOCUMENT v3.3.0.814

Condensed Balance Sheets - USD ($)
$ in Thousands

Sep. 30, 2015

Dec. 31, 2014

Current Assets

Cash and cash equivalents $ 10,210 $ 44,910

Money market funds 20,562

Short-term investments available for sale 79,374

Prepaid and other current assets 245 $ 67

Total Current Assets 110,391 44,977

Property and equipment, net of accumulated depreciation of $794 and $103 1,833 1,532

Total Assets 112,224 46,509

Current Liabilities

Accounts payable 1,161 1,249

Accrued expenses 1,608 328

Accrued payable to officers and former directors 86 86

Total Current Liabilities $ 2,855 $ 1,663

Commitments and contingencies

Stockholders' Equity

Preferred stock, $0.001 par value; 50,000,000 shares authorized, 3,694 shares and 5,694 shares issued and outstanding, respectively

Common stock, $0.000041666 par value; 150,000,000 shares authorized, 47,807,398 and 33,750,188 shares issued and outstanding, respectively $ 2 $ 2

Common stock to be issued, 245,153 shares 245 245

Accumulated other comprehensive income 38

Additional paid-in capital 204,929 121,161

Accumulated deficit (95,845) (76,562)

Total Stockholders' Equity 109,369 44,846

Total Liabilities and Stockholders' Equity $ 112,224 $ 46,509

X

- Definition
Value of common stock to be issued as of balance sheet date.
+ References
No definition available.
+ Details

Name: lbio_CommonStockToBeIssuedValue

Namespace Prefix: lbio_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19(a))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_AccountsPayableCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount for accounts payable to related parties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19(a))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39622-107864

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(k)(1))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

+ Details

Name: us-gaap_AccountsPayableRelatedPartiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_AccruedLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 11

-URI http://asc.fasb.org/extlink&oid=36458714&loc=d3e637-108580

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 14

-URI http://asc.fasb.org/extlink&oid=36458714&loc=d3e681-108580

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 14A

-URI http://asc.fasb.org/extlink&oid=36458714&loc=SL7669686-108580

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 31

-Article 5

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

+ Details

Name: us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.30(a)(1))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 31

-Article 5

+ Details

Name: us-gaap_AdditionalPaidInCapital

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.18)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 12

-Article 7

+ Details

Name: us-gaap_Assets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.9)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6801-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

+ Details

Name: us-gaap_AssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_AssetsCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of investment in debt and equity securities categorized neither as trading securities nor held-to-maturity securities and intended be sold or mature one year or operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 25

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=51813488&loc=d3e22054-111558

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=49167202&loc=d3e26626-111562

+ Details

Name: us-gaap_AvailableForSaleSecuritiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash

-URI http://asc.fasb.org/extlink&oid=6506951

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3044-108585

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash Equivalents

-URI http://asc.fasb.org/extlink&oid=6507016

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.1)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-03.(a),19)

-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 450

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14326-108349

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-03.17)

-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.25)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_CommitmentsAndContingencies

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.32)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 25

-Article 7

+ Details

Name: us-gaap_LiabilitiesAndStockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.21)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_LiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_LiabilitiesCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Investment in short-term money-market instruments (such as commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and so forth) which are highly liquid (that is, readily convertible to known amounts of cash) and so near their maturity that they present an insignificant risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify as cash equivalents by definition. Original maturity means an original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three-years ago does not become a cash equivalent when its remaining maturity is three months.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash Equivalents

-URI http://asc.fasb.org/extlink&oid=6507016

+ Details

Name: us-gaap_MoneyMarketFundsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

+ Details

Name: us-gaap_PreferredStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 8

-Article 5

+ Details

Name: us-gaap_PrepaidExpenseAndOtherAssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.13)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 13

-Subparagraph a

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 8

-Article 7

+ Details

Name: us-gaap_PropertyPlantAndEquipmentNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
The cumulative amount of the reporting entity's undistributed earnings or deficit.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.31(a)(3))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

+ Details

Name: us-gaap_RetainedEarningsAccumulatedDeficit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SAB TOPIC 4.E)

-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29-31)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 4

-Section E

+ Details

Name: us-gaap_StockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_StockholdersEquityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 29 R6.htm IDEA: XBRL DOCUMENT v3.3.0.814

Condensed Statements of Comprehensive Loss - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended

Sep. 30, 2015

Sep. 30, 2014

Sep. 30, 2015

Sep. 30, 2014

Statement of Comprehensive Income [Abstract]

Net Loss $ (7,635) $ (2,798) $ (19,283) $ (7,168)

Other comprehensive income:

Unrealized gain on short-term investments 38 38

Comprehensive Loss $ (7,597) $ (2,798) $ (19,245) $ (7,168)

X

- Definition
Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Other Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=51831270

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=51831223

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=36458714&loc=d3e557-108580

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Net Income

-URI http://asc.fasb.org/extlink&oid=51831255

+ Details

Name: us-gaap_ComprehensiveIncomeNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Net Income

-URI http://asc.fasb.org/extlink&oid=51831255

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.18)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.22)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Other Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=51831270

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 19

-Article 5

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 20

-Article 9

+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount after tax, before reclassification adjustments, of unrealized holding gain (loss) on available-for-sale securities.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 10A

-Subparagraph (e)

-URI http://asc.fasb.org/extlink&oid=36458714&loc=SL7669646-108580

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 11

-URI http://asc.fasb.org/extlink&oid=36458714&loc=d3e637-108580

+ Details

Name: us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 30 R35.htm IDEA: XBRL DOCUMENT v3.3.0.814

STOCK OPTIONS AND WARRANTS (Narrative) (Details) - USD ($)
$ in Thousands
1 Months Ended 9 Months Ended

Apr. 10, 2015

Sep. 30, 2015

Sep. 30, 2014

Nov. 30, 2014

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Proceeds from warrant exercises $ 9,618 $ 3,002

Warrant [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Granted

Exercised 3,847,210

Employee Stock Option [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Granted 943,750

Exercised 10,000

Share-based compensation $ 4,100 $ 1,900

Unrecognized compensation cost 10,300

Fair value of options $ 8,300

Expected volatility 211.00%

Discount rate 1.57%

Expected dividend yield 0.00%

Expected life 6 years

2014 Plan [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Number of shares authorized 4,000,000 2,350,000

Number of additional shares authorized 1,650,000

Minimum [Member] | Employee Stock Option [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Unrecognized compensation cost, period for recognition 9 months

Vesting period 1 year

Maximum [Member] | Employee Stock Option [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Unrecognized compensation cost, period for recognition 3 years

Vesting period 3 years

X

- Definition
Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 14.F)

-URI http://asc.fasb.org/extlink&oid=27013229&loc=d3e301413-122809

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (h)(1)(i)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 14

-Section F

+ Details

Name: us-gaap_AllocatedShareBasedCompensationExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Unrecognized cost of unvested share-based compensation awards.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (i)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Weighted average period over which unrecognized compensation is expected to be recognized for equity-based compensation plans, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (i)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
The cash inflow associated with the amount received from holders exercising their stock warrants.
+ References
No definition available.
+ Details

Name: us-gaap_ProceedsFromWarrantExercises

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Period which an employee's right to exercise an award is no longer contingent on satisfaction of either a service condition, market condition or a performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (a)(1)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (f)(2)(iii)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (f)(2)(ii)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
The risk-free interest rate assumption that is used in valuing an option on its own shares.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (f)(2)(iv)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of additional shares authorized for issuance under an established share-based compensation plan.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
The maximum number of shares (or other type of equity) originally approved (usually by shareholders and board of directors), net of any subsequent amendments and adjustments, for awards under the equity-based compensation plan. As stock or unit options and equity instruments other than options are awarded to participants, the shares or units remain authorized and become reserved for issuance under outstanding awards (not necessarily vested).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (a)(3)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Gross number of share options (or share units) granted during the period.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 14.D.2)

-URI http://asc.fasb.org/extlink&oid=27013229&loc=d3e301413-122809

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (f)(2)(i)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 14

-Section D

-Subsection 2

+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Number of share options (or share units) exercised during the current period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(iv)(2)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28,29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30

-Article 5

+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_AwardTypeAxis=us-gaap_WarrantMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PlanNameAxis=lbio_PlanTwoMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RangeAxis=us-gaap_MinimumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RangeAxis=us-gaap_MaximumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 31 R22.htm IDEA: XBRL DOCUMENT v3.3.0.814

STOCK OPTIONS AND WARRANTS (Tables)
9 Months Ended

Sep. 30, 2015

STOCK OPTIONS AND WARRANTS [Abstract]

Schedule of Status of Stock Options

Weighted

Weighted Average Aggregate

Shares Average Remaining Intrinsic

Under Exercise Contractual Value

Option Price Life
(in thousands)

Outstanding at January 1, 2015 1,857,877 $ 7.31 8.2 $ 2,875

Granted 943,750
9.18 9.8

Exercised (10,000 )

Expired/Forfeited (87,432 ) 5.92 7.29
-

Outstanding at September 30, 2015 2,704,195 $ 8.05 8.16 $ 64

Exercisable at September 30, 2015 883,449 $ 8.63 6.67 $ 98

Schedule of Status of Stock Warrants

Weighted

Weighted Average Aggregate

Shares Average Remaining Intrinsic

Under Exercise Contractual Value

Warrants Price Life
(in thousands)

Outstanding at December 31, 2014 11,084,426 $ 2.51 3.85 years $ 59,518

Issued -

Exercised (3,847,210 ) $ 2.50

Expired -

Outstanding and exercisable at September 30, 2015 7,237,216 $ 2.51 3.3 years $ 23,593

X

- References
No definition available.
+ Details

Name: us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the number and weighted-average exercise prices (or conversion ratios) for share options (or share units) that were outstanding at the beginning and end of the year, vested and expected to vest, exercisable or convertible at the end of the year, and the number of share options or share units that were granted, exercised or converted, forfeited, and expired during the year.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(i))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 50

-Section S99

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 50

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=51659978&loc=d3e25284-112666

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 28

-Article 5

+ Details

Name: us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 32 R36.htm IDEA: XBRL DOCUMENT v3.3.0.814

STOCK OPTIONS AND WARRANTS (Schedule of Status of Stock Options) (Details) - Employee Stock Option [Member] - USD ($)
$ / shares in Units, $ in Thousands
9 Months Ended 12 Months Ended

Sep. 30, 2015

Dec. 31, 2014

Shares Under Option

Outstanding, beginning balance 1,857,877

Granted 943,750

Exercised (10,000)

Expired/Forfeited (87,432)

Outstanding, ending balance 2,704,195 1,857,877

Exercisable 883,449

Weighted Average Exercise Price

Outstanding, beginning balance $ 7.31

Granted 9.18

Expired/Forfeited 5.92

Outstanding, ending balance 8.05 $ 7.31

Exercisable $ 8.63

Weighted Average Remaining Contractual Life

Outstanding 8 years 1 month 28 days 8 years 2 months 12 days

Granted 9 years 9 months 18 days

Expired/Forfeited 7 years 3 months 14 days

Exercisable 6 years 8 months 1 day

Aggregate Intrinsic Value

Outstanding, beginning balance $ 2,875

Expired/Forfeited

Outstanding, ending balance $ 64 $ 2,875

Exercisable $ 98

X

- References
No definition available.
+ Details

Name: lbio_AggregateIntrinsicValueAbstract

Namespace Prefix: lbio_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The total intrinsic value of expirations and forfeitures during the period.
+ References
No definition available.
+ Details

Name: lbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationsAndForfeituresInPeriodIntrinsicValue

Namespace Prefix: lbio_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: lbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract1Abstract

Namespace Prefix: lbio_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average remaining contractual term for option awards forfeitures and expirations in period, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
No definition available.
+ Details

Name: lbio_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageRemainingContractualTerm

Namespace Prefix: lbio_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average remaining contractual term for option awards grants in period, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
No definition available.
+ Details

Name: lbio_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm

Namespace Prefix: lbio_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(iii)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(iii)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(iv)(3)-(4)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average price of options that were either forfeited or expired.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(iv)(3)-(4)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Gross number of share options (or share units) granted during the period.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of options outstanding, including both vested and non-vested options.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(i)-(ii)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(i)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of fully vested and expected to vest options that are exercisable.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (e)(2)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount by which the current fair value of the underlying stock exceeds the exercise price of fully vested and expected to vest options outstanding.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (e)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (e)(1)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of share options (or share units) exercised during the current period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(iv)(2)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28,29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30

-Article 5

+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 33 R24.htm IDEA: XBRL DOCUMENT v3.3.0.814

GENERAL ORGANIZATION AND BUSINESS (Details) - USD ($)
$ / shares in Units, $ in Thousands
1 Months Ended 3 Months Ended 9 Months Ended

Mar. 03, 2015

Dec. 22, 2014

Nov. 05, 2013

Sep. 30, 2015

Sep. 30, 2014

Sep. 30, 2015

Sep. 30, 2014

Dec. 31, 2014

GENERAL ORGANIZATION AND BUSINESS [Abstract]

Net loss $ (7,635) $ (2,798) $ (19,283) $ (7,168)

Net cash used in operating activities (11,802) $ (5,318)

Cash, money market funds and short-term investments 110,146 110,146 $ 45

Stockholder's equity 109,369 109,369 $ 44,846

Working capital $ 107,500 107,500

Shares issued during period 9,200,000 6,000,000

Share price $ 8.00 $ 5.75

Proceeds from the issuance of common stock, net $ 68,300 $ 32,200 $ 68,308

Proceeds from issuance of private placement $ 23,300

X

- Definition
Represents the value of working capital which is the difference between current assets and current liabilities.
+ References
No definition available.
+ Details

Name: lbio_WorkingCapital

Namespace Prefix: lbio_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash Equivalents

-URI http://asc.fasb.org/extlink&oid=6507016

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash

-URI http://asc.fasb.org/extlink&oid=6506951

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.1)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_CashCashEquivalentsAndShortTermInvestments

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 25

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3536-108585

+ Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: na

Period Type: duration

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Net Income

-URI http://asc.fasb.org/extlink&oid=51831255

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.18)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.22)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Other Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=51831270

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 19

-Article 5

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 20

-Article 9

+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The cash inflow from the additional capital contribution to the entity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 14

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3255-108585

+ Details

Name: us-gaap_ProceedsFromIssuanceOfCommonStock

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 14

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3255-108585

+ Details

Name: us-gaap_ProceedsFromIssuanceOfPrivatePlacement

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Price of a single share of a number of saleable stocks of a company.
+ References
No definition available.
+ Details

Name: us-gaap_SharePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of new stock issued during the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30

-Article 5

+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SAB TOPIC 4.E)

-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29-31)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 4

-Section E

+ Details

Name: us-gaap_StockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

XML 34 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 35 R7.htm IDEA: XBRL DOCUMENT v3.3.0.814

Condensed Statements of Stockholders' Equity - 9 months ended Sep. 30, 2015 - USD ($)
$ in Thousands

Total

Preferred Stock [Member]

Common Stock [Member]

Common Stock To Be Issued [Member]

Additional Paid-In Capital [Member]

Comprehensive Income [Member]

Accumulated Deficit [Member]

Balance at Dec. 31, 2014 $ 44,846 $ 2 $ 245 $ 121,161 $ (76,562)

Balance (in shares) at Dec. 31, 2014 5,694 33,750,188

Fair value of vested stock options 4,223 4,223

Common stock issued upon exercise of warrants 9,618 9,618

Common stock issued upon exercise of warrants (in shares) 3,847,210

Common stock issued upon exercise of options $ 66 66

Common stock issued upon exercise of options (in shares) 10,000

Common stock issued upon conversion of preferred shares

Common stock issued upon conversion of preferred shares (in shares) (2,000) 1,000,000

Common stock sold in public offering, net of offering costs $ 68,308 68,308

Common stock sold in public offering, net of offering costs (in shares) 9,200,000

Vesting of restricted shares issued for services 1,553 1,553

Unrealized gain on short-term investments 38 $ 38

Net loss (19,283) (19,283)

Balance at Sep. 30, 2015 $ 109,369 $ 2 $ 245 $ 204,929 $ 38 $ (95,845)

Balance (in shares) at Sep. 30, 2015 3,694 47,807,398

X

- Definition
The amount of exchange transaction inducement costs capitalized during the period.
+ References
No definition available.
+ Details

Name: lbio_CommonStockIssuedUponExerciseOfWarrantsAmount

Namespace Prefix: lbio_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Number of shares issued upon exercise of warrant.
+ References
No definition available.
+ Details

Name: lbio_CommonStockIssuedUponExerciseOfWarrantsShares

Namespace Prefix: lbio_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of increase (decrease) to additional paid in capital (APIC) resulting from changes in fair value of common and preferred stock issued to employee benefit trust but unearned.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 31

-Article 5

+ Details

Name: us-gaap_AdjustmentsToAdditionalPaidInCapitalMarkToMarket

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of equity-based compensation, related to restricted stock units or restricted stock awards, recognized as expense or an asset, if compensation is capitalized.
+ References
No definition available.
+ Details

Name: us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Net Income

-URI http://asc.fasb.org/extlink&oid=51831255

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.18)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.22)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Other Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=51831270

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 19

-Article 5

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 20

-Article 9

+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount after tax, before reclassification adjustments, of unrealized holding gain (loss) on available-for-sale securities.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 10A

-Subparagraph (e)

-URI http://asc.fasb.org/extlink&oid=36458714&loc=SL7669646-108580

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 11

-URI http://asc.fasb.org/extlink&oid=36458714&loc=d3e637-108580

+ Details

Name: us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Number of shares issued which are neither cancelled nor held in the treasury.
+ References
No definition available.
+ Details

Name: us-gaap_SharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of shares issued during the period as a result of the conversion of convertible securities.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29-30)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of shares of stock issued during the period that is attributable to transactions involving issuance of stock not separately disclosed.
+ References
No definition available.
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesOther

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of share options (or share units) exercised during the current period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(iv)(2)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28,29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30

-Article 5

+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
The gross value of stock issued during the period upon the conversion of convertible securities.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29-31)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

+ Details

Name: us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Value of shares of stock issued during the period that is attributable to transactions involving issuance of stock not separately disclosed.
+ References
No definition available.
+ Details

Name: us-gaap_StockIssuedDuringPeriodValueOther

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Value of stock issued as a result of the exercise of stock options.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29-31)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

+ Details

Name: us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SAB TOPIC 4.E)

-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29-31)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 4

-Section E

+ Details

Name: us-gaap_StockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=lbio_CommonStockToBeIssuedMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 36 R3.htm IDEA: XBRL DOCUMENT v3.3.0.814

Condensed Balance Sheets (Parenthetical) - USD ($)
$ in Thousands

Sep. 30, 2015

Dec. 31, 2014

Condensed Balance Sheets [Abstract]

Property and equipment, accumulated depreciation $ 794 $ 103

Preferred stock, par value (in dollars per share) $ 0.001 $ 0.001

Preferred stock, shares authorized 50,000,000 50,000,000

Preferred stock, shares issued 3,694 5,694

Preferred stock, shares outstanding 3,694 5,694

Common stock, par value (in dollars per share) $ 0.000041666 $ 0.000041666

Common stock, shares authorized 150,000,000 150,000,000

Common stock, shares issued 47,807,398 33,750,188

Common stock, shares outstanding 47,807,398 33,750,188

Common stock to be issued shares 245,153 245,153

X

- Definition
Number of shares of common stock to be issued.
+ References
No definition available.
+ Details

Name: lbio_CommonStockToBeIssuedShares

Namespace Prefix: lbio_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.14)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Face amount or stated value per share of common stock.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
The maximum number of common shares permitted to be issued by an entity's charter and bylaws.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

+ Details

Name: us-gaap_PreferredStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

+ Details

Name: us-gaap_PreferredStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

+ Details

Name: us-gaap_PreferredStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

+ Details

Name: us-gaap_PreferredStockSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_StatementOfFinancialPositionAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 37 R17.htm IDEA: XBRL DOCUMENT v3.3.0.814

SUMMARY OF SIGNIFICANT ACCOUNTING PRACTICES (Policies)
9 Months Ended

Sep. 30, 2015

SUMMARY OF SIGNIFICANT ACCOUNTING PRACTICES [Abstract]

Cash and Cash Equivalents

Cash and Cash Equivalents

The Company considers highly liquid investments with an original maturity of 90 days or less when purchased to be cash equivalents. The carrying amounts reported in the Balance Sheets for cash and cash equivalents are valued at cost, which approximates their fair value.

Short-term Investments

Short-term Investments

The Company's short-term investments represent available for sale securities and are recorded at fair value and unrealized gains and losses are recorded within accumulated other comprehensive income (loss). The estimated fair value of the available for sale securities is determined based on quoted market prices or rates for similar instruments. In addition, the cost of debt securities in this category is adjusted for amortization of premium and accretion of discount to maturity. The Company evaluates securities with unrealized losses to determine whether such losses, if any, are other than temporary.

Property and Equipment

Property and Equipment

Property and equipment are recorded at cost and depreciated using the straight-line method over their estimated useful lives of two to five years. Maintenance and repairs of depreciable assets are charged against earnings as incurred. When properties are retired or otherwise disposed of, the cost and accumulated depreciation are removed from the accounts and gains or losses are credited or charged to earnings. Leasehold improvements are amortized over the lesser of their estimated useful life or lease term, whichever is shorter.

Net Income (Loss) Per Share

Net Income (Loss) Per Share

Basic net income (loss) per share is computed by dividing net income (loss) by the weighted average number of common shares outstanding for the period, excluding unvested shares of restricted common stock. Shares of restricted stock subject to vesting are included in basic weighted average common shares outstanding from the time they vest. Diluted earnings per share is computed by dividing the net income applicable to common stock holders by the weighted average number of common shares outstanding plus the number of additional common shares that would have been outstanding if all dilutive potential common shares had been issued, using the treasury stock method. Potential common shares are excluded from the computation when their effect is antidilutive. When calculating diluted net income per share, shares of restricted stock subject to vesting are included in diluted weighted average common shares outstanding as of their grant date.

At September 30, 2015 and 2014, basic and diluted net loss per share are the same, as the effect of potentially dilutive securities was antidilutive. At September 30, 2015, potentially dilutive securities include options to acquire 2,704,195 shares of common stock, warrants to acquire 7,237,216 shares of common stock, preferred stock that can be converted into 1,847,000 shares of common stock, and 494,001 shares of non-vested restricted stock. At September 30, 2014, potentially dilutive securities include options to acquire 1,098,750 shares of common stock, warrants to acquire 11,172,426 shares of common stock, and preferred stock that can be converted into 2,847,000 shares of common stock.

Fair Value Measurements

Fair Value Measurements

Under FASB ASC 820, Fair Value Measurements and Disclosures, fair value is defined as the price at which an asset could be exchanged or a liability transferred in a transaction between knowledgeable, willing parties in the principal or most advantageous market for the asset or liability. Where available, fair value is based on observable market prices or parameters or derived from such prices or parameters. Where observable prices or parameters are not available, valuation models are applied.

Assets and liabilities recorded at fair value in our financial statements are categorized based upon the level of judgment associated with the inputs used to measure their fair value. Hierarchical levels directly related to the amount of subjectivity associated with the inputs to fair valuation of these assets and liabilities, are as follows:

Level 1—Inputs are unadjusted, quoted prices in active markets for identical assets at the reporting date. Active markets are those in which transactions for the asset or liability occur in sufficient frequency and volume to provide pricing information on an ongoing basis.

The fair valued assets we hold that are generally included under this Level 1 are money market securities where fair value is based on publicly quoted prices.

Level 2—Are inputs, other than quoted prices included in Level 1, that are either directly or indirectly observable for the asset or liability through correlation with market data at the reporting date and for the duration of the instrument's anticipated life.

The fair valued assets we hold that are generally assessed under Level 2 are corporate bonds and commercial paper. We utilize third party pricing services in developing fair value measurements where fair value is based on valuation methodologies such as models using observable market inputs, including benchmark yields, reported trades, broker/dealer quotes, bids, offers and other reference data. We use quotes from external pricing service providers and other on-line quotation systems to verify the fair value of investments provided by our third party pricing service providers. We review independent auditor's reports from our third party pricing service providers particularly regarding the controls over pricing and valuation of financial instruments and ensure that our internal controls address certain control deficiencies, if any, and complementary user entity controls are in place.

Level 3—Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities and which reflect management's best estimate of what market participants would use in pricing the asset or liability at the reporting date. Consideration is given to the risk inherent in the valuation technique and the risk inherent in the inputs to the model.

We do not have fair valued assets classified under Level 3.

Fair Value on a Recurring Basis

Fair Value on a Recurring Basis

Financial assets measured at fair value on a recurring basis are categorized in the tables below based upon the lowest level of significant input to the valuations (in thousands):

Assets at Fair Value as of September 30, 2015

Level 1 Level 2 Level 3 Total

Money market funds $ 20,562 $ - $ - $ 20,562

Corporate debt securities - 79,374 - 79,374

Total $ 20,562 $ 79,374 $ $ 99,936

Use of Estimates

Use of Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates include accounting for potential liabilities and the assumptions made in valuing stock instruments issued for services.

Stock-Based Compensation

Stock-Based Compensation

The Company periodically grants stock options and warrants to employees and non-employees in non-capital raising transactions as compensation for services rendered. The Company accounts for stock option grants to employees based on the authoritative guidance provided by the Financial Accounting Standards Board where the value of the award is measured on the date of grant and recognized over the vesting period. The Company accounts for stock option grants to non-employees in accordance with the authoritative guidance of the Financial Accounting Standards Board where the value of the stock compensation is determined based upon the measurement date at either a) the date at which a performance commitment is reached, or b) at the date at which the necessary performance to earn the equity instruments is complete. Non-employee stock-based compensation charges generally are amortized over the vesting period on a straight-line basis. In certain circumstances where there are no future performance requirements by the non-employee, option grants are immediately vested and the total stock-based compensation charge is recorded in the period of the measurement date.

The Company issues restricted shares of its common stock for share-based compensation programs. The Company measures the compensation cost with respect to restricted shares to employees based upon the estimated fair value of the equity instruments at the date of the grant, and is recognized as expense over the period which an employee is required to provide services in exchange for the award.

The fair value of the Company's common stock option grants is estimated using a Black-Scholes option pricing model, which uses certain assumptions related to risk-free interest rates, expected volatility, expected life of the common stock options, and future dividends. Compensation expense is recorded based upon the value derived from the Black-Scholes option pricing model, and based on actual experience. The assumptions used in the Black-Scholes option pricing model could materially affect compensation expense recorded in future periods.

Total stock-based compensation expense related to all of our stock-based awards was as follows (in thousands):

For the Three Months Ended
September 30, For the Nine Months Ended
September 30,

2015 2014 2015 2014

Operating expenses $ 1,492 $ 658 $ 3,726 $ 1,905

Research and development 895 282 2,050 817

 Total stock-based compensation expense $ 2,387 $ 940 $ 5,776 $ 2,722

Research and Development

Research and Development

Research and development costs consist primarily of fees paid to consultants and outside service providers, patent fees and costs, and other expenses relating to the acquisition, design, development and testing of the Company's treatments and product candidates. Research and development costs are expensed as incurred, unless the achievement of milestones, the completion of contracted work, or other information indicates that a different expensing schedule is more appropriate. The Company reviews the status of its research and development contracts on a quarterly basis.

Concentrations

Concentrations

Financial instruments, which potentially subject the Company to concentrations of credit risk, consist principally of cash and short-term investments.

The Company maintains cash balances at one bank. As of September 30, 2015, the Company's cash balances were in excess of insured limits maintained at this bank. Management believes that the financial institution that hold the Company's cash are financially sound and, accordingly, minimal credit risk exists.

At September 30, 2015, the Company's short-term investments were invested in short-term fixed income debt securities of domestic and foreign high credit issuers and in money market funds. The Company's investment policy limits investments to certain types of instruments such as certificates of deposit, money market instruments, obligations issued by the U.S. government and U.S. government agencies as well as corporate debt securities, and places restrictions on maturities and concentration by type and issuer. At September 30, 2015, approximately 56% of the Company's short-term investments were invested in notes of five companies, 25% were invested in notes of various domestic issuers, and 19% were invested in notes of a foreign issuers. The average maturity of these notes was 66 days (See Note 3).

Recent Accounting Pronouncements

Recent Accounting Pronouncements

In May 2014, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2014-09, Revenue from Contracts with Customers. ASU 2014-09 is a comprehensive revenue recognition standard that will supersede nearly all existing revenue recognition guidance under current U.S. GAAP and replace it with a principle based approach for determining revenue recognition. ASU 2014-09 will require that companies recognize revenue based on the value of transferred goods or services as they occur in the contract. The ASU also will require additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to obtain or fulfill a contract. ASU 2014-09 is effective for interim and annual periods beginning after December 15, 2017. Early adoption is permitted in annual reporting periods beginning after December 15, 2016, and the interim periods within that year, and either full retrospective adoption or modified retrospective adoption is permitted. The Company is in the process of evaluating the impact of ASU 2014-09 on the Company's financial statements and disclosures.

In June 2014, the FASB issued Accounting Standards Update No. 2014-12, Compensation – Stock Compensation (Topic 718). The pronouncement was issued to clarify the accounting for share-based payments when the terms of an award provide that a performance target could be achieved after the requisite service period. The pronouncement is effective for reporting periods beginning after December 15, 2015. The adoption of ASU 2014-12 is not expected to have a significant impact on the Company's consolidated financial position or results of operations.

Other recent accounting pronouncements issued by the FASB, including its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the Securities and Exchange Commission did not or are not believed by management to have a material impact on the Company's present or future consolidated financial statements.

Reclassifications

Reclassifications

In presenting the Company's statement of operations for the three and nine month periods ended September 30, 2014, the Company has reclassified $0.8 million and $0.3 million, respectively, of stock-based compensation that was previously reflected as operating expenses to research and development expenses. The reclassification relates to stock-based compensation attributable to individuals working in the Company's research and development activities, and had no impact on total costs and expenses, or on net loss.

X

- References
No definition available.
+ Details

Name: us-gaap_AccountingPoliciesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 305

-SubTopic 10

-Section 05

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6375392&loc=d3e26790-107797

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4273-108586

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash

-URI http://asc.fasb.org/extlink&oid=6506951

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18780-107790

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash Equivalents

-URI http://asc.fasb.org/extlink&oid=6507016

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Financial Reporting Release (FRR)

-Number 203

-Paragraph 02-03

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 1

-Article 5

+ Details

Name: us-gaap_CashAndCashEquivalentsPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for credit risk.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 55

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6875567&loc=d3e14489-108613

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 825

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=51676700&loc=d3e61082-112788

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 825

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=28088331&loc=SL29635902-196195

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 21

-URI http://asc.fasb.org/extlink&oid=49121117&loc=d3e13537-108611

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 20

-URI http://asc.fasb.org/extlink&oid=49121117&loc=d3e13531-108611

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 825

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=51676700&loc=d3e61044-112788

+ Details

Name: us-gaap_ConcentrationRiskCreditRisk

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18780-107790

+ Details

Name: us-gaap_EarningsPerSharePolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.
+ References
No definition available.
+ Details

Name: us-gaap_FairValueMeasurementPolicyPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for determining the fair value of financial instruments.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=49121117&loc=d3e13279-108611

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 60

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260

+ Details

Name: us-gaap_FairValueOfFinancialInstrumentsPolicy

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for investments in debt and equity securities that have readily determinable fair values (marketable securities). At a minimum, the disclosure might address accounting policies for investments classified as trading, available for sale, or held to maturity and may include how the entity determines whether impairments of available for sale or held to maturity investments are other than temporary, how the fair values of the entity's securities are determined, and the entity's accounting treatment for transfers between investment categories.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section S50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6381980&loc=d3e87707-122711

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 320

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6957658&loc=d3e62652-112803

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 5

-Section M

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 2, 12

-Article 5

+ Details

Name: us-gaap_MarketableSecuritiesPolicy

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.
+ References
No definition available.
+ Details

Name: us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for reclassifications that affects the comparability of the financial statements.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6359566&loc=d3e326-107755

+ Details

Name: us-gaap_PriorPeriodReclassificationAdjustmentDescription

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, basis of assets, depreciation and depletion methods used, including composite deprecation, estimated useful lives, capitalization policy, accounting treatment for costs incurred for repairs and maintenance, capitalized interest and the method it is calculated, disposals and impairments.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18780-107790

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.13(a))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_PropertyPlantAndEquipmentPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 730

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18780-107790

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Research and Development

-URI http://asc.fasb.org/extlink&oid=6523717

+ Details

Name: us-gaap_ResearchAndDevelopmentExpensePolicy

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for stock option and stock incentive plans. This disclosure may include (1) the types of stock option or incentive plans sponsored by the entity (2) the groups that participate in (or are covered by) each plan (3) significant plan provisions and (4) how stock compensation is measured, and the methodologies and significant assumptions used to determine that measurement.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18780-107790

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (b),(f)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=51801978&loc=d3e6061-108592

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-Section 50

-Paragraph 9

-URI http://asc.fasb.org/extlink&oid=51801978&loc=d3e6143-108592

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-Section 50

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=51801978&loc=d3e6132-108592

+ Details

Name: us-gaap_UseOfEstimates

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 38 R1.htm IDEA: XBRL DOCUMENT v3.3.0.814

Document And Entity Information - shares
9 Months Ended

Sep. 30, 2015

Oct. 31, 2015

Document Information [Line Items]

Entity Registrant Name Lion Biotechnologies, Inc.

Entity Central Index Key 0001425205

Current Fiscal Year End Date --12-31

Entity Filer Category Accelerated Filer

Entity Common Stock, Shares Outstanding 47,833,934

Document Type 10-Q

Amendment Flag false

Document Period End Date Sep. 30, 2015

Document Fiscal Period Focus Q3

Document Fiscal Year Focus 2015

X

- Definition
If the value is true, then the document is an amendment to previously-filed/accepted document.
+ References
No definition available.
+ Details

Name: dei_AmendmentFlag

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
End date of current fiscal year in the format --MM-DD.
+ References
No definition available.
+ Details

Name: dei_CurrentFiscalYearEndDate

Namespace Prefix: dei_

Data Type: xbrli:gMonthDayItemType

Balance Type: na

Period Type: duration

X

- Definition
This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.
+ References
No definition available.
+ Details

Name: dei_DocumentFiscalPeriodFocus

Namespace Prefix: dei_

Data Type: dei:fiscalPeriodItemType

Balance Type: na

Period Type: duration

X

- Definition
This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.
+ References
No definition available.
+ Details

Name: dei_DocumentFiscalYearFocus

Namespace Prefix: dei_

Data Type: xbrli:gYearItemType

Balance Type: na

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: dei_DocumentInformationLineItems

Namespace Prefix: dei_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.
+ References
No definition available.
+ Details

Name: dei_DocumentPeriodEndDate

Namespace Prefix: dei_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition
The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".
+ References
No definition available.
+ Details

Name: dei_DocumentType

Namespace Prefix: dei_

Data Type: dei:submissionTypeItemType

Balance Type: na

Period Type: duration

X

- Definition
A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation 12B

-Number 240

-Section 12b

-Subsection 1

+ Details

Name: dei_EntityCentralIndexKey

Namespace Prefix: dei_

Data Type: dei:centralIndexKeyItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.
+ References
No definition available.
+ Details

Name: dei_EntityCommonStockSharesOutstanding

Namespace Prefix: dei_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.
+ References
No definition available.
+ Details

Name: dei_EntityFilerCategory

Namespace Prefix: dei_

Data Type: dei:filerCategoryItemType

Balance Type: na

Period Type: duration

X

- Definition
The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation 12B

-Number 240

-Section 12b

-Subsection 1

+ Details

Name: dei_EntityRegistrantName

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

XML 39 R18.htm IDEA: XBRL DOCUMENT v3.3.0.814

SUMMARY OF SIGNIFICANT ACCOUNTING PRACTICES (Tables)
9 Months Ended

Sep. 30, 2015

SUMMARY OF SIGNIFICANT ACCOUNTING PRACTICES [Abstract]

Schedule of Assets Measured at Fair Value

Assets at Fair Value as of September 30, 2015

Level 1 Level 2 Level 3 Total

Money market funds $ 20,562 $ - $ - $ 20,562

Corporate debt securities - 79,374 - 79,374

Total $ 20,562 $ 79,374 $ $ 99,936

Schedule of Stock-Based Compensation

For the Three Months Ended
September 30, For the Nine Months Ended
September 30,

2015 2014 2015 2014

Operating expenses $ 1,492 $ 658 $ 3,726 $ 1,905

Research and development 895 282 2,050 817

 Total stock-based compensation expense $ 2,387 $ 940 $ 5,776 $ 2,722

X

- References
No definition available.
+ Details

Name: us-gaap_AccountingPoliciesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (a),(b)

-URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19207-110258

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19190-110258

+ Details

Name: us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the allocation of equity-based compensation costs to a given line item on the balance sheet and income statement for the period. This may include the reporting line for the costs and the amount capitalized and expensed.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (h)(1)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 14.F)

-URI http://asc.fasb.org/extlink&oid=27013229&loc=d3e301413-122809

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 14

-Section F

+ Details

Name: us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 40 R4.htm IDEA: XBRL DOCUMENT v3.3.0.814

Condensed Statements of Operations - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended

Sep. 30, 2015

Sep. 30, 2014

Sep. 30, 2015

Sep. 30, 2014

Condensed Statements of Operations [Abstract]

Revenues

Costs and expenses

Operating expenses $ 2,660 $ 2,449 $ 7,259 $ 6,155

Research and development 4,983 354 12,147 1,018

Total costs and expenses 7,643 2,803 19,406 7,173

Loss from operations (7,643) (2,803) (19,406) (7,173)

Other income (expense)

Interest income 8 5 123 5

Net Loss $ (7,635) $ (2,798) $ (19,283) $ (7,168)

Net Loss Per Share, Basic and Diluted $ (0.16) $ (0.11) $ (0.44) $ (0.30)

Weighted-Average Common Shares Outstanding, Basic and Diluted 47,271,593 26,632,908 43,398,650 24,107,787

X

- Definition
The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.
+ References
No definition available.
+ Details

Name: us-gaap_EarningsPerShareBasicAndDiluted

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_IncomeStatementAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.7(b))

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_InvestmentIncomeInterest

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Net Income

-URI http://asc.fasb.org/extlink&oid=51831255

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.18)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.22)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Other Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=51831270

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 19

-Article 5

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 20

-Article 9

+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NonoperatingIncomeExpenseAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Excludes Selling, General and Administrative Expense.
+ References
No definition available.
+ Details

Name: us-gaap_OperatingCostsAndExpenses

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.
+ References
No definition available.
+ Details

Name: us-gaap_OperatingExpenses

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_OperatingExpensesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The net result for the period of deducting operating expenses from operating revenues.
+ References
No definition available.
+ Details

Name: us-gaap_OperatingIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 730

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 985

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756

+ Details

Name: us-gaap_ResearchAndDevelopmentExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.1)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_Revenues

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).
+ References
No definition available.
+ Details

Name: us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

XML 41 R12.htm IDEA: XBRL DOCUMENT v3.3.0.814

PROPERTY AND EQUIPMENT
9 Months Ended

Sep. 30, 2015

PROPERTY AND EQUIPMENT [Abstract]

PROPERTY AND EQUIPMENT

NOTE 4. PROPERTY AND EQUIPMENT

Property and equipment are comprised of the following as of (in thousands):

September 30, 2015 December 31, 2014

Laboratory equipment $ 1,563 $ 688

Leasehold improvements 853 762

Computer, software, and office equipment 211 185

2,627 1,635

Accumulated depreciation (794 ) (103 )

$ 1,833 $ 1,532

Depreciation expense for the three and nine months ended September 30, 2015 and 2014 was $266, $691, $5, and $23, respectively.

X

- References
No definition available.
+ Details

Name: us-gaap_PropertyPlantAndEquipmentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, accounting policies and methodology, roll forwards, depreciation, depletion and amortization expense, including composite depreciation, accumulated depreciation, depletion and amortization expense, useful lives and method used, income statement disclosures, assets held for sale and public utility disclosures.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.13-14)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=51717284&loc=d3e1361-107760

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=51719941&loc=d3e2921-110230

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

+ Details

Name: us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 42 R11.htm IDEA: XBRL DOCUMENT v3.3.0.814

CASH, MONEY MARKET FUNDS, AND SHORT-TERM INVESTMENTS
9 Months Ended

Sep. 30, 2015

CASH, MONEY MARKET FUNDS, AND SHORT-TERM INVESTMENTS [Abstract]

CASH, MONEY MARKET FUNDS, AND SHORT-TERM INVESTMENTS

NOTE 3. CASH, MONEY MARKET FUNDS, AND SHORT-TERM INVESTMENTS

Cash, money market funds, and short-term investments consist of the following (in thousands):

September 30,
2015

December 31,

2014

Checking and savings accounts (reported as cash and cash equivalents) $ 10,210 $ 45

Money market funds 20,562 -

Corporate debt securities (reported as short-term investments) 79,374 -

$ 110,146 $ 45

Money market funds and short-term investments include the following securities with gross unrealized gains and losses (in thousands):

Gross Gross

Unrealized Unrealized

September 30, 2015 Cost Gains Gains Fair Value

Money market funds $ 20,562 $ - $ - $ 20,562

Corporate debt securities 79,336 38 - 79,374

Total $ 99,897 $ 38 $ - $ 99,936



As of September 30, 2015, the contractual maturities of our money market funds and short-term investments were (in thousands):

Within One

Year

Money market funds $ 20,562

Corporate debt securities 79,374

$ 99,936

At September 30, 2015,the Company's short-term investments were invested in short-term fixed income debt securities and notes of domestic and foreign high credit issuers and in money market funds. The Company's investment policy limits investments to certain types of instruments such as certificates of deposit, money market instruments, obligations issued by the U.S. government and U.S. government agencies as well as corporate debt securities, and places restrictions on maturities and concentration by type and issuer. At September 30, 2015, the Company's short-term investments totaled $80 million, of which 56% were invested in notes of five companies, 25% were invested in notes of other domestic issuers, and 19% were invested in notes of foreign issuers. The average maturity of these notes was 66 days. At September 30, 2015 the Company's money-market funds totaled $20.6 million and were invested in a single fund, the Dreyfus Cash Management Money Market Fund, a no-load money market fund.

X

- References
No definition available.
+ Details

Name: us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure of the components of cash, cash equivalents, and short-term investments. Short-term investments may include current marketable securities.
+ References
No definition available.
+ Details

Name: us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 43 R23.htm IDEA: XBRL DOCUMENT v3.3.0.814

LICENSE AND COMMITMENTS (Tables)
9 Months Ended

Sep. 30, 2015

LICENSE AND COMMITMENTS [Abstract]

Schedule of Purchase Obligation

Year Amount

2015 $ 3,104

2016 2,874

Total $ 5,978

X

- References
No definition available.
+ Details

Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of unconditional purchase obligations that are recognized as a liability on the balance sheet, including the nature and term of the unconditional purchase obligations; the aggregate amount of payments for each of the five years following the date of the latest balance sheet; and the combined aggregate amount of maturities and sinking fund requirements for all long-term borrowings associated with suppliers' financing arrangements.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 440

-SubTopic 10

-Section 50

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6394976&loc=d3e25383-109308

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 440

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6394976&loc=d3e25287-109308

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 470

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6802200&loc=d3e1835-112601

+ Details

Name: us-gaap_RecordedUnconditionalPurchaseObligationsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 44 R19.htm IDEA: XBRL DOCUMENT v3.3.0.814

CASH, MONEY MARKET FUNDS, AND SHORT-TERM INVESTMENTS (Tables)
9 Months Ended

Sep. 30, 2015

CASH, MONEY MARKET FUNDS, AND SHORT-TERM INVESTMENTS [Abstract]

Schedule of Cash, Money Market Funds and Short-Term Investments

September 30,
2015

December 31,

2014

Checking and savings accounts (reported as cash and cash equivalents) $ 10,210 $ 45

Money market funds 20,562 -

Corporate debt securities (reported as short-term investments) 79,374 -

$ 110,146 $ 45

Schedule of Unrealized Gains and Losses

Gross Gross

Unrealized Unrealized

September 30, 2015 Cost Gains Gains Fair Value

Money market funds $ 20,562 $ - $ - $ 20,562

Corporate debt securities 79,336 38 - 79,374

Total $ 99,897 $ 38 $ - $ 99,936



Schedule of Contractual Maturities

Within One

Year

Money market funds $ 20,562

Corporate debt securities 79,374

$ 99,936

X

- References
No definition available.
+ Details

Name: us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.
+ References
No definition available.
+ Details

Name: us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the components of cash, cash equivalents, and investments.
+ References
No definition available.
+ Details

Name: us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of unrealized gains and losses on investments.
+ References
No definition available.
+ Details

Name: us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 45 R15.htm IDEA: XBRL DOCUMENT v3.3.0.814

LICENSE AND COMMITMENTS
9 Months Ended

Sep. 30, 2015

LICENSE AND COMMITMENTS [Abstract]

LICENSE AND COMMITMENTS

NOTE 7. LICENSE AND COMMITMENTS

National Institutes of Health and the National Cancer Institute

Cooperative Research and Development Agreement

Effective August 5, 2011, the Company signed a Cooperative Research and Development Agreement (CRADA) with the National Institutes of Health and the National Cancer Institute (NCI). Under the terms of the five-year cooperative research and development agreement, the Company will work with Dr. Steven A. Rosenberg, M.D., Ph.D., chief of NCI's Surgery Branch, to develop adoptive cell immunotherapies that are designed to destroy metastatic melanoma cells using a patient's tumor infiltrating lymphocytes.

On January 22, 2015, the Company executed an amendment (the “Amendment”) to the CRADA to include four new indications. As amended, in addition to metastatic melanoma, the CRADA now also includes the development of TIL therapy for the treatment of patients with bladder, lung, triple-negative breast, and HPV-associated cancers. Under the Amendment, the NCI also has agreed to provide the Company with samples of all tumors covered by the Amendment for performing studies related to improving TIL selection and/or TIL scale-out production and process development. Although the CRADA has a five year term, either party to the CRADA has the right to terminate the CRADA upon 60 days' notice to the other party.

National Institutes of Health

Development and Manufacture TIL

Effective October 5, 2011, the Company entered into a Patent License Agreement with the National Institutes of Health, an agency of the United States Public Health Service within the Department of Health and Human Services (“NIH”), which License Agreement was subsequently amended on February 9, 2015 and October 2, 2015. Pursuant to the License Agreement as amended, NIH granted to the Company an exclusive worldwide right and license to develop and manufacture certain proprietary autologous tumor infiltrating lymphocyte adoptive cell therapy products for the treatment of metastatic melanoma, ovarian cancer, breast cancer, and colorectal cancer. The License Agreement requires the Company to pay royalties based on a percentage of net sales (which percentage is in the mid-single digits and subject to certain annual minimum royalty payments), a percentage of revenues from sublicensing arrangements, and lump sum benchmark royalty payments on the achievement of certain clinical and regulatory milestones for each of the various indications and other direct costs incurred by NIH pursuant to the agreement.

NIH - Exclusive Patent License Agreement

On February 10, 2015, the Company entered into an exclusive Patent License Agreement with the NIH under which the Company received an exclusive, world-wide license to the NIH's rights in and to two patent-pending technologies related to methods for improving tumor-infiltrating lymphocytes for adoptive cell therapy. The licensed technologies relate to the more potent and efficient production of TIL from melanoma tumors by selecting for T-cell populations that express various inhibitory receptors. Unless terminated sooner, the license shall remain in effect until the last licensed patent right expires.

In consideration for the exclusive rights granted under the exclusive Patent License Agreement, the Company agreed to pay the NIH a non-refundable upfront licensing fee which was recognized as research and development expense during the nine months ended September 30, 2015. The Company also agreed to pay customary royalties based on a percentage of net sales (which percentage is in the mid-single digits), a percentage of revenues from sublicensing arrangements, and lump sum benchmark payments upon the successful completion of the Company's first Phase 2 clinical study, the successful completion of the Company's first Phase 3 clinical study, the receipt of the first FDA approval or foreign equivalent for a licensed product or process resulting from the licensed technologies, the first commercial sale of a licensed product or process in the United States, and the first commercial sale of a licensed product or process in any foreign country.

H. Lee Moffitt Cancer Center

Research Collaboration Agreement

In September, 2014, we entered into a research collaboration agreement with the H. Lee Moffitt Cancer Center and Research Institute, Inc. to jointly engage in transitional research and development of adoptive tumor-infiltrating lymphocyte cell therapy with improved anti-tumor properties and process.

Exclusive License Agreement

On July 21, 2014, the Company entered into an Exclusive License Agreement (the “Moffitt License Agreement”), effective as of June 28, 2014, with the H. Lee Moffitt Cancer Center and Research Institute, Inc. (“Moffitt”) under which the Company received an exclusive, world-wide license to Moffitt's rights in and to two patent-pending technologies related to methods for improving tumor-infiltrating lymphocytes for adoptive cell therapy. Unless earlier terminated, the term of the license extends until the earlier of the expiration of the last patent related to the licensed technology or 20 years after the effective date of the license agreement.

Pursuant to the Moffitt License Agreement, the Company paid an upfront licensing fee which was recognized as research and development expense during 2014. A patent issuance fee will also be payable under the Moffitt License Agreement, upon the issuance of the first U.S. patent covering the subject technology. In addition, the Company agreed to pay milestone license fees upon completion of specified milestones, customary royalties based on a specified percentage of net sales (which percentage is in the low single digits) and sublicensing payments, as applicable, and annual minimum royalties beginning with the first sale of products based on the licensed technologies, which minimum royalties will be credited against the percentage royalty payments otherwise payable in that year. The Company will also be responsible for all costs associated with the preparation, filing, maintenance and prosecution of the patent applications and patents covered by the Moffitt License Agreement related to the treatment of any cancers in the United States, Europe and Japan and in other countries selected that the Company and Moffitt agreed to.

During the nine months ended September 30, 2015 and 2014, the Company recognized $2.5 million and $0.9 million respectively, of expenses related to its license agreements. The amounts were recorded as part of research and development expenses in the statement of operations. Additionally, during the nine months ended September 30, 2015, there were no net sales subject to certain annual minimum royalty payments or sales that would require us to pay a percentage of revenues from sublicensing arrangements. In addition, there were no benchmarks or milestones achieved that would require payment under the lump sum benchmark royalty payments on the achievement of certain clinical regulatory milestones for each of the various indications.

Future guaranteed commitments under all of the Company's agreements amount to (in thousands):

Year Amount

2015 $ 3,104

2016 2,874

Total $ 5,978

X

- References
No definition available.
+ Details

Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for commitments and contingencies.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6449706&loc=d3e16207-108621

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 460

-SubTopic 10

-Section 50

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=51674963&loc=d3e12565-110249

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 450

-SubTopic 20

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14435-108349

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.25)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 440

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6394976&loc=d3e25287-109308

+ Details

Name: us-gaap_CommitmentsAndContingenciesDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 46 R13.htm IDEA: XBRL DOCUMENT v3.3.0.814

STOCKHOLDERS' EQUITY
9 Months Ended

Sep. 30, 2015

STOCKHOLDERS' EQUITY [Abstract]

STOCKHOLDERS' EQUITY

NOTE 5. STOCKHOLDERS' EQUITY

Public offering

On March 3, 2015, the Company completed an underwritten public offering of 9,200,000 shares of its common stock at a price of $8.00 per share of common stock. The net proceeds to the Company from the offering were $68.3 million, after deducting underwriting discounts and commissions and offering expenses. The offering was made pursuant to the Company's existing shelf registration statement on Form S-3, including a base prospectus, which was filed with the SEC on November 20, 2014 and declared effective on December 10, 2014, a preliminary prospectus supplement thereunder, and a registration statement on Form S-3 filed with the SEC on February 26, 2015.

Issuance of common stock upon conversion of preferred stock

During the nine months ended September 30, 2015, the Company issued 1,000,000 shares of common stock upon the conversion of 2,000 shares of Series A Convertible Preferred Stock. The number of conversion shares issued was determined on a formula basis of 500 common shares for each Series A Convertible Preferred Stock held consistent with the contract.

Common stock with vesting terms

During 2014, the Company granted 797,500 shares of its restricted common stock to nine of its employees in accordance with the terms of their employment agreements. The 797,500 shares vest over a period of three years. As these shares were granted to employees, the Company calculated the aggregate fair value of the 797,500 shares based on the trading prices of the Company's stock at their grant dates and determined it to be $5.3 million, of which $1.3 million was expensed in 2014. The allocable portion of the fair value of the stock that vested during the nine months ended September 30, 2015 amounted to $1.5 million and was recognized as expense in the accompanying statements of operations. As of September 30, 2015, the amount of unvested compensation related to the unvested outstanding shares of restricted common stock was $2.5 million, which will be recorded as expense in future periods as the shares vest.

When calculating basic net income (loss) per share, these shares are included in basic weighted average common shares outstanding from the time they vest. When calculating diluted net income (loss) per share, these shares are included in diluted weighted average common shares outstanding from the time they are granted, unless they are antidilutive. Shares of restricted stock granted above are subject to forfeiture to the Company or other restrictions that will lapse in accordance with a vesting schedule determined by our Board.

The following table summarizes restricted common stock activity:

Number of

Shares

Weighted

Average

Grant Date

Fair Value

Non-vested shares, January 1, 2015 757,500 $ 6.84

Granted

Vested (233,499 ) 4.37

Forfeited (30,000 ) 8.24

Non-vested shares, September 30, 2015 494,001 $ 6.56

X

- References
No definition available.
+ Details

Name: us-gaap_StockholdersEquityNoteAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(d),(e))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SAB TOPIC 4.E)

-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29-31)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 4

-Subparagraph (SAB TOPIC 4.C)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 30

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Preferred Stock

-URI http://asc.fasb.org/extlink&oid=6521494

Reference 12: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 13: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 11

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

Reference 14: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 4

-Section E

Reference 15: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 4

-Section C

+ Details

Name: us-gaap_StockholdersEquityNoteDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 47 R14.htm IDEA: XBRL DOCUMENT v3.3.0.814

STOCK OPTIONS AND WARRANTS
9 Months Ended

Sep. 30, 2015

STOCK OPTIONS AND WARRANTS [Abstract]

STOCK OPTIONS AND WARRANTS

NOTE 6. STOCK OPTIONS AND WARRANTS

Stock Options

A summary of the status of stock options at September 30, 2015, and the changes during the nine months then ended, is presented in the following table:

Weighted

Weighted Average Aggregate

Shares Average Remaining Intrinsic

Under Exercise Contractual Value

Option Price Life
(in thousands)

Outstanding at January 1, 2015 1,857,877 $ 7.31 8.2 $ 2,875

Granted 943,750
9.18 9.8

Exercised (10,000 )

Expired/Forfeited (87,432 ) 5.92 7.29
-

Outstanding at September 30, 2015 2,704,195 $ 8.05 8.16 $ 64

Exercisable at September 30, 2015 883,449 $ 8.63 6.67 $ 98

During the nine months ended September 30, 2015, the Company granted options to purchase 943,750 shares of common stock to new employees and directors of the Company. The stock options generally vest between one and three years. The fair value of these options was determined to be $8.3 million using the Black-Scholes option pricing model based on the following assumptions: (i) volatility rate of 211%, (ii) discount rate of 1.57%, (iii) zero expected dividend yield, and (iv) expected life of 6 years.

During the nine months ended September 30, 2015 and 2014, the Company recorded compensation costs of $4.1 million and $1.9 million, respectively, relating to the vesting of stock options. As of September 30, 2015, the aggregate value of unvested options was $10.3 million, which will continue to be amortized as compensation cost as the options vest over terms ranging from nine months to three years, as applicable.

On September 19, 2014, The Company's Board of Directors adopted the Lion Biotechnologies, Inc. 2014 Equity Incentive Plan (the “2014 Plan”). The 2014 Plan was approved by our stockholders at the annual meeting of stockholders held in November 2014. The 2014 Plan as approved by the stockholders authorized the issuance up to an aggregate of 2,350,000 shares of common stock. On April 10, 2015 the Board amended the 2014 Plan, subject to stockholder approval, to increase the total number of shares that can be issued under the 2014 Plan by 1,650,000 from 2,350,000 shares to 4,000,000 shares. The increase in shares available for issuance under the 2014 Plan was approved by stockholders on June 12, 2015.

Warrants

A summary of the status of stock warrants at September 30, 2015, and the changes during the nine months then ended, is presented in the following table:

Weighted

Weighted Average Aggregate

Shares Average Remaining Intrinsic

Under Exercise Contractual Value

Warrants Price Life
(in thousands)

Outstanding at December 31, 2014 11,084,426 $ 2.51 3.85 years $ 59,518

Issued -

Exercised (3,847,210 ) $ 2.50

Expired -

Outstanding and exercisable at September 30, 2015 7,237,216 $ 2.51 3.3 years $ 23,593

During the nine months ended September 30, 2015, the Company received $9.6 million in cash from the exercise of 3,847,210 warrants for the purchase of an equal number of shares of its common stock.

X

- Definition
The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 40

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6418621&loc=d3e17540-113929

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 50

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=51659978&loc=d3e25284-112666

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5444-113901

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 14

+ Details

Name: us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 48 R16.htm IDEA: XBRL DOCUMENT v3.3.0.814

LEGAL PROCEEDINGS
9 Months Ended

Sep. 30, 2015

LEGAL PROCEEDINGS [Abstract]

LEGAL PROCEEDINGS
NOTE 8. LEGAL PROCEEDINGS

On August 18, 2015, MBA Holdings, LLC filed a breach of contract lawsuit against the Company in the Superior Court of California, County of Los Angeles (MBA Holdings, LLC v. Lion Biotechnologies, Inc., Case BC 591513). The complaint alleges that the Company and MBA Holdings, LLC were parties to (i) a June 15, 2012 “Finder's Fee Agreement”, (ii) a Confidentiality, Non-Disclosure and Non-Circumvention Agreement, dated June 13, 2012, and (iii) a Consulting Agreement, dated July 9, 2012, and that the Company breached these agreements by failing to compensate MBA Holdings for introducing Roth Capital Partners, LLC and Highline Research Advisors LLC to the Company in connection with the $23.3 million equity funding the Company completed in November 2013. MBA Holdings also alleges that the Company failed to register certain shares underlying a common stock purchase warrant that the Company issued to MBA Holdings. MBA Holdings has asked for damages in the amount of $7,746,000. The Company has not yet been served in the foregoing lawsuit.

The Company believes that there is no merit to the claims made by MBA Holdings in the complaint. On September 9, 2015 the Company provided MBA Holdings with evidence that the Company dealt with a certain investment banker on a financing transaction at least six months before MBA Holdings purportedly introduced the Company to the banker, and that a certain research analyst group were known to the Company prior to the purported introduction. Accordingly, the Company has demanded that MBA Holdings dismiss the lawsuit. To date, MBA Holdings has not served the complaint on the Company, dismissed the lawsuit, or responded to the Company's last communications. Accordingly, on October 26, 2015 the Company renewed its demand on MBA and its counsel to dismiss the suit or face exposure to damages for malicious prosecution, voluntarily entered an appearance in the case, and initiated discovery proceedings for the purpose of pursuing an early resolution of the case in the Company's favor. The Company intends to vigorously defend itself in this matter and will seek a prevailing-party award of its attorney's fees and other litigation costs pursuant to contractual provisions in the agreements appended to MBA's complaint.

There are no other pending legal proceedings to which the Company is a party or of which its property is the subject other than as previously reported.

X

- References
No definition available.
+ Details

Name: us-gaap_LossContingencyAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for loss and gain contingencies. Describes any existing condition, situation, or set of circumstances involving uncertainty as of the balance sheet date (or prior to issuance of the financial statements) as to a probable or reasonably possible loss incurred by an entity that will ultimately be resolved when one or more future events occur or fail to occur, and typically discloses the amount of loss recorded or a range of possible loss, or an assertion that no reasonable estimate can be made.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 450

-SubTopic 20

-Section 50

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14472-108349

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 460

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6851643&loc=d3e12021-110248

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 450

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14326-108349

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 450

-SubTopic 20

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14394-108349

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 450

-SubTopic 20

-Section 50

-Paragraph 9

-URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14557-108349

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 460

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6851643&loc=d3e12053-110248

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 450

-SubTopic 20

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14435-108349

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 450

-SubTopic 20

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14453-108349

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 450

-SubTopic 20

-Section 50

-Paragraph 10

-URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14615-108349

+ Details

Name: us-gaap_LossContingencyDisclosures

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 49 R34.htm IDEA: XBRL DOCUMENT v3.3.0.814

STOCKHOLDER'S EQUITY (Schedule of Restricted Stock Activity) (Details)
9 Months Ended

Sep. 30, 2015

$ / shares

shares

Number of Shares

Non-vested shares, January 1, 2015 | shares 757,500

Vested | shares (233,499)

Forfeited | shares (30,000)

Non-vested shares, September 30, 2015 | shares 494,001

Weighted Average Grant Date Fair Value

Non-vested shares, January 1, 2015 $ 6.84

Vested 4.37

Forfeited 8.24

Non-vested shares, September 30, 2015 $ 6.56

X

- Definition
The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(iv)(3)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(2)(iii)(3)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(2)(i)-(ii)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The weighted average fair value of nonvested awards on equity-based plans excluding option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, revenue or profit achievement stock award plan) for which the employer is contingently obligated to issue equity instruments or transfer assets to an employee who has not yet satisfied service or performance criteria necessary to gain title to proceeds from the sale of the award or underlying shares or units.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(2)(i)-(ii)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(2)(iii)(2)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(2)(iii)(2)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

XML 50 R21.htm IDEA: XBRL DOCUMENT v3.3.0.814

STOCKHOLDERS' EQUITY (Tables)
9 Months Ended

Sep. 30, 2015

STOCKHOLDERS' EQUITY [Abstract]

Schedule of Restricted Stock Activity

Number of

Shares

Weighted

Average

Grant Date

Fair Value

Non-vested shares, January 1, 2015 757,500 $ 6.84

Granted

Vested (233,499 ) 4.37

Forfeited (30,000 ) 8.24

Non-vested shares, September 30, 2015 494,001 $ 6.56

X

- Definition
Tabular disclosure of the changes in outstanding nonvested restricted stock units.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(2)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_StockholdersEquityNoteAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 51 R26.htm IDEA: XBRL DOCUMENT v3.3.0.814

SUMMARY OF SIGNIFICANT ACCOUNTING PRACTICES (Schedule of Assets Measured at Fair Value) (Details) - Fair Value, Measurements, Recurring [Member]
$ in Thousands

Sep. 30, 2015

USD ($)

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Assets, fair value $ 99,936

Money Market Funds [Member]

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Assets, fair value 20,562

Corporate Debt Securities [Member]

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Assets, fair value 79,374

Fair Value, Inputs, Level 1 [Member]

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Assets, fair value 20,562

Fair Value, Inputs, Level 1 [Member] | Money Market Funds [Member]

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Assets, fair value $ 20,562

Fair Value, Inputs, Level 1 [Member] | Corporate Debt Securities [Member]

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Assets, fair value

Fair Value, Inputs, Level 2 [Member]

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Assets, fair value $ 79,374

Fair Value, Inputs, Level 2 [Member] | Money Market Funds [Member]

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Assets, fair value

Fair Value, Inputs, Level 2 [Member] | Corporate Debt Securities [Member]

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Assets, fair value $ 79,374

Fair Value, Inputs, Level 3 [Member] | Money Market Funds [Member]

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Assets, fair value

Fair Value, Inputs, Level 3 [Member] | Corporate Debt Securities [Member]

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Assets, fair value

X

- Definition
Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19207-110258

+ Details

Name: us-gaap_AssetsFairValueDisclosure

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateDebtSecuritiesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 52 R41.htm IDEA: XBRL DOCUMENT v3.3.0.814

SUBSEQUENT EVENTS (Details) - USD ($)
$ in Thousands
9 Months Ended

Sep. 30, 2015

Sep. 30, 2014

Subsequent Event [Line Items]

Proceeds from warrant exercises $ 9,618 $ 3,002

Warrant [Member]

Subsequent Event [Line Items]

Purchase of common stock 3,847,210

X

- Definition
The cash inflow associated with the amount received from holders exercising their stock warrants.
+ References
No definition available.
+ Details

Name: us-gaap_ProceedsFromWarrantExercises

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Number of share options (or share units) exercised during the current period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(iv)(2)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28,29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30

-Article 5

+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.
+ References
No definition available.
+ Details

Name: us-gaap_SubsequentEventLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_AwardTypeAxis=us-gaap_WarrantMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 53 R5.htm IDEA: XBRL DOCUMENT v3.3.0.814

Condensed Statements of Operations (Parenthetical) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended

Sep. 30, 2015

Sep. 30, 2014

Sep. 30, 2015

Sep. 30, 2014

Operating Expense [Member]

Share-based Compensation $ 1,452 $ 658 $ 3,726 $ 1,905

Research and Development Expense [Member]

Share-based Compensation $ 895 $ 282 $ 2,050 $ 817

X

- Definition
The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

+ Details

Name: us-gaap_ShareBasedCompensation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_IncomeStatementLocationAxis=us-gaap_OperatingExpenseMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

ZIP 54 0001144204-15-063327-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001144204-15-063327-xbrl.zip M4$L#!!0````(`)EZ9D?AQ1QPSJ(``'K$"0`1`!P`;&)I;RTR,#$U,#DS,"YX M;6Q55`D``Z(+/5:B"SU6=7@+``$$)0X```0Y`0``[%WI;^,XEO^^P/X/&@\P MU0/$B0Z?J:X:.%=W,%5)-DEU+_9+H$BTPRD='AU)/'_]/E*V+E,V14N)[:C1 MZ'9T\/W>XSLI'K_^X]6VI&?D^=AUOK240[DE(<=P3>Q,OK1"OZW[!L8MR0]T MQ]0MUT%?6C/DM_[Q];__Z]>_M-NG'M(#9$J/,^GR]O+N0+IQ7Y"77)!.=>_1 M==IM\OSKHV?A8_)?":@Z_C'VW8ZJ]+^TGH)@>GQT]/+RY$B59>UH M_D1K_H*%G9\KGB:W'W4?+1X/`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`S7Z^`)>40T'GHB`GQ&T4#'Q^AZ7CGLIQK;QQMW=I`W;F3:\K1HT,?\]R\L:.UC;S86$6ITC*KNS("LS M!%&+CLS+`+4M:TD9H,&_.R&??-Y,V"B9-VNI5RK.FW=&C%E7E)9(E6K6:2M* M6U7C:8A@X:JZ$_+)S<^C;)11LSFO=:C9+HDQ/Z":2*1*-8/0(;?E[ES---); MO6G[GG@ M#AJ=6JM3&4DU^E0X]=5Y1EZ`'RVT3S/;WD3#ULBNT;GBI5F!AXV@T31>36-* MK-&O@N5;3>ZU>[G7]BSM*M:K)O?:G=QK%_2IR;WV*_?:+IUCYUX7(%,B?MT! MD49">1CY/@K\>W?GOV5_U__E>J>A'[@V\M)3%1A9%W21Q!8KZAPYMA3[]XGP&_>D'V*!33+R/H[9K9=`H M\78K\87K(3QQHC[[,&K+X+I1U&U0U/2TE@L=>W_H5HB^(]T//3HGQ+\EV98' MV=A<5^.'+AU(V/QO9#,097[ON^N@V7>0.0HN0L?<\7DQ,:6[N?2=+:2O)49ONU$ M,6&+4AN+VD6+4AN+VE:+TAJ+VD6+TAJ+V@:+:JSF/:RF4<\*BI)3UYNZ4!FB M,_08)&/'C09OM=]_G]IDI:XT]L4L41K[VD7[>I]*I;&O\@5+8U^[:%_O4[Y,4&XT.,W7!Y_.4GSHW*GK!]?C.]W:];2?Z[B>)6[? M2R^V_D"Y1B_>7B]VX;"X1B\^>API6J'3Z,7'7463+C#V:TX$G;I]/YLB_WI, M!N1&CAGM!U>TW&K?)R&L*"2:CG^_CM_2@)'=_'8P-]1`?. MY'P_K;KIY/?NY#<_+^X.VD+^GNZU%(_HTBEWUV/*4FHK!B[F/WAAQAK^7YPL MN4\;5;[HGKGL%[9G:TFA@?^,,ZE\]_A&!_8[-C`9?WB/(V'VMGNWU.E?KM." M1@=V-<<_MZ>6.T-H?[8!9G=I(9_[Y;G9J5G3R1\[12N.Z8UF-)&]T87W"P5O M$.'W8R-V=E>^R];I[QG)F\[\Z!$[(Z6]J[[?7P>V,S8W=K]S,9ASN=W^I5V; M+L3;AQ1O2UW*"IW47S^:3J8Y;G1RJ[XH-@7ICB7!M25`])1LT`4R;>/^Q=WM M_B=,7.DV2LTYR/#U/A6L4E_R0PZ?3@)-A_S5=&2-+IW(NZ1+[Z1>J:-R:?J[ M'L.M=9\816YK[S&TL*%$*.PJ)!(Z.!+'C[NSG!CL:*N8K]AW.ZK2/X8G%@TM M;J4;)RT5M;PXQ"]'P<3/()@\H^3%J]!&GAZX2WDI-ZRT*-@MILB=(<>UL;.: MX%RQ"1\^#\7E1A=W4WROE1Z5FU_0->L@K6W])ESJE&S;4_C)UW*\V$OWGT:. M2?Y'II4^ZQ;HN#\*3G7/FV%G0K8O&&7?:DDC3]"I13FH&XQJ"0N@ZW!)\]?&Q@ZTOK<`+44LZRI(;/>O8TA\M=.%Z9%>"9$'A:>AY M(,L%P:Z@./I#K=_)B&,M24&$O8I$;$0D'26&,`T%;Z_4W@\@$,Q1U48JL4=-/J5%)THHL[G3Z?5[2A>L%KE"" M1-A1#S0MURG%U`1PB;IEI:NI@K@B4<8(1)VNHJBJVF%TTDIJ_$XTIQ&]KCQ< M3\PPW!""T8T^(^XKKXZB#E51>CE#8-(IA87?=>:PJ)VA"!9PN^8WK#]BB^7( M%5&WJO3D01X.FU191*).5%-%`:7%>(LLJ*_-&ZC,&=A$?>J@MZKKF#3%4:JB MWG=CE,6]JHKZ8770S<;O=?VY`H.PS^WUM%(8LJN2LNDXO]M=FSH5TJ@J8SUU M;=MU&`1$'6HV=.6;YR0NZD%YB-.!H]2M>_<$T8-_S2R&3;/1-73*@1'UF*7` MI+Q":(?4%="TE)Q#[Z$G,A[WC*)]V;ZYO@_9Q_7X7G^-08JZ3FW)JY'.Q,;&T%8$C-S#=R!-^6XCNZ.F8(]N%C/,_]'IAL1N/U8FZ\/ZP4Q1G-@)6 M,[O"$4+6WH#=;(X*E<.U1U?X1WG%XN-*S`QO3(F_RJ28`I[D0YE,BBA'?"/` MO.'EK0!'WUQ&8?#D>O@_R(R!;%$:Y]96$:CDWX+2*I!`\KE#T1O"B MQ#>&QA62F-`@5'=6PXI(K8=T'0;D0ZD);CC&Q56`".)*T2LM+ZY:A-V5M6.TNOUF#4NGSLI`Y@W]+P5X"+OTN4* M*\RN5Y;=RPJ"Y9%QQ8_ZD65-N"L>+#K]@=S7AH,5H%@VO/00PX"[7$-.HJAX M+)@I*ZZQ*+8;UOI=61G4(BNN*D44U9*LBH>/HA=B6%P%"A.6VNDJ76W52%7T M6DE`XD&A'*!D#.$9.6$"H)=S^H4G`)4KJI;(*,MDF`?*;$A&97*SO)1A0S(: MDYOEV>GER%Q/R30K4&IR;`0I?.>?WQ.Z'<'.RHT5]GI9OUU(N"R^KF`OYP>% M<]\9*\/7$U2/7*&N=FO"UQ?4J]Q<#B7WP8H3WRWR$3G_$!XX(^<;NK2>GC\; M8QQ4HH.=X2!;_J\D+H)S6(DN:MU.K3#[;/];5B455>GTZP7*]N!E=5.!T"Z* M,U;CO-WTV6Z_K$[V>QV-;3=K['D)#SL^E/:#`[DB/.RX45K)AAVY5PT@=J`H MJTQ]I2\FH.0K78R('1K*JE"[6(<2FOR@V/&@K!ZUBQ5)!!0[`)15IO8*;1)! MQ7;W936J7:Q21:`NG6?DTV\5T1.7``+2[F1&IFB&G9L9DT%51+0D--&L/`NM M6PU.L")YO^;R^T*!%@,R#5 M9/K@I-18*KHV>( MOQ-T%9*UDM=C^F)J_*^(#X&*H&#D5NTKW:&6<"$&K%+F!,H+]A!BKZ>I0WFP M5*.8&ZIV#P5Y'[_4&_6N865HE,,J<1"B@ZTR(&SULB M/>3+L/FZ[M696J>;G>W&!E,*,&_Y)`2XUQU4C9>WLA+"J_757M6`>8LN,8T8 MRMV*`2LR;S'VL')MYZ;7/TZJ!J:U1DWI*N`O14S#K3/XTYGVY8$B;I2%LWF4%6O%'YB' MOY6:T+AF`E3Q6@B%M8*<$Q>'H:Z01_'RQH?45!P^82Q/>-I`(,7SF%<"6[M6 M47R5C[)BO7D:4S)OB0M=SA0WP5<\5^VA8,T:5_FRO`)N$Y#%LYH?.!8D"JG_ M"C3%T]8>\JO4>&3%6.RV3E8C\U]A]+G$OW>+NDGW0*VB[762;2]XP\$FG=]1 MRL*MBEE&4!&(?16QDY^J&)G[CZGKG+\BS\`^NA[/-_KVL_,DE?S*^>)> M*^]_!YV^JC`6(:^'5YZMD4TV-$C88A25Y=E:8]%*Z+HE4[92>.$MVG+P>GR:GSR853<(6;TTGE+JU&6Y: M&',]_#/*MHIV2\T24HVH>+. M!TJKRU`MHRX4%K^,@,MMPO46H#"_/#&ZIH1\^1> M[!'CW)&E/P"E?XL@N?9Q`,;I/6,#1;1OD>%.')P9`,]O&E%+?RK=;OE,LT)N MMT34U60FVR7,VL=K\YMWK%!0T8IY"X:]F;/,E/RV(*L^K@G4YZ7FP16/FZW8 M($0H&=4J&D=D;2;"B6NC<<05>X64SS:6%YF*"X2UJP=W`E'3..**S3FV8AR1 MM1='!1&1L;/7)B"+EU;7Y!4W`5N\XEK,C2WO_,6%KBAC3YW%XR]*?#-!SQV. MQ.I0SK*""9(_!U[#8R6U]H9EQQJ(W`7Q)F4(8SNR,F@K8U:TG*Z3G?1V3KE= MG&+@^5$:/_X`"!IF+X=??R'^120X9B&J7))/.;SZR:>U5 M%LBF\*M96CE0NQN@3]8T&5#Z^.@,1?^_=.8'"YS-C2[%S=Q54O;FR?\5;-(5%&&^?5[PMAJ8+*B-:>* MK*CU<`E%.CDKY\9SR:E)YLGL!P1G:&TQ&WMD!/@YVD2<[K$9PK7Y30CG,:,% MF\24GT$%VJKF1Q$V`%@/LQ7-P^IJRM*"O> M9E!L@KN>;7;`?!8CH`94?!XJ/G,H@5)-4C#LJEHVA2D!I@(N1'.#=><`N`9" MIG_AN3:A#([INQX0XK/K,0^LBL(\W94G=S"-"+"*N:MG%O%2_Z_=J52'Q@&""M9HPN_R)?2T$8<3UA-0"9;[`#D`I86L5;7C7S_O\S?#5PVLU)?62 MGE?)*OO\TF@T-9\:)XQ5M.&21G>(6W^<*AM.%8Q45"^KG=RWZ*KY*#IQ-[^5 M$_D>I7&==3#L]7D@5W?FKI+?V^F2.SGJ*T,>-5F)-9,TK_QB4=%&3[DO%FOI M,Z:FW.&)@\?8@$!VY3H&<'L/0B3BZFEAEA.H-`A\=9_[3]7Z274JS9U`I^5VE^$Y4Z9+/I/WNW.4QVB_Q MH?<*O=!;2;0IV&!*;G=_=D7:/2,,+ M(DP+^F2`=T(KMYJ^X$^01(XPBE8LZT;*`S(==!IBD$:NT9(0C-@ M)R#-9.\*27=,\IA-HB>9RAA]&'?'DN/"0Y)!C,Z3L&V'CDL"C#Z=25//-4,C M\*$A'T0$#0>N!)2)]5$"4_<%7H)&=&D*#0*=3[[DOCA1.TCR9WZ`;/(6-&@" MU``M*!G(LOQ#Z3KT)`OI)J$U\72;,NQ(NNF"83\C^IBTP`/<`G(R_2X(;==K M8V>,K2`:>Y>LF3U]X3CV+`3TMW0*T.I7MX"HC0QN$-0$R* M"#+QBDH:O4)_0*T!/Z1G_.S2B_0YP$R[Z%$G?LD!T5!!1E"(I,9D%RAR$7L1 MKH6H",FYLDDO.LC9PZ#*N@5^!SM@]E-B^=`R-7S:JJ6_^(0#\IMP@,@?5^A9 M-W6B(G=H&M"9,9+2/Y`@BO4/I1]0`%G2=[+Y"5Q19!`B@G^!2YU@IURB6-]^ M.J2S`O@A<=T%`JN5-`!/WKS!M3N@=)@\:3[DR(GD+O.[J-"-^_(5`K MZ/V3A79'YG9`18<=\K)"WR5*#"H4O6W,C^=]G`>%P[=S$3E7]38TEQPFC7ND M7].1C_S]P]%#$Q.%@#S0))^,36E>\H+'N'1`UVWZ\)LX6@-\J'(*I1<#5%5T/%KR70L!(AI$X44+WB+^B-Q* MO9(.1`<+U.X40GIDJ';L,P\D!ZHTW]>]1-G&.L2!:FY!0Q,8PL-W,3MSRDOF@?=>82+ MC]$T7MK@_[?WKLUMX\C"\/=3=?X#7S\[E61+5G2UI.Q.JAS;F?6>2>(3.SLU MGZ8@$K(XH4@-0=K1^?5O=P.\292LNT@)53M92R*!1J/O:'0#UD-`V,`6:)9, M./.EWNHSAVA=##G>;4\3`H%Y#1-*_JE7)-N@ALMH:YPYXMM<;E7D%A.&8ENP M2'(?EQ-+.I2H1G`50\_",W_T2]<-8>BOQ#%I=OD?F-B!-XC!\9W4V2+.>_-# MZD$<:V0+O&PY;5S>WUREK4$OUJ874LP0=D4^>>,^AXZ%>^2CA06``^W^&;H4 M(XB@8H'B]:UKS@(IR5]MD"]`.I/#.A6'0,9OG+A:V4G`S]Q]9(\)':=]!,G? M8&J37R$2:U3:[&2Z*=E.6@V58N)3).X"$C<]@$].@.&E]);&\03H335C(KY& M*V[6HXGM.>.W-/!J=M!<-B@&M&B)@M%&M4'N1/-DI[$H""/5EZ. M;>+U"%1T`WHM6D45;"00XS*AG)8>+^FEY8#>@I&C)1ACD'W';IC^ED+/D$TA M!ND!B1">=YP\PB._%BR)2#>I1]`4("F+V[/85DLV"`0UD@O,"&HL,!R\8P=; M^[L1ALIY*1)B1 M'`WQS,^=&D4&:_JA]8AD`7Q"/*#L(A&/"W0RYO*2)-G1LI(J;6XF'A63?,48 M@I(!X,=LXGLP.X]Z#8&)]LP3@*5H]0:<3"7)_H,!^1P@'039=,+#BQB1T95P M&$4:`/\/@"!6,3Z"-VI;\$<,WX"9F(`++@S-BE8_DO:C1XZ(2B]*Q5:N/#4X MB)ROZ46F"L8:EX\^E]&0UU=?+Z\OW\12BE-O$$M&@&(#\3.3MY>,*QDDNW5A M]X,0%-KKSU>W;ZH&W>J.PGO$FA&7LRB/+1O9R4B#/G=L@"[6F02)"`<#4*8( M9,1P1%"N#+`DJM9*H3/>(C+Z`PSAB(66D997 MO4JC5JO4:K6LS!*R/A;PG@V49=)QAY2A%"!P);$]@\,08/`@[(.I`D\/N'0P M@ZQ0Q-.>[/BP67(.VB34A6-UT#(C42^Z<_0A<,,`"!4X%VVBS,XK9S`"B$)] ML=O4:$BWZ07,7"!6=HV9=K737ALSS4:U,4=;K8*8S]Z31(R,@C8K*I))P0DT M53*3-IKSS!.P+#'(C":ER2.;'=E4)*XE<.\3N.Y>B#)9R@\I5&0@U0*Q:Z'# M"M852"!;AE)0G7L^R/AK+D`(3&L'*6HR`HO-QCS\T9,1M2$5"=R;9$I M,^5E(,0/M[^>]TFBP6"/@`N7O$)N@$B["/M^@#F\)(CQCB)UG.W-S%1NN,!2OYVCX' MDN&D4!T^(U-Q7?R'B@Z11E6!#R'U:C\C;M-B-G%QT%O`<(J#*,N&<.9(VTJL MMPE@&%9B,/9>8+/EFNQ(<02A3P_&\3&$(;U)TF=!YPMC1"Z=_`C.O\/[>$*3 M'5CNLN^%C\.8]`91=A5P?>B;N`_25"!]"D8YEI,B+TS,TG`<]*=3#-#"N%%H M=T:S"#SUX8_`]K"9=H1AU/AD!DTYDUZ>ARE="Y@LI:SH+V`0_#LYGU[]P'FC MQ(2\ED.M\WK]O-&(\S+JC7.LI[@X,>%BI5IGRR@EA.8D)S<9T(L=67S[NO/0M^4LV1NG@_5JU;;L[ MP$!V;W>\F'FG"]M:33JEPU39FH+"(2`#'3JTR(3:Y%&Q&Z=^`-#R'AN:4+V: M8;&)H*`VAIV?A^0<@9\JK6PZK2.CE"=D(H_G3)4'K(Q@H8Z$DE."#^K\[A[/ M[Z0=:D:4-STDA7J?,`750F,5/8+X!!3M]A_D*@B5XD+GF_1T=>&.OMTN:^;N M;Y$HN'22Z!ZCP^=DI2>-<+48*ID8>B5DF/]\)LSO"CK6))&9`PN3PSB&:ZL!FEOXVX M\1J'>",E6A*12,VM(C.+X;#S+2N=*TQ1_(18QSD9N.61ZD5Z8)&,`"L M?V2'(XEO#.5$/X"Y2P:\C(U(_9#-'N2(#H([!0#IEM3.J/V`06)TH$HA]%.Z MC'P`W'HZ-ZW0SLG=P9C*K(`P\F1!P$>8M^A/]BK]M1&ZU;5&EZUE5DMTTWK_ MHK_8VUH299#93!Y?X)\6Z23'Y*&>JGZ&J<&!&'V2 MAV<@D!/Y'`H^"!VP=I]D)#`="`^>O6P<'*11^OELD3[/M&5 M<0P?37*U!LRW5^!7C5_Q[!1/Y0U[A%'S*/W-YY%*X$_3]5 MMHNJ!T(R+)V7VR=XZCETUHJ[OL19X&9V4L96@E(W'CFV2 MEI'G;,D9MDJ1V@C=8R>45["2AU.'-NSDC(2(EA:25G<2KU(84 MO5(Z:##`C:>;88$=0:F4LIB(M&C MCUA=Q<`#Z<6*L212Y[CB'Y?!HAL\%257R-A-41AEEB9R0=T$-`0;<4HBH\0( M2;KHKD><@%G,$:.EW6\V3=ZY4%5>'"BZ=>/)>@E(TTS6Q,J8SHU*I]:JU'M3 MJ3$)DZ1%%IAXJE[LO.$ZE483_JM?+#?<.&K)H!B01)3)7`I1RW9347)<>I9Z MI=OJ+,H7RLZ".Y9^O=5KP2^[GGNN5-6TA,C?C=;6=J->J?6ZE4Y[R86] MM!OU>J7>:51:C26W@ZZ$K;-%HQF+1AJQ%\XFT.B]$ M*+_1J;;30&M=EK>:;Y2A_/'R_H-Q>7]E=!NU2A*!G;.S,F_9%B:H-/@NM=.5 M=/B<(N,#"HLK]49A<(P&J>,]5T94@//4Q3/^([[JC9<#'57F&`Q?K%:CY`U& M^.47LGP-O!@\HYF)U\L=;CUR-*,KE.(FL['])&3.HUNB,L]K1&$6ZPFD(QAG MF(@6W6-0_HD$D"[^*%C(D/13QP+3BX[/`+R^X/X3V?0SYP``%"C^`.UZS\_> M7*1H>=Z3TAS<.L0%J9FU37,3A5]Q,.O M5''R.0=GZCY&_EU6#`3*@R,*YTF*#,_BG2;_S99(_ZHU[(<3?B4"K:OUM>O_ MN)6T@!L;NM$Q:"4ZA%5"TE955R)I+(]A;=P#(LV(7`)U:SVJ:$!>N'&9?56Z M;YZ\^"3564HEB07ZP_!,,/?QM51N]P#3UKEKRF.4)\\)9963L2Q"24N@T$OJ M*CQ=@8OO'*'3*78KRM,;K8EUE6R)1!Q:$9GA?0$\92&_":DI*5D1QY&BZV-@ M5"B2IR88K]$E(A1Y@O!D^2(U4TO# M"OU,M9(D*>:5R-PIQ/-$3;0E6=CJH@^?$"(6?8KJI<$:E2PS^AY>3LI6J`/_ M9\Q]NH$DR[ZA>K9]B[R_2:P_1=P]RXWN+]'!3B(S1VE'=Z%$3?E4='RAROY) M_PWL2^5IR4./65\P8M[DFE,?#(`A_FI,;.[@-?HXKQ9L"POWM>][W[G_UN+, M`?00L^.W-CY,-P@E7J1`H`@=UCXC+I2X`8-%OB5]3:`"[KM4C".#H,CPR(SG MN3(]`P>0"Y<%^^0=0J2X25*#*$ZA2R<%JE'I)`R]DP5;E$!`@/O\R0:J0Y,9 MKXN34X+5?3S_591^G*JHL=2X,C"`IT$^.2*/S(]/YO"RBN_![E&F0S0$V69I M/R-=,2O.XI.9,*[RAM0U/RJ=),_:U,C,LGS,NS:Y3[?OU`\4,T&CT+0SV7*2 MVL<.4296?`HQ\0)MUV"2&I2T@KSOJ<5D218FI5PST>W?W)2XB/S<2%B*<*R$ M0A^3_H-`%J9QXYNM+/::W92,%&C%%WIXJ@R9ZD:9,!] M?8[Y3RKQ!T=ZQCFCB!?Q&"AO$J<4YU/5(B*FFF-8S''#,D6J41P_@E?FQG7I M;(%WOE%JX\TY&D`M2-J'\=[GHE@>\^HE.)`=EKYD72/A'NL&X3Q MFL;U0@&Z0;Q9'!7>$9OT_;?EV,\E"9&V*)JOCZ<4_KGI.0X;"Q@N^DO.H=8U M!8<"HX+6.ZSKC(I;CS%US7W$H@6RV/68F='G9]L*AC^?U6NUG]3%;06*'\&! MF0E4'5V)W+X7!-[H'ZEKWH&5P5%J\1(;,J<+WW2LK/@VJ4[3/PP%(>+_AWHI MQO34SJ4NJK\-K+E`S-VHJ&BP/VI]D._9-_'I-1T?%#;WCI[>FHZ/BIM[Q MTUO3$5'Q@QS5CFKHS/?I>Z%KG41:Y:7(^&"SI5J8)QN"I!+(7, M93$G'>%W1O/BI^UC\=-,Q>_-*&351352:UIVHED4KS(U#O+#4/_]PYA'!\]# M.^#G&(^`>5WOV6?C&.CZ#C;B;VOC/8T.'_ESU:U8"P6-*1QL&Q^-6J5]D6,X M;HJA-0BF3?2Z9WK8ECK;VB*G-[P@B]3"X`2$P;F6`UH.:#F@Y8"6`UH.:#EP M\G)`.P=[BGW0P@X7^9@&-/#&A10ZFZ]J%GM%7.=FO#)GY;G,H]X[]V7`D;@L M^@YGEE]I'&D<'2N.=B%3C@U'FHXTCC2.M#PJ"HXT'6D<:1QI>504'&DZTCC2 M."I20.W0R41;Q]Q57,MAJJ_-?@3[<7#+^AF#I>2B[9Y7;("\50XW3OE@LXB4 MLIH&.F(VT2)&BY@E,-?I59J=EI8S6LYH.:/EC#9E"D0I6L1H$:-%C#9EBA&B M6CGG*RY^7H#PS18N.>K0$\B#1K4+`QJ6%V+=G]5EPI1,K<^5ON7.E=T1]O8N M4=K9K3JHGJ>R`@]T-L?L' MM1!CIHG=0&WLX2N;]F+!]U2S*-/$ZLYQ1?AOKHV?[G%0*OY\.8)UFUA1GGJ> MBU3?$FI9RK[SN'&);'/"A`A'4>]U:ITR&&##DZ05"=:LIR:E-$-^BU'Z;,4- MDF5;@#BV6C:VD9#LEV>0RQE+5N$_5TD^0%S6N3^T9 M]G:+^]W/H$>U?8FQ/6(6M87!BOSXMNPJGVZK9,/37+:,B]IX[;=!?)&XOY1+ MFQ'I][C)YQ^H><.5-T*")2FA17L95H.B'7>-N1,E3]!D!L'\Z%.[)\G"GF)P MZB+%?/D32%\^&CO>A"MQX'KN>?(-R`'\PF1C.T#IQ&QJHI?IL,L$-42+2"8C M%T">86L?#@(N#:023K([;QJZ".(,6'&C/Q)5(0A"W\:^=T_<>`QMB[E),SGJ MQ86/)8U.+A-!"`K)M9AO">.#!_^GN@I&[4>2YEO/^*.=:HZBYHY4`@%)V,*> MWR"%L1L*-:BCL5`8IR3[J@N?V0%\R9?+C)MNSTL$FJY=097844&%A1_N1 M[>BPD&N9+J-#0""93:DLU[L/V99]32)9+/I?KRBS< M'`(W9TT=GWJC@^Y>L.>R?0[,S-!'EKT:95MHX]9-^@S:OAF.P*!PD5'BW<`) MX#_7,P9A@$9+>HG*@)(+4J2>II?*%#E1&\+1B%O8LQW`1SC14E%Z/\#S]I>6 M+S=&];97%EZTSD$N">RV29M6$1NJ"++?<$^!0FT3Z4'`1DM+W2;;BRXWADJ\2,UKI_O#IOK;\!S`0 MN!I&W+89%8MFCL*M)ML>.:(31B%JLTEM+"N*HD+T"R.%D/;"J(>W)"ULC7D^\)'FL((]]E/#&WN`,J16XILG M#SM^8[O.U)?8H3M:2\X*A&0!I63`C0'R=2U1S=C_,4.D=<`41TJD@94'EH@5 M^:I\*20@`+%UQZ0'C#/ZV':72ZF2QDHH$A7T\OC*B<:]\6VIO640PQH MG7Z--`P8DXS^LI)PM?;?>QK.BX2+H"(+/9V'^.:CHN$3U`* M[]K@W5:1RO7,H(VF7-`)Y)#E.G.9H%18V2D0!9*7>]O]`JWY5/;V5-:I:?AX M]_94UJEIN.1[>_!BWZMA4_4;;%[LH.'@ES''2S_N8WP794\DDM-L5'<"U9U` M8WS4*ZU>P>L6%:$1J.X*K&7!T$7 MJ67!"J57RSDDUK+@T&6CY_97+CCSZ<:>95C\B3O>&.\# M[B?L40YA>9@Z_%.8?"`\Q#\1:25U53NT==6U$)&"YG% M"53=@L=_BT@K6LAH(:.%S`I"IE)KU[28T6)&BQDM9G;H,-4[6LCL)CRUUUR< M7:(IYZ_EBG_HT-5>6DSJ:OVE%\.-2K.K!;&V]K2,T3)F5S*FU]+^I)8P6L)H M";,K"=.N=#H%3X(J(IMI&:-EC)8Q2WM*G<8)'[^5H[G97@5-3M.>]-_'V],L MDS%V/94QIAO@%'PU\_+]J.$`UF]WA2T"K`X.T,$$U/P,FPN,F4WEE/&)T`E8 MU-?+"P.1*N"DDH&6VG*H3B(S1>@#G[,@Z3P&$%DAUC*'#[8E.X*]@`9L!J*` MHV8'MFN&OH_M5D+7X4(H((0G5G^"ID?2Z6D9)]#74WRE*L)NE0E>K6$G7%B)L5`H>*L/]GU/@QD@!2 M8*?VG&012#([H&X9E;3$QW:5-!(^PX04#F((IODYMK2"^;$I$LVO&ST4;C69 MOD+,=K%1BI#[V&>.;)T%.L6C#EON]ZIQ2<20J4AL8*'!RG1/E\P0S]AV2[;L M046(^L25K=\<>X2J)9H;-2<2HRW4?)^23J9][J#J5&HNVS<4J=P.0M*']//0 M,Q.-)L1?6!`V7I3"J@F%TP9IPTV0/T0/.:BHNWFLM@"8K, METD1::K.;4"CJ><&]@_Z#JPR[,#3!V`YV'2RN2L0L07?PY),V>D'K"I8IC&T M'X<1V5`K,%]:E##T"/@(^\5/N>/(WI7^V,.&2M,(E#;]V&&RCZ5L4B:UC8M- MA2(\2R<@I8X((EBW:C&&&`:YE$\"9.7^H/Y1P.SI0$\[&_W]:=8C6)9@7$_A M=X"](DUZG]:7GJ[1GIIN_C!/X$-Y8'7'U*6H2"(L/6B]M_2@+*9/-9KJ_@1[ M![L6X7NBL""X>A,[W5Q<&!:;"./U/>?&9_C::+[1-GVIEI83CT%^2K67836W+MA'$Q1UKSW4]/)*U@GR"R4+?!B]`Y&'!B)19\/,1KQQ./^ M[:H[)$EUH6:7]MNS#>I#A&,8C5O8D99A/`';F'&PV1:+R?=$;']\X!C[`BTJP?[D6[YS"@T`Y+:A-5%W?JB"(R4Z@@0 M4\%'N+8FUH&WE],HT`9X/0&2`&6`H_4Y3)J64ATB1N M-76`M$=R/M?%?HFJ22%X'\#>1`-L``\9UR!!R=A`,P,&[%2-&TFCEFJ6"*./ MD7`"I8O5@$!]V-\X[F;\\M`7E;BC<`1@]"K2KZU&Y>-T@>]1 M,UA<9`P<+';D6;`%W)KW2!K^;(C0%G&C8M^+/#J.]*L"L@@I/&I2C#.-<47J MB9&5N'`8:^3)=BG50\HE65T2JQ-ZHU*MA>JPE`;UG!/ MC50SO[Y^\,9@"W?JW3>2&,=I@X4,534[ND<.R*+!1$7<8V"FFRV/V439]*"8 M9,=N('AI+[NJ3WW4>5C%UC,-T;%]=Z#:H/;CV+ZEV!C'(]D+/E?JJ"/5MCZ[ MA!EIM+JD:"NK/N;R%/?5&S@#F/5)"UO`U)`ARV?D<<2YTZR*03\\>I?=H6.^ M)9]2B11@UM`)"(&>+(H)[VCV+=QJOI!^\*43D&*0#$%.1P"0P],Z',,2-Z#A M'_'#K6QZ_L#$=^.CYYM<2H5+^!VIRKA5`3HR<*YD8`*&O@O[#G"U$AC,C8[Z M\-W[)-:"7]U$[;Z!(D<`&9*<95M$T4!Z&-C#/U64D*`>)<'#A-2C?L5SZ7R, MYUQN(`T(:E0\A_(3C75X=SA;(Z;1J;;3SE^I?>3]N,,.V)/Q`RQD[HTUZ1\S$E1/ M&"ET\-!^X$B=SD2$@E0]:NIS/^_T/GI(V@[^%"NHKM@TQ%R06!#X=C^4K8#A M04Q)`*L)W!U!F0ND+J;E[%R`&*(A%2,>,I3R:7E-5_I4U@7Z.VH%,D'"!:(* M#/`=5A++^9_2?__S;2C.'QD;O[M/K*7$U+W#>#W`_`#L\`';>+__[_\RC']& M[UR!GWSI6OA_-V`3@K.$BH->FL2O&+;U\]D#>ZSWVF?DL$/7_G@Y[-K-.[. M:W7XWQ\/WA_R4^^\63M[KP0NOOKJQGID_OWE9;W1;+4[W1[F3+[*83]C[E7G MPDJSV;2$Z+"9_DCA]%"QR[A`6[5MNUJ>+W_P3-D$F/U%9V<.GGG!;EK94Q<* MU*&380.LP/WI$XM>39Y0`/=3HA6Y<^,09`N)*A!(X)U1H(HG9"+%G89MW`\YAI]0I\1I#M-#DA%*83PZQD8!%>5CDYE39LW7P;D8']`[*2=["L`.!%!%[,BJ'5> MZR0BJ*5$D!&ZMGSFV_WU&8AR$X_.Q<]GY^VS]UU*W/[GVY4!V1C^3B[\]17A M;VX&?[1E=SYJY6!RYZ#2<"W<-])VO_B@J!*@NUF@;Y7K?MZL__$KAVDPK^%V MA$$)Z7E\(JMEP1*:9^\[%PU:PG*P9.'^1(?$J-<3=TP26@)S3^NJ%W35?7*4 M?)L(-:VHRJ6HYN<$@-)000/VQ&R'S&`*-H)D3N>,T+F"+X^/?$MJB40-J*,6 MG\.:\'SCD9*Q\$LT9KG(OJI"_\PTPU'H4&A"Y@9GC]I4]LIK'$)%3C&K8"1C M&AG[)OY`,5 MP\9(,OASN'-R=\![.Y0^`G$A`=B\TD>$8$`3N1Q*/@@=,#_>9)96^G04?#L94-'('W2OV/V6?8! M/!`6F$*+I\8N>3$J_0'$?I012/"BO%?GZ[@V$O\1UP:::#`@''PT$FD;[54 MC=_(RY(8LF/M%-AX#!]=5'FV!4>A._9(50Q2HF/^ MU$F>5(E2.:+'E^A&F74IIX_6`%B*P*\:L0F-P:38AJ9WE0KAR(U[40?T&R M?08SYE893K^BX60`4@W"JI;DI93DX*+;)@6&,P8Q'@/(E`!D5[2'5(` M&R7X[#OJ/%2VEDBHN,]!OZ4'0V/>P>0Y6#2Z5O$]JJF!\+R"7I;G MYY64*8"W3$4('HQM.NLD<*M)O>. M!1EC\L!4RA69O)=0&,K,E%Q@E!<+1C$;8:ZIY$Y%NNBYI^XFQHR6]L39-'G/ MN?GQTD"*:`V9*46^/%T@!_#25G6CTJFU*O6I7ATI)DF+++#^F.\S=4KL][V?7<L/S7.8EHU!JS)Q'*+_CCRV!@FSQ^<9DSB$:]OO89Q+(0 M-^>?G:P!<;W;WCG$K;DX?@&;%XW.VL!]!.__/QCS_42V"$\H\Y&>,F# M0J0:A%4CA=:#'_$<.!&P)(;--[HL1!GLE_=71K=1JR21^3D[*RL9)9<4DIVN MI(]5Z,1D("^V"W5E`M/`T=60B0&NC+PE:>1<);I2&(L9CLWZMH.9#NE[07CR M([]@IKP4RX-G]#F^N]ZSPZU'CCY5A6X`D2/$_.0HA2>%&^1%$`S'64\@.L!2 MQZNGT15EY:Q*`#'0%<%"7H6?.BZ:7G1\-N3U,?.='+R9\R$`"JS``)T\NF?E MVW&\CTY1\IZ,9DZ-FSM@E`^<@E!=4,'KQ9[%'17W0P>46X=P-S2KKN&#J"@U M'HHJ8HRNUN4E"'PJ)`5 MI2)1#JATN#$;`2#,BET!= M7XIN(%%(QKC,OBI]>4\0HTEUEE))8H'^2&ZOBA!-Z:\KCMR7/" M$44%HRM8N`2929P4/Z,D:_CWT<-?EJ@WMLV-UL2Z2A9-(@[CR[S//"K4P^2I MZB-W04YBE"`.*LJ;W)3_H4B>GLS4,$D'B,@ZF&.,C.FZ$8R>88K]$B%5_ M/%\6I<3`/*IH19X@/%F^2(TJ!]%/5NBGE7J5#'JBQ1Y0T:S!CN/CFF@/ M*/KP"2%BT:>H7AJL<36EON=:47&DT8C[\BXN&V,QI-_``@AL3%5#N8F7F!DF ML43Z,RXE@>U[WO?N?_6XLP!]!"SX['$`N7$S`T!H) M>2H67SO/IE:FDT75J'0LBM[)@BU*("#`96E6E$]\S,EN-AA@+?#\5]'%!;6D MI<>5@0$\&O3)$7ED?GQ,2T4S/-@]RHB)AB#;+.UG#/)J33!JQJ969:/-S:B>F;J!XJ9H%%HVIDL2DGM8XG$H0PY&><PF..&7:D+4RRJT_((7ID;K8AJ5=KN4):`MI/B0NKZ*#>' MKOV72C>?^T(26$=U/OK^VW+LYY*$*,LBJ/E48R/3<0ZUK"@X%1@7M=U@7B$/N.*K#S\]G-?D9._M$GY]M*QC^?%:OU7Y2 MDFS)YM`IN?=2&S"9XH=O.E96L6%9(>Y/]V7*8CI?XA+J%O1$6K;UV$N#Y4'[ MT@3KMZ1"]87;X\*.M':G#2[CV'U*';`Y!=L7*8)M;L`^>&W]7NBYY+X.<:Q$ M?]D._9-_'I-1T?%.0T$]8X?^YJ.CHJ;>L=/;TU' M1,4/6''N]/9[-6/:Z#/S^Z./'970O_5\V#_3Y'PP6-*MG.URFTD12R%S68A^TL,-%/J8!#;QQ(87.YJN:Q5X1U[D9K\Q9>2[S MJ/?.?1EP)"Z+OL.9Y5<:1QI'QXJC76,EC-:SF@YHTV9`E&*%C%: MQ&@1HTV98H2H5L[YBLN?%R!\LX5+CCKT!/*@4>W"@(;EA5CW9W69,"53ZW.E M;[ES97>$O;U+U#(DU!:1W[3EIH6-%C;:?-/"1@N;<@F;#;&S`75-;=P#X>`S MGRVB6&KJ.VIF/.G%:TFDS9YUD-;K57K-BUG,G8K9LVK\*OJ(E8>3GT^@C]_; M3$WJ!07K%U6>SQ:K_R;@X1O5VB'5O+E3[JKT>^JQX$R7J@=T8D7B&*&T3P=H MD7PDW27VV,5J['-LL#O;]R?5557V\,'^C-B_A)J@,=/$?J8V=B&6;8>Q8'VJ MW95I8G7JN*+]-]?&3_H::K[#N/6Z_(1BU, MB'`TE@7M9?.7P0!;MB3-5+#F/K59I1GRFZ329RMN\8P/(L/#0E0[V-QWY"R6 M:@-#+69RV\]&S5=RP/'Y$W=5@Q;^8\Q=`0-;(34#R/:#&0-F/(L:Z=;$2I?W$[QSFSC0:Z6J1OHY(O\=-/B>D&VFL:]%>AM6@ M:,==8^Y$R1,T^8%<'WUJ6"59V%,,3GVPF"]_`NG+1V/'FW`E#ES//4^^`3F` M7YAL;`^)&X^A;3$W:8='W<3PL:11RV4B"$$AN1;S+6%\\.#_5%_$ MJ'U*TC[L&7^T4\U=U-R12B`@"5O8M1RD,'9SH19[-!8*XY1D7W7A,SN`+_ER MF7';\#EH4"O89/42JLR.`BHL'G"P"-S9-NNI3I.J(6H0M61E;Q*TP;>R^1I# MQ%#[9P086U_:U%819_$Y,X?8\AJPTW^3T<3Q^_B-RX&V!+8/3(^%1,-\"14: M&L%D2FVIUH/8@.US"LERR>=R79F%FZ"*'K.FCD_=W4%W+]ASV?X'9F;HX\MN MD[*QM7'K)IT2;=\,1V!0N,@H\6[@!/"?ZQF#,$"C);U$94#)!2E23]-+98J< MJ)'B:,0M[#H/X".<:*DHO1]@OL!+RY<;@R286'C1.@>Y)+#;-G-:16RH(LA^ MPST%"K5-I`>!)A<9KC;9GJ,1=D4E04"""G_.(Q"0ND!H(Y$5F\./?23U0M1HU!JQ%E1%!6B7Q@IA+071EW()6EA M<\_S@8\TAQ7XL1\=BS'!N.IK[$'N/16G)6("0+*"4#GA"0 MKVN):L;^CQDBK0.F.%(B#:P\L$2LR%?E2R$!`8BM.R8]8)S1Q\;!7$J5-%9" MD:B@E\=73C3NC6]+[2V#"&;>"M,J+M&\P/PO.+U^H(&45'U.(L M6XP=!@OK8RO8K80\]HSBF45ONT?EOM<3.BP;!(M&QK^FS_S\U25PZ\C^M- MN`^AL1_:W$$#V8@X/V.DZ>1I<]^DLH6&M5K$'UN_N;A#LQ;3Q1;3Y:6OG$L$ M>KN/?4W'1<(%$)'%WNYC7--QD?`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`#I`AV2,_=VP?\*8 MV50Q&I\(G8!%KA^O&P((Q[<_CSUR_A%++YS%\A\P/N`QW( MQC-+B?I$H"\AC[,"_,ZW/?^.ZN5_Y:;#A*#6=*0`+&0*?/^:"].W9:7^2)K7 M:^66YGL1W%F$'J#AIA;."U=SBYTG@&5DHZVL4(L[1E*]?GD3'WM91$UA`BHH M3:W7L'KO",8?1ITG#$Y%?#/U=0VL.59)3V(,&77G4$0"+_PM[3'4JMF+E2CP M'&1!G'/JR6;NDY6H70^8<,ZD@@N9>UQ)\@_[#XQ1B'FA<%"<#1S9DX2)"`6I M8@2J"5"^7(L>D@+2GV(%U1*!AI@+$@L"W^Z'L@X\/(C"&E1=R!Q!,AUA44U% MDFV;"Q"VO7NB]IE2(PX9-LTSP-N#7ZA3')WG*GV4ZO\I58<+1!48CB=6ELFK MBMAI`8V(#R9H@@<@UF]`4=."?O$!ED0.&_"#Z%KRV^_W5^? M`5),L#4<\?/9>?/L??VBV089G`9WT819X*X\\A`D:WRUQ?47$K7R!:$?;_C-HB1]I`VOJI/2DE5TLX"-G.FD?`9)J2X$T//#\ZQX2/,CRT#:7[=!JEPJ\ETW6.VBVW$A-S' M/G-D8TF&2@G[3[K?J\8E$<.,/=&N3'<\RPSQC$TI94,[]*'0%7%E8U3''J%7 M$LV-&AZ)T19JOD])G^\^=]#K4AY2MJLV4KD=A(D!,?0<*P\D]._BUY#^,4D, M:;:BNJ2"+D<+962[J)O29`_0`\UK*B[>:BZ#)2@R7R9%I*GZF@*-IIX;V#_H M.S`&L3]='X#E9NC+UN=`Q!9\#TLR91\\<,AAF<;0?AQ&9$.-,GUIQ<'08)IS MY#/_.UAP@Y":Y3UD@$P@`RE-04O%(&F043ZKCG_!9,PC?HI;5HH0K4[9%E!: M>`I'K5)"7W5I5TUBOU7OJ\8CMK5TXSC,S'>/'/B*4^NP M9^XXLK.S/_:PW>`T`J7Q.W:8[/(L6WA*;>-BR[T(SS)^E%)'!!&L6S7@1`R# M7,HG`0J0_*#NBL#L:5>EG3T;_6DVF+0LP;B>PN\`.RF;]#ZM+SU=HSTUW?QA MGIB/;D]"78J*),+2@]9[2P_*8OI4HZG>B+!WL&L1OB<*"X*K-]$/N[@P+#81 MQNM[<#,_P]=&\\VJKL<"^SQKR(-<23I.@P?@PI^F;%U=;]F;`A9-]7F.XMU;>^7836W+EA*DU1D9ZD&[J\_7MY_>!,)^MP'OXVI M\_'KR_MO;X#YJS0%,%+%^`JVF!MRV:_U*@X>4W/F*U@G2"^4,O!B]`Z&K1D) M2)\/,:3]A/$8.8KJHDSR7:C952C(!D4BPC&,QBWLW,XP*(WM*\D>0W#S!HD[ MVH.:!95`47S`-:FL7RXO[TB8^ISTCV&KIM(L\F@N&'`\@``]B_$\;*8==8AF%-\' MF6W"ZJ(`5!3&E_(=`6*.\++0X,$Y`@S48=G"=#RTQ0W6]T)I5[NH#7@%^]2' MV.D:*(_Z$@/&4"Z0Z2%U100^*6FTKP?4+Q0T&!U8$&V8BAB2$X8*VE1.:-&9 M!C`&&2FP.7^&UF-R>B-[7U,C[.P/3`@>9!IORWDH8!8=V*"5Y/7)2`*<#4)G M@!A@*?Q,42:GUKY(D[C5U"G9'LGY7!?["D\Y78G)*I]K^*M!C3/OT.7IU4/*)5E=$JL3>J-2K9G MN,)0&]9P3PW',[^^?O#&8!5WZMTWDAC':8.%3%8U.SI*#LBBP40=V\;`((L+ MS#E1X?XQFRCK'A23/%4!@I>6LRN;(D?GV]$!+7`$'=^BC@D`\3Q0[<+[\0&Q MI=@XH(,'>;"=.B\GSLU;PHPT6EU2M)5]'W-YBOOJ#9P!#/RDU3M@:LB0Y3/R M.'4D,=7.WJ44->HEG?`M>9=*I`"SADX@LD=6FGT+MYHOI!]\Z02D&"1#D-.Q M`.3PM`['`,4-:/A'_'"+CPKC@8GOQD?/-[F4"I?P.U*5<:M"=63@7,D0!0Q] M%_;!L8L$!G.C?!%\]SZ)NN!7-S^D:8`4.0+(D.0LVR**!M+#$!_^J>*%!/4H M"2,FI(Y1`9^BAW/H7!W)2@,"3:)YE)]HK%4=XU7]W:RW_)'9_G_06+PDD^@3 M9Q15_>)^18R!*?OX`9,W4Y@QVLV]P.^CS'\1\I,/"P!66(04*$DBOR#G<617ZVN0'[X+4MMZ'3 M;99+WH#Q5\S,,>HK$?9.MF/?Q*_7='14G',51^_XL:_IZ*BXJ7?\]-9T1%1, MY9A.;[\/7J(K4T-^KXB M-,C0S7*T,#AZ87"NY8"6`UH.:#F@Y8"6`UH.G+PJF:Q5\1U;EA_/G_E)U^K4.-(XV@_,N78<*3I2.-(XTC+HZ+@2-.1QI'& MD99'1<&1IB.-(XVC(@74#IU,M'7,7TG-%R1LL9;W"@(;EA5CW1S=+W2_V]M\PM00)M47D M-VVY:6&CA8TVW[2PT<*F7,)F0^QL0%U3&_=`./C,9XLHEIKZCIH93WKQ6A)I MLV<=I/5ZE5[S8A9SIV+VK!J_BCYBY>'DY]W4+Y\*9'6J[7@!>Q(^"ZMQKUI/ M.UN-^UZU9_\RN!F-'6_"^;TL]7^/G08^8*.!=".#2P>&H+^^#+[&O4QD?]XK M[&624[:[?:"RW=%HZAW+%F.'P<;T$;QT#'-MLCD/O#&13OQ%)(AJ.R&1:<+8 M=B'Q?:\G)GEC1W\N9*483;$,>%%2'HKKCZ_"NJY!G5M$/E7D\6+KQ/;1DVU= M'H8^Y\8G>&0HC!O0:[)#XSS1LJWILT7:-_,O#KR/ZTU8(#]E0]K<097_B#@_ MVZZFS8(?#&L1OQH;K>G%'KHH<-Q&0XOI8HOI\M)7SDF/WNYC7]-QD7`!1&2Q MM_L8UW1<)'R"4GC7!N^V;D*O9P9M-.6"RP2EPLI.@2B0O-S;[A=H MS:>RMZ>R3DW#Q[NWI[).3<,EW]N#5Y19#9N[[$7U9^0_,1MA7#1G= MB^J0Z5WK9VOMK=Q\O=+J%?QR3!&JS>O6$UH6'+TLN&AWM230DD!+@I.7!,U* MIU'P=&XM"PZ_2"T+3D`6U"N]6LXAL98%AZY-,K]X;FWV*N*^#S*_4#&H;J_@@K>(M+*:RCWZ M"[Q:R&@ALSB!JEOP^&\1:44+&2UDM)!90D<+ MF=V$I_::B[-+-.7\195U81K/_'[>QYHAAIDJ&A*E[.C0U5[JF.N24*47PXU* MLZL%L;;VM(S1,F97,J;7TOZDEC!:PF@)LRL)TZYT.@5/@BHBFVD9HV6,EC%+ M>TJ=Q@D?OY6C@NY>!4U.L=STWTGAW)V5OLU6V+UT`]NRG3"PGV""J`/ZS0_3 M"2UN?83EXBQAH(:^8;X+-"5@8(+C^T$05N!?*?(Z"R+C-^8[X,86PX1 MG4:S`X@N$R*ZRR+BRG-)=@/7W_E\P'V?6T0IRZ&FWFUU0$>4"36]95'SE8O` MM\U@)82TP(VNU4N$CT9M%A^M##Y:ZPJ0>JW7[;3+1!R-^K+(6$F`U.OU3J/5 M*),$:326Q<2&$J2Q!PD"(&)1+I]>^6J+[_`P?L$>>3U9<7-9P?`1($,8F`N` MR57^(8OMT[G7S+KO0I^G5]TX>U^KME/4L`B^=5;26G8E_V%@K83B2S#D_K4' M]A48\;="A-Q?>UV-]N[6M6SG@#\^>CX'BU,N9=V5U'OKK$1.$S=AN+:%Z7C8 M@2%9QI3)=IL&/'I/M6W`#'\1-VY0*XD?NG6!#\2O>!F@KG[[Y+E\\HGYWWGP M,70M,;/4;_?7Z96>-X$%:^V+1I8'YRUBY;5V=K#6QDIK_2'L=Z[M_'P6^"%L M\MN5E]#=P1*:^UU";\,E%(RJFK4=OTVMV6CO:O,8.^6F_F]?<<"4%W:#6[KCK<"*CO3M&.]Q.;6A)+`:\U^LU M+]8!_,[WQN`13.X<\)`N7>OFK]"FNXK?!!^$SJ_V(+6$I4,VGVS7'H4C!?G[ MN\;O"6!+S+@!B,L&4P"H]B9`D?_2GXDSHJ/Y2/OW89(\($@$7P;WS%E._M1;O2RG;@_XG2.EE1_RZ.3YMBLAY:+=+2U. M7JU=6J3DQTER1$IT91UDWW5R8?U&)O\N M@Z9NK[Q8RHG!Y,N8C;'4Z)97$B\=T=D<2\1Q)453SB%?OAS:G.7JG=)B*=^4 MG!5,+Q!*LUM>%.28JKE2YP7+OU5>5EGV>&\Q!MJ=3FFMEO:R)WHO\$&GL1^] M4IY,G!+S4@_?XC>G58DUJW>J/:?',$_*!S)4WSTQWV:(T\RW48N9S)_3:5T.;;+SX=Y[[Z$DJA1;M0(669-UJIUV8YGN>:YW=WTSLU@9/U^ M1*NWVUOB"N^';Z=UYY$/\8_?[&!HN\875]Y5[*^<3UC`2\Z[Z'1T>`K< M<+`CZM\5$^_OX`EL2K9%O5M[\-O7;_^>K1`HG_O[V_6Z"71;.RBT2(>VJ*^^ M\\`8X+'MOJX@Z!8)N@#JHAS]6J5]4?`D?5T!=4LB;NO8BP_-P5_MPXCQL?E^ MI-L>1-IAJO(4_?;7"5UBZO0JS4Y.$];]"\@5\5E&\MNM*5G@NCW[%9<%6L#6 M)'*CVL7HG>6%&.32]TKWB[W]5\CH57K-0EQ@7P.GI1;-^9=3WV8BS2IP7KIP M^>Q%U$T.1*92")^8[>#O'ST?DU.2'-/DX&1^.N[*>8US9UL=JIS4VM9YO7&. M"=.K9/%>,3'$_S#Y[@GF`IQ>NM;]$-CB@?NC%*J3N>?GO[Z0U5,'(+/'ALM/ MOSG8.1FN;SGG'XNGZ):[-//K0?!IPGRZ__2K& M:";J7:&6.0(9Z3P`3C+LE/0$KA$VR"EO8`1##@,[CO<,@L!X#8(@&'JA@)?% MFW?+GWCO+Q6@,)A?DF16R050ZYJ"8^HP?NF#]WIM:R?O2P&VG]//Y4`YT+0' M/E'=1?D:M8S=*:M[/@[(+&;BD[ M;'69LTX0=!JJP!MOT8+9');9!>[&OMH:[O+RTHJ-Q\.IUN4`+4FOFX+1G-[5 M0AYFSZCE+65!SN)7J>*+[D_3!U*[R2D:L*"8P4P32XD)X[7/ MTS#3'SP)UKY9^RQP-63I[$J=7;D('_5:I5$O>"N'(F17;HDA M7U[D](879)%:&)R`,&@5O-]Y$02!3K/.P]ZA;H_LV:@I9V)44>38B5P3.3HB M.>G%:UHX4H%QKF5%2>)&I;&"YEXVRP:%\I.+]A01*KI0T9?>#G7#0E]Z*U'K M+FW+:3FCYJM0ER#+:`4U8:: MEC9:VIS.`>;AS;5]-&Z>3EJ>J?.77) M,17/?+:#H0$&O1!&&-^*-AZ9[L;U*R\586\[VE=XMWPE)[C+'_A?4&=M<[C%NX3&N29-EZ;?P&-=4 M;+(\Y7T\JLX#VH+3%MR1R*2D"MKIR22])DV;Q[&/Q[BF8M/F*>_C`6RY7>=W M;1V7V7)><5FM@]+)GIFQH#VRL#1LJ?>B'$+B9.D+RPCKX-,)KDG3\&GM]S&N MZ8AH^".S?>,_S`GYZ6WZP:_TY=SG6PES46V(YH5NCKF-'+:ZKMA2@HHMQ:EZ M4.RJ+;I\DQ8&1R\,"GY73QR$O=>60#83K,50.P0I%Q>C_7,#[J/KBNY8S6LYL!7/-KI8Q M6L9H&:-ES,E&E(I(*5K$:!&C1WS"!S M5G[$TX)&"QHM:'1VEY8S6LYH.5,P.0/>4T_?B%FO0]N6FZ7M$-C-FBK!5JBF;"*SXS@Y`Y`$@0M46#-[S0-T8K-5M[YCXO5Z>T^+47 MN6ZO[*1[HRD9MZ@W6O?(>J/%@TV1^JL77R]XN7#D0_SC-SL8@G#XXLJJA/V5 MU>82&#J8LCLJ"MQPL".JI!D3[^^<^9N2;5'/EPY>,O/MW_,R\__^=E7O5%;@ MZ+9TX9ES&14X+UVX?,N',1G*^C,4 M@3V8[."$)L@[GL'3F2MO-&;NY)58>.0BO^`6_)%^;F#_H.],;S1CWM,QCNL% M\JC'@B=@;29]._!\#NLUAD#&ANESRPX,6XB0^_(MF&3V6*AJ/&3`36`TQF#8 MF!/#L4=V(#+`!YYA@CAB>&(T&4M0;%<$?BA_%Z$Y-)B@A^P!2*T(7#[VA!U4 MLG"DWJP87A_VC`6VYPH)O&7T)W3@]:UZ7S4>/9"#+H&'2YKY[I&[)F$),>PX M!,0\3ZE"0XP=D`7"\&%QOFW*B3TW?:2&3YF>BP%1GR`CB&#=$JN$X:J13PO& M4L008"X\K/1O:9G=K648Q@`*=6#R"B(2Q!A@./UT.RN1?YHEL)AH!O83'A\B M3(2%]#"-]M+#>+`T/Z%`16D2J>DAZ[WE(5,4K,:2M,E@=V%?HQV9X(,PM>#J MO6?8XXL+PV(3,6<7IC:!B.\\4&W_M M\\D@%,85$T/C$W-A&42F,B;Y24+PD1YGL)ISQV/6+(]6EQ*<_WP;BO-'QL;O M<#;\[^:OT'Z"90&%7;K6/9+>`U#>;4)X#R`D/SB>^?W]?_^78?PS&N#>''(K M=/B7P0I#H5**QS-LZ^>S!_;8:/?.Z*0:?OC*!S^?7>-^G-?J\+\_'KP_Y*?> M>;-V]EX=FN*KKVZL1^;?7U[6&\U6N]/MH59_E2.QC;EG2OL^D-YX@CWKVU5. MI-6ZIN"8.A)>^OBW7MO:^>]2@.WG#&XY4`XT[8'/]79ATZEE[.[<,*M&%IP@ MIB3#MH`P8BCB)LQS3B_3BN`PQ'G@B$;)X%V?7T^='Z^YJ=BQ7EF2(TJV0N#U MUN:\7HKTL3P"SS\]CWFWE%LZ)216W-@MY2BM+G.V=3'_0(;3JF41MRJOMX:[ MO.RH8N/Q<*IUR9HL6:"*DXQ8:)K3NUK((]49M;RE7+R<2D92%5]T?YH^%ME- M9LN0F]]A#GEA@3W!G\)@I@F8"83QVN=HY7*+0KL85Z/P+/[!DR#5F[5/I%9# MEL[QTSE^B_!1KU4:]=HL4C;%T+'E^.EFF%H8'+TP:+6U(-#)OF6ZP[!GHZ:< MZ3E%D6,GO:>%(!48A*OJ4DSZ.Y%;G_JX\98-"^3EV>XH(%5VH MZ*M7A\KSUU>OCJ5.DK;EM)S1W=)BW/N9DV>R]P\VM]V6N"WUR? M`TS_QZU?F.W^Z@GQQ7WY1N!%3=$+.2-0%VP=MZ-Q=Z1%:P]3#[`]@K<%F-M M.=M7>C]T)R2YRZ3R7WQ0.]M<[C%NX3&N29-EZ;?P&-=4;+(\Y7T\JH+OVH+3 M%MR1R*0DBG!Z,DFO2=/F<>SC,:ZIV+1YROMX`%MNUPE-6\?E;!G$P]/)GIFQ MH*V)KCP1E'HORB$D3I:^\#1.!Y].<$V:AD]KOX]Q34=$PQ^9[1O_84[(3V_3 M#WZ'+><"VTJ8BXHA-"]T3$M)&W5=8F2$I0H*"MVS:KGN5;/MSE9J3Y;M;';-QSXW;1;8 MGILT+JOG-B[KS#8N,T+7EL]\N[\^,RP8:L0<\?/9>?/L?>/B`K@M`3,]5Q:* M!Y\AA=W']R63%?W+<_`G7%0"7V/)QFI_4/FI3U1]ZB,6G_I$=6*GP?XA['>N M[?Q\%O@A/S/>9H%+,/GEV>7698#5SJC860)0,PO0[I<,%;=K]OK[)IT>\OV@2P8<7:6;F"Y M;?+KU-?>S]Z4*%J6P*:[A`97S/N.\65\-V(MN=^>P MMN(@]?,\)7H#<(SV`R#Q'6`?/'3L>BM?_/SEX<9H58V[KU_N;KX^_&Y< M?KXV;O[WV^W=IYO/#[-^43_/0]J2DY=UQ[8Y_GS$171D,-$1$!O,Y4`J( M%UMPR_`&1C#DX$XZCO<,^L)@`K][#39',/1"`>^*-^^FH=ZN'_S"WN^H8W0V M'Z16;=ON2YN%7$-@_GPFJVRG$T].H/=S])T*]16C(;3N';CU6NXD">>TPNGO M`5M9!BS8/$79GVMNJNVIT_:TLMO3SUGARGNW,6_%%1@SK+`\;`>OB+_6:B^B M\O>_LCY:)YX_213P#D^XCJ!._=]V?(RSA8J1S9R*D?4*.+F%.T>9J>NX<\&Z M0BW6C86OIM/5Z?2BFY//5!XJ/7`)AM5-C#B>8]BI@$XQC+YQ=IQ6.9H"],4"]NWZG[D,Q MP%Z]F6,.PQ;,_BBLO=>H7#1R+DX>-<;+`&,Y,7M86JY7+IJ'$OG:>\E*\$O3 M#$>APP)N&58JK^4X](8VVW9GMKWN]'+*#1?],("6\49K(NU@!XI; MYPSMZ12!+_=[TW/7)Z2'O)!9KW2;Q3ONUUZ2YH-]\T&[>:@CI"W$W?9RRSQ#87!8B&7,9HS2 M@YB;:#PS8?PM$XNZR%Y"KV1_ONC5%_W)^V6@4YVXKQ/W2W*`711^THG[I8"QG)C5B?LZ]04GT8G[^IA? M)^X?N<+1#*`3]W4ZBT[)^:3263EC6B?M:/VD^T(G[94[<7R*Y?$Y*^?V0^;S/!+?PN(F[@IRT2]]G M[B,E)GR8)(_(5QJGI.%Y6HP<97>-2W37C\/@#87VQ7T3Y[3]TJ MTNT0#K?$+*HO'4`_^L,TVX=I@&[4=8@8+3GMPZ9[0ZR-I/HTDI8#+H=V9AZ= M1>R'E1'['T+?K7L'S.-9#U[`G-GN.]WFLDVIVF]^AB8Z5D)/G2-(@)UA+9=`)%`E,1U"E<=HX>W]1[;;VBM$7 MEW88X9L@-*=?TDM=FW*IM=%LMGJ]_B6_'#IU M:4N9)8 MGGT["+AKC+/XPO9EZ5!'K]*HU2K`!1FR,01)"WS8#@2./O)<6!MR(`L,9HQ] MS-^$GS/7RKO5Z7'`D9=CX;/I8:K&`X#O\@"&\DS.+6$$7F9)`]\;T1@^]6L_%*`YC7`8ZI&&P0P-P6MT(SP)=CI.`'"R2+%X*I@"_96`-VU!,XDA=P8&N-CP63(SK!^T M"36;@P\@&$?&_3ELJNV:3HAA($`O^O&(&+J4'P*Q/`]MV'J<>&`[L,O/=C"D M*>]OKG"8SW@'`TWQAKS4VJ*%@`1Q`/>6P0%TNMV/S\8W+.OJV0IM*'?LD>TR M?Y*:V!#A&.B*@$6)S@F+,H>7+;&J.=!^Y'T_Q)D:%Y*89TH.[/+R_=Y%UJU` M*C%G>,`(Q_"GB=:SC]2'O\,^`)7AGM$C1R[4KD-B*"2-90IF9&4>L&P(CV4# MM[7%TFP6_3AB=@NRJ64+!L/%PE^7`)%+\68,2=_%&WB?DG/23R8`XJG40&H9 MR-L62'`?F!`[3[K`8`-@H]`A<6"+:=#:TX!%:Y/#8DD2SD!H+`.E`5(*Y:`+ M\P3(PS''HHWE,S,X$@Y=LI$J<=Q5FE8((>CE$KW"+HF]L&;!D*3X52J--"\^ MHI=G/]='G\G:BY$0%5`0'[J@!NM-'%2B=K"DVHY(^V35,./-AN$N!TX&B M5F.1>1(A`E800SUEJC''5$EE^#6+`O#&`!Q,XXG\:=5W=@I8BNX;2F8%LL.\ MM,2BM:!)LR MI"SN1>,`O8HCO`03TE?ZK<[@PE%%D-8CSIZL593'08;H<$G=V8*\'8^ MX(@F!-Z/XZ]&LA3#EMN`U$@H)V,OLH%H/_`4BVPC22ND,/(UFH0-GPBCDR4S MY8`#!(I>I)D9/^2%`4SI6M+0C!AK'E/-%IF:L_+8W(2/2!>(`-^:6?X@#,`U M5VPC\$?:J82QJON64=GCQT:GVAX'!Y26OPW!_XK8'?<(];A)3@\8^]Z(&Z\= M3X@WB9=4R4H4])ND6R!91[[_K`)4!I,1JBG%GR:*V(?",V?\8R(WQI@!S;*= M$,=<'[AHA,W`8XD,K0"A.UR(Y`?XVJ9IP).I&O=Y%"])/9+"K`^RG5X58?]/ M<&F0A08R%H6T.^5R@LGDH9L3#T@N(4D=X@6J=96G@UAL&@AS""XGB+24@.W# MR*%O?/"8;^W5CG)>JDFS=2_B(=,M714/"T?P),C/^?J>H7-J!Y/%K=0QB*>` M!`=^[+#).Z./4<$=1>9V5*'MY6ILJ323$RB_]G*EM6QQNJCP6KU6XLIKBG"F M1IK&UH&FSJ;OF`W,(REDV M>[$D`!P?$4JIJ["[K7=;W7N]R2X45#U,6L)%3%K#3GHU`[P^=Y2I@N;T]UP4L5Z=43-4L M,YGNOX)E[T"6S;:N.NN2*(6#>O^TC)=1#D;'19;P![#< MX]LD.Q;QA:\W="(U@YJS.;VE"$YH[:$+:NV:.;K51O$B1P5S*U87_3GQ_SF- MXXY5^RQ9:*<03+:7HD"M7@NTD*Y'7U9MH\MC;8L3+JKMB]*Q03FK8^T;$&=N MVFL60?F?4I4$EKW0/U4'0&5/?QG$-46F"O)\<^U`7*ITX0?LT99VF7((LX8,#<'Q$K-.4=9JR3E/66<%%!JB=WZC3E8\*L)N/");'I-.5R"W:=IJP3S0H(M4Y3 M+HR$UVG*.DU9IREK[:'3E'6:LDY3/AKMH].4IPU`G:9\:%<Y0+P0DZ35FG M*<\F)F^289Q-5KZ*6WE\&=";,EONEOIYU)-LY)PFN&LU:ZO7IOJ,+@9@*6!5 M3Y`,O,OVI'VQ2>(RP"8`K`UO:]D>NK(32JH-2MP%);_7:^ZJVALL:G?]]>B0 M4,PT"NRUM]6`.;]I:V]?35NSZ]L25NF?_\C"[7+@%%5=;(:Y]W?-W[>`F!P0 M]]Q^,H1M7[X!:&^-#JOS&X"BT[C'[I1++?70/99[W;G-JU]B5W`-P#/0/98S M!-M;!IV+>BRW+XK88]GB]KM+&,G"T3XZ[#%:<;.V?.?4`:R2__/MS%C)%%Y?P0^/GC])9EW:=GI_:9K;33,;UVSF@8B.\\T%%<<&\,Y MMV"=__@?GD)!CLDQ!PRP#^NM1KM1:Z>GG1IX9E[J&Y(RMKZD&LK$0.1T3F^? MUVLO-:*__?P1Q&2GVVSVFJT,4`MFG27)A&H_PCI=MRO__?9MZLJ4%GYWV8C%-4N'1K:O!GSO\W.QF.-.]":/Z-TM^83Y;A M%_\KBD4Q7K!ZYO#-WUU;W>P'N-2@5<\]W$KK)\=JM1PO718DG>3 M*F]SUEZ%D;D-FEY.D5%!$?\2;F&YX=XJX960WI+UUQNY%M[ZN0D%5[LO`+'W M"?>OX?:.@:*I_Q49?:Y:.2;M73"X#L(T*ZXT7>WAR-!?5+A*01:/CSY_C*IN M[&X#M+8^&FV](H6E2B7MAH_T/I9%@>P$KT44[<>SDD*0WE<^8K8+0^HM.ZF5 M%(+X;MW`MUUAF]I"TIIU)Q3VS;6X7SB!4*8)"[&--S^X;]I"6TBGM9)"T-Z5 MA[E!9A`R1V_:2:VD$.0G4T>U@;0<&6U$./NF^0,!NPZVMU@=>@T>B#+NM-0Z MJ964CU#O?-O41NIIK:1\5/JK/=!$BF^H]-\I$+?3::2XZRE#]X<7"JZOB-S7 MMFL$0R\4S+7$FQ<1O&2C@95)8CM6]F'*O[=J4Z69%R(\?3^&!<8U-U5Y&%DA M?OVJ/&O!7E\%]"W8W-LN-7\`L`];\GNI%=?KE5JW56DU<@IN['_75B@5OD_/ MK[30%Z9J_E(+_MNI,%VCVLXI\Z39K>S0']MN%(.M%J\RQ7O-:K>=6:LQX=Z':6&WJMRPJIR]J]2KO>+9\VVYD;N4JYZO4\X!?W1-81VX][6"(9<,3* M/2\"VVZA[N=N=G0#L*80,/_(>`=@'^EN'+[UCMXNS3PEW0W-/*5:EF:> M(NV&9I[=+:N,AWG+[TF4<*U=L>+`6E!7['6STFUU*HUZ3A>B0_ADVVE2L-32 MHAR8JT&YIY2NCC M%>"D[>;'V/:U?[=I.G[!G<%#M=Y<"B6%.,1[J6W:#O?V]$3T(;O=%D;]'C<2 MCLBT.HI%:";53*J9M."+T$RJF;0P3%J0D\V]'=-E+BNZEL'EV2?UW&'!O.;V MVF?>I,MV2?WFO?007PHMG4JCB8>N!;_\6-A;(H75``=GS:,]A2T\3Q?_^XEOOO(L3OUATGRR!V;X%>7S\RWOHSQP71'\,\AQ2CB%M3UV6[D+=GL M_H^;T=CQ)IP3Z'*D3Q3A6-BG'+MG=]N=;J>30L.VX=\9>J+>;:K52I3?3@4; M$Z0U-D/:M_OK.^X32&G,-<[>=ZK-^D[0MFA=VT7F+T30MZ[LR_Z+[XFDV7N] MN63#\_5IK]=J=MJU[>$P9SDKXDNL-,-R!-C:)A[GDV.O6N^N@,KMK32+XFM; MF(XG0A_D:'KJK]QA`4(C`C$S<2)+$[2UET3;V7L4YR#-\=57-]8C\^\O+^N- M9@L$6P\5YZN<!#[WQFW82:"`KE(9B`.#868/]&?REO@QY#/\`'_:"^>V*^ MS1#XS+=1G=_,ER+P>6`.I[]->3DHE>_.=72F:]9*_"@_I%:MCZGP+'<< MY:&@B4"?T:F)/E/MG)_/ZK7:3V=IGZ0,C0PV;.BPQ/'R?GI,KP_K,2YU5Y&H M(DS]4JPBKYYS'HJ7"K#VLQ`;F=;*;"3,^Z"X;:.$XK_;(0%#>UB:!-J M`S]K1Z#KX?1P>Q\N>6#9O^9&;8_!/GH!B+U/N']39.\8*)J=MCQW+6$Y%-WR MVO_4!R'X%QJIE20X'Q;^:&F%!?WV==H7)VP2T$V"5H:ENO=-N=2K?3F5WP M_C>M>*V8RPV];B1=2)[#R[V:W32[E6D])6"K;K6AN4ISE59B>^&V!AB-.1[( MR?#;,?1TH3H,NJ=+@6`M:(/`7JM9Z>@>@3N-LI1D5478O7FUQ$K.9-5Z5W.8 MYK!3V;U2L*3FR$7KU*T]=ZC#=*?.$BRKR&>.JZP.+`65"6^KM1S'G%/7 M*6>[#FG??...JB55^`7J%UOIU%J5>J_@R?5:\Y>.-74/Z$/Q=+=:T^RLV7G+ M=%M&Q!P/1]-#4[:W;6WORQ/H[6"/A`[]PIQ:_\@ MWGST$7WBU,^6_91\BDM/QP6E7UQ8'C#C%\?'0>5J-BAM_6 MW@=#;KBVRXT1S#`4!GM2-#4-M/PQL8IC>":6&-GOD=QT`T\='8\28<'F"N95BVS\W`\^GQ M%`15XP$^R!<;,-LWGJB5C`0'EAO-_LR$8?&`^R/`IH6KZ7/C;^FQN]6LK6L`B3CPKA&* M:"<^.,S\?GYO#CT',41#&V/?-O&!D6=QQ^@#C@'Q+CT_\!S'>Z8D#"'"D03E MG?':?F,\>0X+;,<.)H;/`@(X#4RCGBV<^E,%WH+7+%N87@B\E/=2O=KNY+P% MKZ6?^C_N>]F%\A]CV$6.V_ED6T!BQL3FCE4A]+^VG]XD3SCV8&;:B[P-F6:< MW;"*_-(&IL!!&YUJ>XX\V3DDZS`MX1?^:&6Y%U@*]8Z%_#?FKF!$9J8G`F*S M#-&VJO5\HL6A_Y8ECE[NDQ683^#NVD_`G)$Q+6-2S.N'(T,7!4G()F3(+9&T.$U90O9A#XQD^`BI<``G&E%S,1J!^09U8 MP&6S.,,O$9YH3A(^'JAF`X6!`$9R'W%]`U``&;+&'9R"16XGS+J,3*K@S&P\ M=L`$`!VU?8XX')U_<5/;7N]5%!$_)$3\2A@?/.9;N.W7L9)@%NP"2E]X\%?< MH`^V%W!SZ'J.]V@C(+>N6:71C)N_0A2.\`7P-M"F<>2%T0_T)$!MO@PYY;1G]B>*$O*1FD.%AW`@/J1+"N&S+'&'&>H??H MJ2%(1,-VC<\P#JT;9YB>:VJJ(%*"\51A,/1\HE7\S0:MP&"!1CA&JL(!8JZ9 M5@B59GNV'L4<95TU8($A_SA.FD[X'AC=[B-`9.6;!O#9E?9!!4@0;$FP6=8/C`S&TI['HVJ@A$F4`0;"Q@[^DOYM/08 M>M[^B#GJNR?FVPR7F_DV:K65^5($/@_,X?2WJ2"!`W1[/LQ[=ZX[/=UP2F)4 MQ<5JU?J8ND9QQU'AA)_/:O(SAA&BSU3<^N>S>JWVTUG:]R]#^\T-^Y8N4?M@ M>^U:=P/K,2X5>,5S'[?"^MFA2@W72^'SO#9N>9NS]BJ,WXB+ M!8/K($RSXDHO00"RQYR^Q^5'?U'A*@591#'<'6^`UM9'HZU7I+![BF#OD(_T M/I9%@>P$KT44[<>SDD*0WE<^8K8+0^HM.ZF5%(+X;MW`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`GV=WT):-G//ZT&-3UYY MHS%S)X;/36YC^_*_I0F_5\WZD0;0GV-[+K:?-ID8RO[K.(X*CDQ5I/4&2T&> MZ=:>GS:<--3&;NPXXSCTS2&V;/<&!G,-_E>8UVT>_K+A)=,;`3H,ZLU=76I/ M__DV%.>/C(W?7=O"=#P1^OS+`-'%7<$"0,)7[K"`6U>>"`1UW/D`T%AW;#+B M`.<#[.4'!Z9[_]__91C_C`:[-X?<"AT8*GDE/>@]0OAEC'^*2S.PG^Q@\H"L M$H]GV-;/9P_LL5F_P!IK+A+-5S[X^>P:=_6\5H?__?'@_2$_]BH57.5%S8VXBUE[(_0#=Q.[?3EN>N)2R'HEM> M^Y_Z(`3_XF+FMJ(M)A+U_DWOW_RFXP5!HU:3I5.3+^[]O$;D)<+[GH72+$G@V$Y'Z8."?`1-HY>W,7/Z M1<^Q-7?5*OI`5F@)>TO_F[DA\R=&?9^U&@,6"]TFUW*MU.9W;! M^]^TXK6S+#?TNAEG(7FN4VT6O/:!9C>]&Z5CJVZUH;E* MR,GPVS'4Q?\%;Y_KNO@%@K6@399ZK6:EH_LL[33*4I)5%6'WYM5C*3F35>M= MS6&:PTYE]TK!DIHC%ZU3MT?;H0[3W^6YHYBG5LC3S:$522NP7Q[DJP!F;ZCW]]J/G M#[BM3]LV3L0ON#]6Z"[4K[N=2JM9C#29]1,S=N"T;<9LQ9*:!6'44B+E&)B\ M7>T5@\-U#Q[-R9J3-VE\66WT-"=K3BX6)^\G^Z;0C'E^:EQY',><4]CVQI5#JU5J7>*WARO=;\I6--W4?S4#S=K=8T.VMVWC+=EA$QQ\/1 M]0O-T9JCM8(^"G:^:)T:,Q_'V3JE+5/S6NW/:W^^D**EVVU66BT=Q]?&@C86 MCH2CJQ=-S-HK:`/Q,Z]0MS:/X@W'WU$GSCU MLV4_)9_BTM-Q0>D7%Y8'S'AV_'^^#<7Y(V/C=_?FD%NAP[\,J%_F!R:X=>6- MQMP5#%LVW`>>^5UV;Q"79F`_V<'D`8%^`)Q_<.#']__]7X;QSWB\W%$N?9^Y MCWS$W>##)'GDCDWPJ\MGYEMJ#BIU)6[=.^[;GO6+[PEAV-;/9P_LL5GO8(UN M%W?[*Q_\?':-H8/S6AW^]\>#]X?\U#MOUO[XC>&$P2>*,OQ1/S-"UY;OR*Z@ M9\8/8;]S;>?GL\`/^9GQ=FH5N.I;(4)N78<^$(H$1[Z<1DE$3L!LKL]("UN MVB/FB)_/:F?OF]U6IU&OI;9N92"WM\C>LHN\&8T=;$Y:CRYX)>66T=9M<7% M;DB7ZEI("+-=NA9=%J$18E*-<=.H[1PWW4ZKV4CA9M=KVS,JH];MJBULM*/4 M\R-!:V\/E3/P[PP]R]%CSF;`WQEVEB.U]NY([:*Y$[2M2&K]ER?MKTS?<0?I5'_'!^Z/&@EB+V9U M2BNC4UKG]<9YL[X`S>_ONK\W/M4;UU-XW.^2MDN@_^$"YR2%Q4WX\\'#KU)P M73X^^OR1!3QNP"Q[(L:8["VJ:^J=&5VN: M#!EMZ+SD:)J+5I'TS+;V>KYU-F^OZPF2F]L@WXO?NY_J6Z3>-5:T%^I-P?4B M]6[H#N50;Z^[#^I]>8W[BEXT<[RCR-3,A%Q?C$#6:]U6JW%QM"&+YL7JF)KO M.S:J[7H1PA2'TN@YAQ/YOF,6M>_OFK_7:Y\NM!;/R,'N6J0Y+?O:O79]+^)O M+>6]"`RQ7&R%KQ8T;R[MN\P_G%HH`5;!]%:7N.V(W/SSG=;2?LK&IY`[TY&M M^GPS8R4=V6DT.XWZ\:K(U@)O0JO(%55D:VFO89IS4$DV95!**\D$GPN.ECU#+"5`CO;2UOPG]F-)=#3WAXX-1)Y4(9%[\Y'9/BF(%&JVG6&548OML_?=9JTV MJQ5WL*0MT5$\X*40X2CV%$G__L=S8!C'#B9?0>V\*BXKFY_P2V\*6LB0\ M7WV%SZ4$P0YLZ=ZG/6`O=UF%0.G%CNWQ0Z)T;4THG4-U14M1T3QU-O6;88.VSRSN@C@.F'QNF!Y9U38VK0BORB8H!4LP?_,.+[ MHO!H+540/.\Z*]V=A;WSY'GG.]A8B_N.[:J:49^_/-P8G:KQZ^W5S>?[&^/R M\[5Q]>73I]N'3S>?'^YGK[O&LZ0OGFYI$7,OMNX`23:MGDF&-&Y=$=A!&,"( MWL#X%V=.,#28:QG!D!OQ4U?,-;F?/$Q@VGM!30QZ%D?[F/+*\\8>)&U^Y MX,PW)6ZN^1-WO#&RI7'Y".XO_K5#L#(7P?\,81,&$U6!;##@)@%X&3["#T:; M"H_5*[1_*)*8.S$$O`C2D!FKK?[ZZ?5,U MOB$KTJ,!^'(T!'X8`%CG$P`*9%<"IY^&TTK!R2(XLXM]MAW'>/;\[Q+L:[]J MW`?PFFM<5@'9@KL@=Q\KQJ?J=;5BW`WI_\RAS0<(!P#X2ACWH?_(_8GQ`<2X M.83QO6AF@UG>F.`R.%8'O38P1#Y@( M8%4F_`E:!S:>1A%&**@DO#&&'V%!`$$0CCS?L-V![02("/C9F8S&0\^<`-*K M.Y08N<0FO[1AWW#01J?:GE,A8#]D_\4U_LWM]!P#@?L5P0A^QY&K*8X$&`1@%-'B@<&C$+T M+("QG[@/;_8GV3EH=<#R\'\CI'41A!;RDP^8"^1,]HCF@A\1*X([*/@`U;": MM_`R?6DR6*\7!@B6%<:_XT>3"Y%&+^P=R"PO?!RF-H761G+((#F$XJEB#S^(D*E]!/'.''J&3R4#@&*"YJAL4FXA7L>X#GG6H8+QFYND?^ M.:SX6-,JV8O1L0!G,^!.8;$`H*75.-+])Q"2`SS;!XT$#')@$^6+&7AX@)UK MHW`Z00"7S0768,8=\!`LXE?@%0QR)C;)DJ3R+KXYF+W4[`%&#YY M%_8=D,R*M%34A`8',8Z/7W/DRDC.IBR=XCU[X@B4S94Y%NDZ);Y&O]'(UJ_?$?!N6(S59 M12F[^","386#@1:!9N375>,A%WD^[(SM*Y4LL2*$XZ` M^V'@/G#+$+CZ^\P4N$@$F:&9_,2C?8@`-,&KQH):-)S/'T/0V1X0P<@&'`2> MR^4^<)RX/(^R\I(5:OY1KG&5&?ED!+2'U8.D5RE'1-CPM$PV$4*S-F M18JU0P/C?&7A`I>CX8V"9Z`FG+5SD0)`1B MAU,9XL!,RH0&X!"@AW."9.R-D7V)(KF'2C96+F2?XBSBM!$+W40@GWBH?<<<7%JST!> M#6P?N.0.?$]N-!+EBR[SI++N0,W<@4BBCH,D0($D M:CG^IV>3?\S=1Y+/P,X@6(4Z3)ZO:9"'(_MJH2V6]3H):&G% MD1$9V.?2>47/%HL&8=#I0.9>;LOPZ9C:1[&X\#^3)JG$9 M;;4O+2.#^5XST;6 MAXH"G,EN1CY0A>+5XS'\@@B7-GINW)-`Y$![>'4QD:L2QY$!'X>/X\4L\"_D M$F9G(4H`(C!!<9#_P!Z9#4*9QDJM>#98BJ+KV18)_1!&6$#R(NO.9L@-Z'>, MKC^^0@+1<50,-'52&R]Y[.,)!9,T`F+5QB-?C*P`B1'Y*5-%X$EX2M(I&E38 M3D*O\ON9(]JY%#\M)C,A>ER;.E.>XX7=A&A4TY@/A#:C%X7D#3;"S0<&!#(D0'U+RG<\D).1E\5R M/B8Y/"2*3RM41I%,VX@S4A'&%0-2A$D`C>!SO90X7/WP!@T)^2Z1][,7.E9T M_&3@X9D4]&O&GF8520KL.!)%0*3.:M0ICY4'DH([I1&W>'RT]M'1T3/]QY!. M6A]#1C%?3-A)$H/59J"VF`GQ);REV`HIZC6Q!^`0^$>\>3>]COQ>+3OR)?VW M^_9@Y^X?9BW3&S^?F>20I7O+DAY70*G^0Q3[&`O^SHC^4FULZ#%LMN./F*.^ MDZ?3P=2WSURV8,I\*4"3!N9P^MM47R#,8CX?YKT[MX,.<+]$ETBC2[7"JE7K MV"I(?:?:0LDOS\@;4VV%,`5>9BR.F1E]!B\R&/Y\UJS]=)9N`?1B2]_E.O>F M]U'NRMK]H>I`&<)SP+-XN=DLA2]^!RTS%H,VLXY+D478-6UG@2HC.DPE;;5/]_TR3\\%@A^2>2SBM MWD]RRK@-]7YZCF$S.4/]MUJKM0CR^D\O;DH9P/_;NE`OV01O_9YV,8ET?TI$ M2V3&-ROU6DXO^@,WK%N!-O;:5WYC=HU8]*((6-XKVZVO4C9O^+GQ$C=K5+G, M&C=J4MFH=#O%8^)C4[4T#=VA+H6"*@)W[[=S[:Y5\"'[T+8KO4Y.E]FRL/A* M;6)W>16EVK;=0MR)20$R/RZ215#^I^1N^FJ7Q[,7S[^JN.LWU_3<*%AZ%_HF M9HM]Z<-29.@MY^[YLE6$=G/W7`>L=,!*!ZQTP$H'K,IA1>N`54'`UP$K';#2 M`2L=L-(!*QVP*H2"*@)WZX"5#ECI@-7F`:LD*+5R8&FMN-1UR'^C6AY?7(Y> M<1*=RND-&<6C%O:Z:8*9F:G\N"8DZR[GUKWG^$QV-?.[I;S89'[=U:0!66LQ M"?3S*S6_U/ZPTUT'^BRX*J/Y2E:9B&!:MO3QXHK1C?94G=#T9$N`TWG7UXN'FH<(&:\PSFG-$.D%[ZX457*>C=*G?[TX=+XE^>@:H8I M?OWU"J\N4&U*+-@CLWR1R+`CE>&P9Q':0>;F193!KE*\[\,Q%JCVX?M09H=? M`7`#SW=M5L$OW8`J0`%]&Y=`VW1K91:()]A%%$T?;"][.P3OWL$X>$7^PY71 M[M7;]>8;F:=.-VSPO@6FWO+'*(=[YHK"S&24@8W)[%0Q$O-QW\#ZZ.SYYXGC$S`X%=7MF^& MHR=\,'W?N$*7UBP%1U/"(6_BP`31#-&M_9S7G*AH52.Z8S^%#;G#E%C.,WG_ M>-=DP.@*"^7.1Y64>09Y\D8AD`9>[L%'OWK!$+9F;&-%ISO`I\M]A6(JU`5& M,3)KF*F'95'?#544%XULVV=L1S6HSP]OQI0=,CP="PY(9 MT56":&!U$8MNGP+^G^1E`D!3LYI=GBQM,8^4$#_R[H3/'VV!5PZC!'I!):25 M=)K(2J*8'PYP"2P;CR632!,:S[(MV.SH>&=-CIX&:0I`JHXHOL-SN!,6&['' MY*Z%2B\'5LN@K%/IM"XJ(/(S>,M>@L)Q70^O1P5&GW,7CWR>)+[H;I<'*_;H MQJB4!]5#"K5BB-8T^OK?1BN>5,8IDA M)4^ZH!M^E'.F1%8"6>JB$7,F,"F&;\92?G\'#]*=%B)C4D7JRQB$&`!<0=6X M--%8Q9N1D^RE+.0#BP.=6-'EF\R2+%N,;"'4=67)"<:#1_*W,LNIR%&*D3)[ M&]W&4;-6HG'5^9+:#1]2$@FE$]C` MMDGWA%)7("O&D^>`E&*^[21%`?#NX7C,\6J-R6-6`'%947<2P9\@%0=`T.7( MB:P`P1.M%&^WD/=/\=8SR6&7;I[C8@7,G+Z&B1-$DZ5*\K`G;^J**%WHM,A0 M>+(?/:!`X2`G#;A$$W<&\/.;S)ZE>SV416X8="!`2 M*CL8!&`N<9J>\W0=/C`C(I]-WD--U]Z+K#2\WD;"0-!5TD@=I"X>C<<\(B+8 MWEKLO`0#P_O/MCSZX=._P7_CX_P-02P,$%``` M``@`F7IF1WJ/2U>8#```4:<``!4`'`!L8FEO+3(P,34P.3,P7V-A;"YX;6Q5 M5`D``Z(+/5:B"SU6=7@+``$$)0X```0Y`0``[5U?D]HX$G^_JOL.W.SK$6:2 MRU8EE=P6`;*A;ABH@61WG[:$+4"WQIJ3;&9F/_U)QF;`MN26,&,QFX=,9G!W MJ[O]4W?K+Q]^>E@'K0UFG-#PX\75J\N+%@X]ZI-P^?$BYFW$/4(N6CQ"H8\" M&N*/%X^87_ST[[__[<,_VNT>PRC"?FO^V!K>#J?_;$WH/69/'[1ZB,UIV&Y+ M^H"$?[R7/^:(XY9H..3)GQ\O5E%T][[3N;^_?_4P9\$KRI:=UY>7;SH9]45* M+I_ZT8YAG_AM9_MPGY1H1)-0&N4]B0XTQ+]>"T6>*/-*W[])2*_>O7O729[N M2+E?1BAD7G5^'5U/O15>HR=B4DWBA*WF"E)UM*"OE7.R-K MRX_:5Z_;;ZY>"2,NQ/MKM;9OD-$`W^)%2_[_]79XT&8P)_251]<=^;`S%'^U M/4ZIT#5AC1[O!(`X6=\%./MLQ?#BXX5D%&U>O;U\]^92MOC#'G/'JO5I)*"Y MQF'4[M'0QR''_NXC3A<]NKYC>"4^)QM\33FW4=*\#3M;^H1[`>4QP^U>=_IE M-+X9_#;JWOYG,/O\]:8_[8I_7\:WL_9L<#L:WGP;3&>CP'-@WNV^QAP(O#I+G,H\=J(0?(BPBEY\I M)0T'A?1$?M9"0+T#J8%,2)0=6KJ?M!>(SY/4(VJ,)4)W'>F!#@XBGGV2^*1] M>95FH!_2CW\?WV$F3`F7@X<[&7!W+@[0'`=)T:*GBT@D3=30=1JWK4=YQ+NA M#[511:^RM4A_:/,>8KKLT'S$O$RZ^+4`E\.:(J7H\'B]3J2UB4B.&?^"T37D MA5%SBWM/!K3>MY1-M"):?%@439F/F2B/+UKWF"Q74?)KK`!&)7T.(AIZ!\`"B9M0BRWBID9T M"I/7;L3-/F9D(\S8X*$80[,X&43..#5UQ[$X!+27XNR-(VGY%G,LWL%*U-)]O,$!O9-= M0U^S@7AR`*O@<0!O""6"Q0_4^K?DR!05?\V,O)C`S,99X*T8SQC@3S#YE(D_NM8)!8GUN0G MO\O2=$:'H1][(LIZ*Z$.GC$4MD\$JB6*F?1EE%YEG/"DX43ZBV>\DVE>'KK")[$F&%KB!Q` M=#>("/`$>$9[=+VFX32BWA\K&@B5^2?$B:>`F*64_-2'J10WO`;Q"<1B%SJ6 M[8ND,+O+NY9AHP<30H>-97.%EVZ4EN/#6*$!BX92M:[B,'"TJRG'@*-T#<44 M`(W6RD`GV2TU53BJL,CT^E*7A=R$D*WQM;F)$(@9DWN!1)CL MDPWQ<>C+)<6N_]\XW;VB6Z5<1=X\ M"BJ3%M!6PW2EEII-L!XB(^:B#7HGQ:/=!.*'3MYMU^+OTVSH,M[!VA24#S39 M.E>\A?%BAAX4:`9PY`"MY?@^L*V[CT)>T%$T#U0-62$]MJL(L,>QKR#`* MR)_8_R+*$SFCGJY`C\,I]M+-P%U&N'C4%W^&RPEFA/H5G>C4S955KR=I[NS@ M_DR>/ZKGG$['\G%=X^FRD0,.C:5D8]Q-BC@/8W%,2J[0Y&O"7.`?`Z$/C,84"/&3B!7#I>57.>.2#.WU(G%RI:SE7$W4;B;3OM,V508_50+J);) M*QGRB^0:AG.''=@9=2).UVBV;/[B:C3=.K,X`7C4D*!BR`$D)4@$]9U+:G85O#,[)?EL5=`\>YF&: M/FRN)R8*]&+&!"ZT%N1H2@W9T33?Q7)NIS!SRGO/EN.@EQS*<.L0\_=)$Q`V M\@@XR;S(05/V4Q^.(&O"\!TBV>E]H7XR20V)(0:<.52!.,\`4^8>,$04J`&W MCDM^'W688:B.0882/^`),#>PHRY4*ZH9*!]X1'%.4D,,`<07#X0TF]'D M[M?H<1*@,)(7TXA5-])`&$IY#`=BRNP*<]:8&.AM;->I%N'9:\)FI-@ MNZ0>^OL[5*76T:,"(E"V'$RJV5QPA#Z\J@G5QCH40,%OCAJ87-XSJIK:[S-E M3;@U-.AZR7T)?((>9?ROR,%:XGSB51`[!19=RH486PF1LF2K$.S81FFA)HNQ M#XX@E?1%?*CHSP@B(),M4:*2[=@!GQR>T_NN)HB!,`-FU8<7!>L9(T<2MW$:FI77_)9N::O.M*R8Z5!EW?)]L-#!-$_&'80W)B9:Q,*E)++=YHT>(([0B3$_@"QD(1++LK?>!TG-6\? M+XA'5.,2.&/AU'X4H:64XBC8 M3,JY@.\X]U@%-=,64UC^Z`XLRR>,Q`A/7DAN-WE7R@R=RJ#"U`5<_>.'*5:-C_QHQO9\,7>4U,3A(Z]C_4('0#7LSH"HCX6XQ"/;%]P MZ._?VZR`%("C\,4Z&HZ7"#>XBTX-/JTF63GF"!23PG*/%-\PC[/^"&$/RZZ'D3^S+'F\4Z'17*ULB<&1B)@O9H=A>IZGGRZ6EY[K443, MXX05KB*U$_:24%^K8T\=D6V5S)9']GI$H_HBMBY^_FQAHFJW9.)(]%%[97CQ4\ZR9H5#8K!E8:/-]YD2S9G9N M?999,[!J609Q9`U)T<.S]2^S"DK-"DL).=;F<5P3#JMCO\YI1D$>J!H@R.=4 MRB;J7/G2=9%[DF6U&>UZHO\R;'QADH6$_,9E$PDO$2I]";`Q_'"'.?'22N>T[:3]B+Q7XMK3]X7;+7,YB<=.3]; MZ-/*8_+0B%\IH"K@:P2\2+S;.O#9P[U&L6Q6TY5HK_#"[EMBZQR8&@J%#4S! M0IOO$B<:F-JY]5D&IF#5LND:1P:F^TDK7:,8/&#F$0XJ=%0LFFJFR-(\7FO" MFZ)DJ7"24=`&JJ2J2XJJN'5WQ[ZN\I26L!6/%WO'MP"8U/)I@*G@>^GHA+CK M.2&JT,>MZP(/:OVG;0<\ZU@^`*=:/MUPL)SOI>,4XJ[GQ*E"'\T]`@U]/<+U ML#>XF0ZZ-_W>>#0:YK\'81(S;R6*G/$$,ND[::_!.$6>]*+_M?0H^'N6&9! M3447,^0NG'8$=,"`!4`'`!L8FEO M+3(P,34P.3,P7V1E9BYX;6Q55`D``Z(+/5:B"SU6=7@+``$$)0X```0Y`0`` M[5U;<]LXLGX_5><_^&1?C\=Q,IG93.V<+466$U4LR2O)R>9IBA9AF1N*$"4 M+_/K#T'=2.).XD:%M379A`+0W>BO&T`#:/SCG\^K\.01Q$D`H]]?G?_T^M4) MB!;0#Z+E[Z_6R:F7+(+@U4F2>I'OA3`"O[]Z``DXQPE.3__/W5 M?9H^_'9V]O3T]-/S;1S^!./EV9O7K]^>[4J_VA9'O_KIOD*Q\+NSS8_%H@&C MZ2!"0BT.38>,PO^^RA@YE*PR_?0V+WK^_OW[L_S7?='$)Q7,VCP_^_?H:K:X M!ROO4#C@%SXM\)T$OR7YQRNX\-)<@]R>/*&60/\ZW14[19].S]^IEQ,_?O7[_]G7.P*%N/=JS-'/X68^GIWT8 M^5G/`W__*8%WDPSPN2M*KKTX^W0/TF#A"5@^SFE=2O7DN@B210B3=0Q.9S>C M46_Z;7(Y&WX<#R^'_=YXWNOW)S?C^7#\\7K:Z\^'_<$,^6-_'0)XUTL2D"8C MX*'JOI=>>D'\Q0O7X`*D7A`F=:37RT_S/II/^I\_3:XN!M/9X%\WP_FWL1ME_ MGR;3^>E\,!T-QU\&L_EH,)X75/TQADER$V73L##X"_@?,^>29%.UJ^PK2-1H M0B=C"FSU`X)'1GOP!3&@RN(HK39`W"(#"JB-M6UM4[Y-M3'7I6K>E\]2N/A^ M^B&;`OM]N'K(AIU\D+'DR7G<&/4ZBD'1C'1CR:^GD^O!=/XM(XG&EVM$1XU@ MS)8;CEE1L^$J4C%2Y4/SY'H^G(R1PK[VIM->R?>C:=HZV:+W*U)=-F-3."VH M3[LH>[9<"*(`F1-:W)?8`L\IR*:<^[Y&/2`R'\];W[4?PD6IT1`MTF%,7#CD MBX8$+'Y:PL>SK*5L\7#^,_H+ZHB?3U^?;]?A?\L^_7$!%VLT"1Y&=S!>>5L) MP#";&N^[-_1N0?C[*]'B:9`B"?G%SZR)./=N#TAABU<_]FO$?N@ER63C"'K/0=4TA,MO^UN@O$(4,>)23%25 MM0GEQ12!54X$04J\<0Q7;S!`4>;\HA=4JB*$7K$"%5%`A1FA1 MP`U`Q'4#)40KP8-+HH@11M,8.-X>$SC^.+<.CW+052D^,.G,(.1G30@1G:`, MHDS;G@B(5&MJPFP7T_\[)_3? MSV2*O7"8K16>/X,7*@`HY3`$8.5`7RR#HKV.T\W"9+4^] M\!OPXD'D7V2.CH`#7M$"%.A%W42#H&BU`,%M&\/$KTXXALL@!'$_8W0)8[I; M();"G$*EE)L@X`O4P"&0F\54_W&NXL^$$-?F9SR'IM6;&]C$B1/0/R]H-K*[V[JEB5$+>62&\2UB\-(X'-P*(7T$8 M?H[@4S0#7@(CX`^39'WH9VR=P"F/+1&HY=U$B(R0#18&/`(X6MP(-WZ!X3I* MO7BS(";Y#F8Y#!U8.9=1P1:J`1IH#>,HL!UOW"YK-S&Q*7B`<9HM93XR-(1$;!)(8+>/`\6-(.3U^C8,%IDC>>%@O;$0_N' MV#4Y%_`1Y!"!\00R*#DT3-BA$*U71\V)*7OMD8)D./ MAU)1@V[S])MZ#-S*!)QU(ESE#%SL>+C1.3@/;.9B-5IS/-@RG#TC&PXS]W`5 M>+=!F/48V/,[B:9@L8[C;`J<%1C#*-[],YL&!`EO$JF%1L4L%=.PYLA4R,$* MSBEO7X,>#-SRU`M-J+^_B8Y9J31%5ZY>BAINW_&9\+Z//KQL>R0_XA"#/]<@ M6KPP`LH2-6G6QJII(\"L'C`DFQ+N+VW6@H6W97AK8>!H+QY)..9L6Z(F#>2L MFL8#WS**)F%7N!O8V*53)Z)2@.J1H#+9VRTS"B%350"7>%6S<0@917-0R>D% M-BSIY'FPI))M,RX_O.S_^BD`,0K$O%RA,(S8K$"@,GUBP*QLOVN*JL=9E1Y2 MN&V(&#&]#9O#C`@*>#8MV#N\,8?!"M>^N2RTV="'T<,Z3?+..!<;=^@U:$@E MU;`_RO#U2L(F5WKA889*GPA(!MT6PF^S@#G$%/>!2@KXN.4KT&.4MP0\7>$: MT9XQ&W[A<]5"T!:&DUR^/)^,V'R(7)X^!:J6MR]S>3^@@(D1GS!G:^S"%3.@%;8Z5*K7.93L'I$A4QF71?1SN%.% MW>,*K(N''*S$UD78:^$Q%M+ZY(WT.O*-]#KRS1&M(\G2ZU]'5NFV$'Y]&#_` MV$O!!;A-9\@8M_;*`*!0G6HJ37:=XQTH93K+VG@IQF0+X4VRVK?2WO6MM'=] M>T3>E2R]?N]:I5OC)/4/,&MC!D:L3-0H'*E2W[$-[9X^(%UZ%C?Z0>Q M(\@6SS^X/+"9VDR5@JOQ[51!X.K<3Y5&L=4=59Y(.=]06A(K%[0I>\%R M:8MS.%SNYIT7_A.?+CSW@6WO,E[\P+>"Z4]^7#EP.61WGVC+TH>7G$%F+A9^ MC>H-9U8-$UX M!&AU+W)U+W+Q2+CP(A?^P"?Z\L<,Q`%(^C!Z!'$:9'B^SDJ#.$8)S#(.B6%5 M^8K;7I.I:#;(RM`*;"`P=\0Z1$UKT##V/E>#(XU/7NRC)P(8XQ"Q3/7H8KF, M8REI>NC!V^5F%?_AY5#FVGM!WW+F#Q)$_G7H1>BE+:9[U4E**!U.4U+&73P9 M2-Q4.DJ[E&CQ)<;X.7@4,63N,8Y&>6?2.%BDK.%&J"R>6X94UG!^)YW:A7(= M0YZP:&"PDJV&P5@;\)GSG2?=@\[+1&#SE/]$76#*5L=666&5[ M\R3VJKZ.[#47^'*D["0VT[6L94V>FBQER>WB*Q1=V=D;3M&N,[=##:9A!4C3 MH6T!5\V+)D--$\*;PT-BKU^[I^SK&"X`\)/+K!N1G7O1(D-VX0TZ"@:$ZU6@ M(5#/4<3(2EP/2.)4"/@BA%QMXVNS%$?>>BOU9E39C#;G%'")5<(.4[(K.0HK M*5GK84J0!`%0;UL#J&W(1QI3>#TQ6!7KM0M95(F5@HM`A8"OG]W#%W=)1UO1 M#?Y=E`EC+R MCAJ-I?YO,.LTR2S!A-\=D0GG?WP!2;I?`]-&$QTD5)DBD<2QF1N_'PV;%(LA M@MG\XJC9W/)%OY7V)KWE,@9++P7#*(V#*`D6^;&R,9HC)"E@CH56&2*9I"6& M7#9@%W34P-SMLD]P#K^ZYQQZ8=XX\,D.STP M2Y(B`.^]>\#3-\?]DMOA;HX[AZD7[D\\&U^=B3!C;*W&9L910W-"-ZZMXX18 M)QS>?>V>(QBL'D+X`L`,Q(_!`I#[;#^\YMV3Y`(7?^_#)!W#]!O(+RDLH^"O MHK?<5*KV(<476.>GX@XL\N.H1W!%0_6<@GWN"7[AW#V_T."X-?56FKD#UZS[ M9`U/7(O=!%-^YMI!B+3\T"D5IFTZ=LH"NI5SIV+FXD\) M1/_S[;W!7G?2C,T95"WR\,F(H@7;E5MW+FLC7_"&IIKVZ?`EC]*/JX5>(F*HAF4/,L7LR]08+$XHP,7+H ME>,'L-^>[^IOA? M12S,G'\].G,N7P3\&,-$^;8YGY)BDR92ZHRZKEI::M8LP?"3C^X9-BMI4V$& MD@R>0;P($OHMN]H-R23>^>S33LOZS#[D"0YH&0 MR!\\/P1QWH*VI`ZR=!4/E`)TC]:`#:NLI8.HN)BM2%;9L#>V3A&=^]&Z]J72 M46S_!#J=O==324OMFRX6;L\MW!07[]^O(%C>HWM6CR#VEF`W_>&FR31'75_< MBTV]71Y![,"'GJ"8A!:UN`NF[)HB9D(RBYS$=MZ74#19*)S-/ITVG)?4T]TWK.F MY^ZE@=<>![*P?E+"D^F(:N>J'-&XXY[+2$_@\R9'#SC<\GOJ5GJM.@7(0K+O M?1CE"EI[X1S$JSV1!@(SUZPTF:F726PQ@MTM,<_(43L99S1LT\+[@'.[[-^4UJXTU_`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`H53+(JM`>' MPF(KPYX`11[>?G8/;\:"(-0]0NMA$-;&GXDXB-@^GQ.1$-[\W\JVWNSFPVSP MKYO!>#[X@K;NK._)K6\3\.1J!4@*11R`*C=*ZD=4V?JRE=0O#JGR5\Q4(;+!0Z'.CP MGM)V'SS,Z!.S+!LTEAX^Y:J(CA>)ETMI5!AHX3T]ZB!2KF.X`,!/+K,N_NJA M\W+I_EXL!3`B52JX85>Q"A_FA$="U-H3'R$:;8`2\=QH!3ODLZ5EL%3*=.>4 M&QY?;>\I9<:4PQAFBD\V.]VL:2NQ(&E:6BEH>-I)UT1UPLD2B#R, M86UC4TERF_@:Q_8857S-@37`D,J1QH9R.2=5SA&GCL:I3>)NU694U?_/>G=V M&AYR2EU[@3^,^MY#D'HA.N,^AYN3[K3`:\UFJK%9Z69<1%/#SJ@!MMH4,2R^ M59F`*YN3K&!46$;?/,!HMUB>W&UC/DEO!==1%5GU&RBFPI)LP"4T->X`"1PU MH(4AZ&<+"-HXVP8(*C=0`T&[!MJ*(&(':$)0A19^^LKVM!>/^>5GD_LP>LSF M;UEWH+/.Z.]I`_,O[H%Y8W^* MT2S9J,R6Q7'AN5Y'J0.T+'T,T;^ZA^C<2"?I/?T4FF@]"3>[K=PN MRR0P`/W=/0!M5^OR"")4E'%M[<,076#5+HJ#HO<6430&Z3!:P!5@7'8EEJE@ MHU+&11BPQ*BA<7)SQ',>%GW$5@+F[1MB(5I$W^2-&T'K9K!?RY*)[>&*Q1_> M=/UFS4ZR3=P>[;/!"$7:6/=K1.K0L$*N8^68"%FI)!@)",I&%7[+1JAIIX+I M%4Z96_3,LA5H4,J:OT@CI!(H)R0;%B1*192P*2@*;ZNZ"P'N0!P#/Y_U,,^I MLHIB=Q](1%`)%"^YWJJBH8&_,S&''\!F$4/4J&AQRJX#7MPQ_4K*)Z=FX<:=LY!3$*BK8NU4!FBC)M1,`?>#%Z28N=THU=N`(26F%'T2$D M6SU8<)IV:B.RMUBL5^LPFP;[>2`,B16#>S1+?P2;$`K;GFYW5L,_948^D#X%21H' MZ,FI?!)WD_57,@69Z$F0@AF('X,%V(3^IV`!EYON;'#44`,7-4XJ*N7"Q;T! MNZK0=$Y2!\.X'=L,4]+&)V*V=+1/,XD*B?'B3.1H6=RN&X-T\\4F6^I>_:Y]LD;SU M?6XSHM`E)K!R-,8L*FLE(SC?!S8L)9D=C7K3;Y/+V?#C>'@Y[/?&\UZ_/[D9 MSX?CC]?37G\^[`]F8W17L+SV8B$.\7:6E;;=?;N96D'(Y0 M;V>3+\PK$J*T>%3*/.Z4;1YH/"3Q;RBEV&N=*HE0W_540\3$D3V=)J>UTXW9 MGB8I\","[]MV/+%A?WQX(3?`2K*IGZ+:<91-T>XCMDKAK&ZDE5`2YU$8%0(J M'(6%!,-OK+Q^;?-`.IEE;A8HT6I"UF8W':L!I7.-1S)1JSZ6^>8@FL+5;FQJ M$[!@9X^GE2-%ELKE7%@UL9.P\H23P!4YJ2J=@%MH.(K4O740()V&5T;[@BEU MW]C4?.'JL<3Q>,%:V$EI3BWW\2(G>&,$B9+#S][:Q%1EJYYSD))1%CM'22SK M/FI$A&R,%381_*CM$;HKOH^,TLT,01AP5Y&NTY=ZD53@\E=B5OF3));OIHGAE[>>"R6 MH1,H+R']?>X2B5(*&6[3JJ);E*N_E]FT$,TSO2B;%=*O_#**%:_Z$HN9G4_P M>Q0*RT14*)7`_HHOJV'-ZOSBQ0%<;])-95QEZ]A@D1^TBQG*%:Y45+5`)5<5 M+RMO31B(DU$UE:39.(Q!L(PVM!DV3B]6LG%2,5=5S9>IKHTS&G8KA*AL/*>& MA(R/Z*Q84,,A72QVHWQ0=VOM^.'E`X@6]RLO_LY8`XA6XZTGL6INKP\DQ:ZY M6A"FXE32,)SK'<],ER-:C8ND:C7C"PIAM3$!Q91>#%`5NFQH4>@YM2SM)0E` M-UVYJ6=HY:K[&'@YRX%/FAJ@N'""V"@3*NT64`DX!09-?H8ZP['E:5@3'1VN M1FSV8\;9V!S'KF.8S1O2%_288-J+?)39XD'D?3SQBECJ0WY%][KC)@%WZ_`J MN*/M-$C4%.V08DVS'EM"N;!)%Q"-CD^\G$-2G*A3GOUPV)HJ@MBU'+'JU`LW MO.HF=K_JX:UF%R@`G31EDL]OUX;9%+U-RU@C8[]7SV$=?K=[=T-08Y`O&N<. M!9M0Z1061L`I3Y6SQSZ0AY<@J5_'\D-HL8IW<%6]XHN,?5N8!EU>1XPR05;K M%5.+Q#+57>YR&;/3$E(O0S'^Z:K<%"_M7Q/;<4N=WC-?G:0RV*&%9W?5R>!? M2IW$=IQ:A4EY6.K:W8"/92W319VLV-*[OIO=*]+E-"F[:0*\RP]>GV*IZVRG M3QFL'D+X`G99\LCY]7IASD%^;'>;0>\OX&]RW/1ADB:\*((F*M5DIJJIV'WI M_19C'5T96N9+A0\OAR+7W@OZU'ORXE)Q)`WMC*UZ`J2WY141,)S"6!-6JR_: MZ^A]Q$`5;.[+Q= M3`=07#(90)"NY]-:=PH&4Y"`C)?[7N1?@$<0PGSK8O",G"DG5"5>$[^KSZ_I M.'CDI6\&)QEZ3L4\E8]4U+BHE;&*%2E5.5B)15/U#E=V(Z[]WNS3:#(>?!OU MII\'\\N;\<6LE_WW:3*=G\X'T]%P_&4PFX\&X[D[V:F[6__=K7_BU,/=6__U M9B.4FUHC&(&7D1=_!^GE.O*3;/B:W<,XG8-X-8P>P?:]GZ\@6-ZGP.\]@CCC M;I[YUSD<>2E*[O%2`8SR=HMWP=2TZR+T='5;#7RJ9\6I&4_O,1MR4(3A$L9H M_G](4D-Q??P*U:/^C`HN8D]:T`9.3X"&4Z\18W:0]K/)RTL0+?,W;6B'/L1J M58^!\&JY#!XYD1L@2)204R\4=^ERW$N7\ZYMFR!=MIPN6TZ7+:>*",>RY73) M4*HEVP[92JU/VD`37F:VG3,^I8:6W6*Q7Z]!+@7\!'F*P"+87=!]"D.LS M\GLK&*?!7_EWJHBTJ8GBYJLS&F7-MP'/FCI3`?*5<^;4$H_*[AC0<"]21=3C MYE7:@$\)H75ZVR(UIPZ]%$V#@AM2D0I.RD7:@`N&4`IP0&S=J5,J73*\'SD9 M7NO.PU`%_?`RSV@SPN,2-44'OV+-MJ76D^\.94GW9$@[M1ZABYA19D:Z)&J* M@J]8TWA<74:%(J"C=H.-LSRHRP4TI5,S%52SDR.2/H`(K* M)@>.`Z4B.&@4G`+"%?`2<`]#?[AZB.%C/AJS[X@+U*@`A%FC%6`1EUD%<$2H M.14IF-S=!0L@YE.892O`H91M!61$Y%0!%C8=IP(!6BOGF. MV-:>R9F.A0V^(3H?F4#O*?*M[>)1$A9A"?,^5!/F84$!4D)')0V3$CDV;-AN M'LTZS(_7R&=.[O)?D]XZO8=DNIV5RZNG;3;.%`FW\%8>>6'YMHO@,?!!Y)L>RTET38SD M9;J=AU3\XDT;M]$PA%-5J:IDTV8F'+6_ MMKUO"].@R^D?1ID@J_6*J45BF>K37^4R9F>4I%Z&8OS35;DI7GK4B]B.6_'' MD??,UR>I#/:4V[.[^F3P+Z5/8CMN19ND?"PU!8(!+\M*=2#J9L42%]1WM%:3 MJ89>A!Z+8:61(Q2I'@$K%3FZ*1>C!\S-NHA,N'7<<,LA.V4*L1`%3_:RO9$Z MFX`(B0QNA19):C7ZY"(B.G^"](?8B`6*3[!5"AA.?43N,RC`/%,WE0?6R.VH M>BG/FLW1,Q(9L3IF\B$ILQ-,*-30\&R.SIN1@)WEE5BF>D>P7.;H!FA6'Y@; MH9Q-U0;&.J+>G4H.Q(D[)##D%L/V%M4/2`W82 M9%YYVB5)O/QQ@E"T@ZP`DL^<4Q/1ED\;J$N>-DT<6`LG*S,'L?67(W,'NX\Y MSN:3_N?)]7PX&<]ZXXNOO>FT-Y[/=LL0>#=+O72=H/_/_,%VM$IL/_>H[K!& MERC60%*[R3I-4B_R@V@YA6%X"6/THVH5"!%3G-J.1LRQB8N5['9"BG#YK*"8 M'$[-U17*NLG`J=](RW3TV>>.3DM,4PQ\>LR5J!*UELH43Y/U5L1R:HNRJ9A= MWM@?W'Q-YY(U9L!2^66M)I/I\LNZ;%]NY9P5-Q^%>6A;F;9E+]Y#$.=U]KY` MTP#'H*1X@"-2.EH#U*Z6E@YP+,&.)!U+V46AXPE:5Y=4.LKM%Z/366\]E;36 M=FEBN74LOJF\V26-OD6JR8B&:BBV:0[,EUJTUK"NCEA9$=\7$ M:=>>M[A;_`J"Y3U*,_P(8F\)=FN(ZSA8*,^<5(^ZOH`PFWI+3%T*Q7JBQ1): MU#+*,V77%$H6DMFQ?!*U3S40`W$Z/(=Z#I2=JJG!P8_N0;1ITW$OHD%N8N:, M]GJ2?59XF\ZD%A.J_8DD$YU+T:?3EGN5>J+CCL7FPT$*HS$6%C:2U/7%(CL? M8ER+CCL/Q3+C7J/>OCOE$KC6?CNG1"TM4"Y>6S=%N2763XQ@VE.1QCBF#:&< MRHJ6"W;+E_U6.BHS!0B@V?<^C/(.6'LA2K7[AC4!L,.)XI>;:G%BQC78P+O" M5Y^:Z[CD2PSVALH7HYKT@EMI2IKV!'WJ1.L)78_#->!$L?>IQ4GG?8SH^!B\ M3Y->P+V/TOQ5O>4R!DLO14_OQ$&4!(M-SG^1Q8=LW>+R0;QNZQ<`-;M)]Q1> MFBT,B4YO#G*ZN&F'JIR]&*P9[5!\[E:'7ZW+G;N=:4G^%B MD>I2M!(9ZU*T=BE:NQ2MG6?NLF!V63#ELF!NOZ,_T+Y0]N7_`5!+`P04```` M"`"9>F9''.X7.[=V``!4@@@`%0`<`&QB:6\M,C`Q-3`Y,S!?;&%B+GAM;%54 M"0`#H@L]5J(+/59U>`L``00E#@``!#D!``#MO6USXT:6)OK]1MS_D-<[$6U' MJ-HNE;MGW#O##9:DSKK=B8@,B4A#$)J`%05?*OO\@$0.(E7TXF M3@()4AL[[1*9>__S^O7ITD-,CHDMP^ MD_./Y]='Y"K^0I/=!^0D2&[CZ-4KUGX51K__C?W/;9!2DCN.4O[G?WSSD&6/ M?_O^^R]?OOSYZVVR^G.S:=^Q_><-; MO_[IIY^^Y]]NFZ:AJ&%N]O7W_]^']]>+![H.7M4L_?TV7W^2_'B'%[Y?$*_J1WA'VWT\?SZ4^?_J> MM?@^HO?L!KT/;NDJCYF;R)X?\]N8ANO'%:T^>TCHG=C6*DD:IEAL/['87O^5 MQ?8_FAZ^[QWJ30Y&ZC[>NIMZT"OVT?O\7PWG]&M&HR5=5NZ9`\7MYOXYN+CE MK>UXT;"Z8L")D^8UK6[#.(_Y]5]^^.G-#SQB]LE_G<1I=A.?1\O-@IY]73P$ MT3V]28(H#18,>Y4-'GYA!-HE"S-V,;`NWSC5Y]NOZ&A$LC`[.;!TJ"=;R),A+?$5HV M(=FN#0EY;Q8M6>3F4K(('L,L6(5_Y&JYW"2YX)(L-_-(DS!>_OG?O]_]?-V? M?)XT@10DB^KR\W]J?KJRQ?>+.->QQ^S5JLZUNR1>&\(GMKF]Y5WB!"1_(Y"N M)(N)B2/G4/VOUT9RT)`T4Y!R7_U@FIN8L2;D)B9%(U*U(K5F^XJ\W=URCCWF MRCWZCD'H4]4!QB`\[@_"XQ*$^0]:2*)0+O<6A,?#@?"X`\(>Y<>[($Q^"58; M>GGW"TUS)/T:)+FO+/V9_2]=OHN3:YH\A8M\<"`H12RZU\L2H^[]F6<1+4(& M,/.JH:&)L1EK3'AK5KX4[4G5@90]R%V]%?T.$>RZ M`?]`<,>:##!Q"9L:*`'_1)/;6%N_F0>`BOOC+>Y3CGN-NJ?DVS`J,\%W!PE^ MS43#4.!'G80`NI[SF?@>15W3@$515QD8C/?-B(U5<+`!7W MIE7?00(>H])#`+RK2N\F?DL+]Q\HF^+1U'6RYI(JKML89UR MYB`P!BY,[%'F;`EEYX@OYH`EN-%:J\!E:T=,:<3B9H3<=69#DJ+O;+L>OZA7 M0#D6;FE5!P4I^_XV6+$=R21]H#0CRR"CGHUR97@`4$<$(#UOBI\.0)L!$.=J M&"IR8XTVM2+S)OL%*0LQ-@,5^OBO;=_M8$_DS1Y=[6%<7<2.R/&/?SEZ_9NA2 ME@8X>K[H%JD&AIK[?&^UM4#079'Q?=PTT!]:%DG?%%P.T[[-TCYD8Z;.60^, MJ?*^Y^G>&F/F"=\88Z@I_[1,=_-H>1;E,3^?1W=QLN;9;WZ;9DFP$"ZEF_2K M%P&P?OTY9!(?@E(#W6G(!+(RJUJ1O!DIVI%:0_*Y:NK#')H13F+K6RAB&Z1_ MBW96Z.S!OE_CY/"9N46=4NT5_[HA](A;/'0<:7K3:SS[2Q_PJ M*%OI9GL[GJJILB]%NVH/"/GR$"X>\H3#6RW#NSN:4#95=DNS+Y1&9+%)$D:D M($UI;BO(^51]M`J#VW`59B%-?:BQ)3"(`?=-1(UFRQ8)7`,*M406F#8"$RN$ MRT](^=$T;[>ZNC6XX3@U;,LF>MDJL&]VWX]W]WTQZ?NNK#A-[CMJ7=?D*GCF6?=+D"PO'UG#=+YHT3!>K M.-WDF*M2\&M593JLYWHF'LIS?W8.^QLAR/Q@`6M$9*`X9MP(X59(W1.IN2)O MGTF]7>F.<'^D=$AV'DG-)=GZ]&NX,#!YXQ%9(9+K82)HI8$7V6I&ZF(WS8"1 M>Z%@O*RFX?T#>\YZGO]&P3TE'^DZ""->:<<1;[;)5>E]>.?#ZO(!*(]ZB+#' MVH.[,8H'=*N/^582,W_V/3V/KO@C*15+2I)L.5*CR`U-UM)*=ZQ`.H7O$$@ M)92Q?D'$";6QK@.2:P8/:Y=X@C+Q)-O$LZ@EGBQOS$_]B+DW$C#/*;DO'J$) MH_*9L2/VSS]=1;]%'Z+3F^CO^7^N_T2*:>$CWI]^#=C9E$=YJ]>__>7#ZS>G M?\I=-J8H\S_CA)^BPS0POB-Q1,DS#9+<0OA$R3J/ZR$]XE.0V4.8-Z4160;/ M7DP^CJLS@DPYLN9UT^;0`8FRZ(O^`@-'G7\>[PI\U%Y6]G.KKV[54Q>WY=1% MV:XQ=7%4S5T<%6>/<2V^*K48.*A@P;PHIQ>`>-%.\<\R5?5TL/-XO`OQ4D2/ MOYF5YZ.]2)@7M^-%PL0_B\6<2HE'CL64+OY\'S]]OZ1ACLG7/[)_L/F6'U_] M\+I\]<'_R#_ZKWD>$(%_6X5W+?D4/I]>;,$W_<27JF_?K6DR*Q6D:'GV]3%,N`4?UFVP M8\-UHKPI@O0M0UW M!L&1]*).*6#%B#S+\)(9/%^*0KVHB60%[`6K=ZTL<=;,$H>YBG4@FNYVK6O/ M5=V/%3&TJ_%PD0SUVJ8B[\??S'AONOR^M+D7BVJ'HJA.E][V75%1G^?33-XI MG\@S[6NP1(+Z>(EIG.X730R>3`-;4BRC>/I0F#%^C*:X00]F06V837F/@MX1 M5E^,'E`RL#7E]1@LU/9:H>F+6^0UFSR]T31/8SGHLO!V1:_RUC3)BS=^$)+\ M_'>CCHW5#EA'A(&)2808?H1-JBGF5:#_NE$Z!%Q>;EM7Y,FFLUG[$^2_^V3Y(OO4:S_ M5442WFC8DFJW]QIUP:AKV>0^L_I[+^ZTNH(&WVN<&>RF2?1CL[KFC6[Y\3XXZQ_8N?*)LSC"(\F)/GFX4S>I)1]BL/T`5WA$3D-B+ M!JNB3C/V(=E^ZA-H5?-&M`>(N1R0&^X['I71$,0%7=FH-0(U3UJ`]^"9(PWJ27V0--3N,U3;-P MP4^&3Q35`KA3O78`=.J?+<"1(=85$)^:;*(W,2N;$-Z&5(U(V)K,IYP:*F(D)'X[C5TDUPNQ+-Q.N:JJNDLJF+ M"JD1A9/JJ/)@7!D5'255$?_2SX*H>6-UQ9`(!II"B'?1%D%BT/29((D3&MY' M!=L4$R3R9HT)$E$SA$&PW#OF!(G0BVX@+.@T*S\L,X)/"4%U'V/H;RX; MMP?!@V$#=X)$8M\<%WR"9#^1H9D@L<&&@V>7;0[%K6T6G4?+VD;2:NMH'"=W56>2FDY2=A36>RYW.(17V\>LAV2I$BGE??3B(9,#Q4#UGGE>RQ1^`^Q M#A6T)_*T?0BUUPM?ZH^:LC=#UA]%/:\>/?5PG_2!B)FCER],0\X0G^X<(EKT M;3>#1NZ+JOG\[.4!Z(W^VMYCV+,.0[X97M!)/OK79H,^]"_WC3 M[FWSL#GW9J_=A'M9M/BS[5U]%X4S[:H;+IIF;[07S[&KL=%CYNE#'-'G#T'R M.\W>;:(EX]KU0YQD['GB\^B)IAESG[:>0+X)U_0F_A#DA`RS9]&L$J;=^HP1 MCMW^E0GF]2'.]""%I2DH4+SP&9HO99-7U0EM6=Z(46!=-N-'J*V9O_PCYI#< M,8]\UB9E/E_QT]O"G5?E'7\(O3.L/XE3X7%`-OWK M1;]9__[:8Q,O8A%OZ%XC)4;6>%$>K.--Q,\A3EG+\@#,17V-8I$W)ME#D)$O M04J2K8N\G9?KIU8(C'N#0J08)G9:RN`S#U`+8V/'B!Q@A6Z[/;F\*\\T$:S7 ML4Z'!W%U:3H0R'%*32./Z"6EL7=,K. M\A][D[ZZ#X)'MK[QE^_I*DNK3WC55UOH*#_^+[X6"*)I MU2%)JQ42-X2^L2C1-@YA0K-/10#^*:D^]@7VXALG0+OJ#G=!WF@MPK8:"FXA M?;6Y786+=ZLX:"]F*-MTX-QH@P1F@5\L*#=-0X!<[U'!N/B,\`]]`;'H9@D@ M++^G70#7VHK@J[KU;L'[D=Z'[*3V*+L(UJ)=J:IF'0BWFR&A6.P="\@=ZQ`L MMSI5<-Y]3-CGOB!:Z"ZNF\U%T-9`PG&13MD+;U;GT9)^_0>5UQN2 M=MVRO-T.JQX7^TV]"X^)_P+DG_C"\IE=U%4;"MON*#*;K87 MEM<:;#A&>KQ>QQ%?%.#/1Z27FRS-@FB9%_IRV`,Z=3F@[(1%"$!D:.Q0^P)1 M165BRQO>J%@7/BH>TTQ)K:$W-(*@0L0I.)H$!%-T%K+-!(6NG^S9O5S@7?Z) MZA122*[HX*G_11W_XZ M*R0]Q$_[Z+`R#/Z+9XY@#!"TE7*@T1:9!8(XL'G0=&'"A'K/#A?*!]^\9(/H M[BKX(`>#G!&U/BI.J+#CFA5L$5M!A/K7`NP77Z/!O>X-#^&E51BH>>,=CMF? M_@"W<3>$6!7<+Q$\^18.(2*%=W3`G3F+!=NFF]='5_$J7(0TE;R1%=ZAO6=' MT0%G`X\V(J3=/"H_@*T]\NZSZT\?/LP__D8NWY'K\Y\OSM^=G\PO;LC\Y.3R MT\7-^<7/Y.KC_.3F_.3LVIM7K!H`HKLS"`JBBDOZCH(]0W#@#< MEJMO:JY)&HMYUFF,R3%))*C\ZOH`9HDON1KH*,G1*3 M9.S=J"8"K.RJEF-)5Q?D4D;I1*IE'HW9)C8DD/&R(2E;^JWK:MCH&`H!G8:M M0A-:[HX-V6&R@]PU#GK+S)%L(%"TS MP7R"V`TQM65WK:$W!#9!BHC"YD@34!A@1$ABWY!JEI`T3VU:N,:";#TE-9[5 MK/)3&)&T6(BNGMX_)$!#LI)#2/N9F4R3D6G^<4WD@;),/Y8*I\;H?=@=$Z$R1!8X:\/OHYW M^*)?66&QE^"2G>>`"JY1SVM8+#;K#1\VG]+'A"Y"7B#F_UY1?O)VM)ROV?-B M?_#/KY+XD2;9\U6.&U;,G/US$SZNE54#JOEND8%D'HO=J%>+5L)@1042#!QG MLYHE4C=U1+;&^)1:W=P1J0SF_V(FCWB3K55O%`J7%")!8G+[($F[)#+A#[0*`V?Z'FTB->T^59O^<0# MK+]\9D'7'UO68/&BSPUHW1H)D<;:;'YY(V^/ M))6H&(%1H1EJ.TI1\`O/KI95#+PC`IL-:1M?DN+;`\:TR0C4&:K'7FK71?D^ M3M,+FEW>W01?[3.:R(IY7FM:&4H-1+$/EN-:SE$$H6&S45?S'D0H$]^R7M\= MD;PCVY&3=YV,8`C!9R,;"A1;2$?=FI6`C$^'L5)D)P9T7I2[%+;,B#DS%@UF MA+S78=,`(X>B$F'5'AS1I2 M7/IWH'K,OWN5@VJQCZ#2RW=/6/DHQ^KI.4@?F#3C3EM`XG(JTR;3;4H+;SLW719/7I+XD?7WY3&*T9@`2)E#<\&?Q/J1LGL7KN@%S7;3KP(#14/RW&[8-C:YS<^'>,HDN2 MJ=77#:65^HSD4J/A^R\@SF8`'(4ZCI84\PT--4FV:A+E:K+*K;)/V;\73$@V MA7:0>"L=P=;JWUX$`QN\>R<9_I2&DCJ6OQZC\Z+XC_G`(PD7^>"#OT/C4Q1F MZ4?V_%4:9O2:)D_A@A:'I[/?Z3[BEGM,V3B(PF+&!S6*P8;'#GZ[X>:;<(/' M&9-CQF0RV\7]OKIECDG=,SOELO)=O!^(,.\D3KI?S+\$R9)U*`,C9635"R%J ML7F8O094!ZMY"'OE:+.1V-?@G7"R2OV7O".KN..[O$K? MZEQY(%V8INQPF;M!ZP\(+.BC.99!6[ M4>=VH0WLC*/W1I$BE;50GP!1A9F:;=M):T12MO5$`\T`U)4N&P!V]`9D1"`3 M_@'839T!=XV%9#[_QENR1SH?V5/&.73S_)X]4'*W6_K,'H*L6OQ,"D7](_]G MD%:'R1T2S/6)U2G0\E%K^'PV5H?$@E%\`=@+9:*[-Z M$Y:76"-2M2+?ENV^\X2^8)!TF6N(KPYE=?T%;/4%FL!BROA\+I!?!)3R(JJ% MTV4%T?S/'#EY6LQ"5F)%<>;-O(A#M.I+)`=X'7=\WXCN71@%T2*,[D_B-&N_ M7MNDBS*=M+LXH*LX*A=)I./)E)DM`QU*;K\GO(&/))1@0,,_)7+4Q&MVU7%N M<+P-DAD$+OM!CV\;WH)ML<]@,]3Y/G`;5]VC+%R&JTT6/M%KNM@D?$_)V=?% M:K.DRW?YK\P&.INLC/PL2*(\[O2*)GPH]#Z,Z'E&U]),@&R^G370S.,P'OEJ MD;(17E0`^ZUZN.S!+J(,*(M<5ZD\HY=: M1CHQ&87/Q^L;^;O$,&WCJG9EVP=];EZG%TJ\#L$:Q1Z0PN!=RW"(` MMO`*^84LL84/=#&5T'=`V4Q3FFD?SA3`D4NX&20-2[%,;Z*5MD M][5/)%'=<@E?]"@1$T?03\:A$8#E4%MEWGH@C"MNB;'=YN[]`Q90D_M!RP.E M5LJR4H-1>>%"70V`7F':)QSK0`O"IPR,J#?/4,'B+%A!%DS!BC]45QY'L#UJ`BFB& M%P]T\F23)%2^XB%J(]3';1M$!K3\8NKBSC04\%6/K1Z6'_@$[?:-DL!:?#_% M@"[;RL#L\+8[K./J'@SO_ZZJJWX9_ZH[,Q@`E0T&!'\4#;26(6FK4C@G,]N2 M.!PHGL4Z1[MG6P$]7?>0W5LU&XQ605I]--P8`CFN#FF5^K($$7]-L>\":@D= M,T$U!,^X`OL4A"MVL,:[.+D.5K65;IG*:CNTI5;1`8??9 M]KM7=W'R*LV_K6TP\81&^OO>Y1(4*QTZ23L*.#4>OLRD^3%.0[:9!*#-:H]] ML%:\3#YYC),@HV3)3BI(]QII>NE&P1K>@3=R%T:'W$"GC-3N>D'M6#J)%%2= MBJ,8\VY["3WM&38XT.N>58,.O3=N:E"UPU[@>Z/0.?)M0MDY8L7I8*D0H[X< MUX*+R#?#(/*-EQ6M9F(4V@];M(PHFEZ2M-%$O(7 M*LZCY=L@#=/+NZN<(GF`_"F`&_HU>YL'\KLDQ=@;:N4<&T,H5+>_`IRL9.5? MKP$69F=5'U+K1()H27@W]NQ/O2/YS+H2WM>3.?4>:.RH1F]DMT7$W&!752;$ M$B<9TC(,%W1A.?3GLXNSC_/WY/+CS_.+\_\]OSF_O"#SBU/R]M/U^<79M2>/ M6(Q+"VUV'8<8H^9?]O:T/#[VG[-_;L*GO$#(BZ^K>!4NGG4IUZAO*\L"^Z)( MAE&<.+D4ZE*O!S!+,_Z2598A^3]J+8](T99\+O_K7:XT@U%'!VQ0V"8^R$:7 MZ]Z!V$FJ@WM&0C-?1Y'A^7`PJTU7+E$[>E)JA9<'S.<);FBR/M_-$D!2E*4E M0<(RMH3&?,MKP$MFY@'`Q,#4+A>&(T&68UI1FTDZKV^K]C+EV<)2*";],"X2 M%D.+8IF9#&&<)4Z;.)PPAR?5^?7?C\B'RXNSW\B'^<=_G-V0=Y\N3J^/^%#Q M^N^7'V]>W9Q]_$#.+WXYN[[Y<';AR[/Y8Q,&E(O'H,SH>;I;2NRYMR^VV)=7@,18!3MF'>T<"LG+<>$3RH/G*`;^"PX&QY3`2 M!\AH6_=@WHQV\150OLZ"),,",VQ;']26"LQOZ7T81>7+F`\.TKK-?TXAC;4E M$.;-:'=@KQD]D6TWUFE:J(R/0 M6;Y!F>$U3;>*OUSD-R[_9Q%<+H%Y MQ-L72<\76?C$GWW;G>,-D!T,LP(1ZF<639(PK@Y/H'I&`Y.K7DZ*8IF9."*E M$;*UPB>#=B]_WQFJOD74R#I+?:4;N-M$R M+3;S"`]P.43`(SXFT`?RJ+LN@2[-#E"$SS<;N$<%_;%W\]`#PABROW(`&'=W M6@Y8QZV"-+V\N\[BQ>_OPXB>9W0M+=E4;=O5F;@M#EU5<2#57!(7`.X)>\[X MQVP3,_^"?&9?$?Z=+Y,CRIO;91D`"QTZB?H(F`."SC@4.8W701@!^-%LJ"!' MU1"=&+U.BP7 M0*+E21RQ60H:+>0G_`-ZM"FAZH'##7U,2"11.@*P1=%_5ONRV)!9_]H3\@!N M?I=%8,1TZ"3O*>#5F#!S-5NM\=@+<<5A_TW,+?8?<_H1+A+JQIW$E<>UFV[6 MGCUC900N_T(CKJFJB-QYDA#[[L5BD3RPX=SKT["L$.5 M"9QSQ<:GRB09),P&_F\W0*"SRCL?2EG48$1N=9L4G MQ?3'4?'LP1$Y3],-]>6(`]D]%/)(<;=%5*DW%[-A`%PX')!UW)A#I!IZY2!) M"Y#\RP]__B'_?S^^_NM?_TH>@X0\L7;_D[S^RP]'^>?L_TCZ$.2_!0DVV4.< MA'_0Y1'Y\5^/_NV'?SUZ\]._\>';FS='_YIW>/UO_U8U#CGJ^)?Q)DNS_!^Y M^AR1_+M'RG:@T-7SU#$)&M&9H7+TL5L9S#6_BX5TZ/58U%HNR\W6V"P4Q8(N MTBTG1D1L]&U)=O&=MYHMO,\JFBB`H>!*O9>2,L,AR^ATN=[##:.Z,3G2YX8C"T+5^@MUFNP:>$HKP>W7 M4TN*&2VY=CT!!!L2:,/(=\M?+\1)93S8<\R92[HEZGR1]JL@N4RNLR"C2SX$ MN*()#U4O\;J>?"#C`J4H1W M%-5"1D55(-X4A)594!)W?+"ZG]11>D;!;3>A;&=[R+=A1);Q:A4D*7G,L0 MS\6G'BULB6^ABB["NZV@1M%>202WP'"OT34_%ABIZ>^^H<1$0L$X\44>BV'# MY6X-`SKU(NBBFWMI='$S)A9$Y6CVI>G)8C!<-R"9)Z\U\8Y&\(C,LRP);S=9<+OB`[!\G$6CS!LJ:N$A8B(04P(:RGH*63@>$%UE`*6_ M7H@L];^&R9!_OY]`@R@^"M3P'K17^'#R9+W&7S^P';?!QH1O3Z&F?50>"VJC M/@S/?M@H2X(LC*./8?K[24*78<;^)2TMM#TZI86B!Q+)M#%AE18J1Q!NR?O/ M&E\2]MD1*;XO_RC>Y$T^E__U[^7'`&@(*`C%4Y>`TIXB`HX(0D=EA=I?+S06 M947M:V]4'A=B@(("!V0C#R!;<;W7G7NB[:#3^/?8)Z!H(W*D\._-SD*1=Q?H MNX^'HNCOO)Y?,K1HR?5><48*'&$C$NLMC18/[!PU];$IP&XZDG6ZN:&:)#I' MA.MZLZ!=VXB(?-LVOAW%`D6'GHAJ7&GIV.H.(*4.D2-2\X;-Q$$)V6BLHV'9 MV`WY&I$XHESEPX)H15=A;N-?^F;)@:/E5ZTK@&7# MPFV8,7_;83_<=4;])&%*_KCWP#.?!K"&GE\3`6^?MQ7;_&L(G@Z0=-..5]K= M'(U7Q-&Y&J]TO-F,5UI&-.,5UL;7RDJ&#*CH+&2A"0!'YV#Q<69,PVX_&!/K_5R2L1N?4SXVW%E3LF9%RL/9J@"F$.3-`MO5_0J-TN3A"XASPF!>@D)JNB%2$]M M;)CD5#F#4E-N8U9K0+8M/'VL!(8+"2NA@!)S4MI;QD@X$H?D8_(8YQ4U/:6W MV35=;!+^[C8-&P%].EQ4]D%B(B`N+!ZJ74%8J+(PVWY-V/=DU\`[!D*P(.`? M'$)=]BGZBKAG@KPAF9=F>7X.5EJV2=IU&-9IA\0JB7\L)G7-0]C3[C5C'_%" MDGWH'4MD]U#`#/7M[K*AU5[$@(&0X6C.7.3%`B)L=OSRD;+IH^B>T*^/-$KW M"BF`67!SK(PZWWU*'Q.Z"/F$WSQ:SM=Q7D3]P?^4J"6@1TLWE3U0>`*("4=+ MU8[TE%'UG]6_/,JKDL<5Y7/;[`S6>DO^[O7')%YN%NQ//V@%@46'8'`LM8FF MZ-FEW*@`='2N@B7A4Y#Q9P+3+-GPMV%< MQ-DI3);TC7AZ7( M_<.!$+JOE]G.!*DUR0ONC.RLD"`EI9UZJR/"3-7/.O!%/;"P+I`<7!IU5:JG M?9&T[0E#':51C*@&H"K?B?F0.V'G.9"[(*S.PHSOR')'XE48W(8K/A_]0D8X MHB9$QW'+D^U[N"[OV`D&>]_I,)*OM MTJ2O51S9P[DVI+*D=S``I>OI8[8SP+2M;H*4-@@W4F[M>77+[)#*$/GLW2D( M6/#N"B`J;SKBU\^Z0/KV@9!NJA"$F)PSDU4@US>7)_\@EU_/*7%^IIJ\T/"/;-*J,VWKLFG?QXABUK3$D1H=5-.65#5QAR&)!E#&Q M"X6&>?>.7R3,VJL9A`O64B8TWD/)8!P;3L;.@B3*AW%I]0*%XI0NW6`(V*LE M1-I>*$H#C`U'2O3.]%JALS&K&NQ>@>/_J6I0A'1H;P:M-J\UO;O$]0*33NIU MB,_>X&3U-IM":API[-NKFEQA45LP8Z-QU(*W'5M>DX>+>;0\#5>;3/KR3&`O M3:;H]'+"2DEL;C)%UYDY&=LVA)F"-^+[U`3\ M>[3D9=V*L+V@J,7;JX=*=6A!P>0(62?L_JZ M36-]9YXD;(6;#>#)[;-H?8?,OP3)\JC9C3^HX]_)J:Y(U!5(IVSMR"FN-X'\ M.I:%$<2:/9E[^UPIE,6#+&H"-P;RU.D]J[XJ'S4OOO3L M^2S]/9?S70,3*7/;_10&OX2?!-$-OGV*4JVCY['II(Z3UN4AF@H-[S1#-"3ADK>0R8)WP7EVG5LV.7KOHJ M]44DW"%TCV5B/RO'G:6BTV7V0).;AR`J9L![K9:[C&>HRE,?C]_)`_I[>EZY M`BYCQ)RCC0ZQ\A7-(M>-%9T(#X%D>0SE&J`G#\>/#O0!TZ*AE@V6-'5Q#9A4 M]UU>IU6[@Z[&8YT]^-I_@B(XWMAA0C(X[MCCGYOPD>U$5&_D$K=JU^GM5CCR M+O:-5--VC`,4L-5GMOW`MZU8DKO6U0?E[>UPMME:P*0A<.`F^0I\&`."):K< M%7NE0IP\$[IGZ-!KNB$^1M>_[)E)>!SE$35?(R]006E;@18*VJ(Q01H'GBZ* M7,#(T.TY*SXFV\_)Y^(;C\@@O[5"2NB0(*)%IX^8''K@#$>0=T&8_,).YGO[ M/$]3FIVL@C15O$I7V[Y%%$5[%+)HX\$AC,J-GC3RWC/^-^$?>/5:7/U][K`& M"HTVY7OG M))&+GUM:2K43V:U">ET+P0C*75X,&[,4YVS`SCXR[B_35GU_7+&$QHNL?@"W M!G*FM39C30EO2VJ-_3\QR1Q74>$.9N.$@/= MDU7C(=&LG;P:`L^C3GBUTO0\6K[?G;$O2-IY@XN8+;O5WF12=42VG?E10/7NY#/OZUMR1B.`;BR!QC'- MX,'>CW:T@$CC:4GI>\W)14Y\.)#4]\BG%CFY;G^D];W1B46X'FL2>T0*BUQ2 M:S8KZ5T2_I8*J?!RRQX>5>2&-4YT6$9.%UK\7GY(D5L-&'?*)MU&K=SD8M(5 M,%'3[>IL%"N+TMWTC,"CW9"U8ZBA3K(*T*^=%$;``8U=-;"##%K;)F#C52UH M1UEXK@7X+J'_W-!H\0Q;@M;UE"]&RWMB+TOK8D1?H%8X-%JJEMJ9U;XAVZ]\ M7;[68D2UD`T$F&))6V9!N;@-1NX%G,:.O(#.DKX[*Z+RZ5(7$B,UGCTH#(2DOUZ=3XCFQ;-M][/9GU M3A"@Y$PWP*.4Z"H;"I[[`F>W:YM:STBX;JUIQA$):J-#/AEQ.,B%KVDZP*X? M:YGU$6PWG\*V2YK8@$S_R&VXFP?2Q>UP0DCAVG)F2&JQ3OU:;>KG!D,C6,$F MAX#H!,T2R6P!IXO`(!]7%+9C9&,ID/0$"$"GIS/:2V)T1_:N0SN*M^W(YG[K MLUR&&!"WU7"#,+IE`<9C'5:]>U@"O//6T(S=PPW.=BH:1C_HPPB6NW*A M1D6KU.)5Z7(1NMAHXN_8U12)MD\0&._ MZ'*SXA,\;:($>>[<\NC0"0$?*`]&"3^&S_PYG)1/.[^!;9&0]Y!E4%$/7#F0 MQX2<%X6.#+@MZ-_(=L7W1X2W(&]\W>V@P("BF>O>_+LM9YGKR?`LS8&0#P3`P?"L]'1OS[-B8 M9\?.>78\%,^.>_+L6,^SXPGPK(T!$,_$P('P[-B$9S*T#<>S\_5C'A>;-[J\ M.X^R'"5A/O0N*MZSKXO59IG7N3_'\?)+N%I)F&=EH\5%0QLH[+2*&X>OIJ[U M##:S.-LU9T/-78=JU/GMM@^I.GWG!\?MT-9A?1_0MG7`R%97&;S'OI-9%_,( MD$G`YEN:-`AW-`A8G\,%O'9Z94C(CSJQ$E-B4C@`,5O2?%5^2[;>D^MJKS:R0^]]E)Q@T'2;*>PIX9X"T MT3@VOTVS)%AD,'ZU6ZNYM6OM@E?M6)QPJN;$F$_;OK.3.%K2B+V(8OMERG+@ MY2--@N)8[<]5:S^)U;GQ.E))D*(A5-5+2R8IM$9/5LJ=,J`^L(2%NCL&%)?3 MI&6P(T9M096XO-H#`\,"-'F!]KTH^X(3V.A[7?*X$AJD])06_SV/^*L!3C9) MPJ2!%[9R`H*[=GD(Z(I%1W"4:*R$>`214V]H5K4BWU;MOLL'A.7[FR( M-V2%XT;$65/4":BK-2%DL$^8!)E@>#6?W,A3/4CCU/T0ZPJ.2C^Y/@,@/0RA``B2&0$+@"\K-INF? M:'(;@R;JS0+`!#Q+:R;Y8 MQ!OV4&/PS+:1SZ-E_DFRH?53L,R&8B8682,TF$671;#)-3D=SP$#L:Z30?;5 MH[_*!"EM<`4JK=2/VO-6B(Q!#"V]+9@!K,%PE5"'X-P>4KO:#Z`7YX5(,LC+R[(;+K6 MQ)BV/(`9<89Q)>9<690+*<$+9Z3(\)(U(R?PC.:DS,K( MI)E9V*J3]Z,09$L6)80H+N`R0``FH&BI$E[RF/A.^0_A+1Y3S;/C\D53]=AXX0 MRCL@L4$7$98\*OQ`B"'M/MM]1_B71SZ>P@"X\P+N`-'2)9&LHXA/HR',S2,K M:G=]H-8\!7,?<0609PQD>2+:Q3[%*J%H)5O<7"K8[>;(9!)'@RW6'2\F_&EU MK@MU\15[5+GXTCZU@DI*=,AIU.RF(M&@>'(LS0)G]L!J5,DA_VK?X&2@ MR[:`\D234_XF\O`NI,NWSR=QQ''FF(`F6%UO0FB%R- MS$VK%&N2M'.<2BT#K8P\Q*OE^?HQ MB9^*YV.5YT\!>K1ROK('BK8`8L+)V&I'>D%0]9]MOR3U;ST[>@IR^SM,AF.F M35-%SRX+1P6:DQRE\]<+<2S#[#`7'@[FM,D!"W7C2OMN5UKY^)9,T:4-VT(N M:(A#*VD$2+(ML@_@3K?;K/;94?6XK"AV,99 ML`*(K=B-#4Z8M-XPK]LGJKW;/M\/+GH)M0*,9X*I>914WT$KH,@/T>DC+:^S>/$[*\OSD=;9/S=A]@Q7Y^S`@Q!*@*;8%!!9J49);5]0K&;R143YWAPYM,NY_.WY^_/;\[/ MKLG\XI1_./OE^]/SSY>_XF<_>>G\YO?#@W3)BG*$:J]3E^6:EH&GRUYVE/=IJS??9[G-6/^R^ M(I^]V\D)N/]=XD`QTR&1M*.`4N/AS(WJJMWU`1Q7Y+.?Y^_)UJ;39#+NG;)8]_<^&:^ZPC$72F M6]Q+2QX/7F+2IG.P#NYI>AUO[A\RU0/PX'Z:.DC0STF:DL;GIBH2N3//55TK M,]:$U-HT7`*"NK*DRF M_./]!Z-QA84!QU'KK0_!?\?)3>XEO;P[I;?9/%H6 M,>B/0EKC>''RBHE;/7?AUF:\*>%MV7-?K'5]T\.N@VW0/K``GFS2+UWD&4KRB5=Y0Q.E60SSR"B-`9&G;/I".S6ZSZD^O7K*J MN(-B]JCNMI`FC0X2/JB1X57JT[$!WML\[6'S!A[K8"G/C&$`6R;ISC=>&F#) M)M5!&:RW8I7F1NZD;>U)Z%])5O`H7LHU0^@X=1LL[()%8%Q$6;Q5^(%25 M=I_MOJLQ\8@47Y//Y7^]6R0"8$'`2"!^NB24=13Q;C3,.9G;T+CK`SY^`,9# MG&2O\EC6I';$PCYB3#N/@8.RD6X&VV0>"/PBR7/3=,0 M4M1[S,H_/7LJ7WRG!)"7W]`NQFMM1;!6W?AR+VK1QW&R#@V.17R0< MMTP#<-SH,2O_]`W'PCO5Q;'BAG9P7&\KP+'RO@^(8_;VY")7O&/O3E8#6MFX MC6Q)8QR(*R-!PKK,!P#TXJXS_CDIOB#\&]^(H+[#749`$-&AAK"3@",P!(U' MEGEV$B3)U%\&: M7MXUEDF4R^_:]JUG#51(_A4MV:NJGE"[/HW=A%$2+G.+S118^%8>-\#TYF_RS M\CWM<91JMAOC&F]3$\DX#H]1KQ2)]%@Q`10"Q]4LMT.8(5)98N>=?\N,D3#Z MCFSMD9W!([(S278VO=N2CXE5Y[-&J^5,0KO@K<.*3>+V.H_JQ2F^#-%S(:QL;*]TBQLP* MEL+9Q(Y6EA@Z!PF5D4U>:!0]R+>LSW=DVXMAONC7.+?LB/"NWHB4%?A$:M0# MQ0+1,;$F5!?_Z>#DC#Z;&-!YP3(U8P9_NGR>94EXN\D4G#AL,D!R\*!T&#NK MB@J#8J>TMC`PFT`P-`J;.``;=3G(,+PRIQ,%\%BL1Q)0%[J)@:T=_<2`-YJ% M`6SHZ,*.,,`Q!=`X>"PQ)2*ZJ@7ZAN2:D56EL&"EF M.X@?B7`^EA?`>0T'Y$_X[>]F M-XS;_\;5OJZ6#U,`O"D`L)HV`-Y@`N"-$P#\"`+`3P4`(GH?9'1I"H`?+0#P MXR'4!KM?'P,@/_HWHPV6]I''4!?9C=NI97ZL.".L;.>U-7B`OL4]EY M;\L%Y$7`?COO#9U@+PEZR>5A=][;!#<4K44[[T5,?N&I^YWWGC#5QT5\X/.2 M9J6.H5'4TQ2\>/)ZD)(&'HOK!ZPQ3TOP6@]-@8W\T+6=^@&-8S]B[041A]PC M:!*2:T8V%O$?:YR\VS)Q(JN*(U/.\?D&V*0;N<3X,E\LX@U_85I^`5'^SP5_ MR7IYZ'CQO^PE`?P=`=*BPLY,IXPP-8.D5W;18Y4*QMXA4F1H-)>>+V37A33[ M^/_6"&L$"L2G%Y:[8F-F3B0ODV"%HW5>BR#PZ<%R\T>ZR+^7<^30>0!(NT,S M8=S4FM^LO"KX0)-[FGRD*[:N=1*GF71@KFO?3I;R]CC\U\6#E/X4;@!$EO:> ME5^1XCM2?DGXMYYP57O'NZ0$@J3#/5D_`YV'=Q]O611BG5 M[5^`]NO6$+I^6`2$Q8=64VC=@5BHL3*K-]GN)"I;?>??RCX8)2).&@%,P$QU M?R%#_<"FJ[H$X!4!I*Q.N
\@HX+/%)2WSN/R@A50HZ+#&K%HTG9]4+P"\& M-(^;T#P`0`(J&'Q`CEG17-[=A0O*WD_]R.9IE*^I4[9M52Z2MBC$4\:!4Z'( M7.A9)>XY*SXFV\\]>S^=^M9VB`1!0ILZPCY=N@P.'"?E@]R3)8**Z8SUXR8/ MX(BD\5WV)4CH$0FB)8D+;-$]QI:V4NB#KE&GH;?/MI990;<57MN^+<3R]CB< MTL6#),@*-P!*27O/=H>A5-]Y-R[4W_(NB8`HZ=!(UD]`I;&`Y6A#M-I?#XQ5 M,]$I%^MR=.?)$@!K`Q%PL`4#Q0QRUQZ`H6LH$$OT(#$4,R")I M>#R*J%]-*!N/0WM&`\C3S_I[+R6"ZCGH08'B5C>-STT1]YSQ'XK=J>K8*V^> M!.D+&+AV&D+&#_TLU5P]%:MLK"DS<>?4E)&X*3A-IF/%7;NEIV^39NH;K"TP M8%.RPD[Z0D,"H!&XPL?5\V@)'9#)VLL8TVV/2QI9/,B\$;@QH$ZG=XT]NXD- M3X=PTCLNIY`&)%(6M?LIB#0TKES/F0G]]8`8WQ6Q!9FGPSX$:,%+F1[@&K>L M2>Z#*/R#UY\G>0D:K\(E_R,/\"H'-8TR_N?E7?D\7K"ZSC\IGAK0K85@VFZG M`!S;.+3&O$ZDU((4$D`C4#S-?CZ[./LX?T\N/_X\OSC_W_.;\\L+,K\X)6\_ M79]?G%U?^[?L@XKNKB8Y($]'O3!\")3."3<'U$2VJ>HZO(_"NW`11%FYV?EF MMSG\EV"UH9=W[.+"93EZ9P^XA4]T^5JFACA6VSK8URJ.`N)<&Y+V]0X&H'H] M?90;]VH62/7`5%6V#,R#3ND,N2)$B(ANZN!J)3IJ%\_ZP+=VP./^>09!/AE]$U76P2?B;*/`G3 M_*O3_,_H_HHF8;R\H-GEW4WP556(.'0GJE"_!F)-XR9*H*ZZ<%Y6 M00W3S274(U)3Y-(+86ZJ$Z?9.Z*WODCIC!3>2.'NB+!SH?(:*G?ID6R[9*!8 MS]US7BCS#MQ*]/_P5,9=M>8JV/'D9JKUW5X(!:PBG+14C%]#2I]E4U6"VDZB M>D[1"4\OM9$AUE8J7T#)DILHZQSEX^X>"8X>$6+9@"))2'UI9PF!QT6@FSUF M>I=]H;C;M1M[_%"[&Q3"4A`:#L=/!U>Y09HD='G-#KLY#=GQJM&2+3W/E_^] M*0L=56HP,B!*$T`#>(0UBA@Q?4#]`OD+,U>FE6UCPEN3;7.^[Z?6P2-RFR%+ M3'0;=`HI#S(DH;^?"`>F)].WAAD&@`EVEKA.*5WG*%^6+;:'Q.5WYI9&]"YD M*\DDA^!3/LYERV1W-,@V"5\_*S[-0O9BLLJ]LI<_.@[*>L3'U! M)L1WD]GL6'%N4_+>1?^V3"%S`CQ[U8]TT*DJ0R_PF:E)LWK0*6J;V`:C]^XL MN46#X,4@_&\O'+6#U419.FKM[.J,4-RV9QLV[^ZBY-7:=ZCMHSN MAQ#9`*PC-O8H;3!:81H**>I=JK_$=Z"%(^_/=YD7=HH&LS MYU!0]RL#7B5L'C][OLI1F+''LZI3Z*`)4&M`E_\4!MQH@C9B1]E/Y=="!N3F MA+FO:IX/GUF'XI#&;1]/-4$/+KTD0`&JU0.I(8`<^`/RH?*>.@!,O->S7LK2 MWF/9LCB=Z9`A;I[TG(!\W)271W,1K.G\:R@=U0F:M--6HPD.9P5>D5)/TS*` M;/4.,_8787^2S^P#3Z91A3>IRPWYK>Q@O]94@&[5#1\>O:?Q.@@C#7Z;C20( MKAJA8KCI&1?%6]MP')==ZD@N/O(,RZT;)D6S\,;*\%PTEB-:`H`!,=U8)+T* MDLN$/PF]Y`\K7='D^B%(9+LWS3JW.0#LC,,-HTB1.`/U">`2S-2LM1'GB"W# MD3@A1>/R6=XK]M@O:^\)_\Q`U.6E#0@[?`49$?#8/Q`[.LG'P#D6GOE@HKE3 MYHB]CY$\<1Q_FPOK,EZM@B0E>:U+4M;'D_VCPX!:/Z1P"NMQAQ*-$'EZ\N1UO7T1 M:JCN<(QZI-L\CZ2%KH#D6]1!J>+-#@[(*8K(A::W_)CRL]&]J_#%UQXKO/#& M:VBD`(N:2_6..DH-"C`G6]DT[OH@39@0&DJ^CU@S5&Y;M'FGX_-M%C?0\FXG M@)[7.SFC7#\&7'N)H)J;[OVOC+.P$@0-R3`@G"OEUG&`,'!N!@NM]R MV1>)*OT/#@*+5KG`'HW>Y83+W2#-("D(>@&R0J.7,U8*8G.7%YK.[.A8MR'- M#+5&_M)1!`L0'^5X@M"QUAO&Q\&!.%A^:/OLC4A5AH@/!9-62:(/*CU*$\K7 M&*F:*A,"ZBN,5%&XD'Z#UQ<).[9%WK-7%REOJH8ZH-<6B;KH*.(<,(/,WQN] M1U[2=>_18ZBV)O@96UU"T:'I&RJ345!;Y@J.6[X>6SQ97O[^`6]Z&'"%9!0G@!TYWX1Q4IQ`^I$N5OD- MYT??\\?.MR?LG-)TD82/[$-I\K$ST\E$IF:0N&X7/5:.,O8.H;ZAT5F[&3L7 M9A4NGLGG\K\W]&M&WN98_-V;*M(2=`)YZ`7?KE*8F1/)QB2(X&C*RB((?$:P MS-ANZ$TJ'`OX@"0Y-/1'3I_Q@M)E^BZ_/[\&21)$V=E7FBQ"^6N*(5TZ:5'5 M!8GY^JBPTIW2$X3("@.SZEO"*$/*[\FV@2\$!F!`0%8PHW+G@`\;@,P'VCR_7E! MCHGB\-KUFKVIA,\';Q[S?U;09-^6<-U?E!X/A])C3RJ2\_+N7][E1=53D-&K M5;"@JM-HC#HKJA159W0"ZR/%KUR4/LV8K##58O1YCS-^'D7X@FO5/B2 MK%&B$O0#Y:A&/X?D%L3G,C,UW=DRN6Y%D8^*9L5N`Y_9*\((D+AR>,$86^L/ M)>L(R!PPX[2](D"TFV=4PZ`C$E&OI-7>#27?*XXK<9H\H>; M@/T4>472#YV]ROCP\XK,G1EIQ59:E"T@5[;:SMUZ\X@)%")*HD+0I:*IL+^: MIJ,"TWE:D7M%0*A96NG.KL6/7BT?ND.P4:K!PK`_J298L3T^']@+P\+L^?+. M_(4(_:RITI*)-7Q-,+\6!RG,*`A#V3"PW4YW[,4);/-=U9DIQA3>K=`3JVIU ML0:_4G'@5C4Z-!4VN<^[AK$XHQ7+T66[L#BXVNOW-7A"'K.$/0)]QD[NXB.X MV69(OA=2GL>!';LI6]L12T^`$:(E8KT_D#CHS,Q:[V9HOIJ!?+[A+SCT<#LK M&#(B\IO!3;MG;C=%QIFDX[$';FAUUKCDBK*%?KWTP M0`R[6S)+HG7,Z*[7'K1N&]-Q MV__GHPR1!>>[&IM@TK?,&#!_7'0/6VZ*G./!O%S:F%ZYB8YB^](3#<=^EJ'M MUW%#,UCG-=[`U(7\"GIP?(Z35G7V\^8W,+T[)V7]^.K_Z M<'9QDU>;90O?TY#^+>^FR`(35OY>=G-0>D#03RF]VZS>AW?R]V>`>T))6N_I MEJ;=&!T3M>&P!U5K=G2U9-&4L+:>LU:`&#AOI7`#,W=GP8"[8V!UV!JQY1<% MM)W*D.[PNBGPNCH8O-H7AST1ZV=)R.9=U._0A/<$KX#5>CI>5^C$Z'H-K.ZP MSX+"S@YL9M*OUW@:8,9@:4$&./C*PM:"R=*"'*T>\/>"&H_F:EV@C.5=W%*U M%A6$HTMZ%T8AVS[X\R9J2'RE<_O-7K.4E2N-A?X-D7<,;0PSRF0N[$Z)B*+,Z"58_Q1>6P M)P*/#U+S(&=/8$&O>_:$`^B],8&>R0DI:I<]P?=&"3ZV[298+#;KS8J_:'M) M'Q.Z"/G!8^R[?_G7GW[DW?[E]0]O]A:I;X9#ZAL?Z^*?DS@UWFS3Z`2MCQJFBU6<;A)JO?E280+*8Z$) MMXQ61.V8VV+//5@N,JCA^ZX+^3R=S9@JI,%%0(]7L!P(3!D(@Q^H'[;>E`6` M"W]>BPJW?!TJPNT+5'2,CUJ\?LQ!1I7O8!2T:*6Q1@L4O@I\XB2AIF$]R>KM M9_P/S]:]17>G0PSY+6RCOM:R"VK5?1X8L8KGVCK?B]"*^(Q:QQ\B4L'/F^U: M5RCUZ+FQ[AT1(Q3P#-BVG02=(S_/]9$NXF1)EY^B_&=9\KT"P>HJA]!#D-++ MVU5X7[P+1C>VL+;3QKJY'1Q.V,:/Q!T+]P".&5N=55U(HP^I.I%:+V_/%K#' M8I?E/6'=40-3>P+5F`I#G`Q+[*)P0)7.(09=AKRP03MF&8,/XXY>8-'VR[+] MC%*'L64!).<.2E%Z*T#.-RW9ORP.#;,=K`=:B:^T0#-,ML-B^^PT(J5 MJZSQ.H6\=+JAY]$U96U^HX%T`JZ7,;NLU3$V)/DE5S)H3NO&@*8(;=,&&8_D M?4D8D:(W8=TG)2LRC-JJC!KSEI+3,FJM0#YQ:,S1HR@45V1BV3;7Y+^^L$)T M[[WDQ402]:]A]A!&EQ%%R=1":]:INF5M8)T17LO0R;H=!*;`-&U;I.L+-J=[ M\X6NGBCY$$?9@R=[/_OBM8=`J0A@KT\-JWT$RB-&C9RZN[$XHU:9O/_R0@[Q M_?>4'B,G\#0/8?$PCY:G](FN8K[+YNSK(XU2V8E&H#Z=9*SL@R00@+BP$JO: M%83C*@NSZFN^S[+6@)0M?.$X!`D")L,!U&6KHJ^(DR/CSE'ZT7GL"4"62AH0 M7-8@2/<=@H"4@0="M"?6U5Z,'ED'/S>L]]D7B,=R(.XQ`'5/K:,"L/O58!!`VJ_:Z0%3?P>^Z@XHKK@Q$G-4D6!IKL0'A#+"KK/JTKMP$?I7(V/@":"^?1#EE?[6 M[FEY2X%:+.^HT6511R<4DT?H1J^%_LSY)C`CT/%O!63\SD\2*I"B):0693IJ M=@WH:3HB0@=*"!+'&&!M)XIE\?$A0-,X;^"`<^1\\D2C#94>6M/ZNI,;JJ^1 M^-7TAJ7S6ZL0@I2-9]6_?$%^ZT8(\"V\55T,%\U$2'5R,YU)8LT\_+X6\Q#3 MO+,`?=+=VU&UYOHA2.AMD-+E2;QF$\A\V^X\2=@)26Q:^>WSKLE5\,P^FG\) MDD;SDSC-7DO4"M]!2^\P':"0#/^*<307-2X]NQ'=S7C#5[PEJ7]-:N;([3.I MMRM-$F[SJ-F-F?5#:1S0HZ-5SBC8UCH\1UVUW&.:.UDM0`YO2+[S`Y[8W'K) MY$6=NEYMR)X6>[6URC3X.\UZZ5T0)K\$JPV=I^EF_@L3I4(_U[C'J,>:%<#>DYN>(5)X(5E< MR>4F2[,@6H;1_:\TO'_(+VK^1)/@GGZD[%T#^>IO2[`82;I$1=&67M9U;&U`(Y(%0(I8R#;($@MBGTH M>1&T`2_AH0D56AZTCP@Q01ZB:IK5VX\T">/E6;1T6'/WO!8O)915Z0WAH_R_ MY#;(8UU,O6;?$VUS5^5/7-W03B<9(W:CNK#0M^LL2#(_%<[;(I&=T=)0N%MZ M'T;1B\CY)G(O)9S\AYFLR+WQ:=*TYW7X*6]O&O+VHF5>:-F;%RV3_C"3U;(? MG6S!'>M*_%2S'U_4S#\U^_%%S:0_S&27I7ZA:7Z)Y]$5'UENE^#0=S4!W2$O M,,G=>9%^=+^&'TM%BBC=9P^I<]1%G\(+>XU#X:>^S6D_LH^6>.@I!DAU["PB MI(8>OZ$?):G=!;C/(S9QH1:RM0`.#THUO=V]9'LM7DIH\8S!MMN+EOF@9[E6QB M-]JM--#<@>UU^*EEQPTMV\N-F).7-M=[E"8K;;[L4;*)W6B/TF#K^K97XJ>X MO7DIU/Q3,]>[E":K9MU=2A.8L#W[YR;,GL^C-$LV[,/T,GN@R>S,6X#H=Y MKG]X&%.[112D%@;A<9`L#V0W\;N-A6R#*;8O')%M/!//MWA"@I=VL<4-+??V M#@PQ!;\(KE][+G`NQV?E93/"VS^.R-UV"\>+!/HG@>YFBO=*!,?=/[)XH,O- MBE[>S:,L7(:K318^T6NZV"1A%M)\>+58;99T^2['.?MA-AG_72[OJJ/ZKVC" M?Y<;-@*3#3&<.&D/&Y"=X&0F)U>.5-YCQP9('+@N9Y4]MH&O;I'L3)+*)F%2 M36I66:?MJV9RPT6Q3CYSVYZ\Z\D1<[I)PB5#.[*/ZDP@Y6Z58`QQYN&\;6,++Q]KQ!;;'O$8R*PUFX: MHGJ=4V.3%O]B;R&]]&J7-!Z*%8*(Q!"Y"-HZ4`D?&OO&$+MM9=QZL^NG*,QL M=:Z'3:G$6=E$5K<>UX4M;':AF&B:C8>&G.W&?YU7=7,;I#)25H&$V2'>*8'S@28YLFL M%GM!R0>:/<3+E[RJM#%1=D05('R5VGE=Z-%$1A:&&5+!VK]:\ M(:FU]'6F!H`;A2Z`42I. MM(,0N^ZU-[EWQF`$9^T)[S`-EG(]VQ=3-CO8X( M^U]2ZTR"2%1U^#PST!O;*M'"X8U"SBP=*(5NZIQT/&70*ZPAR-F>/"BH^B&. MZ#/Y$"2_TXR\VT3+@JSW!#-%%; M3,\-^:T,D])R8YM[W?@1V9DO)GTK!^5Y?'SHY^U,C@N6*63;':GE.H[H4R7M M+C5DPEH/'JXZ\N=:\YT5THY^#T^UWW(HC.U]B!S@\[C:%0G=IP3C43BRWP%2 MPU2DQO%0WD6T(VI.>^#/5YU?O>V(S(M4N,/I'HN%)S,'5TG\2)/L^2JG63:/ M^"-%CVRB`S89`.LNK?5TW9'U%!8M=B6F]6HB\@?O>CVP'ZF0A83^L,2 M`D=&3T%T^G?+"79.`V_@*S/E"%`]MJ"!C9Q_G9[*!PVT6//G<:G:P[QI^33O MV_;3O$!.XM@W?'C*P/X@SU`97^\PCU*9A-7_B2JXMZ;R``Z0294GR'BK5DC< M,'XDRY9^"B7LY\?\`2U[AH]6RSS$JR5-TN(4A(LXH[\&["*R]#+YR(YC,YCD MMK2GKH-,[+FHDLROQTD-912&<85E8%WY>&G5S3M-LT2FKCZS!KNF>H/;U=9V M/?@S\*&**C65B2G_'_9BGS"Z+R:(E*^W078A.O@0S07>R5K(5XUX."%>9,!# MK[`<8AP@6%2!I>%R+2HZ?VE_?NSLC##'!8`6#K M6A5S'U^8BX*NR7-W_!<)VER(]OR[GWFY6+TW$;N\LG2/57H9NQ]7GBU_K9%+ M-O.H':JY:3`#GA5=>-Z][7KB.<66VGCYII^XH&4BPS`0L]1^RYM?E:E-\/[H M'*MH^2=>'4=_$++CK@2>C/`<1.G<>K\-__(TR.CV5>0CU];@^$8JO@'Q32I] M@7_O:97OD,OR)^_IHQUQ`"!X53AO0EB$A(58O$OFL#(V7*=&2^FF4CI6QM?& M.5Y)<'!J/^G1#.SJ)B3[!SL>V@=U]69$-65]W=,QV?8LU(O-^I8F@X^Y)/X' M&U-U_'N>126_E^]CHF[88R:_=C0#CFEJKWLKG.][.I41?,!TJ=:8X9)A*XXA MD]W$9?%6^0")E1G-YNLYU@G)POOGAB+!J MY$6?Q@/[`2N4H-SV7:..S37J.@N2S">5.O9,I8Z%*O7_!M$F2)[)ZQ>)&AOK MARQ1QS[/"$B?N"LOYNPK319A2F4S(-7W5TG84=AQ@S"=&T`.8IBLY.27&VB6 M`#MVA(2$&Q)HOD#]O//1;DI@ZUNYTEFU(CR$B:0\-_PWSWLN=<@X]:$&8Y'_ M7O1PG+5%_$OP31C9I$+UP536"?=2HOI/(>R52`TWF8`;MM&,0F[@-O90J)"F M%+"#>A$J+X2J]T3"?@F5?U,*1D-_HR&Z4TT>8LC;0]CD0TB?U6@ M=TQ!G6+T[^D(\]"&W\0S_5VRYK_R9+;^^/XDA$&@XVP8>GGZP5*'QE@H\_>9 M!WB(HRRN'9*&3WE?D__/.!B%^K(;:I_$U8<]5!.5URGMO-)?S*0W9<$N;R(2 M^[*5:Y_TU8,-8%/55__F>%%_@(_Q:O4N3EBG\>:H!$$,/QO5"&(J*57PRTUF MAJD9NQ=YL1[2F(^9;=_2D9+/+"92!N7+"S?&D80Q+D"S&.T="#WB*CY4Q0-ORI- M39RCJ`>K&<_3=#.9';V>4]Q=S3?\M(QR'Z\;X<1N@+TYVM MYHS-]$FNM;P/(WJ>T37ZL*QC&&L45C,\KK!VKG#D,58]'H=:N7/3?P1%/C-K MA)N;^NI`%_!XNAU&Y68;-A*?\Q=(O#+7%V*0X.LU9YF+9YO)NOER&K$NP*I9OYIOL(4[" M/RCZMA"X1ZQZ!^)Q7'V%_R8C5TB@0!T*,<`_QJST;C%SYZC:D+%S-7$Q-R`B MGLH;LQ]-_/6>$;/"/DB.7[4>,-Y1M:>Y#R+824=9$@8OTC$08O=7Z;FPP6V=1G:QPK MF9>/.GFU7]LD6C\??]K[W.#7(,?A-4XN2;#!U,L9*OLOTSYL5M\KH=[3P6%^ M=7IQ4CV`:B;/[FTUDQ-,(W(/,5XMG^+%+WG_[]/.!)%0! MV8?/FE+%&3PQ[B(9(?M-6?:F.2AHQ>^5_AUB>>^9&HU?J'NB1^,_`6X1,^S) M\)\*18KH?3[&&/6D>/$5^*5)QR^:-+8FC7>2L&>:-/JSZMI7O6M?PX[^2F!7 MKR\W?+5X_;7?WKV`&_)"1_"+JU6O071S=]U5VL8O2MZ^Q+BXT8]3O=&P.D][ MJ_V>F-2]>+-Y'`CD9:BF$Y/X$9A.3&)&X,<+DLU_LX$F)E$#'^!]R`;Q@"8F M4_MC%SN;)RKWWJ72@=F.__)E:\DQKKKQ(G'PTN5]UCW#=\;%:9B%3T.\%M[P M$KS20%;TE4?*'1%:R9-O!>`!R5/_J3.T,WGU3I#V&OY4?[W:!!^W^('=H+*CO@*DYW9=Y M2&1.HY\O;RJONP:MT]+S=-TLZXN^)$N\JL\#9_")8V6'X,,O5(V]8M5(\/]CIM' M3'^?D>MB@W`=I@MP%!BU<.TNQKDRSE-V6ZX]A MPOMLI[F=3?-*/:%/Z0H\>3+1(?T-?)FJ%04XQ)Q%UR_R%.S6P=X\C0X@EH/Y M#1V+\6)@SV!J(AU%/E:'D<.\XAST$X<+7W:\K9R=5-2/;9V*7H\B*N4Q/7 M$0^WVA]YG>:0K+L!IGCAI?MMTTT_[C9(5WX\F1B37+\O,^G=\`;=^U=Z=;>1 MN7`P\12E)9/+'8)"WCK<"5B^P]GEGC^_)6(*.XAKD8Z@%_N^*WAP=@^YTW
+04K`B,\`X<2$W+AUS,F+S(`RN_J1T'9]U+<)Y-^$:(6JK50 M2!`MQ=L_#N19/!QM0<^4F)*'G5-[Q8:??P]>B?V:GT:[(L\EN;:'YOM].9]\ MCS71^4ACGU1QTB.8^7(9LG\$J],P7:SBE/\&MVF6!(O,T0@%Y!-Y!*+QZ45> M`_TN?HP@=*&Z3T?J"%!'`#M7I.:+?*Z\_9_]2&0P6J(G*A,UP$Y#2M_X:6;R M(N1E\:R/>&0U8L7O04P/^*@@SDM9GS1D_->`@:(T.DT7[_C*WC&/K2/'+SHR MGHXX>ZV7CSHR^JN[!M@[-O)S*B,_AC)VHK#\M:;U$(E7FX7'?`1DXGG)EMJC M;2[V9.?P>!N#)R9O?@VL;8+W1^=VSSR0;W,!2IG-]+L7!1H+T0>K0>./QDT# MGMH;N07A>Z1#QX?Y[)4'VC/>*[B]T9Y)CN!5YZ3]$J]R,ZO\1QCZ6%RQYR$. MQFU[]O?42?%OY/'AN)V`1SIPLA7'(`?D[GSN^Q&Y$NH.,VPOU:AR8^[3]ZD5?AH7O@2G,-/=?&M;S-W$6K'PY8DTU@)C7C(OXEI[7(U;D&?Z9@6J&->@;:H9YS)A&+T2:'E.(UUD11,ZCQIHWV M2$S]*N?[7XJOJLJ*_OG]?<)7`\@=4[FG%Y7S2^6\68SS4^F.X`?GO$]6FN:XG6[3Z&Z>_O$DK/ MHYSY>74ZU`8NE5^7V[?$?OW;!Z'Z?3S'MXYP9O;$DXXQ78<_XM7Q MB35:_R,NPN#W0JT,^4'I$11G_8.@1-&7296QU/ES:V!"05^E) M&*7APLGC!!:NW;QI4./:BU1A\BOY4=("(Q[LE6/J0%R\M9`V7OVR=;@7V_MM MR.OJW6EP+7?VD9ZDV+'HJ+ MA\5N$7U>FY_GT(RR\(E>Y;1,K^)5N'@VJEU!ED"EJ,:20X$&78/+0E$7@*UJ MJNU*R[BJ.N,3C=NNA//%1/)92S+#Q4SQN M8O91[870VZ=(!YF=ZAT/\I15CWB\&`[V_CW]F-SJS)\+V?)^HL(^O@62]>PA[S6<>&/@P]6:LVJVT<^ M1W`6#;#NW.^*/-;=8IUZVXK0:!E&]^0VR`/>E]:=ZKE]NMQ>J-\FS,]17?;G)TBS@-8D7LR_P M>(:9?8'$XW,FA/^>7L^^@"YCM`0(B&ZXV9=:,($4>ZRZ;?6D(X@%-OTQ2!<>:?IF4#OH^_0*X`J/IET()K[,@ MR7S6PE$G84#Q-;7PEMZ'4?0BAS[+X4CS,M.20Z_G95+99?/_NELBI6K87)6CU]AH#D0NP@14HN-XUGYPA/>A'PN/O5Z M]RP2(\RS0'_^&2K$E$M8Q3',WH:`ID6=.FX,``H'$Y%R:S*A5_,ZWF+7Z!U_^+7W9"3"VRE4<:0C MZ,5!3'F.R7;G4Y1C\-V;*<5N9/Y.%8IC'8/S!S*U-RKM74_%C4)[KZ?.X%?S M*PWO']CLX1--@GM:/>=^E80=N1K)N[LQG=J[;Z(.^:V\&_]I@AY4\96QN!LK M5FY)Z7=[$A+AGO',M]PA^"6\&XPW8QPT%=1=NQIJD\_,"RG=3&6C33^RN4P7!$!%U#<2QGP<41:#\]H M`)H7N+?QB%(P^%BSZ;PI!;\&S&*6OHB!"SCNIQB,/AJL!Z8:R(G:B<9@S79X M0B?RCSCR:9D':DJC5RD&C;&"1U(@O(%B%BONM9!^]?82Y@P!"[?K.!U/%AAA MU>/;8MJ1?!M&).4-OIL^2F`UFR%.<"NEAF7'L^P=7S98.=Y7K(!2NBE61DVD MX7T4WH6+O/B;+_@[N_.(^('@(4W9&PWX"PUDV=6HS?.RK,(-2EJ`T$.ZP%&1%0V3\(NYD,@[O&PC*?K/KT MX?[/5)::I`W;:4C0$(>OT@B0THO(/H!^W6ZS[6?D M,_N4\(]]21#R&]GEC^ZF=YC2Z2!@A1X@(^#_\HZ_9NHY_?IED2 M+#(=)2!]92Q1]\4E#B1.9"YI7!K02VEI=A)'2QJQ5=MMAY3$=Z3>YT^D/!WA M<]7/-TJ"@"1GJ0$.I<15V5!PV0C&H]#[)$@?WJWB+RFA#?O_#)UI^"F:CB14Y06%6L#EK$CLZC8'.C9@-LEFK@QG#ZRU)T=1GKAOA M345_"^`J%`%B32D25@P803>*(H(%&4-U8@7'S_1RD]WX51 M$"W"8'45IR'?I0.N-[5=Y46FHBMV9:F-$KV<5'DTJB'EAFJCQ&K9^_J!TLSK ML:$>+ZHB$8HV164H-:$L!^%8'8'`)ZL@3R(%F0@[W&R(L8K"`4W8-IE\ M:+Z.(Y)R,H0%7S;Y8)W0ZA2E/#/&1<<7:NAWSXQ`CI'WU`BC+?:I(F1>@"%8 MZE4:*"5:;9VL.')T8EC&WN=DP9O(=]S%T;/0W4K[K5A>&$ M,F#`"?@B`72!../'FF]DT MYCJ&(L$;/TGP9CP2_`@BP4\%"2+^WD/(P\1V@3@AP8\O))#<WA7_SL+;%;VFB[QE%E+Y M#A($FP8+W@";SI?WP-?E?B$<$DJ_U3Z]!\@"^S6.KL?3'0B'6#06_?9$1K^7T6TU6'"R$).YTD MY!H61^X&F&)7MH!BN>1=$";DB4W#L93Q1%/VGO@BL_CW3%-O3,&DW1I5N#N5 MN^8=O8!)[LP:6<<'ARS03F%[9(WZ$H-=2!_H^E:]K4O43I[:JW;8K&GZ1T_H M6_-&!"E[56=GE?G[<_&Q-P"7X),D:?5^-+5A:;&[O] M#/:'#+!MK!N?^WT>O3FQIW_VQD[H.6A:C'S&IB\@53PV/DY1VG]6_V[[[8YYE27B[R:HC M3*^"A)_>ZMVYDEI``,@)/D-2UA%"O\&`YW(-4.ZP#P;YAAT!"O<18[!*KC?* M/*S=C+5=U`E4I3FGFB@RE_583ZUOF!!67A,0=B$:@)67M<#7.T-K+"\.!FX' M!B8=F&C.R.6:4)8D,BJ4?"61"7&,R0(AB#/4N'N3O=B5#81J[[+?!X!8E#(0 MB.`N%C=-.WR)O=B9%4R.]PLFH!5@+QFA!72HDCE:4`]%:IJ&'7I4H27.@I456@R.-&IWG-TPK\*WO.X%9D!G M$)EC9M0SA#:W:ZM;M8E[6&HM]_(KB9.I[F:.>^EKV9' MH4XG&B?/$\*DAGM)I+UGUY_>7I_]YZ>SBQMR]DO^O]=>$D9PFW6DD2)# M0YQ4M1$$#*;Q"*1;&M0TU]`'>SE0$XT;\I@M`\*YIJ.(3YNG=%%&Z8`W_UNZBC8*SC MU7O@53=52Q+(.^$%7?34&/G]\#=)L`RC^]V)"I^BA`:K\`^Z_'N\8E_]+$\X M9IU;S(%V1N&26:0X[`+[U/,-:&I6MJL=/71$=DU)V9:PQGZ0TA!!'9I:(;!- M7)B1+I4]1+"31\0,7&-!F>VB^3F)T[0.7_:%)\^!#8-;[>8;M\@==7^Q/L3W M.3RL$U.]LW%B*CH/1.MZI$,EIM(G!INY*6AB8HVG0O`&@BP(+D"@.;V9$1MZ M#X[@D1+3UC46E(6)B7WARRF/PP`7(3/U@:Y?F>DD3F6SVLJVNKQ3M'5#TGH< MCK)*Z<*">;RG,&>P;SSE6>/.ZFDE`(*60ZP/@#*N<3.,EF\]60*(*?5\'2<9 ME^C]`HZY_!I`9U1QWI:STDSB[/6,)]\RWI\1^*(U#J5$\J$]2.\HR=SRW:(ZW"]#W#;"F!D MJZL,WN/?21(RCP"9"/PI^<4#76Y6_.3(]NP7"2*_AAMC(%^;_8;$_KC9,J67 M=V=I%JZ#3/HZ"W&C=KYK-<(AM-`S4L9JVP8PL=EEEO_-.+;]Y(A+V-M@;0TAL.H7E>")+FV,0"H:6=Z5O4C M94=2]&2%2OE6Q%KO(\+[\[%C:<$3QO>#:5<:,&#?41`KHP*IF1Z-')TRV",8 M5XSB6;'L^:KB5'E:]0NAK&'C):5V:;Y^T][G_\H_K#[*_^D>-PXT$``*X*!0`5`!P`;&)I;RTR,#$U,#DS,%]P&UL550)``.B"SU6H@L]5G5X"P`!!"4.```$.0$``.U]6W/;.+;N^ZDZ_R$G M^_6X8R?3ETQ-GUV*+*=5;4L:24EVGJ9H";8YH0@/23EQ__H#D*+$"^X$"8!F M34V2M@&L"[ZUB,O"6O_X[Q^[X-43B&(?AK^_OOCI_/4K$&[@U@_O?W^]C\^\ M>./[KU_%B1=NO0"&X/?7SR!^_=__[W__KW_\G[.S<02\!&Q?W3Z_FBZGJ__[ M:@&_@^CT@U=C+[J%X=D9;A_XX;>_XS]NO1B\0H3#./W/WU\_),GCW]^\^?[] M^T\_;J/@)QC=OWE[?O[N3=[Z]:$Y_NTV.78H-O[Y3?;+8E.?,;0?8J$VIZ$# M1N/_N4:,G%I6F?[^+FUZ\?[]^S?I;X]-XRVI(1KSXLW_W%RO-@]@YYT:^_S& M9P6^8__OO81N(_`8T"<@@T1%/8#$BA M%@Q]^H#%F\S6D\_HCY4FY=%&U<#OS>'WWV M@GVWA(_IQ6]_.?>ORS#^C#OQW#W2,(XW0]86CV>=PTM=!F M!MJ(_B:&FSME^H?>3>C?*LWFJ6]C;(Y'JS]NYK/)5X2)/R?KJT^S2[P:6?TQ M7Z[/UI/ES73V&9G"S:2T-!E[\<,-VGX\WWC1-Y!<[<-MC+8DJP<8)6=K$.VF MX1.(DQW0MEKJD$]3.H5A$GF;9.\%-VCA%_F)#\PJC\E0IUKJ4/Z.)=.\S&I& MNE/)M7S*50@:LN^/$8SC3V$$O,#_"VP_>GZ(?=$U^JE9.Q=CK+'6KM&J8K:: M('[&\YN;J1;#IHS9#J^:35601CNR:#$^YLCM\'U"[6(?;1[0FG1^&_CW&I?' MZF0;GF4T.LEH3#UI1#YIN@J/09-5..ZM1A^?L0&\_#M#JYTMVMJ`[?%',;R; M/X(HG>1XX47H1P\@\3=>H,*K*J5F>H5-U`IU6/'DX^AZL9R/)Y-+M+UL[/!K MPVGG4),;H8W:8#[OH7>K?N!YZ-V0?B/R+5DI/I6(P`/Z.?IPXF5+"_9)H-$8 M>0@>B\ER_15]:_#Y^`)_:O2@CSER*WQK65"P!FZ%ZQ;X;>5FYK3^6((XB?Q- M@M$)-]]&&[18])/GMFYLQ`DW.P53/P3,.K>@+ M!J0OQ&D7[\+?9PR$X!X'-UQ[MT!@`48:*XBBTE#X5OT]OE6_^"5ELTRA.:MK M$,6@?7Z+9(I,H^]5C#Y>Z:KR&OV@Q`/XD0#TF3LN)S`=D=B!=/R<0@`WI4$# M'/@`(QX<\$_^=0DW>_QM'87;29@@3S(-[V"T2[D=W<;IR6,^4("%RT:2ZH=^ MC:62Z/=&7KYB\$L,-C_=PZO7\%H"Z+?7U^8!`@R83!% MZ]%8#"2UYFR@%)IW).((<;#%7%P%WCU!)N+O"T)4?F\,XL+ZAWRY*G#F#9VC MN#(D$;K=87>\C["NKM`JR`N^`B^:A-M+]*$BS#&O:6&ZZ4V=F7E!:15!0!^= MA(=?.W=E"X#8V-*QP&Q'<%Z5=LZ@0$1.10A0AB;Z@[>=`2#["'\!0?!G"+^' M*^#%,`3;:1SO040`@E#[`B`X[9T!AHS>.@?(9!GLD6?1\Y0=H M9T,%"*5=#1BU=HX!@BUG(R#4AB8"X)>.`7#XD"W!(XP2/[S/XJ"I.&`WK\&! MUMPQ5`A)W0@<-`I$C'2WG,B82P$[1E^W>Q@]4Z%!;%5#1*658T!@R=AH_BL# MDZ;]MXYG?;&_#?S-50"]ZM$0LTUMQDMM')MONGR-9KLT+-'$NY[L);CW\6%- MF,R\'6G#P&I6F_)J,\=FG2EEHXFOCDR:^ZZ7@&.`(T^#:;@%/_X$=/].:5?_ MYE?;.3;[;#F;?>6K0Y/FO_,5(-SM8)C>,ZX>D"[C^3Y)W[RB90@=#`*=ZLA@ M=G(-)N(::(89)AT2@-YW?MIT.@:[0C]AG9E36A).G&HMG<&'F*P-3YUJ@Q.7 M$7\S!(7L3$P,#(2V5#B4VCH*"+J\6B!1&IX(BG>=@V*-AF7@H/AKPM1GOW9N MM@E2-9S@;$3BG)[;IZ#R#3+]IKFN2!EEI508%\R%T4F*:^X@[[SX-M76/CZ[ M][Q';!`_OP%!$N<_2>,Q"I9Q^/&_CA&/X\"+XWGV]'/TPZ^Z3.'V!\4)M+<> M*[(R2X)%8'@26II?XZBCI_SK_`+\^X<$;$=/(/+NP1)@O*,=9N%9,G[!39TT4XS4YK![1LR& M^W5L,M"B22>%(W:C#OR9,*F&?#ER@;](X`Y$T2&0FH&G%$QHX%M8B5^VP1E= MP>@.^$FJ['`[^?'H'][G6>"?=/.FTV7IXVWP8O9`HP>.39]F-^09V]I9T?F..D>C)A@I.7YN'LF7:S_LRH'G+O=2[KO9+:.S,'?=?D M!X@V?HQ/W015=M&2[VK`B6;?I<3)X+M,37L_?)>2'O+SS7>V[#)']_=1^@IW MBECUP]C?I'E162>*@EV*>S)N%\W;9A4@%1;4:'E=6&SGR^LR[UK/6A5I:SEM ME:9MUG&*H@^:G1.2C^.P7MXH=L)R[HY^=7";+<I[S]6Y4V]GK)F(:'DP3A=A%X(7[>RXS2;I.4K&=3(F4\4IP, M+!DOU5S%E/CR$FM2_D:)I5,@NIPG"0R[C]/MU_RNJ(\E"'"JU3&,D[AVK153 MKGOT#EHQH::#FO-HAY32\SMUZ)&2I;8V?M5WZ1O?N,/2A$S8OO8I;JV9`"4_ MJ(_Q4[98#<[/Q(,G[7,(Q19?M+=1NO@ISG>%#ZUS9M/ZD*:0:THZ8?T#Z]K5 M%@;NMXEH5WV7=J6#^=/;5D<=J+X);!R'T>0=(@TWC<5K'JLA*9;J?H05-]8/ M8,F%H[6/""X_IS0)[CZ^:`OQ+1UM"]'4?'C-H=DS4S0Q4ZW:N(, M"J?Z2Q@$5S#"OVS)"["):39_&K'![M7GQ@F#ITFBND%W(W:&NK^B!2M6WDSD MOU]$_D;Y@KL5)K3=_*@QX:Z_D/JB:[ECTC#-NEV,B!+TW&:I"5^HD?`2W1(S M64@G/DF>`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`7$3TI@!,MQ[&^?(O)CQ,%Y6ENO0P,N5@%-\!#![&'@\SE)CJA8_1 M46O*5B\CG9K9HAO5TX.4H>@4[P714'1*\STT&5@ON.B4+3NFIT:)3>DJ6NA2/ M6I_`H>B4%K'R3[)X*.M0=+[7VS%"(:BA$I6>FG*A+(U:(ZD)Z M^6!/6&8#Y0QUJ`:S%Y\;)^R=4X=*NN"+*U_]H1)52TRXZS&,U7X9*E$-E:@$ MM354HAHJ40V5J%RN1.6&'Q+/.S?4H1I\C]F)M=[OZ))ZJ);@1+6$]H]H!K\S M5&GI4&KERE"#W^F2^E"EI;>>9ZC2XG*5ED/>*V9E%F*;BAU7VMAO;9HJL+!T M8ZCJ2H4E5T/RFYKQ4&G%&ENS)E'J4&GE11T$=E5=H;MZ"D,%A;9GRED',%1) M8)]?#K66!NL?:BV]S(.QH4+*B[?]H4+*8/L=V/Y0(<4-ZQ\JI-A]+CU42''- M0H<**4Y62/EC?GTY6:XF__PT77^=X:N#Q'\"ZF50AG1>0SJO(9U73])Y/2)' M&/G)\^^OSU7.$BVY21P'7AS/LSI/UYST)\RV%?A3VIK+@1BD@X,M&0PX,608 MTP*!Y#I7W:Q@9^.FS9Y>V%`=%*,E$BWE)!(D1C+'W\[?2S]XMN0AY!B&B),8 M27A03K;DRI9BM*(Q8IVJELKIY`XNI<17Q2./"!F'[_3D[3$/P.S'B30&Z_W$ M8%CLYSP2J4K0#,8B'3(>_^8<'B>[QP`^`[`"T9._`>2OP0P+GN9ZQ@NW>`T3 M+RC^'N<^G,'D*TB68`/O0_^OXG./#K%.K MF82NZ``B"V7%V9K7*=5?KV@VPX5R>NR46GR+\!^FTU) MY[8MS2[9[G]VV.ZYK\BY"29L>8DMAVZ)]`IB^#L,2$;(>4^3QRD;5E;7+C>L M]*#GRO.C5FH\:F&FLZ\&FQG'K,ST=-GW16$S3SZJ/'?U*I@9@S<#W]-?4=]O M2W66">LL=';(GE34H8Q_06(DO+Z5CB2RXEM7U`DS$H_>D!%(1(Z"$Q(/!WJF M3)^_?W>>LIS56D$SJ3V'9/CRG>A&L[$CK0:_56.]A''8B\FBKG%>EP*B% M1X+7.^G]B#7%N.2T+!+XV4S;%`I$H]:C]4X7<%Z2KG>+4C*"][GM:\LT:GO7 MD"8J>C.T,:@0UV*N`6Z)MD>1CPO=TUM!B'-AEJE$#S!`W,?9,02LVU'10&T[+ ME+$G>+:F9WSZ25S3\8U[+$W()"^FM&J?XM>:"4!9FC5EW-7\U+D79ZR=2$VJ MKR9*38P+PUSS"*U6K%MG$"5T%7AP]GY3-2;]FI,<3]_` MNAY)7-/2[O7--+2KODN;TL%\ONW6XSF'K(PV9674".Z64C@VYU`EW^,!\S\[ M^JBGM4Q.V1N3*Q@=?H3;T9(WF&&BJ\1E%"9Z:M%&Y[(3S]"UA*K;$2O.LEM3 M5M>NI&NO,3B(AC/DMB\XFKV;N0:*.?.^9+6N\\H*XMTS37K+%Y% MR4.:4B>MN9UYZ,Z"M?&??ZBE\Y2X;;;$M)`?(QAKOUOE4])D+:+1_OD`4:,\^,.*.HR=1&*@\DW MG"6[35]$'-7D,6Y_VUG'$Y?^D[\%X7;I)=K3T\K2U>4,Q.D.+D'+C-GM&,2% M4GY2TE__\!D&:)C`3YZ[]A!DREWXB"KEP4MHFC5W_415+.7G)VY[BGR-U=4& MHJMMP[!9T#0C=ELX70C5I`YNFS/)XRW]^-M5!'`U-H"4E'3UV6?1;?.C3Z8[ MF+^6&;/;'8@+I?S$V`[_P*IYD/YRGJ]VLE@EZO=<>2"9(A:4@?IJDDUUVHV- M*7"IFO#?DO/V8SCK23IFR@9N>UJT=+V]_5#7E+Q95&>&$C@SV',U#?DA*I6) M9&*;"GHK;5X,8EFZ,832"DL.YA8^Y?D[6WWZL)K\\]-DMIY\1G^L+D'B^4$\ MI!P>4@X/*8?E]W-]23G<8LV$X>,[?'RU?7S[@=/5_C8&_]DC34R>T!^U+8!K%=H]*O1<41&O M<`FO.?OS8D6QDM+-.96 MG=F6#2I[MN[<53T=5E+[C;3&CJ!/2F8EJ/$H.)NB_YAF?81D MW_K!'G]J5F"S1Y]9I(/)CTVP1Y\W?**(K6F?'(QLXD4ATE6\`%%Z#"-6VU,G M$6J!3SU$'(-^JSIN9#*Z.7,U0N^DAT4$'T&4/./;YV04;G'U^<<=[Z!+LCO5 M/'C=G06^E%XT09I'T]6BL@U-M;8AK&X--`]?W4AH&][5"1CM,(S;T7YY;+VJ MS\K@CVJN]0V;TL]1CLP$G"$[W4Q;C)"TPEZ\Z2+C_%6NGTF#>7)3IN!TC79/L`PLW#SHN^,4]D1+OQ MX%?K9FZ]$,<@R8KO,9>9U';5;W.]G7WF19LU*"ZOJ&552)4^9G42^I//V:!N M:E"@\"=,5-NUP$`6!5SZBC+%.%^W&]5W5;BX#CJT#?;"KT7$U)N'& M^S>,QOLX@3ODL`(S4T"%(<>54!A%I9*W1`3;HE6:`3*-E+KJ$O\QE MRFSSK5)T-4H#;Y7G=R5D,1>\W/858V:T-XX]AJ5">8DI,*L3*0*+,;B!@PM* MN/N5_P3P:8T7^B`F;@IXS8K!Z\1FQK'`GV4H+"8%"502QT!TXM#VX."S%_EP M'\^3AY1S7!UODSZICABH$.Y4Q(A`)X<0(ZL"9?P($#)PCT'S*C`"_GV8\LY9+@=[5/'IQC<[8-K_XX6 M#2[14U0AQ9[&;4]BOF$3K5#LDD^^DG:'3];I2A1+G%6/'5)5;U$-I"JV,'CB M\S9)CSCJO4,1!L^:]>N11&L7UX\N6WDSJ M>^E!6]S2\FIHE4?CDX_KVC7=;^<.)TFQ'38207BN(8DMVA%JV[Z>M:)C0&:U#AE\'F-IO$#HOV-%H&/$?M^@O\E&B!5[\&+C2KV<`V$PM+K38=4).-VBO'JRE/,'0KVJI8, MY/5R#'UR6FB$0"XIIS.^'2O9W@`/)XW$Z[Y,0C$X2O>O`%.BOV,05=5,([!* M$#W`]F>W83N_N_)#+]SX7C`-D3[VN]/2A`=9D;XTN++[N@I5"8WH@2F;X`&B MOS@)T1LO^@82O(4^'2(Q<"'8N*ZM&1%5B;@>\%#40P M1/_<@((MB7W,58>I!O5*#^,86AOJJ1&&Y6GGNR0W]^4+G)`]J\933<0\VOY[ M'R=8]$L0;R(_3>)!#6=2&Z86VR0[C&/0;JBG1M"6IYU#VTVO33UX%_/6LMU% MP_1<]\Z*>FD(75&:JJ](K4#L$JD(31L^#+X$3R"`J8R3'S@'/F`N;B5ZUM.C M\7LZ!E%Y;31"IQ"Y`S"EDV5:`4QRL>8LK1>2>IH>(OM/`-LG>Q?68"2ATO*< MD1P#4\9&H*J. M?,#+K\WQ8GLEJ#PF!-YEN48.A\A;+SD>V`TUHLR>=V<3@WS;M>_=^D%ZA)5/ MTSQ4PV-\6$$(X:?VYYF#O7VYF4N^_X""M)I_Q3"VQA$3WCV MI^'C/D&_AN$&82>%8E$@9J:(MLFQ'9!&=ZSTM"J]-;P6)L2(L>J1 M0\#`W2L`5'!HA7HW/5R3UN0 M_/C//WP0X4OLYVM\A2UF$0*=Z4;![/QB[$)XF2)/5W+'>S[: M%1BO/;$F`[%]+V!?7Q35"CGPE=4BVJ^)-7'I?+7R";`BVH'TG.GX_1.[7N#W M%'B15NMICQT(K%PXC]+8:N&?Y-/H\]ZEU>CV>RE3D#RN?[.DP`83_89^>HH;IWIZQSR/%^A!@S6IAST@EH(B":*JCMM@,=P*=!59]=:Z6HEDVK:,M])E*T8"R!4&N*O; M&N'VW:[M`?7IN>40+&_VMIP69R*P>`_@,P`I$3_X&D!_"C8*4ES3/,0ZBN@_]O\`V>V$_AG'"-8'6Z56?3+9' MSS&CZDKSS9Y?ML>DOG0\MJ\13H_N5@D2_:RFMN')73]\+>/Y7:NTVO:Q3C[+ MZT+C=OG6C$%7J^CH44+MYK^:7+<=*M5DO+JIF$V[<5MC/8IPH0!\*/#A^=1D MX3WC'XV^>U&I.9;F@N88M1,@)>G01,"X"VP+OM6$'VU,",59:A:IECQ$DRA. M[RJG(5J^@A72?2KV]4&7C!!+@1X5.V/VL$UR9C"&4!\QZ:T)MA"93ZBF`HI= M,R@6;91#R=75#/8:\[N5%W#?Z5+:U=[FUMK9BBG6HUJVL')((KV&K8WOM-MF M9G5CE](5[RF3C,]=Z,DKI"D8A2CJSTEMM*99&SMMV-7FC5M&3:-TI?(CNJ7J M3XV\EO$DOL@UA0TFATY7Z!L.NSL^R/$1VG"R;;3%K?''O264ZEP]@!'L;-SO M2)XOJ^BDV8&Q($5B&(YKUVRII]C$<'-GSE,<4]+':YBG*`$SD&1>^1K&Z.>X M9.(B@D\^$NW#\R?D\:?A_!'@/R38N6@SR!.P/:+AP_LDO@C_A-LKV!T^,A6SZY4NQ\4)-_=O,=J M$S:PL49IWJX%KK&?E.?6Z0IIEP`QO MO8>_O-XZ1KP0@ZHK@"<0W4+S,$]C9K*$[SC)^^$`A;9093:N+DPIC5\,KH6T M90C2--Z/P)>#"Y!]G?!SX^]1S_Q`HX/DQ^@ M?@,O/(!-:L*P.1SGQ`OO&9\`XR7<9A/M03&UC+C>9$?D*U)\1..^2`%'L`UM MTJ\/!=FK7`.HLZ5Z'63)^K\N.U+MH^=O+P_"'):&2/I,*>D[(6%KD1F,:RAB M@_7.1A1TV+)YB'$D_<5]GUE&".Z]Y-#6:$WHA+3!(JQ@>OU8_6,[BCJF]%Y:VHV@)GI1F(L"5]4QR:'N[+Y<&;<9UG4);>9D#D M?4V[/"3U!H!M?(4@4Z-[U?G#S$*7UGZ'94;U,WBV*;?J.I)BO2(U).\HP?722C<#M!/TTSEXA:!G<`GF$P!GA)=B&J1W-F MP>`P7ZF)?R\L,XOB3967AM;>>`DV^N?YG?S7H]EHK,M-F='Z;#U:--R=*:FR MZW04P#&-S?PN?WC#.T@1Z5)[U:I MC:<7[DYIL[O]=J94FB>=3\5-I(N\-5A#+;VCYJ5Y)#:J)FBL-#*VK&9&8C!C M+:R)IJ`H''+DH.6\*HU6"JBN1"BX&9B729$'78A`F=*6"(=:6V?0P992$2RU M01T/J*/>!J&/$_U>A-NE?OG!Z.(`HB1DE@86>VS7X_5+9B/BE42\D368H?D8 MFC.2P4IE;*HO4O=!=GR^J!=G'-"(]JL"B=_/(7!)*D$9<'PZRB=X-EQR#O=\ MF@"I\8*/"TJYJQ)7DTWU7@R.WE#A#E%*`*02X5 MIU_&'_*Q$?.PL3_.$CUK6P6!GN[`4%X1JE`4HJ1Z;6R)+RQDR!0[[^!WJ,"/ MU<'<$KF<,92S+F8V)A>]JC4V;F`"$P5[/9U*-+: MNX<_(>J;EW8F=17U_I;).-BH%`Y#/`TA#?BIE\ M"'TA*O3SS\5[)X]&<)9//\O%AH\@T_B<>Q!NZ,_)!'I4#X=9/9S&J+@N-`*3 M232/<]1ZC^_8K`@?EFB<%!9-^>>HUBXHB?I07`$H?OG[`TX1K;0#40KE_.I3 M>H]MQ8)5>HDJO2@57X8Z!DIA36B$(XMF_A5S];"G$#E]>*G@!0L8^RD/YV&AY2OM/0RVY=12FMM6MH%)*Z M&>IH)')TN1HB4/@B,,-@*%?G@?%[[SE^#.W_BTLP'Q MCA6DB71T#'C2NFB$0Q%J.2Q=C1L1/M@7/LJW\O"^ZC-:_CE97WV:7:Y&Z/]_S)?KL_5D>3.=?9ZLUC>3 MV7JUVCR`[3X`,$TR47V(X(7;U0.,DK,UB'991HGTYO,2&V1@+N$"YK7Z8.?` M:H53SGFO^D"$)UBR`UGX6)*VW9/-4VMU*MH&DR[T:%+,1\ES(?:4\C5J@ZC" MQVP;B?V8#W%VV=]?GY\N&5U=O0U/++O`ML;WE\U@+LB(`.+E]RM6',N)JZ_Q M%Z[QEZU7\%?266LV(,J-@"'\[&9`]/"`63_.M;QN;@9N+@L"B'ZGP;6[MEF# M8:K*O1<BG^PZ;;;7\)PPW`9RD82TL__K;&VS=J M<"*K<2U$D=RX+XY-1!?M^"X*9>4E6F!Z\UP5"/DT,$W`CIX$@->!A\5"!WUO M;VH+;/*1\^XYNV9CP;8GB9I M)DYEZOA&2`\S;E_OOO0S7R'H:CO;96)2A(K&"R<;OC,+$.$?(*NZ$/W2$+KP MOC6E+HY!3D+^1J!CT]&XN1J.4YW"GYYC4R$(BB8A5SC4MP&%-25\`.'F88?D MO80[SP]%'2"E&\\)UKH9+J6SQAA%B@O.60#K>TK;N8IJ.Z7$_)(6**B6H;7N@.##\Q%EHQ^^ M\#$!I1O7=U6[N0PXM@[TP:Y&1S5/BFGPW7C_AM%X'R=PAWP.`V[TAM5%&J&A M0Y#BRJD,(M+(JA\((FQLT"O-`)E&RUQT"7^9RY39YENEJ'4>.C3?F;<#\[L2 MLI@+7F[[BC$SVAO''L-2H;S$%)C5B92J<],'5][5JT.*.1-W%H>W#PV8M\N(_3=$>('$".K`F7\"!`R<`M*\RHP`OY]F/''\"KT9B6O0FKF$$;X M8JI[%=+0RE<5)1PX$8N3KJ.'"!Q'(W`*W(P#+X[].Q]L/SS77S@]7WH)2.>: M%[JH8\B*2IL-:=Q/Z8GYT:C75B*#FO'7SMM9&^X^\G>#\SN)N$\10],W<#5W MD8:!>V)TVG7RIK$^G\([O"0I?$Q@G-R!Y M@-NJ@?"7)-RN]$4'HVM/G**"GMI>.##X:&5I8/IJ)CW362,J\?SN$MSBTH99 M&LI3R"GSJD:Z/^D>5JR_P="'Z!%&:+>&&3SQQ8Q<$NI3"WI@]C%N]/)S#=44 MPKKE$J%?OE5ETNVG45?"*)E(93?FQ+;V`YM"*M`)2AK!5E[_&TN:4]D'<*VHH8T@5N<>B^_O2=1Y]]#L!TE5YX?L9X\ M\3M0+R7K'6S';!U[Q(M&CB;4D'I->O_$HMG1":P!D*XC;^N']Z?/S>E$]0\8 MX%]]I!]`R'6N@%>TL]-`5M*01E"+TN]O`G6^!O"-@3+`BYVE`9YU[CG`"1KJ M%.`9_?[>+=QZUZ^EX,EM-1K/+\?SF M9FHZH23<[?S#_5.XQ;%@:$I`N,'G(D>>>;>P*F,02I9*C&&T4"N73V[R2*5! M5#1F5;B*$DR@)K51G\%),%4M(RO##-&/V>F,[,G>.#@G*7U=^QL0Q@!_1VEK M=E*3BK3E)NZ[#8;(NIU"F92^[!5V^0?3+TH&KR"EKR788"1N/X4;&&[];&&] MV$>;!R\&\]O`OT]1PTUYK3Q.K>"S]#CN.Z&FRM/MJ13XZ:L[.P7-UN4?5D"] M]'7-/%PSO_:"O)D=/DP]LY45]78$I;S<@VFX`KC-5^#10NJ:#:8&^-I@+P;_ M;#4:,H<:4ZJIMZPXWQ<7^HN?//CA/`1:S(,XFK)]5$9[20;"4J0Y"ZEPY>K2 M=XISC\30^VYL`7N:$'PUM'L$89QE$0.!EX!M>E*R>D"`O$53L%UXSR+/OO0, M6K'6IH,:PAI.B"X*L$H0HN=IK$(\VB3^$X*U9&J0I@-3P[;5!^ZAC]6N M[];=K`Z.M7A:TX'B!45@D1]@@.2(LW<@,YB`+_BV&BEQ'BUQ*23NPJ;Q>'2+ MDQVOWX;62+M=VIV$Y\]')SO&GX`:5;)+3U]IT#S8AI/9G/CWH(]$5!:9(J-$\D>+$UBBW40@0?DY/PG,`V1`0-V41K9_M5B->+][0=C M4Z7(HE.!W@&NOSAY\C[:'D]0/7\[#H\^MFB32IPI*=A^'@"@AO#+XV#3R MUWB.^L>"[^>DN*&T(T0U5-JY`R>>D*H0(HRK>D-H"6P6.=-\Y+":5L!#;NH. M?@1$5840>6C5`PA+4+3$H6`AV$Z\*/3#>W;J(G;CVCTQN;$[6!(25Q5-M,$/ M>/K543RMD"8`/IZXYB7RH#:LGD01&K:R\\TV79_0A$U^@&CCQV!^EY^7I*M(3"GYOA^9;3]]SY/_P-I6S,O^K:&6<8]ZJY9;9C:1EIV M&,OQJTD_4BA6IZD1ODL-FX%/H)_$2H#5?["=@!:(G M?P,6(/+A%D?GW8<^(S[?$!<*=J25BQZ987NSTYH5:V4YWP.[&6P]`TEV@,U( M"D1L4ZV*6F[C"+Y9DBFAKS)@C@U75SNTVPYB4JVLK$$+">\OT3_&=YG MAH/4,[];>S\H0&N;7`6S[9%S!/X=Z5O)DMKC+3=*-Y=MV4Y^OD_BQ`NQ_+0C M)EJ[Z@E3O9TCZ.5)J`0[PJ`Y7J3O=!]3X$W"K;.8^==%_U%3DU$S;J37A1EL M$+DH,0ZF26*+T:KY<<^6!BS5<6K'X=+CN`++AAI2`ZT\4:?C6RCR M9K:K`<\"`XD!FCF0VX@6UY%.2#.IJMXZ/L+8QSG5K(9UNHY6@7&IHPQL#QW[ M`%.2#O3#\D`E7V>Z&DW!^IJ,88BXC)'*<)`__G?BWP;@M&-36#@(CRFQB!`8 MTVU<*VE.^^)"@(&#-?S6+V/(#%ZS-4@.*N/+>V\/:KK3_PT0MXCW_;*(U!\H M+%+J_23O5RTP8%Q>49%8M8V<[*1)Q-(I'+47EMP*KO*]2'!B]R'WO0QI2I@#*1 MQ_<\L)%H%4%&H:$ELX(-NJ87(.6][.!IMEY4E#"BZE;003T*6*JZ2LF#JU[< M&LS_<93H;`Q1MS#&08R''\7P;HX61%GR]T4Z-P\@\3=>8"Q72!;*-9&0;!DKKE@Y>PC%]Y/?N"8?G9>'7;C M:J`PI;%M(*&X12@IMIP#K;_NIA&QW7U22SO%[3B/RBG`O4-(I<.R7JE`_JL"!Z9AD\@ M>U6>Z64:(K;03ZBFQVY>LSU:D]^>C)\X.T M'@`L)-TY7/BFQD>!H^(HK"?^(J.X!-YF*E+'M#1=$K:E7ZY8406SKZDG5%'7 M#J;(B)&.QK,#,3"$^=EB)N'A?(>S$A;N5T46OY]3:)-40P,$\BEIJ;AAQ3>Z M>MS-J\?%;<^Y?:!6T;(;?:)BJZ..08%XCN#H0XIYV;(87T]&2QK&7/V2\D75 M@"O>5_7M3VY^5]/W'>4,WY?^D[\%X1:7XRVD5*,!37H`4BHFP0&<@J6J8AJ@ M58(D"<3BJ1W>9Q`.P3VNC&(:Q$OP!,(]]>UD]=>U>]C\UR[!BR*4.GA.`VHI M-&C)%_,+P/7>P':$^/'NP6R/;X,/51@+*7O$#IB;#5:!G>I@+H%4B\+4(:U* MGKA!L2AQ>IRLX33<[C=H;[5Y\,)[L(Z\,$;2U^_49;J4DZ-SNAC'H?B>%BJI M@8([+ME">G0..:*C%3^MMNLC/-K!*/'_2M4UO[L$MPDN[XDSOR-%[OS]CN)4 MA?M5$S?S^[D%456%-,&I!$TB6-_])+Z5MAFN5W[HA1NDJ;3FK!!2R5V8(*UV MZ0,^F6K0#\TJ.;(+_4E\N6H7*B]!Y#]Y29KR%JEBGV[69C"Y!+%_'V(.1_$? M8'N?*N[8(,^#.Z,6G=`V;@7?&L9UTPAT*U2'I6C@B>+DI7=_5IS.YT$"!Y51 M`S:(K6IQ&I56;L*6+:P.$-8HD"'EJ'].3]BH^F`=D7([D8Y%&9W0>);OYE'^=/?H^5&6#P)9(=IMXC1BHS@&28RVG\$^39D/X?:['P0T9Z@R M1M55RHUA',C\VTFH1T$4/%/IE]RJ'%T2K-]+[-5L^HPCZ]UX\<,-B.Y!M`1I M+7;6-HW;OA[J06OO%C9%!6^"0P8-(N:<1%Q-$Z+A'*)A'*XABR=H$T01QJ8] ME7'PHWR4+C624;@5A12M/0U:]?:.0HPCN!:HU6EHB:VUY,Z3^1Z6>D"D9.ZXHQ4%L;>K=;8Y^E>73OA8?(!C0; M,0S\;0:^<%N<,GOR7AKI'+MZYJ!G;'T1D5]@]`WOZK,2[Z0`2'*+ M8KQCM85QUZ!W!J&((FC[6AV<'*,BJQP05[]N?O#&7OR`_X]S"S]Y02I^N%T] MP"A9@VAW2F)`VX')#U`Q39D!^H?PQFILVP!4&!1,(^6@NT`E:V5MFCGYW26=-N_[0,6L\ST&C0_IJ:5G5W97Y- MF18P2?F\')989"_SH!WSHLP1TX&Y MF6N$+'(A6924&1#Z"5E`J=]+`S]=:69Q7^*+^'C535V\:Q0=KD=[%88(>+4W2N]X4;/F1L]/7K_L(_]$,3Q)8@W MD?]XX!SG=8GQKO`DP!I!ZD-`WRRI#U31J,I`_75^C=7:E7-4851+NBS3OI-3 M1117D(G``_JY_Y2=,QI]@5MBYW3X.0/)_&[M_5C@C!%HYI(D\F_W2996.RM_ MRG.R>DG5,;K9]\\$"3Z%$?`"_R^P_0.M+/!3Q$-6@7FX`ANT1,:7*:/( M1]9U7UPQYU)+3H=>N&=C5-]WM3Q+M$Z!'L-J;\58$ZN]=_O%C M@9\G8V6ASR9!A1SWJS@*K?"=Z"CF`H;J7'$\HD"/:D@0JX=QOZ0ZXU!%)107 M(LE#*9"'15O`VM^Y^:JUKW$"&M"H$!'0`'\5:AU_7]R5X$'IJ*<(M/6M.7 MOA^>UXAVL?AH_;Y>M&?]QI[?TV3\`ID[S%NYG+2H1NH]1352[&G/L7(3[B2+4@MW):O,`MOL@#:RB37FQ9'!U M,R?9O;J+$^YNKP$S+P35U"-KP\0K0&'2KIKQ48X;@'/^4Q!*:54M$%QM92_> M")X?BHHK"ZP3K5)AX"H-?1K M4!-7@Q[8,>DY_8A^?G?G;X"8/V.VK=YUD-NZ"C@1T?5`C4+)Z3J65!6@73J8 M)F`GO5FM=11=]Q8ZFJL-L=GL=_LTM^4E0-.Y\5/,H'\'X!`24*Q*0)6%HC3= MPU=K3F@;WEYG4(<7;%V_LN[CR&.IFH4VWJ2_:N5,ZFL;_$Y1!11C(36I%:$H M-G$4M`PYM0"O/'[^%*I?7RMZ_1.1+J)?*#NJEJBA3$(/6E#'IJ>\9K+A#I0J MVL>(?BDJUDD4B8=.?<,B21?MHO%`4?]9A8D;4MES19$IH=X]T:X]!9D0FITB M<:T'DGV9'=IFJXO)*=!6/6=(AW%+X\MNC) MAM+5D[1*=%PZB1!U]?4$QXT,#L1F!W*:/&57PAA"5$/$(7KF7OAJ:M71$,GW MP.6LUO/QGW_,KR\GRQ7V.>NO^0H/WBT!4I"_2?!S+B3O(;/9L^GPN/2E_`Z_03G]P3L9 MF^T7Y)YJBLCSH$K[I\?4P4U"XY7'7XR/^M?%X*5>DI>JS??@IQ0>:69^:I5X M4=)?3X7FY@[X"<[5;FBO1^6@,U]%X&#P5@9G_`5Y*X(J\C@R<7]5CD+LKZ_Z MG,Z1,4=%)M^9EZJ2'UR4J;E^0?ZIJ@?Y'"LOQ3D=Y^@+\.\?T-^C)Q!Y]R`] MUKM$LE]Y?I26(+7B%D6%R^XWCW)<]A!5Y4-AKCH,7]0(\V?H)D>`OY?P556R M?0-W0;)P,O==EM&HB=LD`4T.UTU-Y]CBC[G%7_#!Y9IUN[.> M.UN3MVV#N^V-N[7H$J\7#G>X`&3=0.P1N.QSNBK,=7UM*,CP]"MB:N4&EA0=[QQ+W/>EDH>%*&D0:>`"C.3$ M<[8V2%H(>',;/YI[WWPJ^W*L/+J`L9_.J'`--&Y7>N$S1E>%3R16;RKJ^?MW MYZF@^">X^M4.ABG"U_`#R`JBIQBMYC\3;7X0B-_<`O92J:9MNJA8@2B7G(Y/7DXY0>L\^(%50+_H12R=,0NXO??F6 MS_=)G'@AKG$NZDX)77C^M-2E#S#E::(MCUJB2`+F>R==ZB)G6<6KRG6N96D4 MZ^PL:)6THPF^HK2)=8H=];!EF04V3/P.3,CV9-LDK(56H,G?/+E:/Z4N)7?_ M)-9)`)2]V$5)::-%<#`;SQ5PFE>Q3FUNSOPK+''-G=>>([)5YLR;/2@O M-\UP*:1*)DLGH6BBA]_@/VZ]&*"?_']02P,$%`````@`F7IF1S``L``00E M#@``!#D!``#M7&USVS82_GXS]Q]P^M)V)K0L.W%B3YP.+@2%]1"QN`&W()I18EJ)_XMX%=^=H`8$-N1#+ MBV;S\?'QZ/'TB+)9LW5^?M[4;QL1*??R"$^.CUO-WWMWCNXV)L;EQ!8F2BL7 M15P989XFS(\83YOJ]03R-;EZZXDU0Y+X33-\&9$R-"WL^*PIWT:$A!(2+/)I M/<&:XGF)FI+(DE2(87?-5\Z48D`SA5NA5.=-1GW)%9(E5<8&$Z4M^N0;B'^_ M2\#K3S#=H%4-1RY=2-K6F^/ST^.(TD-XT^803+X_8H%",#P)!+JA;'&-IC#P)<`!^3.`/IYB90CDHP4B M8H,@\5I`-D.B#Q>(+Z&+2E2200&`#@M("!50R"#4;5'KLG$L.R$+A$3&/%$%#7WII8+_6W5DBQNX!^T5AZ:;JN59,$$ M'[)2/IQLJY1D0?ZWU4?U,Y8:`/7'_:B;'[9:FJY21Z::!L`R>ZZ?UAU&7<90 M?)"S#K#`-74#E3F2?]K$`QTBL)"3I8QSMM`.^;Z9[B'=><"1-R`?]-_I`%UQ MKTA,G*D8J,ZXZ6;Y?*O6R+(O-+@[X0F#JR>SP4^DE1UI$[2R>)L2#Q$I(;B" MOIJA@#-'2/#:U'FF7F[:>EEB[-.*Q@8_#R&3)',DL#3(+[7QL\;GE":-KQ[- MQG]=:/QU*P=T"@8R"VH3U#Z_8?:UE:RUY6+#T6ELM@W?#3':D=<,Z)NM`:WC MZ@4`M^E"6F`NV_$#NJ.<5X(VRV4&]:PBJ!O]`M5Q#69>DE1%7#)+RFIS9XQN\PP,%D5A\]FPY^D#>_<]WKVZ`L8W`"G>]OOWG3;=G\,['9[<-\? M=_NW8#BRV^-NNU-#D`-!,N67Y/N6KJ(VC3\>M'_[.+B[[HPNW5&_:.C6;=R9CO.QUIJ_:@ MU^N.>QUIK1"&4BHS.F_3Z*PZT;@DNJFA*8"F;3L?>X-^YXM,W;]UQC?W_6M' MVL[Y.!B-K7%GU.OV/W6<`L2V8C8#>9H&4O7]"NC>0=@]T/V_TM#&0X#$* M10'8N;7OAJ-!N].YEA-Q3NRE"('B0YJ*')F^-;&%-\J,?)YML"Z M_*B6A;\/*0^=C'B]24[;<9N0/GTATN$0-$:I`C2(D(S>I66/35,YO6/2"V` M1(G1MU@!U:;?9[U=$#L[=&$&>"^U=PV]>5?32VUK>D907A_OLK,)?KY&`F*_ M!N&EE4@?,O7U\0&M#+IK39+IQPSZ21;TK>J3]7"_U*ZP+U=0IVF]P$=T:G.. M!.\AJ-@]*&X@9I^@'[S42;88H1H*HSU2A*""2!4`!E#1`BU.[URZU M<'E2*6)%2,81.T)<,.P*=7Z"NE]M5QH5B^?J"%?NJ@SY M;.C'8_WDK)%/QG@\8G@P`$1CUEY1MH@B7FH51&ME7_EY;] MK$*!"&Y,JCOW5N8?F=7QKOX1#5P[R(Y?C$OKIVI<9L#?9M-TP3?E.D=_LYVO M.'35:;D>)>BY!]E7)&X"XG%(/&=.F;#&B"VZY$%6,?IT79%;?+^1S:YUFG6M MW7;:DEE&B2E[4(*"4%*@17T%I+`@EA8DQ*W=]5NYZRVCG-\3AJ"/_T+>+<1$ M.8TZZ8SV[)^5ABISR$SQ\W*'U'*!6#"@)=/>&,I6>]\W2Y:4"`9=$4"_)VL/ MAM7O`O><%4U#E'G;GCXT;*2_6!X0"U2[V'Y=K+3R>E%G96[S>C]N4U=K6VV. M1V>-PJ-&Q5O<^71F3,_SOG.D#C?5(.W_"X9>B%I74(JF?HJ%9,6@I-[;]XN2 M_LN^7F27VKM^O4@(`I*2U*%?[E7#T6#8&8V_R%RJ-HV'*GUF7".7R'R>,9/& MHSYTUE[W4N.R!2X%1T0,I.:C(!4QJ@][[`)649HUT9I3YNOL/%H$6)WV=MER M+(@O$ZTYP*K^8*6.L)WPBDN18<#"`>L*Y:MO^)2R':!71F,-_E?!5(_^3E_P*D]\WTQ6VKELT+WO3U;GBQI$P` MDGM;7-'E@^$%BG?4U9T96-23%?%9JLEJG5BGK2,Y='0%EEF,_"L-*PH0,:B1 MWU0?L^!ZQ(J#:FHUXIEU?&*=O-UQW/RK%JO(D.3LAXQ*G'-E^M;9B\79391] MR9%S+V0507S&-KCV(DCRLLGM0B+BVRDD"J^QK"Z#OWLL%EUU63!X+H_ZPXJ9 MJTM@O#G3)$$N8Q/Y@D4+,Q;("G48Z.G/(-JRQ)5_2'ERW[=L:WT9O>T$#(K;7.^+[ MKG[@,N3MPQ'&]`J%RO708H)8OOI9JE#9\,KE"X\N("9[T#5\WI]..H;+5%H1 M'0A\X0PKMM74%+19JN\;HN4J19>ZVL0+KW1-W.AJKP9(Z%:-?$-)P3"9_5@/ M_4S95RE$&RZQB&Y!U.JD7QS&A%*.FO:FS/<86V7%F::[>HY)AO!90_8(F;^_((OU8.[M]KP$/S'*W4I%SO28'>NFKA73+4PWY&>#:718S] M@!BS9C.F%6)7;'ZX_QN?R+]_5PQ+W]69SDXYY3DB$M8'M1] M]++W(4-3Q-CJYTR9VK4B_<%5L4,Y*X\?:4:?5/O!R7V#'Y"*44BDV3/2Y[X] M.!T^04D>\(&8(W9-%W+=CUU=-K.L1A5H#TX_F0UENB.AF%F,\MX>G`X[5X") MY"^G@L3$$$T%FREQ'T7GUD,>R`JT`@SIGR[8JY\NI'ZYD)I>QWB!QG1UD/8Y M8>+]='>`<_0(N3[D'$]QN+<["`^Q9;Q)[;M$7ZW"S>VY>-_ M`5!+`0(>`Q0````(`)EZ9D?AQ1QPSJ(``'K$"0`1`!@```````$```"D@0`` M``!L8FEO+3(P,34P.3,P+GAM;%54!0`#H@L]5G5X"P`!!"4.```$.0$``%!+ M`0(>`Q0````(`)EZ9D=ZCTM7F`P``%&G```5`!@```````$```"D@1FC``!L M8FEO+3(P,34P.3,P7V-A;"YX;6Q55`4``Z(+/59U>`L``00E#@``!#D!``!0 M2P$"'@,4````"`"9>F9'+F+T+%@G``!YTP(`%0`8```````!````I($`L``` M;&)I;RTR,#$U,#DS,%]D968N>&UL550%``.B"SU6=7@+``$$)0X```0Y`0`` M4$L!`AX#%`````@`F7IF1QSN%SNW=@``5(((`!4`&````````0```*2!I]<` M`&QB:6\M,C`Q-3`Y,S!?;&%B+GAM;%54!0`#H@L]5G5X"P`!!"4.```$.0$` M`%!+`0(>`Q0````(`)EZ9D<>D>-PXT$``*X*!0`5`!@```````$```"D@:U. M`0!L8FEO+3(P,34P.3,P7W!R92YX;6Q55`4``Z(+/59U>`L``00E#@``!#D! M``!02P$"'@,4````"`"9>F9',!R'=M\*```J;0``$0`8```````!````I('? MD`$`;&)I;RTR,#$U,#DS,"YX`L``00E#@``!#D!``!0 52P4&``````8`!@`:`@``"9P!```` ` end XML 55 R10.htm IDEA: XBRL DOCUMENT v3.3.0.814

SUMMARY OF SIGNIFICANT ACCOUNTING PRACTICES
9 Months Ended

Sep. 30, 2015

SUMMARY OF SIGNIFICANT ACCOUNTING PRACTICES [Abstract]

SUMMARY OF SIGNIFICANT ACCOUNTING PRACTICES

NOTE 2. SUMMARY OF SIGNIFICANT ACCOUNTING PRACTICES

Cash and Cash Equivalents

The Company considers highly liquid investments with an original maturity of 90 days or less when purchased to be cash equivalents. The carrying amounts reported in the Balance Sheets for cash and cash equivalents are valued at cost, which approximates their fair value.

Short-term Investments

The Company's short-term investments represent available for sale securities and are recorded at fair value and unrealized gains and losses are recorded within accumulated other comprehensive income (loss). The estimated fair value of the available for sale securities is determined based on quoted market prices or rates for similar instruments. In addition, the cost of debt securities in this category is adjusted for amortization of premium and accretion of discount to maturity. The Company evaluates securities with unrealized losses to determine whether such losses, if any, are other than temporary.

Property and Equipment

Property and equipment are recorded at cost and depreciated using the straight-line method over their estimated useful lives of two to five years. Maintenance and repairs of depreciable assets are charged against earnings as incurred. When properties are retired or otherwise disposed of, the cost and accumulated depreciation are removed from the accounts and gains or losses are credited or charged to earnings. Leasehold improvements are amortized over the lesser of their estimated useful life or lease term, whichever is shorter.

Net Income (Loss) Per Share

Basic net income (loss) per share is computed by dividing net income (loss) by the weighted average number of common shares outstanding for the period, excluding unvested shares of restricted common stock. Shares of restricted stock subject to vesting are included in basic weighted average common shares outstanding from the time they vest. Diluted earnings per share is computed by dividing the net income applicable to common stock holders by the weighted average number of common shares outstanding plus the number of additional common shares that would have been outstanding if all dilutive potential common shares had been issued, using the treasury stock method. Potential common shares are excluded from the computation when their effect is antidilutive. When calculating diluted net income per share, shares of restricted stock subject to vesting are included in diluted weighted average common shares outstanding as of their grant date.

At September 30, 2015 and 2014, basic and diluted net loss per share are the same, as the effect of potentially dilutive securities was antidilutive. At September 30, 2015, potentially dilutive securities include options to acquire 2,704,195 shares of common stock, warrants to acquire 7,237,216 shares of common stock, preferred stock that can be converted into 1,847,000 shares of common stock, and 494,001 shares of non-vested restricted stock. At September 30, 2014, potentially dilutive securities include options to acquire 1,098,750 shares of common stock, warrants to acquire 11,172,426 shares of common stock, and preferred stock that can be converted into 2,847,000 shares of common stock.

Fair Value Measurements

Under FASB ASC 820, Fair Value Measurements and Disclosures, fair value is defined as the price at which an asset could be exchanged or a liability transferred in a transaction between knowledgeable, willing parties in the principal or most advantageous market for the asset or liability. Where available, fair value is based on observable market prices or parameters or derived from such prices or parameters. Where observable prices or parameters are not available, valuation models are applied.

Assets and liabilities recorded at fair value in our financial statements are categorized based upon the level of judgment associated with the inputs used to measure their fair value. Hierarchical levels directly related to the amount of subjectivity associated with the inputs to fair valuation of these assets and liabilities, are as follows:

Level 1—Inputs are unadjusted, quoted prices in active markets for identical assets at the reporting date. Active markets are those in which transactions for the asset or liability occur in sufficient frequency and volume to provide pricing information on an ongoing basis.

The fair valued assets we hold that are generally included under this Level 1 are money market securities where fair value is based on publicly quoted prices.

Level 2—Are inputs, other than quoted prices included in Level 1, that are either directly or indirectly observable for the asset or liability through correlation with market data at the reporting date and for the duration of the instrument's anticipated life.

The fair valued assets we hold that are generally assessed under Level 2 are corporate bonds and commercial paper. We utilize third party pricing services in developing fair value measurements where fair value is based on valuation methodologies such as models using observable market inputs, including benchmark yields, reported trades, broker/dealer quotes, bids, offers and other reference data. We use quotes from external pricing service providers and other on-line quotation systems to verify the fair value of investments provided by our third party pricing service providers. We review independent auditor's reports from our third party pricing service providers particularly regarding the controls over pricing and valuation of financial instruments and ensure that our internal controls address certain control deficiencies, if any, and complementary user entity controls are in place.

Level 3—Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities and which reflect management's best estimate of what market participants would use in pricing the asset or liability at the reporting date. Consideration is given to the risk inherent in the valuation technique and the risk inherent in the inputs to the model.

We do not have fair valued assets classified under Level 3.

Fair Value on a Recurring Basis

Financial assets measured at fair value on a recurring basis are categorized in the tables below based upon the lowest level of significant input to the valuations (in thousands):

Assets at Fair Value as of September 30, 2015

Level 1 Level 2 Level 3 Total

Money market funds $ 20,562 $ - $ - $ 20,562

Corporate debt securities - 79,374 - 79,374

Total $ 20,562 $ 79,374 $ $ 99,936

Use of Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates include accounting for potential liabilities and the assumptions made in valuing stock instruments issued for services.

Stock-Based Compensation

The Company periodically grants stock options and warrants to employees and non-employees in non-capital raising transactions as compensation for services rendered. The Company accounts for stock option grants to employees based on the authoritative guidance provided by the Financial Accounting Standards Board where the value of the award is measured on the date of grant and recognized over the vesting period. The Company accounts for stock option grants to non-employees in accordance with the authoritative guidance of the Financial Accounting Standards Board where the value of the stock compensation is determined based upon the measurement date at either a) the date at which a performance commitment is reached, or b) at the date at which the necessary performance to earn the equity instruments is complete. Non-employee stock-based compensation charges generally are amortized over the vesting period on a straight-line basis. In certain circumstances where there are no future performance requirements by the non-employee, option grants are immediately vested and the total stock-based compensation charge is recorded in the period of the measurement date.

The Company issues restricted shares of its common stock for share-based compensation programs. The Company measures the compensation cost with respect to restricted shares to employees based upon the estimated fair value of the equity instruments at the date of the grant, and is recognized as expense over the period which an employee is required to provide services in exchange for the award.

The fair value of the Company's common stock option grants is estimated using a Black-Scholes option pricing model, which uses certain assumptions related to risk-free interest rates, expected volatility, expected life of the common stock options, and future dividends. Compensation expense is recorded based upon the value derived from the Black-Scholes option pricing model, and based on actual experience. The assumptions used in the Black-Scholes option pricing model could materially affect compensation expense recorded in future periods.

Total stock-based compensation expense related to all of our stock-based awards was as follows (in thousands):

For the Three Months Ended
September 30, For the Nine Months Ended
September 30,

2015 2014 2015 2014

Operating expenses $ 1,492 $ 658 $ 3,726 $ 1,905

Research and development 895 282 2,050 817

 Total stock-based compensation expense $ 2,387 $ 940 $ 5,776 $ 2,722

Research and Development

Research and development costs consist primarily of fees paid to consultants and outside service providers, patent fees and costs, and other expenses relating to the acquisition, design, development and testing of the Company's treatments and product candidates. Research and development costs are expensed as incurred, unless the achievement of milestones, the completion of contracted work, or other information indicates that a different expensing schedule is more appropriate. The Company reviews the status of its research and development contracts on a quarterly basis.

Concentrations

Financial instruments, which potentially subject the Company to concentrations of credit risk, consist principally of cash and short-term investments.

The Company maintains cash balances at one bank. As of September 30, 2015, the Company's cash balances were in excess of insured limits maintained at this bank. Management believes that the financial institution that hold the Company's cash are financially sound and, accordingly, minimal credit risk exists.

At September 30, 2015, the Company's short-term investments were invested in short-term fixed income debt securities of domestic and foreign high credit issuers and in money market funds. The Company's investment policy limits investments to certain types of instruments such as certificates of deposit, money market instruments, obligations issued by the U.S. government and U.S. government agencies as well as corporate debt securities, and places restrictions on maturities and concentration by type and issuer. At September 30, 2015, approximately 56% of the Company's short-term investments were invested in notes of five companies, 25% were invested in notes of various domestic issuers, and 19% were invested in notes of a foreign issuers. The average maturity of these notes was 66 days (See Note 3).

Recent Accounting Pronouncements

In May 2014, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2014-09, Revenue from Contracts with Customers. ASU 2014-09 is a comprehensive revenue recognition standard that will supersede nearly all existing revenue recognition guidance under current U.S. GAAP and replace it with a principle based approach for determining revenue recognition. ASU 2014-09 will require that companies recognize revenue based on the value of transferred goods or services as they occur in the contract. The ASU also will require additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to obtain or fulfill a contract. ASU 2014-09 is effective for interim and annual periods beginning after December 15, 2017. Early adoption is permitted in annual reporting periods beginning after December 15, 2016, and the interim periods within that year, and either full retrospective adoption or modified retrospective adoption is permitted. The Company is in the process of evaluating the impact of ASU 2014-09 on the Company's financial statements and disclosures.

In June 2014, the FASB issued Accounting Standards Update No. 2014-12, Compensation – Stock Compensation (Topic 718). The pronouncement was issued to clarify the accounting for share-based payments when the terms of an award provide that a performance target could be achieved after the requisite service period. The pronouncement is effective for reporting periods beginning after December 15, 2015. The adoption of ASU 2014-12 is not expected to have a significant impact on the Company's consolidated financial position or results of operations.

Other recent accounting pronouncements issued by the FASB, including its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the Securities and Exchange Commission did not or are not believed by management to have a material impact on the Company's present or future consolidated financial statements.

Reclassifications

In presenting the Company's statement of operations for the three and nine month periods ended September 30, 2014, the Company has reclassified $0.8 million and $0.3 million, respectively, of stock-based compensation that was previously reflected as operating expenses to research and development expenses. The reclassification relates to stock-based compensation attributable to individuals working in the Company's research and development activities, and had no impact on total costs and expenses, or on net loss.

X

- References
No definition available.
+ Details

Name: us-gaap_AccountingPoliciesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for all significant accounting policies of the reporting entity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18861-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18780-107790

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18726-107790

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18743-107790

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18854-107790

+ Details

Name: us-gaap_SignificantAccountingPoliciesTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 56 R27.htm IDEA: XBRL DOCUMENT v3.3.0.814

SUMMARY OF SIGNIFICANT ACCOUNTING PRACTICES (Schedule of Stock-Based Compensation) (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended

Sep. 30, 2015

Sep. 30, 2014

Sep. 30, 2015

Sep. 30, 2014

Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]

Stock-based compensation expense $ 2,387 $ 940 $ 5,776 $ 2,722

Operating expenses [Member]

Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]

Stock-based compensation expense 1,492 658 3,726 1,905

Research and development [Member]

Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]

Stock-based compensation expense $ 895 $ 282 $ 2,050 $ 817

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of capitalized and expensed compensation cost from equity-based compensation arrangements.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (h)(1)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 57 FilingSummary.xml IDEA: XBRL DOCUMENT 3.3.0.814 html 94 174 1 false 35 0 false 4 false false R1.htm 001 - Document - Document And Entity Information Sheet http://www.lbio.com/role/Ibio-dei Document And Entity Information Cover 1 false false R2.htm 002 - Statement - Condensed Balance Sheets Sheet http://www.lbio.com/role/Ibio-cbs Condensed Balance Sheets Statements 2 false false R3.htm 003 - Statement - Condensed Balance Sheets (Parenthetical) Sheet http://www.lbio.com/role/Ibio-cbsp Condensed Balance Sheets (Parenthetical) Statements 3 false false R4.htm 004 - Statement - Condensed Statements of Operations Sheet http://www.lbio.com/role/Ibio-csoo Condensed Statements of Operations Statements 4 false false R5.htm 005 - Statement - Condensed Statements of Operations (Parenthetical) Sheet http://www.lbio.com/role/Statement-CondensedStatementsofOperationsParenthetical Condensed Statements of Operations (Parenthetical) Statements 5 false false R6.htm 006 - Statement - Condensed Statements of Comprehensive Loss Sheet http://www.lbio.com/role/Statement-CondensedStatementsofComprehensiveLoss Condensed Statements of Comprehensive Loss Statements 6 false false R7.htm 007 - Statement - Condensed Statements of Stockholders' Equity Sheet http://www.lbio.com/role/Ibio-csose Condensed Statements of Stockholders' Equity Statements 7 false false R8.htm 008 - Statement - Condensed Statements of Cash Flows Sheet http://www.lbio.com/role/Ibio-csocf Condensed Statements of Cash Flows Statements 8 false false R9.htm 101 - Disclosure - GENERAL ORGANIZATION AND BUSINESS Sheet http://www.lbio.com/role/Ibio-goab GENERAL ORGANIZATION AND BUSINESS Notes 9 false false R10.htm 102 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING PRACTICES Sheet http://www.lbio.com/role/Ibio-sosap SUMMARY OF SIGNIFICANT ACCOUNTING PRACTICES Notes 10 false false R11.htm 103 - Disclosure - CASH, MONEY MARKET FUNDS, AND SHORT-TERM INVESTMENTS Sheet http://www.lbio.com/role/Disclosure-CASHMONEYMARKETFUNDSANDSHORT-TERMINVESTMENTS CASH, MONEY MARKET FUNDS, AND SHORT-TERM INVESTMENTS Notes 11 false false R12.htm 104 - Disclosure - PROPERTY AND EQUIPMENT Sheet http://www.lbio.com/role/Disclosure-PROPERTYANDEQUIPMENT PROPERTY AND EQUIPMENT Notes 12 false false R13.htm 105 - Disclosure - STOCKHOLDERS' EQUITY Sheet http://www.lbio.com/role/Ibio-se STOCKHOLDERS' EQUITY Notes 13 false false R14.htm 106 - Disclosure - STOCK OPTIONS AND WARRANTS Sheet http://www.lbio.com/role/Ibio-soaw STOCK OPTIONS AND WARRANTS Notes 14 false false R15.htm 107 - Disclosure - LICENSE AND COMMITMENTS Sheet http://www.lbio.com/role/Disclosure-LICENSEANDCOMMITMENTS LICENSE AND COMMITMENTS Notes 15 false false R16.htm 108 - Disclosure - LEGAL PROCEEDINGS Sheet http://www.lbio.com/role/Disclosure-LEGALPROCEEDINGS LEGAL PROCEEDINGS Notes 16 false false R17.htm 202 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING PRACTICES (Policies) Sheet http://www.lbio.com/role/Ibio-sosapp SUMMARY OF SIGNIFICANT ACCOUNTING PRACTICES (Policies) Policies 17 false false R18.htm 302 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING PRACTICES (Tables) Sheet http://www.lbio.com/role/Disclosure-SUMMARYOFSIGNIFICANTACCOUNTINGPRACTICESTables SUMMARY OF SIGNIFICANT ACCOUNTING PRACTICES (Tables) Tables http://www.lbio.com/role/Ibio-sosap 18 false false R19.htm 303 - Disclosure - CASH, MONEY MARKET FUNDS, AND SHORT-TERM INVESTMENTS (Tables) Sheet http://www.lbio.com/role/Disclosure-CASHMONEYMARKETFUNDSANDSHORT-TERMINVESTMENTSTables CASH, MONEY MARKET FUNDS, AND SHORT-TERM INVESTMENTS (Tables) Tables http://www.lbio.com/role/Disclosure-CASHMONEYMARKETFUNDSANDSHORT-TERMINVESTMENTS 19 false false R20.htm 304 - Disclosure - PROPERTY AND EQUIPMENT (Tables) Sheet http://www.lbio.com/role/Disclosure-PROPERTYANDEQUIPMENTTables PROPERTY AND EQUIPMENT (Tables) Tables http://www.lbio.com/role/Disclosure-PROPERTYANDEQUIPMENT 20 false false R21.htm 305 - Disclosure - STOCKHOLDERS' EQUITY (Tables) Sheet http://www.lbio.com/role/Disclosure-STOCKHOLDERSEQUITYTables STOCKHOLDERS' EQUITY (Tables) Tables http://www.lbio.com/role/Ibio-se 21 false false R22.htm 306 - Disclosure - STOCK OPTIONS AND WARRANTS (Tables) Sheet http://www.lbio.com/role/Ibio-soawt STOCK OPTIONS AND WARRANTS (Tables) Tables http://www.lbio.com/role/Ibio-soaw 22 false false R23.htm 307 - Disclosure - LICENSE AND COMMITMENTS (Tables) Sheet http://www.lbio.com/role/Disclosure-LICENSEANDCOMMITMENTSTables LICENSE AND COMMITMENTS (Tables) Tables http://www.lbio.com/role/Disclosure-LICENSEANDCOMMITMENTS 23 false false R24.htm 40101 - Disclosure - GENERAL ORGANIZATION AND BUSINESS (Details) Sheet http://www.lbio.com/role/Ibio-goabd GENERAL ORGANIZATION AND BUSINESS (Details) Details http://www.lbio.com/role/Ibio-goab 24 false false R25.htm 40201 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING PRACTICES (Narrative) (Details) Sheet http://www.lbio.com/role/Disclosure-SUMMARYOFSIGNIFICANTACCOUNTINGPRACTICESNarrativeDetails SUMMARY OF SIGNIFICANT ACCOUNTING PRACTICES (Narrative) (Details) Details http://www.lbio.com/role/Disclosure-SUMMARYOFSIGNIFICANTACCOUNTINGPRACTICESTables 25 false false R26.htm 40202 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING PRACTICES (Schedule of Assets Measured at Fair Value) (Details) Sheet http://www.lbio.com/role/Disclosure-SUMMARYOFSIGNIFICANTACCOUNTINGPRACTICESScheduleofAssetsMeasuredatFairValueDetails SUMMARY OF SIGNIFICANT ACCOUNTING PRACTICES (Schedule of Assets Measured at Fair Value) (Details) Details http://www.lbio.com/role/Disclosure-SUMMARYOFSIGNIFICANTACCOUNTINGPRACTICESTables 26 false false R27.htm 40203 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING PRACTICES (Schedule of Stock-Based Compensation) (Details) Sheet http://www.lbio.com/role/Disclosure-SUMMARYOFSIGNIFICANTACCOUNTINGPRACTICESScheduleofStock-BasedCompensationDetails SUMMARY OF SIGNIFICANT ACCOUNTING PRACTICES (Schedule of Stock-Based Compensation) (Details) Details http://www.lbio.com/role/Disclosure-SUMMARYOFSIGNIFICANTACCOUNTINGPRACTICESTables 27 false false R28.htm 40301 - Disclosure - CASH, MONEY MARKET FUNDS, AND SHORT-TERM INVESTMENTS (Schedule of Cash, Money Market Funds, and Short-Term Investments) (Details) Sheet http://www.lbio.com/role/Disclosure-CASHMONEYMARKETFUNDSANDSHORT-TERMINVESTMENTSScheduleofCashMoneyMarketFundsandShort-TermInvestmentsDetails CASH, MONEY MARKET FUNDS, AND SHORT-TERM INVESTMENTS (Schedule of Cash, Money Market Funds, and Short-Term Investments) (Details) Details http://www.lbio.com/role/Disclosure-CASHMONEYMARKETFUNDSANDSHORT-TERMINVESTMENTSTables 28 false false R29.htm 40302 - Disclosure - CASH, MONEY MARKET FUNDS, AND SHORT-TERM INVESTMENTS (Schedule of Gross Unrealized Gains and Losses) (Details) Sheet http://www.lbio.com/role/Disclosure-CASHMONEYMARKETFUNDSANDSHORT-TERMINVESTMENTSScheduleofGrossUnrealizedGainsandLossesDetails CASH, MONEY MARKET FUNDS, AND SHORT-TERM INVESTMENTS (Schedule of Gross Unrealized Gains and Losses) (Details) Details http://www.lbio.com/role/Disclosure-CASHMONEYMARKETFUNDSANDSHORT-TERMINVESTMENTSTables 29 false false R30.htm 40303 - Disclosure - CASH, MONEY MARKET FUNDS, AND SHORT-TERM INVESTMENTS (Schedule of Contractual Maturities) (Details) Sheet http://www.lbio.com/role/Disclosure-CASHMONEYMARKETFUNDSANDSHORT-TERMINVESTMENTSScheduleofContractualMaturitiesDetails CASH, MONEY MARKET FUNDS, AND SHORT-TERM INVESTMENTS (Schedule of Contractual Maturities) (Details) Details http://www.lbio.com/role/Disclosure-CASHMONEYMARKETFUNDSANDSHORT-TERMINVESTMENTSTables 30 false false R31.htm 40304 - Disclosure - CASH, MONEY MARKET FUNDS, AND SHORT-TERM INVESTMENTS (Narrative) (Details) Sheet http://www.lbio.com/role/Disclosure-CASHMONEYMARKETFUNDSANDSHORT-TERMINVESTMENTSNarrativeDetails CASH, MONEY MARKET FUNDS, AND SHORT-TERM INVESTMENTS (Narrative) (Details) Details http://www.lbio.com/role/Disclosure-CASHMONEYMARKETFUNDSANDSHORT-TERMINVESTMENTSTables 31 false false R32.htm 40401 - Disclosure - PROPERTY AND EQUIPMENT (Details) Sheet http://www.lbio.com/role/Disclosure-PROPERTYANDEQUIPMENTDetails PROPERTY AND EQUIPMENT (Details) Details http://www.lbio.com/role/Disclosure-PROPERTYANDEQUIPMENTTables 32 false false R33.htm 40501 - Disclosure - STOCKHOLDERS' EQUITY (Narrative) (Details) Sheet http://www.lbio.com/role/Disclosure-STOCKHOLDERSEQUITYNarrativeDetails STOCKHOLDERS' EQUITY (Narrative) (Details) Details http://www.lbio.com/role/Disclosure-STOCKHOLDERSEQUITYTables 33 false false R34.htm 40502 - Disclosure - STOCKHOLDER'S EQUITY (Schedule of Restricted Stock Activity) (Details) Sheet http://www.lbio.com/role/Disclosure-STOCKHOLDERSEQUITYScheduleofRestrictedStockActivityDetails STOCKHOLDER'S EQUITY (Schedule of Restricted Stock Activity) (Details) Details 34 false false R35.htm 40601 - Disclosure - STOCK OPTIONS AND WARRANTS (Narrative) (Details) Sheet http://www.lbio.com/role/Ibio-soawnd STOCK OPTIONS AND WARRANTS (Narrative) (Details) Details http://www.lbio.com/role/Ibio-soawt 35 false false R36.htm 40602 - Disclosure - STOCK OPTIONS AND WARRANTS (Schedule of Status of Stock Options) (Details) Sheet http://www.lbio.com/role/Ibio-soawsososod STOCK OPTIONS AND WARRANTS (Schedule of Status of Stock Options) (Details) Details http://www.lbio.com/role/Ibio-soawt 36 false false R37.htm 40603 - Disclosure - STOCK OPTIONS AND WARRANTS (Schedule of Status of Stock Warrants) (Details) Sheet http://www.lbio.com/role/Disclosure-STOCKOPTIONSANDWARRANTSScheduleofStatusofStockWarrantsDetails STOCK OPTIONS AND WARRANTS (Schedule of Status of Stock Warrants) (Details) Details http://www.lbio.com/role/Ibio-soawt 37 false false R38.htm 40701 - Disclosure - LICENSE AND COMMITMENTS (Narrative) (Details) Sheet http://www.lbio.com/role/Disclosure-LICENSEANDCOMMITMENTSNarrativeDetails LICENSE AND COMMITMENTS (Narrative) (Details) Details http://www.lbio.com/role/Disclosure-LICENSEANDCOMMITMENTSTables 38 false false R39.htm 40702 - Disclosure - LICENSE AND COMMITMENTS (Schedule of Purchase Obligation) (Details) Sheet http://www.lbio.com/role/Disclosure-LICENSEANDCOMMITMENTSScheduleofPurchaseObligationDetails LICENSE AND COMMITMENTS (Schedule of Purchase Obligation) (Details) Details http://www.lbio.com/role/Disclosure-LICENSEANDCOMMITMENTSTables 39 false false R40.htm 40801 - Disclosure - LEGAL PROCEEDINGS (Details) Sheet http://www.lbio.com/role/Disclosure-LEGALPROCEEDINGSDetails LEGAL PROCEEDINGS (Details) Details http://www.lbio.com/role/Disclosure-LEGALPROCEEDINGS 40 false false R41.htm 40901 - Disclosure - SUBSEQUENT EVENTS (Details) Sheet http://www.lbio.com/role/Disclosure-SUBSEQUENTEVENTSDetails SUBSEQUENT EVENTS (Details) Details 41 false false All Reports Book All Reports In ''Condensed Balance Sheets'', column(s) 3, 4 are contained in other reports, so were removed by flow through suppression. In ''Condensed Statements of Cash Flows'', column(s) 1, 2, 3, 4 are contained in other reports, so were removed by flow through suppression. lbio-20150930.xml lbio-20150930_cal.xml lbio-20150930_def.xml lbio-20150930_lab.xml lbio-20150930_pre.xml lbio-20150930.xsd true true XML 58 R38.htm IDEA: XBRL DOCUMENT v3.3.0.814

LICENSE AND COMMITMENTS (Narrative) (Details) - USD ($)
$ in Millions
9 Months Ended

Sep. 30, 2015

Sep. 30, 2014

LICENSE AND COMMITMENTS [Abstract]

License agreement expense $ 2.5 $ 0.9

X

- References
No definition available.
+ Details

Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Costs incurred and are directly related to generating license revenue. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.2(e))

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_LicenseCosts

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

XML 59 R20.htm IDEA: XBRL DOCUMENT v3.3.0.814

PROPERTY AND EQUIPMENT (Tables)
9 Months Ended

Sep. 30, 2015

PROPERTY AND EQUIPMENT [Abstract]

Schedule of Property and Equipment

September 30, 2015 December 31, 2014

Laboratory equipment $ 1,563 $ 688

Leasehold improvements 853 762

Computer, software, and office equipment 211 185

2,627 1,635

Accumulated depreciation (794 ) (103 )

$ 1,833 $ 1,532

X

- References
No definition available.
+ Details

Name: us-gaap_PropertyPlantAndEquipmentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.13)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 13

-Subparagraph b

-Article 5

+ Details

Name: us-gaap_PropertyPlantAndEquipmentTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

LICENSE AND COMMITMENTS (Schedule of Purchase Obligation) (Details) $ in Thousands	Sep. 30, 2015 USD ($)
LICENSE AND COMMITMENTS [Abstract]
2015	$ 3,104
2016	2,874
Total	$ 5,978

STOCKHOLDERS' EQUITY (Narrative) (Details) - USD ($) $ / shares in Units, $ in Thousands	1 Months Ended		9 Months Ended		12 Months Ended
	Mar. 03, 2015	Dec. 22, 2014	Sep. 30, 2015	Sep. 30, 2014	Dec. 31, 2014
Class of Stock [Line Items]
Shares issued during period	9,200,000	6,000,000
Share price	$ 8.00	$ 5.75
Proceeds from the issuance of common stock, net	$ 68,300	$ 32,200	$ 68,308
Conversion of Stock, Shares Issued			1,000,000
Conversion of Stock, Shares Converted			2,000
Restricted Stock [Member]
Class of Stock [Line Items]
Granted					797,500
Vesting period					3 years
Nonvested, fair value					$ 5,300
Share-based compensation					$ 1,300
Vested, fair value			$ 1,500
Unrecognized compensation cost			$ 2,500
Series A Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Conversion of Stock, Shares Converted			500

STOCK OPTIONS AND WARRANTS (Schedule of Status of Stock Warrants) (Details) - Warrant [Member] - USD ($) $ / shares in Units, $ in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2015	Dec. 31, 2014
Shares Under Warrants
Outstanding, beginning balance	11,084,426
Issued
Exercised	(3,847,210)
Expired
Outstanding, ending balance	7,237,216	11,084,426
Exercisable	7,237,216
Weighted Average Exercise Price
Outstanding, beginning balance	$ 2.51
Exercised	2.50
Outstanding, ending balance	2.51	$ 2.51
Exercisable	$ 2.51
Weighted Average Remaining Contractual Life
Outstanding	3 years 3 months 18 days	3 years 10 months 6 days
Exercisable	3 years 3 months 18 days
Aggregate Intrinsic Value
Outstanding, beginning balance	$ 59,518
Outstanding, ending balance	23,593	$ 59,518
Exercisable ending balance	$ 23,593

GENERAL ORGANIZATION AND BUSINESS	9 Months Ended
GENERAL ORGANIZATION AND BUSINESS	Sep. 30, 2015
GENERAL ORGANIZATION AND BUSINESS [Abstract]
GENERAL ORGANIZATION AND BUSINESS	NOTE 1. GENERAL ORGANIZATION AND BUSINESS Lion Biotechnologies, Inc. (the “Company,” “we,” “us” or “our”) is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel cancer immunotherapy products designed to harness the power of a patient's own immune system to eradicate cancer cells. Our lead program is an adoptive cell therapy utilizing tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients' tumors, for the treatment of metastatic melanoma. The TIL are then activated and expanded ex vivo and then infused back into the patient to fight their tumor cells. The Company was originally incorporated under the laws of the state of Nevada on September 17, 2007. Until March 2010, we were an inactive company known as Freight Management Corp. On March 15, 2010, we changed our name to Genesis Biopharma, Inc., and in 2011 we commenced our current business. *Basis of Presentation of Unaudited Condensed Financial Information* The unaudited condensed financial statements of the Company for the nine months ended September 30, 2015 and 2014 have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and pursuant to the requirements for reporting on Form 10-Q and Regulation S-K. Accordingly, they do not include all the information and footnotes required by accounting principles generally accepted in the United States of America for complete financial statements. However, such information reflects all adjustments (consisting solely of normal recurring adjustments), which are, in the opinion of management, necessary for the fair presentation of the financial position and the results of operations. Results shown for interim periods are not necessarily indicative of the results to be obtained for a full fiscal year. The balance sheet information as of December 31, 2014 was derived from the audited financial statements included in the Company's financial statements as of and for the year ended December 31, 2014 included in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission (the “SEC”) on March 16, 2015. These financial statements should be read in conjunction with that report. *Liquidity* We are currently engaged in the development of therapeutics to fight cancer, we do not have any commercial products and have not yet generated any revenues from our biopharmaceutical business. We currently do not anticipate that we will generate any revenues during 2015 from the sale or licensing of any products. In addition, we have not generated any revenues from our prior business plans. We have not had any revenues and are still in the development stage. As shown in the accompanying condensed financial statements, we have incurred a net loss of $19.3 million for the nine months ended September 30, 2015 and used $11.8 million of cash in our operating activities during the nine months ended September 30, 2015. As of September 30, 2015, we had $110.1 million of cash, money market funds, and short term investments on hand, stockholders' equity of $109.4 million and had working capital of $107.5 million. During 2015, we expect to further ramp up our operations, which will increase the amount of cash we will use in our operations. Our budget for 2015 includes increased spending on research and development activities, higher payroll expenses as we increase our professional staff, the costs associated with operating our new Tampa, Florida, research facility, as well as ongoing payments under the Cooperative Research and Development Agreement (CRADA) we have entered into with the National Cancer Institute (NCI). Based on the funds we had available on September 30, 2015, we believe that we have sufficient capital to fund our anticipated operating expenses for at least 24 months. On March 3, 2015, the Company sold 9,200,000 shares of its common stock in an underwritten public offering at $8.00 per share for net proceeds of $68.3 million, after deducting expenses of the offering. On December 22, 2014, the Company sold 6,000,000 shares of its common stock in an underwritten public offering at $5.75 per share for net proceeds of $32.2 million after deducting expenses of the offering. On November 5, 2013, we completed a $23.3 million private placement of our securities to various institutional and individual accredited investors. Despite the amount of funds that we have raised, the estimated cost of completing the development of our TIL-based therapy, and of obtaining all required regulatory approvals to market those product candidates, may be substantially greater than the amount of funds we have available. Therefore, while we believe that our existing cash balances will be sufficient to fund our currently planned level of operations for at least 24 months, we will have to obtain additional funds in the future to complete our development plans. We intend to seek this additional funding through various financing sources, including possible sales of our securities, and in the longer term through strategic alliances with other pharmaceutical or biopharmaceutical companies.

CASH, MONEY MARKET FUNDS, AND SHORT-TERM INVESTMENTS (Schedule of Gross Unrealized Gains and Losses) (Details) $ in Thousands	9 Months Ended
	Sep. 30, 2015 USD ($)
Schedule of Cost-method Investments [Line Items]
Amortized Cost	$ 99,897
Gross Unrealized Gains	$ 38
Gross Unrealized Losses
Fair Value	$ 99,936
Money Market Funds [Member]
Schedule of Cost-method Investments [Line Items]
Amortized Cost	$ 20,562
Gross Unrealized Gains
Gross Unrealized Losses
Fair Value	$ 20,562
Corporate Debt Securities [Member]
Schedule of Cost-method Investments [Line Items]
Amortized Cost	79,336
Gross Unrealized Gains	$ 38
Gross Unrealized Losses
Fair Value	$ 79,374

CASH, MONEY MARKET FUNDS, AND SHORT-TERM INVESTMENTS (Schedule of Cash, Money Market Funds, and Short-Term Investments) (Details) - USD ($) $ in Thousands	Sep. 30, 2015	Dec. 31, 2014	Sep. 30, 2014	Dec. 31, 2013
CASH, MONEY MARKET FUNDS, AND SHORT-TERM INVESTMENTS [Abstract]
Checking and savings accounts (reported as cash and cash equivalents)	$ 10,210	$ 44,910	$ 17,190	$ 19,673
Money market funds	20,562
Corporate debt securities (reported as short-term investments)	79,374
Total	$ 110,146	$ 45

CASH, MONEY MARKET FUNDS, AND SHORT-TERM INVESTMENTS (Narrative) (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2015	Dec. 31, 2014
Concentration Risk [Line Items]
Short-term investments available for sale	$ 79,374
Money market funds	$ 20,562
Five Companies [Member] \| Short-term investments [Member]
Concentration Risk [Line Items]
Concentration risk percentage	56.00%
Various Other Domestic Issuers [Member] \| Short-term investments [Member]
Concentration Risk [Line Items]
Concentration risk percentage	25.00%
Foreign Issuer [Member] \| Short-term investments [Member]
Concentration Risk [Line Items]
Concentration risk percentage	19.00%

Condensed Statements of Cash Flows - USD ($) $ in Thousands	9 Months Ended
Condensed Statements of Cash Flows - USD ($) $ in Thousands	Sep. 30, 2015	Sep. 30, 2014
Cash Flows From Operating Activities
Net loss	$ (19,283)	$ (7,168)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	691	23
Fair value of vested stock options	4,223	1,896
Vesting of restricted shares issued for services	1,553	825
Changes in assets and liabilities:
Prepaid and other current assets	(179)	118
Accounts payable and accrued expenses	1,193	(1,012)
Net cash used in operating activities	(11,802)	$ (5,318)
Cash Flows From Investing Activities
Increase in money market funds	(20,562)
Purchase of short-term investments	(95,236)
Maturities of short-term investments	15,900
Purchases of property and equipment	(992)	$ (167)
Net cash used in investing activities	(100,890)	(167)
Cash Flows From Financing Activities
Proceeds from the issuance of common stock upon exercise of warrants	9,618	$ 3,002
Proceeds from the issuance of common stock upon exercise of options	66
Proceeds from the issuance of common stock, net	68,308
Net cash provided by financing activities	77,992	$ 3,002
Net Decrease In Cash And Cash Equivalents	(34,700)	(2,483)
Cash and Cash Equivalents, Beginning of Period	44,910	19,673
Cash and Cash Equivalents, End of Period	10,210	$ 17,190
Supplement non-cash financing activities
Unrealized gain on short-term investments	$ 38

PROPERTY AND EQUIPMENT (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
PROPERTY AND EQUIPMENT (Details) - USD ($) $ in Thousands	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014	Dec. 31, 2014
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 2,627		$ 2,627		$ 1,635
Accumulated depreciation	(794)		(794)		(103)
Property and equipment, net	1,833		1,833		1,532
Depreciation expense	266	$ 5	691	$ 23
Laboratory equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	1,563		1,563		688
Leasehold improvements [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	853		853		762
Computer, software, and office equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 211		$ 211		$ 185

LEGAL PROCEEDINGS (Details) - USD ($)	1 Months Ended	9 Months Ended
LEGAL PROCEEDINGS (Details) - USD ($)	Nov. 05, 2013	Sep. 30, 2015
LEGAL PROCEEDINGS [Abstract]
Proceeds from issuance of private placement	$ 23,300,000
Damages sought		$ 7,746,000

Condensed Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2015	Dec. 31, 2014
Current Assets
Cash and cash equivalents	$ 10,210	$ 44,910
Money market funds	20,562
Short-term investments available for sale	79,374
Prepaid and other current assets	245	$ 67
Total Current Assets	110,391	44,977
Property and equipment, net of accumulated depreciation of $794 and $103	1,833	1,532
Total Assets	112,224	46,509
Current Liabilities
Accounts payable	1,161	1,249
Accrued expenses	1,608	328
Accrued payable to officers and former directors	86	86
Total Current Liabilities	$ 2,855	$ 1,663
Commitments and contingencies
Stockholders' Equity
Preferred stock, $0.001 par value; 50,000,000 shares authorized, 3,694 shares and 5,694 shares issued and outstanding, respectively
Common stock, $0.000041666 par value; 150,000,000 shares authorized, 47,807,398 and 33,750,188 shares issued and outstanding, respectively	$ 2	$ 2
Common stock to be issued, 245,153 shares	245	245
Accumulated other comprehensive income	38
Additional paid-in capital	204,929	121,161
Accumulated deficit	(95,845)	(76,562)
Total Stockholders' Equity	109,369	44,846
Total Liabilities and Stockholders' Equity	$ 112,224	$ 46,509

STOCK OPTIONS AND WARRANTS (Narrative) (Details) - USD ($) $ in Thousands	1 Months Ended	9 Months Ended
	Apr. 10, 2015	Sep. 30, 2015	Sep. 30, 2014	Nov. 30, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Proceeds from warrant exercises		$ 9,618	$ 3,002
Warrant [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted
Exercised		3,847,210
Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted		943,750
Exercised		10,000
Share-based compensation		$ 4,100	$ 1,900
Unrecognized compensation cost		10,300
Fair value of options		$ 8,300
Expected volatility		211.00%
Discount rate		1.57%
Expected dividend yield		0.00%
Expected life		6 years
2014 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares authorized		4,000,000		2,350,000
Number of additional shares authorized	1,650,000
Minimum [Member] \| Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation cost, period for recognition		9 months
Vesting period		1 year
Maximum [Member] \| Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation cost, period for recognition		3 years
Vesting period		3 years

STOCK OPTIONS AND WARRANTS (Schedule of Status of Stock Options) (Details) - Employee Stock Option [Member] - USD ($) $ / shares in Units, $ in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2015	Dec. 31, 2014
Shares Under Option
Outstanding, beginning balance	1,857,877
Granted	943,750
Exercised	(10,000)
Expired/Forfeited	(87,432)
Outstanding, ending balance	2,704,195	1,857,877
Exercisable	883,449
Weighted Average Exercise Price
Outstanding, beginning balance	$ 7.31
Granted	9.18
Expired/Forfeited	5.92
Outstanding, ending balance	8.05	$ 7.31
Exercisable	$ 8.63
Weighted Average Remaining Contractual Life
Outstanding	8 years 1 month 28 days	8 years 2 months 12 days
Granted	9 years 9 months 18 days
Expired/Forfeited	7 years 3 months 14 days
Exercisable	6 years 8 months 1 day
Aggregate Intrinsic Value
Outstanding, beginning balance	$ 2,875
Expired/Forfeited
Outstanding, ending balance	$ 64	$ 2,875
Exercisable	$ 98

Condensed Statements of Stockholders' Equity - 9 months ended Sep. 30, 2015 - USD ($) $ in Thousands	Total	Preferred Stock [Member]	Common Stock [Member]	Common Stock To Be Issued [Member]	Additional Paid-In Capital [Member]	Comprehensive Income [Member]	Accumulated Deficit [Member]
Balance at Dec. 31, 2014	$ 44,846		$ 2	$ 245	$ 121,161		$ (76,562)
Balance (in shares) at Dec. 31, 2014		5,694	33,750,188
Fair value of vested stock options	4,223				4,223
Common stock issued upon exercise of warrants	9,618				9,618
Common stock issued upon exercise of warrants (in shares)			3,847,210
Common stock issued upon exercise of options	$ 66				66
Common stock issued upon exercise of options (in shares)			10,000
Common stock issued upon conversion of preferred shares
Common stock issued upon conversion of preferred shares (in shares)		(2,000)	1,000,000
Common stock sold in public offering, net of offering costs	$ 68,308				68,308
Common stock sold in public offering, net of offering costs (in shares)			9,200,000
Vesting of restricted shares issued for services	1,553				1,553
Unrealized gain on short-term investments	38					$ 38
Net loss	(19,283)						(19,283)
Balance at Sep. 30, 2015	$ 109,369		$ 2	$ 245	$ 204,929	$ 38	$ (95,845)
Balance (in shares) at Sep. 30, 2015		3,694	47,807,398

Condensed Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Sep. 30, 2015	Dec. 31, 2014
Condensed Balance Sheets [Abstract]
Property and equipment, accumulated depreciation	$ 794	$ 103
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized	50,000,000	50,000,000
Preferred stock, shares issued	3,694	5,694
Preferred stock, shares outstanding	3,694	5,694
Common stock, par value (in dollars per share)	$ 0.000041666	$ 0.000041666
Common stock, shares authorized	150,000,000	150,000,000
Common stock, shares issued	47,807,398	33,750,188
Common stock, shares outstanding	47,807,398	33,750,188
Common stock to be issued shares	245,153	245,153

Document And Entity Information - shares	9 Months Ended
Document And Entity Information - shares	Sep. 30, 2015	Oct. 31, 2015
Document Information [Line Items]
Entity Registrant Name	Lion Biotechnologies, Inc.
Entity Central Index Key	0001425205
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Entity Common Stock, Shares Outstanding		47,833,934
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2015
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2015

Condensed Statements of Operations - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
Condensed Statements of Operations - USD ($) $ in Thousands	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Condensed Statements of Operations [Abstract]
Revenues
Costs and expenses
Operating expenses	$ 2,660	$ 2,449	$ 7,259	$ 6,155
Research and development	4,983	354	12,147	1,018
Total costs and expenses	7,643	2,803	19,406	7,173
Loss from operations	(7,643)	(2,803)	(19,406)	(7,173)
Other income (expense)
Interest income	8	5	123	5
Net Loss	$ (7,635)	$ (2,798)	$ (19,283)	$ (7,168)
Net Loss Per Share, Basic and Diluted	$ (0.16)	$ (0.11)	$ (0.44)	$ (0.30)
Weighted-Average Common Shares Outstanding, Basic and Diluted	47,271,593	26,632,908	43,398,650	24,107,787

STOCKHOLDER'S EQUITY (Schedule of Restricted Stock Activity) (Details)	9 Months Ended
	Sep. 30, 2015 $ / shares shares
Number of Shares
Non-vested shares, January 1, 2015 \| shares	757,500
Vested \| shares	(233,499)
Forfeited \| shares	(30,000)
Non-vested shares, September 30, 2015 \| shares	494,001
Weighted Average Grant Date Fair Value
Non-vested shares, January 1, 2015	$ 6.84
Vested	4.37
Forfeited	8.24
Non-vested shares, September 30, 2015	$ 6.56

SUMMARY OF SIGNIFICANT ACCOUNTING PRACTICES (Schedule of Assets Measured at Fair Value) (Details) - Fair Value, Measurements, Recurring [Member] $ in Thousands	Sep. 30, 2015 USD ($)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets, fair value	$ 99,936
Money Market Funds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets, fair value	20,562
Corporate Debt Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets, fair value	79,374
Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets, fair value	20,562
Fair Value, Inputs, Level 1 [Member] \| Money Market Funds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets, fair value	$ 20,562
Fair Value, Inputs, Level 1 [Member] \| Corporate Debt Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets, fair value
Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets, fair value	$ 79,374
Fair Value, Inputs, Level 2 [Member] \| Money Market Funds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets, fair value
Fair Value, Inputs, Level 2 [Member] \| Corporate Debt Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets, fair value	$ 79,374
Fair Value, Inputs, Level 3 [Member] \| Money Market Funds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets, fair value
Fair Value, Inputs, Level 3 [Member] \| Corporate Debt Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets, fair value

SUBSEQUENT EVENTS (Details) - USD ($) $ in Thousands	9 Months Ended
SUBSEQUENT EVENTS (Details) - USD ($) $ in Thousands	Sep. 30, 2015	Sep. 30, 2014
Subsequent Event [Line Items]
Proceeds from warrant exercises	$ 9,618	$ 3,002
Warrant [Member]
Subsequent Event [Line Items]
Purchase of common stock	3,847,210